(lp0
(I-1
S'Cytokines measurements during IFN - alpha treatment showed a trend to decreasing levels of IL - 4 at 4 , 12 , and 24 weeks .'
p1
(lp2
I3
aI4
aI5
a(lp3
I14
aI15
aI16
atp4
a(I-1
S'Levels of IFN - gamma were slightly increased following IFN - alpha treatment ( P = 0 . 09 ) .'
p5
(lp6
I2
aI3
aI4
a(lp7
I9
aI10
aI11
atp8
a(I-1
S'In patients with a complete response to IFN - alpha , the levels of IFN - gamma were higher at 24 weeks following IFN - alpha treatment than that of pre - treatment ( P = 0 . 04 ) , and the levels of IL - 4 decreased markedly at 12 and 24 weeks ( P = 0 . 02 , 0 . 03 , respectively ) . mRNA expression positively correlated with the level of Th1 / Th2 type cytokines in the supernatant .'
p9
(lp10
I7
aI8
aI9
a(lp11
I14
aI15
aI16
atp12
a(I-1
S'In patients with a complete response to IFN - alpha , the levels of IFN - gamma were higher at 24 weeks following IFN - alpha treatment than that of pre - treatment ( P = 0 . 04 ) , and the levels of IL - 4 decreased markedly at 12 and 24 weeks ( P = 0 . 02 , 0 . 03 , respectively ) . mRNA expression positively correlated with the level of Th1 / Th2 type cytokines in the supernatant .'
p13
(lp14
I7
aI8
aI9
a(lp15
I23
aI24
aI25
atp16
a(I-1
S'In patients with a complete response to IFN - alpha , the levels of IFN - gamma were higher at 24 weeks following IFN - alpha treatment than that of pre - treatment ( P = 0 . 04 ) , and the levels of IL - 4 decreased markedly at 12 and 24 weeks ( P = 0 . 02 , 0 . 03 , respectively ) . mRNA expression positively correlated with the level of Th1 / Th2 type cytokines in the supernatant .'
p17
(lp18
I7
aI8
aI9
a(lp19
I45
aI46
aI47
atp20
a(I-1
S'In patients with a complete response to IFN - alpha , the levels of IFN - gamma were higher at 24 weeks following IFN - alpha treatment than that of pre - treatment ( P = 0 . 04 ) , and the levels of IL - 4 decreased markedly at 12 and 24 weeks ( P = 0 . 02 , 0 . 03 , respectively ) . mRNA expression positively correlated with the level of Th1 / Th2 type cytokines in the supernatant .'
p21
(lp22
I14
aI15
aI16
a(lp23
I23
aI24
aI25
atp24
a(I-1
S'In patients with a complete response to IFN - alpha , the levels of IFN - gamma were higher at 24 weeks following IFN - alpha treatment than that of pre - treatment ( P = 0 . 04 ) , and the levels of IL - 4 decreased markedly at 12 and 24 weeks ( P = 0 . 02 , 0 . 03 , respectively ) . mRNA expression positively correlated with the level of Th1 / Th2 type cytokines in the supernatant .'
p25
(lp26
I14
aI15
aI16
a(lp27
I45
aI46
aI47
atp28
a(I-1
S'In patients with a complete response to IFN - alpha , the levels of IFN - gamma were higher at 24 weeks following IFN - alpha treatment than that of pre - treatment ( P = 0 . 04 ) , and the levels of IL - 4 decreased markedly at 12 and 24 weeks ( P = 0 . 02 , 0 . 03 , respectively ) . mRNA expression positively correlated with the level of Th1 / Th2 type cytokines in the supernatant .'
p29
(lp30
I23
aI24
aI25
a(lp31
I45
aI46
aI47
atp32
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p33
(lp34
I6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp35
I19
aI20
aI21
aI22
atp36
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p37
(lp38
I6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp39
I24
atp40
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p41
(lp42
I6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp43
I31
aI32
atp44
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p45
(lp46
I6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp47
I37
aI38
atp48
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p49
(lp50
I19
aI20
aI21
aI22
a(lp51
I24
atp52
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p53
(lp54
I19
aI20
aI21
aI22
a(lp55
I31
aI32
atp56
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p57
(lp58
I19
aI20
aI21
aI22
a(lp59
I37
aI38
atp60
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p61
(lp62
I24
a(lp63
I31
aI32
atp64
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p65
(lp66
I24
a(lp67
I37
aI38
atp68
a(I-1
S'This study describes the distributions of bone morphogenetic protein ( BMP ) - 2 as well as mRNAs for BMP receptor type IB ( BMPRIB ) . collagen types II ( Col II ) and III ( Col III ) in a growing " cartilage cap " of osteochondroma .'
p69
(lp70
I31
aI32
a(lp71
I37
aI38
atp72
a(I-1
S'BMP - 2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix , positive for Col III and Col II , respectively .'
p73
(lp74
I0
aI1
aI2
a(lp75
I23
aI24
atp76
a(I-1
S'BMP - 2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix , positive for Col III and Col II , respectively .'
p77
(lp78
I0
aI1
aI2
a(lp79
I26
aI27
atp80
a(I-1
S'BMP - 2 was detected in mesenchymal cells in the outer fibrous layer and chondrocytes in the inner cartilaginous matrix , positive for Col III and Col II , respectively .'
p81
(lp82
I23
aI24
a(lp83
I26
aI27
atp84
a(I-1
S'This is the first study to provide observational evidence of the involvement of BMP - 2 signaling in the pathogenesis of cartilage cap of osteochondroma . and suggests the role of BMP - 2 in the growth of cartilage cap in osteochondroma .'
p85
(lp86
I13
aI14
aI15
a(lp87
I31
aI32
aI33
atp88
a(I-1
S'The molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) is not useful to assess vitamin A status during infection in hospitalised children .'
p89
(lp90
I5
aI6
aI7
aI8
a(lp91
I10
atp92
a(I-1
S'The molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) is not useful to assess vitamin A status during infection in hospitalised children .'
p93
(lp94
I5
aI6
aI7
aI8
a(lp95
I13
atp96
a(I-1
S'The molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) is not useful to assess vitamin A status during infection in hospitalised children .'
p97
(lp98
I5
aI6
aI7
aI8
a(lp99
I15
atp100
a(I-1
S'The molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) is not useful to assess vitamin A status during infection in hospitalised children .'
p101
(lp102
I10
a(lp103
I13
atp104
a(I-1
S'The molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) is not useful to assess vitamin A status during infection in hospitalised children .'
p105
(lp106
I10
a(lp107
I15
atp108
a(I-1
S'The molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) is not useful to assess vitamin A status during infection in hospitalised children .'
p109
(lp110
I13
a(lp111
I15
atp112
a(I-1
S'OBJECTIVE : To assess the usefulness of the molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) to determine vitamin A ( VA ) status during infection .'
p113
(lp114
I12
aI13
aI14
aI15
a(lp115
I17
atp116
a(I-1
S'OBJECTIVE : To assess the usefulness of the molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) to determine vitamin A ( VA ) status during infection .'
p117
(lp118
I12
aI13
aI14
aI15
a(lp119
I20
atp120
a(I-1
S'OBJECTIVE : To assess the usefulness of the molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) to determine vitamin A ( VA ) status during infection .'
p121
(lp122
I12
aI13
aI14
aI15
a(lp123
I22
atp124
a(I-1
S'OBJECTIVE : To assess the usefulness of the molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) to determine vitamin A ( VA ) status during infection .'
p125
(lp126
I17
a(lp127
I20
atp128
a(I-1
S'OBJECTIVE : To assess the usefulness of the molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) to determine vitamin A ( VA ) status during infection .'
p129
(lp130
I17
a(lp131
I22
atp132
a(I-1
S'OBJECTIVE : To assess the usefulness of the molar ratio of serum retinol - binding protein ( RBP ) to transthyretin ( TTR ) to determine vitamin A ( VA ) status during infection .'
p133
(lp134
I20
a(lp135
I22
atp136
a(I-1
S'DESIGN : We took advantage of previously collected data during a randomised double - blind , placebo - controlled clinical trial to conduct a secondary analysis of the RBP / TTR ratio and its relationship to infection and VA status .'
p137
(lp138
I28
a(lp139
I30
atp140
a(I-1
S'MAIN OUTCOME MEASURES : RBP / TTR molar ratio after 7 days hospitalisation .'
p141
(lp142
I4
a(lp143
I6
atp144
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p145
(lp146
I8
a(lp147
I10
atp148
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p149
(lp150
I8
a(lp151
I132
atp152
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p153
(lp154
I8
a(lp155
I134
atp156
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p157
(lp158
I8
a(lp159
I172
atp160
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p161
(lp162
I8
a(lp163
I174
atp164
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p165
(lp166
I10
a(lp167
I132
atp168
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p169
(lp170
I10
a(lp171
I134
atp172
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p173
(lp174
I10
a(lp175
I172
atp176
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p177
(lp178
I10
a(lp179
I174
atp180
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p181
(lp182
I132
a(lp183
I134
atp184
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p185
(lp186
I132
a(lp187
I172
atp188
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p189
(lp190
I132
a(lp191
I174
atp192
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p193
(lp194
I134
a(lp195
I172
atp196
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p197
(lp198
I134
a(lp199
I174
atp200
a(I-1
S'RESULTS : After 7 days hospitalisation , molar RBP : TTR ratio ( mean + / - s . d . ) of infected children ( C - reactive proteins > 10 mg / l ) was 0 . 67 + / - 0 . 31 in the high - dose group ( n = 81 ) , 0 . 74 + / - 0 . 44 in the low dose group ( n = 71 ) and 0 . 73 + / - 0 . 39 in the placebo group ( n = 81 ) . These values did not differ significantly ( one - way ANOVA P = 0 . 472 ) . In patients with baseline serum retinol concentrations < 0 . 70 micromol / l , changes in RBP : TTR ratio between admission and day 7 were not statistically different in the three groups ( one - way ANOVA P = 0 . 548 ) . CONCLUSIONS : In this population of malnourished hospitalised children , molar RBP : TTR ratio does not appear to be useful to assess VA status during infection . SPONSORSHIP : Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale ( contract 3 . 4505 . 94 ) and the David and Alice Van Buuren Foundation .'
p201
(lp202
I172
a(lp203
I174
atp204
a(I-1
S'Temporally following this growth arrest , the cells develop a senescence morphology and express senescence - associated beta - galactosidase ( SA - beta - gal ) .'
p205
(lp206
I17
aI18
aI19
a(lp207
I14
aI15
aI16
aI17
aI18
aI19
atp208
a(I-1
S'Temporally following this growth arrest , the cells develop a senescence morphology and express senescence - associated beta - galactosidase ( SA - beta - gal ) .'
p209
(lp210
I17
aI18
aI19
a(lp211
I21
aI22
aI23
aI24
aI25
atp212
a(I-1
S'Temporally following this growth arrest , the cells develop a senescence morphology and express senescence - associated beta - galactosidase ( SA - beta - gal ) .'
p213
(lp214
I14
aI15
aI16
aI17
aI18
aI19
a(lp215
I21
aI22
aI23
aI24
aI25
atp216
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p217
(lp218
I2
a(lp219
I4
atp220
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p221
(lp222
I2
a(lp223
I7
atp224
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p225
(lp226
I2
a(lp227
I9
atp228
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p229
(lp230
I2
a(lp231
I20
atp232
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p233
(lp234
I4
a(lp235
I7
atp236
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p237
(lp238
I4
a(lp239
I9
atp240
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p241
(lp242
I4
a(lp243
I20
atp244
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p245
(lp246
I7
a(lp247
I9
atp248
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p249
(lp250
I7
a(lp251
I20
atp252
a(I-1
S'Levels of p16 ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .'
p253
(lp254
I9
a(lp255
I20
atp256
a(I-1
S'The induced expression of p57 , similar to p16 , produces a senescent - like phenotype .'
p257
(lp258
I4
a(lp259
I8
atp260
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p261
(lp262
I0
a(lp263
I2
aI3
atp264
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p265
(lp266
I0
a(lp267
I5
atp268
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p269
(lp270
I0
a(lp271
I7
atp272
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p273
(lp274
I0
a(lp275
I10
atp276
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p277
(lp278
I0
a(lp279
I12
atp280
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p281
(lp282
I2
aI3
a(lp283
I5
atp284
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p285
(lp286
I2
aI3
a(lp287
I7
atp288
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p289
(lp290
I2
aI3
a(lp291
I10
atp292
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p293
(lp294
I2
aI3
a(lp295
I12
atp296
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p297
(lp298
I5
a(lp299
I7
atp300
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p301
(lp302
I5
a(lp303
I10
atp304
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p305
(lp306
I5
a(lp307
I12
atp308
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p309
(lp310
I7
a(lp311
I10
atp312
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p313
(lp314
I7
a(lp315
I12
atp316
a(I-1
S'pRB , cyclin D , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .'
p317
(lp318
I10
a(lp319
I12
atp320
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p321
(lp322
I3
a(lp323
I5
atp324
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p325
(lp326
I3
a(lp327
I7
atp328
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p329
(lp330
I3
a(lp331
I10
atp332
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p333
(lp334
I3
a(lp335
I12
atp336
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p337
(lp338
I5
a(lp339
I7
atp340
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p341
(lp342
I5
a(lp343
I10
atp344
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p345
(lp346
I5
a(lp347
I12
atp348
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p349
(lp350
I7
a(lp351
I10
atp352
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p353
(lp354
I7
a(lp355
I12
atp356
a(I-1
S'We find that p53 , p21 ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre - senescent growth arrest , then return to low proliferating levels at terminal senescence .'
p357
(lp358
I10
a(lp359
I12
atp360
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p361
(lp362
I2
a(lp363
I4
atp364
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p365
(lp366
I2
a(lp367
I6
atp368
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p369
(lp370
I2
a(lp371
I9
atp372
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p373
(lp374
I2
a(lp375
I11
atp376
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p377
(lp378
I2
a(lp379
I14
atp380
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p381
(lp382
I2
a(lp383
I16
atp384
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p385
(lp386
I2
a(lp387
I20
atp388
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p389
(lp390
I2
a(lp391
I22
atp392
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p393
(lp394
I4
a(lp395
I6
atp396
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p397
(lp398
I4
a(lp399
I9
atp400
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p401
(lp402
I4
a(lp403
I11
atp404
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p405
(lp406
I4
a(lp407
I14
atp408
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p409
(lp410
I4
a(lp411
I16
atp412
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p413
(lp414
I4
a(lp415
I20
atp416
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p417
(lp418
I4
a(lp419
I22
atp420
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p421
(lp422
I6
a(lp423
I9
atp424
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p425
(lp426
I6
a(lp427
I11
atp428
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p429
(lp430
I6
a(lp431
I14
atp432
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p433
(lp434
I6
a(lp435
I16
atp436
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p437
(lp438
I6
a(lp439
I20
atp440
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p441
(lp442
I6
a(lp443
I22
atp444
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p445
(lp446
I9
a(lp447
I11
atp448
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p449
(lp450
I9
a(lp451
I14
atp452
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p453
(lp454
I9
a(lp455
I16
atp456
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p457
(lp458
I9
a(lp459
I20
atp460
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p461
(lp462
I9
a(lp463
I22
atp464
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p465
(lp466
I11
a(lp467
I14
atp468
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p469
(lp470
I11
a(lp471
I16
atp472
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p473
(lp474
I11
a(lp475
I20
atp476
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p477
(lp478
I11
a(lp479
I22
atp480
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p481
(lp482
I14
a(lp483
I16
atp484
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p485
(lp486
I14
a(lp487
I20
atp488
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p489
(lp490
I14
a(lp491
I22
atp492
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p493
(lp494
I16
a(lp495
I20
atp496
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p497
(lp498
I16
a(lp499
I22
atp500
a(I-1
S'Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non - tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .'
p501
(lp502
I20
a(lp503
I22
atp504
a(I-1
S'Positive inotropic responses mediated by endothelin ET ( A ) and ET ( B ) receptors in human myocardial trabeculae .'
p505
(lp506
I6
aI7
aI8
aI9
a(lp507
I11
aI12
aI13
aI14
atp508
a(I-1
S'The aim of the present study was to determine possible inotropic effects mediated by endothelin ET ( A ) and ET ( B ) receptors in human myocardial trabeculae from the right atrium and the left ventricle .'
p509
(lp510
I15
aI16
aI17
aI18
a(lp511
I20
aI21
aI22
aI23
atp512
a(I-1
S'Endothelin - 1 ( ET - 1 ) and ET - 3 had a strong positive inotropic effect in all trabeculae .'
p513
(lp514
I0
aI1
aI2
a(lp515
I4
aI5
aI6
atp516
a(I-1
S'Endothelin - 1 ( ET - 1 ) and ET - 3 had a strong positive inotropic effect in all trabeculae .'
p517
(lp518
I0
aI1
aI2
a(lp519
I9
aI10
aI11
atp520
a(I-1
S'Endothelin - 1 ( ET - 1 ) and ET - 3 had a strong positive inotropic effect in all trabeculae .'
p521
(lp522
I4
aI5
aI6
a(lp523
I9
aI10
aI11
atp524
a(I-1
S'ET - 1 was significantly more potent than ET - 3 in both atrial ( P < 0 . 001 ) and ventricular ( P < 0 . 05 ) trabeculae .'
p525
(lp526
I0
aI1
aI2
a(lp527
I8
aI9
aI10
atp528
a(I-1
S'Preincubation with the ET ( A ) receptor antagonist FR139317 ( 1 microM ) decreased significantly ( P < 0 . 005 ) the potency of ET - I in both atrial and ventricular trabeculae , without any significant changes in Emax ( maximum effect obtained with an agonist ) .'
p529
(lp530
I3
aI4
aI5
aI6
aI7
a(lp531
I26
aI27
aI28
atp532
a(I-1
S'The ET ( B ) receptor agonist IRL 1620 had a positive inotropic effect only in some trabeculae , and the ET ( B ) receptor antagonist BQ 788 ( 1 microM ) almost completely blocked this effect .'
p533
(lp534
I1
aI2
aI3
aI4
aI5
a(lp535
I21
aI22
aI23
aI24
aI25
atp536
a(I-1
S'These results suggest that both ET ( A ) and ET ( B ) receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart .'
p537
(lp538
I5
aI6
aI7
aI8
a(lp539
I10
aI11
aI12
aI13
atp540
a(I-1
S'Apoptotic proteins . p53 and c - myc related pathways .'
p541
(lp542
I3
a(lp543
I5
aI6
aI7
atp544
a(I-1
S'c - Myc and p53 are two proteins that have critical roles in the regulation of apoptosis and the cell cycle .'
p545
(lp546
I0
aI1
aI2
a(lp547
I4
atp548
a(I-1
S'A comparative study of E - cadherin and stromelysin - 3 expression in de novo and ex adenoma carcinoma of the colorectum .'
p549
(lp550
I4
aI5
aI6
a(lp551
I8
aI9
aI10
atp552
a(I-1
S'The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule ( E - cadherin ) and protease [ stromelysin - 3 ( ST - 3 ) ] expression in groups of de novo ( n = 64 ) and ex adenoma ( n = 42 ) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression .'
p553
(lp554
I17
aI18
aI19
a(lp555
I24
aI25
aI26
atp556
a(I-1
S'The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule ( E - cadherin ) and protease [ stromelysin - 3 ( ST - 3 ) ] expression in groups of de novo ( n = 64 ) and ex adenoma ( n = 42 ) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression .'
p557
(lp558
I17
aI18
aI19
a(lp559
I28
aI29
aI30
atp560
a(I-1
S'The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule ( E - cadherin ) and protease [ stromelysin - 3 ( ST - 3 ) ] expression in groups of de novo ( n = 64 ) and ex adenoma ( n = 42 ) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression .'
p561
(lp562
I24
aI25
aI26
a(lp563
I28
aI29
aI30
atp564
a(I-1
S'The rates of extensive ST - 3 expression and decreased E - cadherin expression were significantly higher in the de novo group ( P = 0 . 014 and 0 . 005 , respectively ) .'
p565
(lp566
I4
aI5
aI6
a(lp567
I10
aI11
aI12
atp568
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p569
(lp570
I11
aI12
aI13
a(lp571
I15
atp572
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p573
(lp574
I11
aI12
aI13
a(lp575
I17
atp576
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p577
(lp578
I11
aI12
aI13
a(lp579
I19
atp580
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p581
(lp582
I11
aI12
aI13
a(lp583
I21
atp584
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p585
(lp586
I15
a(lp587
I17
atp588
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p589
(lp590
I15
a(lp591
I19
atp592
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p593
(lp594
I15
a(lp595
I21
atp596
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p597
(lp598
I17
a(lp599
I19
atp600
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p601
(lp602
I17
a(lp603
I21
atp604
a(I-1
S'Genetic profile of 22 pancreatic carcinoma cell lines . Analysis of K - ras , p53 , p16 and DPC4 / Smad4 .'
p605
(lp606
I19
a(lp607
I21
atp608
a(I-1
S'The K - ras , p53 , p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma .'
p609
(lp610
I1
aI2
aI3
a(lp611
I5
atp612
a(I-1
S'The K - ras , p53 , p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma .'
p613
(lp614
I1
aI2
aI3
a(lp615
I7
atp616
a(I-1
S'The K - ras , p53 , p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma .'
p617
(lp618
I1
aI2
aI3
a(lp619
I9
atp620
a(I-1
S'The K - ras , p53 , p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma .'
p621
(lp622
I5
a(lp623
I7
atp624
a(I-1
S'The K - ras , p53 , p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma .'
p625
(lp626
I5
a(lp627
I9
atp628
a(I-1
S'The K - ras , p53 , p16 and DPC4 genes are among those most frequently altered in pancreatic ductal carcinoma .'
p629
(lp630
I7
a(lp631
I9
atp632
a(I-1
S'These cell lines showed mutations in K - ras and p53 at frequencies of 91 % and 95 % , respectively .'
p633
(lp634
I6
aI7
aI8
a(lp635
I10
atp636
a(I-1
S'The most typical mutational profile involved K - ras , p53 , and p16INK4a , concurrently aberrated in 20 cases ( 91 % ) .'
p637
(lp638
I6
aI7
aI8
a(lp639
I10
atp640
a(I-1
S'The most typical mutational profile involved K - ras , p53 , and p16INK4a , concurrently aberrated in 20 cases ( 91 % ) .'
p641
(lp642
I6
aI7
aI8
a(lp643
I13
atp644
a(I-1
S'The most typical mutational profile involved K - ras , p53 , and p16INK4a , concurrently aberrated in 20 cases ( 91 % ) .'
p645
(lp646
I10
a(lp647
I13
atp648
a(I-1
S'We investigated the mechanism of calcium - stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium - sensing receptor ( CaR ) .'
p649
(lp650
I8
a(lp651
I21
aI22
aI23
aI24
atp652
a(I-1
S'We investigated the mechanism of calcium - stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium - sensing receptor ( CaR ) .'
p653
(lp654
I8
a(lp655
I26
atp656
a(I-1
S'We investigated the mechanism of calcium - stimulated gastrin release from gastrinoma cells in vitro with a particular focus on the calcium - sensing receptor ( CaR ) .'
p657
(lp658
I21
aI22
aI23
aI24
a(lp659
I26
atp660
a(I-1
S'Our results demonstrated that CaR was expressed in human gastrinoma cells and could be involved in the mechanism of calcium - evoked gastrin release .'
p661
(lp662
I4
a(lp663
I22
atp664
a(I-1
S'BMP - 4 and BMP - 6 involvement in the osteogenic properties of the HeLa cell line .'
p665
(lp666
I0
aI1
aI2
a(lp667
I4
aI5
aI6
atp668
a(I-1
S'We postulate that the mechanism of bone induction is based on the secretion of bone morphogenetic proteins BMP - 4 and BMP - 6 by the grafted HeLa cells .'
p669
(lp670
I17
aI18
aI19
a(lp671
I21
aI22
aI23
atp672
a(I-1
S'BACKGROUND : To elucidate the relationship between the expression of epidermal growth factor receptor family members ( ErbB - 1 , neu / ErbB - 2 , ErbB - 3 , and ErbB - 4 ) and tumor recurrence .'
p673
(lp674
I17
aI18
aI19
a(lp675
I23
aI24
aI25
atp676
a(I-1
S'BACKGROUND : To elucidate the relationship between the expression of epidermal growth factor receptor family members ( ErbB - 1 , neu / ErbB - 2 , ErbB - 3 , and ErbB - 4 ) and tumor recurrence .'
p677
(lp678
I17
aI18
aI19
a(lp679
I27
aI28
aI29
atp680
a(I-1
S'BACKGROUND : To elucidate the relationship between the expression of epidermal growth factor receptor family members ( ErbB - 1 , neu / ErbB - 2 , ErbB - 3 , and ErbB - 4 ) and tumor recurrence .'
p681
(lp682
I17
aI18
aI19
a(lp683
I32
aI33
aI34
atp684
a(I-1
S'BACKGROUND : To elucidate the relationship between the expression of epidermal growth factor receptor family members ( ErbB - 1 , neu / ErbB - 2 , ErbB - 3 , and ErbB - 4 ) and tumor recurrence .'
p685
(lp686
I23
aI24
aI25
a(lp687
I27
aI28
aI29
atp688
a(I-1
S'BACKGROUND : To elucidate the relationship between the expression of epidermal growth factor receptor family members ( ErbB - 1 , neu / ErbB - 2 , ErbB - 3 , and ErbB - 4 ) and tumor recurrence .'
p689
(lp690
I23
aI24
aI25
a(lp691
I32
aI33
aI34
atp692
a(I-1
S'BACKGROUND : To elucidate the relationship between the expression of epidermal growth factor receptor family members ( ErbB - 1 , neu / ErbB - 2 , ErbB - 3 , and ErbB - 4 ) and tumor recurrence .'
p693
(lp694
I27
aI28
aI29
a(lp695
I32
aI33
aI34
atp696
a(I-1
S'RESULTS : Using Cox univariate analysis , we determined that angiolymphatic tumor emboli and non - well - differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence , and that ErbB - 1 and ErbB - 3 were also significant predictors .'
p697
(lp698
I33
aI34
aI35
a(lp699
I37
aI38
aI39
atp700
a(I-1
S'Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis : a comparative analysis of serum and blister fluid samples .'
p701
(lp702
I1
aI2
a(lp703
I1
aI2
aI3
atp704
a(I-1
S'Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis : a comparative analysis of serum and blister fluid samples .'
p705
(lp706
I1
aI2
a(lp707
I5
aI6
atp708
a(I-1
S'Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis : a comparative analysis of serum and blister fluid samples .'
p709
(lp710
I1
aI2
aI3
a(lp711
I5
aI6
atp712
a(I-1
S'MAIN OUTCOME MEASURES : Measurement of soluble interleukin ( IL ) 2 receptor ( sIL - 2R ) and IL - 1alpha in serum samples and fluid of recent blisters .'
p713
(lp714
I7
aI8
aI9
aI10
aI11
aI12
a(lp715
I14
aI15
aI16
atp716
a(I-1
S'MAIN OUTCOME MEASURES : Measurement of soluble interleukin ( IL ) 2 receptor ( sIL - 2R ) and IL - 1alpha in serum samples and fluid of recent blisters .'
p717
(lp718
I7
aI8
aI9
aI10
aI11
aI12
a(lp719
I19
aI20
aI21
atp720
a(I-1
S'MAIN OUTCOME MEASURES : Measurement of soluble interleukin ( IL ) 2 receptor ( sIL - 2R ) and IL - 1alpha in serum samples and fluid of recent blisters .'
p721
(lp722
I14
aI15
aI16
a(lp723
I19
aI20
aI21
atp724
a(I-1
S'RESULTS : In the blister fluid of patients with TEN , we found significantly higher levels of sIL - 2R than in patients with burns , whereas IL - 1alpha levels were higher in the blister fluid of burned patients .'
p725
(lp726
I17
aI18
aI19
a(lp727
I27
aI28
aI29
atp728
a(I-1
S'No significant differences were found in serum samples of patients with TEN and burns , in either sIL - 2R or IL - 1alpha .'
p729
(lp730
I17
aI18
aI19
a(lp731
I21
aI22
aI23
atp732
a(I-1
S'In TEN we also found significantly higher levels of sIL - 2R in the blister fluid compared with serum samples , pointing to a predominantly local production contrasting with the low concentration of sIL - 2R in the blister fluid of burned patients .'
p733
(lp734
I9
aI10
aI11
a(lp735
I33
aI34
aI35
atp736
a(I-1
S'We performed cell - free in vitro infection of primary bone marrow derived CD34 + cells using semi - purified HHV8 and a mature IL - 2 dependent T cell line , KIT 225 , using highly concentrated viral stocks prepared from an infectious molecular clone of HTLV - 1 .'
p737
(lp738
I13
a(lp739
I24
aI25
aI26
atp740
a(I-1
S'Of these 400 , interferon regulatory factor 4 ( IRF4 ) , cyclin B2 , TBP - associated factor , eukaryotic elongation factor and pim 2 were up - regulated more than 3 . 5 fold .'
p741
(lp742
I4
aI5
aI6
aI7
a(lp743
I9
atp744
a(I-1
S'Of these 400 , interferon regulatory factor 4 ( IRF4 ) , cyclin B2 , TBP - associated factor , eukaryotic elongation factor and pim 2 were up - regulated more than 3 . 5 fold .'
p745
(lp746
I4
aI5
aI6
aI7
a(lp747
I12
aI13
atp748
a(I-1
S'Of these 400 , interferon regulatory factor 4 ( IRF4 ) , cyclin B2 , TBP - associated factor , eukaryotic elongation factor and pim 2 were up - regulated more than 3 . 5 fold .'
p749
(lp750
I4
aI5
aI6
aI7
a(lp751
I24
aI25
atp752
a(I-1
S'Of these 400 , interferon regulatory factor 4 ( IRF4 ) , cyclin B2 , TBP - associated factor , eukaryotic elongation factor and pim 2 were up - regulated more than 3 . 5 fold .'
p753
(lp754
I9
a(lp755
I12
aI13
atp756
a(I-1
S'Of these 400 , interferon regulatory factor 4 ( IRF4 ) , cyclin B2 , TBP - associated factor , eukaryotic elongation factor and pim 2 were up - regulated more than 3 . 5 fold .'
p757
(lp758
I9
a(lp759
I24
aI25
atp760
a(I-1
S'Of these 400 , interferon regulatory factor 4 ( IRF4 ) , cyclin B2 , TBP - associated factor , eukaryotic elongation factor and pim 2 were up - regulated more than 3 . 5 fold .'
p761
(lp762
I12
aI13
a(lp763
I24
aI25
atp764
a(I-1
S'Concentrations of glial fibrillary acidic protein ( GFAp ) and light subunit neurofilament protein ( NFL ) in cerebrospinal fluid ( CSF ) were measured in patients with second - stage Trypanosoma brucei gambiense sleeping sickness .'
p765
(lp766
I2
aI3
aI4
aI5
a(lp767
I7
atp768
a(I-1
S'Concentrations of glial fibrillary acidic protein ( GFAp ) and light subunit neurofilament protein ( NFL ) in cerebrospinal fluid ( CSF ) were measured in patients with second - stage Trypanosoma brucei gambiense sleeping sickness .'
p769
(lp770
I2
aI3
aI4
aI5
a(lp771
I10
aI11
aI12
aI13
atp772
a(I-1
S'Concentrations of glial fibrillary acidic protein ( GFAp ) and light subunit neurofilament protein ( NFL ) in cerebrospinal fluid ( CSF ) were measured in patients with second - stage Trypanosoma brucei gambiense sleeping sickness .'
p773
(lp774
I2
aI3
aI4
aI5
a(lp775
I15
atp776
a(I-1
S'Concentrations of glial fibrillary acidic protein ( GFAp ) and light subunit neurofilament protein ( NFL ) in cerebrospinal fluid ( CSF ) were measured in patients with second - stage Trypanosoma brucei gambiense sleeping sickness .'
p777
(lp778
I7
a(lp779
I10
aI11
aI12
aI13
atp780
a(I-1
S'Concentrations of glial fibrillary acidic protein ( GFAp ) and light subunit neurofilament protein ( NFL ) in cerebrospinal fluid ( CSF ) were measured in patients with second - stage Trypanosoma brucei gambiense sleeping sickness .'
p781
(lp782
I7
a(lp783
I15
atp784
a(I-1
S'Concentrations of glial fibrillary acidic protein ( GFAp ) and light subunit neurofilament protein ( NFL ) in cerebrospinal fluid ( CSF ) were measured in patients with second - stage Trypanosoma brucei gambiense sleeping sickness .'
p785
(lp786
I10
aI11
aI12
aI13
a(lp787
I15
atp788
a(I-1
S'Correlations between GFAp and NFL in CSF as markers for astrogliosis and neurodegeneration , and clinical and biological data were investigated .'
p789
(lp790
I2
a(lp791
I4
atp792
a(I-1
S'Abnormal levels of GFAp and NFL were significantly associated with increasing CSF cell number and protein concentration , and with the absence of lymph nodes or the absence of trypanosomes in lymph node aspirate .'
p793
(lp794
I3
a(lp795
I5
atp796
a(I-1
S'We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti - inflammatory cytokines within the prostate , namely interleukin ( IL ) - 8 , interferon - gamma and IL - 2 versus IL - 10 .'
p797
(lp798
I29
aI30
aI31
aI32
aI33
aI34
a(lp799
I36
aI37
aI38
atp800
a(I-1
S'We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti - inflammatory cytokines within the prostate , namely interleukin ( IL ) - 8 , interferon - gamma and IL - 2 versus IL - 10 .'
p801
(lp802
I29
aI30
aI31
aI32
aI33
aI34
a(lp803
I40
aI41
aI42
atp804
a(I-1
S'We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti - inflammatory cytokines within the prostate , namely interleukin ( IL ) - 8 , interferon - gamma and IL - 2 versus IL - 10 .'
p805
(lp806
I29
aI30
aI31
aI32
aI33
aI34
a(lp807
I44
aI45
aI46
atp808
a(I-1
S'We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti - inflammatory cytokines within the prostate , namely interleukin ( IL ) - 8 , interferon - gamma and IL - 2 versus IL - 10 .'
p809
(lp810
I36
aI37
aI38
a(lp811
I40
aI41
aI42
atp812
a(I-1
S'We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti - inflammatory cytokines within the prostate , namely interleukin ( IL ) - 8 , interferon - gamma and IL - 2 versus IL - 10 .'
p813
(lp814
I36
aI37
aI38
a(lp815
I44
aI45
aI46
atp816
a(I-1
S'We investigated whether the chronic inflammation and pain experienced by patients may be caused by an imbalance of proinflammatory versus anti - inflammatory cytokines within the prostate , namely interleukin ( IL ) - 8 , interferon - gamma and IL - 2 versus IL - 10 .'
p817
(lp818
I40
aI41
aI42
a(lp819
I44
aI45
aI46
atp820
a(I-1
S'MATERIALS AND METHODS : We measured levels of IL - 8 , interferon - gamma , IL - 2 and IL - 10 in the seminal plasma of 31 patients with chronic prostatitis - chronic pelvic pain syndrome and 14 controls using enzyme - linked immunosorbent assay .'
p821
(lp822
I8
aI9
aI10
a(lp823
I12
aI13
aI14
atp824
a(I-1
S'MATERIALS AND METHODS : We measured levels of IL - 8 , interferon - gamma , IL - 2 and IL - 10 in the seminal plasma of 31 patients with chronic prostatitis - chronic pelvic pain syndrome and 14 controls using enzyme - linked immunosorbent assay .'
p825
(lp826
I8
aI9
aI10
a(lp827
I16
aI17
aI18
atp828
a(I-1
S'MATERIALS AND METHODS : We measured levels of IL - 8 , interferon - gamma , IL - 2 and IL - 10 in the seminal plasma of 31 patients with chronic prostatitis - chronic pelvic pain syndrome and 14 controls using enzyme - linked immunosorbent assay .'
p829
(lp830
I8
aI9
aI10
a(lp831
I20
aI21
aI22
atp832
a(I-1
S'MATERIALS AND METHODS : We measured levels of IL - 8 , interferon - gamma , IL - 2 and IL - 10 in the seminal plasma of 31 patients with chronic prostatitis - chronic pelvic pain syndrome and 14 controls using enzyme - linked immunosorbent assay .'
p833
(lp834
I12
aI13
aI14
a(lp835
I16
aI17
aI18
atp836
a(I-1
S'MATERIALS AND METHODS : We measured levels of IL - 8 , interferon - gamma , IL - 2 and IL - 10 in the seminal plasma of 31 patients with chronic prostatitis - chronic pelvic pain syndrome and 14 controls using enzyme - linked immunosorbent assay .'
p837
(lp838
I12
aI13
aI14
a(lp839
I20
aI21
aI22
atp840
a(I-1
S'MATERIALS AND METHODS : We measured levels of IL - 8 , interferon - gamma , IL - 2 and IL - 10 in the seminal plasma of 31 patients with chronic prostatitis - chronic pelvic pain syndrome and 14 controls using enzyme - linked immunosorbent assay .'
p841
(lp842
I16
aI17
aI18
a(lp843
I20
aI21
aI22
atp844
a(I-1
S'Interferon - gamma , IL - 2 and IL - 10 levels were statistically greater in patients .'
p845
(lp846
I0
aI1
aI2
a(lp847
I4
aI5
aI6
atp848
a(I-1
S'Interferon - gamma , IL - 2 and IL - 10 levels were statistically greater in patients .'
p849
(lp850
I0
aI1
aI2
a(lp851
I8
aI9
aI10
atp852
a(I-1
S'Interferon - gamma , IL - 2 and IL - 10 levels were statistically greater in patients .'
p853
(lp854
I4
aI5
aI6
a(lp855
I8
aI9
aI10
atp856
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p857
(lp858
I9
aI10
a(lp859
I12
atp860
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p861
(lp862
I9
aI10
a(lp863
I15
aI16
aI17
aI18
aI19
aI20
atp864
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p865
(lp866
I9
aI10
a(lp867
I22
atp868
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p869
(lp870
I9
aI10
a(lp871
I26
aI27
aI28
atp872
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p873
(lp874
I9
aI10
a(lp875
I30
atp876
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p877
(lp878
I12
a(lp879
I15
aI16
aI17
aI18
aI19
aI20
atp880
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p881
(lp882
I12
a(lp883
I22
atp884
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p885
(lp886
I12
a(lp887
I26
aI27
aI28
atp888
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p889
(lp890
I12
a(lp891
I30
atp892
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p893
(lp894
I15
aI16
aI17
aI18
aI19
aI20
a(lp895
I22
atp896
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p897
(lp898
I15
aI16
aI17
aI18
aI19
aI20
a(lp899
I26
aI27
aI28
atp900
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p901
(lp902
I15
aI16
aI17
aI18
aI19
aI20
a(lp903
I30
atp904
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p905
(lp906
I22
a(lp907
I26
aI27
aI28
atp908
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p909
(lp910
I22
a(lp911
I30
atp912
a(I-1
S'METHODS : The genes for dopamine synthetic enzymes , tyrosine hydroxylase ( TH ) , aromatic L - amino acid decarboxylase ( AADC ) , and GTP cyclohydrolase I ( GCH , an enzyme critical for tetrahydrobiopterin synthesis ) were contransduced into 293 cells with separate AAV vectors .'
p913
(lp914
I26
aI27
aI28
a(lp915
I30
atp916
a(I-1
S'Expressions of TH , AADC and GCH were detected by Western blot analysis .'
p917
(lp918
I2
a(lp919
I4
atp920
a(I-1
S'Expressions of TH , AADC and GCH were detected by Western blot analysis .'
p921
(lp922
I2
a(lp923
I6
atp924
a(I-1
S'Expressions of TH , AADC and GCH were detected by Western blot analysis .'
p925
(lp926
I4
a(lp927
I6
atp928
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p929
(lp930
I2
a(lp931
I4
atp932
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p933
(lp934
I2
a(lp935
I6
atp936
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p937
(lp938
I2
a(lp939
I21
atp940
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p941
(lp942
I2
a(lp943
I25
atp944
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p945
(lp946
I2
a(lp947
I29
atp948
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p949
(lp950
I4
a(lp951
I6
atp952
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p953
(lp954
I4
a(lp955
I21
atp956
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p957
(lp958
I4
a(lp959
I25
atp960
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p961
(lp962
I4
a(lp963
I29
atp964
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p965
(lp966
I6
a(lp967
I21
atp968
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p969
(lp970
I6
a(lp971
I25
atp972
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p973
(lp974
I6
a(lp975
I29
atp976
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p977
(lp978
I21
a(lp979
I25
atp980
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p981
(lp982
I21
a(lp983
I29
atp984
a(I-1
S'RESULTS : TH , AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors , AAV - TH , AAV - AADC and AAV - GCH .'
p985
(lp986
I25
a(lp987
I29
atp988
a(I-1
S"CONCLUSION : The triple transduction of TH , AADC and GCH genes with separate AAV vectors is effective , which might be important to gene therapy for Parkinson ' s disease ."
p989
(lp990
I6
a(lp991
I8
atp992
a(I-1
S"CONCLUSION : The triple transduction of TH , AADC and GCH genes with separate AAV vectors is effective , which might be important to gene therapy for Parkinson ' s disease ."
p993
(lp994
I6
a(lp995
I10
atp996
a(I-1
S"CONCLUSION : The triple transduction of TH , AADC and GCH genes with separate AAV vectors is effective , which might be important to gene therapy for Parkinson ' s disease ."
p997
(lp998
I8
a(lp999
I10
atp1000
a(I-1
S'This overview summarizes the current knowledge on plasminogen activator inhibitor - 1 ( PAI - 1 ) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation .'
p1001
(lp1002
I7
aI8
aI9
aI10
aI11
a(lp1003
I13
aI14
aI15
atp1004
a(I-1
S'In addition , a possible role for Gas6 , the product of growth arrest - specific gene 6 , in atherosclerotic lesion development is put into perspective .'
p1005
(lp1006
I7
a(lp1007
I12
aI13
aI14
aI15
aI16
aI17
atp1008
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1009
(lp1010
I1
aI2
aI3
a(lp1011
I5
aI6
aI7
atp1012
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1013
(lp1014
I1
aI2
aI3
a(lp1015
I9
aI10
aI11
atp1016
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1017
(lp1018
I1
aI2
aI3
a(lp1019
I13
aI14
aI15
atp1020
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1021
(lp1022
I1
aI2
aI3
a(lp1023
I17
aI18
aI19
atp1024
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1025
(lp1026
I1
aI2
aI3
a(lp1027
I26
aI27
aI28
atp1028
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1029
(lp1030
I1
aI2
aI3
a(lp1031
I31
aI32
aI33
aI34
atp1032
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1033
(lp1034
I1
aI2
aI3
a(lp1035
I36
atp1036
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1037
(lp1038
I1
aI2
aI3
a(lp1039
I41
aI42
aI43
atp1040
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1041
(lp1042
I1
aI2
aI3
a(lp1043
I45
aI46
aI47
atp1044
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1045
(lp1046
I1
aI2
aI3
a(lp1047
I50
aI51
aI52
atp1048
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1049
(lp1050
I5
aI6
aI7
a(lp1051
I9
aI10
aI11
atp1052
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1053
(lp1054
I5
aI6
aI7
a(lp1055
I13
aI14
aI15
atp1056
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1057
(lp1058
I5
aI6
aI7
a(lp1059
I17
aI18
aI19
atp1060
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1061
(lp1062
I5
aI6
aI7
a(lp1063
I26
aI27
aI28
atp1064
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1065
(lp1066
I5
aI6
aI7
a(lp1067
I31
aI32
aI33
aI34
atp1068
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1069
(lp1070
I5
aI6
aI7
a(lp1071
I36
atp1072
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1073
(lp1074
I5
aI6
aI7
a(lp1075
I41
aI42
aI43
atp1076
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1077
(lp1078
I5
aI6
aI7
a(lp1079
I45
aI46
aI47
atp1080
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1081
(lp1082
I5
aI6
aI7
a(lp1083
I50
aI51
aI52
atp1084
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1085
(lp1086
I9
aI10
aI11
a(lp1087
I13
aI14
aI15
atp1088
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1089
(lp1090
I9
aI10
aI11
a(lp1091
I17
aI18
aI19
atp1092
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1093
(lp1094
I9
aI10
aI11
a(lp1095
I26
aI27
aI28
atp1096
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1097
(lp1098
I9
aI10
aI11
a(lp1099
I31
aI32
aI33
aI34
atp1100
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1101
(lp1102
I9
aI10
aI11
a(lp1103
I36
atp1104
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1105
(lp1106
I9
aI10
aI11
a(lp1107
I41
aI42
aI43
atp1108
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1109
(lp1110
I9
aI10
aI11
a(lp1111
I45
aI46
aI47
atp1112
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1113
(lp1114
I9
aI10
aI11
a(lp1115
I50
aI51
aI52
atp1116
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1117
(lp1118
I13
aI14
aI15
a(lp1119
I17
aI18
aI19
atp1120
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1121
(lp1122
I13
aI14
aI15
a(lp1123
I26
aI27
aI28
atp1124
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1125
(lp1126
I13
aI14
aI15
a(lp1127
I31
aI32
aI33
aI34
atp1128
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1129
(lp1130
I13
aI14
aI15
a(lp1131
I36
atp1132
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1133
(lp1134
I13
aI14
aI15
a(lp1135
I41
aI42
aI43
atp1136
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1137
(lp1138
I13
aI14
aI15
a(lp1139
I45
aI46
aI47
atp1140
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1141
(lp1142
I13
aI14
aI15
a(lp1143
I50
aI51
aI52
atp1144
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1145
(lp1146
I17
aI18
aI19
a(lp1147
I26
aI27
aI28
atp1148
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1149
(lp1150
I17
aI18
aI19
a(lp1151
I31
aI32
aI33
aI34
atp1152
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1153
(lp1154
I17
aI18
aI19
a(lp1155
I36
atp1156
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1157
(lp1158
I17
aI18
aI19
a(lp1159
I41
aI42
aI43
atp1160
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1161
(lp1162
I17
aI18
aI19
a(lp1163
I45
aI46
aI47
atp1164
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1165
(lp1166
I17
aI18
aI19
a(lp1167
I50
aI51
aI52
atp1168
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1169
(lp1170
I26
aI27
aI28
a(lp1171
I31
aI32
aI33
aI34
atp1172
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1173
(lp1174
I26
aI27
aI28
a(lp1175
I36
atp1176
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1177
(lp1178
I26
aI27
aI28
a(lp1179
I41
aI42
aI43
atp1180
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1181
(lp1182
I26
aI27
aI28
a(lp1183
I45
aI46
aI47
atp1184
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1185
(lp1186
I26
aI27
aI28
a(lp1187
I50
aI51
aI52
atp1188
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1189
(lp1190
I31
aI32
aI33
aI34
a(lp1191
I36
atp1192
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1193
(lp1194
I31
aI32
aI33
aI34
a(lp1195
I41
aI42
aI43
atp1196
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1197
(lp1198
I31
aI32
aI33
aI34
a(lp1199
I45
aI46
aI47
atp1200
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1201
(lp1202
I31
aI32
aI33
aI34
a(lp1203
I50
aI51
aI52
atp1204
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1205
(lp1206
I36
a(lp1207
I41
aI42
aI43
atp1208
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1209
(lp1210
I36
a(lp1211
I45
aI46
aI47
atp1212
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1213
(lp1214
I36
a(lp1215
I50
aI51
aI52
atp1216
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1217
(lp1218
I41
aI42
aI43
a(lp1219
I45
aI46
aI47
atp1220
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1221
(lp1222
I41
aI42
aI43
a(lp1223
I50
aI51
aI52
atp1224
a(I-1
S'Cytokines IL - 1alpha , IL - 1beta , IL - 6 , IL - 8 , IL - 10 ( Immunotech , France ) , endothelin - 1 , and soluble cell adhesion molecules ( sCAM ) sP - and sE - selectin , sICAM - 1 , and sVCAM - 1 ( R & D , UK ) have been determined using ELISA kits ( photometer , Biomek - 1000 , Beckman , USA ) .'
p1225
(lp1226
I45
aI46
aI47
a(lp1227
I50
aI51
aI52
atp1228
a(I-1
S'Endothelin - 1 and sP - and sE - selectin levels were not related to function of lymphocytes ( by MDM data ) as seen in both tests ; it is probable that another cell - cell communication mechanism had been switched on .'
p1229
(lp1230
I0
aI1
aI2
a(lp1231
I7
aI8
aI9
atp1232
a(I-1
S'We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL - 1beta , IL - 6 , and IL - 10 , which are the active participants in the pro - and anti - inflammatory program in atherogenesis .'
p1233
(lp1234
I15
aI16
aI17
a(lp1235
I19
aI20
aI21
atp1236
a(I-1
S'We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL - 1beta , IL - 6 , and IL - 10 , which are the active participants in the pro - and anti - inflammatory program in atherogenesis .'
p1237
(lp1238
I15
aI16
aI17
a(lp1239
I24
aI25
aI26
atp1240
a(I-1
S'We established a strong correlation between chromatin activity of lymphocytes and the serum concentration of IL - 1beta , IL - 6 , and IL - 10 , which are the active participants in the pro - and anti - inflammatory program in atherogenesis .'
p1241
(lp1242
I19
aI20
aI21
a(lp1243
I24
aI25
aI26
atp1244
a(I-1
S'Several genes are involved in this process , and two have been the focus of recent interest : the natural resistance - associated protein ( NRAMP1 ) gene and the genes coding for the vitamin D receptor .'
p1245
(lp1246
I19
aI20
aI21
aI22
aI23
a(lp1247
I25
atp1248
a(I-1
S'Several genes are involved in this process , and two have been the focus of recent interest : the natural resistance - associated protein ( NRAMP1 ) gene and the genes coding for the vitamin D receptor .'
p1249
(lp1250
I19
aI20
aI21
aI22
aI23
a(lp1251
I34
aI35
aI36
atp1252
a(I-1
S'Several genes are involved in this process , and two have been the focus of recent interest : the natural resistance - associated protein ( NRAMP1 ) gene and the genes coding for the vitamin D receptor .'
p1253
(lp1254
I25
a(lp1255
I34
aI35
aI36
atp1256
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1257
(lp1258
I22
aI23
aI24
aI25
aI26
aI27
aI28
a(lp1259
I32
aI33
aI34
aI35
aI36
aI37
aI38
atp1260
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1261
(lp1262
I22
aI23
aI24
aI25
aI26
aI27
aI28
a(lp1263
I42
aI43
aI44
aI45
aI46
atp1264
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1265
(lp1266
I22
aI23
aI24
aI25
aI26
aI27
aI28
a(lp1267
I52
aI53
atp1268
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1269
(lp1270
I22
aI23
aI24
aI25
aI26
aI27
aI28
a(lp1271
I56
atp1272
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1273
(lp1274
I22
aI23
aI24
aI25
aI26
aI27
aI28
a(lp1275
I70
aI71
aI72
aI73
aI74
aI75
aI76
aI77
aI78
atp1276
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1277
(lp1278
I32
aI33
aI34
aI35
aI36
aI37
aI38
a(lp1279
I42
aI43
aI44
aI45
aI46
atp1280
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1281
(lp1282
I32
aI33
aI34
aI35
aI36
aI37
aI38
a(lp1283
I52
aI53
atp1284
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1285
(lp1286
I32
aI33
aI34
aI35
aI36
aI37
aI38
a(lp1287
I56
atp1288
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1289
(lp1290
I32
aI33
aI34
aI35
aI36
aI37
aI38
a(lp1291
I70
aI71
aI72
aI73
aI74
aI75
aI76
aI77
aI78
atp1292
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1293
(lp1294
I42
aI43
aI44
aI45
aI46
a(lp1295
I52
aI53
atp1296
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1297
(lp1298
I42
aI43
aI44
aI45
aI46
a(lp1299
I56
atp1300
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1301
(lp1302
I42
aI43
aI44
aI45
aI46
a(lp1303
I70
aI71
aI72
aI73
aI74
aI75
aI76
aI77
aI78
atp1304
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1305
(lp1306
I52
aI53
a(lp1307
I56
atp1308
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1309
(lp1310
I52
aI53
a(lp1311
I70
aI71
aI72
aI73
aI74
aI75
aI76
aI77
aI78
atp1312
a(I-1
S'Accordingly , a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors ( TNF ) alpha and beta , transforming growth factors ( TGF ) beta1 and 2 , interleukin ( IL ) 1 and its receptor antagonist ( IL 1ra ) , CD14 ( the receptor for lipopolysaccharide ) , P and E selectins , and platelet endothelial cell adhesion molecule ( PECAM ) 1 .'
p1313
(lp1314
I56
a(lp1315
I70
aI71
aI72
aI73
aI74
aI75
aI76
aI77
aI78
atp1316
a(I-1
S'Many of the same signaling molecules , including protein kinase C ( PKC ) , tyrosine kinase , phosphatidylinositol 3 - kinase ( P13 - K ) , and protein phosphatase , regulate the transporters for different neurotransmitters .'
p1317
(lp1318
I8
aI9
aI10
a(lp1319
I12
atp1320
a(I-1
S'Many of the same signaling molecules , including protein kinase C ( PKC ) , tyrosine kinase , phosphatidylinositol 3 - kinase ( P13 - K ) , and protein phosphatase , regulate the transporters for different neurotransmitters .'
p1321
(lp1322
I8
aI9
aI10
a(lp1323
I15
aI16
aI17
aI18
aI19
aI20
aI21
atp1324
a(I-1
S'Many of the same signaling molecules , including protein kinase C ( PKC ) , tyrosine kinase , phosphatidylinositol 3 - kinase ( P13 - K ) , and protein phosphatase , regulate the transporters for different neurotransmitters .'
p1325
(lp1326
I8
aI9
aI10
a(lp1327
I23
aI24
aI25
atp1328
a(I-1
S'Many of the same signaling molecules , including protein kinase C ( PKC ) , tyrosine kinase , phosphatidylinositol 3 - kinase ( P13 - K ) , and protein phosphatase , regulate the transporters for different neurotransmitters .'
p1329
(lp1330
I12
a(lp1331
I15
aI16
aI17
aI18
aI19
aI20
aI21
atp1332
a(I-1
S'Many of the same signaling molecules , including protein kinase C ( PKC ) , tyrosine kinase , phosphatidylinositol 3 - kinase ( P13 - K ) , and protein phosphatase , regulate the transporters for different neurotransmitters .'
p1333
(lp1334
I12
a(lp1335
I23
aI24
aI25
atp1336
a(I-1
S'Many of the same signaling molecules , including protein kinase C ( PKC ) , tyrosine kinase , phosphatidylinositol 3 - kinase ( P13 - K ) , and protein phosphatase , regulate the transporters for different neurotransmitters .'
p1337
(lp1338
I15
aI16
aI17
aI18
aI19
aI20
aI21
a(lp1339
I23
aI24
aI25
atp1340
a(I-1
S'Present data concerning the renin - angiotensin system of extrarenal origin .'
p1341
(lp1342
I4
a(lp1343
I6
atp1344
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1345
(lp1346
I6
a(lp1347
I16
atp1348
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1349
(lp1350
I6
a(lp1351
I23
atp1352
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1353
(lp1354
I6
a(lp1355
I25
atp1356
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1357
(lp1358
I6
a(lp1359
I29
aI30
atp1360
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1361
(lp1362
I6
a(lp1363
I38
atp1364
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1365
(lp1366
I16
a(lp1367
I23
atp1368
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1369
(lp1370
I16
a(lp1371
I25
atp1372
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1373
(lp1374
I16
a(lp1375
I29
aI30
atp1376
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1377
(lp1378
I16
a(lp1379
I38
atp1380
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1381
(lp1382
I23
a(lp1383
I25
atp1384
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1385
(lp1386
I23
a(lp1387
I29
aI30
atp1388
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1389
(lp1390
I23
a(lp1391
I38
atp1392
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1393
(lp1394
I25
a(lp1395
I29
aI30
atp1396
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1397
(lp1398
I25
a(lp1399
I38
atp1400
a(I-1
S'After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin - forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .'
p1401
(lp1402
I29
aI30
a(lp1403
I38
atp1404
a(I-1
S'In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system , regulating the major functions of the organism and maintaining the main homeostatic equilibria .'
p1405
(lp1406
I10
a(lp1407
I17
atp1408
a(I-1
S'In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system , regulating the major functions of the organism and maintaining the main homeostatic equilibria .'
p1409
(lp1410
I10
a(lp1411
I27
atp1412
a(I-1
S'In the end we refer to the relations between circulating RAS of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system , regulating the major functions of the organism and maintaining the main homeostatic equilibria .'
p1413
(lp1414
I17
a(lp1415
I27
atp1416
a(I-1
S'While the circulating RAS of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions , tissue RAS , in paracrine or autocrine ways , exerts local - regional adaptive actions of long duration .'
p1417
(lp1418
I3
a(lp1419
I22
atp1420
a(I-1
S'In the present study , we examined the presence of glucocorticoid receptors ( GRs ) and cyclooxygenase - 2 ( COX - 2 ) in the nasal polyps of nonallergic patients as compared with normal controls .'
p1421
(lp1422
I16
aI17
aI18
a(lp1423
I20
aI21
aI22
atp1424
a(I-1
S'In contrast , in normal nasal tissues , COX - 2 labeling was only found in the vascular wall , and the expression was weaker - - a finding demonstrating that COX - 2 is upregulated in nasal polyps .'
p1425
(lp1426
I8
aI9
aI10
a(lp1427
I31
aI32
aI33
atp1428
a(I-1
S'Therefore , 1 ) the presence of GRs and COX - 2 in nasal polyps from nonallergic patients , as well as upregulation of COX - 2 expression , suggests that inflammation may play an important role in the pathophysiology of nasal polyps ; and 2 ) glucocorticoid could be a potential treatment method for suppressing inflammatory processes .'
p1429
(lp1430
I9
aI10
aI11
a(lp1431
I24
aI25
aI26
atp1432
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1433
(lp1434
I11
aI12
a(lp1435
I14
atp1436
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1437
(lp1438
I11
aI12
a(lp1439
I16
atp1440
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1441
(lp1442
I11
aI12
a(lp1443
I18
aI19
aI20
aI21
atp1444
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1445
(lp1446
I11
aI12
a(lp1447
I23
atp1448
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1449
(lp1450
I11
aI12
a(lp1451
I25
atp1452
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1453
(lp1454
I11
aI12
a(lp1455
I27
atp1456
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1457
(lp1458
I11
aI12
a(lp1459
I29
atp1460
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1461
(lp1462
I11
aI12
a(lp1463
I32
atp1464
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1465
(lp1466
I14
a(lp1467
I16
atp1468
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1469
(lp1470
I14
a(lp1471
I18
aI19
aI20
aI21
atp1472
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1473
(lp1474
I14
a(lp1475
I23
atp1476
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1477
(lp1478
I14
a(lp1479
I25
atp1480
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1481
(lp1482
I14
a(lp1483
I27
atp1484
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1485
(lp1486
I14
a(lp1487
I29
atp1488
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1489
(lp1490
I14
a(lp1491
I32
atp1492
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1493
(lp1494
I16
a(lp1495
I18
aI19
aI20
aI21
atp1496
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1497
(lp1498
I16
a(lp1499
I23
atp1500
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1501
(lp1502
I16
a(lp1503
I25
atp1504
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1505
(lp1506
I16
a(lp1507
I27
atp1508
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1509
(lp1510
I16
a(lp1511
I29
atp1512
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1513
(lp1514
I16
a(lp1515
I32
atp1516
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1517
(lp1518
I18
aI19
aI20
aI21
a(lp1519
I23
atp1520
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1521
(lp1522
I18
aI19
aI20
aI21
a(lp1523
I25
atp1524
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1525
(lp1526
I18
aI19
aI20
aI21
a(lp1527
I27
atp1528
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1529
(lp1530
I18
aI19
aI20
aI21
a(lp1531
I29
atp1532
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1533
(lp1534
I18
aI19
aI20
aI21
a(lp1535
I32
atp1536
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1537
(lp1538
I23
a(lp1539
I25
atp1540
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1541
(lp1542
I23
a(lp1543
I27
atp1544
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1545
(lp1546
I23
a(lp1547
I29
atp1548
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1549
(lp1550
I23
a(lp1551
I32
atp1552
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1553
(lp1554
I25
a(lp1555
I27
atp1556
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1557
(lp1558
I25
a(lp1559
I29
atp1560
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1561
(lp1562
I25
a(lp1563
I32
atp1564
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1565
(lp1566
I27
a(lp1567
I29
atp1568
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1569
(lp1570
I27
a(lp1571
I32
atp1572
a(I-1
S'Comparison of messenger RNA gene expression of extracellular matrix proteins ( procollagen I , collagenase , elastin , hyaluronic acid synthase 2 , hyaluronidase , fibronectin , cd44 , fibromodulin , and decorin ) across cell passages ( 3 , 4 , 5 , 6 , 10 , and 12 fornormal laminapropria and 3 , 4 , 5 , 6 , and 10 for tracheal scar ) revealed varied growth patterns .'
p1573
(lp1574
I29
a(lp1575
I32
atp1576
a(I-1
S'Assaying of tumor necrosis factor alpha , complement factors , and alpha - 1 - antitrypsin in the diagnosis of malignant serous effusions .'
p1577
(lp1578
I2
aI3
aI4
aI5
a(lp1579
I11
aI12
aI13
aI14
aI15
atp1580
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1581
(lp1582
I11
aI12
aI13
aI14
aI15
a(lp1583
I17
atp1584
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1585
(lp1586
I11
aI12
aI13
aI14
aI15
a(lp1587
I31
atp1588
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1589
(lp1590
I11
aI12
aI13
aI14
aI15
a(lp1591
I33
aI34
aI35
aI36
aI37
atp1592
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1593
(lp1594
I11
aI12
aI13
aI14
aI15
a(lp1595
I39
atp1596
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1597
(lp1598
I11
aI12
aI13
aI14
aI15
a(lp1599
I45
atp1600
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1601
(lp1602
I11
aI12
aI13
aI14
aI15
a(lp1603
I47
atp1604
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1605
(lp1606
I17
a(lp1607
I31
atp1608
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1609
(lp1610
I17
a(lp1611
I33
aI34
aI35
aI36
aI37
atp1612
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1613
(lp1614
I17
a(lp1615
I39
atp1616
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1617
(lp1618
I17
a(lp1619
I45
atp1620
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1621
(lp1622
I17
a(lp1623
I47
atp1624
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1625
(lp1626
I31
a(lp1627
I33
aI34
aI35
aI36
aI37
atp1628
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1629
(lp1630
I31
a(lp1631
I39
atp1632
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1633
(lp1634
I31
a(lp1635
I45
atp1636
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1637
(lp1638
I31
a(lp1639
I47
atp1640
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1641
(lp1642
I33
aI34
aI35
aI36
aI37
a(lp1643
I39
atp1644
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1645
(lp1646
I33
aI34
aI35
aI36
aI37
a(lp1647
I45
atp1648
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1649
(lp1650
I33
aI34
aI35
aI36
aI37
a(lp1651
I47
atp1652
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1653
(lp1654
I39
a(lp1655
I45
atp1656
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1657
(lp1658
I39
a(lp1659
I47
atp1660
a(I-1
S'The objective of this study was to measure the concentrations of tumor necrosis factor - alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha - 1 - antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .'
p1661
(lp1662
I45
a(lp1663
I47
atp1664
a(I-1
S'TNFalpha , alpha1AT , and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .'
p1665
(lp1666
I0
a(lp1667
I2
atp1668
a(I-1
S'TNFalpha , alpha1AT , and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .'
p1669
(lp1670
I0
a(lp1671
I7
atp1672
a(I-1
S'TNFalpha , alpha1AT , and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .'
p1673
(lp1674
I0
a(lp1675
I9
atp1676
a(I-1
S'TNFalpha , alpha1AT , and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .'
p1677
(lp1678
I2
a(lp1679
I7
atp1680
a(I-1
S'TNFalpha , alpha1AT , and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .'
p1681
(lp1682
I2
a(lp1683
I9
atp1684
a(I-1
S'TNFalpha , alpha1AT , and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .'
p1685
(lp1686
I7
a(lp1687
I9
atp1688
a(I-1
S'Their order of selection was alpha1AT effusion , C4 serum , TNFalpha - effusion , and C3 effusion .'
p1689
(lp1690
I5
a(lp1691
I8
atp1692
a(I-1
S'Their order of selection was alpha1AT effusion , C4 serum , TNFalpha - effusion , and C3 effusion .'
p1693
(lp1694
I5
a(lp1695
I11
atp1696
a(I-1
S'Their order of selection was alpha1AT effusion , C4 serum , TNFalpha - effusion , and C3 effusion .'
p1697
(lp1698
I5
a(lp1699
I16
atp1700
a(I-1
S'Their order of selection was alpha1AT effusion , C4 serum , TNFalpha - effusion , and C3 effusion .'
p1701
(lp1702
I8
a(lp1703
I11
atp1704
a(I-1
S'Their order of selection was alpha1AT effusion , C4 serum , TNFalpha - effusion , and C3 effusion .'
p1705
(lp1706
I8
a(lp1707
I16
atp1708
a(I-1
S'Their order of selection was alpha1AT effusion , C4 serum , TNFalpha - effusion , and C3 effusion .'
p1709
(lp1710
I11
a(lp1711
I16
atp1712
a(I-1
S'Determination of TNFalpha , complement factors C3 and C4 , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .'
p1713
(lp1714
I2
a(lp1715
I6
atp1716
a(I-1
S'Determination of TNFalpha , complement factors C3 and C4 , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .'
p1717
(lp1718
I2
a(lp1719
I8
atp1720
a(I-1
S'Determination of TNFalpha , complement factors C3 and C4 , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .'
p1721
(lp1722
I2
a(lp1723
I11
atp1724
a(I-1
S'Determination of TNFalpha , complement factors C3 and C4 , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .'
p1725
(lp1726
I6
a(lp1727
I8
atp1728
a(I-1
S'Determination of TNFalpha , complement factors C3 and C4 , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .'
p1729
(lp1730
I6
a(lp1731
I11
atp1732
a(I-1
S'Determination of TNFalpha , complement factors C3 and C4 , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .'
p1733
(lp1734
I8
a(lp1735
I11
atp1736
a(I-1
S'Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer .'
p1737
(lp1738
I3
a(lp1739
I5
atp1740
a(I-1
S'Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer .'
p1741
(lp1742
I3
a(lp1743
I16
atp1744
a(I-1
S'Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression withprogression of cancer .'
p1745
(lp1746
I5
a(lp1747
I16
atp1748
a(I-1
S'Granulysin has been identified as an effector molecule co - localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer ( NK ) cells , and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells .'
p1749
(lp1750
I0
a(lp1751
I12
atp1752
a(I-1
S'Granulysin has been identified as an effector molecule co - localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer ( NK ) cells , and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells .'
p1753
(lp1754
I0
a(lp1755
I44
atp1756
a(I-1
S'Granulysin has been identified as an effector molecule co - localized with perforin in the cytotoxic granules of cytotoxic T lymphocytes and natural killer ( NK ) cells , and has been reported to kill intracellular pathogens in infected cells in the presence of perforin and to induce a cytotoxic effect against tumor cells .'
p1757
(lp1758
I12
a(lp1759
I44
atp1760
a(I-1
S'The aim of the present study was to elucidate whether intracellular expression of granulysin and perforin by NK cells might be associated with progression of cancer .'
p1761
(lp1762
I13
a(lp1763
I15
atp1764
a(I-1
S'Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3 ( - ) CD16 ( + ) cells in healthy controls .'
p1765
(lp1766
I7
a(lp1767
I9
atp1768
a(I-1
S'Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3 ( - ) CD16 ( + ) cells in healthy controls .'
p1769
(lp1770
I7
a(lp1771
I12
atp1772
a(I-1
S'Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3 ( - ) CD16 ( + ) cells in healthy controls .'
p1773
(lp1774
I7
a(lp1775
I16
atp1776
a(I-1
S'Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3 ( - ) CD16 ( + ) cells in healthy controls .'
p1777
(lp1778
I9
a(lp1779
I12
atp1780
a(I-1
S'Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3 ( - ) CD16 ( + ) cells in healthy controls .'
p1781
(lp1782
I9
a(lp1783
I16
atp1784
a(I-1
S'Flow cytometric analysis demonstrated high levels of perforin and granulysin expression by CD3 ( - ) CD16 ( + ) cells in healthy controls .'
p1785
(lp1786
I12
a(lp1787
I16
atp1788
a(I-1
S'In contrast , cancer patients exhibited significantly decreased levels of granulysin expression ( P < 0 . 005 ) , despite having equally high levels of perforin expression in comparison with healthy controls .'
p1789
(lp1790
I10
a(lp1791
I26
atp1792
a(I-1
S'The tumor - free patients expressed granulysin at levels similar to healthy controls , while the progressive tumor - bearing patients expressed remarkably lower levels of granulysin compared to healthy controls ( P < 0 . 0001 ) .'
p1793
(lp1794
I6
a(lp1795
I26
atp1796
a(I-1
S'In conclusion , impaired expression of granulysin by NK cells correlates with progression of cancer , and determination of granulysin expression might prove informative for assessing the immunological condition of cancer patients .'
p1797
(lp1798
I6
a(lp1799
I19
atp1800
a(I-1
S'Activin A , a member of the TGFbeta superfamily , has various effects on diverse biological systems , including cell growth inhibition in many cell types .'
p1801
(lp1802
I0
aI1
a(lp1803
I7
atp1804
a(I-1
S'Based on the experiences of all the authors , we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl - 2 family .'
p1805
(lp1806
I16
a(lp1807
I18
atp1808
a(I-1
S'Based on the experiences of all the authors , we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl - 2 family .'
p1809
(lp1810
I16
a(lp1811
I25
atp1812
a(I-1
S'Based on the experiences of all the authors , we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl - 2 family .'
p1813
(lp1814
I16
a(lp1815
I30
aI31
aI32
atp1816
a(I-1
S'Based on the experiences of all the authors , we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl - 2 family .'
p1817
(lp1818
I18
a(lp1819
I25
atp1820
a(I-1
S'Based on the experiences of all the authors , we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl - 2 family .'
p1821
(lp1822
I18
a(lp1823
I30
aI31
aI32
atp1824
a(I-1
S'Based on the experiences of all the authors , we emphasized cell cycle inhibitors such as p16 and p21 and regulators of apoptosis such as p53 and members of the bcl - 2 family .'
p1825
(lp1826
I25
a(lp1827
I30
aI31
aI32
atp1828
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1829
(lp1830
I12
a(lp1831
I12
aI13
atp1832
a(I1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1833
(lp1834
I12
a(lp1835
I15
atp1836
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1837
(lp1838
I12
a(lp1839
I23
atp1840
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1841
(lp1842
I12
a(lp1843
I40
atp1844
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1845
(lp1846
I12
a(lp1847
I33
aI34
aI35
aI36
aI37
aI38
aI39
aI40
aI41
aI42
atp1848
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1849
(lp1850
I12
aI13
a(lp1851
I15
atp1852
a(I1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1853
(lp1854
I12
aI13
a(lp1855
I23
atp1856
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1857
(lp1858
I12
aI13
a(lp1859
I40
atp1860
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1861
(lp1862
I12
aI13
a(lp1863
I33
aI34
aI35
aI36
aI37
aI38
aI39
aI40
aI41
aI42
atp1864
a(I1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1865
(lp1866
I15
a(lp1867
I23
atp1868
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1869
(lp1870
I15
a(lp1871
I40
atp1872
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1873
(lp1874
I15
a(lp1875
I33
aI34
aI35
aI36
aI37
aI38
aI39
aI40
aI41
aI42
atp1876
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1877
(lp1878
I23
a(lp1879
I40
atp1880
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1881
(lp1882
I23
a(lp1883
I33
aI34
aI35
aI36
aI37
aI38
aI39
aI40
aI41
aI42
atp1884
a(I-1
S'We have identified a new TNF - related ligand , designated human GITR ligand ( hGITRL ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid - induced TNFR - related ( mGITR ) protein [ 4 ] .'
p1885
(lp1886
I40
a(lp1887
I33
aI34
aI35
aI36
aI37
aI38
aI39
aI40
aI41
aI42
atp1888
a(I-1
S'The hGITRL gene mapped to chromosome 1q23 , near the gene for the TNF homolog Fas / CD95 ligand [ 5 ] .'
p1889
(lp1890
I1
a(lp1891
I15
atp1892
a(I-1
S'The hGITRL gene mapped to chromosome 1q23 , near the gene for the TNF homolog Fas / CD95 ligand [ 5 ] .'
p1893
(lp1894
I1
a(lp1895
I17
aI18
atp1896
a(I-1
S'The hGITRL gene mapped to chromosome 1q23 , near the gene for the TNF homolog Fas / CD95 ligand [ 5 ] .'
p1897
(lp1898
I15
a(lp1899
I17
aI18
atp1900
a(I-1
S'We found hGITRL mRNA in several peripheral tissues , and detected hGITRL protein on cultured vascular endothelial cells .'
p1901
(lp1902
I2
a(lp1903
I11
atp1904
a(I-1
S'The levels of hGITR mRNA in tissues were generally low ; in peripheral blood T cells , however , antigen - receptor stimulation led to a substantial induction of hGITR transcripts .'
p1905
(lp1906
I3
a(lp1907
I29
atp1908
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1909
(lp1910
I2
a(lp1911
I4
atp1912
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1913
(lp1914
I2
a(lp1915
I17
aI18
aI19
atp1916
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1917
(lp1918
I2
a(lp1919
I28
aI29
aI30
aI31
aI32
atp1920
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1921
(lp1922
I2
a(lp1923
I34
atp1924
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1925
(lp1926
I2
a(lp1927
I40
aI41
aI42
atp1928
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1929
(lp1930
I2
a(lp1931
I40
aI41
aI42
aI43
aI44
aI45
atp1932
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1933
(lp1934
I2
a(lp1935
I47
atp1936
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1937
(lp1938
I4
a(lp1939
I17
aI18
aI19
atp1940
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1941
(lp1942
I4
a(lp1943
I28
aI29
aI30
aI31
aI32
atp1944
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1945
(lp1946
I4
a(lp1947
I34
atp1948
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1949
(lp1950
I4
a(lp1951
I40
aI41
aI42
atp1952
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1953
(lp1954
I4
a(lp1955
I40
aI41
aI42
aI43
aI44
aI45
atp1956
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1957
(lp1958
I4
a(lp1959
I47
atp1960
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1961
(lp1962
I17
aI18
aI19
a(lp1963
I28
aI29
aI30
aI31
aI32
atp1964
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1965
(lp1966
I17
aI18
aI19
a(lp1967
I34
atp1968
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1969
(lp1970
I17
aI18
aI19
a(lp1971
I40
aI41
aI42
atp1972
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1973
(lp1974
I17
aI18
aI19
a(lp1975
I40
aI41
aI42
aI43
aI44
aI45
atp1976
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1977
(lp1978
I17
aI18
aI19
a(lp1979
I47
atp1980
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1981
(lp1982
I28
aI29
aI30
aI31
aI32
a(lp1983
I34
atp1984
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1985
(lp1986
I28
aI29
aI30
aI31
aI32
a(lp1987
I40
aI41
aI42
atp1988
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1989
(lp1990
I28
aI29
aI30
aI31
aI32
a(lp1991
I40
aI41
aI42
aI43
aI44
aI45
atp1992
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1993
(lp1994
I28
aI29
aI30
aI31
aI32
a(lp1995
I47
atp1996
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p1997
(lp1998
I34
a(lp1999
I40
aI41
aI42
atp2000
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p2001
(lp2002
I34
a(lp2003
I40
aI41
aI42
aI43
aI44
aI45
atp2004
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p2005
(lp2006
I34
a(lp2007
I47
atp2008
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p2009
(lp2010
I40
aI41
aI42
a(lp2011
I40
aI41
aI42
aI43
aI44
aI45
atp2012
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p2013
(lp2014
I40
aI41
aI42
a(lp2015
I47
atp2016
a(I-1
S'Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti - apoptotic transcription factor NF - kappaB , via a pathway that appeared to involve TNFR - associated factor 2 ( TRAF2 ) [ 7 ] and NF - kappaB - inducing kinase ( NIK ) [ 8 ] .'
p2017
(lp2018
I40
aI41
aI42
aI43
aI44
aI45
a(lp2019
I47
atp2020
a(I-1
S'Cotransfection of hGITRL and hGITR in Jurkat T leukemia cells inhibited antigen - receptor - induced cell death .'
p2021
(lp2022
I2
a(lp2023
I4
atp2024
a(I-1
S'Thus , hGITRL and hGITR may modulate T lymphocyte survival in peripheral tissues .'
p2025
(lp2026
I2
a(lp2027
I4
atp2028
a(I-1
S'We have probed an epitope sequence ( His18 - Pro19 - Lys20 - Phe21 ) in interleukin - 8 ( IL - 8 ) by site - directed mutagenesis .'
p2029
(lp2030
I16
aI17
aI18
a(lp2031
I20
aI21
aI22
atp2032
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2033
(lp2034
I14
aI15
aI16
a(lp2035
I27
aI28
aI29
atp2036
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2037
(lp2038
I14
aI15
aI16
a(lp2039
I27
aI28
aI29
aI30
aI31
aI32
atp2040
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2041
(lp2042
I14
aI15
aI16
a(lp2043
I34
atp2044
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2045
(lp2046
I14
aI15
aI16
a(lp2047
I39
atp2048
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2049
(lp2050
I14
aI15
aI16
a(lp2051
I44
aI45
atp2052
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2053
(lp2054
I27
aI28
aI29
a(lp2055
I27
aI28
aI29
aI30
aI31
aI32
atp2056
a(I1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2057
(lp2058
I27
aI28
aI29
a(lp2059
I34
atp2060
a(I1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2061
(lp2062
I27
aI28
aI29
a(lp2063
I39
atp2064
a(I1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2065
(lp2066
I27
aI28
aI29
a(lp2067
I44
aI45
atp2068
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2069
(lp2070
I27
aI28
aI29
aI30
aI31
aI32
a(lp2071
I34
atp2072
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2073
(lp2074
I27
aI28
aI29
aI30
aI31
aI32
a(lp2075
I39
atp2076
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2077
(lp2078
I27
aI28
aI29
aI30
aI31
aI32
a(lp2079
I44
aI45
atp2080
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2081
(lp2082
I34
a(lp2083
I39
atp2084
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2085
(lp2086
I34
a(lp2087
I44
aI45
atp2088
a(I-1
S'This work shows that single and double Ala substitutions of His18 and Phe21 in IL - 8 reduced up to 77 - fold the binding affinity to IL - 8 receptor subtypes A ( CXCR1 ) and B ( CXCR2 ) and to the Duffy antigen .'
p2089
(lp2090
I39
a(lp2091
I44
aI45
atp2092
a(I-1
S'These Ala mutants triggered neutrophil degranulation and induced calcium responses mediated by CXCR1 and CXCR2 .'
p2093
(lp2094
I12
a(lp2095
I14
atp2096
a(I-1
S'Single Asp or Ser substitutions , H18D , F21D , F21S , and double substitutions , H18A / F21D , H18A / F21S , and H18D / F21D , reduced up to 431 - fold the binding affinity to CXCR1 , CXCR2 , and the Duffy antigen .'
p2097
(lp2098
I39
a(lp2099
I41
atp2100
a(I-1
S'Single Asp or Ser substitutions , H18D , F21D , F21S , and double substitutions , H18A / F21D , H18A / F21S , and H18D / F21D , reduced up to 431 - fold the binding affinity to CXCR1 , CXCR2 , and the Duffy antigen .'
p2101
(lp2102
I39
a(lp2103
I45
aI46
atp2104
a(I-1
S'Single Asp or Ser substitutions , H18D , F21D , F21S , and double substitutions , H18A / F21D , H18A / F21S , and H18D / F21D , reduced up to 431 - fold the binding affinity to CXCR1 , CXCR2 , and the Duffy antigen .'
p2105
(lp2106
I41
a(lp2107
I45
aI46
atp2108
a(I1
S'This study demonstrates that IL - 8 recognizes and activates CXCR1 , CXCR2 , and the Duffy antigen by distinct mechanisms .'
p2109
(lp2110
I4
aI5
aI6
a(lp2111
I10
atp2112
a(I1
S'This study demonstrates that IL - 8 recognizes and activates CXCR1 , CXCR2 , and the Duffy antigen by distinct mechanisms .'
p2113
(lp2114
I4
aI5
aI6
a(lp2115
I12
atp2116
a(I1
S'This study demonstrates that IL - 8 recognizes and activates CXCR1 , CXCR2 , and the Duffy antigen by distinct mechanisms .'
p2117
(lp2118
I4
aI5
aI6
a(lp2119
I16
aI17
atp2120
a(I-1
S'This study demonstrates that IL - 8 recognizes and activates CXCR1 , CXCR2 , and the Duffy antigen by distinct mechanisms .'
p2121
(lp2122
I10
a(lp2123
I12
atp2124
a(I-1
S'This study demonstrates that IL - 8 recognizes and activates CXCR1 , CXCR2 , and the Duffy antigen by distinct mechanisms .'
p2125
(lp2126
I10
a(lp2127
I16
aI17
atp2128
a(I-1
S'This study demonstrates that IL - 8 recognizes and activates CXCR1 , CXCR2 , and the Duffy antigen by distinct mechanisms .'
p2129
(lp2130
I12
a(lp2131
I16
aI17
atp2132
a(I1
S'Isolation of human delta - catenin and its binding specificity with presenilin 1 .'
p2133
(lp2134
I3
aI4
aI5
a(lp2135
I11
aI12
atp2136
a(I1
S'We screened proteins for interaction with presenilin ( PS ) 1 , and cloned the full - length cDNA of human delta - catenin , which encoded 1225 amino acids .'
p2137
(lp2138
I6
aI7
aI8
aI9
aI10
a(lp2139
I21
aI22
aI23
atp2140
a(I1
S'Yeast two - hybrid assay , GST binding assay and immunoprecipitation demonstrated that delta - catenin interacted with a hydrophilic loop region in the endoproteolytic C - terminal fragment of PS1 , but not with that of PS - 2 .'
p2141
(lp2142
I13
aI14
aI15
a(lp2143
I30
atp2144
a(I-1
S'Yeast two - hybrid assay , GST binding assay and immunoprecipitation demonstrated that delta - catenin interacted with a hydrophilic loop region in the endoproteolytic C - terminal fragment of PS1 , but not with that of PS - 2 .'
p2145
(lp2146
I13
aI14
aI15
a(lp2147
I37
aI38
aI39
atp2148
a(I-1
S'Yeast two - hybrid assay , GST binding assay and immunoprecipitation demonstrated that delta - catenin interacted with a hydrophilic loop region in the endoproteolytic C - terminal fragment of PS1 , but not with that of PS - 2 .'
p2149
(lp2150
I30
a(lp2151
I37
aI38
aI39
atp2152
a(I-1
S'These results suggest that PS1 and PS2 partly differ in function .'
p2153
(lp2154
I4
a(lp2155
I6
atp2156
a(I-1
S'We also found another armadillo - protein , p0071 , interacted with PS1 .'
p2157
(lp2158
I4
aI5
aI6
a(lp2159
I8
atp2160
a(I-1
S'We also found another armadillo - protein , p0071 , interacted with PS1 .'
p2161
(lp2162
I4
aI5
aI6
a(lp2163
I12
atp2164
a(I1
S'We also found another armadillo - protein , p0071 , interacted with PS1 .'
p2165
(lp2166
I8
a(lp2167
I12
atp2168
a(I-1
S'A newly identified member of tumor necrosis factor receptor superfamily ( TR6 ) suppresses LIGHT - mediated apoptosis .'
p2169
(lp2170
I11
a(lp2171
I14
atp2172
a(I-1
S'TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .'
p2173
(lp2174
I0
a(lp2175
I2
aI3
aI4
atp2176
a(I-1
S'TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .'
p2177
(lp2178
I0
a(lp2179
I6
atp2180
a(I-1
S'TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .'
p2181
(lp2182
I2
aI3
aI4
a(lp2183
I6
atp2184
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2185
(lp2186
I5
a(lp2187
I12
atp2188
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2189
(lp2190
I5
a(lp2191
I19
atp2192
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2193
(lp2194
I5
a(lp2195
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
atp2196
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2197
(lp2198
I5
a(lp2199
I25
aI26
atp2200
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2201
(lp2202
I5
a(lp2203
I28
atp2204
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2205
(lp2206
I5
a(lp2207
I30
atp2208
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2209
(lp2210
I12
a(lp2211
I19
atp2212
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2213
(lp2214
I12
a(lp2215
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
atp2216
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2217
(lp2218
I12
a(lp2219
I25
aI26
atp2220
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2221
(lp2222
I12
a(lp2223
I28
atp2224
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2225
(lp2226
I12
a(lp2227
I30
atp2228
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2229
(lp2230
I19
a(lp2231
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
atp2232
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2233
(lp2234
I19
a(lp2235
I25
aI26
atp2236
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2237
(lp2238
I19
a(lp2239
I28
atp2240
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2241
(lp2242
I19
a(lp2243
I30
atp2244
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2245
(lp2246
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
a(lp2247
I25
aI26
atp2248
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2249
(lp2250
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
a(lp2251
I28
atp2252
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2253
(lp2254
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
a(lp2255
I30
atp2256
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2257
(lp2258
I25
aI26
a(lp2259
I28
atp2260
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2261
(lp2262
I25
aI26
a(lp2263
I30
atp2264
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p2265
(lp2266
I28
a(lp2267
I30
atp2268
a(I-1
S'TR6 inhibited LIGHT - induced cytotoxicity in HT29 cells .'
p2269
(lp2270
I0
a(lp2271
I2
atp2272
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2273
(lp2274
I5
a(lp2275
I18
aI19
atp2276
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2277
(lp2278
I5
a(lp2279
I18
aI19
aI20
atp2280
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2281
(lp2282
I5
a(lp2283
I22
atp2284
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2285
(lp2286
I5
a(lp2287
I25
atp2288
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2289
(lp2290
I5
a(lp2291
I27
atp2292
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2293
(lp2294
I18
aI19
a(lp2295
I18
aI19
aI20
atp2296
a(I1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2297
(lp2298
I18
aI19
a(lp2299
I22
atp2300
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2301
(lp2302
I18
aI19
a(lp2303
I25
atp2304
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2305
(lp2306
I18
aI19
a(lp2307
I27
atp2308
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2309
(lp2310
I18
aI19
aI20
a(lp2311
I22
atp2312
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2313
(lp2314
I18
aI19
aI20
a(lp2315
I25
atp2316
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2317
(lp2318
I18
aI19
aI20
a(lp2319
I27
atp2320
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2321
(lp2322
I22
a(lp2323
I25
atp2324
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2325
(lp2326
I22
a(lp2327
I27
atp2328
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p2329
(lp2330
I25
a(lp2331
I27
atp2332
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2333
(lp2334
I4
a(lp2335
I9
atp2336
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2337
(lp2338
I4
a(lp2339
I11
atp2340
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2341
(lp2342
I4
a(lp2343
I13
atp2344
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2345
(lp2346
I4
a(lp2347
I15
atp2348
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2349
(lp2350
I4
a(lp2351
I19
atp2352
a(I1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2353
(lp2354
I9
a(lp2355
I11
atp2356
a(I1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2357
(lp2358
I9
a(lp2359
I13
atp2360
a(I1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2361
(lp2362
I9
a(lp2363
I15
atp2364
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2365
(lp2366
I9
a(lp2367
I19
atp2368
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2369
(lp2370
I11
a(lp2371
I13
atp2372
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2373
(lp2374
I11
a(lp2375
I15
atp2376
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2377
(lp2378
I11
a(lp2379
I19
atp2380
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2381
(lp2382
I13
a(lp2383
I15
atp2384
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2385
(lp2386
I13
a(lp2387
I19
atp2388
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p2389
(lp2390
I15
a(lp2391
I19
atp2392
a(I-1
S'Thus , TR6 may play a regulatory role for suppressing in FasL - and LIGHT - mediated cell death .'
p2393
(lp2394
I2
a(lp2395
I11
atp2396
a(I-1
S'Thus , TR6 may play a regulatory role for suppressing in FasL - and LIGHT - mediated cell death .'
p2397
(lp2398
I2
a(lp2399
I14
atp2400
a(I-1
S'Thus , TR6 may play a regulatory role for suppressing in FasL - and LIGHT - mediated cell death .'
p2401
(lp2402
I11
a(lp2403
I14
atp2404
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2405
(lp2406
I6
a(lp2407
I8
atp2408
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2409
(lp2410
I6
a(lp2411
I6
aI7
aI8
aI9
aI10
atp2412
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2413
(lp2414
I6
a(lp2415
I15
atp2416
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2417
(lp2418
I6
a(lp2419
I17
atp2420
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2421
(lp2422
I6
a(lp2423
I17
aI18
aI19
atp2424
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2425
(lp2426
I8
a(lp2427
I6
aI7
aI8
aI9
aI10
atp2428
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2429
(lp2430
I8
a(lp2431
I15
atp2432
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2433
(lp2434
I8
a(lp2435
I17
atp2436
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2437
(lp2438
I8
a(lp2439
I17
aI18
aI19
atp2440
a(I1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2441
(lp2442
I6
aI7
aI8
aI9
aI10
a(lp2443
I15
atp2444
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2445
(lp2446
I6
aI7
aI8
aI9
aI10
a(lp2447
I17
atp2448
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2449
(lp2450
I6
aI7
aI8
aI9
aI10
a(lp2451
I17
aI18
aI19
atp2452
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2453
(lp2454
I15
a(lp2455
I17
atp2456
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2457
(lp2458
I15
a(lp2459
I17
aI18
aI19
atp2460
a(I-1
S'Shared and unique determinants of the erythropoietin ( EPO ) receptor are important for binding EPO and EPO mimetic peptide .'
p2461
(lp2462
I17
a(lp2463
I17
aI18
aI19
atp2464
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2465
(lp2466
I12
a(lp2467
I14
atp2468
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2469
(lp2470
I12
a(lp2471
I12
aI13
aI14
aI15
aI16
atp2472
a(I1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2473
(lp2474
I12
a(lp2475
I18
atp2476
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2477
(lp2478
I12
a(lp2479
I24
atp2480
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2481
(lp2482
I12
a(lp2483
I37
atp2484
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2485
(lp2486
I12
a(lp2487
I49
atp2488
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2489
(lp2490
I12
a(lp2491
I51
atp2492
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2493
(lp2494
I12
a(lp2495
I51
aI52
aI53
aI54
atp2496
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2497
(lp2498
I12
a(lp2499
I56
atp2500
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2501
(lp2502
I14
a(lp2503
I12
aI13
aI14
aI15
aI16
atp2504
a(I1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2505
(lp2506
I14
a(lp2507
I18
atp2508
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2509
(lp2510
I14
a(lp2511
I24
atp2512
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2513
(lp2514
I14
a(lp2515
I37
atp2516
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2517
(lp2518
I14
a(lp2519
I49
atp2520
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2521
(lp2522
I14
a(lp2523
I51
atp2524
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2525
(lp2526
I14
a(lp2527
I51
aI52
aI53
aI54
atp2528
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2529
(lp2530
I14
a(lp2531
I56
atp2532
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2533
(lp2534
I12
aI13
aI14
aI15
aI16
a(lp2535
I18
atp2536
a(I1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2537
(lp2538
I12
aI13
aI14
aI15
aI16
a(lp2539
I24
atp2540
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2541
(lp2542
I12
aI13
aI14
aI15
aI16
a(lp2543
I37
atp2544
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2545
(lp2546
I12
aI13
aI14
aI15
aI16
a(lp2547
I49
atp2548
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2549
(lp2550
I12
aI13
aI14
aI15
aI16
a(lp2551
I51
atp2552
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2553
(lp2554
I12
aI13
aI14
aI15
aI16
a(lp2555
I51
aI52
aI53
aI54
atp2556
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2557
(lp2558
I12
aI13
aI14
aI15
aI16
a(lp2559
I56
atp2560
a(I1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2561
(lp2562
I18
a(lp2563
I24
atp2564
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2565
(lp2566
I18
a(lp2567
I37
atp2568
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2569
(lp2570
I18
a(lp2571
I49
atp2572
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2573
(lp2574
I18
a(lp2575
I51
atp2576
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2577
(lp2578
I18
a(lp2579
I51
aI52
aI53
aI54
atp2580
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2581
(lp2582
I18
a(lp2583
I56
atp2584
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2585
(lp2586
I24
a(lp2587
I37
atp2588
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2589
(lp2590
I24
a(lp2591
I49
atp2592
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2593
(lp2594
I24
a(lp2595
I51
atp2596
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2597
(lp2598
I24
a(lp2599
I51
aI52
aI53
aI54
atp2600
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2601
(lp2602
I24
a(lp2603
I56
atp2604
a(I1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2605
(lp2606
I37
a(lp2607
I49
atp2608
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2609
(lp2610
I37
a(lp2611
I51
atp2612
a(I1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2613
(lp2614
I37
a(lp2615
I51
aI52
aI53
aI54
atp2616
a(I1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2617
(lp2618
I37
a(lp2619
I56
atp2620
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2621
(lp2622
I49
a(lp2623
I51
atp2624
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2625
(lp2626
I49
a(lp2627
I51
aI52
aI53
aI54
atp2628
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2629
(lp2630
I49
a(lp2631
I56
atp2632
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2633
(lp2634
I51
a(lp2635
I51
aI52
aI53
aI54
atp2636
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2637
(lp2638
I51
a(lp2639
I56
atp2640
a(I-1
S'We have shown previously that Phe93 in the extracellular domain of the erythropoietin ( EPO ) receptor ( EPOR ) is crucial for binding EPO . Substitution of Phe93 with alanine resulted in a dramatic decrease in EPO binding to the Escherichia coli - expressed extracellular domain of the EPOR ( EPO - binding protein or EBP ) and no detectable binding to full - length mutant receptor expressed in COS cells .'
p2641
(lp2642
I51
aI52
aI53
aI54
a(lp2643
I56
atp2644
a(I-1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2645
(lp2646
I16
a(lp2647
I20
atp2648
a(I-1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2649
(lp2650
I16
a(lp2651
I20
aI21
aI22
aI23
atp2652
a(I1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2653
(lp2654
I16
a(lp2655
I25
atp2656
a(I1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2657
(lp2658
I16
a(lp2659
I35
atp2660
a(I-1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2661
(lp2662
I20
a(lp2663
I20
aI21
aI22
aI23
atp2664
a(I-1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2665
(lp2666
I20
a(lp2667
I25
atp2668
a(I-1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2669
(lp2670
I20
a(lp2671
I35
atp2672
a(I-1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2673
(lp2674
I20
aI21
aI22
aI23
a(lp2675
I25
atp2676
a(I-1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2677
(lp2678
I20
aI21
aI22
aI23
a(lp2679
I35
atp2680
a(I-1
S'Remarkably , Phe93 forms extensive contacts with a peptide ligand in the crystal structure of the EBP bound to an EPO - mimetic peptide ( EMP1 ) , suggesting that Phe93 is also important for EMP1 binding .'
p2681
(lp2682
I25
a(lp2683
I35
atp2684
a(I1
S'We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding .'
p2685
(lp2686
I5
a(lp2687
I9
atp2688
a(I1
S'We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding .'
p2689
(lp2690
I5
a(lp2691
I23
atp2692
a(I1
S'We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding .'
p2693
(lp2694
I5
a(lp2695
I25
atp2696
a(I-1
S'We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding .'
p2697
(lp2698
I9
a(lp2699
I23
atp2700
a(I-1
S'We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding .'
p2701
(lp2702
I9
a(lp2703
I25
atp2704
a(I-1
S'We used alanine substitution of EBP residues that contact EMP1 in the crystal structure to investigate the function of these residues in both EMP1 and EPO binding .'
p2705
(lp2706
I23
a(lp2707
I25
atp2708
a(I-1
S'Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding , Met150 is not important for EPO binding but is critical for EMP1 binding , and Thr151 is not important for binding either ligand .'
p2709
(lp2710
I11
a(lp2711
I13
atp2712
a(I-1
S'Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding , Met150 is not important for EPO binding but is critical for EMP1 binding , and Thr151 is not important for binding either ligand .'
p2713
(lp2714
I11
a(lp2715
I21
atp2716
a(I-1
S'Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding , Met150 is not important for EPO binding but is critical for EMP1 binding , and Thr151 is not important for binding either ligand .'
p2717
(lp2718
I11
a(lp2719
I27
atp2720
a(I-1
S'Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding , Met150 is not important for EPO binding but is critical for EMP1 binding , and Thr151 is not important for binding either ligand .'
p2721
(lp2722
I13
a(lp2723
I21
atp2724
a(I-1
S'Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding , Met150 is not important for EPO binding but is critical for EMP1 binding , and Thr151 is not important for binding either ligand .'
p2725
(lp2726
I13
a(lp2727
I27
atp2728
a(I-1
S'Our results indicate that Phe93 and Phe205 are important for both EPO and EMP1 binding , Met150 is not important for EPO binding but is critical for EMP1 binding , and Thr151 is not important for binding either ligand .'
p2729
(lp2730
I21
a(lp2731
I27
atp2732
a(I-1
S'Thus , Phe93 and Phe205 are important binding determinants for both EPO and EMP1 , even though these ligands share no sequence or structural homology , suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding .'
p2733
(lp2734
I11
a(lp2735
I13
atp2736
a(I1
S'Thus , Phe93 and Phe205 are important binding determinants for both EPO and EMP1 , even though these ligands share no sequence or structural homology , suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding .'
p2737
(lp2738
I11
a(lp2739
I37
atp2740
a(I1
S'Thus , Phe93 and Phe205 are important binding determinants for both EPO and EMP1 , even though these ligands share no sequence or structural homology , suggesting that these residues may represent a minimum epitope on the EPOR for productive ligand binding .'
p2741
(lp2742
I13
a(lp2743
I37
atp2744
a(I1
S'Native C8 and C9 formed a heterodimer in solution of physiological ionic strength with a free - energy change DeltaG degrees of - 8 . 3 kcal / mol and a dissociation constant Kd of 0 . 6 microM ( at 20 degrees C ) that was ionic strength - and temperature - dependent .'
p2745
(lp2746
I1
a(lp2747
I3
atp2748
a(I1
S"A van ' t Hoff plot of the change in Kd was linear between 10 and 37 degrees C and yielded values of DeltaH degrees = - 12 . 9 kcal / mol and DeltaS degrees = - 15 . 9 cal mol - 1 deg - 1 , suggesting that electrostatic forces play a prominent role in the interaction of C8 with C9 ."
p2749
(lp2750
I61
a(lp2751
I63
atp2752
a(I1
S'Native C8 also formed a heterodimer with C5 , and low concentrations of polyionic ligands such as protamine and suramin inhibited the interaction .'
p2753
(lp2754
I1
a(lp2755
I7
atp2756
a(I-1
S'Suramin induced high - affinity trimerization of C8 ( Kd = 0 . 10 microM at 20 degrees C ) and dimerization of C9 ( Kd = 0 . 86 microM at 20 degrees C ) .'
p2757
(lp2758
I7
a(lp2759
I23
atp2760
a(I-1
S'Analysis of sedimentation equilibria and also of the fluorescence enhancement of suramin when bound to protein provided evidence for two suramin - binding sites on each C9 and three on each C8 in the oligomers .'
p2761
(lp2762
I26
a(lp2763
I31
atp2764
a(I-1
S"Presenilin 1 ( PS1 ) mutations account for the majority of early - onset dominant cases of familial Alzheimer ' s disease ."
p2765
(lp2766
I0
aI1
a(lp2767
I3
atp2768
a(I-1
S'We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11 , a small GTPase belonging to the Ras - related superfamily .'
p2769
(lp2770
I7
a(lp2771
I9
atp2772
a(I1
S'We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11 , a small GTPase belonging to the Ras - related superfamily .'
p2773
(lp2774
I7
a(lp2775
I13
atp2776
a(I1
S'We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11 , a small GTPase belonging to the Ras - related superfamily .'
p2777
(lp2778
I9
a(lp2779
I13
atp2780
a(I1
S'Interaction domains were mapped to codons 374 - 400 for PS1 and to codons 106 - 179 for Rab11 , a region including the fourth GTP - binding domain .'
p2781
(lp2782
I10
a(lp2783
I18
atp2784
a(I-1
S"Most familial early - onset Alzheimer ' s disease cases are caused by mutations in the presenilin 1 ( PS1 ) gene ."
p2785
(lp2786
I16
aI17
a(lp2787
I19
atp2788
a(I-1
S'Although numerous studies revealed predominant localization of PS1 to endoplasmic reticulum and Golgi , there are conflicting reports on the localization of PS1 to the cell surface .'
p2789
(lp2790
I7
a(lp2791
I22
atp2792
a(I1
S'Cell surface PS1 formed complexes in vivo with actin - binding protein filamin ( ABP - 280 ) , which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility .'
p2793
(lp2794
I2
a(lp2795
I12
atp2796
a(I1
S'Cell surface PS1 formed complexes in vivo with actin - binding protein filamin ( ABP - 280 ) , which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility .'
p2797
(lp2798
I2
a(lp2799
I14
aI15
aI16
atp2800
a(I-1
S'Cell surface PS1 formed complexes in vivo with actin - binding protein filamin ( ABP - 280 ) , which is known to form bridges between cell surface receptors and cytoskeleton and mediate cell adhesion and cell motility .'
p2801
(lp2802
I12
a(lp2803
I14
aI15
aI16
atp2804
a(I1
S"Molecular determinants of the interaction between the C - terminal domain of Alzheimer ' s beta - amyloid peptide and apolipoprotein E alpha - helices ."
p2805
(lp2806
I15
aI16
aI17
aI18
a(lp2807
I20
aI21
atp2808
a(I-1
S'In a previous work , we predicted and demonstrated that the 29 - 42 - residue fragment of beta - amyloid peptide ( Abeta peptide ) has in vitro capacities close to those of the tilted fragment of viral fusion proteins .'
p2809
(lp2810
I18
aI19
aI20
aI21
a(lp2811
I23
aI24
atp2812
a(I-1
S'We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta ( 29 - 42 ) via a direct interaction .'
p2813
(lp2814
I4
aI5
a(lp2815
I10
aI11
atp2816
a(I1
S'We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta ( 29 - 42 ) via a direct interaction .'
p2817
(lp2818
I4
aI5
a(lp2819
I18
atp2820
a(I-1
S'We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta ( 29 - 42 ) via a direct interaction .'
p2821
(lp2822
I10
aI11
a(lp2823
I18
atp2824
a(I-1
S"Therefore , we suggested that this fragment is implicated in the neurotoxicity of Abeta and in the protective effects of apolipoprotein E in Alzheimer ' s disease ."
p2825
(lp2826
I13
a(lp2827
I20
aI21
atp2828
a(I-1
S'In this study , we simulated interactions of all amphipathic helices of apolipoproteins E and A - I with Abeta and simian immunodeficiency virus ( SIV ) fusogenic fragments by molecular modeling .'
p2829
(lp2830
I12
aI13
a(lp2831
I19
atp2832
a(I-1
S'CCR5 binds multiple CC - chemokines : MCP - 3 acts as a natural antagonist .'
p2833
(lp2834
I0
a(lp2835
I7
aI8
aI9
atp2836
a(I1
S'CCR5 was first characterized as a receptor for MIP - 1alpha , MIP - 1beta , and RANTES , and was rapidly shown to be the main coreceptor for M - tropic human immunodeficiency virus ( HIV ) - 1 strains and simian immunodeficiency virus ( SIV ) .'
p2837
(lp2838
I0
a(lp2839
I8
aI9
aI10
atp2840
a(I1
S'CCR5 was first characterized as a receptor for MIP - 1alpha , MIP - 1beta , and RANTES , and was rapidly shown to be the main coreceptor for M - tropic human immunodeficiency virus ( HIV ) - 1 strains and simian immunodeficiency virus ( SIV ) .'
p2841
(lp2842
I0
a(lp2843
I12
aI13
aI14
atp2844
a(I1
S'CCR5 was first characterized as a receptor for MIP - 1alpha , MIP - 1beta , and RANTES , and was rapidly shown to be the main coreceptor for M - tropic human immunodeficiency virus ( HIV ) - 1 strains and simian immunodeficiency virus ( SIV ) .'
p2845
(lp2846
I0
a(lp2847
I17
atp2848
a(I-1
S'CCR5 was first characterized as a receptor for MIP - 1alpha , MIP - 1beta , and RANTES , and was rapidly shown to be the main coreceptor for M - tropic human immunodeficiency virus ( HIV ) - 1 strains and simian immunodeficiency virus ( SIV ) .'
p2849
(lp2850
I8
aI9
aI10
a(lp2851
I12
aI13
aI14
atp2852
a(I-1
S'CCR5 was first characterized as a receptor for MIP - 1alpha , MIP - 1beta , and RANTES , and was rapidly shown to be the main coreceptor for M - tropic human immunodeficiency virus ( HIV ) - 1 strains and simian immunodeficiency virus ( SIV ) .'
p2853
(lp2854
I8
aI9
aI10
a(lp2855
I17
atp2856
a(I-1
S'CCR5 was first characterized as a receptor for MIP - 1alpha , MIP - 1beta , and RANTES , and was rapidly shown to be the main coreceptor for M - tropic human immunodeficiency virus ( HIV ) - 1 strains and simian immunodeficiency virus ( SIV ) .'
p2857
(lp2858
I12
aI13
aI14
a(lp2859
I17
atp2860
a(I-1
S'All CC - chemokines currently available were tested for their ability to compete with [ ( 125 ) I ] - MIP - 1beta binding on a stable cell line expressing recombinant CCR5 , and / or to induce a functional response in these cells .'
p2861
(lp2862
I21
aI22
aI23
a(lp2863
I32
atp2864
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2865
(lp2866
I6
aI7
aI8
a(lp2867
I10
aI11
aI12
atp2868
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2869
(lp2870
I6
aI7
aI8
a(lp2871
I15
atp2872
a(I1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2873
(lp2874
I6
aI7
aI8
a(lp2875
I32
aI33
aI34
atp2876
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2877
(lp2878
I6
aI7
aI8
a(lp2879
I37
aI38
aI39
atp2880
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2881
(lp2882
I6
aI7
aI8
a(lp2883
I41
aI42
aI43
atp2884
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2885
(lp2886
I6
aI7
aI8
a(lp2887
I45
aI46
aI47
atp2888
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2889
(lp2890
I6
aI7
aI8
a(lp2891
I49
aI50
aI51
atp2892
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2893
(lp2894
I6
aI7
aI8
a(lp2895
I54
atp2896
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2897
(lp2898
I10
aI11
aI12
a(lp2899
I15
atp2900
a(I1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2901
(lp2902
I10
aI11
aI12
a(lp2903
I32
aI33
aI34
atp2904
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2905
(lp2906
I10
aI11
aI12
a(lp2907
I37
aI38
aI39
atp2908
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2909
(lp2910
I10
aI11
aI12
a(lp2911
I41
aI42
aI43
atp2912
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2913
(lp2914
I10
aI11
aI12
a(lp2915
I45
aI46
aI47
atp2916
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2917
(lp2918
I10
aI11
aI12
a(lp2919
I49
aI50
aI51
atp2920
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2921
(lp2922
I10
aI11
aI12
a(lp2923
I54
atp2924
a(I1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2925
(lp2926
I15
a(lp2927
I32
aI33
aI34
atp2928
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2929
(lp2930
I15
a(lp2931
I37
aI38
aI39
atp2932
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2933
(lp2934
I15
a(lp2935
I41
aI42
aI43
atp2936
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2937
(lp2938
I15
a(lp2939
I45
aI46
aI47
atp2940
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2941
(lp2942
I15
a(lp2943
I49
aI50
aI51
atp2944
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2945
(lp2946
I15
a(lp2947
I54
atp2948
a(I1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2949
(lp2950
I32
aI33
aI34
a(lp2951
I37
aI38
aI39
atp2952
a(I1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2953
(lp2954
I32
aI33
aI34
a(lp2955
I41
aI42
aI43
atp2956
a(I1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2957
(lp2958
I32
aI33
aI34
a(lp2959
I45
aI46
aI47
atp2960
a(I1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2961
(lp2962
I32
aI33
aI34
a(lp2963
I49
aI50
aI51
atp2964
a(I1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2965
(lp2966
I32
aI33
aI34
a(lp2967
I54
atp2968
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2969
(lp2970
I37
aI38
aI39
a(lp2971
I41
aI42
aI43
atp2972
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2973
(lp2974
I37
aI38
aI39
a(lp2975
I45
aI46
aI47
atp2976
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2977
(lp2978
I37
aI38
aI39
a(lp2979
I49
aI50
aI51
atp2980
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2981
(lp2982
I37
aI38
aI39
a(lp2983
I54
atp2984
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2985
(lp2986
I41
aI42
aI43
a(lp2987
I45
aI46
aI47
atp2988
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2989
(lp2990
I41
aI42
aI43
a(lp2991
I49
aI50
aI51
atp2992
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2993
(lp2994
I41
aI42
aI43
a(lp2995
I54
atp2996
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p2997
(lp2998
I45
aI46
aI47
a(lp2999
I49
aI50
aI51
atp3000
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p3001
(lp3002
I45
aI46
aI47
a(lp3003
I54
atp3004
a(I-1
S'We found that in addition to MIP - 1beta , MIP - 1alpha , and RANTES , five other CC - chemokines could compete for [ ( 125 ) I ] - MIP - 1beta binding : MCP - 2 , MCP - 3 , MCP - 4 , MCP - 1 , and eotaxin binding was characterized by IC ( 50 ) values of 0 . 22 , 2 . 14 , 5 . 89 , 29 . 9 , and 21 . 7 nmol / L , respectively .'
p3005
(lp3006
I49
aI50
aI51
a(lp3007
I54
atp3008
a(I1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3009
(lp3010
I4
aI5
aI6
a(lp3011
I13
atp3012
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3013
(lp3014
I4
aI5
aI6
a(lp3015
I23
aI24
aI25
atp3016
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3017
(lp3018
I4
aI5
aI6
a(lp3019
I32
atp3020
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3021
(lp3022
I4
aI5
aI6
a(lp3023
I34
aI35
aI36
atp3024
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3025
(lp3026
I4
aI5
aI6
a(lp3027
I47
atp3028
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3029
(lp3030
I13
a(lp3031
I23
aI24
aI25
atp3032
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3033
(lp3034
I13
a(lp3035
I32
atp3036
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3037
(lp3038
I13
a(lp3039
I34
aI35
aI36
atp3040
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3041
(lp3042
I13
a(lp3043
I47
atp3044
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3045
(lp3046
I23
aI24
aI25
a(lp3047
I32
atp3048
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3049
(lp3050
I23
aI24
aI25
a(lp3051
I34
aI35
aI36
atp3052
a(I1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3053
(lp3054
I23
aI24
aI25
a(lp3055
I47
atp3056
a(I1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3057
(lp3058
I32
a(lp3059
I34
aI35
aI36
atp3060
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3061
(lp3062
I32
a(lp3063
I47
atp3064
a(I-1
S'Among these ligands , MCP - 3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP - 3 could also inhibit the activation of CCR5 by MIP - 1beta and may therefore be considered as a natural antagonist for CCR5 .'
p3065
(lp3066
I34
aI35
aI36
a(lp3067
I47
atp3068
a(I-1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3069
(lp3070
I8
aI9
aI10
a(lp3071
I17
atp3072
a(I-1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3073
(lp3074
I8
aI9
aI10
a(lp3075
I26
atp3076
a(I-1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3077
(lp3078
I8
aI9
aI10
a(lp3079
I33
aI34
aI35
atp3080
a(I-1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3081
(lp3082
I8
aI9
aI10
a(lp3083
I42
aI43
aI44
atp3084
a(I-1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3085
(lp3086
I17
a(lp3087
I26
atp3088
a(I-1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3089
(lp3090
I17
a(lp3091
I33
aI34
aI35
atp3092
a(I-1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3093
(lp3094
I17
a(lp3095
I42
aI43
aI44
atp3096
a(I1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3097
(lp3098
I26
a(lp3099
I33
aI34
aI35
atp3100
a(I1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3101
(lp3102
I26
a(lp3103
I42
aI43
aI44
atp3104
a(I-1
S'Chemokines that could compete with high affinity for MIP - 1beta binding could also compete for monomeric gp120 binding , although with variable potencies ; maximal gp120 binding inhibition was 80 % for MCP - 2 , but only 30 % for MIP - 1beta .'
p3105
(lp3106
I33
aI34
aI35
a(lp3107
I42
aI43
aI44
atp3108
a(I1
S'MCP - 3 could compete efficiently for gp120 binding but was , however , found to be a weak inhibitor of HIV infection , probably as a consequence of its inability to downregulate the receptor .'
p3109
(lp3110
I0
aI1
aI2
a(lp3111
I7
atp3112
a(I1
S'Molecular cloning of a novel human CC chemokine ( Eotaxin - 3 ) that is a functional ligand of CC chemokine receptor 3 .'
p3113
(lp3114
I9
aI10
aI11
a(lp3115
I19
aI20
aI21
aI22
atp3116
a(I-1
S'Previously , we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 ( MPIF - 2 ) / eotaxin - 2 to chromosome 7q11 . 23 ( Nomiyama , H . , Osborne , L . R . , Imai , T . , Kusuda , J . , Miura , R . , Tsui , L . - C . , and Yoshie , O . ( 1998 ) Genomics 49 , 339 - 340 ) .'
p3117
(lp3118
I8
aI9
aI10
aI11
aI12
a(lp3119
I14
aI15
aI16
atp3120
a(I-1
S'Previously , we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 ( MPIF - 2 ) / eotaxin - 2 to chromosome 7q11 . 23 ( Nomiyama , H . , Osborne , L . R . , Imai , T . , Kusuda , J . , Miura , R . , Tsui , L . - C . , and Yoshie , O . ( 1998 ) Genomics 49 , 339 - 340 ) .'
p3121
(lp3122
I8
aI9
aI10
aI11
aI12
a(lp3123
I19
aI20
aI21
atp3124
a(I-1
S'Previously , we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 ( MPIF - 2 ) / eotaxin - 2 to chromosome 7q11 . 23 ( Nomiyama , H . , Osborne , L . R . , Imai , T . , Kusuda , J . , Miura , R . , Tsui , L . - C . , and Yoshie , O . ( 1998 ) Genomics 49 , 339 - 340 ) .'
p3125
(lp3126
I14
aI15
aI16
a(lp3127
I19
aI20
aI21
atp3128
a(I-1
S'Prompted by this hypothesis , we analyzed the genomic region containing the gene for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and have identified a novel CC chemokine termed eotaxin - 3 .'
p3129
(lp3130
I14
aI15
aI16
a(lp3131
I18
aI19
aI20
atp3132
a(I-1
S'Prompted by this hypothesis , we analyzed the genomic region containing the gene for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and have identified a novel CC chemokine termed eotaxin - 3 .'
p3133
(lp3134
I14
aI15
aI16
a(lp3135
I22
atp3136
a(I-1
S'Prompted by this hypothesis , we analyzed the genomic region containing the gene for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and have identified a novel CC chemokine termed eotaxin - 3 .'
p3137
(lp3138
I14
aI15
aI16
a(lp3139
I32
aI33
aI34
atp3140
a(I-1
S'Prompted by this hypothesis , we analyzed the genomic region containing the gene for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and have identified a novel CC chemokine termed eotaxin - 3 .'
p3141
(lp3142
I18
aI19
aI20
a(lp3143
I22
atp3144
a(I-1
S'Prompted by this hypothesis , we analyzed the genomic region containing the gene for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and have identified a novel CC chemokine termed eotaxin - 3 .'
p3145
(lp3146
I18
aI19
aI20
a(lp3147
I32
aI33
aI34
atp3148
a(I-1
S'Prompted by this hypothesis , we analyzed the genomic region containing the gene for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and have identified a novel CC chemokine termed eotaxin - 3 .'
p3149
(lp3150
I22
a(lp3151
I32
aI33
aI34
atp3152
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3153
(lp3154
I3
aI4
aI5
a(lp3155
I7
aI8
aI9
atp3156
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3157
(lp3158
I3
aI4
aI5
a(lp3159
I11
atp3160
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3161
(lp3162
I3
aI4
aI5
a(lp3163
I14
aI15
aI16
atp3164
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3165
(lp3166
I3
aI4
aI5
a(lp3167
I18
atp3168
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3169
(lp3170
I7
aI8
aI9
a(lp3171
I11
atp3172
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3173
(lp3174
I7
aI8
aI9
a(lp3175
I14
aI15
aI16
atp3176
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3177
(lp3178
I7
aI8
aI9
a(lp3179
I18
atp3180
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3181
(lp3182
I11
a(lp3183
I14
aI15
aI16
atp3184
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3185
(lp3186
I11
a(lp3187
I18
atp3188
a(I-1
S'The genes for MPIF - 2 / eotaxin - 2 ( SCYA24 ) and eotaxin - 3 ( SCYA26 ) are localized within a region of approximately 40 kilobases .'
p3189
(lp3190
I14
aI15
aI16
a(lp3191
I18
atp3192
a(I-1
S'Eotaxin - 3 induced transient calcium mobilization specifically in CC chemokine receptor 3 ( CCR3 ) - expressing L1 . 2 cells with an EC ( 50 ) of 3 nM .'
p3193
(lp3194
I0
aI1
aI2
a(lp3195
I9
aI10
aI11
aI12
atp3196
a(I-1
S'Eotaxin - 3 induced transient calcium mobilization specifically in CC chemokine receptor 3 ( CCR3 ) - expressing L1 . 2 cells with an EC ( 50 ) of 3 nM .'
p3197
(lp3198
I0
aI1
aI2
a(lp3199
I14
atp3200
a(I-1
S'Eotaxin - 3 induced transient calcium mobilization specifically in CC chemokine receptor 3 ( CCR3 ) - expressing L1 . 2 cells with an EC ( 50 ) of 3 nM .'
p3201
(lp3202
I9
aI10
aI11
aI12
a(lp3203
I14
atp3204
a(I-1
S'Eotaxin - 3 competed the binding of ( 125 ) I - eotaxin to CCR3 - expressing L1 . 2 cells with an IC ( 50 ) of 13 nM .'
p3205
(lp3206
I0
aI1
aI2
a(lp3207
I10
aI11
aI12
atp3208
a(I1
S'Eotaxin - 3 competed the binding of ( 125 ) I - eotaxin to CCR3 - expressing L1 . 2 cells with an IC ( 50 ) of 13 nM .'
p3209
(lp3210
I0
aI1
aI2
a(lp3211
I14
atp3212
a(I1
S'Eotaxin - 3 competed the binding of ( 125 ) I - eotaxin to CCR3 - expressing L1 . 2 cells with an IC ( 50 ) of 13 nM .'
p3213
(lp3214
I10
aI11
aI12
a(lp3215
I14
atp3216
a(I1
S'Collectively , eotaxin - 3 is yet another functional ligand for CCR3 .'
p3217
(lp3218
I2
aI3
aI4
a(lp3219
I11
atp3220
a(I1
S'The potency of eotaxin - 3 as a CCR3 ligand seems , however , to be approximately 10 - fold less than that of eotaxin .'
p3221
(lp3222
I3
aI4
aI5
a(lp3223
I8
atp3224
a(I-1
S'The potency of eotaxin - 3 as a CCR3 ligand seems , however , to be approximately 10 - fold less than that of eotaxin .'
p3225
(lp3226
I3
aI4
aI5
a(lp3227
I24
atp3228
a(I1
S'The potency of eotaxin - 3 as a CCR3 ligand seems , however , to be approximately 10 - fold less than that of eotaxin .'
p3229
(lp3230
I8
a(lp3231
I24
atp3232
a(I-1
S'Identification of eotaxin - 3 will further promote our understanding of the control of eosinophil trafficking and other CCR3 - mediated biological phenomena .'
p3233
(lp3234
I2
aI3
aI4
a(lp3235
I18
atp3236
a(I-1
S'Presenilin 1 suppresses the function of c - Jun homodimers via interaction with QM / Jif - 1 .'
p3237
(lp3238
I0
aI1
a(lp3239
I6
aI7
aI8
atp3240
a(I1
S'Presenilin 1 suppresses the function of c - Jun homodimers via interaction with QM / Jif - 1 .'
p3241
(lp3242
I0
aI1
a(lp3243
I13
atp3244
a(I1
S'Presenilin 1 suppresses the function of c - Jun homodimers via interaction with QM / Jif - 1 .'
p3245
(lp3246
I0
aI1
a(lp3247
I15
aI16
aI17
atp3248
a(I-1
S'Presenilin 1 suppresses the function of c - Jun homodimers via interaction with QM / Jif - 1 .'
p3249
(lp3250
I6
aI7
aI8
a(lp3251
I13
atp3252
a(I-1
S'Presenilin 1 suppresses the function of c - Jun homodimers via interaction with QM / Jif - 1 .'
p3253
(lp3254
I6
aI7
aI8
a(lp3255
I15
aI16
aI17
atp3256
a(I-1
S'Presenilin 1 suppresses the function of c - Jun homodimers via interaction with QM / Jif - 1 .'
p3257
(lp3258
I13
a(lp3259
I15
aI16
aI17
atp3260
a(I-1
S"Presenilin 1 ( PS1 ) is the causative gene for an autosomal dominant familial Alzheimer ' s disease ( AD ) mapped to chromosome 14 ."
p3261
(lp3262
I0
aI1
a(lp3263
I3
atp3264
a(I-1
S'Here we show that QM / Jun - interacting factor ( Jif ) - 1 , a negative regulator of c - Jun , is a candidate to mediate the function of PS1 in the cell .'
p3265
(lp3266
I4
a(lp3267
I6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
atp3268
a(I1
S'Here we show that QM / Jun - interacting factor ( Jif ) - 1 , a negative regulator of c - Jun , is a candidate to mediate the function of PS1 in the cell .'
p3269
(lp3270
I4
a(lp3271
I20
aI21
aI22
atp3272
a(I-1
S'Here we show that QM / Jun - interacting factor ( Jif ) - 1 , a negative regulator of c - Jun , is a candidate to mediate the function of PS1 in the cell .'
p3273
(lp3274
I4
a(lp3275
I32
atp3276
a(I1
S'Here we show that QM / Jun - interacting factor ( Jif ) - 1 , a negative regulator of c - Jun , is a candidate to mediate the function of PS1 in the cell .'
p3277
(lp3278
I6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
a(lp3279
I20
aI21
aI22
atp3280
a(I-1
S'Here we show that QM / Jun - interacting factor ( Jif ) - 1 , a negative regulator of c - Jun , is a candidate to mediate the function of PS1 in the cell .'
p3281
(lp3282
I6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
a(lp3283
I32
atp3284
a(I-1
S'Here we show that QM / Jun - interacting factor ( Jif ) - 1 , a negative regulator of c - Jun , is a candidate to mediate the function of PS1 in the cell .'
p3285
(lp3286
I20
aI21
aI22
a(lp3287
I32
atp3288
a(I1
S'We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two - hybrid method and isolated one clone encoding the QM / Jif - 1 gene .'
p3289
(lp3290
I7
a(lp3291
I27
atp3292
a(I1
S'We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two - hybrid method and isolated one clone encoding the QM / Jif - 1 gene .'
p3293
(lp3294
I7
a(lp3295
I29
aI30
aI31
atp3296
a(I-1
S'We screened for proteins that bind to PS1 from a human embryonic brain cDNA library using the two - hybrid method and isolated one clone encoding the QM / Jif - 1 gene .'
p3297
(lp3298
I27
a(lp3299
I29
aI30
aI31
atp3300
a(I-1
S'The binding of QM / Jif - 1 to full - length PS1 was confirmed in vitro by pull - down assay , and in vivo by immunoprecipitation assays with human samples , including AD brains .'
p3301
(lp3302
I3
a(lp3303
I5
aI6
aI7
atp3304
a(I1
S'The binding of QM / Jif - 1 to full - length PS1 was confirmed in vitro by pull - down assay , and in vivo by immunoprecipitation assays with human samples , including AD brains .'
p3305
(lp3306
I3
a(lp3307
I12
atp3308
a(I1
S'The binding of QM / Jif - 1 to full - length PS1 was confirmed in vitro by pull - down assay , and in vivo by immunoprecipitation assays with human samples , including AD brains .'
p3309
(lp3310
I5
aI6
aI7
a(lp3311
I12
atp3312
a(I-1
S'Immunoelectronmicroscopic analysis showed that QM / Jif - 1 and PS1 are colocalized at the endoplasmic reticulum , and the nuclear matrix in human brain neurons .'
p3313
(lp3314
I4
a(lp3315
I6
aI7
aI8
atp3316
a(I-1
S'Immunoelectronmicroscopic analysis showed that QM / Jif - 1 and PS1 are colocalized at the endoplasmic reticulum , and the nuclear matrix in human brain neurons .'
p3317
(lp3318
I4
a(lp3319
I10
atp3320
a(I-1
S'Immunoelectronmicroscopic analysis showed that QM / Jif - 1 and PS1 are colocalized at the endoplasmic reticulum , and the nuclear matrix in human brain neurons .'
p3321
(lp3322
I6
aI7
aI8
a(lp3323
I10
atp3324
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3325
(lp3326
I8
a(lp3327
I12
aI13
aI14
atp3328
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3329
(lp3330
I8
a(lp3331
I16
aI17
aI18
atp3332
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3333
(lp3334
I8
a(lp3335
I22
aI23
aI24
atp3336
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3337
(lp3338
I8
a(lp3339
I26
aI27
aI28
atp3340
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3341
(lp3342
I8
a(lp3343
I37
atp3344
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3345
(lp3346
I8
a(lp3347
I39
aI40
aI41
atp3348
a(I1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3349
(lp3350
I12
aI13
aI14
a(lp3351
I16
aI17
aI18
atp3352
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3353
(lp3354
I12
aI13
aI14
a(lp3355
I22
aI23
aI24
atp3356
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3357
(lp3358
I12
aI13
aI14
a(lp3359
I26
aI27
aI28
atp3360
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3361
(lp3362
I12
aI13
aI14
a(lp3363
I37
atp3364
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3365
(lp3366
I12
aI13
aI14
a(lp3367
I39
aI40
aI41
atp3368
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3369
(lp3370
I16
aI17
aI18
a(lp3371
I22
aI23
aI24
atp3372
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3373
(lp3374
I16
aI17
aI18
a(lp3375
I26
aI27
aI28
atp3376
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3377
(lp3378
I16
aI17
aI18
a(lp3379
I37
atp3380
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3381
(lp3382
I16
aI17
aI18
a(lp3383
I39
aI40
aI41
atp3384
a(I1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3385
(lp3386
I22
aI23
aI24
a(lp3387
I26
aI27
aI28
atp3388
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3389
(lp3390
I22
aI23
aI24
a(lp3391
I37
atp3392
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3393
(lp3394
I22
aI23
aI24
a(lp3395
I39
aI40
aI41
atp3396
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3397
(lp3398
I26
aI27
aI28
a(lp3399
I37
atp3400
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3401
(lp3402
I26
aI27
aI28
a(lp3403
I39
aI40
aI41
atp3404
a(I-1
S'Chloramphenicol acetyltransferase assays in F9 cells showed that PS1 suppresses transactivation by c - Jun / c - Jun but not by c - Jun / c - Fos heterodimers , consistent with the reported function of QM / Jif - 1 .'
p3405
(lp3406
I37
a(lp3407
I39
aI40
aI41
atp3408
a(I-1
S'By monitoring fluorescent recombinant protein and by gel mobility shift assays , PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c - Jun homodimer to 12 - O - tetradecanoylphorbol - 13 - acetate ( TPA ) - responsive element ( TRE ) .'
p3409
(lp3410
I12
a(lp3411
I20
atp3412
a(I-1
S'By monitoring fluorescent recombinant protein and by gel mobility shift assays , PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c - Jun homodimer to 12 - O - tetradecanoylphorbol - 13 - acetate ( TPA ) - responsive element ( TRE ) .'
p3413
(lp3414
I12
a(lp3415
I34
aI35
aI36
atp3416
a(I-1
S'By monitoring fluorescent recombinant protein and by gel mobility shift assays , PS1 was shown to accelerate the translocation of QM from the cytoplasm to the nucleus and to thereby suppress the binding of c - Jun homodimer to 12 - O - tetradecanoylphorbol - 13 - acetate ( TPA ) - responsive element ( TRE ) .'
p3417
(lp3418
I20
a(lp3419
I34
aI35
aI36
atp3420
a(I-1
S'PS1 suppressed c - jun - associated apoptosis by retinoic acid in F9 embryonic carcinoma cells , whereas this suppression of apoptosis is attenuated by mutation in PS1 .'
p3421
(lp3422
I0
a(lp3423
I2
aI3
aI4
atp3424
a(I-1
S'PS1 suppressed c - jun - associated apoptosis by retinoic acid in F9 embryonic carcinoma cells , whereas this suppression of apoptosis is attenuated by mutation in PS1 .'
p3425
(lp3426
I0
a(lp3427
I27
atp3428
a(I-1
S'PS1 suppressed c - jun - associated apoptosis by retinoic acid in F9 embryonic carcinoma cells , whereas this suppression of apoptosis is attenuated by mutation in PS1 .'
p3429
(lp3430
I2
aI3
aI4
a(lp3431
I27
atp3432
a(I-1
S'Collectively , the novel function of PS1 via QM / Jif - 1 influences c - jun - mediated transcription and apoptosis .'
p3433
(lp3434
I6
a(lp3435
I8
atp3436
a(I-1
S'Collectively , the novel function of PS1 via QM / Jif - 1 influences c - jun - mediated transcription and apoptosis .'
p3437
(lp3438
I6
a(lp3439
I10
aI11
aI12
atp3440
a(I-1
S'Collectively , the novel function of PS1 via QM / Jif - 1 influences c - jun - mediated transcription and apoptosis .'
p3441
(lp3442
I6
a(lp3443
I14
aI15
aI16
atp3444
a(I-1
S'Collectively , the novel function of PS1 via QM / Jif - 1 influences c - jun - mediated transcription and apoptosis .'
p3445
(lp3446
I8
a(lp3447
I10
aI11
aI12
atp3448
a(I-1
S'Collectively , the novel function of PS1 via QM / Jif - 1 influences c - jun - mediated transcription and apoptosis .'
p3449
(lp3450
I8
a(lp3451
I14
aI15
aI16
atp3452
a(I-1
S'Collectively , the novel function of PS1 via QM / Jif - 1 influences c - jun - mediated transcription and apoptosis .'
p3453
(lp3454
I10
aI11
aI12
a(lp3455
I14
aI15
aI16
atp3456
a(I1
S'We have crystallized a complex between human FGF1 and a two - domain extracellular fragment of human FGFR2 .'
p3457
(lp3458
I7
a(lp3459
I17
atp3460
a(I-1
S'Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor .'
p3461
(lp3462
I7
a(lp3463
I10
atp3464
a(I1
S'Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor .'
p3465
(lp3466
I7
a(lp3467
I10
aI11
atp3468
a(I-1
S'Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor .'
p3469
(lp3470
I10
a(lp3471
I10
aI11
atp3472
a(I-1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3473
(lp3474
I0
a(lp3475
I4
atp3476
a(I1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3477
(lp3478
I0
a(lp3479
I4
aI5
atp3480
a(I1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3481
(lp3482
I0
a(lp3483
I7
atp3484
a(I-1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3485
(lp3486
I0
a(lp3487
I19
atp3488
a(I-1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3489
(lp3490
I4
a(lp3491
I4
aI5
atp3492
a(I-1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3493
(lp3494
I4
a(lp3495
I7
atp3496
a(I-1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3497
(lp3498
I4
a(lp3499
I19
atp3500
a(I-1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3501
(lp3502
I4
aI5
a(lp3503
I7
atp3504
a(I-1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3505
(lp3506
I4
aI5
a(lp3507
I19
atp3508
a(I-1
S'HFE binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron - loaded transferrin .'
p3509
(lp3510
I7
a(lp3511
I19
atp3512
a(I1
S'The 2 . 8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer .'
p3513
(lp3514
I15
a(lp3515
I17
atp3516
a(I-1
S'The 2 . 8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer .'
p3517
(lp3518
I15
a(lp3519
I20
atp3520
a(I-1
S'The 2 . 8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer .'
p3521
(lp3522
I15
a(lp3523
I30
atp3524
a(I-1
S'The 2 . 8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer .'
p3525
(lp3526
I17
a(lp3527
I20
atp3528
a(I-1
S'The 2 . 8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer .'
p3529
(lp3530
I17
a(lp3531
I30
atp3532
a(I1
S'The 2 . 8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer .'
p3533
(lp3534
I20
a(lp3535
I30
atp3536
a(I-1
S"On a cell membrane containing both proteins , HFE would ' lie down ' parallel to the membrane , such that the HFE helices that delineate the counterpart of the MHC peptide - binding groove make extensive contacts with helices in the TfR dimerization domain ."
p3537
(lp3538
I8
a(lp3539
I22
atp3540
a(I-1
S"On a cell membrane containing both proteins , HFE would ' lie down ' parallel to the membrane , such that the HFE helices that delineate the counterpart of the MHC peptide - binding groove make extensive contacts with helices in the TfR dimerization domain ."
p3541
(lp3542
I8
a(lp3543
I42
atp3544
a(I1
S"On a cell membrane containing both proteins , HFE would ' lie down ' parallel to the membrane , such that the HFE helices that delineate the counterpart of the MHC peptide - binding groove make extensive contacts with helices in the TfR dimerization domain ."
p3545
(lp3546
I22
a(lp3547
I42
atp3548
a(I1
S'The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces , providing a mechanism for communicating binding events between TfR chains .'
p3549
(lp3550
I3
a(lp3551
I8
atp3552
a(I-1
S'The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces , providing a mechanism for communicating binding events between TfR chains .'
p3553
(lp3554
I3
a(lp3555
I26
atp3556
a(I-1
S'The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces , providing a mechanism for communicating binding events between TfR chains .'
p3557
(lp3558
I8
a(lp3559
I26
atp3560
a(I1
S'The HFE - TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis .'
p3561
(lp3562
I1
a(lp3563
I3
atp3564
a(I-1
S'The HFE - TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis .'
p3565
(lp3566
I1
a(lp3567
I12
atp3568
a(I-1
S'The HFE - TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis .'
p3569
(lp3570
I1
a(lp3571
I20
atp3572
a(I-1
S'The HFE - TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis .'
p3573
(lp3574
I3
a(lp3575
I12
atp3576
a(I-1
S'The HFE - TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis .'
p3577
(lp3578
I3
a(lp3579
I20
atp3580
a(I-1
S'The HFE - TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis .'
p3581
(lp3582
I12
a(lp3583
I20
atp3584
a(I-1
S'The BMP receptors belong to the family of serine / threonine kinase receptors , whose activation has been investigated intensively for the transforming growth factor - beta ( TGF - beta ) receptor subfamily .'
p3585
(lp3586
I22
aI23
aI24
aI25
aI26
a(lp3587
I28
aI29
aI30
atp3588
a(I-1
S'Using several complementary approaches , we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( BR - Ia and BR - Ib ) and the BMP type II receptor ( BR - II ) .'
p3589
(lp3590
I23
aI24
aI25
a(lp3591
I27
aI28
aI29
atp3592
a(I-1
S'Using several complementary approaches , we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( BR - Ia and BR - Ib ) and the BMP type II receptor ( BR - II ) .'
p3593
(lp3594
I23
aI24
aI25
a(lp3595
I33
aI34
aI35
aI36
atp3596
a(I-1
S'Using several complementary approaches , we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( BR - Ia and BR - Ib ) and the BMP type II receptor ( BR - II ) .'
p3597
(lp3598
I23
aI24
aI25
a(lp3599
I38
aI39
aI40
atp3600
a(I-1
S'Using several complementary approaches , we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( BR - Ia and BR - Ib ) and the BMP type II receptor ( BR - II ) .'
p3601
(lp3602
I27
aI28
aI29
a(lp3603
I33
aI34
aI35
aI36
atp3604
a(I-1
S'Using several complementary approaches , we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( BR - Ia and BR - Ib ) and the BMP type II receptor ( BR - II ) .'
p3605
(lp3606
I27
aI28
aI29
a(lp3607
I38
aI39
aI40
atp3608
a(I-1
S'Using several complementary approaches , we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ( BR - Ia and BR - Ib ) and the BMP type II receptor ( BR - II ) .'
p3609
(lp3610
I33
aI34
aI35
aI36
a(lp3611
I38
aI39
aI40
atp3612
a(I1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3613
(lp3614
I22
aI23
aI24
a(lp3615
I26
aI27
aI28
atp3616
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3617
(lp3618
I22
aI23
aI24
a(lp3619
I30
aI31
aI32
atp3620
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3621
(lp3622
I22
aI23
aI24
a(lp3623
I34
aI35
aI36
atp3624
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3625
(lp3626
I22
aI23
aI24
a(lp3627
I41
aI42
aI43
atp3628
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3629
(lp3630
I22
aI23
aI24
a(lp3631
I45
aI46
aI47
atp3632
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3633
(lp3634
I22
aI23
aI24
a(lp3635
I49
aI50
aI51
atp3636
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3637
(lp3638
I22
aI23
aI24
a(lp3639
I53
aI54
aI55
atp3640
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3641
(lp3642
I22
aI23
aI24
a(lp3643
I57
aI58
aI59
atp3644
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3645
(lp3646
I22
aI23
aI24
a(lp3647
I61
aI62
aI63
atp3648
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3649
(lp3650
I22
aI23
aI24
a(lp3651
I67
aI68
aI69
atp3652
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3653
(lp3654
I22
aI23
aI24
a(lp3655
I71
aI72
aI73
atp3656
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3657
(lp3658
I26
aI27
aI28
a(lp3659
I30
aI31
aI32
atp3660
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3661
(lp3662
I26
aI27
aI28
a(lp3663
I34
aI35
aI36
atp3664
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3665
(lp3666
I26
aI27
aI28
a(lp3667
I41
aI42
aI43
atp3668
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3669
(lp3670
I26
aI27
aI28
a(lp3671
I45
aI46
aI47
atp3672
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3673
(lp3674
I26
aI27
aI28
a(lp3675
I49
aI50
aI51
atp3676
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3677
(lp3678
I26
aI27
aI28
a(lp3679
I53
aI54
aI55
atp3680
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3681
(lp3682
I26
aI27
aI28
a(lp3683
I57
aI58
aI59
atp3684
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3685
(lp3686
I26
aI27
aI28
a(lp3687
I61
aI62
aI63
atp3688
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3689
(lp3690
I26
aI27
aI28
a(lp3691
I67
aI68
aI69
atp3692
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3693
(lp3694
I26
aI27
aI28
a(lp3695
I71
aI72
aI73
atp3696
a(I1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3697
(lp3698
I30
aI31
aI32
a(lp3699
I34
aI35
aI36
atp3700
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3701
(lp3702
I30
aI31
aI32
a(lp3703
I41
aI42
aI43
atp3704
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3705
(lp3706
I30
aI31
aI32
a(lp3707
I45
aI46
aI47
atp3708
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3709
(lp3710
I30
aI31
aI32
a(lp3711
I49
aI50
aI51
atp3712
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3713
(lp3714
I30
aI31
aI32
a(lp3715
I53
aI54
aI55
atp3716
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3717
(lp3718
I30
aI31
aI32
a(lp3719
I57
aI58
aI59
atp3720
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3721
(lp3722
I30
aI31
aI32
a(lp3723
I61
aI62
aI63
atp3724
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3725
(lp3726
I30
aI31
aI32
a(lp3727
I67
aI68
aI69
atp3728
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3729
(lp3730
I30
aI31
aI32
a(lp3731
I71
aI72
aI73
atp3732
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3733
(lp3734
I34
aI35
aI36
a(lp3735
I41
aI42
aI43
atp3736
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3737
(lp3738
I34
aI35
aI36
a(lp3739
I45
aI46
aI47
atp3740
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3741
(lp3742
I34
aI35
aI36
a(lp3743
I49
aI50
aI51
atp3744
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3745
(lp3746
I34
aI35
aI36
a(lp3747
I53
aI54
aI55
atp3748
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3749
(lp3750
I34
aI35
aI36
a(lp3751
I57
aI58
aI59
atp3752
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3753
(lp3754
I34
aI35
aI36
a(lp3755
I61
aI62
aI63
atp3756
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3757
(lp3758
I34
aI35
aI36
a(lp3759
I67
aI68
aI69
atp3760
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3761
(lp3762
I34
aI35
aI36
a(lp3763
I71
aI72
aI73
atp3764
a(I1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3765
(lp3766
I41
aI42
aI43
a(lp3767
I45
aI46
aI47
atp3768
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3769
(lp3770
I41
aI42
aI43
a(lp3771
I49
aI50
aI51
atp3772
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3773
(lp3774
I41
aI42
aI43
a(lp3775
I53
aI54
aI55
atp3776
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3777
(lp3778
I41
aI42
aI43
a(lp3779
I57
aI58
aI59
atp3780
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3781
(lp3782
I41
aI42
aI43
a(lp3783
I61
aI62
aI63
atp3784
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3785
(lp3786
I41
aI42
aI43
a(lp3787
I67
aI68
aI69
atp3788
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3789
(lp3790
I41
aI42
aI43
a(lp3791
I71
aI72
aI73
atp3792
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3793
(lp3794
I45
aI46
aI47
a(lp3795
I49
aI50
aI51
atp3796
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3797
(lp3798
I45
aI46
aI47
a(lp3799
I53
aI54
aI55
atp3800
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3801
(lp3802
I45
aI46
aI47
a(lp3803
I57
aI58
aI59
atp3804
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3805
(lp3806
I45
aI46
aI47
a(lp3807
I61
aI62
aI63
atp3808
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3809
(lp3810
I45
aI46
aI47
a(lp3811
I67
aI68
aI69
atp3812
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3813
(lp3814
I45
aI46
aI47
a(lp3815
I71
aI72
aI73
atp3816
a(I1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3817
(lp3818
I49
aI50
aI51
a(lp3819
I53
aI54
aI55
atp3820
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3821
(lp3822
I49
aI50
aI51
a(lp3823
I57
aI58
aI59
atp3824
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3825
(lp3826
I49
aI50
aI51
a(lp3827
I61
aI62
aI63
atp3828
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3829
(lp3830
I49
aI50
aI51
a(lp3831
I67
aI68
aI69
atp3832
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3833
(lp3834
I49
aI50
aI51
a(lp3835
I71
aI72
aI73
atp3836
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3837
(lp3838
I53
aI54
aI55
a(lp3839
I57
aI58
aI59
atp3840
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3841
(lp3842
I53
aI54
aI55
a(lp3843
I61
aI62
aI63
atp3844
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3845
(lp3846
I53
aI54
aI55
a(lp3847
I67
aI68
aI69
atp3848
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3849
(lp3850
I53
aI54
aI55
a(lp3851
I71
aI72
aI73
atp3852
a(I1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3853
(lp3854
I57
aI58
aI59
a(lp3855
I61
aI62
aI63
atp3856
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3857
(lp3858
I57
aI58
aI59
a(lp3859
I67
aI68
aI69
atp3860
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3861
(lp3862
I57
aI58
aI59
a(lp3863
I71
aI72
aI73
atp3864
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3865
(lp3866
I61
aI62
aI63
a(lp3867
I67
aI68
aI69
atp3868
a(I-1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3869
(lp3870
I61
aI62
aI63
a(lp3871
I71
aI72
aI73
atp3872
a(I1
S'Using antibody - mediated immunofluorescence copatching of epitope - tagged receptors , we provide evidence in live cells for preexisting heteromeric ( BR - II / BR - Ia and BR - II / BR - Ib ) and homomeric ( BR - II / BR - II , BR - Ia / BR - Ia , BR - Ib / BR - Ib , and also BR - Ia / BR - Ib ) oligomers in the absence of ligand .'
p3873
(lp3874
I67
aI68
aI69
a(lp3875
I71
aI72
aI73
atp3876
a(I1
S'BMP - 2 binding significantly increased hetero - and homo - oligomerization ( except for the BR - II homo - oligomer , which binds ligand poorly in the absence of BR - I ) .'
p3877
(lp3878
I0
aI1
aI2
a(lp3879
I16
aI17
aI18
atp3880
a(I-1
S'BMP - 2 binding significantly increased hetero - and homo - oligomerization ( except for the BR - II homo - oligomer , which binds ligand poorly in the absence of BR - I ) .'
p3881
(lp3882
I0
aI1
aI2
a(lp3883
I31
aI32
aI33
atp3884
a(I1
S'BMP - 2 binding significantly increased hetero - and homo - oligomerization ( except for the BR - II homo - oligomer , which binds ligand poorly in the absence of BR - I ) .'
p3885
(lp3886
I16
aI17
aI18
a(lp3887
I31
aI32
aI33
atp3888
a(I1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3889
(lp3890
I6
a(lp3891
I11
aI12
aI13
atp3892
a(I1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3893
(lp3894
I6
a(lp3895
I15
atp3896
a(I-1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3897
(lp3898
I6
a(lp3899
I20
atp3900
a(I-1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3901
(lp3902
I6
a(lp3903
I25
aI26
aI27
atp3904
a(I-1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3905
(lp3906
I11
aI12
aI13
a(lp3907
I15
atp3908
a(I-1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3909
(lp3910
I11
aI12
aI13
a(lp3911
I20
atp3912
a(I-1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3913
(lp3914
I11
aI12
aI13
a(lp3915
I25
aI26
aI27
atp3916
a(I-1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3917
(lp3918
I15
a(lp3919
I20
atp3920
a(I-1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3921
(lp3922
I15
a(lp3923
I25
aI26
aI27
atp3924
a(I1
S'Although the individual amino acids in TrkA involved in binding to nerve growth factor ( NGF ) and those in TrkC involved in binding to neurotrophin - 3 have been mapped in this domain , the Trk amino acids that provide specificity remained unclear .'
p3925
(lp3926
I20
a(lp3927
I25
aI26
aI27
atp3928
a(I-1
S'In this study , a minimum set of residues in the human TrkC second immunoglobulin - like domain , which does not bind nerve growth factor ( NGF ) , were substituted with those from human TrkA .'
p3929
(lp3930
I12
a(lp3931
I23
aI24
aI25
atp3932
a(I-1
S'In this study , a minimum set of residues in the human TrkC second immunoglobulin - like domain , which does not bind nerve growth factor ( NGF ) , were substituted with those from human TrkA .'
p3933
(lp3934
I12
a(lp3935
I27
atp3936
a(I-1
S'In this study , a minimum set of residues in the human TrkC second immunoglobulin - like domain , which does not bind nerve growth factor ( NGF ) , were substituted with those from human TrkA .'
p3937
(lp3938
I12
a(lp3939
I36
atp3940
a(I-1
S'In this study , a minimum set of residues in the human TrkC second immunoglobulin - like domain , which does not bind nerve growth factor ( NGF ) , were substituted with those from human TrkA .'
p3941
(lp3942
I23
aI24
aI25
a(lp3943
I27
atp3944
a(I-1
S'In this study , a minimum set of residues in the human TrkC second immunoglobulin - like domain , which does not bind nerve growth factor ( NGF ) , were substituted with those from human TrkA .'
p3945
(lp3946
I23
aI24
aI25
a(lp3947
I36
atp3948
a(I-1
S'In this study , a minimum set of residues in the human TrkC second immunoglobulin - like domain , which does not bind nerve growth factor ( NGF ) , were substituted with those from human TrkA .'
p3949
(lp3950
I27
a(lp3951
I36
atp3952
a(I1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3953
(lp3954
I7
a(lp3955
I10
atp3956
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3957
(lp3958
I7
a(lp3959
I13
aI14
aI15
atp3960
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3961
(lp3962
I7
a(lp3963
I19
atp3964
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3965
(lp3966
I7
a(lp3967
I24
aI25
aI26
aI27
atp3968
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3969
(lp3970
I7
a(lp3971
I35
atp3972
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3973
(lp3974
I10
a(lp3975
I13
aI14
aI15
atp3976
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3977
(lp3978
I10
a(lp3979
I19
atp3980
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3981
(lp3982
I10
a(lp3983
I24
aI25
aI26
aI27
atp3984
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3985
(lp3986
I10
a(lp3987
I35
atp3988
a(I1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3989
(lp3990
I13
aI14
aI15
a(lp3991
I19
atp3992
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3993
(lp3994
I13
aI14
aI15
a(lp3995
I24
aI25
aI26
aI27
atp3996
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p3997
(lp3998
I13
aI14
aI15
a(lp3999
I35
atp4000
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p4001
(lp4002
I19
a(lp4003
I24
aI25
aI26
aI27
atp4004
a(I-1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p4005
(lp4006
I19
a(lp4007
I35
atp4008
a(I1
S'The resulting Trk variant recruited binding of NGF equivalent to TrkA , maintained neurotrophin - 3 binding equivalent to TrkC , and also bound brain - derived neurotrophin , although with lower affinity compared with TrkB .'
p4009
(lp4010
I24
aI25
aI26
aI27
a(lp4011
I35
atp4012
a(I1
S'Characterization of the CD30L binding domain on the human CD30 molecule using anti - CD30 antibodies .'
p4013
(lp4014
I3
a(lp4015
I9
atp4016
a(I-1
S'Characterization of the CD30L binding domain on the human CD30 molecule using anti - CD30 antibodies .'
p4017
(lp4018
I3
a(lp4019
I14
atp4020
a(I-1
S'Characterization of the CD30L binding domain on the human CD30 molecule using anti - CD30 antibodies .'
p4021
(lp4022
I9
a(lp4023
I14
atp4024
a(I-1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4025
(lp4026
I0
a(lp4027
I6
atp4028
a(I1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4029
(lp4030
I0
a(lp4031
I6
aI7
atp4032
a(I1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4033
(lp4034
I0
a(lp4035
I9
atp4036
a(I-1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4037
(lp4038
I0
a(lp4039
I19
atp4040
a(I-1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4041
(lp4042
I6
a(lp4043
I6
aI7
atp4044
a(I-1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4045
(lp4046
I6
a(lp4047
I9
atp4048
a(I-1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4049
(lp4050
I6
a(lp4051
I19
atp4052
a(I-1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4053
(lp4054
I6
aI7
a(lp4055
I9
atp4056
a(I-1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4057
(lp4058
I6
aI7
a(lp4059
I19
atp4060
a(I-1
S'CD30 and its counter - receptor CD30 ligand ( CD30L ) are members of the TNF - receptor / TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .'
p4061
(lp4062
I9
a(lp4063
I19
atp4064
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4065
(lp4066
I3
a(lp4067
I5
atp4068
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4069
(lp4070
I3
a(lp4071
I16
atp4072
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4073
(lp4074
I3
a(lp4075
I23
atp4076
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4077
(lp4078
I3
a(lp4079
I25
atp4080
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4081
(lp4082
I5
a(lp4083
I16
atp4084
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4085
(lp4086
I5
a(lp4087
I23
atp4088
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4089
(lp4090
I5
a(lp4091
I25
atp4092
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4093
(lp4094
I16
a(lp4095
I23
atp4096
a(I-1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4097
(lp4098
I16
a(lp4099
I25
atp4100
a(I1
S'Using a soluble CD30L / CD8alpha chimeric protein , we assessed the ability of anti - CD30 MAb to inhibit the binding of CD30L to CD30 expressed by the CD30 + Karpas 299 cell line .'
p4101
(lp4102
I23
a(lp4103
I25
atp4104
a(I1
S'CD30L binding by CD30 is blocked by MAb that recognize epitopes belonging to cluster Group A ( like Ber - H2 , Ber - H8 , and HRS - 4 ) as well as cluster Group C ( like HeFi - 1 and M44 ) .'
p4105
(lp4106
I0
a(lp4107
I3
atp4108
a(I1
S'Cluster Group B antibodies , including M67 and Ki - 1 , do not affect CD30L binding to CD30 .'
p4109
(lp4110
I15
a(lp4111
I18
atp4112
a(I-1
S'The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti - CD30 MAb to trigger CD30 signaling .'
p4113
(lp4114
I3
a(lp4115
I18
atp4116
a(I-1
S'The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti - CD30 MAb to trigger CD30 signaling .'
p4117
(lp4118
I3
a(lp4119
I22
atp4120
a(I-1
S'The pattern of CD30L binding inhibition shows only limited correspondence to the functional capacity of some anti - CD30 MAb to trigger CD30 signaling .'
p4121
(lp4122
I18
a(lp4123
I22
atp4124
a(I-1
S'Finally , we demonstrate that the anti - CD30L MAb M81 also completely inhibits CD30 / CD30L interaction .'
p4125
(lp4126
I8
a(lp4127
I14
atp4128
a(I-1
S'Finally , we demonstrate that the anti - CD30L MAb M81 also completely inhibits CD30 / CD30L interaction .'
p4129
(lp4130
I8
a(lp4131
I16
atp4132
a(I1
S'Finally , we demonstrate that the anti - CD30L MAb M81 also completely inhibits CD30 / CD30L interaction .'
p4133
(lp4134
I14
a(lp4135
I16
atp4136
a(I-1
S'This information is useful for applying these MAbs in functional studies to further investigate the CD30 / CD30L system and for designing assays for soluble CD30L .'
p4137
(lp4138
I15
a(lp4139
I17
atp4140
a(I-1
S'This information is useful for applying these MAbs in functional studies to further investigate the CD30 / CD30L system and for designing assays for soluble CD30L .'
p4141
(lp4142
I15
a(lp4143
I25
atp4144
a(I-1
S'This information is useful for applying these MAbs in functional studies to further investigate the CD30 / CD30L system and for designing assays for soluble CD30L .'
p4145
(lp4146
I17
a(lp4147
I25
atp4148
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4149
(lp4150
I5
aI6
aI7
a(lp4151
I9
aI10
aI11
atp4152
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4153
(lp4154
I5
aI6
aI7
a(lp4155
I9
aI10
aI11
aI12
atp4156
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4157
(lp4158
I5
aI6
aI7
a(lp4159
I17
aI18
aI19
atp4160
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4161
(lp4162
I5
aI6
aI7
a(lp4163
I17
aI18
aI19
aI20
atp4164
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4165
(lp4166
I5
aI6
aI7
a(lp4167
I17
aI18
aI19
aI20
aI21
aI22
atp4168
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4169
(lp4170
I5
aI6
aI7
a(lp4171
I24
aI25
aI26
atp4172
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4173
(lp4174
I5
aI6
aI7
a(lp4175
I24
aI25
aI26
aI27
aI28
atp4176
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4177
(lp4178
I9
aI10
aI11
a(lp4179
I9
aI10
aI11
aI12
atp4180
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4181
(lp4182
I9
aI10
aI11
a(lp4183
I17
aI18
aI19
atp4184
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4185
(lp4186
I9
aI10
aI11
a(lp4187
I17
aI18
aI19
aI20
atp4188
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4189
(lp4190
I9
aI10
aI11
a(lp4191
I17
aI18
aI19
aI20
aI21
aI22
atp4192
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4193
(lp4194
I9
aI10
aI11
a(lp4195
I24
aI25
aI26
atp4196
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4197
(lp4198
I9
aI10
aI11
a(lp4199
I24
aI25
aI26
aI27
aI28
atp4200
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4201
(lp4202
I9
aI10
aI11
aI12
a(lp4203
I17
aI18
aI19
atp4204
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4205
(lp4206
I9
aI10
aI11
aI12
a(lp4207
I17
aI18
aI19
aI20
atp4208
a(I1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4209
(lp4210
I9
aI10
aI11
aI12
a(lp4211
I17
aI18
aI19
aI20
aI21
aI22
atp4212
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4213
(lp4214
I9
aI10
aI11
aI12
a(lp4215
I24
aI25
aI26
atp4216
a(I1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4217
(lp4218
I9
aI10
aI11
aI12
a(lp4219
I24
aI25
aI26
aI27
aI28
atp4220
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4221
(lp4222
I17
aI18
aI19
a(lp4223
I17
aI18
aI19
aI20
atp4224
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4225
(lp4226
I17
aI18
aI19
a(lp4227
I17
aI18
aI19
aI20
aI21
aI22
atp4228
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4229
(lp4230
I17
aI18
aI19
a(lp4231
I24
aI25
aI26
atp4232
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4233
(lp4234
I17
aI18
aI19
a(lp4235
I24
aI25
aI26
aI27
aI28
atp4236
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4237
(lp4238
I17
aI18
aI19
aI20
a(lp4239
I17
aI18
aI19
aI20
aI21
aI22
atp4240
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4241
(lp4242
I17
aI18
aI19
aI20
a(lp4243
I24
aI25
aI26
atp4244
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4245
(lp4246
I17
aI18
aI19
aI20
a(lp4247
I24
aI25
aI26
aI27
aI28
atp4248
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4249
(lp4250
I17
aI18
aI19
aI20
aI21
aI22
a(lp4251
I24
aI25
aI26
atp4252
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4253
(lp4254
I17
aI18
aI19
aI20
aI21
aI22
a(lp4255
I24
aI25
aI26
aI27
aI28
atp4256
a(I-1
S'A mutant form of human interferon - gamma ( IFN - gamma SC1 ) that binds one IFN - gamma receptor alpha chain ( IFN - gamma R alpha ) has been designed and characterized .'
p4257
(lp4258
I24
aI25
aI26
a(lp4259
I24
aI25
aI26
aI27
aI28
atp4260
a(I-1
S'IFN - gamma SC1 was derived by linking the two peptide chains of the IFN - gamma dimer by a seven - residue linker and changing His111 in the first chain to an aspartic acid residue .'
p4261
(lp4262
I0
aI1
aI2
a(lp4263
I0
aI1
aI2
aI3
atp4264
a(I-1
S'IFN - gamma SC1 was derived by linking the two peptide chains of the IFN - gamma dimer by a seven - residue linker and changing His111 in the first chain to an aspartic acid residue .'
p4265
(lp4266
I0
aI1
aI2
a(lp4267
I14
aI15
aI16
atp4268
a(I-1
S'IFN - gamma SC1 was derived by linking the two peptide chains of the IFN - gamma dimer by a seven - residue linker and changing His111 in the first chain to an aspartic acid residue .'
p4269
(lp4270
I0
aI1
aI2
aI3
a(lp4271
I14
aI15
aI16
atp4272
a(I-1
S'Isothermal titration calorimetry shows that IFN - gamma SC1 forms a 1 : 1 complex with its high - affinity receptor ( IFN - gamma R alpha ) with an affinity of 27 ( + / - 9 ) nM .'
p4273
(lp4274
I5
aI6
aI7
a(lp4275
I5
aI6
aI7
aI8
atp4276
a(I-1
S'Isothermal titration calorimetry shows that IFN - gamma SC1 forms a 1 : 1 complex with its high - affinity receptor ( IFN - gamma R alpha ) with an affinity of 27 ( + / - 9 ) nM .'
p4277
(lp4278
I5
aI6
aI7
a(lp4279
I22
aI23
aI24
atp4280
a(I-1
S'Isothermal titration calorimetry shows that IFN - gamma SC1 forms a 1 : 1 complex with its high - affinity receptor ( IFN - gamma R alpha ) with an affinity of 27 ( + / - 9 ) nM .'
p4281
(lp4282
I5
aI6
aI7
a(lp4283
I22
aI23
aI24
aI25
aI26
atp4284
a(I-1
S'Isothermal titration calorimetry shows that IFN - gamma SC1 forms a 1 : 1 complex with its high - affinity receptor ( IFN - gamma R alpha ) with an affinity of 27 ( + / - 9 ) nM .'
p4285
(lp4286
I5
aI6
aI7
aI8
a(lp4287
I22
aI23
aI24
atp4288
a(I1
S'Isothermal titration calorimetry shows that IFN - gamma SC1 forms a 1 : 1 complex with its high - affinity receptor ( IFN - gamma R alpha ) with an affinity of 27 ( + / - 9 ) nM .'
p4289
(lp4290
I5
aI6
aI7
aI8
a(lp4291
I22
aI23
aI24
aI25
aI26
atp4292
a(I-1
S'Isothermal titration calorimetry shows that IFN - gamma SC1 forms a 1 : 1 complex with its high - affinity receptor ( IFN - gamma R alpha ) with an affinity of 27 ( + / - 9 ) nM .'
p4293
(lp4294
I22
aI23
aI24
a(lp4295
I22
aI23
aI24
aI25
aI26
atp4296
a(I-1
S'The crystal structure of IFN - gamma SC1 has been determined at 2 . 9 A resolution from crystals grown in 1 . 4 M citrate solutions at pH 7 . 6 .'
p4297
(lp4298
I4
aI5
aI6
a(lp4299
I4
aI5
aI6
aI7
atp4300
a(I-1
S'Comparison of the wild - type receptor - binding domain and the Asp111 - containing domain of IFN - gamma SC1 show that they are structurally equivalent but have very different electrostatic surface potentials .'
p4301
(lp4302
I17
aI18
aI19
a(lp4303
I17
aI18
aI19
aI20
atp4304
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4305
(lp4306
I4
aI5
aI6
aI7
a(lp4307
I16
aI17
aI18
atp4308
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4309
(lp4310
I4
aI5
aI6
aI7
a(lp4311
I26
aI27
aI28
atp4312
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4313
(lp4314
I4
aI5
aI6
aI7
a(lp4315
I30
aI31
aI32
atp4316
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4317
(lp4318
I4
aI5
aI6
aI7
a(lp4319
I30
aI31
aI32
aI33
aI34
atp4320
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4321
(lp4322
I16
aI17
aI18
a(lp4323
I26
aI27
aI28
atp4324
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4325
(lp4326
I16
aI17
aI18
a(lp4327
I30
aI31
aI32
atp4328
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4329
(lp4330
I16
aI17
aI18
a(lp4331
I30
aI31
aI32
aI33
aI34
atp4332
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4333
(lp4334
I26
aI27
aI28
a(lp4335
I30
aI31
aI32
atp4336
a(I1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4337
(lp4338
I26
aI27
aI28
a(lp4339
I30
aI31
aI32
aI33
aI34
atp4340
a(I-1
S'The AB loops of IFN - gamma SC1 adopt conformations similar to the ordered loops of IFN - gamma observed in the crystal structure of the IFN - gamma / IFN - gamma R alpha complex .'
p4341
(lp4342
I30
aI31
aI32
a(lp4343
I30
aI31
aI32
aI33
aI34
atp4344
a(I-1
S'Thus , IFN - gamma R alpha binding does not result in a large conformational change in the AB loop as previously suggested .'
p4345
(lp4346
I2
aI3
aI4
a(lp4347
I2
aI3
aI4
aI5
aI6
atp4348
a(I-1
S'The structure also reveals the final six C - terminal amino acid residues of IFN - gamma SC1 ( residues 253 - 258 ) that have not been observed in any other reported IFN - gamma structures .'
p4349
(lp4350
I14
aI15
aI16
a(lp4351
I14
aI15
aI16
aI17
atp4352
a(I-1
S'The structure also reveals the final six C - terminal amino acid residues of IFN - gamma SC1 ( residues 253 - 258 ) that have not been observed in any other reported IFN - gamma structures .'
p4353
(lp4354
I14
aI15
aI16
a(lp4355
I33
aI34
aI35
atp4356
a(I-1
S'The structure also reveals the final six C - terminal amino acid residues of IFN - gamma SC1 ( residues 253 - 258 ) that have not been observed in any other reported IFN - gamma structures .'
p4357
(lp4358
I14
aI15
aI16
aI17
a(lp4359
I33
aI34
aI35
atp4360
a(I-1
S'Despite binding to only one IFN - gamma R alpha , IFN - gamma SC1 is biologically active in cell proliferation , MHC class I induction , and anti - viral assays .'
p4361
(lp4362
I5
aI6
aI7
a(lp4363
I5
aI6
aI7
aI8
aI9
atp4364
a(I-1
S'Despite binding to only one IFN - gamma R alpha , IFN - gamma SC1 is biologically active in cell proliferation , MHC class I induction , and anti - viral assays .'
p4365
(lp4366
I5
aI6
aI7
a(lp4367
I11
aI12
aI13
aI14
atp4368
a(I1
S'Despite binding to only one IFN - gamma R alpha , IFN - gamma SC1 is biologically active in cell proliferation , MHC class I induction , and anti - viral assays .'
p4369
(lp4370
I5
aI6
aI7
aI8
aI9
a(lp4371
I11
aI12
aI13
aI14
atp4372
a(I-1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4373
(lp4374
I6
aI7
aI8
a(lp4375
I13
aI14
aI15
atp4376
a(I1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4377
(lp4378
I6
aI7
aI8
a(lp4379
I13
aI14
aI15
aI16
aI17
atp4380
a(I-1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4381
(lp4382
I6
aI7
aI8
a(lp4383
I19
aI20
aI21
atp4384
a(I1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4385
(lp4386
I6
aI7
aI8
a(lp4387
I19
aI20
aI21
aI22
aI23
atp4388
a(I-1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4389
(lp4390
I13
aI14
aI15
a(lp4391
I13
aI14
aI15
aI16
aI17
atp4392
a(I-1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4393
(lp4394
I13
aI14
aI15
a(lp4395
I19
aI20
aI21
atp4396
a(I-1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4397
(lp4398
I13
aI14
aI15
a(lp4399
I19
aI20
aI21
aI22
aI23
atp4400
a(I-1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4401
(lp4402
I13
aI14
aI15
aI16
aI17
a(lp4403
I19
aI20
aI21
atp4404
a(I-1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4405
(lp4406
I13
aI14
aI15
aI16
aI17
a(lp4407
I19
aI20
aI21
aI22
aI23
atp4408
a(I-1
S'This suggests that one domain of IFN - gamma is sufficient to recruit IFN - gamma R alpha and IFN - gamma R beta into a complex competent for eliciting biological activity .'
p4409
(lp4410
I19
aI20
aI21
a(lp4411
I19
aI20
aI21
aI22
aI23
atp4412
a(I-1
S'The current data are consistent with the main role of the IFN - gamma dimer being to decrease the dissociation constant of IFN - gamma for its cellular receptors .'
p4413
(lp4414
I11
aI12
aI13
a(lp4415
I22
aI23
aI24
atp4416
a(I-1
S'BMP - 2 antagonists emerge from alterations in the low - affinity binding epitope for receptor BMPR - II .'
p4417
(lp4418
I0
aI1
aI2
a(lp4419
I16
aI17
aI18
atp4420
a(I-1
S'Bone morphogenetic protein - 2 ( BMP - 2 ) induces bone formation and regeneration in adult vertebrates and regulates important developmental processes in all animals .'
p4421
(lp4422
I0
aI1
aI2
aI3
aI4
a(lp4423
I6
aI7
aI8
atp4424
a(I-1
S'BMP - 2 is a homodimeric cysteine knot protein that , as a member of the transforming growth factor - beta ( TGF - beta ) superfamily , signals by oligomerizing type I and type II receptor serine - kinases in the cell membrane .'
p4425
(lp4426
I0
aI1
aI2
a(lp4427
I16
aI17
aI18
aI19
aI20
atp4428
a(I-1
S'BMP - 2 is a homodimeric cysteine knot protein that , as a member of the transforming growth factor - beta ( TGF - beta ) superfamily , signals by oligomerizing type I and type II receptor serine - kinases in the cell membrane .'
p4429
(lp4430
I0
aI1
aI2
a(lp4431
I22
aI23
aI24
atp4432
a(I-1
S'BMP - 2 is a homodimeric cysteine knot protein that , as a member of the transforming growth factor - beta ( TGF - beta ) superfamily , signals by oligomerizing type I and type II receptor serine - kinases in the cell membrane .'
p4433
(lp4434
I16
aI17
aI18
aI19
aI20
a(lp4435
I22
aI23
aI24
atp4436
a(I1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4437
(lp4438
I4
aI5
aI6
a(lp4439
I8
aI9
aI10
atp4440
a(I1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4441
(lp4442
I4
aI5
aI6
a(lp4443
I16
aI17
aI18
atp4444
a(I1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4445
(lp4446
I4
aI5
aI6
a(lp4447
I20
aI21
aI22
atp4448
a(I-1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4449
(lp4450
I4
aI5
aI6
a(lp4451
I30
aI31
aI32
atp4452
a(I-1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4453
(lp4454
I8
aI9
aI10
a(lp4455
I16
aI17
aI18
atp4456
a(I-1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4457
(lp4458
I8
aI9
aI10
a(lp4459
I20
aI21
aI22
atp4460
a(I-1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4461
(lp4462
I8
aI9
aI10
a(lp4463
I30
aI31
aI32
atp4464
a(I-1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4465
(lp4466
I16
aI17
aI18
a(lp4467
I20
aI21
aI22
atp4468
a(I-1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4469
(lp4470
I16
aI17
aI18
a(lp4471
I30
aI31
aI32
atp4472
a(I-1
S'The binding epitopes of BMP - 2 for BMPR - IA ( type I ) and BMPR - II or ActR - II ( type II ) were characterized using BMP - 2 mutant proteins for analysis of interactions with receptor ectodomains .'
p4473
(lp4474
I20
aI21
aI22
a(lp4475
I30
aI31
aI32
atp4476
a(I1
S'A large epitope 1 for high - affinity BMPR - IA binding was detected spanning the interface of the BMP - 2 dimer .'
p4477
(lp4478
I8
aI9
aI10
a(lp4479
I19
aI20
aI21
atp4480
a(I1
S'Crystal structure of the BMP - 2 - BRIA ectodomain complex .'
p4481
(lp4482
I4
aI5
aI6
a(lp4483
I8
atp4484
a(I-1
S'Bone morphogenetic proteins ( BMPs ) belong to the large transforming growth factor - beta ( TGF - beta ) superfamily of multifunctional cytokines .'
p4485
(lp4486
I10
aI11
aI12
aI13
aI14
a(lp4487
I16
aI17
aI18
atp4488
a(I-1
S'Here we report the crystal structure of human dimeric BMP - 2 in complex with two high affinity BMP receptor IA extracellular domains ( BRIAec ) .'
p4489
(lp4490
I9
aI10
aI11
a(lp4491
I18
aI19
aI20
atp4492
a(I1
S'Here we report the crystal structure of human dimeric BMP - 2 in complex with two high affinity BMP receptor IA extracellular domains ( BRIAec ) .'
p4493
(lp4494
I9
aI10
aI11
a(lp4495
I18
aI19
aI20
aI21
aI22
atp4496
a(I1
S'Here we report the crystal structure of human dimeric BMP - 2 in complex with two high affinity BMP receptor IA extracellular domains ( BRIAec ) .'
p4497
(lp4498
I9
aI10
aI11
a(lp4499
I24
atp4500
a(I-1
S'Here we report the crystal structure of human dimeric BMP - 2 in complex with two high affinity BMP receptor IA extracellular domains ( BRIAec ) .'
p4501
(lp4502
I18
aI19
aI20
a(lp4503
I18
aI19
aI20
aI21
aI22
atp4504
a(I-1
S'Here we report the crystal structure of human dimeric BMP - 2 in complex with two high affinity BMP receptor IA extracellular domains ( BRIAec ) .'
p4505
(lp4506
I18
aI19
aI20
a(lp4507
I24
atp4508
a(I-1
S'Here we report the crystal structure of human dimeric BMP - 2 in complex with two high affinity BMP receptor IA extracellular domains ( BRIAec ) .'
p4509
(lp4510
I18
aI19
aI20
aI21
aI22
a(lp4511
I24
atp4512
a(I-1
S"The receptor chains bind to the ' wrist ' epitopes of the BMP - 2 dimer and contact both BMP - 2 monomers ."
p4513
(lp4514
I12
aI13
aI14
a(lp4515
I19
aI20
aI21
atp4516
a(I1
S'LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8 .'
p4517
(lp4518
I0
a(lp4519
I8
atp4520
a(I1
S'LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8 .'
p4521
(lp4522
I0
a(lp4523
I10
atp4524
a(I-1
S'LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8 .'
p4525
(lp4526
I8
a(lp4527
I10
atp4528
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4529
(lp4530
I0
aI1
aI2
aI3
a(lp4531
I5
atp4532
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4533
(lp4534
I0
aI1
aI2
aI3
a(lp4535
I19
atp4536
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4537
(lp4538
I0
aI1
aI2
aI3
a(lp4539
I21
aI22
aI23
atp4540
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4541
(lp4542
I0
aI1
aI2
aI3
a(lp4543
I25
aI26
aI27
atp4544
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4545
(lp4546
I0
aI1
aI2
aI3
a(lp4547
I30
atp4548
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4549
(lp4550
I5
a(lp4551
I19
atp4552
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4553
(lp4554
I5
a(lp4555
I21
aI22
aI23
atp4556
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4557
(lp4558
I5
a(lp4559
I25
aI26
aI27
atp4560
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4561
(lp4562
I5
a(lp4563
I30
atp4564
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4565
(lp4566
I19
a(lp4567
I21
aI22
aI23
atp4568
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4569
(lp4570
I19
a(lp4571
I25
aI26
aI27
atp4572
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4573
(lp4574
I19
a(lp4575
I30
atp4576
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4577
(lp4578
I21
aI22
aI23
a(lp4579
I25
aI26
aI27
atp4580
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4581
(lp4582
I21
aI22
aI23
a(lp4583
I30
atp4584
a(I-1
S'Liver - expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC - 4 , NCC - 4 , and CCL16 .'
p4585
(lp4586
I25
aI26
aI27
a(lp4587
I30
atp4588
a(I1
S'We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK - 293 cells .'
p4589
(lp4590
I9
a(lp4591
I14
atp4592
a(I1
S'We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK - 293 cells .'
p4593
(lp4594
I9
a(lp4595
I16
atp4596
a(I-1
S'We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK - 293 cells .'
p4597
(lp4598
I14
a(lp4599
I16
atp4600
a(I-1
S'LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89 . 3 nmol / L and cell adhesion at 5 . 6 nmol / L .'
p4601
(lp4602
I0
a(lp4603
I5
atp4604
a(I-1
S'LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89 . 3 nmol / L and cell adhesion at 5 . 6 nmol / L .'
p4605
(lp4606
I0
a(lp4607
I7
atp4608
a(I-1
S'LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89 . 3 nmol / L and cell adhesion at 5 . 6 nmol / L .'
p4609
(lp4610
I5
a(lp4611
I7
atp4612
a(I-1
S'The molar concentration of LEC required to induce maximum cell migration is 20 - to 200 - fold greater than that required for RANTES or I309 , respectively .'
p4613
(lp4614
I4
a(lp4615
I23
atp4616
a(I-1
S'The molar concentration of LEC required to induce maximum cell migration is 20 - to 200 - fold greater than that required for RANTES or I309 , respectively .'
p4617
(lp4618
I4
a(lp4619
I25
atp4620
a(I-1
S'The molar concentration of LEC required to induce maximum cell migration is 20 - to 200 - fold greater than that required for RANTES or I309 , respectively .'
p4621
(lp4622
I23
a(lp4623
I25
atp4624
a(I-1
S'A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination .'
p4625
(lp4626
I5
a(lp4627
I16
atp4628
a(I-1
S'A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination .'
p4629
(lp4630
I5
a(lp4631
I25
atp4632
a(I-1
S'A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination .'
p4633
(lp4634
I16
a(lp4635
I25
atp4636
a(I1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4637
(lp4638
I0
aI1
aI2
a(lp4639
I10
aI11
atp4640
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4641
(lp4642
I0
aI1
aI2
a(lp4643
I14
aI15
aI16
atp4644
a(I1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4645
(lp4646
I0
aI1
aI2
a(lp4647
I14
aI15
aI16
aI17
atp4648
a(I1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4649
(lp4650
I0
aI1
aI2
a(lp4651
I19
atp4652
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4653
(lp4654
I0
aI1
aI2
a(lp4655
I23
aI24
aI25
atp4656
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4657
(lp4658
I0
aI1
aI2
a(lp4659
I29
atp4660
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4661
(lp4662
I0
aI1
aI2
a(lp4663
I31
atp4664
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4665
(lp4666
I0
aI1
aI2
a(lp4667
I34
atp4668
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4669
(lp4670
I0
aI1
aI2
a(lp4671
I39
atp4672
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4673
(lp4674
I10
aI11
a(lp4675
I14
aI15
aI16
atp4676
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4677
(lp4678
I10
aI11
a(lp4679
I14
aI15
aI16
aI17
atp4680
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4681
(lp4682
I10
aI11
a(lp4683
I19
atp4684
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4685
(lp4686
I10
aI11
a(lp4687
I23
aI24
aI25
atp4688
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4689
(lp4690
I10
aI11
a(lp4691
I29
atp4692
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4693
(lp4694
I10
aI11
a(lp4695
I31
atp4696
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4697
(lp4698
I10
aI11
a(lp4699
I34
atp4700
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4701
(lp4702
I10
aI11
a(lp4703
I39
atp4704
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4705
(lp4706
I14
aI15
aI16
a(lp4707
I14
aI15
aI16
aI17
atp4708
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4709
(lp4710
I14
aI15
aI16
a(lp4711
I19
atp4712
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4713
(lp4714
I14
aI15
aI16
a(lp4715
I23
aI24
aI25
atp4716
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4717
(lp4718
I14
aI15
aI16
a(lp4719
I29
atp4720
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4721
(lp4722
I14
aI15
aI16
a(lp4723
I31
atp4724
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4725
(lp4726
I14
aI15
aI16
a(lp4727
I34
atp4728
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4729
(lp4730
I14
aI15
aI16
a(lp4731
I39
atp4732
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4733
(lp4734
I14
aI15
aI16
aI17
a(lp4735
I19
atp4736
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4737
(lp4738
I14
aI15
aI16
aI17
a(lp4739
I23
aI24
aI25
atp4740
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4741
(lp4742
I14
aI15
aI16
aI17
a(lp4743
I29
atp4744
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4745
(lp4746
I14
aI15
aI16
aI17
a(lp4747
I31
atp4748
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4749
(lp4750
I14
aI15
aI16
aI17
a(lp4751
I34
atp4752
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4753
(lp4754
I14
aI15
aI16
aI17
a(lp4755
I39
atp4756
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4757
(lp4758
I19
a(lp4759
I23
aI24
aI25
atp4760
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4761
(lp4762
I19
a(lp4763
I29
atp4764
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4765
(lp4766
I19
a(lp4767
I31
atp4768
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4769
(lp4770
I19
a(lp4771
I34
atp4772
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4773
(lp4774
I19
a(lp4775
I39
atp4776
a(I1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4777
(lp4778
I23
aI24
aI25
a(lp4779
I29
atp4780
a(I1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4781
(lp4782
I23
aI24
aI25
a(lp4783
I31
atp4784
a(I1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4785
(lp4786
I23
aI24
aI25
a(lp4787
I34
atp4788
a(I1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4789
(lp4790
I23
aI24
aI25
a(lp4791
I39
atp4792
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4793
(lp4794
I29
a(lp4795
I31
atp4796
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4797
(lp4798
I29
a(lp4799
I34
atp4800
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4801
(lp4802
I29
a(lp4803
I39
atp4804
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4805
(lp4806
I31
a(lp4807
I34
atp4808
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4809
(lp4810
I31
a(lp4811
I39
atp4812
a(I-1
S'FGF - 7 recognizes one FGFR isoform known as the FGFR2 IIIb isoform or keratinocyte growth factor receptor ( KGFR ) , whereas FGF - 2 binds well to FGFR1 , FGFR2 , and FGFR4 but interacts poorly with KGFR .'
p4813
(lp4814
I34
a(lp4815
I39
atp4816
a(I1
S'FGF - 7 contains this primary site as well as a region that restricts interaction with FGFR1 .'
p4817
(lp4818
I0
aI1
aI2
a(lp4819
I16
atp4820
a(I1
S'The sequences that confer on FGF - 7 its specific binding to KGFR have not been identified .'
p4821
(lp4822
I5
aI6
aI7
a(lp4823
I12
atp4824
a(I1
S'By utilizing domain swapping and site - directed mutagenesis we have found that the loop connecting the beta4 - beta5 strands of FGF - 7 contributes to high affinity receptor binding and is critical for KGFR recognition .'
p4825
(lp4826
I22
aI23
aI24
a(lp4827
I35
atp4828
a(I-1
S'Replacement of this loop with the homologous loop from FGF - 2 dramatically reduced both the affinity of FGF - 7 for KGFR and its biological potency but did not result in the ability to bind FGFR1 .'
p4829
(lp4830
I9
aI10
aI11
a(lp4831
I18
aI19
aI20
atp4832
a(I-1
S'Replacement of this loop with the homologous loop from FGF - 2 dramatically reduced both the affinity of FGF - 7 for KGFR and its biological potency but did not result in the ability to bind FGFR1 .'
p4833
(lp4834
I9
aI10
aI11
a(lp4835
I22
atp4836
a(I-1
S'Replacement of this loop with the homologous loop from FGF - 2 dramatically reduced both the affinity of FGF - 7 for KGFR and its biological potency but did not result in the ability to bind FGFR1 .'
p4837
(lp4838
I9
aI10
aI11
a(lp4839
I36
atp4840
a(I1
S'Replacement of this loop with the homologous loop from FGF - 2 dramatically reduced both the affinity of FGF - 7 for KGFR and its biological potency but did not result in the ability to bind FGFR1 .'
p4841
(lp4842
I18
aI19
aI20
a(lp4843
I22
atp4844
a(I-1
S'Replacement of this loop with the homologous loop from FGF - 2 dramatically reduced both the affinity of FGF - 7 for KGFR and its biological potency but did not result in the ability to bind FGFR1 .'
p4845
(lp4846
I18
aI19
aI20
a(lp4847
I36
atp4848
a(I-1
S'Replacement of this loop with the homologous loop from FGF - 2 dramatically reduced both the affinity of FGF - 7 for KGFR and its biological potency but did not result in the ability to bind FGFR1 .'
p4849
(lp4850
I22
a(lp4851
I36
atp4852
a(I-1
S'The reciprocal loop replacement mutant ( FGF2 - L4 / 7 ) retained FGF - 2 like affinity for FGFR1 and for KGFR .'
p4853
(lp4854
I6
a(lp4855
I13
aI14
aI15
atp4856
a(I-1
S'The reciprocal loop replacement mutant ( FGF2 - L4 / 7 ) retained FGF - 2 like affinity for FGFR1 and for KGFR .'
p4857
(lp4858
I6
a(lp4859
I19
atp4860
a(I-1
S'The reciprocal loop replacement mutant ( FGF2 - L4 / 7 ) retained FGF - 2 like affinity for FGFR1 and for KGFR .'
p4861
(lp4862
I6
a(lp4863
I22
atp4864
a(I1
S'The reciprocal loop replacement mutant ( FGF2 - L4 / 7 ) retained FGF - 2 like affinity for FGFR1 and for KGFR .'
p4865
(lp4866
I13
aI14
aI15
a(lp4867
I19
atp4868
a(I1
S'The reciprocal loop replacement mutant ( FGF2 - L4 / 7 ) retained FGF - 2 like affinity for FGFR1 and for KGFR .'
p4869
(lp4870
I13
aI14
aI15
a(lp4871
I22
atp4872
a(I-1
S'The reciprocal loop replacement mutant ( FGF2 - L4 / 7 ) retained FGF - 2 like affinity for FGFR1 and for KGFR .'
p4873
(lp4874
I19
a(lp4875
I22
atp4876
a(I-1
S'Type I interferons bind to two cell surface receptors , ifnar1 and ifnar2 , as the first step in the activation of several signal transduction pathways that elicit an anti - viral state and an anti - proliferative response .'
p4877
(lp4878
I10
a(lp4879
I12
atp4880
a(I1
S'Here , we quantitatively mapped the complete binding region of ifnar2 on interferon ( IFN ) alpha2 by 35 individual mutations to alanine and isosteric residues .'
p4881
(lp4882
I10
a(lp4883
I12
aI13
aI14
aI15
aI16
atp4884
a(I1
S'Interestingly , the ifnar2 binding site overlaps the largest continuous hydrophobic patch on IFNalpha2 .'
p4885
(lp4886
I3
a(lp4887
I13
atp4888
a(I-1
S'Relating the anti - viral and anti - proliferative activity of the various interferon mutants with their affinity toward ifnar2 results in linear function over the whole range of affinities investigated , suggesting that ifnar2 binding is the rate - determining step in cellular activation .'
p4889
(lp4890
I19
a(lp4891
I34
atp4892
a(I1
S'Here we report the crystal structure of the FGFR2 ectodomain in a dimeric form that is induced by simultaneous binding to FGF1 and a heparin decasaccharide .'
p4893
(lp4894
I8
a(lp4895
I21
atp4896
a(I1
S'The structure of the FGF1 - FGFR2 - heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling .'
p4897
(lp4898
I4
a(lp4899
I6
atp4900
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4901
(lp4902
I12
a(lp4903
I14
atp4904
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4905
(lp4906
I12
a(lp4907
I27
atp4908
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4909
(lp4910
I12
a(lp4911
I29
atp4912
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4913
(lp4914
I12
a(lp4915
I36
atp4916
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4917
(lp4918
I12
a(lp4919
I38
atp4920
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4921
(lp4922
I12
a(lp4923
I44
atp4924
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4925
(lp4926
I12
a(lp4927
I46
atp4928
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4929
(lp4930
I12
a(lp4931
I49
atp4932
a(I1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4933
(lp4934
I14
a(lp4935
I27
atp4936
a(I1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4937
(lp4938
I14
a(lp4939
I29
atp4940
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4941
(lp4942
I14
a(lp4943
I36
atp4944
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4945
(lp4946
I14
a(lp4947
I38
atp4948
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4949
(lp4950
I14
a(lp4951
I44
atp4952
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4953
(lp4954
I14
a(lp4955
I46
atp4956
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4957
(lp4958
I14
a(lp4959
I49
atp4960
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4961
(lp4962
I27
a(lp4963
I29
atp4964
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4965
(lp4966
I27
a(lp4967
I36
atp4968
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4969
(lp4970
I27
a(lp4971
I38
atp4972
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4973
(lp4974
I27
a(lp4975
I44
atp4976
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4977
(lp4978
I27
a(lp4979
I46
atp4980
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4981
(lp4982
I27
a(lp4983
I49
atp4984
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4985
(lp4986
I29
a(lp4987
I36
atp4988
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4989
(lp4990
I29
a(lp4991
I38
atp4992
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4993
(lp4994
I29
a(lp4995
I44
atp4996
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p4997
(lp4998
I29
a(lp4999
I46
atp5000
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5001
(lp5002
I29
a(lp5003
I49
atp5004
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5005
(lp5006
I36
a(lp5007
I38
atp5008
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5009
(lp5010
I36
a(lp5011
I44
atp5012
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5013
(lp5014
I36
a(lp5015
I46
atp5016
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5017
(lp5018
I36
a(lp5019
I49
atp5020
a(I1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5021
(lp5022
I38
a(lp5023
I44
atp5024
a(I1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5025
(lp5026
I38
a(lp5027
I46
atp5028
a(I1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5029
(lp5030
I38
a(lp5031
I49
atp5032
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5033
(lp5034
I44
a(lp5035
I46
atp5036
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5037
(lp5038
I44
a(lp5039
I49
atp5040
a(I-1
S'We show that the S252W mutation allows the mesenchymal splice form of FGFR2 ( FGFR2c ) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 ( FGFR2b ) to be activated by FGF2 , FGF6 , and FGF9 .'
p5041
(lp5042
I46
a(lp5043
I49
atp5044
a(I-1
S"Kaposi ' s sarcoma - associated herpesvirus encodes a functional homolog of human interleukin - 6 ( IL - 6 ) that activates human gp130 ."
p5045
(lp5046
I13
aI14
aI15
a(lp5047
I17
aI18
aI19
atp5048
a(I1
S"Kaposi ' s sarcoma - associated herpesvirus encodes a functional homolog of human interleukin - 6 ( IL - 6 ) that activates human gp130 ."
p5049
(lp5050
I13
aI14
aI15
a(lp5051
I24
atp5052
a(I1
S"Kaposi ' s sarcoma - associated herpesvirus encodes a functional homolog of human interleukin - 6 ( IL - 6 ) that activates human gp130 ."
p5053
(lp5054
I17
aI18
aI19
a(lp5055
I24
atp5056
a(I1
S'In the 2 . 4 angstrom crystal structure of the extracellular signaling assembly between viral IL - 6 and human gp130 , two complexes are cross - linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL - 6 , which is necessary for receptor activation .'
p5057
(lp5058
I15
aI16
aI17
a(lp5059
I20
atp5060
a(I-1
S'In the 2 . 4 angstrom crystal structure of the extracellular signaling assembly between viral IL - 6 and human gp130 , two complexes are cross - linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL - 6 , which is necessary for receptor activation .'
p5061
(lp5062
I15
aI16
aI17
a(lp5063
I39
atp5064
a(I-1
S'In the 2 . 4 angstrom crystal structure of the extracellular signaling assembly between viral IL - 6 and human gp130 , two complexes are cross - linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL - 6 , which is necessary for receptor activation .'
p5065
(lp5066
I15
aI16
aI17
a(lp5067
I45
aI46
aI47
atp5068
a(I-1
S'In the 2 . 4 angstrom crystal structure of the extracellular signaling assembly between viral IL - 6 and human gp130 , two complexes are cross - linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL - 6 , which is necessary for receptor activation .'
p5069
(lp5070
I20
a(lp5071
I39
atp5072
a(I-1
S'In the 2 . 4 angstrom crystal structure of the extracellular signaling assembly between viral IL - 6 and human gp130 , two complexes are cross - linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL - 6 , which is necessary for receptor activation .'
p5073
(lp5074
I20
a(lp5075
I45
aI46
aI47
atp5076
a(I1
S'In the 2 . 4 angstrom crystal structure of the extracellular signaling assembly between viral IL - 6 and human gp130 , two complexes are cross - linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL - 6 , which is necessary for receptor activation .'
p5077
(lp5078
I39
a(lp5079
I45
aI46
aI47
atp5080
a(I1
S'Unlike human IL - 6 ( which uses many hydrophilic residues ) , the viral cytokine largely uses hydrophobic amino acids to contact gp130 , which enhances the complementarity of the viral IL - 6 - gp130 binding interfaces .'
p5081
(lp5082
I2
aI3
aI4
a(lp5083
I23
atp5084
a(I-1
S'Unlike human IL - 6 ( which uses many hydrophilic residues ) , the viral cytokine largely uses hydrophobic amino acids to contact gp130 , which enhances the complementarity of the viral IL - 6 - gp130 binding interfaces .'
p5085
(lp5086
I2
aI3
aI4
a(lp5087
I32
aI33
aI34
atp5088
a(I-1
S'Unlike human IL - 6 ( which uses many hydrophilic residues ) , the viral cytokine largely uses hydrophobic amino acids to contact gp130 , which enhances the complementarity of the viral IL - 6 - gp130 binding interfaces .'
p5089
(lp5090
I2
aI3
aI4
a(lp5091
I36
atp5092
a(I-1
S'Unlike human IL - 6 ( which uses many hydrophilic residues ) , the viral cytokine largely uses hydrophobic amino acids to contact gp130 , which enhances the complementarity of the viral IL - 6 - gp130 binding interfaces .'
p5093
(lp5094
I23
a(lp5095
I32
aI33
aI34
atp5096
a(I-1
S'Unlike human IL - 6 ( which uses many hydrophilic residues ) , the viral cytokine largely uses hydrophobic amino acids to contact gp130 , which enhances the complementarity of the viral IL - 6 - gp130 binding interfaces .'
p5097
(lp5098
I23
a(lp5099
I36
atp5100
a(I1
S'Unlike human IL - 6 ( which uses many hydrophilic residues ) , the viral cytokine largely uses hydrophobic amino acids to contact gp130 , which enhances the complementarity of the viral IL - 6 - gp130 binding interfaces .'
p5101
(lp5102
I32
aI33
aI34
a(lp5103
I36
atp5104
a(I-1
S'The cross - reactivity of gp130 is apparently due to a chemical plasticity evident in the amphipathic gp130 cytokine - binding sites .'
p5105
(lp5106
I5
a(lp5107
I17
atp5108
a(I-1
S'Platelet - derived growth factor C ( PDGF - C ) , a novel growth factor that binds to PDGF alpha and beta receptor .'
p5109
(lp5110
I0
aI1
aI2
aI3
aI4
aI5
a(lp5111
I7
aI8
aI9
atp5112
a(I1
S'Platelet - derived growth factor C ( PDGF - C ) , a novel growth factor that binds to PDGF alpha and beta receptor .'
p5113
(lp5114
I0
aI1
aI2
aI3
aI4
aI5
a(lp5115
I19
aI20
atp5116
a(I1
S'Platelet - derived growth factor C ( PDGF - C ) , a novel growth factor that binds to PDGF alpha and beta receptor .'
p5117
(lp5118
I7
aI8
aI9
a(lp5119
I19
aI20
atp5120
a(I-1
S'PDGF - C is a multidomain protein with the N - terminal region homologous to the extracellular CUB domain of neuropilin - 1 , and the C - terminal region consists of a growth factor domain ( GFD ) with homology to vascular endothelial growth factor ( 25 % ) and PDGF A - chain ( 23 % ) .'
p5121
(lp5122
I0
aI1
aI2
a(lp5123
I20
aI21
aI22
atp5124
a(I-1
S'PDGF - C is a multidomain protein with the N - terminal region homologous to the extracellular CUB domain of neuropilin - 1 , and the C - terminal region consists of a growth factor domain ( GFD ) with homology to vascular endothelial growth factor ( 25 % ) and PDGF A - chain ( 23 % ) .'
p5125
(lp5126
I0
aI1
aI2
a(lp5127
I43
aI44
aI45
atp5128
a(I-1
S'PDGF - C is a multidomain protein with the N - terminal region homologous to the extracellular CUB domain of neuropilin - 1 , and the C - terminal region consists of a growth factor domain ( GFD ) with homology to vascular endothelial growth factor ( 25 % ) and PDGF A - chain ( 23 % ) .'
p5129
(lp5130
I0
aI1
aI2
a(lp5131
I51
aI52
atp5132
a(I-1
S'PDGF - C is a multidomain protein with the N - terminal region homologous to the extracellular CUB domain of neuropilin - 1 , and the C - terminal region consists of a growth factor domain ( GFD ) with homology to vascular endothelial growth factor ( 25 % ) and PDGF A - chain ( 23 % ) .'
p5133
(lp5134
I20
aI21
aI22
a(lp5135
I43
aI44
aI45
atp5136
a(I-1
S'PDGF - C is a multidomain protein with the N - terminal region homologous to the extracellular CUB domain of neuropilin - 1 , and the C - terminal region consists of a growth factor domain ( GFD ) with homology to vascular endothelial growth factor ( 25 % ) and PDGF A - chain ( 23 % ) .'
p5137
(lp5138
I20
aI21
aI22
a(lp5139
I51
aI52
atp5140
a(I-1
S'PDGF - C is a multidomain protein with the N - terminal region homologous to the extracellular CUB domain of neuropilin - 1 , and the C - terminal region consists of a growth factor domain ( GFD ) with homology to vascular endothelial growth factor ( 25 % ) and PDGF A - chain ( 23 % ) .'
p5141
(lp5142
I43
aI44
aI45
a(lp5143
I51
aI52
atp5144
a(I-1
S'Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD ( PDGF - CC ) to PDGF receptor - alpha homodimers and PDGF receptor - alpha / beta heterodimers .'
p5145
(lp5146
I9
aI10
a(lp5147
I23
aI24
aI25
atp5148
a(I-1
S'Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD ( PDGF - CC ) to PDGF receptor - alpha homodimers and PDGF receptor - alpha / beta heterodimers .'
p5149
(lp5150
I9
aI10
a(lp5151
I28
aI29
aI30
aI31
atp5152
a(I-1
S'Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD ( PDGF - CC ) to PDGF receptor - alpha homodimers and PDGF receptor - alpha / beta heterodimers .'
p5153
(lp5154
I9
aI10
a(lp5155
I34
aI35
aI36
aI37
atp5156
a(I1
S'Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD ( PDGF - CC ) to PDGF receptor - alpha homodimers and PDGF receptor - alpha / beta heterodimers .'
p5157
(lp5158
I23
aI24
aI25
a(lp5159
I28
aI29
aI30
aI31
atp5160
a(I1
S'Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD ( PDGF - CC ) to PDGF receptor - alpha homodimers and PDGF receptor - alpha / beta heterodimers .'
p5161
(lp5162
I23
aI24
aI25
a(lp5163
I34
aI35
aI36
aI37
atp5164
a(I-1
S'Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD ( PDGF - CC ) to PDGF receptor - alpha homodimers and PDGF receptor - alpha / beta heterodimers .'
p5165
(lp5166
I28
aI29
aI30
aI31
a(lp5167
I34
aI35
aI36
aI37
atp5168
a(I-1
S'PDGF - CC exhibits greater mitogenic potency than PDGF - AA and comparable or greater mitogenic activity than PDGF - AB and PDGF - BB on several mesenchymal cell types .'
p5169
(lp5170
I0
aI1
aI2
a(lp5171
I8
aI9
aI10
atp5172
a(I-1
S'PDGF - CC exhibits greater mitogenic potency than PDGF - AA and comparable or greater mitogenic activity than PDGF - AB and PDGF - BB on several mesenchymal cell types .'
p5173
(lp5174
I0
aI1
aI2
a(lp5175
I18
aI19
aI20
atp5176
a(I-1
S'PDGF - CC exhibits greater mitogenic potency than PDGF - AA and comparable or greater mitogenic activity than PDGF - AB and PDGF - BB on several mesenchymal cell types .'
p5177
(lp5178
I0
aI1
aI2
a(lp5179
I22
aI23
aI24
atp5180
a(I-1
S'PDGF - CC exhibits greater mitogenic potency than PDGF - AA and comparable or greater mitogenic activity than PDGF - AB and PDGF - BB on several mesenchymal cell types .'
p5181
(lp5182
I8
aI9
aI10
a(lp5183
I18
aI19
aI20
atp5184
a(I-1
S'PDGF - CC exhibits greater mitogenic potency than PDGF - AA and comparable or greater mitogenic activity than PDGF - AB and PDGF - BB on several mesenchymal cell types .'
p5185
(lp5186
I8
aI9
aI10
a(lp5187
I22
aI23
aI24
atp5188
a(I-1
S'PDGF - CC exhibits greater mitogenic potency than PDGF - AA and comparable or greater mitogenic activity than PDGF - AB and PDGF - BB on several mesenchymal cell types .'
p5189
(lp5190
I18
aI19
aI20
a(lp5191
I22
aI23
aI24
atp5192
a(I-1
S'Analysis of PDGF - CC in vivo in a diabetic mouse model of delayed wound healing showed that PDGF - CC significantly enhanced repair of a full - thickness skin excision .'
p5193
(lp5194
I2
aI3
aI4
a(lp5195
I18
aI19
aI20
atp5196
a(I-1
S'Together , these studies describe a third member of the PDGF family ( PDGF - C ) as a potent mitogen for cells of mesenchymal origin in in vitro and in vivo systems with a binding pattern similar to PDGF - AB .'
p5197
(lp5198
I13
aI14
aI15
a(lp5199
I39
aI40
aI41
atp5200
a(I-1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5201
(lp5202
I1
aI2
aI3
aI4
aI5
aI6
a(lp5203
I8
atp5204
a(I1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5205
(lp5206
I1
aI2
aI3
aI4
aI5
aI6
a(lp5207
I14
atp5208
a(I1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5209
(lp5210
I1
aI2
aI3
aI4
aI5
aI6
a(lp5211
I16
atp5212
a(I1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5213
(lp5214
I1
aI2
aI3
aI4
aI5
aI6
a(lp5215
I18
atp5216
a(I1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5217
(lp5218
I8
a(lp5219
I14
atp5220
a(I1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5221
(lp5222
I8
a(lp5223
I16
atp5224
a(I1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5225
(lp5226
I8
a(lp5227
I18
atp5228
a(I-1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5229
(lp5230
I14
a(lp5231
I16
atp5232
a(I-1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5233
(lp5234
I14
a(lp5235
I18
atp5236
a(I-1
S'Human CC chemokine liver - expressed chemokine / CCL16 is a functional ligand for CCR1 , CCR2 and CCR5 , and constitutively expressed by hepatocytes .'
p5237
(lp5238
I16
a(lp5239
I18
atp5240
a(I-1
S'Liver - expressed chemokine ( LEC ) / CCL16 is a human CC chemokine selectively expressed in the liver .'
p5241
(lp5242
I0
aI1
aI2
aI3
a(lp5243
I5
atp5244
a(I-1
S'Liver - expressed chemokine ( LEC ) / CCL16 is a human CC chemokine selectively expressed in the liver .'
p5245
(lp5246
I0
aI1
aI2
aI3
a(lp5247
I8
atp5248
a(I-1
S'Liver - expressed chemokine ( LEC ) / CCL16 is a human CC chemokine selectively expressed in the liver .'
p5249
(lp5250
I5
a(lp5251
I8
atp5252
a(I1
S'At relatively high concentrations , LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2 .'
p5253
(lp5254
I5
a(lp5255
I12
atp5256
a(I1
S'At relatively high concentrations , LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2 .'
p5257
(lp5258
I5
a(lp5259
I14
atp5260
a(I-1
S'At relatively high concentrations , LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2 .'
p5261
(lp5262
I12
a(lp5263
I14
atp5264
a(I1
S'LEC also induced calcium mobilization , but marginal chemotaxis via CCR5 .'
p5265
(lp5266
I0
a(lp5267
I10
atp5268
a(I1
S'Consistently , LEC was found to bind to CCR1 , CCR2 and CCR5 with relatively low affinities .'
p5269
(lp5270
I2
a(lp5271
I8
atp5272
a(I1
S'Consistently , LEC was found to bind to CCR1 , CCR2 and CCR5 with relatively low affinities .'
p5273
(lp5274
I2
a(lp5275
I10
atp5276
a(I1
S'Consistently , LEC was found to bind to CCR1 , CCR2 and CCR5 with relatively low affinities .'
p5277
(lp5278
I2
a(lp5279
I12
atp5280
a(I-1
S'Consistently , LEC was found to bind to CCR1 , CCR2 and CCR5 with relatively low affinities .'
p5281
(lp5282
I8
a(lp5283
I10
atp5284
a(I-1
S'Consistently , LEC was found to bind to CCR1 , CCR2 and CCR5 with relatively low affinities .'
p5285
(lp5286
I8
a(lp5287
I12
atp5288
a(I-1
S'Consistently , LEC was found to bind to CCR1 , CCR2 and CCR5 with relatively low affinities .'
p5289
(lp5290
I10
a(lp5291
I12
atp5292
a(I1
S'The binding of LEC to CCR8 was much less significant .'
p5293
(lp5294
I3
a(lp5295
I5
atp5296
a(I1
S'In spite of its binding to CCR5 , LEC was unable to inhibit infection of an R5 - type HIV - 1 to activated human peripheral blood mononuclear cells even at high concentrations .'
p5297
(lp5298
I6
a(lp5299
I8
atp5300
a(I1
S'Taken together , LEC is a new low - affinity functional ligand for CCR1 , CCR2 and CCR5 , and is constitutively expressed by liver parenchymal cells .'
p5301
(lp5302
I3
a(lp5303
I13
atp5304
a(I1
S'Taken together , LEC is a new low - affinity functional ligand for CCR1 , CCR2 and CCR5 , and is constitutively expressed by liver parenchymal cells .'
p5305
(lp5306
I3
a(lp5307
I15
atp5308
a(I1
S'Taken together , LEC is a new low - affinity functional ligand for CCR1 , CCR2 and CCR5 , and is constitutively expressed by liver parenchymal cells .'
p5309
(lp5310
I3
a(lp5311
I17
atp5312
a(I-1
S'Taken together , LEC is a new low - affinity functional ligand for CCR1 , CCR2 and CCR5 , and is constitutively expressed by liver parenchymal cells .'
p5313
(lp5314
I13
a(lp5315
I15
atp5316
a(I-1
S'Taken together , LEC is a new low - affinity functional ligand for CCR1 , CCR2 and CCR5 , and is constitutively expressed by liver parenchymal cells .'
p5317
(lp5318
I13
a(lp5319
I17
atp5320
a(I-1
S'Taken together , LEC is a new low - affinity functional ligand for CCR1 , CCR2 and CCR5 , and is constitutively expressed by liver parenchymal cells .'
p5321
(lp5322
I15
a(lp5323
I17
atp5324
a(I1
S'Cloning of TRAP , a ligand for CD40 on human T cells .'
p5325
(lp5326
I2
a(lp5327
I7
atp5328
a(I-1
S'A cDNA clone , designated TRAP ( TNF - related activation protein ) was isolated from a collection of T cell activation genes .'
p5329
(lp5330
I5
a(lp5331
I7
aI8
aI9
aI10
aI11
atp5332
a(I-1
S'TRAP is highly similar to an identified murine CD40 ligand both at the cDNA ( 82 . 8 % identity ) and the protein ( 77 . 4 % identity ) levels , and related to tumor necrosis factor / lymphotoxin .'
p5333
(lp5334
I0
a(lp5335
I8
aI9
atp5336
a(I-1
S'TRAP is highly similar to an identified murine CD40 ligand both at the cDNA ( 82 . 8 % identity ) and the protein ( 77 . 4 % identity ) levels , and related to tumor necrosis factor / lymphotoxin .'
p5337
(lp5338
I0
a(lp5339
I40
atp5340
a(I-1
S'TRAP is highly similar to an identified murine CD40 ligand both at the cDNA ( 82 . 8 % identity ) and the protein ( 77 . 4 % identity ) levels , and related to tumor necrosis factor / lymphotoxin .'
p5341
(lp5342
I8
aI9
a(lp5343
I40
atp5344
a(I1
S'Expressed in a murine myeloma , TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct .'
p5345
(lp5346
I6
a(lp5347
I13
atp5348
a(I1
S'Expressed in a murine myeloma , TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct .'
p5349
(lp5350
I6
a(lp5351
I19
atp5352
a(I-1
S'Expressed in a murine myeloma , TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct .'
p5353
(lp5354
I13
a(lp5355
I19
atp5356
a(I1
S'Reconstitution of the multiprotein complex of pp60src , hsp90 , and p50 in a cell - free system .'
p5357
(lp5358
I6
a(lp5359
I8
atp5360
a(I-1
S'Reconstitution of the multiprotein complex of pp60src , hsp90 , and p50 in a cell - free system .'
p5361
(lp5362
I6
a(lp5363
I11
atp5364
a(I-1
S'Reconstitution of the multiprotein complex of pp60src , hsp90 , and p50 in a cell - free system .'
p5365
(lp5366
I8
a(lp5367
I11
atp5368
a(I-1
S'A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90 - kDa heat shock protein ( hsp90 ) has been used here to form complexes between the pp60src tyrosine kinase and hsp90 .'
p5369
(lp5370
I25
a(lp5371
I36
atp5372
a(I-1
S'A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90 - kDa heat shock protein ( hsp90 ) has been used here to form complexes between the pp60src tyrosine kinase and hsp90 .'
p5373
(lp5374
I25
a(lp5375
I40
atp5376
a(I1
S'A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90 - kDa heat shock protein ( hsp90 ) has been used here to form complexes between the pp60src tyrosine kinase and hsp90 .'
p5377
(lp5378
I36
a(lp5379
I40
atp5380
a(I1
S'Reticulocyte lysate forms complexes between hsp90 and a temperature - sensitive mutant of Rous sarcoma virus pp60v - src , which is normally present in cytosol virtually entirely in the multiprotein complex form .'
p5381
(lp5382
I5
a(lp5383
I16
aI17
aI18
atp5384
a(I1
S'In addition , hsp90 in the lysate complexes with wild - type pp60v - src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c - src , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .'
p5385
(lp5386
I3
a(lp5387
I12
aI13
aI14
atp5388
a(I1
S'In addition , hsp90 in the lysate complexes with wild - type pp60v - src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c - src , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .'
p5389
(lp5390
I3
a(lp5391
I39
aI40
aI41
atp5392
a(I-1
S'In addition , hsp90 in the lysate complexes with wild - type pp60v - src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c - src , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .'
p5393
(lp5394
I3
a(lp5395
I59
atp5396
a(I-1
S'In addition , hsp90 in the lysate complexes with wild - type pp60v - src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c - src , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .'
p5397
(lp5398
I12
aI13
aI14
a(lp5399
I39
aI40
aI41
atp5400
a(I-1
S'In addition , hsp90 in the lysate complexes with wild - type pp60v - src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c - src , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .'
p5401
(lp5402
I12
aI13
aI14
a(lp5403
I59
atp5404
a(I-1
S'In addition , hsp90 in the lysate complexes with wild - type pp60v - src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c - src , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .'
p5405
(lp5406
I39
aI40
aI41
a(lp5407
I59
atp5408
a(I1
S'The native and reconstituted pp60src - hsp90 complexes have similar thermal stability and , like steroid receptor heterocomplexes , they are stabilized by molybdate .'
p5409
(lp5410
I4
a(lp5411
I6
atp5412
a(I1
S'As previously shown with reticulocyte lysate - reconstituted steroid receptor heteroprotein complexes , the reconstituted pp60src multiprotein complex contains hsp70 , which is a major candidate for providing the protein unfoldase activity required for hsp90 association .'
p5413
(lp5414
I15
a(lp5415
I19
atp5416
a(I-1
S'As previously shown with reticulocyte lysate - reconstituted steroid receptor heteroprotein complexes , the reconstituted pp60src multiprotein complex contains hsp70 , which is a major candidate for providing the protein unfoldase activity required for hsp90 association .'
p5417
(lp5418
I15
a(lp5419
I34
atp5420
a(I-1
S'As previously shown with reticulocyte lysate - reconstituted steroid receptor heteroprotein complexes , the reconstituted pp60src multiprotein complex contains hsp70 , which is a major candidate for providing the protein unfoldase activity required for hsp90 association .'
p5421
(lp5422
I19
a(lp5423
I34
atp5424
a(I-1
S'A cDNA clone encoding a novel , widely expressed protein ( called growth factor receptor - bound protein 2 or GRB2 ) containing one src homology 2 ( SH2 ) domain and two SH3 domains was isolated .'
p5425
(lp5426
I12
aI13
aI14
aI15
aI16
aI17
aI18
a(lp5427
I20
atp5428
a(I-1
S'While injection of GRB2 or H - ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect , microinjection of GRB2 together with H - ras protein stimulated DNA synthesis .'
p5429
(lp5430
I3
a(lp5431
I5
aI6
aI7
atp5432
a(I-1
S'While injection of GRB2 or H - ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect , microinjection of GRB2 together with H - ras protein stimulated DNA synthesis .'
p5433
(lp5434
I3
a(lp5435
I22
atp5436
a(I-1
S'While injection of GRB2 or H - ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect , microinjection of GRB2 together with H - ras protein stimulated DNA synthesis .'
p5437
(lp5438
I3
a(lp5439
I25
aI26
aI27
atp5440
a(I-1
S'While injection of GRB2 or H - ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect , microinjection of GRB2 together with H - ras protein stimulated DNA synthesis .'
p5441
(lp5442
I5
aI6
aI7
a(lp5443
I22
atp5444
a(I-1
S'While injection of GRB2 or H - ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect , microinjection of GRB2 together with H - ras protein stimulated DNA synthesis .'
p5445
(lp5446
I5
aI6
aI7
a(lp5447
I25
aI26
aI27
atp5448
a(I-1
S'While injection of GRB2 or H - ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect , microinjection of GRB2 together with H - ras protein stimulated DNA synthesis .'
p5449
(lp5450
I22
a(lp5451
I25
aI26
aI27
atp5452
a(I-1
S'These results suggest that GRB2 / sem - 5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling .'
p5453
(lp5454
I4
a(lp5455
I6
aI7
aI8
atp5456
a(I-1
S'Analysis of the oligomerization of myogenin and E2A products in vivo using a two - hybrid assay system .'
p5457
(lp5458
I5
a(lp5459
I7
atp5460
a(I-1
S'Myogenin is a muscle - specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products E12 and E47 .'
p5461
(lp5462
I0
a(lp5463
I26
atp5464
a(I1
S'Myogenin is a muscle - specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products E12 and E47 .'
p5465
(lp5466
I0
a(lp5467
I29
atp5468
a(I1
S'Myogenin is a muscle - specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products E12 and E47 .'
p5469
(lp5470
I0
a(lp5471
I31
atp5472
a(I-1
S'Myogenin is a muscle - specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products E12 and E47 .'
p5473
(lp5474
I26
a(lp5475
I29
atp5476
a(I-1
S'Myogenin is a muscle - specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products E12 and E47 .'
p5477
(lp5478
I26
a(lp5479
I31
atp5480
a(I-1
S'Myogenin is a muscle - specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products E12 and E47 .'
p5481
(lp5482
I29
a(lp5483
I31
atp5484
a(I1
S'The results show that myogenin heterodimerizes with E12 and E47 in vivo , but it does not homodimerize to a measurable extent .'
p5485
(lp5486
I4
a(lp5487
I7
atp5488
a(I1
S'The results show that myogenin heterodimerizes with E12 and E47 in vivo , but it does not homodimerize to a measurable extent .'
p5489
(lp5490
I4
a(lp5491
I9
atp5492
a(I-1
S'The results show that myogenin heterodimerizes with E12 and E47 in vivo , but it does not homodimerize to a measurable extent .'
p5493
(lp5494
I7
a(lp5495
I9
atp5496
a(I-1
S'Peptide growth factors , as well as the immediate early gene products c - Jun , v - Fos , and c - Myc , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .'
p5497
(lp5498
I12
aI13
aI14
a(lp5499
I16
aI17
aI18
atp5500
a(I-1
S'Peptide growth factors , as well as the immediate early gene products c - Jun , v - Fos , and c - Myc , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .'
p5501
(lp5502
I12
aI13
aI14
a(lp5503
I21
aI22
aI23
atp5504
a(I-1
S'Peptide growth factors , as well as the immediate early gene products c - Jun , v - Fos , and c - Myc , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .'
p5505
(lp5506
I12
aI13
aI14
a(lp5507
I38
atp5508
a(I-1
S'Peptide growth factors , as well as the immediate early gene products c - Jun , v - Fos , and c - Myc , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .'
p5509
(lp5510
I16
aI17
aI18
a(lp5511
I21
aI22
aI23
atp5512
a(I-1
S'Peptide growth factors , as well as the immediate early gene products c - Jun , v - Fos , and c - Myc , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .'
p5513
(lp5514
I16
aI17
aI18
a(lp5515
I38
atp5516
a(I-1
S'Peptide growth factors , as well as the immediate early gene products c - Jun , v - Fos , and c - Myc , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .'
p5517
(lp5518
I21
aI22
aI23
a(lp5519
I38
atp5520
a(I-1
S'Activation of mitogen - activated protein kinase kinase by v - Raf in NIH 3T3 cells and in vitro .'
p5521
(lp5522
I2
aI3
aI4
aI5
aI6
a(lp5523
I2
aI3
aI4
aI5
aI6
aI7
atp5524
a(I-1
S'Activation of mitogen - activated protein kinase kinase by v - Raf in NIH 3T3 cells and in vitro .'
p5525
(lp5526
I2
aI3
aI4
aI5
aI6
a(lp5527
I9
aI10
aI11
atp5528
a(I1
S'Activation of mitogen - activated protein kinase kinase by v - Raf in NIH 3T3 cells and in vitro .'
p5529
(lp5530
I2
aI3
aI4
aI5
aI6
aI7
a(lp5531
I9
aI10
aI11
atp5532
a(I1
S'MAP kinase and the protein kinase that activates it ( MAP kinase kinase ) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms ( p35EC12 , p3722W ) of the c - Raf - 1 protein kinase .'
p5533
(lp5534
I0
aI1
a(lp5535
I10
aI11
aI12
atp5536
a(I1
S'MAP kinase and the protein kinase that activates it ( MAP kinase kinase ) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms ( p35EC12 , p3722W ) of the c - Raf - 1 protein kinase .'
p5537
(lp5538
I0
aI1
a(lp5539
I37
aI38
aI39
aI40
aI41
atp5540
a(I1
S'MAP kinase and the protein kinase that activates it ( MAP kinase kinase ) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms ( p35EC12 , p3722W ) of the c - Raf - 1 protein kinase .'
p5541
(lp5542
I10
aI11
aI12
a(lp5543
I37
aI38
aI39
aI40
aI41
atp5544
a(I-1
S'The v - Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro .'
p5545
(lp5546
I1
aI2
aI3
a(lp5547
I15
aI16
atp5548
a(I1
S'The v - Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro .'
p5549
(lp5550
I1
aI2
aI3
a(lp5551
I15
aI16
aI17
atp5552
a(I-1
S'The v - Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro .'
p5553
(lp5554
I15
aI16
a(lp5555
I15
aI16
aI17
atp5556
a(I-1
S'Furthermore , a bacterially expressed v - Raf fusion protein ( glutathione S - transferase - p3722W ) also activated MAP kinase kinase in vitro .'
p5557
(lp5558
I5
aI6
aI7
a(lp5559
I20
aI21
atp5560
a(I-1
S'Furthermore , a bacterially expressed v - Raf fusion protein ( glutathione S - transferase - p3722W ) also activated MAP kinase kinase in vitro .'
p5561
(lp5562
I5
aI6
aI7
a(lp5563
I20
aI21
aI22
atp5564
a(I-1
S'Furthermore , a bacterially expressed v - Raf fusion protein ( glutathione S - transferase - p3722W ) also activated MAP kinase kinase in vitro .'
p5565
(lp5566
I20
aI21
a(lp5567
I20
aI21
aI22
atp5568
a(I-1
S'These findings suggest that one function of c - Raf - 1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase .'
p5569
(lp5570
I7
aI8
aI9
aI10
aI11
a(lp5571
I20
aI21
atp5572
a(I1
S'These findings suggest that one function of c - Raf - 1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase .'
p5573
(lp5574
I7
aI8
aI9
aI10
aI11
a(lp5575
I20
aI21
aI22
atp5576
a(I-1
S'These findings suggest that one function of c - Raf - 1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase .'
p5577
(lp5578
I20
aI21
a(lp5579
I20
aI21
aI22
atp5580
a(I-1
S'An expression plasmid encoding the human 75 - kDa tumor necrosis factor ( TNF ) type 2 receptor ( TNF - R2 ) was constructed and used to generate a stable human cell line ( 293 / TNF - R2 ) overexpressing TNF - R2 .'
p5581
(lp5582
I9
aI10
aI11
aI12
aI13
aI14
aI15
aI16
aI17
a(lp5583
I19
aI20
aI21
atp5584
a(I-1
S'An expression plasmid encoding the human 75 - kDa tumor necrosis factor ( TNF ) type 2 receptor ( TNF - R2 ) was constructed and used to generate a stable human cell line ( 293 / TNF - R2 ) overexpressing TNF - R2 .'
p5585
(lp5586
I9
aI10
aI11
aI12
aI13
aI14
aI15
aI16
aI17
a(lp5587
I37
aI38
aI39
atp5588
a(I-1
S'An expression plasmid encoding the human 75 - kDa tumor necrosis factor ( TNF ) type 2 receptor ( TNF - R2 ) was constructed and used to generate a stable human cell line ( 293 / TNF - R2 ) overexpressing TNF - R2 .'
p5589
(lp5590
I9
aI10
aI11
aI12
aI13
aI14
aI15
aI16
aI17
a(lp5591
I42
aI43
aI44
atp5592
a(I-1
S'An expression plasmid encoding the human 75 - kDa tumor necrosis factor ( TNF ) type 2 receptor ( TNF - R2 ) was constructed and used to generate a stable human cell line ( 293 / TNF - R2 ) overexpressing TNF - R2 .'
p5593
(lp5594
I19
aI20
aI21
a(lp5595
I37
aI38
aI39
atp5596
a(I-1
S'An expression plasmid encoding the human 75 - kDa tumor necrosis factor ( TNF ) type 2 receptor ( TNF - R2 ) was constructed and used to generate a stable human cell line ( 293 / TNF - R2 ) overexpressing TNF - R2 .'
p5597
(lp5598
I19
aI20
aI21
a(lp5599
I42
aI43
aI44
atp5600
a(I-1
S'An expression plasmid encoding the human 75 - kDa tumor necrosis factor ( TNF ) type 2 receptor ( TNF - R2 ) was constructed and used to generate a stable human cell line ( 293 / TNF - R2 ) overexpressing TNF - R2 .'
p5601
(lp5602
I37
aI38
aI39
a(lp5603
I42
aI43
aI44
atp5604
a(I-1
S'Ligand binding analysis revealed high affinity binding ( Kd = 0 . 2 nM ) with approximately 94 , 000 + / - 7 , 500 sites / cell for 125I - TNF - alpha and approximately 5 - fold lower affinity for TNF - beta ( Kd = 1 . 1 nM ) with 264 , 000 + / - 2 , 000 sites / cell .'
p5605
(lp5606
I32
aI33
aI34
a(lp5607
I43
aI44
aI45
atp5608
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5609
(lp5610
I6
aI7
aI8
a(lp5611
I12
aI13
aI14
atp5612
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5613
(lp5614
I6
aI7
aI8
a(lp5615
I18
aI19
aI20
atp5616
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5617
(lp5618
I6
aI7
aI8
a(lp5619
I34
aI35
aI36
atp5620
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5621
(lp5622
I6
aI7
aI8
a(lp5623
I46
aI47
aI48
atp5624
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5625
(lp5626
I6
aI7
aI8
a(lp5627
I57
aI58
aI59
atp5628
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5629
(lp5630
I12
aI13
aI14
a(lp5631
I18
aI19
aI20
atp5632
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5633
(lp5634
I12
aI13
aI14
a(lp5635
I34
aI35
aI36
atp5636
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5637
(lp5638
I12
aI13
aI14
a(lp5639
I46
aI47
aI48
atp5640
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5641
(lp5642
I12
aI13
aI14
a(lp5643
I57
aI58
aI59
atp5644
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5645
(lp5646
I18
aI19
aI20
a(lp5647
I34
aI35
aI36
atp5648
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5649
(lp5650
I18
aI19
aI20
a(lp5651
I46
aI47
aI48
atp5652
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5653
(lp5654
I18
aI19
aI20
a(lp5655
I57
aI58
aI59
atp5656
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5657
(lp5658
I34
aI35
aI36
a(lp5659
I46
aI47
aI48
atp5660
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5661
(lp5662
I34
aI35
aI36
a(lp5663
I57
aI58
aI59
atp5664
a(I-1
S'Cross - linking of 125I - TNF - alpha and 125I - TNF - beta to 293 / TNF - R2 cells yielded predominant complexes with apparent molecular weights of 211 , 000 for TNF - alpha and 205 , 000 and 244 , 000 for TNF - beta , suggesting these complexes contain two or three TNF - R2 molecules .'
p5665
(lp5666
I46
aI47
aI48
a(lp5667
I57
aI58
aI59
atp5668
a(I-1
S'Immunoprecipitation of TNF - R2 from 32P - labeled 293 / TNF - R2 cells demonstrated that the receptor is phosphorylated .'
p5669
(lp5670
I2
aI3
aI4
a(lp5671
I11
aI12
aI13
atp5672
a(I-1
S'TNF - alpha treatment of 293 / TNF - R2 cells did not significantly affect the degree or pattern of phosphorylation .'
p5673
(lp5674
I0
aI1
aI2
a(lp5675
I7
aI8
aI9
atp5676
a(I-1
S'Shedding of the extracellular domain of TNF - R2 was induced by 4 beta - phorbol 12 - myristate 13 - acetate but not by TNF - alpha or TNF - beta .'
p5677
(lp5678
I6
aI7
aI8
a(lp5679
I25
aI26
aI27
atp5680
a(I-1
S'Shedding of the extracellular domain of TNF - R2 was induced by 4 beta - phorbol 12 - myristate 13 - acetate but not by TNF - alpha or TNF - beta .'
p5681
(lp5682
I6
aI7
aI8
a(lp5683
I29
aI30
aI31
atp5684
a(I-1
S'Shedding of the extracellular domain of TNF - R2 was induced by 4 beta - phorbol 12 - myristate 13 - acetate but not by TNF - alpha or TNF - beta .'
p5685
(lp5686
I25
aI26
aI27
a(lp5687
I29
aI30
aI31
atp5688
a(I-1
S'The crystal structure of the homodimeric BB isoform of human recombinant platelet - derived growth factor ( PDGF - BB ) has been determined by X - ray analysis to 3 . 0 A resolution .'
p5689
(lp5690
I6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
aI15
a(lp5691
I17
aI18
aI19
atp5692
a(I-1
S'Coassociation of CD26 ( dipeptidyl peptidase IV ) with CD45 on the surface of human T lymphocytes .'
p5693
(lp5694
I2
a(lp5695
I4
aI5
aI6
atp5696
a(I1
S'Coassociation of CD26 ( dipeptidyl peptidase IV ) with CD45 on the surface of human T lymphocytes .'
p5697
(lp5698
I2
a(lp5699
I9
atp5700
a(I1
S'Coassociation of CD26 ( dipeptidyl peptidase IV ) with CD45 on the surface of human T lymphocytes .'
p5701
(lp5702
I4
aI5
aI6
a(lp5703
I9
atp5704
a(I-1
S'In the present report , we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 ( 1F7 ) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity .'
p5705
(lp5706
I10
a(lp5707
I17
atp5708
a(I-1
S'In the present report , we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 ( 1F7 ) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity .'
p5709
(lp5710
I10
a(lp5711
I26
atp5712
a(I-1
S'In the present report , we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 ( 1F7 ) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity .'
p5713
(lp5714
I10
a(lp5715
I32
atp5716
a(I-1
S'In the present report , we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 ( 1F7 ) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity .'
p5717
(lp5718
I17
a(lp5719
I26
atp5720
a(I-1
S'In the present report , we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 ( 1F7 ) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity .'
p5721
(lp5722
I17
a(lp5723
I32
atp5724
a(I-1
S'In the present report , we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 ( 1F7 ) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity .'
p5725
(lp5726
I26
a(lp5727
I32
atp5728
a(I-1
S'We further showed that CD26 was comodulated on the T cell surface with CD45 , a known membrane - linked protein tyrosine phosphatase and that anti - CD26 was capable of precipitating CD45 from T cell lysates .'
p5729
(lp5730
I4
a(lp5731
I13
atp5732
a(I-1
S'We further showed that CD26 was comodulated on the T cell surface with CD45 , a known membrane - linked protein tyrosine phosphatase and that anti - CD26 was capable of precipitating CD45 from T cell lysates .'
p5733
(lp5734
I4
a(lp5735
I27
atp5736
a(I-1
S'We further showed that CD26 was comodulated on the T cell surface with CD45 , a known membrane - linked protein tyrosine phosphatase and that anti - CD26 was capable of precipitating CD45 from T cell lysates .'
p5737
(lp5738
I4
a(lp5739
I32
atp5740
a(I-1
S'We further showed that CD26 was comodulated on the T cell surface with CD45 , a known membrane - linked protein tyrosine phosphatase and that anti - CD26 was capable of precipitating CD45 from T cell lysates .'
p5741
(lp5742
I13
a(lp5743
I27
atp5744
a(I-1
S'We further showed that CD26 was comodulated on the T cell surface with CD45 , a known membrane - linked protein tyrosine phosphatase and that anti - CD26 was capable of precipitating CD45 from T cell lysates .'
p5745
(lp5746
I13
a(lp5747
I32
atp5748
a(I-1
S'We further showed that CD26 was comodulated on the T cell surface with CD45 , a known membrane - linked protein tyrosine phosphatase and that anti - CD26 was capable of precipitating CD45 from T cell lysates .'
p5749
(lp5750
I27
a(lp5751
I32
atp5752
a(I-1
S'These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity , zeta chain phosphorylation , and T cell activation .'
p5753
(lp5754
I5
a(lp5755
I12
atp5756
a(I-1
S'These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity , zeta chain phosphorylation , and T cell activation .'
p5757
(lp5758
I5
a(lp5759
I29
atp5760
a(I-1
S'These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity , zeta chain phosphorylation , and T cell activation .'
p5761
(lp5762
I5
a(lp5763
I31
atp5764
a(I-1
S'These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity , zeta chain phosphorylation , and T cell activation .'
p5765
(lp5766
I12
a(lp5767
I29
atp5768
a(I-1
S'These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity , zeta chain phosphorylation , and T cell activation .'
p5769
(lp5770
I12
a(lp5771
I31
atp5772
a(I1
S'These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity , zeta chain phosphorylation , and T cell activation .'
p5773
(lp5774
I29
a(lp5775
I31
atp5776
a(I-1
S'We have isolated and characterized a cDNA clone , phFGFR , encoding a human fibroblast growth factor ( FGF ) receptor . phFGFR contains an open reading frame which encodes an 820 amino acid polypeptide with three immunoglobulin - like domains in the extracellular part and an intracellular split tyrosine kinase domain .'
p5777
(lp5778
I9
a(lp5779
I22
atp5780
a(I-1
S'Transient expression in COS - 1 cells and immunoprecipitation using an antiserum raised against a C - terminal peptide , gave rise to two components , representing mature ( 130 kDa ) and precursor ( 115 kDa ) forms of the phFGFR encoded polypeptide , which was denoted hFGFR - 1 .'
p5781
(lp5782
I41
a(lp5783
I48
aI49
aI50
atp5784
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5785
(lp5786
I3
aI4
a(lp5787
I6
atp5788
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5789
(lp5790
I3
aI4
a(lp5791
I9
aI10
atp5792
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5793
(lp5794
I3
aI4
a(lp5795
I12
atp5796
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5797
(lp5798
I3
aI4
a(lp5799
I35
atp5800
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5801
(lp5802
I3
aI4
a(lp5803
I37
atp5804
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5805
(lp5806
I6
a(lp5807
I9
aI10
atp5808
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5809
(lp5810
I6
a(lp5811
I12
atp5812
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5813
(lp5814
I6
a(lp5815
I35
atp5816
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5817
(lp5818
I6
a(lp5819
I37
atp5820
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5821
(lp5822
I9
aI10
a(lp5823
I12
atp5824
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5825
(lp5826
I9
aI10
a(lp5827
I35
atp5828
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5829
(lp5830
I9
aI10
a(lp5831
I37
atp5832
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5833
(lp5834
I12
a(lp5835
I35
atp5836
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5837
(lp5838
I12
a(lp5839
I37
atp5840
a(I-1
S'Crosslinking of iodinated acidic FGF ( aFGF ) and basic FGF ( bFGF ) to transiently expressing COS - 1 cells revealed a major band of 95 kDa , which was competed for by both aFGF and bFGF .'
p5841
(lp5842
I35
a(lp5843
I37
atp5844
a(I-1
S'From Scatchard analyses , the Kd : s for binding of aFGF and bFGF to hFGFR - 1 were estimated to 25 pM and 41 pM , respectively .'
p5845
(lp5846
I11
a(lp5847
I13
atp5848
a(I1
S'From Scatchard analyses , the Kd : s for binding of aFGF and bFGF to hFGFR - 1 were estimated to 25 pM and 41 pM , respectively .'
p5849
(lp5850
I11
a(lp5851
I15
aI16
aI17
atp5852
a(I1
S'From Scatchard analyses , the Kd : s for binding of aFGF and bFGF to hFGFR - 1 were estimated to 25 pM and 41 pM , respectively .'
p5853
(lp5854
I13
a(lp5855
I15
aI16
aI17
atp5856
a(I1
S'Thus , phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF .'
p5857
(lp5858
I2
a(lp5859
I13
atp5860
a(I1
S'Thus , phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF .'
p5861
(lp5862
I2
a(lp5863
I15
atp5864
a(I-1
S'Thus , phFGFR encodes a human FGF receptor with high affinity for both aFGF and bFGF .'
p5865
(lp5866
I13
a(lp5867
I15
atp5868
a(I1
S'Cross - family dimerization of transcription factors Fos / Jun and ATF / CREB alters DNA binding specificity .'
p5869
(lp5870
I7
a(lp5871
I9
atp5872
a(I-1
S'Cross - family dimerization of transcription factors Fos / Jun and ATF / CREB alters DNA binding specificity .'
p5873
(lp5874
I7
a(lp5875
I11
atp5876
a(I-1
S'Cross - family dimerization of transcription factors Fos / Jun and ATF / CREB alters DNA binding specificity .'
p5877
(lp5878
I7
a(lp5879
I13
atp5880
a(I-1
S'Cross - family dimerization of transcription factors Fos / Jun and ATF / CREB alters DNA binding specificity .'
p5881
(lp5882
I9
a(lp5883
I11
atp5884
a(I-1
S'Cross - family dimerization of transcription factors Fos / Jun and ATF / CREB alters DNA binding specificity .'
p5885
(lp5886
I9
a(lp5887
I13
atp5888
a(I1
S'Cross - family dimerization of transcription factors Fos / Jun and ATF / CREB alters DNA binding specificity .'
p5889
(lp5890
I11
a(lp5891
I13
atp5892
a(I-1
S'The Fos / Jun and ATF / CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .'
p5893
(lp5894
I1
a(lp5895
I3
atp5896
a(I-1
S'The Fos / Jun and ATF / CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .'
p5897
(lp5898
I1
a(lp5899
I5
atp5900
a(I-1
S'The Fos / Jun and ATF / CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .'
p5901
(lp5902
I1
a(lp5903
I7
atp5904
a(I-1
S'The Fos / Jun and ATF / CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .'
p5905
(lp5906
I3
a(lp5907
I5
atp5908
a(I-1
S'The Fos / Jun and ATF / CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .'
p5909
(lp5910
I3
a(lp5911
I7
atp5912
a(I-1
S'The Fos / Jun and ATF / CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .'
p5913
(lp5914
I5
a(lp5915
I7
atp5916
a(I-1
S'Although Fos / Jun and ATF / CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP - 1 / TRE and ATF / CRE sites , respectively ) , we find that members of these two families form selective cross - family heterodimers .'
p5917
(lp5918
I1
a(lp5919
I3
atp5920
a(I-1
S'Although Fos / Jun and ATF / CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP - 1 / TRE and ATF / CRE sites , respectively ) , we find that members of these two families form selective cross - family heterodimers .'
p5921
(lp5922
I1
a(lp5923
I5
atp5924
a(I-1
S'Although Fos / Jun and ATF / CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP - 1 / TRE and ATF / CRE sites , respectively ) , we find that members of these two families form selective cross - family heterodimers .'
p5925
(lp5926
I1
a(lp5927
I7
atp5928
a(I-1
S'Although Fos / Jun and ATF / CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP - 1 / TRE and ATF / CRE sites , respectively ) , we find that members of these two families form selective cross - family heterodimers .'
p5929
(lp5930
I3
a(lp5931
I5
atp5932
a(I-1
S'Although Fos / Jun and ATF / CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP - 1 / TRE and ATF / CRE sites , respectively ) , we find that members of these two families form selective cross - family heterodimers .'
p5933
(lp5934
I3
a(lp5935
I7
atp5936
a(I-1
S'Although Fos / Jun and ATF / CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP - 1 / TRE and ATF / CRE sites , respectively ) , we find that members of these two families form selective cross - family heterodimers .'
p5937
(lp5938
I5
a(lp5939
I7
atp5940
a(I-1
S'These findings indicate that the Fos / Jun and ATF / CREB families of transcription factors are not as distinct as was previously thought .'
p5941
(lp5942
I5
a(lp5943
I7
atp5944
a(I-1
S'These findings indicate that the Fos / Jun and ATF / CREB families of transcription factors are not as distinct as was previously thought .'
p5945
(lp5946
I5
a(lp5947
I9
atp5948
a(I-1
S'These findings indicate that the Fos / Jun and ATF / CREB families of transcription factors are not as distinct as was previously thought .'
p5949
(lp5950
I5
a(lp5951
I11
atp5952
a(I-1
S'These findings indicate that the Fos / Jun and ATF / CREB families of transcription factors are not as distinct as was previously thought .'
p5953
(lp5954
I7
a(lp5955
I9
atp5956
a(I-1
S'These findings indicate that the Fos / Jun and ATF / CREB families of transcription factors are not as distinct as was previously thought .'
p5957
(lp5958
I7
a(lp5959
I11
atp5960
a(I-1
S'These findings indicate that the Fos / Jun and ATF / CREB families of transcription factors are not as distinct as was previously thought .'
p5961
(lp5962
I9
a(lp5963
I11
atp5964
a(I-1
S'Human cyclin E , a new cyclin that interacts with two members of the CDC2 gene family .'
p5965
(lp5966
I1
aI2
a(lp5967
I14
atp5968
a(I1
S'Cyclin E showed genetic interactions with the CDC28 gene , suggesting that it functioned at START by interacting with the CDC28 protein .'
p5969
(lp5970
I0
aI1
a(lp5971
I7
atp5972
a(I1
S'Cyclin E showed genetic interactions with the CDC28 gene , suggesting that it functioned at START by interacting with the CDC28 protein .'
p5973
(lp5974
I0
aI1
a(lp5975
I20
atp5976
a(I-1
S'Cyclin E showed genetic interactions with the CDC28 gene , suggesting that it functioned at START by interacting with the CDC28 protein .'
p5977
(lp5978
I7
a(lp5979
I20
atp5980
a(I-1
S'Two human genes were identified that could interact with cyclin E to perform START in yeast containing a cdc28 mutation .'
p5981
(lp5982
I9
aI10
a(lp5983
I18
atp5984
a(I-1
S'One was CDC2 - HS , and the second was the human homolog of Xenopus CDK2 .'
p5985
(lp5986
I2
a(lp5987
I2
aI3
aI4
atp5988
a(I-1
S'One was CDC2 - HS , and the second was the human homolog of Xenopus CDK2 .'
p5989
(lp5990
I2
a(lp5991
I15
atp5992
a(I-1
S'One was CDC2 - HS , and the second was the human homolog of Xenopus CDK2 .'
p5993
(lp5994
I2
aI3
aI4
a(lp5995
I15
atp5996
a(I1
S'Cyclin E produced in E . coli bound and activated the CDC2 protein in extracts from human G1 cells , and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells .'
p5997
(lp5998
I0
aI1
a(lp5999
I11
atp6000
a(I-1
S'Cyclin E produced in E . coli bound and activated the CDC2 protein in extracts from human G1 cells , and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells .'
p6001
(lp6002
I0
aI1
a(lp6003
I23
aI24
atp6004
a(I-1
S'Cyclin E produced in E . coli bound and activated the CDC2 protein in extracts from human G1 cells , and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells .'
p6005
(lp6006
I11
a(lp6007
I23
aI24
atp6008
a(I1
S'The interactions between cyclin E and CDC2 , or CDK2 , may be important at the G1 to S transition in human cells .'
p6009
(lp6010
I3
aI4
a(lp6011
I6
atp6012
a(I1
S'The interactions between cyclin E and CDC2 , or CDK2 , may be important at the G1 to S transition in human cells .'
p6013
(lp6014
I3
aI4
a(lp6015
I9
atp6016
a(I-1
S'The interactions between cyclin E and CDC2 , or CDK2 , may be important at the G1 to S transition in human cells .'
p6017
(lp6018
I6
a(lp6019
I9
atp6020
a(I-1
S'Two previously unidentified human cdc25 genes have been isolated , cdc25A and cdc25B .'
p6021
(lp6022
I4
a(lp6023
I10
atp6024
a(I-1
S'Two previously unidentified human cdc25 genes have been isolated , cdc25A and cdc25B .'
p6025
(lp6026
I4
a(lp6027
I12
atp6028
a(I-1
S'Two previously unidentified human cdc25 genes have been isolated , cdc25A and cdc25B .'
p6029
(lp6030
I10
a(lp6031
I12
atp6032
a(I-1
S'Microinjection of anti - cdc25A antibodies into HeLa cells causes their arrest in mitosis . cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several - fold , in the absence of cdc2 , by stoichiometric addition of either cyclin B1 or B2 but not A or D1 .'
p6033
(lp6034
I4
a(lp6035
I15
atp6036
a(I-1
S'Microinjection of anti - cdc25A antibodies into HeLa cells causes their arrest in mitosis . cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several - fold , in the absence of cdc2 , by stoichiometric addition of either cyclin B1 or B2 but not A or D1 .'
p6037
(lp6038
I4
a(lp6039
I17
atp6040
a(I-1
S'Microinjection of anti - cdc25A antibodies into HeLa cells causes their arrest in mitosis . cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several - fold , in the absence of cdc2 , by stoichiometric addition of either cyclin B1 or B2 but not A or D1 .'
p6041
(lp6042
I4
a(lp6043
I41
aI42
atp6044
a(I-1
S'Microinjection of anti - cdc25A antibodies into HeLa cells causes their arrest in mitosis . cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several - fold , in the absence of cdc2 , by stoichiometric addition of either cyclin B1 or B2 but not A or D1 .'
p6045
(lp6046
I15
a(lp6047
I17
atp6048
a(I-1
S'Microinjection of anti - cdc25A antibodies into HeLa cells causes their arrest in mitosis . cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several - fold , in the absence of cdc2 , by stoichiometric addition of either cyclin B1 or B2 but not A or D1 .'
p6049
(lp6050
I15
a(lp6051
I41
aI42
atp6052
a(I-1
S'Microinjection of anti - cdc25A antibodies into HeLa cells causes their arrest in mitosis . cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several - fold , in the absence of cdc2 , by stoichiometric addition of either cyclin B1 or B2 but not A or D1 .'
p6053
(lp6054
I17
a(lp6055
I41
aI42
atp6056
a(I1
S'Association between cdc25A and cyclin B1 / cdc2 was detected in the HeLa cells .'
p6057
(lp6058
I2
a(lp6059
I4
aI5
atp6060
a(I1
S'Association between cdc25A and cyclin B1 / cdc2 was detected in the HeLa cells .'
p6061
(lp6062
I2
a(lp6063
I7
atp6064
a(I-1
S'Association between cdc25A and cyclin B1 / cdc2 was detected in the HeLa cells .'
p6065
(lp6066
I4
aI5
a(lp6067
I7
atp6068
a(I-1
S'These findings indicate that B - type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase , but also activate the cdc25 tyrosine phosphatase , of which cdc2 is the physiological substrate .'
p6069
(lp6070
I22
a(lp6071
I30
atp6072
a(I-1
S'These findings indicate that B - type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase , but also activate the cdc25 tyrosine phosphatase , of which cdc2 is the physiological substrate .'
p6073
(lp6074
I22
a(lp6075
I36
atp6076
a(I-1
S'These findings indicate that B - type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase , but also activate the cdc25 tyrosine phosphatase , of which cdc2 is the physiological substrate .'
p6077
(lp6078
I30
a(lp6079
I36
atp6080
a(I-1
S'The motif may represent an activating domain that has to be provided to cdc25 by intermolecular interaction with cyclin B .'
p6081
(lp6082
I13
a(lp6083
I18
aI19
atp6084
a(I1
S'Activation of protein kinase C decreases phosphorylation of c - Jun at sites that negatively regulate its DNA - binding activity .'
p6085
(lp6086
I2
aI3
aI4
a(lp6087
I8
aI9
aI10
atp6088
a(I1
S'In resting human epithelial and fibroblastic cells , c - Jun is phosphorylated on serine and threonine at five sites , three of which are phosphorylated in vitro by glycogen synthase kinase 3 ( GSK - 3 ) .'
p6089
(lp6090
I8
aI9
aI10
a(lp6091
I29
aI30
aI31
aI32
atp6092
a(I1
S'In resting human epithelial and fibroblastic cells , c - Jun is phosphorylated on serine and threonine at five sites , three of which are phosphorylated in vitro by glycogen synthase kinase 3 ( GSK - 3 ) .'
p6093
(lp6094
I8
aI9
aI10
a(lp6095
I34
aI35
aI36
atp6096
a(I-1
S'In resting human epithelial and fibroblastic cells , c - Jun is phosphorylated on serine and threonine at five sites , three of which are phosphorylated in vitro by glycogen synthase kinase 3 ( GSK - 3 ) .'
p6097
(lp6098
I29
aI30
aI31
aI32
a(lp6099
I34
aI35
aI36
atp6100
a(I1
S'Activation of protein kinase C results in rapid , site - specific dephosphorylation of c - Jun at one or more of these three sites and is coincident with increased AP - 1 - binding activity .'
p6101
(lp6102
I2
aI3
aI4
a(lp6103
I14
aI15
aI16
atp6104
a(I-1
S'Activation of protein kinase C results in rapid , site - specific dephosphorylation of c - Jun at one or more of these three sites and is coincident with increased AP - 1 - binding activity .'
p6105
(lp6106
I2
aI3
aI4
a(lp6107
I30
aI31
aI32
atp6108
a(I-1
S'Activation of protein kinase C results in rapid , site - specific dephosphorylation of c - Jun at one or more of these three sites and is coincident with increased AP - 1 - binding activity .'
p6109
(lp6110
I14
aI15
aI16
a(lp6111
I30
aI31
aI32
atp6112
a(I1
S'Phosphorylation of recombinant human c - Jun proteins in vitro by GSK - 3 decreases their DNA - binding activity .'
p6113
(lp6114
I4
aI5
aI6
a(lp6115
I11
aI12
aI13
atp6116
a(I1
S'We propose that c - Jun is present in resting cells in a latent , phosphorylated form that can be activated by site - specific dephosphorylation in response to protein kinase C activation .'
p6117
(lp6118
I3
aI4
aI5
a(lp6119
I29
aI30
aI31
atp6120
a(I-1
S'Interaction of the regulatory subunit ( RII ) of cAMP - dependent protein kinase with RII - anchoring proteins occurs through an amphipathic helix binding motif .'
p6121
(lp6122
I6
a(lp6123
I9
aI10
aI11
aI12
aI13
atp6124
a(I-1
S'Interaction of the regulatory subunit ( RII ) of cAMP - dependent protein kinase with RII - anchoring proteins occurs through an amphipathic helix binding motif .'
p6125
(lp6126
I6
a(lp6127
I15
atp6128
a(I-1
S'Interaction of the regulatory subunit ( RII ) of cAMP - dependent protein kinase with RII - anchoring proteins occurs through an amphipathic helix binding motif .'
p6129
(lp6130
I9
aI10
aI11
aI12
aI13
a(lp6131
I15
atp6132
a(I-1
S'The type II cAMP - dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit ( RII ) dimer to RII - anchoring proteins .'
p6133
(lp6134
I1
aI2
aI3
aI4
aI5
aI6
aI7
a(lp6135
I22
atp6136
a(I-1
S'The type II cAMP - dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit ( RII ) dimer to RII - anchoring proteins .'
p6137
(lp6138
I1
aI2
aI3
aI4
aI5
aI6
aI7
a(lp6139
I26
atp6140
a(I-1
S'The type II cAMP - dependent protein kinase is localized to specific subcellular environments through the binding of the regulatory subunit ( RII ) dimer to RII - anchoring proteins .'
p6141
(lp6142
I22
a(lp6143
I26
atp6144
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6145
(lp6146
I11
a(lp6147
I18
aI19
aI20
aI21
aI22
atp6148
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6149
(lp6150
I11
a(lp6151
I24
atp6152
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6153
(lp6154
I11
a(lp6155
I30
aI31
atp6156
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6157
(lp6158
I11
a(lp6159
I33
aI34
atp6160
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6161
(lp6162
I18
aI19
aI20
aI21
aI22
a(lp6163
I24
atp6164
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6165
(lp6166
I18
aI19
aI20
aI21
aI22
a(lp6167
I30
aI31
atp6168
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6169
(lp6170
I18
aI19
aI20
aI21
aI22
a(lp6171
I33
aI34
atp6172
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6173
(lp6174
I24
a(lp6175
I30
aI31
atp6176
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6177
(lp6178
I24
a(lp6179
I33
aI34
atp6180
a(I-1
S'Computer - aided analysis of secondary structure , performed on four RII - anchoring protein sequences ( the microtubule - associated protein 2 , P150 , and two thyroid proteins Ht 21 and Ht 31 ) , has identified common regions of approximately 14 residues which display high probabilities of forming amphipathic helices .'
p6181
(lp6182
I30
aI31
a(lp6183
I33
aI34
atp6184
a(I-1
S'A bacterially expressed 318 - amino acid fragment , Ht 31 ( 418 - 736 ) , containing the amphipathic helix region , was able to bind RII alpha .'
p6185
(lp6186
I9
aI10
a(lp6187
I27
atp6188
a(I1
S'A bacterially expressed 318 - amino acid fragment , Ht 31 ( 418 - 736 ) , containing the amphipathic helix region , was able to bind RII alpha .'
p6189
(lp6190
I9
aI10
a(lp6191
I27
aI28
atp6192
a(I-1
S'A bacterially expressed 318 - amino acid fragment , Ht 31 ( 418 - 736 ) , containing the amphipathic helix region , was able to bind RII alpha .'
p6193
(lp6194
I27
a(lp6195
I27
aI28
atp6196
a(I-1
S'Specifically , substitution of proline for Ala - 498 significantly diminished RII alpha binding , and similar mutation of Ile - 502 or Ile - 507 abolished interaction .'
p6197
(lp6198
I11
a(lp6199
I11
aI12
atp6200
a(I-1
S'Mutation of Ala - 522 to proline , which is located outside the predicted amphipathic helix region , had no effect on RII alpha binding .'
p6201
(lp6202
I22
a(lp6203
I22
aI23
atp6204
a(I-1
S'These data suggest that anchoring proteins interact with RII alpha via an amphipathic helix binding motif .'
p6205
(lp6206
I8
a(lp6207
I8
aI9
atp6208
a(I-1
S'The proto - oncogene c - jun is a component of the AP - 1 transcription factor family involved in the mediation of nuclear events elicited by extracellular stimuli .'
p6209
(lp6210
I4
aI5
aI6
a(lp6211
I12
aI13
aI14
atp6212
a(I-1
S'We present evidence that mitogen - activated protein - serine ( MAP ) kinases ( pp54 and pp42 / 44 ) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c - jun .'
p6213
(lp6214
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp6215
I15
atp6216
a(I-1
S'We present evidence that mitogen - activated protein - serine ( MAP ) kinases ( pp54 and pp42 / 44 ) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c - jun .'
p6217
(lp6218
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp6219
I17
atp6220
a(I-1
S'We present evidence that mitogen - activated protein - serine ( MAP ) kinases ( pp54 and pp42 / 44 ) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c - jun .'
p6221
(lp6222
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp6223
I35
aI36
aI37
atp6224
a(I-1
S'We present evidence that mitogen - activated protein - serine ( MAP ) kinases ( pp54 and pp42 / 44 ) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c - jun .'
p6225
(lp6226
I15
a(lp6227
I17
atp6228
a(I1
S'We present evidence that mitogen - activated protein - serine ( MAP ) kinases ( pp54 and pp42 / 44 ) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c - jun .'
p6229
(lp6230
I15
a(lp6231
I35
aI36
aI37
atp6232
a(I1
S'We present evidence that mitogen - activated protein - serine ( MAP ) kinases ( pp54 and pp42 / 44 ) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c - jun .'
p6233
(lp6234
I17
a(lp6235
I35
aI36
aI37
atp6236
a(I-1
S'The MAP kinase enzymes pp54 and pp42 / 44 are regulated by tyrosine as well as serine / threonine phosphorylation .'
p6237
(lp6238
I1
aI2
a(lp6239
I4
atp6240
a(I-1
S'The MAP kinase enzymes pp54 and pp42 / 44 are regulated by tyrosine as well as serine / threonine phosphorylation .'
p6241
(lp6242
I1
aI2
a(lp6243
I6
atp6244
a(I-1
S'The MAP kinase enzymes pp54 and pp42 / 44 are regulated by tyrosine as well as serine / threonine phosphorylation .'
p6245
(lp6246
I4
a(lp6247
I6
atp6248
a(I-1
S'MAP kinase activation of c - jun may underlie the common stimulation of this transcription factor by mitogens , growth factors and oncogenes .'
p6249
(lp6250
I0
aI1
a(lp6251
I4
aI5
aI6
atp6252
a(I-1
S'A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product .'
p6253
(lp6254
I6
aI7
aI8
a(lp6255
I13
atp6256
a(I-1
S'Tumour - suppressor genes , such as the human retinoblastoma susceptibility gene ( Rb ) , are widely recognized as being vital in the control of cell growth and tumour formation .'
p6257
(lp6258
I9
aI10
aI11
a(lp6259
I13
atp6260
a(I-1
S'How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses , and that two regions of Rb essential for such binding frequently contain mutations in tumour cells .'
p6261
(lp6262
I1
a(lp6263
I17
atp6264
a(I-1
S'How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses , and that two regions of Rb essential for such binding frequently contain mutations in tumour cells .'
p6265
(lp6266
I1
a(lp6267
I36
atp6268
a(I-1
S'How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses , and that two regions of Rb essential for such binding frequently contain mutations in tumour cells .'
p6269
(lp6270
I17
a(lp6271
I36
atp6272
a(I-1
S'We report here the identification of one such human cellular Rb - associated protein of relative molecular mass 46 , 000 ( 46K ) ( RbAP46 ) .'
p6273
(lp6274
I10
a(lp6275
I10
aI11
aI12
aI13
atp6276
a(I-1
S'We report here the identification of one such human cellular Rb - associated protein of relative molecular mass 46 , 000 ( 46K ) ( RbAP46 ) .'
p6277
(lp6278
I10
a(lp6279
I25
atp6280
a(I-1
S'We report here the identification of one such human cellular Rb - associated protein of relative molecular mass 46 , 000 ( 46K ) ( RbAP46 ) .'
p6281
(lp6282
I10
aI11
aI12
aI13
a(lp6283
I25
atp6284
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6285
(lp6286
I8
a(lp6287
I10
aI11
aI12
aI13
aI14
atp6288
a(I1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6289
(lp6290
I8
a(lp6291
I17
atp6292
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6293
(lp6294
I8
a(lp6295
I26
atp6296
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6297
(lp6298
I8
a(lp6299
I39
atp6300
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6301
(lp6302
I8
a(lp6303
I62
atp6304
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6305
(lp6306
I8
a(lp6307
I66
atp6308
a(I1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6309
(lp6310
I10
aI11
aI12
aI13
aI14
a(lp6311
I17
atp6312
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6313
(lp6314
I10
aI11
aI12
aI13
aI14
a(lp6315
I26
atp6316
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6317
(lp6318
I10
aI11
aI12
aI13
aI14
a(lp6319
I39
atp6320
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6321
(lp6322
I10
aI11
aI12
aI13
aI14
a(lp6323
I62
atp6324
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6325
(lp6326
I10
aI11
aI12
aI13
aI14
a(lp6327
I66
atp6328
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6329
(lp6330
I17
a(lp6331
I26
atp6332
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6333
(lp6334
I17
a(lp6335
I39
atp6336
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6337
(lp6338
I17
a(lp6339
I62
atp6340
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6341
(lp6342
I17
a(lp6343
I66
atp6344
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6345
(lp6346
I26
a(lp6347
I39
atp6348
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6349
(lp6350
I26
a(lp6351
I62
atp6352
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6353
(lp6354
I26
a(lp6355
I66
atp6356
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6357
(lp6358
I39
a(lp6359
I62
atp6360
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6361
(lp6362
I39
a(lp6363
I66
atp6364
a(I-1
S'Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb - binding properties : first , several mutated Rb proteins that failed to bind to T also did not associate with RbAP46 ; and second , both T antigen and T peptide ( amino acids 101 - 118 ) were able to compete with RbAP46 for binding to Rb .'
p6365
(lp6366
I62
a(lp6367
I66
atp6368
a(I1
S'The apparent targeting of the RbAP46 - Rb interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important .'
p6369
(lp6370
I5
a(lp6371
I7
atp6372
a(I-1
S'The extracellular cysteine - rich domain of the TNF - R is homologous to the nerve growth factor receptor and the B cell activation protein Bp50 .'
p6373
(lp6374
I21
aI22
aI23
aI24
a(lp6375
I25
atp6376
a(I-1
S'Unlabeled TNF - alpha and TNF - beta were equally effective at displacing the binding of labeled TNF - alpha to TNF - R expressing cells .'
p6377
(lp6378
I1
aI2
aI3
a(lp6379
I5
aI6
aI7
atp6380
a(I-1
S'Unlabeled TNF - alpha and TNF - beta were equally effective at displacing the binding of labeled TNF - alpha to TNF - R expressing cells .'
p6381
(lp6382
I1
aI2
aI3
a(lp6383
I17
aI18
aI19
atp6384
a(I-1
S'Unlabeled TNF - alpha and TNF - beta were equally effective at displacing the binding of labeled TNF - alpha to TNF - R expressing cells .'
p6385
(lp6386
I5
aI6
aI7
a(lp6387
I17
aI18
aI19
atp6388
a(I1
S'Two cDNA clones encoding a receptor for human granulocyte - macrophage colony - stimulating factor ( hGM - CSF - R ) were isolated by expression screening of a library made from human placental mRNA .'
p6389
(lp6390
I8
aI9
aI10
aI11
aI12
aI13
aI14
a(lp6391
I16
aI17
aI18
aI19
aI20
atp6392
a(I-1
S'It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family , but does show some significant sequence homologies with receptors for several other haemopoietic growth factors , including those for interleukin - 6 , erythropoietin and interleukin - 2 ( beta - chain ) and also to the prolactin receptor .'
p6393
(lp6394
I39
aI40
aI41
a(lp6395
I43
atp6396
a(I-1
S'It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family , but does show some significant sequence homologies with receptors for several other haemopoietic growth factors , including those for interleukin - 6 , erythropoietin and interleukin - 2 ( beta - chain ) and also to the prolactin receptor .'
p6397
(lp6398
I39
aI40
aI41
a(lp6399
I45
aI46
aI47
atp6400
a(I-1
S'It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family , but does show some significant sequence homologies with receptors for several other haemopoietic growth factors , including those for interleukin - 6 , erythropoietin and interleukin - 2 ( beta - chain ) and also to the prolactin receptor .'
p6401
(lp6402
I43
a(lp6403
I45
aI46
aI47
atp6404
a(I1
S'When transfected into COS cells the cloned cDNA directed the expression of a GM - CSF - R showing a single class of affinity ( KD = 2 ( - 8 ) nM ) and specificity for human GM - CSF but not interleukin - 3 .'
p6405
(lp6406
I13
aI14
aI15
aI16
aI17
a(lp6407
I38
aI39
aI40
atp6408
a(I-1
S'When transfected into COS cells the cloned cDNA directed the expression of a GM - CSF - R showing a single class of affinity ( KD = 2 ( - 8 ) nM ) and specificity for human GM - CSF but not interleukin - 3 .'
p6409
(lp6410
I13
aI14
aI15
aI16
aI17
a(lp6411
I43
aI44
aI45
atp6412
a(I-1
S'When transfected into COS cells the cloned cDNA directed the expression of a GM - CSF - R showing a single class of affinity ( KD = 2 ( - 8 ) nM ) and specificity for human GM - CSF but not interleukin - 3 .'
p6413
(lp6414
I38
aI39
aI40
a(lp6415
I43
aI44
aI45
atp6416
a(I1
S'The T - cell antigen CD5 acts as a receptor and substrate for the protein - tyrosine kinase p56lck .'
p6417
(lp6418
I5
a(lp6419
I18
atp6420
a(I1
S'CD5 is a T - cell - specific antigen which binds to the B - cell antigen CD72 and acts as a coreceptor in the stimulation of T - cell growth .'
p6421
(lp6422
I0
a(lp6423
I17
atp6424
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6425
(lp6426
I0
a(lp6427
I4
aI5
aI6
aI7
aI8
aI9
atp6428
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6429
(lp6430
I0
a(lp6431
I11
aI12
atp6432
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6433
(lp6434
I0
a(lp6435
I15
atp6436
a(I1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6437
(lp6438
I0
a(lp6439
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
aI15
atp6440
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6441
(lp6442
I0
a(lp6443
I28
aI29
atp6444
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6445
(lp6446
I0
a(lp6447
I31
atp6448
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6449
(lp6450
I4
aI5
aI6
aI7
aI8
aI9
a(lp6451
I11
aI12
atp6452
a(I1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6453
(lp6454
I4
aI5
aI6
aI7
aI8
aI9
a(lp6455
I15
atp6456
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6457
(lp6458
I4
aI5
aI6
aI7
aI8
aI9
a(lp6459
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
aI15
atp6460
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6461
(lp6462
I4
aI5
aI6
aI7
aI8
aI9
a(lp6463
I28
aI29
atp6464
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6465
(lp6466
I4
aI5
aI6
aI7
aI8
aI9
a(lp6467
I31
atp6468
a(I1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6469
(lp6470
I11
aI12
a(lp6471
I15
atp6472
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6473
(lp6474
I11
aI12
a(lp6475
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
aI15
atp6476
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6477
(lp6478
I11
aI12
a(lp6479
I28
aI29
atp6480
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6481
(lp6482
I11
aI12
a(lp6483
I31
atp6484
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6485
(lp6486
I15
a(lp6487
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
aI15
atp6488
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6489
(lp6490
I15
a(lp6491
I28
aI29
atp6492
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6493
(lp6494
I15
a(lp6495
I31
atp6496
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6497
(lp6498
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
aI15
a(lp6499
I28
aI29
atp6500
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6501
(lp6502
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
aI15
a(lp6503
I31
atp6504
a(I-1
S'CD5 associates with the T - cell receptor zeta chain ( TcR zeta ) / CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta / CD3 ligation .'
p6505
(lp6506
I28
aI29
a(lp6507
I31
atp6508
a(I1
S'In this study , we demonstrate that CD5 is coupled to the protein - tyrosine kinase p56lck and can act as a substrate for p56lck .'
p6509
(lp6510
I7
a(lp6511
I16
atp6512
a(I1
S'In this study , we demonstrate that CD5 is coupled to the protein - tyrosine kinase p56lck and can act as a substrate for p56lck .'
p6513
(lp6514
I7
a(lp6515
I24
atp6516
a(I-1
S'In this study , we demonstrate that CD5 is coupled to the protein - tyrosine kinase p56lck and can act as a substrate for p56lck .'
p6517
(lp6518
I16
a(lp6519
I24
atp6520
a(I-1
S'Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues .'
p6521
(lp6522
I2
a(lp6523
I4
atp6524
a(I-1
S'Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues .'
p6525
(lp6526
I2
a(lp6527
I15
atp6528
a(I-1
S'Coexpression of CD5 with p56lck in the baculovirus expression system resulted in the phosphorylation of CD5 on tyrosine residues .'
p6529
(lp6530
I4
a(lp6531
I15
atp6532
a(I-1
S'Further , anti - CD5 and anti - p56lck coprecipitated each other in a variety of detergents , including Nonidet P - 40 and Triton X - 100 .'
p6533
(lp6534
I4
a(lp6535
I8
atp6536
a(I-1
S'Anti - CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta / CD3 or CD4 .'
p6537
(lp6538
I2
a(lp6539
I16
aI17
atp6540
a(I-1
S'Anti - CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta / CD3 or CD4 .'
p6541
(lp6542
I2
a(lp6543
I19
atp6544
a(I-1
S'Anti - CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta / CD3 or CD4 .'
p6545
(lp6546
I2
a(lp6547
I21
atp6548
a(I-1
S'Anti - CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta / CD3 or CD4 .'
p6549
(lp6550
I16
aI17
a(lp6551
I19
atp6552
a(I-1
S'Anti - CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta / CD3 or CD4 .'
p6553
(lp6554
I16
aI17
a(lp6555
I21
atp6556
a(I-1
S'Anti - CD5 also precipitated the kinase from various T cells irrespective of the expression of TcR zeta / CD3 or CD4 .'
p6557
(lp6558
I19
a(lp6559
I21
atp6560
a(I-1
S'No binding between p59fyn ( T ) and CD5 was detected in T cells .'
p6561
(lp6562
I3
a(lp6563
I8
atp6564
a(I1
S'The binding of p56lck to CD5 induced a 10 - to 15 - fold increase in p56lck catalytic activity , as measured by in vitro kinase analysis .'
p6565
(lp6566
I3
a(lp6567
I5
atp6568
a(I-1
S'The binding of p56lck to CD5 induced a 10 - to 15 - fold increase in p56lck catalytic activity , as measured by in vitro kinase analysis .'
p6569
(lp6570
I3
a(lp6571
I16
atp6572
a(I-1
S'The binding of p56lck to CD5 induced a 10 - to 15 - fold increase in p56lck catalytic activity , as measured by in vitro kinase analysis .'
p6573
(lp6574
I5
a(lp6575
I16
atp6576
a(I1
S'In vivo labelling with 32P ( i ) also showed a four - to fivefold increase in Y - 394 occupancy in p56lck when associated with CD5 .'
p6577
(lp6578
I22
a(lp6579
I26
atp6580
a(I1
S'The use of glutathione S - transferase - Lck fusion proteins in precipitation analysis showed that the SH2 domain of p56lck could recognize CD5 as expressed in the baculovirus expression system .'
p6581
(lp6582
I20
a(lp6583
I23
atp6584
a(I-1
S'CD5 interaction with p56lck represents a novel variant of a receptor - kinase complex in which receptor can also serve as substrate . ( ABSTRACT TRUNCATED AT 250 WORDS )'
p6585
(lp6586
I0
a(lp6587
I2
atp6588
a(I1
S'CD5 interaction with p56lck represents a novel variant of a receptor - kinase complex in which receptor can also serve as substrate . ( ABSTRACT TRUNCATED AT 250 WORDS )'
p6589
(lp6590
I0
a(lp6591
I3
atp6592
a(I-1
S'CD5 interaction with p56lck represents a novel variant of a receptor - kinase complex in which receptor can also serve as substrate . ( ABSTRACT TRUNCATED AT 250 WORDS )'
p6593
(lp6594
I0
a(lp6595
I12
aI13
atp6596
a(I-1
S'CD5 interaction with p56lck represents a novel variant of a receptor - kinase complex in which receptor can also serve as substrate . ( ABSTRACT TRUNCATED AT 250 WORDS )'
p6597
(lp6598
I2
a(lp6599
I3
atp6600
a(I-1
S'CD5 interaction with p56lck represents a novel variant of a receptor - kinase complex in which receptor can also serve as substrate . ( ABSTRACT TRUNCATED AT 250 WORDS )'
p6601
(lp6602
I2
a(lp6603
I12
aI13
atp6604
a(I-1
S'CD5 interaction with p56lck represents a novel variant of a receptor - kinase complex in which receptor can also serve as substrate . ( ABSTRACT TRUNCATED AT 250 WORDS )'
p6605
(lp6606
I3
a(lp6607
I12
aI13
atp6608
a(I-1
S'Desmoplakin ( DPI ) , a desmosomal component lacking a transmembrane domain , has been implicated in this interaction , although most studies have been conducted with cells that contain few or no desmosomes , and efforts to demonstrate direct interactions between desmoplakin and intermediate filaments have not been successful .'
p6609
(lp6610
I0
a(lp6611
I2
atp6612
a(I1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6613
(lp6614
I10
a(lp6615
I27
atp6616
a(I1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6617
(lp6618
I10
a(lp6619
I29
atp6620
a(I1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6621
(lp6622
I10
a(lp6623
I31
atp6624
a(I1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6625
(lp6626
I10
a(lp6627
I34
atp6628
a(I-1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6629
(lp6630
I27
a(lp6631
I29
atp6632
a(I-1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6633
(lp6634
I27
a(lp6635
I31
atp6636
a(I-1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6637
(lp6638
I27
a(lp6639
I34
atp6640
a(I-1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6641
(lp6642
I29
a(lp6643
I31
atp6644
a(I-1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6645
(lp6646
I29
a(lp6647
I34
atp6648
a(I-1
S'We show that the carboxy terminal " tail " of DPI associates directly with the amino terminal " head " of type II epidermal keratins , including K1 , K2 , K5 , and K6 .'
p6649
(lp6650
I31
a(lp6651
I34
atp6652
a(I1
S'We have engineered and purified recombinant K5 head and DPI tail , and we demonstrate direct interaction in vitro by solution - binding assays and by ligand blot assays .'
p6653
(lp6654
I6
a(lp6655
I9
atp6656
a(I1
S'We have identified an 18 - amino acid residue stretch in the K5 head that is conserved only among type II epidermal keratins and that appears to play some role in DPI tail binding .'
p6657
(lp6658
I12
a(lp6659
I31
atp6660
a(I-1
S'A newly identified member of tumor necrosis factor receptor superfamily ( TR6 ) suppresses LIGHT - mediated apoptosis .'
p6661
(lp6662
I11
a(lp6663
I14
atp6664
a(I-1
S'TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .'
p6665
(lp6666
I0
a(lp6667
I2
aI3
aI4
atp6668
a(I-1
S'TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .'
p6669
(lp6670
I0
a(lp6671
I6
atp6672
a(I-1
S'TR6 ( decoy receptor 3 ( DcR3 ) ) is a new member of the tumor necrosis factor receptor ( TNFR ) family .'
p6673
(lp6674
I2
aI3
aI4
a(lp6675
I6
atp6676
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6677
(lp6678
I5
a(lp6679
I12
atp6680
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6681
(lp6682
I5
a(lp6683
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
atp6684
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6685
(lp6686
I5
a(lp6687
I25
atp6688
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6689
(lp6690
I5
a(lp6691
I25
aI26
atp6692
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6693
(lp6694
I5
a(lp6695
I28
atp6696
a(I1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6697
(lp6698
I5
a(lp6699
I30
atp6700
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6701
(lp6702
I12
a(lp6703
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
atp6704
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6705
(lp6706
I12
a(lp6707
I25
atp6708
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6709
(lp6710
I12
a(lp6711
I25
aI26
atp6712
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6713
(lp6714
I12
a(lp6715
I28
atp6716
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6717
(lp6718
I12
a(lp6719
I30
atp6720
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6721
(lp6722
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
a(lp6723
I25
atp6724
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6725
(lp6726
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
a(lp6727
I25
aI26
atp6728
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6729
(lp6730
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
a(lp6731
I28
atp6732
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6733
(lp6734
I14
aI15
aI16
aI17
aI18
aI19
aI20
aI21
aI22
a(lp6735
I30
atp6736
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6737
(lp6738
I25
a(lp6739
I25
aI26
atp6740
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6741
(lp6742
I25
a(lp6743
I28
atp6744
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6745
(lp6746
I25
a(lp6747
I30
atp6748
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6749
(lp6750
I25
aI26
a(lp6751
I28
atp6752
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6753
(lp6754
I25
aI26
a(lp6755
I30
atp6756
a(I-1
S'Here , we demonstrate that TR6 specifically binds two cellular ligands , LIGHT ( herpes virus entry mediator ( HVEM ) - L ) and Fas ligand ( FasL / CD95L ) .'
p6757
(lp6758
I28
a(lp6759
I30
atp6760
a(I-1
S'TR6 inhibited LIGHT - induced cytotoxicity in HT29 cells .'
p6761
(lp6762
I0
a(lp6763
I2
atp6764
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6765
(lp6766
I5
a(lp6767
I18
aI19
atp6768
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6769
(lp6770
I5
a(lp6771
I18
aI19
aI20
atp6772
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6773
(lp6774
I5
a(lp6775
I22
atp6776
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6777
(lp6778
I5
a(lp6779
I25
atp6780
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6781
(lp6782
I5
a(lp6783
I27
atp6784
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6785
(lp6786
I18
aI19
a(lp6787
I18
aI19
aI20
atp6788
a(I1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6789
(lp6790
I18
aI19
a(lp6791
I22
atp6792
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6793
(lp6794
I18
aI19
a(lp6795
I25
atp6796
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6797
(lp6798
I18
aI19
a(lp6799
I27
atp6800
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6801
(lp6802
I18
aI19
aI20
a(lp6803
I22
atp6804
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6805
(lp6806
I18
aI19
aI20
a(lp6807
I25
atp6808
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6809
(lp6810
I18
aI19
aI20
a(lp6811
I27
atp6812
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6813
(lp6814
I22
a(lp6815
I25
atp6816
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6817
(lp6818
I22
a(lp6819
I27
atp6820
a(I-1
S'It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor ( LTbetaR ) and HVEM / TR2 receptors .'
p6821
(lp6822
I25
a(lp6823
I27
atp6824
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6825
(lp6826
I4
a(lp6827
I9
atp6828
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6829
(lp6830
I4
a(lp6831
I11
atp6832
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6833
(lp6834
I4
a(lp6835
I13
atp6836
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6837
(lp6838
I4
a(lp6839
I15
atp6840
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6841
(lp6842
I4
a(lp6843
I19
atp6844
a(I1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6845
(lp6846
I9
a(lp6847
I11
atp6848
a(I1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6849
(lp6850
I9
a(lp6851
I13
atp6852
a(I1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6853
(lp6854
I9
a(lp6855
I15
atp6856
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6857
(lp6858
I9
a(lp6859
I19
atp6860
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6861
(lp6862
I11
a(lp6863
I13
atp6864
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6865
(lp6866
I11
a(lp6867
I15
atp6868
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6869
(lp6870
I11
a(lp6871
I19
atp6872
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6873
(lp6874
I13
a(lp6875
I15
atp6876
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6877
(lp6878
I13
a(lp6879
I19
atp6880
a(I-1
S'Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM / TR2 and LTbetaR , thereby suppressing LIGHT - mediated HT29 cell death .'
p6881
(lp6882
I15
a(lp6883
I19
atp6884
a(I-1
S'Thus , TR6 may play a regulatory role for suppressing in FasL - and LIGHT - mediated cell death .'
p6885
(lp6886
I2
a(lp6887
I11
atp6888
a(I-1
S'Thus , TR6 may play a regulatory role for suppressing in FasL - and LIGHT - mediated cell death .'
p6889
(lp6890
I2
a(lp6891
I14
atp6892
a(I-1
S'Thus , TR6 may play a regulatory role for suppressing in FasL - and LIGHT - mediated cell death .'
p6893
(lp6894
I11
a(lp6895
I14
atp6896
a(I1
S'The retinoblastoma protein binds to RIZ , a zinc - finger protein that shares an epitope with the adenovirus E1A protein .'
p6897
(lp6898
I1
a(lp6899
I5
atp6900
a(I-1
S'The retinoblastoma protein binds to RIZ , a zinc - finger protein that shares an epitope with the adenovirus E1A protein .'
p6901
(lp6902
I1
a(lp6903
I19
atp6904
a(I-1
S'The retinoblastoma protein binds to RIZ , a zinc - finger protein that shares an epitope with the adenovirus E1A protein .'
p6905
(lp6906
I5
a(lp6907
I19
atp6908
a(I-1
S'The retinoblastoma protein ( Rb ) is a target of viral oncoproteins .'
p6909
(lp6910
I1
aI2
a(lp6911
I4
atp6912
a(I-1
S'It contains an Rb - binding motif that shares an antigenic epitope with the C terminus of E1A .'
p6913
(lp6914
I3
a(lp6915
I17
atp6916
a(I-1
S'A domain is conserved between RIZ and the PRDI - BF1 / Blimp - 1 differentiation factor .'
p6917
(lp6918
I5
a(lp6919
I8
aI9
aI10
atp6920
a(I-1
S'A domain is conserved between RIZ and the PRDI - BF1 / Blimp - 1 differentiation factor .'
p6921
(lp6922
I5
a(lp6923
I12
aI13
aI14
atp6924
a(I-1
S'A domain is conserved between RIZ and the PRDI - BF1 / Blimp - 1 differentiation factor .'
p6925
(lp6926
I8
aI9
aI10
a(lp6927
I12
aI13
aI14
atp6928
a(I-1
S'While the function of RIZ is not yet clear , its structure and pattern of expression suggest a role for RIZ in transcriptional regulation during neuronal differentiation and pathogenesis of retinoblastoma .'
p6929
(lp6930
I4
a(lp6931
I20
atp6932
a(I1
S'FADD , a novel death domain - containing protein , interacts with the death domain of Fas and initiates apoptosis .'
p6933
(lp6934
I0
a(lp6935
I16
atp6936
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6937
(lp6938
I5
a(lp6939
I22
atp6940
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6941
(lp6942
I5
a(lp6943
I26
atp6944
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6945
(lp6946
I5
a(lp6947
I28
atp6948
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6949
(lp6950
I5
a(lp6951
I30
atp6952
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6953
(lp6954
I5
a(lp6955
I35
atp6956
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6957
(lp6958
I5
a(lp6959
I47
atp6960
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6961
(lp6962
I5
a(lp6963
I49
atp6964
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6965
(lp6966
I5
a(lp6967
I51
atp6968
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6969
(lp6970
I5
a(lp6971
I53
atp6972
a(I1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6973
(lp6974
I22
a(lp6975
I26
atp6976
a(I1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6977
(lp6978
I22
a(lp6979
I28
atp6980
a(I1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6981
(lp6982
I22
a(lp6983
I30
atp6984
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6985
(lp6986
I22
a(lp6987
I35
atp6988
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6989
(lp6990
I22
a(lp6991
I47
atp6992
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6993
(lp6994
I22
a(lp6995
I49
atp6996
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p6997
(lp6998
I22
a(lp6999
I51
atp7000
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7001
(lp7002
I22
a(lp7003
I53
atp7004
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7005
(lp7006
I26
a(lp7007
I28
atp7008
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7009
(lp7010
I26
a(lp7011
I30
atp7012
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7013
(lp7014
I26
a(lp7015
I35
atp7016
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7017
(lp7018
I26
a(lp7019
I47
atp7020
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7021
(lp7022
I26
a(lp7023
I49
atp7024
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7025
(lp7026
I26
a(lp7027
I51
atp7028
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7029
(lp7030
I26
a(lp7031
I53
atp7032
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7033
(lp7034
I28
a(lp7035
I30
atp7036
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7037
(lp7038
I28
a(lp7039
I35
atp7040
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7041
(lp7042
I28
a(lp7043
I47
atp7044
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7045
(lp7046
I28
a(lp7047
I49
atp7048
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7049
(lp7050
I28
a(lp7051
I51
atp7052
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7053
(lp7054
I28
a(lp7055
I53
atp7056
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7057
(lp7058
I30
a(lp7059
I35
atp7060
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7061
(lp7062
I30
a(lp7063
I47
atp7064
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7065
(lp7066
I30
a(lp7067
I49
atp7068
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7069
(lp7070
I30
a(lp7071
I51
atp7072
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7073
(lp7074
I30
a(lp7075
I53
atp7076
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7077
(lp7078
I35
a(lp7079
I47
atp7080
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7081
(lp7082
I35
a(lp7083
I49
atp7084
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7085
(lp7086
I35
a(lp7087
I51
atp7088
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7089
(lp7090
I35
a(lp7091
I53
atp7092
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7093
(lp7094
I47
a(lp7095
I49
atp7096
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7097
(lp7098
I47
a(lp7099
I51
atp7100
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7101
(lp7102
I47
a(lp7103
I53
atp7104
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7105
(lp7106
I49
a(lp7107
I51
atp7108
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7109
(lp7110
I49
a(lp7111
I53
atp7112
a(I-1
S'Using the cytoplasmic domain of Fas in the yeast two - hybrid system , we have identified a novel interacting protein , FADD , which binds Fas and Fas - FD5 , a mutant of Fas possessing enhanced killing activity , but not the functionally inactive mutants Fas - LPR and Fas - FD8 .'
p7113
(lp7114
I51
a(lp7115
I53
atp7116
a(I-1
S'FADD contains a death domain homologous to the death domains of Fas and TNFR - 1 .'
p7117
(lp7118
I0
a(lp7119
I11
atp7120
a(I-1
S'FADD contains a death domain homologous to the death domains of Fas and TNFR - 1 .'
p7121
(lp7122
I0
a(lp7123
I13
aI14
aI15
atp7124
a(I-1
S'FADD contains a death domain homologous to the death domains of Fas and TNFR - 1 .'
p7125
(lp7126
I11
a(lp7127
I13
aI14
aI15
atp7128
a(I-1
S'A point mutation in FADD , analogous to the lpr mutation of Fas , abolishes its ability to bind Fas , suggesting a death domain to death domain interaction .'
p7129
(lp7130
I4
a(lp7131
I12
atp7132
a(I1
S'A point mutation in FADD , analogous to the lpr mutation of Fas , abolishes its ability to bind Fas , suggesting a death domain to death domain interaction .'
p7133
(lp7134
I4
a(lp7135
I19
atp7136
a(I-1
S'A point mutation in FADD , analogous to the lpr mutation of Fas , abolishes its ability to bind Fas , suggesting a death domain to death domain interaction .'
p7137
(lp7138
I12
a(lp7139
I19
atp7140
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7141
(lp7142
I2
a(lp7143
I14
atp7144
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7145
(lp7146
I2
a(lp7147
I22
atp7148
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7149
(lp7150
I2
a(lp7151
I29
aI30
aI31
aI32
atp7152
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7153
(lp7154
I2
a(lp7155
I29
aI30
aI31
aI32
aI33
aI34
aI35
atp7156
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7157
(lp7158
I14
a(lp7159
I22
atp7160
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7161
(lp7162
I14
a(lp7163
I29
aI30
aI31
aI32
atp7164
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7165
(lp7166
I14
a(lp7167
I29
aI30
aI31
aI32
aI33
aI34
aI35
atp7168
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7169
(lp7170
I22
a(lp7171
I29
aI30
aI31
aI32
atp7172
a(I1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7173
(lp7174
I22
a(lp7175
I29
aI30
aI31
aI32
aI33
aI34
aI35
atp7176
a(I-1
S'Overexpression of FADD in MCF7 and BJAB cells induces apoptosis , which , like Fas - induced apoptosis , is blocked by CrmA , a specific inhibitor of the interleukin - 1 beta - converting enzyme .'
p7177
(lp7178
I29
aI30
aI31
aI32
a(lp7179
I29
aI30
aI31
aI32
aI33
aI34
aI35
atp7180
a(I-1
S'These findings suggest that FADD may play an important role in the proximal signal transduction of Fas .'
p7181
(lp7182
I4
a(lp7183
I16
atp7184
a(I1
S'RIP : a novel protein containing a death domain that interacts with Fas / APO - 1 ( CD95 ) in yeast and causes cell death .'
p7185
(lp7186
I0
a(lp7187
I12
atp7188
a(I1
S'RIP : a novel protein containing a death domain that interacts with Fas / APO - 1 ( CD95 ) in yeast and causes cell death .'
p7189
(lp7190
I0
a(lp7191
I14
aI15
aI16
atp7192
a(I1
S'RIP : a novel protein containing a death domain that interacts with Fas / APO - 1 ( CD95 ) in yeast and causes cell death .'
p7193
(lp7194
I0
a(lp7195
I18
atp7196
a(I-1
S'RIP : a novel protein containing a death domain that interacts with Fas / APO - 1 ( CD95 ) in yeast and causes cell death .'
p7197
(lp7198
I12
a(lp7199
I14
aI15
aI16
atp7200
a(I-1
S'RIP : a novel protein containing a death domain that interacts with Fas / APO - 1 ( CD95 ) in yeast and causes cell death .'
p7201
(lp7202
I12
a(lp7203
I18
atp7204
a(I-1
S'RIP : a novel protein containing a death domain that interacts with Fas / APO - 1 ( CD95 ) in yeast and causes cell death .'
p7205
(lp7206
I14
aI15
aI16
a(lp7207
I18
atp7208
a(I-1
S'Ligation of the extracellular domain of the cell surface receptor Fas / APO - 1 ( CD95 ) elicits a characteristic programmed death response in susceptible cells .'
p7209
(lp7210
I10
a(lp7211
I12
aI13
aI14
atp7212
a(I-1
S'Ligation of the extracellular domain of the cell surface receptor Fas / APO - 1 ( CD95 ) elicits a characteristic programmed death response in susceptible cells .'
p7213
(lp7214
I10
a(lp7215
I16
atp7216
a(I-1
S'Ligation of the extracellular domain of the cell surface receptor Fas / APO - 1 ( CD95 ) elicits a characteristic programmed death response in susceptible cells .'
p7217
(lp7218
I12
aI13
aI14
a(lp7219
I16
atp7220
a(I1
S'Using a genetic selection based on protein - protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : Fas itself , and a novel 74 kDa protein we have named RIP , for receptor interacting protein .'
p7221
(lp7222
I26
a(lp7223
I28
atp7224
a(I1
S'Using a genetic selection based on protein - protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : Fas itself , and a novel 74 kDa protein we have named RIP , for receptor interacting protein .'
p7225
(lp7226
I26
a(lp7227
I40
atp7228
a(I1
S'Using a genetic selection based on protein - protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : Fas itself , and a novel 74 kDa protein we have named RIP , for receptor interacting protein .'
p7229
(lp7230
I26
a(lp7231
I43
aI44
aI45
atp7232
a(I-1
S'Using a genetic selection based on protein - protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : Fas itself , and a novel 74 kDa protein we have named RIP , for receptor interacting protein .'
p7233
(lp7234
I28
a(lp7235
I40
atp7236
a(I-1
S'Using a genetic selection based on protein - protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : Fas itself , and a novel 74 kDa protein we have named RIP , for receptor interacting protein .'
p7237
(lp7238
I28
a(lp7239
I43
aI44
aI45
atp7240
a(I-1
S'Using a genetic selection based on protein - protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : Fas itself , and a novel 74 kDa protein we have named RIP , for receptor interacting protein .'
p7241
(lp7242
I40
a(lp7243
I43
aI44
aI45
atp7244
a(I-1
S'RIP also interacts weakly with the p55 tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .'
p7245
(lp7246
I0
a(lp7247
I6
atp7248
a(I1
S'RIP also interacts weakly with the p55 tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .'
p7249
(lp7250
I0
a(lp7251
I12
atp7252
a(I-1
S'RIP also interacts weakly with the p55 tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .'
p7253
(lp7254
I0
a(lp7255
I24
atp7256
a(I-1
S'RIP also interacts weakly with the p55 tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .'
p7257
(lp7258
I6
a(lp7259
I12
atp7260
a(I-1
S'RIP also interacts weakly with the p55 tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .'
p7261
(lp7262
I6
a(lp7263
I24
atp7264
a(I-1
S'RIP also interacts weakly with the p55 tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .'
p7265
(lp7266
I12
a(lp7267
I24
atp7268
a(I-1
S'RIP contains an N - terminal region with homology to protein kinases and a C - terminal region containing a cytoplasmic motif ( death domain ) present in the Fas and TNFR1 intracellular domains .'
p7269
(lp7270
I0
a(lp7271
I29
atp7272
a(I-1
S'RIP contains an N - terminal region with homology to protein kinases and a C - terminal region containing a cytoplasmic motif ( death domain ) present in the Fas and TNFR1 intracellular domains .'
p7273
(lp7274
I0
a(lp7275
I31
atp7276
a(I-1
S'RIP contains an N - terminal region with homology to protein kinases and a C - terminal region containing a cytoplasmic motif ( death domain ) present in the Fas and TNFR1 intracellular domains .'
p7277
(lp7278
I29
a(lp7279
I31
atp7280
a(I-1
S'Identification of an 11 - kDa FKBP12 - rapamycin - binding domain within the 289 - kDa FKBP12 - rapamycin - associated protein and characterization of a critical serine residue .'
p7281
(lp7282
I6
a(lp7283
I17
aI18
aI19
aI20
aI21
aI22
atp7284
a(I1
S'Previously , a mammalian protein that directly associates with FKBP12 - rapamycin has been identified and its encoding gene has been cloned from both human ( designated FRAP ) [ Brown , E . J . , Albers , M . W . , Shin , T . B . , Ichikawa , K . , Keith , C . T . , Lane , W . S . & Schreiber , S . L . ( 1994 ) Nature ( London ) 369 , 756 - 758 ] and rat ( designated RAFT ) [ Sabatini , D . M . , Erdjument - Bromage , H . , Lui , M . , Tempst , P . & Snyder , S . H . ( 1994 ) Cell 78 , 35 - 43 ] .'
p7285
(lp7286
I9
a(lp7287
I27
atp7288
a(I-1
S'Previously , a mammalian protein that directly associates with FKBP12 - rapamycin has been identified and its encoding gene has been cloned from both human ( designated FRAP ) [ Brown , E . J . , Albers , M . W . , Shin , T . B . , Ichikawa , K . , Keith , C . T . , Lane , W . S . & Schreiber , S . L . ( 1994 ) Nature ( London ) 369 , 756 - 758 ] and rat ( designated RAFT ) [ Sabatini , D . M . , Erdjument - Bromage , H . , Lui , M . , Tempst , P . & Snyder , S . H . ( 1994 ) Cell 78 , 35 - 43 ] .'
p7289
(lp7290
I9
a(lp7291
I93
atp7292
a(I-1
S'Previously , a mammalian protein that directly associates with FKBP12 - rapamycin has been identified and its encoding gene has been cloned from both human ( designated FRAP ) [ Brown , E . J . , Albers , M . W . , Shin , T . B . , Ichikawa , K . , Keith , C . T . , Lane , W . S . & Schreiber , S . L . ( 1994 ) Nature ( London ) 369 , 756 - 758 ] and rat ( designated RAFT ) [ Sabatini , D . M . , Erdjument - Bromage , H . , Lui , M . , Tempst , P . & Snyder , S . H . ( 1994 ) Cell 78 , 35 - 43 ] .'
p7293
(lp7294
I27
a(lp7295
I93
atp7296
a(I1
S'Using an in vitro transcription / translation assay method coupled with proteolysis studies , we have identified an 11 - kDa FKBP12 - rapamycin - binding domain within FRAP .'
p7297
(lp7298
I21
a(lp7299
I28
atp7300
a(I-1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7301
(lp7302
I31
aI32
aI33
a(lp7303
I35
atp7304
a(I1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7305
(lp7306
I31
aI32
aI33
a(lp7307
I38
aI39
atp7308
a(I-1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7309
(lp7310
I31
aI32
aI33
a(lp7311
I48
atp7312
a(I-1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7313
(lp7314
I31
aI32
aI33
a(lp7315
I50
atp7316
a(I1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7317
(lp7318
I35
a(lp7319
I38
aI39
atp7320
a(I-1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7321
(lp7322
I35
a(lp7323
I48
atp7324
a(I-1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7325
(lp7326
I35
a(lp7327
I50
atp7328
a(I-1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7329
(lp7330
I38
aI39
a(lp7331
I48
atp7332
a(I-1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7333
(lp7334
I38
aI39
a(lp7335
I50
atp7336
a(I-1
S'By rational mutagenesis , receptor - specific functional analysis , and visualization of complex formation in solution , we identified individual amino acid side chains involved specifically in the interaction of ciliary neurotrophic factor ( CNTF ) with CNTFR alpha and not with the beta - components , gp130 and LIFR .'
p7337
(lp7338
I48
a(lp7339
I50
atp7340
a(I-1
S'Superposition of the CNTF and growth hormone structures showed that the location of these epitopes on CNTF is analogous to the location of the first and second receptor epitopes on the surface of growth hormone .'
p7341
(lp7342
I3
a(lp7343
I16
atp7344
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7345
(lp7346
I6
a(lp7347
I9
aI10
aI11
aI12
aI13
atp7348
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7349
(lp7350
I6
a(lp7351
I15
aI16
aI17
atp7352
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7353
(lp7354
I6
a(lp7355
I21
aI22
aI23
aI24
aI25
aI26
aI27
atp7356
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7357
(lp7358
I6
a(lp7359
I29
aI30
aI31
atp7360
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7361
(lp7362
I6
a(lp7363
I21
aI22
aI23
aI24
aI25
aI26
aI27
aI28
aI29
aI30
aI31
aI32
aI33
atp7364
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7365
(lp7366
I9
aI10
aI11
aI12
aI13
a(lp7367
I15
aI16
aI17
atp7368
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7369
(lp7370
I9
aI10
aI11
aI12
aI13
a(lp7371
I21
aI22
aI23
aI24
aI25
aI26
aI27
atp7372
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7373
(lp7374
I9
aI10
aI11
aI12
aI13
a(lp7375
I29
aI30
aI31
atp7376
a(I1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7377
(lp7378
I9
aI10
aI11
aI12
aI13
a(lp7379
I21
aI22
aI23
aI24
aI25
aI26
aI27
aI28
aI29
aI30
aI31
aI32
aI33
atp7380
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7381
(lp7382
I15
aI16
aI17
a(lp7383
I21
aI22
aI23
aI24
aI25
aI26
aI27
atp7384
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7385
(lp7386
I15
aI16
aI17
a(lp7387
I29
aI30
aI31
atp7388
a(I1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7389
(lp7390
I15
aI16
aI17
a(lp7391
I21
aI22
aI23
aI24
aI25
aI26
aI27
aI28
aI29
aI30
aI31
aI32
aI33
atp7392
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7393
(lp7394
I21
aI22
aI23
aI24
aI25
aI26
aI27
a(lp7395
I29
aI30
aI31
atp7396
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7397
(lp7398
I21
aI22
aI23
aI24
aI25
aI26
aI27
a(lp7399
I21
aI22
aI23
aI24
aI25
aI26
aI27
aI28
aI29
aI30
aI31
aI32
aI33
atp7400
a(I-1
S'Evidence for a differential interaction of SHC and the insulin receptor substrate - 1 ( IRS - 1 ) with the insulin - like growth factor - I ( IGF - I ) receptor in the yeast two - hybrid system .'
p7401
(lp7402
I29
aI30
aI31
a(lp7403
I21
aI22
aI23
aI24
aI25
aI26
aI27
aI28
aI29
aI30
aI31
aI32
aI33
atp7404
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7405
(lp7406
I27
aI28
aI29
aI30
aI31
aI32
aI33
a(lp7407
I27
aI28
aI29
aI30
aI31
aI32
aI33
aI34
atp7408
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7409
(lp7410
I27
aI28
aI29
aI30
aI31
aI32
aI33
a(lp7411
I36
aI37
aI38
atp7412
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7413
(lp7414
I27
aI28
aI29
aI30
aI31
aI32
aI33
a(lp7415
I42
aI43
atp7416
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7417
(lp7418
I27
aI28
aI29
aI30
aI31
aI32
aI33
a(lp7419
I45
atp7420
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7421
(lp7422
I27
aI28
aI29
aI30
aI31
aI32
aI33
a(lp7423
I52
atp7424
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7425
(lp7426
I27
aI28
aI29
aI30
aI31
aI32
aI33
a(lp7427
I55
aI56
atp7428
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7429
(lp7430
I27
aI28
aI29
aI30
aI31
aI32
aI33
a(lp7431
I55
aI56
aI57
aI58
aI59
atp7432
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7433
(lp7434
I27
aI28
aI29
aI30
aI31
aI32
aI33
a(lp7435
I61
aI62
aI63
atp7436
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7437
(lp7438
I27
aI28
aI29
aI30
aI31
aI32
aI33
aI34
a(lp7439
I36
aI37
aI38
atp7440
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7441
(lp7442
I27
aI28
aI29
aI30
aI31
aI32
aI33
aI34
a(lp7443
I42
aI43
atp7444
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7445
(lp7446
I27
aI28
aI29
aI30
aI31
aI32
aI33
aI34
a(lp7447
I45
atp7448
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7449
(lp7450
I27
aI28
aI29
aI30
aI31
aI32
aI33
aI34
a(lp7451
I52
atp7452
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7453
(lp7454
I27
aI28
aI29
aI30
aI31
aI32
aI33
aI34
a(lp7455
I55
aI56
atp7456
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7457
(lp7458
I27
aI28
aI29
aI30
aI31
aI32
aI33
aI34
a(lp7459
I55
aI56
aI57
aI58
aI59
atp7460
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7461
(lp7462
I27
aI28
aI29
aI30
aI31
aI32
aI33
aI34
a(lp7463
I61
aI62
aI63
atp7464
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7465
(lp7466
I36
aI37
aI38
a(lp7467
I42
aI43
atp7468
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7469
(lp7470
I36
aI37
aI38
a(lp7471
I45
atp7472
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7473
(lp7474
I36
aI37
aI38
a(lp7475
I52
atp7476
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7477
(lp7478
I36
aI37
aI38
a(lp7479
I55
aI56
atp7480
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7481
(lp7482
I36
aI37
aI38
a(lp7483
I55
aI56
aI57
aI58
aI59
atp7484
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7485
(lp7486
I36
aI37
aI38
a(lp7487
I61
aI62
aI63
atp7488
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7489
(lp7490
I42
aI43
a(lp7491
I45
atp7492
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7493
(lp7494
I42
aI43
a(lp7495
I52
atp7496
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7497
(lp7498
I42
aI43
a(lp7499
I55
aI56
atp7500
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7501
(lp7502
I42
aI43
a(lp7503
I55
aI56
aI57
aI58
aI59
atp7504
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7505
(lp7506
I42
aI43
a(lp7507
I61
aI62
aI63
atp7508
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7509
(lp7510
I45
a(lp7511
I52
atp7512
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7513
(lp7514
I45
a(lp7515
I55
aI56
atp7516
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7517
(lp7518
I45
a(lp7519
I55
aI56
aI57
aI58
aI59
atp7520
a(I1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7521
(lp7522
I45
a(lp7523
I61
aI62
aI63
atp7524
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7525
(lp7526
I52
a(lp7527
I55
aI56
atp7528
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7529
(lp7530
I52
a(lp7531
I55
aI56
aI57
aI58
aI59
atp7532
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7533
(lp7534
I52
a(lp7535
I61
aI62
aI63
atp7536
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7537
(lp7538
I55
aI56
a(lp7539
I55
aI56
aI57
aI58
aI59
atp7540
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7541
(lp7542
I55
aI56
a(lp7543
I61
aI62
aI63
atp7544
a(I-1
S'Using the yeast two - hybrid system , a genetic assay for studying protein - protein interactions , we have examined and compared the interaction of the insulin - like growth factor - I receptor ( IGF - IR ) and the insulin receptor ( IR ) with their two known substrates p52Shc and the insulin receptor substrate - 1 ( IRS - 1 ) .'
p7545
(lp7546
I55
aI56
aI57
aI58
aI59
a(lp7547
I61
aI62
aI63
atp7548
a(I-1
S'We also mapped the specific domains of the IGF - IR and p52Shc participating in these interactions .'
p7549
(lp7550
I8
aI9
aI10
a(lp7551
I12
atp7552
a(I1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7553
(lp7554
I17
aI18
aI19
a(lp7555
I26
atp7556
a(I1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7557
(lp7558
I17
aI18
aI19
a(lp7559
I28
aI29
aI30
atp7560
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7561
(lp7562
I17
aI18
aI19
a(lp7563
I35
atp7564
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7565
(lp7566
I17
aI18
aI19
a(lp7567
I37
aI38
aI39
atp7568
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7569
(lp7570
I17
aI18
aI19
a(lp7571
I43
aI44
aI45
atp7572
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7573
(lp7574
I17
aI18
aI19
a(lp7575
I58
atp7576
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7577
(lp7578
I17
aI18
aI19
a(lp7579
I60
aI61
aI62
atp7580
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7581
(lp7582
I17
aI18
aI19
a(lp7583
I84
aI85
aI86
atp7584
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7585
(lp7586
I17
aI18
aI19
a(lp7587
I98
atp7588
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7589
(lp7590
I17
aI18
aI19
a(lp7591
I106
atp7592
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7593
(lp7594
I17
aI18
aI19
a(lp7595
I109
aI110
aI111
atp7596
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7597
(lp7598
I26
a(lp7599
I28
aI29
aI30
atp7600
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7601
(lp7602
I26
a(lp7603
I35
atp7604
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7605
(lp7606
I26
a(lp7607
I37
aI38
aI39
atp7608
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7609
(lp7610
I26
a(lp7611
I43
aI44
aI45
atp7612
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7613
(lp7614
I26
a(lp7615
I58
atp7616
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7617
(lp7618
I26
a(lp7619
I60
aI61
aI62
atp7620
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7621
(lp7622
I26
a(lp7623
I84
aI85
aI86
atp7624
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7625
(lp7626
I26
a(lp7627
I98
atp7628
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7629
(lp7630
I26
a(lp7631
I106
atp7632
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7633
(lp7634
I26
a(lp7635
I109
aI110
aI111
atp7636
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7637
(lp7638
I28
aI29
aI30
a(lp7639
I35
atp7640
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7641
(lp7642
I28
aI29
aI30
a(lp7643
I37
aI38
aI39
atp7644
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7645
(lp7646
I28
aI29
aI30
a(lp7647
I43
aI44
aI45
atp7648
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7649
(lp7650
I28
aI29
aI30
a(lp7651
I58
atp7652
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7653
(lp7654
I28
aI29
aI30
a(lp7655
I60
aI61
aI62
atp7656
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7657
(lp7658
I28
aI29
aI30
a(lp7659
I84
aI85
aI86
atp7660
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7661
(lp7662
I28
aI29
aI30
a(lp7663
I98
atp7664
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7665
(lp7666
I28
aI29
aI30
a(lp7667
I106
atp7668
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7669
(lp7670
I28
aI29
aI30
a(lp7671
I109
aI110
aI111
atp7672
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7673
(lp7674
I35
a(lp7675
I37
aI38
aI39
atp7676
a(I1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7677
(lp7678
I35
a(lp7679
I43
aI44
aI45
atp7680
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7681
(lp7682
I35
a(lp7683
I58
atp7684
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7685
(lp7686
I35
a(lp7687
I60
aI61
aI62
atp7688
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7689
(lp7690
I35
a(lp7691
I84
aI85
aI86
atp7692
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7693
(lp7694
I35
a(lp7695
I98
atp7696
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7697
(lp7698
I35
a(lp7699
I106
atp7700
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7701
(lp7702
I35
a(lp7703
I109
aI110
aI111
atp7704
a(I1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7705
(lp7706
I37
aI38
aI39
a(lp7707
I43
aI44
aI45
atp7708
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7709
(lp7710
I37
aI38
aI39
a(lp7711
I58
atp7712
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7713
(lp7714
I37
aI38
aI39
a(lp7715
I60
aI61
aI62
atp7716
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7717
(lp7718
I37
aI38
aI39
a(lp7719
I84
aI85
aI86
atp7720
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7721
(lp7722
I37
aI38
aI39
a(lp7723
I98
atp7724
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7725
(lp7726
I37
aI38
aI39
a(lp7727
I106
atp7728
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7729
(lp7730
I37
aI38
aI39
a(lp7731
I109
aI110
aI111
atp7732
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7733
(lp7734
I43
aI44
aI45
a(lp7735
I58
atp7736
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7737
(lp7738
I43
aI44
aI45
a(lp7739
I60
aI61
aI62
atp7740
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7741
(lp7742
I43
aI44
aI45
a(lp7743
I84
aI85
aI86
atp7744
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7745
(lp7746
I43
aI44
aI45
a(lp7747
I98
atp7748
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7749
(lp7750
I43
aI44
aI45
a(lp7751
I106
atp7752
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7753
(lp7754
I43
aI44
aI45
a(lp7755
I109
aI110
aI111
atp7756
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7757
(lp7758
I58
a(lp7759
I60
aI61
aI62
atp7760
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7761
(lp7762
I58
a(lp7763
I84
aI85
aI86
atp7764
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7765
(lp7766
I58
a(lp7767
I98
atp7768
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7769
(lp7770
I58
a(lp7771
I106
atp7772
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7773
(lp7774
I58
a(lp7775
I109
aI110
aI111
atp7776
a(I1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7777
(lp7778
I60
aI61
aI62
a(lp7779
I84
aI85
aI86
atp7780
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7781
(lp7782
I60
aI61
aI62
a(lp7783
I98
atp7784
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7785
(lp7786
I60
aI61
aI62
a(lp7787
I106
atp7788
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7789
(lp7790
I60
aI61
aI62
a(lp7791
I109
aI110
aI111
atp7792
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7793
(lp7794
I84
aI85
aI86
a(lp7795
I98
atp7796
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7797
(lp7798
I84
aI85
aI86
a(lp7799
I106
atp7800
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7801
(lp7802
I84
aI85
aI86
a(lp7803
I109
aI110
aI111
atp7804
a(I1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7805
(lp7806
I98
a(lp7807
I106
atp7808
a(I1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7809
(lp7810
I98
a(lp7811
I109
aI110
aI111
atp7812
a(I-1
S'Our findings can be summarized as follows : ( i ) the tyrosine kinase activity of the IGF - IR is essential for the interaction with p52Shc and IRS - 1 , ( ii ) p52Shc and IRS - 1 bind to the IGF - IR in the NPEY - juxtamembrane motif , ( iii ) contrary to p52Shc , IRS - 1 binds also to the major autophosphorylation sites ( Tyr - 1131 , - 1135 , and - 1136 ) of the IGF - IR , and ( iv ) the amino - terminal domain of p52Shc is required for its association with the IR and the IGF - IR .'
p7813
(lp7814
I106
a(lp7815
I109
aI110
aI111
atp7816
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7817
(lp7818
I7
aI8
aI9
a(lp7819
I12
atp7820
a(I1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7821
(lp7822
I7
aI8
aI9
a(lp7823
I30
atp7824
a(I1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7825
(lp7826
I7
aI8
aI9
a(lp7827
I32
aI33
aI34
atp7828
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7829
(lp7830
I7
aI8
aI9
a(lp7831
I40
aI41
aI42
atp7832
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7833
(lp7834
I7
aI8
aI9
a(lp7835
I46
aI47
aI48
atp7836
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7837
(lp7838
I7
aI8
aI9
a(lp7839
I59
atp7840
a(I1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7841
(lp7842
I12
a(lp7843
I30
atp7844
a(I1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7845
(lp7846
I12
a(lp7847
I32
aI33
aI34
atp7848
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7849
(lp7850
I12
a(lp7851
I40
aI41
aI42
atp7852
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7853
(lp7854
I12
a(lp7855
I46
aI47
aI48
atp7856
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7857
(lp7858
I12
a(lp7859
I59
atp7860
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7861
(lp7862
I30
a(lp7863
I32
aI33
aI34
atp7864
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7865
(lp7866
I30
a(lp7867
I40
aI41
aI42
atp7868
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7869
(lp7870
I30
a(lp7871
I46
aI47
aI48
atp7872
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7873
(lp7874
I30
a(lp7875
I59
atp7876
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7877
(lp7878
I32
aI33
aI34
a(lp7879
I40
aI41
aI42
atp7880
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7881
(lp7882
I32
aI33
aI34
a(lp7883
I46
aI47
aI48
atp7884
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7885
(lp7886
I32
aI33
aI34
a(lp7887
I59
atp7888
a(I1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7889
(lp7890
I40
aI41
aI42
a(lp7891
I46
aI47
aI48
atp7892
a(I-1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7893
(lp7894
I40
aI41
aI42
a(lp7895
I59
atp7896
a(I1
S'We propose that ( i ) the IGF - IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates , p52Shc and IRS - 1 , and ( ii ) IRS - 1 interacts with the IGF - IR in a fashion that is different from that used by p52Shc .'
p7897
(lp7898
I46
aI47
aI48
a(lp7899
I59
atp7900
a(I-1
S'Finally , our data highlight the crucial role of the juxtamembrane domain in signaling by both the IR and the IGF - IR .'
p7901
(lp7902
I17
a(lp7903
I20
aI21
aI22
atp7904
a(I1
S'Wiskott - Aldrich syndrome protein physically associates with Nck through Src homology 3 domains .'
p7905
(lp7906
I0
aI1
aI2
aI3
aI4
a(lp7907
I8
atp7908
a(I-1
S'In the second of a series of experiments designed to identify p47nck - Src homology 3 ( SH3 ) - binding molecules , we report the cloning of SAKAP II ( Src A box Nck - associated protein II ) from an HL60 cDNA expression library .'
p7909
(lp7910
I11
a(lp7911
I28
aI29
atp7912
a(I-1
S'In the second of a series of experiments designed to identify p47nck - Src homology 3 ( SH3 ) - binding molecules , we report the cloning of SAKAP II ( Src A box Nck - associated protein II ) from an HL60 cDNA expression library .'
p7913
(lp7914
I11
a(lp7915
I31
aI32
aI33
aI34
aI35
aI36
aI37
aI38
atp7916
a(I-1
S'In the second of a series of experiments designed to identify p47nck - Src homology 3 ( SH3 ) - binding molecules , we report the cloning of SAKAP II ( Src A box Nck - associated protein II ) from an HL60 cDNA expression library .'
p7917
(lp7918
I28
aI29
a(lp7919
I31
aI32
aI33
aI34
aI35
aI36
aI37
aI38
atp7920
a(I1
S'Studies in vivo and in vitro demonstrated a highly specific interaction between the SH3 domains of p47nck and Wiskott - Aldrich syndrome protein .'
p7921
(lp7922
I16
a(lp7923
I18
aI19
aI20
aI21
aI22
atp7924
a(I-1
S'In vitro translation studies identified the 66 - kDa protein as the protein product of WASP , and subcellular fractionation experiments showed that p66WASP is mainly present in the cytosol fraction , although significant amounts are also present in membrane and nuclear fractions .'
p7925
(lp7926
I15
a(lp7927
I23
atp7928
a(I1
S'The main p47nck region implicated in the association with p66WASP was found to be the carboxy - terminal SH3 domain .'
p7929
(lp7930
I2
a(lp7931
I9
atp7932
a(I-1
S'For the calibration , we used two sets of proteins , the Myc - Max - Mxi1 helix - loop - helix proteins , and wild - type and dimerization - defective versions of the lambda cI repressor .'
p7933
(lp7934
I12
a(lp7935
I14
atp7936
a(I-1
S'For the calibration , we used two sets of proteins , the Myc - Max - Mxi1 helix - loop - helix proteins , and wild - type and dimerization - defective versions of the lambda cI repressor .'
p7937
(lp7938
I12
a(lp7939
I16
atp7940
a(I-1
S'For the calibration , we used two sets of proteins , the Myc - Max - Mxi1 helix - loop - helix proteins , and wild - type and dimerization - defective versions of the lambda cI repressor .'
p7941
(lp7942
I14
a(lp7943
I16
atp7944
a(I-1
S'Interaction of p85 subunit of PI 3 - kinase with insulin and IGF - 1 receptors analysed by using the two - hybrid system .'
p7945
(lp7946
I2
a(lp7947
I5
aI6
aI7
aI8
atp7948
a(I-1
S'Interaction of p85 subunit of PI 3 - kinase with insulin and IGF - 1 receptors analysed by using the two - hybrid system .'
p7949
(lp7950
I2
a(lp7951
I10
atp7952
a(I-1
S'Interaction of p85 subunit of PI 3 - kinase with insulin and IGF - 1 receptors analysed by using the two - hybrid system .'
p7953
(lp7954
I2
a(lp7955
I12
aI13
aI14
atp7956
a(I-1
S'Interaction of p85 subunit of PI 3 - kinase with insulin and IGF - 1 receptors analysed by using the two - hybrid system .'
p7957
(lp7958
I5
aI6
aI7
aI8
a(lp7959
I10
atp7960
a(I-1
S'Interaction of p85 subunit of PI 3 - kinase with insulin and IGF - 1 receptors analysed by using the two - hybrid system .'
p7961
(lp7962
I5
aI6
aI7
aI8
a(lp7963
I12
aI13
aI14
atp7964
a(I-1
S'Interaction of p85 subunit of PI 3 - kinase with insulin and IGF - 1 receptors analysed by using the two - hybrid system .'
p7965
(lp7966
I10
a(lp7967
I12
aI13
aI14
atp7968
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p7969
(lp7970
I3
a(lp7971
I6
aI7
aI8
aI9
atp7972
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p7973
(lp7974
I3
a(lp7975
I12
atp7976
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p7977
(lp7978
I3
a(lp7979
I12
aI13
atp7980
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p7981
(lp7982
I3
a(lp7983
I15
atp7984
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p7985
(lp7986
I3
a(lp7987
I19
aI20
aI21
atp7988
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p7989
(lp7990
I3
a(lp7991
I19
aI20
aI21
aI22
atp7992
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p7993
(lp7994
I3
a(lp7995
I24
aI25
aI26
atp7996
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p7997
(lp7998
I6
aI7
aI8
aI9
a(lp7999
I12
atp8000
a(I1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8001
(lp8002
I6
aI7
aI8
aI9
a(lp8003
I12
aI13
atp8004
a(I1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8005
(lp8006
I6
aI7
aI8
aI9
a(lp8007
I15
atp8008
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8009
(lp8010
I6
aI7
aI8
aI9
a(lp8011
I19
aI20
aI21
atp8012
a(I1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8013
(lp8014
I6
aI7
aI8
aI9
a(lp8015
I19
aI20
aI21
aI22
atp8016
a(I1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8017
(lp8018
I6
aI7
aI8
aI9
a(lp8019
I24
aI25
aI26
atp8020
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8021
(lp8022
I12
a(lp8023
I12
aI13
atp8024
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8025
(lp8026
I12
a(lp8027
I15
atp8028
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8029
(lp8030
I12
a(lp8031
I19
aI20
aI21
atp8032
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8033
(lp8034
I12
a(lp8035
I19
aI20
aI21
aI22
atp8036
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8037
(lp8038
I12
a(lp8039
I24
aI25
aI26
atp8040
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8041
(lp8042
I12
aI13
a(lp8043
I15
atp8044
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8045
(lp8046
I12
aI13
a(lp8047
I19
aI20
aI21
atp8048
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8049
(lp8050
I12
aI13
a(lp8051
I19
aI20
aI21
aI22
atp8052
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8053
(lp8054
I12
aI13
a(lp8055
I24
aI25
aI26
atp8056
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8057
(lp8058
I15
a(lp8059
I19
aI20
aI21
atp8060
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8061
(lp8062
I15
a(lp8063
I19
aI20
aI21
aI22
atp8064
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8065
(lp8066
I15
a(lp8067
I24
aI25
aI26
atp8068
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8069
(lp8070
I19
aI20
aI21
a(lp8071
I19
aI20
aI21
aI22
atp8072
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8073
(lp8074
I19
aI20
aI21
a(lp8075
I24
aI25
aI26
atp8076
a(I-1
S'Interaction of the p85 subunit of PI 3 - kinase with the insulin receptor ( IR ) and the IGF - 1 receptor ( IGF - 1R ) was investigated using the two - hybrid system by assessing for his3 and lacZ activation in S . cerevisiae .'
p8077
(lp8078
I19
aI20
aI21
aI22
a(lp8079
I24
aI25
aI26
atp8080
a(I-1
S'The experiments were performed with the cytoplasmic beta domain ( wild type or mutated ) of IR and IGF - 1R and p85 or its subdomains ( N + C - SH2 , N - SH2 , C - SH2 , SH3 + N - SH2 ) .'
p8081
(lp8082
I16
a(lp8083
I18
aI19
aI20
atp8084
a(I-1
S'The experiments were performed with the cytoplasmic beta domain ( wild type or mutated ) of IR and IGF - 1R and p85 or its subdomains ( N + C - SH2 , N - SH2 , C - SH2 , SH3 + N - SH2 ) .'
p8085
(lp8086
I16
a(lp8087
I22
atp8088
a(I-1
S'The experiments were performed with the cytoplasmic beta domain ( wild type or mutated ) of IR and IGF - 1R and p85 or its subdomains ( N + C - SH2 , N - SH2 , C - SH2 , SH3 + N - SH2 ) .'
p8089
(lp8090
I18
aI19
aI20
a(lp8091
I22
atp8092
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8093
(lp8094
I7
a(lp8095
I21
atp8096
a(I1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8097
(lp8098
I7
a(lp8099
I21
aI22
atp8100
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8101
(lp8102
I7
a(lp8103
I24
aI25
aI26
atp8104
a(I1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8105
(lp8106
I7
a(lp8107
I24
aI25
aI26
aI27
atp8108
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8109
(lp8110
I7
a(lp8111
I42
atp8112
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8113
(lp8114
I7
a(lp8115
I42
aI43
atp8116
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8117
(lp8118
I21
a(lp8119
I21
aI22
atp8120
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8121
(lp8122
I21
a(lp8123
I24
aI25
aI26
atp8124
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8125
(lp8126
I21
a(lp8127
I24
aI25
aI26
aI27
atp8128
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8129
(lp8130
I21
a(lp8131
I42
atp8132
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8133
(lp8134
I21
a(lp8135
I42
aI43
atp8136
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8137
(lp8138
I21
aI22
a(lp8139
I24
aI25
aI26
atp8140
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8141
(lp8142
I21
aI22
a(lp8143
I24
aI25
aI26
aI27
atp8144
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8145
(lp8146
I21
aI22
a(lp8147
I42
atp8148
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8149
(lp8150
I21
aI22
a(lp8151
I42
aI43
atp8152
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8153
(lp8154
I24
aI25
aI26
a(lp8155
I24
aI25
aI26
aI27
atp8156
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8157
(lp8158
I24
aI25
aI26
a(lp8159
I42
atp8160
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8161
(lp8162
I24
aI25
aI26
a(lp8163
I42
aI43
atp8164
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8165
(lp8166
I24
aI25
aI26
aI27
a(lp8167
I42
atp8168
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8169
(lp8170
I24
aI25
aI26
aI27
a(lp8171
I42
aI43
atp8172
a(I-1
S'The results of his3 activation indicated that p85 , N + C - SH2 and C - SH2 interact with both IR beta and IGF - 1R beta , whereas N - SH2 and SH3 + N - SH2 interact only with IR beta .'
p8173
(lp8174
I42
a(lp8175
I42
aI43
atp8176
a(I1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8177
(lp8178
I2
a(lp8179
I10
aI11
atp8180
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8181
(lp8182
I2
a(lp8183
I13
aI14
aI15
aI16
atp8184
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8185
(lp8186
I2
a(lp8187
I19
aI20
aI21
atp8188
a(I1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8189
(lp8190
I2
a(lp8191
I19
aI20
aI21
aI22
atp8192
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8193
(lp8194
I2
a(lp8195
I24
aI25
aI26
aI27
atp8196
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8197
(lp8198
I10
aI11
a(lp8199
I13
aI14
aI15
aI16
atp8200
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8201
(lp8202
I10
aI11
a(lp8203
I19
aI20
aI21
atp8204
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8205
(lp8206
I10
aI11
a(lp8207
I19
aI20
aI21
aI22
atp8208
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8209
(lp8210
I10
aI11
a(lp8211
I24
aI25
aI26
aI27
atp8212
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8213
(lp8214
I13
aI14
aI15
aI16
a(lp8215
I19
aI20
aI21
atp8216
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8217
(lp8218
I13
aI14
aI15
aI16
a(lp8219
I19
aI20
aI21
aI22
atp8220
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8221
(lp8222
I13
aI14
aI15
aI16
a(lp8223
I24
aI25
aI26
aI27
atp8224
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8225
(lp8226
I19
aI20
aI21
a(lp8227
I19
aI20
aI21
aI22
atp8228
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8229
(lp8230
I19
aI20
aI21
a(lp8231
I24
aI25
aI26
aI27
atp8232
a(I-1
S'Interaction of p85 and N + C - SH2 with IR beta ( delta C - 43 ) or IGF - 1R beta ( delta C - 43 ) in which the C - terminal 43 amino acids ( including the YXXM motif ) were deleted , persisted .'
p8233
(lp8234
I19
aI20
aI21
aI22
a(lp8235
I24
aI25
aI26
aI27
atp8236
a(I-1
S'The internal binding site thus revealed was not altered by further mutating Y960 / F for IR or Y950 / F for IGF - 1R .'
p8237
(lp8238
I16
a(lp8239
I22
aI23
aI24
atp8240
a(I1
S'Activation of lacZ upon interaction of p85 with IR beta ( delta C - 43 ) was 4 - fold less as compared to IR beta .'
p8241
(lp8242
I6
a(lp8243
I8
aI9
atp8244
a(I-1
S'Activation of lacZ upon interaction of p85 with IR beta ( delta C - 43 ) was 4 - fold less as compared to IR beta .'
p8245
(lp8246
I6
a(lp8247
I11
aI12
aI13
aI14
atp8248
a(I1
S'Activation of lacZ upon interaction of p85 with IR beta ( delta C - 43 ) was 4 - fold less as compared to IR beta .'
p8249
(lp8250
I6
a(lp8251
I24
aI25
atp8252
a(I-1
S'Activation of lacZ upon interaction of p85 with IR beta ( delta C - 43 ) was 4 - fold less as compared to IR beta .'
p8253
(lp8254
I8
aI9
a(lp8255
I11
aI12
aI13
aI14
atp8256
a(I-1
S'Activation of lacZ upon interaction of p85 with IR beta ( delta C - 43 ) was 4 - fold less as compared to IR beta .'
p8257
(lp8258
I8
aI9
a(lp8259
I24
aI25
atp8260
a(I-1
S'Activation of lacZ upon interaction of p85 with IR beta ( delta C - 43 ) was 4 - fold less as compared to IR beta .'
p8261
(lp8262
I11
aI12
aI13
aI14
a(lp8263
I24
aI25
atp8264
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8265
(lp8266
I3
a(lp8267
I5
aI6
aI7
atp8268
a(I1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8269
(lp8270
I3
a(lp8271
I5
aI6
aI7
aI8
atp8272
a(I1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8273
(lp8274
I3
a(lp8275
I17
aI18
atp8276
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8277
(lp8278
I3
a(lp8279
I29
aI30
aI31
atp8280
a(I1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8281
(lp8282
I3
a(lp8283
I29
aI30
aI31
aI32
atp8284
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8285
(lp8286
I3
a(lp8287
I34
aI35
aI36
aI37
atp8288
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8289
(lp8290
I5
aI6
aI7
a(lp8291
I5
aI6
aI7
aI8
atp8292
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8293
(lp8294
I5
aI6
aI7
a(lp8295
I17
aI18
atp8296
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8297
(lp8298
I5
aI6
aI7
a(lp8299
I29
aI30
aI31
atp8300
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8301
(lp8302
I5
aI6
aI7
a(lp8303
I29
aI30
aI31
aI32
atp8304
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8305
(lp8306
I5
aI6
aI7
a(lp8307
I34
aI35
aI36
aI37
atp8308
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8309
(lp8310
I5
aI6
aI7
aI8
a(lp8311
I17
aI18
atp8312
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8313
(lp8314
I5
aI6
aI7
aI8
a(lp8315
I29
aI30
aI31
atp8316
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8317
(lp8318
I5
aI6
aI7
aI8
a(lp8319
I29
aI30
aI31
aI32
atp8320
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8321
(lp8322
I5
aI6
aI7
aI8
a(lp8323
I34
aI35
aI36
aI37
atp8324
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8325
(lp8326
I17
aI18
a(lp8327
I29
aI30
aI31
atp8328
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8329
(lp8330
I17
aI18
a(lp8331
I29
aI30
aI31
aI32
atp8332
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8333
(lp8334
I17
aI18
a(lp8335
I34
aI35
aI36
aI37
atp8336
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8337
(lp8338
I29
aI30
aI31
a(lp8339
I29
aI30
aI31
aI32
atp8340
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8341
(lp8342
I29
aI30
aI31
a(lp8343
I34
aI35
aI36
aI37
atp8344
a(I-1
S'This activation with p85 and IGF - 1R beta was 4 - fold less as compared to IR beta and was somewhat increased ( 2 - fold ) for IGF - 1R beta ( delta C - 43 ) .'
p8345
(lp8346
I29
aI30
aI31
aI32
a(lp8347
I34
aI35
aI36
aI37
atp8348
a(I1
S'Thus , the C - terminal domain in IGF - 1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3 - kinase pathway .'
p8349
(lp8350
I8
aI9
aI10
a(lp8351
I20
atp8352
a(I-1
S'Thus , the C - terminal domain in IGF - 1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3 - kinase pathway .'
p8353
(lp8354
I8
aI9
aI10
a(lp8355
I32
aI33
aI34
aI35
atp8356
a(I-1
S'Thus , the C - terminal domain in IGF - 1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3 - kinase pathway .'
p8357
(lp8358
I20
a(lp8359
I32
aI33
aI34
aI35
atp8360
a(I1
S'Interaction of the protein nucleobindin with G alpha i2 , as revealed by the yeast two - hybrid system .'
p8361
(lp8362
I4
a(lp8363
I6
aI7
aI8
atp8364
a(I1
S'The specificity of intehraction between G alpha i2 and nucleobindin was confirmed by an in vitro binding assay using recombinant proteins .'
p8365
(lp8366
I5
aI6
aI7
a(lp8367
I9
atp8368
a(I-1
S'Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector .'
p8369
(lp8370
I2
aI3
aI4
a(lp8371
I6
atp8372
a(I-1
S'Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector .'
p8373
(lp8374
I2
aI3
aI4
a(lp8375
I11
aI12
aI13
atp8376
a(I-1
S'Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector .'
p8377
(lp8378
I2
aI3
aI4
a(lp8379
I20
aI21
aI22
atp8380
a(I-1
S'Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector .'
p8381
(lp8382
I6
a(lp8383
I11
aI12
aI13
atp8384
a(I-1
S'Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector .'
p8385
(lp8386
I6
a(lp8387
I20
aI21
aI22
atp8388
a(I-1
S'Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector .'
p8389
(lp8390
I11
aI12
aI13
a(lp8391
I20
aI21
aI22
atp8392
a(I1
S'The mitogenic effects of the B beta chain of fibrinogen are mediated through cell surface calreticulin .'
p8393
(lp8394
I5
aI6
aI7
aI8
aI9
a(lp8395
I15
atp8396
a(I-1
S'Immunoprecipitation experiments employing a polyclonal anti - calreticulin antibody provided further evidence that the 60 - kDa protein isolated in this study was calreticulin .'
p8397
(lp8398
I7
a(lp8399
I23
atp8400
a(I-1
S'Further , polyclonal antibodies to human calreticulin significantly inhibited the mitogenic activity of fibrinogen B beta chain on human fibroblasts .'
p8401
(lp8402
I6
a(lp8403
I13
aI14
aI15
aI16
atp8404
a(I1
S'The present study has shown that cell surface calreticulin binds to the B beta chain of fibrinogen mediating its mitogenic activity .'
p8405
(lp8406
I8
a(lp8407
I12
aI13
aI14
aI15
aI16
atp8408
a(I-1
S'Multiple proteins physically interact with PU . 1 . Transcriptional synergy with NF - IL6 beta ( C / EBP delta , CRP3 ) .'
p8409
(lp8410
I5
aI6
aI7
a(lp8411
I12
aI13
aI14
aI15
atp8412
a(I-1
S'Multiple proteins physically interact with PU . 1 . Transcriptional synergy with NF - IL6 beta ( C / EBP delta , CRP3 ) .'
p8413
(lp8414
I5
aI6
aI7
a(lp8415
I19
aI20
atp8416
a(I-1
S'Multiple proteins physically interact with PU . 1 . Transcriptional synergy with NF - IL6 beta ( C / EBP delta , CRP3 ) .'
p8417
(lp8418
I5
aI6
aI7
a(lp8419
I22
atp8420
a(I-1
S'Multiple proteins physically interact with PU . 1 . Transcriptional synergy with NF - IL6 beta ( C / EBP delta , CRP3 ) .'
p8421
(lp8422
I12
aI13
aI14
aI15
a(lp8423
I19
aI20
atp8424
a(I-1
S'Multiple proteins physically interact with PU . 1 . Transcriptional synergy with NF - IL6 beta ( C / EBP delta , CRP3 ) .'
p8425
(lp8426
I12
aI13
aI14
aI15
a(lp8427
I22
atp8428
a(I-1
S'Multiple proteins physically interact with PU . 1 . Transcriptional synergy with NF - IL6 beta ( C / EBP delta , CRP3 ) .'
p8429
(lp8430
I19
aI20
a(lp8431
I22
atp8432
a(I-1
S'Using radiolabeled PU . 1 protein as a probe , we screened a B cell cDNA expression library and isolated a number of clones encoding PU . 1 interacting proteins .'
p8433
(lp8434
I2
aI3
aI4
a(lp8435
I25
aI26
aI27
atp8436
a(I-1
S'Three of these clones encode DNA binding proteins ( NF - IL6 beta , HMG I / Y , and SSRP ) , one clone encodes a chaperone protein , and another clone encodes a multifunctional phosphatase .'
p8437
(lp8438
I9
aI10
aI11
aI12
a(lp8439
I14
aI15
aI16
aI17
atp8440
a(I-1
S'Three of these clones encode DNA binding proteins ( NF - IL6 beta , HMG I / Y , and SSRP ) , one clone encodes a chaperone protein , and another clone encodes a multifunctional phosphatase .'
p8441
(lp8442
I9
aI10
aI11
aI12
a(lp8443
I20
atp8444
a(I-1
S'Three of these clones encode DNA binding proteins ( NF - IL6 beta , HMG I / Y , and SSRP ) , one clone encodes a chaperone protein , and another clone encodes a multifunctional phosphatase .'
p8445
(lp8446
I14
aI15
aI16
aI17
a(lp8447
I20
atp8448
a(I1
S'We have characterized the physical and functional interactions between PU . 1 and NF - IL6 beta , a leucine zipper transcription factor implicated in inflammatory responses .'
p8449
(lp8450
I9
aI10
aI11
a(lp8451
I13
aI14
aI15
aI16
atp8452
a(I-1
S'We found that deletion of the carboxyl - terminal 28 amino acids of PU . 1 disrupted PU . 1 - NF - IL6 beta physical interaction .'
p8453
(lp8454
I13
aI14
aI15
a(lp8455
I17
aI18
aI19
atp8456
a(I-1
S'We found that deletion of the carboxyl - terminal 28 amino acids of PU . 1 disrupted PU . 1 - NF - IL6 beta physical interaction .'
p8457
(lp8458
I13
aI14
aI15
a(lp8459
I21
aI22
aI23
aI24
atp8460
a(I1
S'We found that deletion of the carboxyl - terminal 28 amino acids of PU . 1 disrupted PU . 1 - NF - IL6 beta physical interaction .'
p8461
(lp8462
I17
aI18
aI19
a(lp8463
I21
aI22
aI23
aI24
atp8464
a(I-1
S'In transient expression assays , we found that PU . 1 and NF - IL6 beta can functionally cooperate to synergistically activate transcription .'
p8465
(lp8466
I8
aI9
aI10
a(lp8467
I12
aI13
aI14
aI15
atp8468
a(I-1
S"Electrophoretic mobility shift assays showed that PU . 1 and NF - IL6 beta can simultaneously bind to adjacent DNA binding sites , but apparently do not influence the kinetics or affinity of each other ' s DNA binding ."
p8469
(lp8470
I6
aI7
aI8
a(lp8471
I10
aI11
aI12
aI13
atp8472
a(I-1
S'Molecular cloning and expression of the 32 - kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation .'
p8473
(lp8474
I12
a(lp8475
I16
atp8476
a(I-1
S'Molecular cloning and expression of the 32 - kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation .'
p8477
(lp8478
I12
a(lp8479
I18
atp8480
a(I-1
S'Molecular cloning and expression of the 32 - kDa subunit of human TFIID reveals interactions with VP16 and TFIIB that mediate transcriptional activation .'
p8481
(lp8482
I16
a(lp8483
I18
atp8484
a(I-1
S'Transcription factor TFIID consists of TATA binding protein ( TBP ) and at least eight TBP - associated factors ( TAFs ) .'
p8485
(lp8486
I2
a(lp8487
I5
aI6
aI7
atp8488
a(I-1
S'Transcription factor TFIID consists of TATA binding protein ( TBP ) and at least eight TBP - associated factors ( TAFs ) .'
p8489
(lp8490
I2
a(lp8491
I9
atp8492
a(I-1
S'Transcription factor TFIID consists of TATA binding protein ( TBP ) and at least eight TBP - associated factors ( TAFs ) .'
p8493
(lp8494
I2
a(lp8495
I15
atp8496
a(I-1
S'Transcription factor TFIID consists of TATA binding protein ( TBP ) and at least eight TBP - associated factors ( TAFs ) .'
p8497
(lp8498
I5
aI6
aI7
a(lp8499
I9
atp8500
a(I-1
S'Transcription factor TFIID consists of TATA binding protein ( TBP ) and at least eight TBP - associated factors ( TAFs ) .'
p8501
(lp8502
I5
aI6
aI7
a(lp8503
I15
atp8504
a(I-1
S'Transcription factor TFIID consists of TATA binding protein ( TBP ) and at least eight TBP - associated factors ( TAFs ) .'
p8505
(lp8506
I9
a(lp8507
I15
atp8508
a(I-1
S'Here we report the cloning , expression , and biochemical characterization of the 32 - kDa subunit of human ( h ) TFIID , termed hTAFII32 .'
p8509
(lp8510
I22
a(lp8511
I25
atp8512
a(I-1
S'We find that hTAFII32 is the human homologue of Drosophila TAFII40 .'
p8513
(lp8514
I3
a(lp8515
I10
atp8516
a(I-1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8517
(lp8518
I13
a(lp8519
I15
atp8520
a(I-1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8521
(lp8522
I13
a(lp8523
I32
aI33
aI34
atp8524
a(I-1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8525
(lp8526
I13
a(lp8527
I36
atp8528
a(I-1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8529
(lp8530
I13
a(lp8531
I46
atp8532
a(I1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8533
(lp8534
I15
a(lp8535
I32
aI33
aI34
atp8536
a(I1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8537
(lp8538
I15
a(lp8539
I36
atp8540
a(I1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8541
(lp8542
I15
a(lp8543
I46
atp8544
a(I-1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8545
(lp8546
I32
aI33
aI34
a(lp8547
I36
atp8548
a(I-1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8549
(lp8550
I32
aI33
aI34
a(lp8551
I46
atp8552
a(I-1
S'In vitro protein - protein interaction assays reveal that as observed with Drosophila TAFII40 , hTAFII32 interacts with the C - terminal 39 - amino acid activation domain of the acidic transactivator viral protein 16 ( VP16 ) as well as with the general transcription factor TFIIB .'
p8553
(lp8554
I36
a(lp8555
I46
atp8556
a(I-1
S'Moreover , a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain .'
p8557
(lp8558
I5
a(lp8559
I8
atp8560
a(I-1
S'Moreover , a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain .'
p8561
(lp8562
I5
a(lp8563
I19
atp8564
a(I-1
S'Moreover , a partial recombinant TFIID complex containing hTAFII32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain .'
p8565
(lp8566
I8
a(lp8567
I19
atp8568
a(I-1
S'A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation .'
p8569
(lp8570
I4
a(lp8571
I6
atp8572
a(I-1
S'A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation .'
p8573
(lp8574
I4
a(lp8575
I7
atp8576
a(I-1
S'A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation .'
p8577
(lp8578
I6
a(lp8579
I7
atp8580
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8581
(lp8582
I0
aI1
aI2
a(lp8583
I11
atp8584
a(I1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8585
(lp8586
I0
aI1
aI2
a(lp8587
I11
aI12
aI13
atp8588
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8589
(lp8590
I0
aI1
aI2
a(lp8591
I16
atp8592
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8593
(lp8594
I0
aI1
aI2
a(lp8595
I18
atp8596
a(I1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8597
(lp8598
I0
aI1
aI2
a(lp8599
I16
aI17
aI18
aI19
aI20
aI21
aI22
atp8600
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8601
(lp8602
I0
aI1
aI2
a(lp8603
I39
atp8604
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8605
(lp8606
I11
a(lp8607
I11
aI12
aI13
atp8608
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8609
(lp8610
I11
a(lp8611
I16
atp8612
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8613
(lp8614
I11
a(lp8615
I18
atp8616
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8617
(lp8618
I11
a(lp8619
I16
aI17
aI18
aI19
aI20
aI21
aI22
atp8620
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8621
(lp8622
I11
a(lp8623
I39
atp8624
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8625
(lp8626
I11
aI12
aI13
a(lp8627
I16
atp8628
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8629
(lp8630
I11
aI12
aI13
a(lp8631
I18
atp8632
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8633
(lp8634
I11
aI12
aI13
a(lp8635
I16
aI17
aI18
aI19
aI20
aI21
aI22
atp8636
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8637
(lp8638
I11
aI12
aI13
a(lp8639
I39
atp8640
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8641
(lp8642
I16
a(lp8643
I18
atp8644
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8645
(lp8646
I16
a(lp8647
I16
aI17
aI18
aI19
aI20
aI21
aI22
atp8648
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8649
(lp8650
I16
a(lp8651
I39
atp8652
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8653
(lp8654
I18
a(lp8655
I16
aI17
aI18
aI19
aI20
aI21
aI22
atp8656
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8657
(lp8658
I18
a(lp8659
I39
atp8660
a(I-1
S'Nerve growth factor binds independently to two transmembrane receptors , the p75 neurotrophin receptor and the p140trk ( trkA ) tyrosine kinase receptor , which are both co - expressed in the majority of neuronal cells that respond to NGF .'
p8661
(lp8662
I16
aI17
aI18
aI19
aI20
aI21
aI22
a(lp8663
I39
atp8664
a(I-1
S'Here we have utilized affinity crosslinking agents with 125I - NGF to detect an association of trkA and p75 receptors in embryonic spinal cord and brain tissues enriched in the two receptors .'
p8665
(lp8666
I16
a(lp8667
I18
atp8668
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8669
(lp8670
I4
a(lp8671
I6
atp8672
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8673
(lp8674
I4
a(lp8675
I19
atp8676
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8677
(lp8678
I4
a(lp8679
I19
aI20
aI21
atp8680
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8681
(lp8682
I4
a(lp8683
I24
atp8684
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8685
(lp8686
I4
a(lp8687
I34
atp8688
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8689
(lp8690
I6
a(lp8691
I19
atp8692
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8693
(lp8694
I6
a(lp8695
I19
aI20
aI21
atp8696
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8697
(lp8698
I6
a(lp8699
I24
atp8700
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8701
(lp8702
I6
a(lp8703
I34
atp8704
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8705
(lp8706
I19
a(lp8707
I19
aI20
aI21
atp8708
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8709
(lp8710
I19
a(lp8711
I24
atp8712
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8713
(lp8714
I19
a(lp8715
I34
atp8716
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8717
(lp8718
I19
aI20
aI21
a(lp8719
I24
atp8720
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8721
(lp8722
I19
aI20
aI21
a(lp8723
I34
atp8724
a(I-1
S'Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking , immunoprecipitation of cross - linked NGF - receptor complexes with trk - specific antibodies resulted in selective immunoprecipitation of crosslinked p75 .'
p8725
(lp8726
I24
a(lp8727
I34
atp8728
a(I-1
S'Our results indicate that the trkA and p75 receptors can potentially interact , and that such an association may be responsible for the generation of high affinity NGF binding sites .'
p8729
(lp8730
I5
a(lp8731
I7
atp8732
a(I-1
S'Our results indicate that the trkA and p75 receptors can potentially interact , and that such an association may be responsible for the generation of high affinity NGF binding sites .'
p8733
(lp8734
I5
a(lp8735
I27
atp8736
a(I-1
S'Our results indicate that the trkA and p75 receptors can potentially interact , and that such an association may be responsible for the generation of high affinity NGF binding sites .'
p8737
(lp8738
I7
a(lp8739
I27
atp8740
a(I-1
S'Eosinophils undergo chemotaxis , degranulate , and exhibit [ C2 + ] i changes in response to the human CC chemokines macrophage inflammatory protein ( MIP ) - 1 alpha , regulated on activation , normal T expressed and secreted ( RANTES ) , and monocyte chemoattractant protein - 3 ( MCP - 3 ) , but the receptors involved have not been defined .'
p8741
(lp8742
I24
aI25
aI26
aI27
aI28
aI29
a(lp8743
I41
atp8744
a(I-1
S'Eosinophils undergo chemotaxis , degranulate , and exhibit [ C2 + ] i changes in response to the human CC chemokines macrophage inflammatory protein ( MIP ) - 1 alpha , regulated on activation , normal T expressed and secreted ( RANTES ) , and monocyte chemoattractant protein - 3 ( MCP - 3 ) , but the receptors involved have not been defined .'
p8745
(lp8746
I24
aI25
aI26
aI27
aI28
aI29
a(lp8747
I45
aI46
aI47
aI48
aI49
atp8748
a(I-1
S'Eosinophils undergo chemotaxis , degranulate , and exhibit [ C2 + ] i changes in response to the human CC chemokines macrophage inflammatory protein ( MIP ) - 1 alpha , regulated on activation , normal T expressed and secreted ( RANTES ) , and monocyte chemoattractant protein - 3 ( MCP - 3 ) , but the receptors involved have not been defined .'
p8749
(lp8750
I24
aI25
aI26
aI27
aI28
aI29
a(lp8751
I51
aI52
aI53
atp8752
a(I-1
S'Eosinophils undergo chemotaxis , degranulate , and exhibit [ C2 + ] i changes in response to the human CC chemokines macrophage inflammatory protein ( MIP ) - 1 alpha , regulated on activation , normal T expressed and secreted ( RANTES ) , and monocyte chemoattractant protein - 3 ( MCP - 3 ) , but the receptors involved have not been defined .'
p8753
(lp8754
I41
a(lp8755
I45
aI46
aI47
aI48
aI49
atp8756
a(I-1
S'Eosinophils undergo chemotaxis , degranulate , and exhibit [ C2 + ] i changes in response to the human CC chemokines macrophage inflammatory protein ( MIP ) - 1 alpha , regulated on activation , normal T expressed and secreted ( RANTES ) , and monocyte chemoattractant protein - 3 ( MCP - 3 ) , but the receptors involved have not been defined .'
p8757
(lp8758
I41
a(lp8759
I51
aI52
aI53
atp8760
a(I-1
S'Eosinophils undergo chemotaxis , degranulate , and exhibit [ C2 + ] i changes in response to the human CC chemokines macrophage inflammatory protein ( MIP ) - 1 alpha , regulated on activation , normal T expressed and secreted ( RANTES ) , and monocyte chemoattractant protein - 3 ( MCP - 3 ) , but the receptors involved have not been defined .'
p8761
(lp8762
I45
aI46
aI47
aI48
aI49
a(lp8763
I51
aI52
aI53
atp8764
a(I-1
S'We have isolated a human cDNA encoding the first eosinophil - selective chemokine receptor , designated CC chemokine receptor 3 ( CC CKR3 ) .'
p8765
(lp8766
I16
aI17
aI18
aI19
a(lp8767
I21
aI22
atp8768
a(I-1
S'CC CKR3 is a seven - transmembrane domain G protein - coupled receptor most closely related to the previously reported monocyte - and neutrophil - selective receptor CC CKR1 ( also known as the MIP - 1 alpha / RANTES receptor ) .'
p8769
(lp8770
I0
aI1
a(lp8771
I27
aI28
atp8772
a(I-1
S'CC CKR3 is a seven - transmembrane domain G protein - coupled receptor most closely related to the previously reported monocyte - and neutrophil - selective receptor CC CKR1 ( also known as the MIP - 1 alpha / RANTES receptor ) .'
p8773
(lp8774
I0
aI1
a(lp8775
I34
aI35
aI36
aI37
atp8776
a(I-1
S'CC CKR3 is a seven - transmembrane domain G protein - coupled receptor most closely related to the previously reported monocyte - and neutrophil - selective receptor CC CKR1 ( also known as the MIP - 1 alpha / RANTES receptor ) .'
p8777
(lp8778
I0
aI1
a(lp8779
I39
atp8780
a(I-1
S'CC CKR3 is a seven - transmembrane domain G protein - coupled receptor most closely related to the previously reported monocyte - and neutrophil - selective receptor CC CKR1 ( also known as the MIP - 1 alpha / RANTES receptor ) .'
p8781
(lp8782
I27
aI28
a(lp8783
I34
aI35
aI36
aI37
atp8784
a(I-1
S'CC CKR3 is a seven - transmembrane domain G protein - coupled receptor most closely related to the previously reported monocyte - and neutrophil - selective receptor CC CKR1 ( also known as the MIP - 1 alpha / RANTES receptor ) .'
p8785
(lp8786
I27
aI28
a(lp8787
I39
atp8788
a(I-1
S'CC CKR3 is a seven - transmembrane domain G protein - coupled receptor most closely related to the previously reported monocyte - and neutrophil - selective receptor CC CKR1 ( also known as the MIP - 1 alpha / RANTES receptor ) .'
p8789
(lp8790
I34
aI35
aI36
aI37
a(lp8791
I39
atp8792
a(I-1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8793
(lp8794
I18
aI19
aI20
aI21
aI22
aI23
a(lp8795
I24
atp8796
a(I-1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8797
(lp8798
I18
aI19
aI20
aI21
aI22
aI23
a(lp8799
I26
atp8800
a(I1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8801
(lp8802
I18
aI19
aI20
aI21
aI22
aI23
a(lp8803
I32
aI33
atp8804
a(I1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8805
(lp8806
I18
aI19
aI20
aI21
aI22
aI23
a(lp8807
I35
aI36
atp8808
a(I-1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8809
(lp8810
I24
a(lp8811
I26
atp8812
a(I-1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8813
(lp8814
I24
a(lp8815
I32
aI33
atp8816
a(I-1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8817
(lp8818
I24
a(lp8819
I35
aI36
atp8820
a(I1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8821
(lp8822
I26
a(lp8823
I32
aI33
atp8824
a(I1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8825
(lp8826
I26
a(lp8827
I35
aI36
atp8828
a(I-1
S'When [ Ca2 + ] i changes were monitored in stably transfected human embryonic kidney 293 cells , ( MIP ) - 1 alpha MIP and RANTES were both potent agonists for CC CKR3 and CC CKR1 .'
p8829
(lp8830
I32
aI33
a(lp8831
I35
aI36
atp8832
a(I1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8833
(lp8834
I2
aI3
aI4
aI5
a(lp8835
I11
aI12
atp8836
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8837
(lp8838
I2
aI3
aI4
aI5
a(lp8839
I15
aI16
atp8840
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8841
(lp8842
I2
aI3
aI4
aI5
a(lp8843
I18
aI19
aI20
atp8844
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8845
(lp8846
I2
aI3
aI4
aI5
a(lp8847
I25
aI26
atp8848
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8849
(lp8850
I2
aI3
aI4
aI5
a(lp8851
I29
aI30
atp8852
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8853
(lp8854
I11
aI12
a(lp8855
I15
aI16
atp8856
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8857
(lp8858
I11
aI12
a(lp8859
I18
aI19
aI20
atp8860
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8861
(lp8862
I11
aI12
a(lp8863
I25
aI26
atp8864
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8865
(lp8866
I11
aI12
a(lp8867
I29
aI30
atp8868
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8869
(lp8870
I15
aI16
a(lp8871
I18
aI19
aI20
atp8872
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8873
(lp8874
I15
aI16
a(lp8875
I25
aI26
atp8876
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8877
(lp8878
I15
aI16
a(lp8879
I29
aI30
atp8880
a(I1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8881
(lp8882
I18
aI19
aI20
a(lp8883
I25
aI26
atp8884
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8885
(lp8886
I18
aI19
aI20
a(lp8887
I29
aI30
atp8888
a(I-1
S'However , MIP - 1 beta was also an agonist for CC CKR3 but not CC CKR1 ; MCP - 3 was an agonist for CC CKR1 but not CC CKR3 .'
p8889
(lp8890
I25
aI26
a(lp8891
I29
aI30
atp8892
a(I1
S'Mechanism of CDK activation revealed by the structure of a cyclinA - CDK2 complex .'
p8893
(lp8894
I10
a(lp8895
I12
atp8896
a(I1
S'The crystal structure of the human cyclinA - cyclin - dependent kinase2 ( CDK2 ) - ATP complex has been determined at 2 . 3 A resolution .'
p8897
(lp8898
I6
a(lp8899
I8
aI9
aI10
aI11
atp8900
a(I1
S'The crystal structure of the human cyclinA - cyclin - dependent kinase2 ( CDK2 ) - ATP complex has been determined at 2 . 3 A resolution .'
p8901
(lp8902
I6
a(lp8903
I13
atp8904
a(I-1
S'The crystal structure of the human cyclinA - cyclin - dependent kinase2 ( CDK2 ) - ATP complex has been determined at 2 . 3 A resolution .'
p8905
(lp8906
I8
aI9
aI10
aI11
a(lp8907
I13
atp8908
a(I1
S'It binds homophilically , i . e . , PTPmu on the surface of one cell binds to PTPmu on an apposing cell , and the binding site lies within the immunoglobulin domain .'
p8909
(lp8910
I9
a(lp8911
I18
atp8912
a(I-1
S'In this article , we demonstrate that PTPmu associates with a complex containing cadherins , alpha - and beta - catenin in mink lung ( MvLu ) cells , and in rat heart , lung , and brain tissues .'
p8913
(lp8914
I7
a(lp8915
I13
aI14
aI15
atp8916
a(I1
S'In this article , we demonstrate that PTPmu associates with a complex containing cadherins , alpha - and beta - catenin in mink lung ( MvLu ) cells , and in rat heart , lung , and brain tissues .'
p8917
(lp8918
I7
a(lp8919
I18
aI19
aI20
atp8920
a(I-1
S'In this article , we demonstrate that PTPmu associates with a complex containing cadherins , alpha - and beta - catenin in mink lung ( MvLu ) cells , and in rat heart , lung , and brain tissues .'
p8921
(lp8922
I13
aI14
aI15
a(lp8923
I18
aI19
aI20
atp8924
a(I1
S'In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E - cadherin , but not to alpha - or beta - catenin .'
p8925
(lp8926
I10
a(lp8927
I18
aI19
aI20
atp8928
a(I-1
S'In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E - cadherin , but not to alpha - or beta - catenin .'
p8929
(lp8930
I10
a(lp8931
I28
aI29
aI30
atp8932
a(I-1
S'In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E - cadherin , but not to alpha - or beta - catenin .'
p8933
(lp8934
I18
aI19
aI20
a(lp8935
I28
aI29
aI30
atp8936
a(I-1
S'After pervanadate treatment of MvLu cells , which inhibits cellular tyrosine phosphatase activity including PTPmu , the cadherins associated with PTPmu are now found in a tyrosine - phosphorylated form , indicating that the cadherins may be an endogenous substrate for PTPmu .'
p8937
(lp8938
I14
a(lp8939
I20
atp8940
a(I-1
S'After pervanadate treatment of MvLu cells , which inhibits cellular tyrosine phosphatase activity including PTPmu , the cadherins associated with PTPmu are now found in a tyrosine - phosphorylated form , indicating that the cadherins may be an endogenous substrate for PTPmu .'
p8941
(lp8942
I14
a(lp8943
I41
atp8944
a(I-1
S'After pervanadate treatment of MvLu cells , which inhibits cellular tyrosine phosphatase activity including PTPmu , the cadherins associated with PTPmu are now found in a tyrosine - phosphorylated form , indicating that the cadherins may be an endogenous substrate for PTPmu .'
p8945
(lp8946
I20
a(lp8947
I41
atp8948
a(I-1
S'Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ( BMPR - II ) , which is distantly related to DAF - 4 , a BMP type II receptor from Caenorhabditis elegans .'
p8949
(lp8950
I17
aI18
aI19
a(lp8951
I27
aI28
aI29
atp8952
a(I-1
S'Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ( BMPR - II ) , which is distantly related to DAF - 4 , a BMP type II receptor from Caenorhabditis elegans .'
p8953
(lp8954
I17
aI18
aI19
a(lp8955
I32
aI33
aI34
aI35
atp8956
a(I-1
S'Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ( BMPR - II ) , which is distantly related to DAF - 4 , a BMP type II receptor from Caenorhabditis elegans .'
p8957
(lp8958
I27
aI28
aI29
a(lp8959
I32
aI33
aI34
aI35
atp8960
a(I-1
S'In transfected COS - 1 cells , osteogenic protein ( OP ) - 1 / BMP - 7 , and less efficiently BMP - 4 , bound to BMPR - II .'
p8961
(lp8962
I7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp8963
I15
aI16
aI17
atp8964
a(I-1
S'In transfected COS - 1 cells , osteogenic protein ( OP ) - 1 / BMP - 7 , and less efficiently BMP - 4 , bound to BMPR - II .'
p8965
(lp8966
I7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp8967
I22
aI23
aI24
atp8968
a(I1
S'In transfected COS - 1 cells , osteogenic protein ( OP ) - 1 / BMP - 7 , and less efficiently BMP - 4 , bound to BMPR - II .'
p8969
(lp8970
I7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp8971
I28
aI29
aI30
atp8972
a(I-1
S'In transfected COS - 1 cells , osteogenic protein ( OP ) - 1 / BMP - 7 , and less efficiently BMP - 4 , bound to BMPR - II .'
p8973
(lp8974
I15
aI16
aI17
a(lp8975
I22
aI23
aI24
atp8976
a(I1
S'In transfected COS - 1 cells , osteogenic protein ( OP ) - 1 / BMP - 7 , and less efficiently BMP - 4 , bound to BMPR - II .'
p8977
(lp8978
I15
aI16
aI17
a(lp8979
I28
aI29
aI30
atp8980
a(I1
S'In transfected COS - 1 cells , osteogenic protein ( OP ) - 1 / BMP - 7 , and less efficiently BMP - 4 , bound to BMPR - II .'
p8981
(lp8982
I22
aI23
aI24
a(lp8983
I28
aI29
aI30
atp8984
a(I-1
S'Binding of OP - 1 / BMP - 7 to BMPR - II was also observed in nontransfected cell lines .'
p8985
(lp8986
I2
aI3
aI4
a(lp8987
I6
aI7
aI8
atp8988
a(I1
S'Binding of OP - 1 / BMP - 7 to BMPR - II was also observed in nontransfected cell lines .'
p8989
(lp8990
I2
aI3
aI4
a(lp8991
I10
aI11
aI12
atp8992
a(I1
S'Binding of OP - 1 / BMP - 7 to BMPR - II was also observed in nontransfected cell lines .'
p8993
(lp8994
I6
aI7
aI8
a(lp8995
I10
aI11
aI12
atp8996
a(I1
S'Moreover , a transcriptional activation signal was transduced by BMPR - II in the presence of type I receptors after stimulation by OP - 1 / BMP - 7 .'
p8997
(lp8998
I9
aI10
aI11
a(lp8999
I22
aI23
aI24
atp9000
a(I1
S'Moreover , a transcriptional activation signal was transduced by BMPR - II in the presence of type I receptors after stimulation by OP - 1 / BMP - 7 .'
p9001
(lp9002
I9
aI10
aI11
a(lp9003
I26
aI27
aI28
atp9004
a(I-1
S'Moreover , a transcriptional activation signal was transduced by BMPR - II in the presence of type I receptors after stimulation by OP - 1 / BMP - 7 .'
p9005
(lp9006
I22
aI23
aI24
a(lp9007
I26
aI27
aI28
atp9008
a(I1
S'Raf - 1 , which is known to bind 14 - 3 - 3 proteins , has recently been shown to associate with cdc25A and to stimulate its phosphatase activity .'
p9009
(lp9010
I0
aI1
aI2
a(lp9011
I23
atp9012
a(I-1
S'14 - 3 - 3 protein , however , has no effect on the cdc25A - kinase activity of Raf - 1 .'
p9013
(lp9014
I14
a(lp9015
I19
aI20
aI21
atp9016
a(I1
S'Instead , 14 - 3 - 3 may facilitate the association of cdc25 with Raf - 1 in vivo , participating in the linkage between mitogenic signaling and the cell cycle machinery .'
p9017
(lp9018
I12
a(lp9019
I14
aI15
aI16
atp9020
a(I-1
S'The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator Swi / Snf .'
p9021
(lp9022
I2
a(lp9023
I15
atp9024
a(I-1
S'The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator Swi / Snf .'
p9025
(lp9026
I2
a(lp9027
I24
atp9028
a(I-1
S'The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator Swi / Snf .'
p9029
(lp9030
I2
a(lp9031
I26
atp9032
a(I-1
S'The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator Swi / Snf .'
p9033
(lp9034
I15
a(lp9035
I24
atp9036
a(I-1
S'The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator Swi / Snf .'
p9037
(lp9038
I15
a(lp9039
I26
atp9040
a(I-1
S'The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator Swi / Snf .'
p9041
(lp9042
I24
a(lp9043
I26
atp9044
a(I1
S'CSA protein interacts with CSB protein and with p44 protein , a subunit of the human RNA polymerase II transcription factor IIH .'
p9045
(lp9046
I0
a(lp9047
I4
atp9048
a(I1
S'CSA protein interacts with CSB protein and with p44 protein , a subunit of the human RNA polymerase II transcription factor IIH .'
p9049
(lp9050
I0
a(lp9051
I8
atp9052
a(I-1
S'CSA protein interacts with CSB protein and with p44 protein , a subunit of the human RNA polymerase II transcription factor IIH .'
p9053
(lp9054
I4
a(lp9055
I8
atp9056
a(I-1
S'These observations suggest that the products of the CSA and CSB genes are involved in transcription .'
p9057
(lp9058
I8
a(lp9059
I10
atp9060
a(I-1
S'Biochemical studies established that some coactivators are associated with the TATA - binding protein ( TBP ) to form the TFIID complex .'
p9061
(lp9062
I10
aI11
aI12
aI13
a(lp9063
I15
atp9064
a(I-1
S'Biochemical studies established that some coactivators are associated with the TATA - binding protein ( TBP ) to form the TFIID complex .'
p9065
(lp9066
I10
aI11
aI12
aI13
a(lp9067
I20
atp9068
a(I-1
S'Biochemical studies established that some coactivators are associated with the TATA - binding protein ( TBP ) to form the TFIID complex .'
p9069
(lp9070
I15
a(lp9071
I20
atp9072
a(I-1
S'The hTAFII250 gene is identical to a gene , CCG1 , ( ref 7 , 8 ) , implicated in cell - cycle progression .'
p9073
(lp9074
I1
a(lp9075
I9
atp9076
a(I1
S'Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast , and participates in the formation of the TFIID complex .'
p9077
(lp9078
I1
a(lp9079
I5
atp9080
a(I-1
S'Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast , and participates in the formation of the TFIID complex .'
p9081
(lp9082
I1
a(lp9083
I20
atp9084
a(I-1
S'Recombinant hTAFII250 binds directly to TBP both in vitro and in yeast , and participates in the formation of the TFIID complex .'
p9085
(lp9086
I5
a(lp9087
I20
atp9088
a(I-1
S'This largest TAF may therefore play a central role in TFIID assembly by interacting with both TBP and other TAFs , as well as serving to link the control of transcription to the cell cycle .'
p9089
(lp9090
I10
a(lp9091
I16
atp9092
a(I-1
S'The bZIP domains of Fos and Jun mediate a physical association with the TATA box - binding protein .'
p9093
(lp9094
I4
a(lp9095
I6
atp9096
a(I1
S'The bZIP domains of Fos and Jun mediate a physical association with the TATA box - binding protein .'
p9097
(lp9098
I4
a(lp9099
I13
aI14
aI15
aI16
aI17
atp9100
a(I1
S'The bZIP domains of Fos and Jun mediate a physical association with the TATA box - binding protein .'
p9101
(lp9102
I6
a(lp9103
I13
aI14
aI15
aI16
aI17
atp9104
a(I1
S'Fos and Jun oncoproteins form a complex that regulates transcription from promoters containing AP - 1 binding sites .'
p9105
(lp9106
I0
a(lp9107
I2
atp9108
a(I-1
S'The ability of c - Fos and c - Jun proteins to interact directly with the TATA box - binding protein ( TBP ) , the general transcription factor required for initiating the assembly of transcription complexes , was investigated .'
p9109
(lp9110
I3
aI4
aI5
a(lp9111
I7
aI8
aI9
atp9112
a(I1
S'The ability of c - Fos and c - Jun proteins to interact directly with the TATA box - binding protein ( TBP ) , the general transcription factor required for initiating the assembly of transcription complexes , was investigated .'
p9113
(lp9114
I3
aI4
aI5
a(lp9115
I16
aI17
aI18
aI19
aI20
atp9116
a(I1
S'The ability of c - Fos and c - Jun proteins to interact directly with the TATA box - binding protein ( TBP ) , the general transcription factor required for initiating the assembly of transcription complexes , was investigated .'
p9117
(lp9118
I3
aI4
aI5
a(lp9119
I22
atp9120
a(I1
S'The ability of c - Fos and c - Jun proteins to interact directly with the TATA box - binding protein ( TBP ) , the general transcription factor required for initiating the assembly of transcription complexes , was investigated .'
p9121
(lp9122
I7
aI8
aI9
a(lp9123
I16
aI17
aI18
aI19
aI20
atp9124
a(I1
S'The ability of c - Fos and c - Jun proteins to interact directly with the TATA box - binding protein ( TBP ) , the general transcription factor required for initiating the assembly of transcription complexes , was investigated .'
p9125
(lp9126
I7
aI8
aI9
a(lp9127
I22
atp9128
a(I-1
S'The ability of c - Fos and c - Jun proteins to interact directly with the TATA box - binding protein ( TBP ) , the general transcription factor required for initiating the assembly of transcription complexes , was investigated .'
p9129
(lp9130
I16
aI17
aI18
aI19
aI20
a(lp9131
I22
atp9132
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9133
(lp9134
I15
aI16
aI17
a(lp9135
I19
aI20
aI21
atp9136
a(I1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9137
(lp9138
I15
aI16
aI17
a(lp9139
I27
atp9140
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9141
(lp9142
I15
aI16
aI17
a(lp9143
I42
aI43
aI44
atp9144
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9145
(lp9146
I15
aI16
aI17
a(lp9147
I46
aI47
aI48
atp9148
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9149
(lp9150
I15
aI16
aI17
a(lp9151
I57
atp9152
a(I1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9153
(lp9154
I19
aI20
aI21
a(lp9155
I27
atp9156
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9157
(lp9158
I19
aI20
aI21
a(lp9159
I42
aI43
aI44
atp9160
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9161
(lp9162
I19
aI20
aI21
a(lp9163
I46
aI47
aI48
atp9164
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9165
(lp9166
I19
aI20
aI21
a(lp9167
I57
atp9168
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9169
(lp9170
I27
a(lp9171
I42
aI43
aI44
atp9172
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9173
(lp9174
I27
a(lp9175
I46
aI47
aI48
atp9176
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9177
(lp9178
I27
a(lp9179
I57
atp9180
a(I-1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9181
(lp9182
I42
aI43
aI44
a(lp9183
I46
aI47
aI48
atp9184
a(I1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9185
(lp9186
I42
aI43
aI44
a(lp9187
I57
atp9188
a(I1
S'Using co - immunoprecipitation and protein - protein association assays , we show that both c - Fos and c - Jun bind specifically and stably to TBP . Mutational analysis demonstrates that both the basic region and leucine zipper domains of c - Fos and c - Jun are necessary and sufficient for stable association with TBP .'
p9189
(lp9190
I46
aI47
aI48
a(lp9191
I57
atp9192
a(I1
S'A 51 - residue region from the conserved C - terminal region of TBP , previously shown to be the binding site for the viral activator protein E1A , interacts with c - Fos and c - Jun proteins .'
p9193
(lp9194
I13
a(lp9195
I27
atp9196
a(I1
S'A 51 - residue region from the conserved C - terminal region of TBP , previously shown to be the binding site for the viral activator protein E1A , interacts with c - Fos and c - Jun proteins .'
p9197
(lp9198
I13
a(lp9199
I31
aI32
aI33
atp9200
a(I1
S'A 51 - residue region from the conserved C - terminal region of TBP , previously shown to be the binding site for the viral activator protein E1A , interacts with c - Fos and c - Jun proteins .'
p9201
(lp9202
I13
a(lp9203
I35
aI36
aI37
atp9204
a(I-1
S'A 51 - residue region from the conserved C - terminal region of TBP , previously shown to be the binding site for the viral activator protein E1A , interacts with c - Fos and c - Jun proteins .'
p9205
(lp9206
I27
a(lp9207
I31
aI32
aI33
atp9208
a(I-1
S'A 51 - residue region from the conserved C - terminal region of TBP , previously shown to be the binding site for the viral activator protein E1A , interacts with c - Fos and c - Jun proteins .'
p9209
(lp9210
I27
a(lp9211
I35
aI36
aI37
atp9212
a(I-1
S'A 51 - residue region from the conserved C - terminal region of TBP , previously shown to be the binding site for the viral activator protein E1A , interacts with c - Fos and c - Jun proteins .'
p9213
(lp9214
I31
aI32
aI33
a(lp9215
I35
aI36
aI37
atp9216
a(I-1
S'We propose that c - Fos and c - Jun proteins function as transcriptional activators , in part by recruiting TBP to form complexes to initiate RNA synthesis .'
p9217
(lp9218
I3
aI4
aI5
a(lp9219
I7
aI8
aI9
atp9220
a(I1
S'We propose that c - Fos and c - Jun proteins function as transcriptional activators , in part by recruiting TBP to form complexes to initiate RNA synthesis .'
p9221
(lp9222
I3
aI4
aI5
a(lp9223
I20
atp9224
a(I1
S'We propose that c - Fos and c - Jun proteins function as transcriptional activators , in part by recruiting TBP to form complexes to initiate RNA synthesis .'
p9225
(lp9226
I7
aI8
aI9
a(lp9227
I20
atp9228
a(I-1
S'The retinoblastoma - susceptibility gene product binds directly to the human TATA - binding protein - associated factor TAFII250 .'
p9229
(lp9230
I1
a(lp9231
I11
aI12
aI13
aI14
atp9232
a(I-1
S'The retinoblastoma - susceptibility gene product binds directly to the human TATA - binding protein - associated factor TAFII250 .'
p9233
(lp9234
I1
a(lp9235
I11
aI12
aI13
aI14
aI15
aI16
aI17
atp9236
a(I1
S'The retinoblastoma - susceptibility gene product binds directly to the human TATA - binding protein - associated factor TAFII250 .'
p9237
(lp9238
I1
a(lp9239
I18
atp9240
a(I-1
S'The retinoblastoma - susceptibility gene product binds directly to the human TATA - binding protein - associated factor TAFII250 .'
p9241
(lp9242
I11
aI12
aI13
aI14
a(lp9243
I11
aI12
aI13
aI14
aI15
aI16
aI17
atp9244
a(I-1
S'The retinoblastoma - susceptibility gene product binds directly to the human TATA - binding protein - associated factor TAFII250 .'
p9245
(lp9246
I11
aI12
aI13
aI14
a(lp9247
I18
atp9248
a(I-1
S'The retinoblastoma - susceptibility gene product binds directly to the human TATA - binding protein - associated factor TAFII250 .'
p9249
(lp9250
I11
aI12
aI13
aI14
aI15
aI16
aI17
a(lp9251
I18
atp9252
a(I-1
S'RB , the protein product of the retinoblastoma tumor - suppressor gene , regulates the activity of specific transcription factors .'
p9253
(lp9254
I0
a(lp9255
I7
atp9256
a(I-1
S'Here we report that stimulation of Sp1 - mediated transcription by RB is partially abrogated at the nonpermissive temperature in ts13 cells .'
p9257
(lp9258
I6
a(lp9259
I11
atp9260
a(I-1
S'These cells contain a temperature - sensitive mutation in the TATA - binding protein - associated factor TAFII250 , first identified as the cell cycle regulatory protein CCG1 .'
p9261
(lp9262
I10
aI11
aI12
aI13
a(lp9263
I10
aI11
aI12
aI13
aI14
aI15
aI16
atp9264
a(I-1
S'These cells contain a temperature - sensitive mutation in the TATA - binding protein - associated factor TAFII250 , first identified as the cell cycle regulatory protein CCG1 .'
p9265
(lp9266
I10
aI11
aI12
aI13
a(lp9267
I17
atp9268
a(I-1
S'These cells contain a temperature - sensitive mutation in the TATA - binding protein - associated factor TAFII250 , first identified as the cell cycle regulatory protein CCG1 .'
p9269
(lp9270
I10
aI11
aI12
aI13
a(lp9271
I27
atp9272
a(I-1
S'These cells contain a temperature - sensitive mutation in the TATA - binding protein - associated factor TAFII250 , first identified as the cell cycle regulatory protein CCG1 .'
p9273
(lp9274
I10
aI11
aI12
aI13
aI14
aI15
aI16
a(lp9275
I17
atp9276
a(I-1
S'These cells contain a temperature - sensitive mutation in the TATA - binding protein - associated factor TAFII250 , first identified as the cell cycle regulatory protein CCG1 .'
p9277
(lp9278
I10
aI11
aI12
aI13
aI14
aI15
aI16
a(lp9279
I27
atp9280
a(I-1
S'These cells contain a temperature - sensitive mutation in the TATA - binding protein - associated factor TAFII250 , first identified as the cell cycle regulatory protein CCG1 .'
p9281
(lp9282
I17
a(lp9283
I27
atp9284
a(I-1
S'The stimulation of Sp1 - mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild - type human TAFII250 .'
p9285
(lp9286
I3
a(lp9287
I8
atp9288
a(I-1
S'The stimulation of Sp1 - mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild - type human TAFII250 .'
p9289
(lp9290
I3
a(lp9291
I27
atp9292
a(I-1
S'The stimulation of Sp1 - mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild - type human TAFII250 .'
p9293
(lp9294
I8
a(lp9295
I27
atp9296
a(I1
S'Furthermore , we demonstrate that RB binds directly to hTAFII250 in vitro and in vivo .'
p9297
(lp9298
I5
a(lp9299
I9
atp9300
a(I-1
S'These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID , in particular with TAFII250 .'
p9301
(lp9302
I4
a(lp9303
I21
atp9304
a(I1
S'These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID , in particular with TAFII250 .'
p9305
(lp9306
I4
a(lp9307
I26
atp9308
a(I-1
S'These results suggest that RB can confer transcriptional regulation and possibly cell cycle control and tumor suppression through an interaction with TFIID , in particular with TAFII250 .'
p9309
(lp9310
I21
a(lp9311
I26
atp9312
a(I1
S'Cloning and characterization of hTAFII18 , hTAFII20 and hTAFII28 : three subunits of the human transcription factor TFIID .'
p9313
(lp9314
I4
a(lp9315
I6
atp9316
a(I1
S'Cloning and characterization of hTAFII18 , hTAFII20 and hTAFII28 : three subunits of the human transcription factor TFIID .'
p9317
(lp9318
I4
a(lp9319
I8
atp9320
a(I-1
S'Cloning and characterization of hTAFII18 , hTAFII20 and hTAFII28 : three subunits of the human transcription factor TFIID .'
p9321
(lp9322
I4
a(lp9323
I17
atp9324
a(I1
S'Cloning and characterization of hTAFII18 , hTAFII20 and hTAFII28 : three subunits of the human transcription factor TFIID .'
p9325
(lp9326
I6
a(lp9327
I8
atp9328
a(I-1
S'Cloning and characterization of hTAFII18 , hTAFII20 and hTAFII28 : three subunits of the human transcription factor TFIID .'
p9329
(lp9330
I6
a(lp9331
I17
atp9332
a(I-1
S'Cloning and characterization of hTAFII18 , hTAFII20 and hTAFII28 : three subunits of the human transcription factor TFIID .'
p9333
(lp9334
I8
a(lp9335
I17
atp9336
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9337
(lp9338
I9
aI10
aI11
aI12
a(lp9339
I14
atp9340
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9341
(lp9342
I9
aI10
aI11
aI12
a(lp9343
I28
atp9344
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9345
(lp9346
I9
aI10
aI11
aI12
a(lp9347
I30
atp9348
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9349
(lp9350
I9
aI10
aI11
aI12
a(lp9351
I32
atp9352
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9353
(lp9354
I9
aI10
aI11
aI12
a(lp9355
I34
atp9356
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9357
(lp9358
I9
aI10
aI11
aI12
a(lp9359
I36
atp9360
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9361
(lp9362
I9
aI10
aI11
aI12
a(lp9363
I40
atp9364
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9365
(lp9366
I9
aI10
aI11
aI12
a(lp9367
I48
atp9368
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9369
(lp9370
I9
aI10
aI11
aI12
a(lp9371
I55
atp9372
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9373
(lp9374
I9
aI10
aI11
aI12
a(lp9375
I57
atp9376
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9377
(lp9378
I9
aI10
aI11
aI12
a(lp9379
I57
aI58
atp9380
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9381
(lp9382
I9
aI10
aI11
aI12
a(lp9383
I60
atp9384
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9385
(lp9386
I9
aI10
aI11
aI12
a(lp9387
I60
aI61
atp9388
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9389
(lp9390
I9
aI10
aI11
aI12
a(lp9391
I74
aI75
atp9392
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9393
(lp9394
I9
aI10
aI11
aI12
a(lp9395
I77
atp9396
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9397
(lp9398
I9
aI10
aI11
aI12
a(lp9399
I81
atp9400
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9401
(lp9402
I9
aI10
aI11
aI12
a(lp9403
I94
atp9404
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9405
(lp9406
I14
a(lp9407
I28
atp9408
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9409
(lp9410
I14
a(lp9411
I30
atp9412
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9413
(lp9414
I14
a(lp9415
I32
atp9416
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9417
(lp9418
I14
a(lp9419
I34
atp9420
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9421
(lp9422
I14
a(lp9423
I36
atp9424
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9425
(lp9426
I14
a(lp9427
I40
atp9428
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9429
(lp9430
I14
a(lp9431
I48
atp9432
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9433
(lp9434
I14
a(lp9435
I55
atp9436
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9437
(lp9438
I14
a(lp9439
I57
atp9440
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9441
(lp9442
I14
a(lp9443
I57
aI58
atp9444
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9445
(lp9446
I14
a(lp9447
I60
atp9448
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9449
(lp9450
I14
a(lp9451
I60
aI61
atp9452
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9453
(lp9454
I14
a(lp9455
I74
aI75
atp9456
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9457
(lp9458
I14
a(lp9459
I77
atp9460
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9461
(lp9462
I14
a(lp9463
I81
atp9464
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9465
(lp9466
I14
a(lp9467
I94
atp9468
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9469
(lp9470
I28
a(lp9471
I30
atp9472
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9473
(lp9474
I28
a(lp9475
I32
atp9476
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9477
(lp9478
I28
a(lp9479
I34
atp9480
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9481
(lp9482
I28
a(lp9483
I36
atp9484
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9485
(lp9486
I28
a(lp9487
I40
atp9488
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9489
(lp9490
I28
a(lp9491
I48
atp9492
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9493
(lp9494
I28
a(lp9495
I55
atp9496
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9497
(lp9498
I28
a(lp9499
I57
atp9500
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9501
(lp9502
I28
a(lp9503
I57
aI58
atp9504
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9505
(lp9506
I28
a(lp9507
I60
atp9508
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9509
(lp9510
I28
a(lp9511
I60
aI61
atp9512
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9513
(lp9514
I28
a(lp9515
I74
aI75
atp9516
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9517
(lp9518
I28
a(lp9519
I77
atp9520
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9521
(lp9522
I28
a(lp9523
I81
atp9524
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9525
(lp9526
I28
a(lp9527
I94
atp9528
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9529
(lp9530
I30
a(lp9531
I32
atp9532
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9533
(lp9534
I30
a(lp9535
I34
atp9536
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9537
(lp9538
I30
a(lp9539
I36
atp9540
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9541
(lp9542
I30
a(lp9543
I40
atp9544
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9545
(lp9546
I30
a(lp9547
I48
atp9548
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9549
(lp9550
I30
a(lp9551
I55
atp9552
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9553
(lp9554
I30
a(lp9555
I57
atp9556
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9557
(lp9558
I30
a(lp9559
I57
aI58
atp9560
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9561
(lp9562
I30
a(lp9563
I60
atp9564
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9565
(lp9566
I30
a(lp9567
I60
aI61
atp9568
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9569
(lp9570
I30
a(lp9571
I74
aI75
atp9572
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9573
(lp9574
I30
a(lp9575
I77
atp9576
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9577
(lp9578
I30
a(lp9579
I81
atp9580
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9581
(lp9582
I30
a(lp9583
I94
atp9584
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9585
(lp9586
I32
a(lp9587
I34
atp9588
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9589
(lp9590
I32
a(lp9591
I36
atp9592
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9593
(lp9594
I32
a(lp9595
I40
atp9596
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9597
(lp9598
I32
a(lp9599
I48
atp9600
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9601
(lp9602
I32
a(lp9603
I55
atp9604
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9605
(lp9606
I32
a(lp9607
I57
atp9608
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9609
(lp9610
I32
a(lp9611
I57
aI58
atp9612
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9613
(lp9614
I32
a(lp9615
I60
atp9616
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9617
(lp9618
I32
a(lp9619
I60
aI61
atp9620
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9621
(lp9622
I32
a(lp9623
I74
aI75
atp9624
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9625
(lp9626
I32
a(lp9627
I77
atp9628
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9629
(lp9630
I32
a(lp9631
I81
atp9632
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9633
(lp9634
I32
a(lp9635
I94
atp9636
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9637
(lp9638
I34
a(lp9639
I36
atp9640
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9641
(lp9642
I34
a(lp9643
I40
atp9644
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9645
(lp9646
I34
a(lp9647
I48
atp9648
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9649
(lp9650
I34
a(lp9651
I55
atp9652
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9653
(lp9654
I34
a(lp9655
I57
atp9656
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9657
(lp9658
I34
a(lp9659
I57
aI58
atp9660
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9661
(lp9662
I34
a(lp9663
I60
atp9664
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9665
(lp9666
I34
a(lp9667
I60
aI61
atp9668
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9669
(lp9670
I34
a(lp9671
I74
aI75
atp9672
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9673
(lp9674
I34
a(lp9675
I77
atp9676
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9677
(lp9678
I34
a(lp9679
I81
atp9680
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9681
(lp9682
I34
a(lp9683
I94
atp9684
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9685
(lp9686
I36
a(lp9687
I40
atp9688
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9689
(lp9690
I36
a(lp9691
I48
atp9692
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9693
(lp9694
I36
a(lp9695
I55
atp9696
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9697
(lp9698
I36
a(lp9699
I57
atp9700
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9701
(lp9702
I36
a(lp9703
I57
aI58
atp9704
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9705
(lp9706
I36
a(lp9707
I60
atp9708
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9709
(lp9710
I36
a(lp9711
I60
aI61
atp9712
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9713
(lp9714
I36
a(lp9715
I74
aI75
atp9716
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9717
(lp9718
I36
a(lp9719
I77
atp9720
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9721
(lp9722
I36
a(lp9723
I81
atp9724
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9725
(lp9726
I36
a(lp9727
I94
atp9728
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9729
(lp9730
I40
a(lp9731
I48
atp9732
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9733
(lp9734
I40
a(lp9735
I55
atp9736
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9737
(lp9738
I40
a(lp9739
I57
atp9740
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9741
(lp9742
I40
a(lp9743
I57
aI58
atp9744
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9745
(lp9746
I40
a(lp9747
I60
atp9748
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9749
(lp9750
I40
a(lp9751
I60
aI61
atp9752
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9753
(lp9754
I40
a(lp9755
I74
aI75
atp9756
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9757
(lp9758
I40
a(lp9759
I77
atp9760
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9761
(lp9762
I40
a(lp9763
I81
atp9764
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9765
(lp9766
I40
a(lp9767
I94
atp9768
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9769
(lp9770
I48
a(lp9771
I55
atp9772
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9773
(lp9774
I48
a(lp9775
I57
atp9776
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9777
(lp9778
I48
a(lp9779
I57
aI58
atp9780
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9781
(lp9782
I48
a(lp9783
I60
atp9784
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9785
(lp9786
I48
a(lp9787
I60
aI61
atp9788
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9789
(lp9790
I48
a(lp9791
I74
aI75
atp9792
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9793
(lp9794
I48
a(lp9795
I77
atp9796
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9797
(lp9798
I48
a(lp9799
I81
atp9800
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9801
(lp9802
I48
a(lp9803
I94
atp9804
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9805
(lp9806
I55
a(lp9807
I57
atp9808
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9809
(lp9810
I55
a(lp9811
I57
aI58
atp9812
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9813
(lp9814
I55
a(lp9815
I60
atp9816
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9817
(lp9818
I55
a(lp9819
I60
aI61
atp9820
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9821
(lp9822
I55
a(lp9823
I74
aI75
atp9824
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9825
(lp9826
I55
a(lp9827
I77
atp9828
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9829
(lp9830
I55
a(lp9831
I81
atp9832
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9833
(lp9834
I55
a(lp9835
I94
atp9836
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9837
(lp9838
I57
a(lp9839
I57
aI58
atp9840
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9841
(lp9842
I57
a(lp9843
I60
atp9844
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9845
(lp9846
I57
a(lp9847
I60
aI61
atp9848
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9849
(lp9850
I57
a(lp9851
I74
aI75
atp9852
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9853
(lp9854
I57
a(lp9855
I77
atp9856
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9857
(lp9858
I57
a(lp9859
I81
atp9860
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9861
(lp9862
I57
a(lp9863
I94
atp9864
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9865
(lp9866
I57
aI58
a(lp9867
I60
atp9868
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9869
(lp9870
I57
aI58
a(lp9871
I60
aI61
atp9872
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9873
(lp9874
I57
aI58
a(lp9875
I74
aI75
atp9876
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9877
(lp9878
I57
aI58
a(lp9879
I77
atp9880
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9881
(lp9882
I57
aI58
a(lp9883
I81
atp9884
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9885
(lp9886
I57
aI58
a(lp9887
I94
atp9888
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9889
(lp9890
I60
a(lp9891
I60
aI61
atp9892
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9893
(lp9894
I60
a(lp9895
I74
aI75
atp9896
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9897
(lp9898
I60
a(lp9899
I77
atp9900
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9901
(lp9902
I60
a(lp9903
I81
atp9904
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9905
(lp9906
I60
a(lp9907
I94
atp9908
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9909
(lp9910
I60
aI61
a(lp9911
I74
aI75
atp9912
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9913
(lp9914
I60
aI61
a(lp9915
I77
atp9916
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9917
(lp9918
I60
aI61
a(lp9919
I81
atp9920
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9921
(lp9922
I60
aI61
a(lp9923
I94
atp9924
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9925
(lp9926
I74
aI75
a(lp9927
I77
atp9928
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9929
(lp9930
I74
aI75
a(lp9931
I81
atp9932
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9933
(lp9934
I74
aI75
a(lp9935
I94
atp9936
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9937
(lp9938
I77
a(lp9939
I81
atp9940
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9941
(lp9942
I77
a(lp9943
I94
atp9944
a(I-1
S'We have cloned cDNAs encoding three novel TAFIIs [ TATA - binding protein ( TBP ) - associated factors ] from the human ( h ) HeLa cell TFIID complexes hTAFII28 , hTAFII20 and hTAFII18 . hTAFII28 is a core hTAFII present in both of the previously described hTFIID species which either lack or contain hTAFII30 ( hTFIID alpha and hTFIID beta respectively ) , and is the homologue of Drosophila ( d ) TAFII30 beta . hTAFII18 is a novel hTAFII which shows homology to the N - terminal region of the yeast TAFIISPT3 , but has no known Drosophila counterpart .'
p9945
(lp9946
I81
a(lp9947
I94
atp9948
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9949
(lp9950
I3
a(lp9951
I5
atp9952
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9953
(lp9954
I3
a(lp9955
I8
atp9956
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9957
(lp9958
I3
a(lp9959
I8
aI9
atp9960
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9961
(lp9962
I3
a(lp9963
I12
atp9964
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9965
(lp9966
I3
a(lp9967
I14
atp9968
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9969
(lp9970
I3
a(lp9971
I19
atp9972
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9973
(lp9974
I3
a(lp9975
I26
aI27
atp9976
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9977
(lp9978
I3
a(lp9979
I29
atp9980
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9981
(lp9982
I5
a(lp9983
I8
atp9984
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9985
(lp9986
I5
a(lp9987
I8
aI9
atp9988
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9989
(lp9990
I5
a(lp9991
I12
atp9992
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9993
(lp9994
I5
a(lp9995
I14
atp9996
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p9997
(lp9998
I5
a(lp9999
I19
atp10000
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10001
(lp10002
I5
a(lp10003
I26
aI27
atp10004
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10005
(lp10006
I5
a(lp10007
I29
atp10008
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10009
(lp10010
I8
a(lp10011
I8
aI9
atp10012
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10013
(lp10014
I8
a(lp10015
I12
atp10016
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10017
(lp10018
I8
a(lp10019
I14
atp10020
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10021
(lp10022
I8
a(lp10023
I19
atp10024
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10025
(lp10026
I8
a(lp10027
I26
aI27
atp10028
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10029
(lp10030
I8
a(lp10031
I29
atp10032
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10033
(lp10034
I8
aI9
a(lp10035
I12
atp10036
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10037
(lp10038
I8
aI9
a(lp10039
I14
atp10040
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10041
(lp10042
I8
aI9
a(lp10043
I19
atp10044
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10045
(lp10046
I8
aI9
a(lp10047
I26
aI27
atp10048
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10049
(lp10050
I8
aI9
a(lp10051
I29
atp10052
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10053
(lp10054
I12
a(lp10055
I14
atp10056
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10057
(lp10058
I12
a(lp10059
I19
atp10060
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10061
(lp10062
I12
a(lp10063
I26
aI27
atp10064
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10065
(lp10066
I12
a(lp10067
I29
atp10068
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10069
(lp10070
I14
a(lp10071
I19
atp10072
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10073
(lp10074
I14
a(lp10075
I26
aI27
atp10076
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10077
(lp10078
I14
a(lp10079
I29
atp10080
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10081
(lp10082
I19
a(lp10083
I26
aI27
atp10084
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10085
(lp10086
I19
a(lp10087
I29
atp10088
a(I-1
S'In contrast to hTAFII28 , hTAFII18 is a TFIID beta - specific hTAFII . hTAFII20 is the homologue of p22 , an alternatively spliced form of dTAFII30 alpha ( p32 ) .'
p10089
(lp10090
I26
aI27
a(lp10091
I29
atp10092
a(I1
S'We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly ; in contrast to its Drosophila homologue , hTAFII28 also interacts directly with TBP .'
p10093
(lp10094
I3
a(lp10095
I6
atp10096
a(I-1
S'We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly ; in contrast to its Drosophila homologue , hTAFII28 also interacts directly with TBP .'
p10097
(lp10098
I3
a(lp10099
I20
atp10100
a(I-1
S'We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly ; in contrast to its Drosophila homologue , hTAFII28 also interacts directly with TBP .'
p10101
(lp10102
I3
a(lp10103
I25
atp10104
a(I-1
S'We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly ; in contrast to its Drosophila homologue , hTAFII28 also interacts directly with TBP .'
p10105
(lp10106
I6
a(lp10107
I20
atp10108
a(I-1
S'We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly ; in contrast to its Drosophila homologue , hTAFII28 also interacts directly with TBP .'
p10109
(lp10110
I6
a(lp10111
I25
atp10112
a(I1
S'We show that hTAFII28 interacts with hTAFII18 both in vitro and intracellularly ; in contrast to its Drosophila homologue , hTAFII28 also interacts directly with TBP .'
p10113
(lp10114
I20
a(lp10115
I25
atp10116
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10117
(lp10118
I4
a(lp10119
I6
atp10120
a(I1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10121
(lp10122
I4
a(lp10123
I12
atp10124
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10125
(lp10126
I4
a(lp10127
I14
atp10128
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10129
(lp10130
I4
a(lp10131
I18
atp10132
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10133
(lp10134
I4
a(lp10135
I26
atp10136
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10137
(lp10138
I4
a(lp10139
I28
atp10140
a(I1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10141
(lp10142
I6
a(lp10143
I12
atp10144
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10145
(lp10146
I6
a(lp10147
I14
atp10148
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10149
(lp10150
I6
a(lp10151
I18
atp10152
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10153
(lp10154
I6
a(lp10155
I26
atp10156
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10157
(lp10158
I6
a(lp10159
I28
atp10160
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10161
(lp10162
I12
a(lp10163
I14
atp10164
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10165
(lp10166
I12
a(lp10167
I18
atp10168
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10169
(lp10170
I12
a(lp10171
I26
atp10172
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10173
(lp10174
I12
a(lp10175
I28
atp10176
a(I1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10177
(lp10178
I14
a(lp10179
I18
atp10180
a(I1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10181
(lp10182
I14
a(lp10183
I26
atp10184
a(I1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10185
(lp10186
I14
a(lp10187
I28
atp10188
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10189
(lp10190
I18
a(lp10191
I26
atp10192
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10193
(lp10194
I18
a(lp10195
I28
atp10196
a(I-1
S'Deletion analysis indicates that TBP and hTAFII18 bind to distinct domains of hTAFII28 . hTAFII18 also interacts with TBP , but it interacts more strongly with hTAFII28 and hTAFII30 .'
p10197
(lp10198
I26
a(lp10199
I28
atp10200
a(I-1
S'The binding of hTAFII28 and hTAFII30 requires distinct domains of hTAFII18 .'
p10201
(lp10202
I3
a(lp10203
I5
atp10204
a(I1
S'The binding of hTAFII28 and hTAFII30 requires distinct domains of hTAFII18 .'
p10205
(lp10206
I3
a(lp10207
I10
atp10208
a(I1
S'The binding of hTAFII28 and hTAFII30 requires distinct domains of hTAFII18 .'
p10209
(lp10210
I5
a(lp10211
I10
atp10212
a(I1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10213
(lp10214
I8
a(lp10215
I12
atp10216
a(I-1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10217
(lp10218
I8
a(lp10219
I19
atp10220
a(I-1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10221
(lp10222
I8
a(lp10223
I21
atp10224
a(I-1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10225
(lp10226
I8
a(lp10227
I23
atp10228
a(I-1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10229
(lp10230
I12
a(lp10231
I19
atp10232
a(I-1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10233
(lp10234
I12
a(lp10235
I21
atp10236
a(I-1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10237
(lp10238
I12
a(lp10239
I23
atp10240
a(I1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10241
(lp10242
I19
a(lp10243
I21
atp10244
a(I1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10245
(lp10246
I19
a(lp10247
I23
atp10248
a(I-1
S'As observed with the homologous Drosophila proteins , hTAFII20 interacts directly with TBP ; however , additional interactions between hTAFII20 and hTAFII28 or hTAFII30 were detected .'
p10249
(lp10250
I21
a(lp10251
I23
atp10252
a(I-1
S'These results reveal differences not only in subunit composition , but also in the organization of dTFIID and hTFIID complexes .'
p10253
(lp10254
I16
a(lp10255
I18
atp10256
a(I-1
S'This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein ( pRB ) or its relatives p107 and p103 .'
p10257
(lp10258
I9
aI10
aI11
aI12
a(lp10259
I14
atp10260
a(I-1
S'This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein ( pRB ) or its relatives p107 and p103 .'
p10261
(lp10262
I9
aI10
aI11
aI12
a(lp10263
I19
atp10264
a(I-1
S'This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein ( pRB ) or its relatives p107 and p103 .'
p10265
(lp10266
I9
aI10
aI11
aI12
a(lp10267
I21
atp10268
a(I-1
S'This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein ( pRB ) or its relatives p107 and p103 .'
p10269
(lp10270
I14
a(lp10271
I19
atp10272
a(I-1
S'This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein ( pRB ) or its relatives p107 and p103 .'
p10273
(lp10274
I14
a(lp10275
I21
atp10276
a(I-1
S'This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein ( pRB ) or its relatives p107 and p103 .'
p10277
(lp10278
I19
a(lp10279
I21
atp10280
a(I-1
S'The first cDNA from the E2F family to be cloned was designated E2F - 1 , and multiple E2F family members have now been identified .'
p10281
(lp10282
I5
a(lp10283
I12
aI13
aI14
atp10284
a(I-1
S'The first cDNA from the E2F family to be cloned was designated E2F - 1 , and multiple E2F family members have now been identified .'
p10285
(lp10286
I5
a(lp10287
I18
atp10288
a(I-1
S'The first cDNA from the E2F family to be cloned was designated E2F - 1 , and multiple E2F family members have now been identified .'
p10289
(lp10290
I12
aI13
aI14
a(lp10291
I18
atp10292
a(I-1
S'Here we demonstrate that DP is also a family of polypeptides with at least two members ( hDP - 1 and hDP - 2 ) .'
p10293
(lp10294
I17
aI18
aI19
a(lp10295
I21
aI22
aI23
atp10296
a(I-1
S'Both hDP - 1 and hDP - 2 bind to all E2F family members in vivo , and each complex is capable of activating transcription .'
p10297
(lp10298
I1
aI2
aI3
a(lp10299
I5
aI6
aI7
atp10300
a(I-1
S'Both hDP - 1 and hDP - 2 bind to all E2F family members in vivo , and each complex is capable of activating transcription .'
p10301
(lp10302
I1
aI2
aI3
a(lp10303
I11
atp10304
a(I-1
S'Both hDP - 1 and hDP - 2 bind to all E2F family members in vivo , and each complex is capable of activating transcription .'
p10305
(lp10306
I5
aI6
aI7
a(lp10307
I11
atp10308
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10309
(lp10310
I4
a(lp10311
I18
atp10312
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10313
(lp10314
I4
a(lp10315
I20
atp10316
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10317
(lp10318
I4
a(lp10319
I28
atp10320
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10321
(lp10322
I4
a(lp10323
I30
atp10324
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10325
(lp10326
I4
a(lp10327
I36
atp10328
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10329
(lp10330
I18
a(lp10331
I20
atp10332
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10333
(lp10334
I18
a(lp10335
I28
atp10336
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10337
(lp10338
I18
a(lp10339
I30
atp10340
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10341
(lp10342
I18
a(lp10343
I36
atp10344
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10345
(lp10346
I20
a(lp10347
I28
atp10348
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10349
(lp10350
I20
a(lp10351
I30
atp10352
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10353
(lp10354
I20
a(lp10355
I36
atp10356
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10357
(lp10358
I28
a(lp10359
I30
atp10360
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10361
(lp10362
I28
a(lp10363
I36
atp10364
a(I-1
S'However , the various E2F / DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo , and the specificity of pRB or p107 binding is mediated by the E2F subunit .'
p10365
(lp10366
I30
a(lp10367
I36
atp10368
a(I1
S'Two distinct and independent sites on IL - 6 trigger gp 130 dimer formation and signalling .'
p10369
(lp10370
I6
aI7
aI8
a(lp10371
I10
aI11
atp10372
a(I1
S'The helical cytokine interleukin ( IL ) 6 and its specific binding subunit IL - 6R alpha form a 1 : 1 complex which , by promoting homodimerization of the signalling subunit gp130 on the surface of target cells , triggers intracellular responses .'
p10373
(lp10374
I3
aI4
aI5
aI6
aI7
a(lp10375
I13
aI14
aI15
aI16
atp10376
a(I-1
S'The helical cytokine interleukin ( IL ) 6 and its specific binding subunit IL - 6R alpha form a 1 : 1 complex which , by promoting homodimerization of the signalling subunit gp130 on the surface of target cells , triggers intracellular responses .'
p10377
(lp10378
I3
aI4
aI5
aI6
aI7
a(lp10379
I32
atp10380
a(I-1
S'The helical cytokine interleukin ( IL ) 6 and its specific binding subunit IL - 6R alpha form a 1 : 1 complex which , by promoting homodimerization of the signalling subunit gp130 on the surface of target cells , triggers intracellular responses .'
p10381
(lp10382
I13
aI14
aI15
aI16
a(lp10383
I32
atp10384
a(I-1
S'We expressed differently tagged forms of gp130 and used them in solution - phase binding assays to show that the soluble extracellular domains of gp130 undergo dimerization in the absence of membranes .'
p10385
(lp10386
I6
a(lp10387
I24
atp10388
a(I1
S'We demonstrate here that both the site 2 and site 3 IL - 6 variants complexed with IL - 6R alpha bind a single gp130 molecule but are unable to dimerize it , whereas the combined site 2 / 3 variants lose the ability to interact with gp130 .'
p10389
(lp10390
I11
aI12
aI13
a(lp10391
I17
aI18
aI19
aI20
atp10392
a(I1
S'We demonstrate here that both the site 2 and site 3 IL - 6 variants complexed with IL - 6R alpha bind a single gp130 molecule but are unable to dimerize it , whereas the combined site 2 / 3 variants lose the ability to interact with gp130 .'
p10393
(lp10394
I11
aI12
aI13
a(lp10395
I24
atp10396
a(I-1
S'We demonstrate here that both the site 2 and site 3 IL - 6 variants complexed with IL - 6R alpha bind a single gp130 molecule but are unable to dimerize it , whereas the combined site 2 / 3 variants lose the ability to interact with gp130 .'
p10397
(lp10398
I11
aI12
aI13
a(lp10399
I47
atp10400
a(I1
S'We demonstrate here that both the site 2 and site 3 IL - 6 variants complexed with IL - 6R alpha bind a single gp130 molecule but are unable to dimerize it , whereas the combined site 2 / 3 variants lose the ability to interact with gp130 .'
p10401
(lp10402
I17
aI18
aI19
aI20
a(lp10403
I24
atp10404
a(I-1
S'We demonstrate here that both the site 2 and site 3 IL - 6 variants complexed with IL - 6R alpha bind a single gp130 molecule but are unable to dimerize it , whereas the combined site 2 / 3 variants lose the ability to interact with gp130 .'
p10405
(lp10406
I17
aI18
aI19
aI20
a(lp10407
I47
atp10408
a(I-1
S'We demonstrate here that both the site 2 and site 3 IL - 6 variants complexed with IL - 6R alpha bind a single gp130 molecule but are unable to dimerize it , whereas the combined site 2 / 3 variants lose the ability to interact with gp130 .'
p10409
(lp10410
I24
a(lp10411
I47
atp10412
a(I-1
S'The binding properties of these variants in vitro , and the result of using a neutralizing monoclonal antibody directed against site 3 , lead to the conclusion that gp130 dimer is formed through direct binding at two independent and differently oriented sites on IL - 6 .'
p10413
(lp10414
I28
a(lp10415
I43
aI44
aI45
atp10416
a(I1
S'Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL - 6 , two IL - 6R alpha and two gp130 molecules .'
p10417
(lp10418
I14
aI15
aI16
a(lp10419
I19
aI20
aI21
aI22
atp10420
a(I1
S'Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL - 6 , two IL - 6R alpha and two gp130 molecules .'
p10421
(lp10422
I14
aI15
aI16
a(lp10423
I25
atp10424
a(I1
S'Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL - 6 , two IL - 6R alpha and two gp130 molecules .'
p10425
(lp10426
I19
aI20
aI21
aI22
a(lp10427
I25
atp10428
a(I1
S'Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation .'
p10429
(lp10430
I0
a(lp10431
I3
aI4
atp10432
a(I-1
S'The Ras and Raf1 proto - oncogenes transduce extracellular signals that promote cell growth .'
p10433
(lp10434
I1
a(lp10435
I3
atp10436
a(I1
S'We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes .'
p10437
(lp10438
I4
aI5
a(lp10439
I8
atp10440
a(I1
S'Furthermore , Cdc25 phosphatase can be activated in vitro in a Raf1 - dependent manner .'
p10441
(lp10442
I2
aI3
a(lp10443
I11
atp10444
a(I-1
S'We suggest that activation of the cell cycle by the Ras / Raf1 pathways might be mediated in part by Cdc25 .'
p10445
(lp10446
I10
a(lp10447
I12
atp10448
a(I-1
S'We suggest that activation of the cell cycle by the Ras / Raf1 pathways might be mediated in part by Cdc25 .'
p10449
(lp10450
I10
a(lp10451
I20
atp10452
a(I-1
S'We suggest that activation of the cell cycle by the Ras / Raf1 pathways might be mediated in part by Cdc25 .'
p10453
(lp10454
I12
a(lp10455
I20
atp10456
a(I1
S'A direct interaction between G - protein beta gamma subunits and the Raf - 1 protein kinase .'
p10457
(lp10458
I4
aI5
aI6
aI7
aI8
a(lp10459
I12
aI13
aI14
aI15
aI16
atp10460
a(I-1
S'Raf - 1 is a serine / threonine protein kinase positioned downstream of Ras in the mitogen - activated protein kinase cascade .'
p10461
(lp10462
I0
aI1
aI2
a(lp10463
I13
atp10464
a(I-1
S'Raf - 1 is a serine / threonine protein kinase positioned downstream of Ras in the mitogen - activated protein kinase cascade .'
p10465
(lp10466
I0
aI1
aI2
a(lp10467
I16
aI17
aI18
aI19
aI20
atp10468
a(I-1
S'Raf - 1 is a serine / threonine protein kinase positioned downstream of Ras in the mitogen - activated protein kinase cascade .'
p10469
(lp10470
I13
a(lp10471
I16
aI17
aI18
aI19
aI20
atp10472
a(I1
S'Using a yeast two - hybrid strategy to identify other proteins that interact with and potentially regulate Raf - 1 , we isolated a clone encoding the carboxyl - terminal half of the G beta 2 subunit of heterotrimeric G - proteins .'
p10473
(lp10474
I17
aI18
aI19
a(lp10475
I33
aI34
aI35
aI36
atp10476
a(I1
S'In vitro , purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1 - 330 of Raf - 1 ( Raf / 330 ) .'
p10477
(lp10478
I4
aI5
aI6
a(lp10479
I22
aI23
aI24
atp10480
a(I1
S'In vitro , purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1 - 330 of Raf - 1 ( Raf / 330 ) .'
p10481
(lp10482
I4
aI5
aI6
a(lp10483
I26
aI27
aI28
atp10484
a(I-1
S'In vitro , purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1 - 330 of Raf - 1 ( Raf / 330 ) .'
p10485
(lp10486
I22
aI23
aI24
a(lp10487
I26
aI27
aI28
atp10488
a(I-1
S'Binding assays with truncation mutants of GST - Raf indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with G beta gamma .'
p10489
(lp10490
I8
a(lp10491
I27
aI28
aI29
atp10492
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10493
(lp10494
I8
aI9
aI10
aI11
aI12
a(lp10495
I14
aI15
atp10496
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10497
(lp10498
I8
aI9
aI10
aI11
aI12
a(lp10499
I21
aI22
aI23
atp10500
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10501
(lp10502
I8
aI9
aI10
aI11
aI12
a(lp10503
I25
aI26
aI27
atp10504
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10505
(lp10506
I8
aI9
aI10
aI11
aI12
a(lp10507
I32
aI33
aI34
atp10508
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10509
(lp10510
I8
aI9
aI10
aI11
aI12
a(lp10511
I39
atp10512
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10513
(lp10514
I14
aI15
a(lp10515
I21
aI22
aI23
atp10516
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10517
(lp10518
I14
aI15
a(lp10519
I25
aI26
aI27
atp10520
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10521
(lp10522
I14
aI15
a(lp10523
I32
aI33
aI34
atp10524
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10525
(lp10526
I14
aI15
a(lp10527
I39
atp10528
a(I1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10529
(lp10530
I21
aI22
aI23
a(lp10531
I25
aI26
aI27
atp10532
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10533
(lp10534
I21
aI22
aI23
a(lp10535
I32
aI33
aI34
atp10536
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10537
(lp10538
I21
aI22
aI23
a(lp10539
I39
atp10540
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10541
(lp10542
I25
aI26
aI27
a(lp10543
I32
aI33
aI34
atp10544
a(I-1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10545
(lp10546
I25
aI26
aI27
a(lp10547
I39
atp10548
a(I1
S'In competition experiments , the carboxyl terminus of beta - adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf / 330 ; however , the Raf - 1 - binding proteins , Ras and 14 - 3 - 3 , had no effect .'
p10549
(lp10550
I32
aI33
aI34
a(lp10551
I39
atp10552
a(I1
S'Scatchard analysis of in vitro binding between Raf / 330 and G beta gamma revealed an affinity of interaction ( Kd = 163 + / - 36 nM ) , similar to that seen between G beta gamma and beta ARK ( Kd = 87 + / - 24 nM ) .'
p10553
(lp10554
I7
aI8
aI9
a(lp10555
I11
aI12
aI13
atp10556
a(I-1
S'Scatchard analysis of in vitro binding between Raf / 330 and G beta gamma revealed an affinity of interaction ( Kd = 163 + / - 36 nM ) , similar to that seen between G beta gamma and beta ARK ( Kd = 87 + / - 24 nM ) .'
p10557
(lp10558
I7
aI8
aI9
a(lp10559
I35
aI36
aI37
atp10560
a(I-1
S'Scatchard analysis of in vitro binding between Raf / 330 and G beta gamma revealed an affinity of interaction ( Kd = 163 + / - 36 nM ) , similar to that seen between G beta gamma and beta ARK ( Kd = 87 + / - 24 nM ) .'
p10561
(lp10562
I7
aI8
aI9
a(lp10563
I39
aI40
atp10564
a(I-1
S'Scatchard analysis of in vitro binding between Raf / 330 and G beta gamma revealed an affinity of interaction ( Kd = 163 + / - 36 nM ) , similar to that seen between G beta gamma and beta ARK ( Kd = 87 + / - 24 nM ) .'
p10565
(lp10566
I11
aI12
aI13
a(lp10567
I35
aI36
aI37
atp10568
a(I-1
S'Scatchard analysis of in vitro binding between Raf / 330 and G beta gamma revealed an affinity of interaction ( Kd = 163 + / - 36 nM ) , similar to that seen between G beta gamma and beta ARK ( Kd = 87 + / - 24 nM ) .'
p10569
(lp10570
I11
aI12
aI13
a(lp10571
I39
aI40
atp10572
a(I1
S'Scatchard analysis of in vitro binding between Raf / 330 and G beta gamma revealed an affinity of interaction ( Kd = 163 + / - 36 nM ) , similar to that seen between G beta gamma and beta ARK ( Kd = 87 + / - 24 nM ) .'
p10573
(lp10574
I35
aI36
aI37
a(lp10575
I39
aI40
atp10576
a(I-1
S'The formation of native heterotrimeric G alpha beta gamma complexes , as measured by pertussis toxin ADP - ribosylation of G alpha , could be disrupted by increasing amounts of Raf / 330 , with an EC50 of approximately 200 nM , in close agreement with the estimated binding affinity .'
p10577
(lp10578
I5
aI6
aI7
aI8
a(lp10579
I30
aI31
aI32
atp10580
a(I1
S'In vivo complexes of Raf - 1 and G beta gamma were isolated from human embryonic kidney 293 - T cells transfected with epitope - tagged G beta 2 .'
p10581
(lp10582
I4
aI5
aI6
a(lp10583
I8
aI9
aI10
atp10584
a(I-1
S'In vivo complexes of Raf - 1 and G beta gamma were isolated from human embryonic kidney 293 - T cells transfected with epitope - tagged G beta 2 .'
p10585
(lp10586
I4
aI5
aI6
a(lp10587
I26
aI27
aI28
atp10588
a(I-1
S'In vivo complexes of Raf - 1 and G beta gamma were isolated from human embryonic kidney 293 - T cells transfected with epitope - tagged G beta 2 .'
p10589
(lp10590
I8
aI9
aI10
a(lp10591
I26
aI27
aI28
atp10592
a(I1
S'p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60 .'
p10593
(lp10594
I0
a(lp10595
I6
atp10596
a(I1
S'p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60 .'
p10597
(lp10598
I0
a(lp10599
I8
atp10600
a(I-1
S'p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60 .'
p10601
(lp10602
I6
a(lp10603
I8
atp10604
a(I-1
S'The multisubunit transcription factor IID ( TFIID ) is thought to be a primary target for site - specific activators of transcription .'
p10605
(lp10606
I2
aI3
aI4
a(lp10607
I6
atp10608
a(I-1
S'Here , a direct interaction between the activation domain of p53 and two subunits of the TFIID complex , TAFII40 and TAFII60 , is reported .'
p10609
(lp10610
I10
a(lp10611
I16
atp10612
a(I1
S'Here , a direct interaction between the activation domain of p53 and two subunits of the TFIID complex , TAFII40 and TAFII60 , is reported .'
p10613
(lp10614
I10
a(lp10615
I19
atp10616
a(I1
S'Here , a direct interaction between the activation domain of p53 and two subunits of the TFIID complex , TAFII40 and TAFII60 , is reported .'
p10617
(lp10618
I10
a(lp10619
I21
atp10620
a(I-1
S'Here , a direct interaction between the activation domain of p53 and two subunits of the TFIID complex , TAFII40 and TAFII60 , is reported .'
p10621
(lp10622
I16
a(lp10623
I19
atp10624
a(I-1
S'Here , a direct interaction between the activation domain of p53 and two subunits of the TFIID complex , TAFII40 and TAFII60 , is reported .'
p10625
(lp10626
I16
a(lp10627
I21
atp10628
a(I-1
S'Here , a direct interaction between the activation domain of p53 and two subunits of the TFIID complex , TAFII40 and TAFII60 , is reported .'
p10629
(lp10630
I19
a(lp10631
I21
atp10632
a(I1
S'A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and , simultaneously , its ability to interact with both TAFII40 and TAFII60 .'
p10633
(lp10634
I9
a(lp10635
I29
atp10636
a(I1
S'A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and , simultaneously , its ability to interact with both TAFII40 and TAFII60 .'
p10637
(lp10638
I9
a(lp10639
I31
atp10640
a(I-1
S'A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and , simultaneously , its ability to interact with both TAFII40 and TAFII60 .'
p10641
(lp10642
I29
a(lp10643
I31
atp10644
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10645
(lp10646
I4
a(lp10647
I8
aI9
aI10
atp10648
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10649
(lp10650
I4
a(lp10651
I12
atp10652
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10653
(lp10654
I4
a(lp10655
I16
atp10656
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10657
(lp10658
I4
a(lp10659
I18
atp10660
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10661
(lp10662
I4
a(lp10663
I21
atp10664
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10665
(lp10666
I4
a(lp10667
I35
atp10668
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10669
(lp10670
I4
a(lp10671
I40
atp10672
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10673
(lp10674
I4
a(lp10675
I42
atp10676
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10677
(lp10678
I8
aI9
aI10
a(lp10679
I12
atp10680
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10681
(lp10682
I8
aI9
aI10
a(lp10683
I16
atp10684
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10685
(lp10686
I8
aI9
aI10
a(lp10687
I18
atp10688
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10689
(lp10690
I8
aI9
aI10
a(lp10691
I21
atp10692
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10693
(lp10694
I8
aI9
aI10
a(lp10695
I35
atp10696
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10697
(lp10698
I8
aI9
aI10
a(lp10699
I40
atp10700
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10701
(lp10702
I8
aI9
aI10
a(lp10703
I42
atp10704
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10705
(lp10706
I12
a(lp10707
I16
atp10708
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10709
(lp10710
I12
a(lp10711
I18
atp10712
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10713
(lp10714
I12
a(lp10715
I21
atp10716
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10717
(lp10718
I12
a(lp10719
I35
atp10720
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10721
(lp10722
I12
a(lp10723
I40
atp10724
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10725
(lp10726
I12
a(lp10727
I42
atp10728
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10729
(lp10730
I16
a(lp10731
I18
atp10732
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10733
(lp10734
I16
a(lp10735
I21
atp10736
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10737
(lp10738
I16
a(lp10739
I35
atp10740
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10741
(lp10742
I16
a(lp10743
I40
atp10744
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10745
(lp10746
I16
a(lp10747
I42
atp10748
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10749
(lp10750
I18
a(lp10751
I21
atp10752
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10753
(lp10754
I18
a(lp10755
I35
atp10756
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10757
(lp10758
I18
a(lp10759
I40
atp10760
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10761
(lp10762
I18
a(lp10763
I42
atp10764
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10765
(lp10766
I21
a(lp10767
I35
atp10768
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10769
(lp10770
I21
a(lp10771
I40
atp10772
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10773
(lp10774
I21
a(lp10775
I42
atp10776
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10777
(lp10778
I35
a(lp10779
I40
atp10780
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10781
(lp10782
I35
a(lp10783
I42
atp10784
a(I-1
S'Furthermore , a partial TFIID complex containing Drosophila TATA binding protein ( dTBP ) , human TAFII250 , dTAFII60 , and dTAFII40 supported activation by a Gal4 - p53 fusion protein in vitro , whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not .'
p10785
(lp10786
I40
a(lp10787
I42
atp10788
a(I-1
S'Together , these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex .'
p10789
(lp10790
I6
a(lp10791
I8
atp10792
a(I1
S'Together , these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex .'
p10793
(lp10794
I6
a(lp10795
I17
atp10796
a(I1
S'Together , these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex .'
p10797
(lp10798
I8
a(lp10799
I17
atp10800
a(I1
S'Crystal structure of the heterodimeric bZIP transcription factor c - Fos - c - Jun bound to DNA .'
p10801
(lp10802
I8
aI9
aI10
a(lp10803
I12
aI13
aI14
atp10804
a(I1
S"The Fos and Jun families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5 ' - TGAGTCA - 3 ' DNA elements ."
p10805
(lp10806
I1
a(lp10807
I3
atp10808
a(I1
S'We have determined the X - ray crystal structure of a heterodimer of the bZIP regions of c - Fos and c - Jun bound to DNA .'
p10809
(lp10810
I17
aI18
aI19
a(lp10811
I21
aI22
aI23
atp10812
a(I1
S"Comparison of the two crystallographically distinct protein - DNA complexes show that the coiled - coil is flexibly joined to the basic regions and that the Fos - Jun heterodimer does not recognize the asymmetric 5 ' - TGAGTCA - 3 ' recognition element in a unique orientation ."
p10813
(lp10814
I26
a(lp10815
I28
atp10816
a(I-1
S'TFIID is a multisubunit protein complex comprised of the TATA - binding protein ( TBP ) and multiple TBP - associated factors ( TAFs ) .'
p10817
(lp10818
I0
a(lp10819
I9
aI10
aI11
aI12
atp10820
a(I-1
S'TFIID is a multisubunit protein complex comprised of the TATA - binding protein ( TBP ) and multiple TBP - associated factors ( TAFs ) .'
p10821
(lp10822
I0
a(lp10823
I14
atp10824
a(I-1
S'TFIID is a multisubunit protein complex comprised of the TATA - binding protein ( TBP ) and multiple TBP - associated factors ( TAFs ) .'
p10825
(lp10826
I9
aI10
aI11
aI12
a(lp10827
I14
atp10828
a(I-1
S'The cloning of a complementary DNA encoding a human TFIID TAF , TAFII55 , that has no known homolog in Drosophila TFIID is now described .'
p10829
(lp10830
I9
a(lp10831
I12
atp10832
a(I-1
S'The cloning of a complementary DNA encoding a human TFIID TAF , TAFII55 , that has no known homolog in Drosophila TFIID is now described .'
p10833
(lp10834
I9
a(lp10835
I21
atp10836
a(I-1
S'The cloning of a complementary DNA encoding a human TFIID TAF , TAFII55 , that has no known homolog in Drosophila TFIID is now described .'
p10837
(lp10838
I12
a(lp10839
I21
atp10840
a(I1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10841
(lp10842
I0
a(lp10843
I10
atp10844
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10845
(lp10846
I0
a(lp10847
I14
atp10848
a(I1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10849
(lp10850
I0
a(lp10851
I26
atp10852
a(I1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10853
(lp10854
I0
a(lp10855
I28
atp10856
a(I1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10857
(lp10858
I0
a(lp10859
I30
atp10860
a(I1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10861
(lp10862
I0
a(lp10863
I32
atp10864
a(I1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10865
(lp10866
I0
a(lp10867
I35
atp10868
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10869
(lp10870
I0
a(lp10871
I44
atp10872
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10873
(lp10874
I10
a(lp10875
I14
atp10876
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10877
(lp10878
I10
a(lp10879
I26
atp10880
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10881
(lp10882
I10
a(lp10883
I28
atp10884
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10885
(lp10886
I10
a(lp10887
I30
atp10888
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10889
(lp10890
I10
a(lp10891
I32
atp10892
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10893
(lp10894
I10
a(lp10895
I35
atp10896
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10897
(lp10898
I10
a(lp10899
I44
atp10900
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10901
(lp10902
I14
a(lp10903
I26
atp10904
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10905
(lp10906
I14
a(lp10907
I28
atp10908
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10909
(lp10910
I14
a(lp10911
I30
atp10912
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10913
(lp10914
I14
a(lp10915
I32
atp10916
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10917
(lp10918
I14
a(lp10919
I35
atp10920
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10921
(lp10922
I14
a(lp10923
I44
atp10924
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10925
(lp10926
I26
a(lp10927
I28
atp10928
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10929
(lp10930
I26
a(lp10931
I30
atp10932
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10933
(lp10934
I26
a(lp10935
I32
atp10936
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10937
(lp10938
I26
a(lp10939
I35
atp10940
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10941
(lp10942
I26
a(lp10943
I44
atp10944
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10945
(lp10946
I28
a(lp10947
I30
atp10948
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10949
(lp10950
I28
a(lp10951
I32
atp10952
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10953
(lp10954
I28
a(lp10955
I35
atp10956
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10957
(lp10958
I28
a(lp10959
I44
atp10960
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10961
(lp10962
I30
a(lp10963
I32
atp10964
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10965
(lp10966
I30
a(lp10967
I35
atp10968
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10969
(lp10970
I30
a(lp10971
I44
atp10972
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10973
(lp10974
I32
a(lp10975
I35
atp10976
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10977
(lp10978
I32
a(lp10979
I44
atp10980
a(I-1
S'TAFII55 is shown to interact with the largest subunit ( TAFII230 ) of human TFIID through its central region and with multiple activators - - including Sp1 , YY1 , USF , CTF , adenoviral E1A , and human immunodeficiency virus - type 1 Tat proteins - - through a distinct amino - terminal domain .'
p10981
(lp10982
I35
a(lp10983
I44
atp10984
a(I1
S'The TAFII55 - interacting region of Sp1 was localized to its DNA - binding domain , which is distinct from the glutamine - rich activation domains previously shown to interact with Drosophila TAFII110 .'
p10985
(lp10986
I1
a(lp10987
I6
atp10988
a(I-1
S'The TAFII55 - interacting region of Sp1 was localized to its DNA - binding domain , which is distinct from the glutamine - rich activation domains previously shown to interact with Drosophila TAFII110 .'
p10989
(lp10990
I1
a(lp10991
I32
atp10992
a(I1
S'The TAFII55 - interacting region of Sp1 was localized to its DNA - binding domain , which is distinct from the glutamine - rich activation domains previously shown to interact with Drosophila TAFII110 .'
p10993
(lp10994
I6
a(lp10995
I32
atp10996
a(I-1
S'Mutagenesis of the regulatory subunit ( RII beta ) of cAMP - dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and / or anchoring RII beta to the cytoskeleton .'
p10997
(lp10998
I6
aI7
a(lp10999
I10
aI11
aI12
aI13
aI14
aI15
aI16
atp11000
a(I-1
S'Mutagenesis of the regulatory subunit ( RII beta ) of cAMP - dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and / or anchoring RII beta to the cytoskeleton .'
p11001
(lp11002
I6
aI7
a(lp11003
I25
aI26
atp11004
a(I-1
S'Mutagenesis of the regulatory subunit ( RII beta ) of cAMP - dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and / or anchoring RII beta to the cytoskeleton .'
p11005
(lp11006
I6
aI7
a(lp11007
I32
aI33
atp11008
a(I-1
S'Mutagenesis of the regulatory subunit ( RII beta ) of cAMP - dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and / or anchoring RII beta to the cytoskeleton .'
p11009
(lp11010
I10
aI11
aI12
aI13
aI14
aI15
aI16
a(lp11011
I25
aI26
atp11012
a(I-1
S'Mutagenesis of the regulatory subunit ( RII beta ) of cAMP - dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and / or anchoring RII beta to the cytoskeleton .'
p11013
(lp11014
I10
aI11
aI12
aI13
aI14
aI15
aI16
a(lp11015
I32
aI33
atp11016
a(I-1
S'Mutagenesis of the regulatory subunit ( RII beta ) of cAMP - dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and / or anchoring RII beta to the cytoskeleton .'
p11017
(lp11018
I25
aI26
a(lp11019
I32
aI33
atp11020
a(I-1
S'In neurons cAMP - dependent protein kinase II beta ( PKAII beta ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( RII beta ) of the enzyme is tightly bound by A Kinase Anchor Proteins ( AKAPs ) .'
p11021
(lp11022
I2
aI3
aI4
aI5
aI6
aI7
aI8
a(lp11023
I10
aI11
atp11024
a(I-1
S'In neurons cAMP - dependent protein kinase II beta ( PKAII beta ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( RII beta ) of the enzyme is tightly bound by A Kinase Anchor Proteins ( AKAPs ) .'
p11025
(lp11026
I2
aI3
aI4
aI5
aI6
aI7
aI8
a(lp11027
I24
aI25
atp11028
a(I-1
S'In neurons cAMP - dependent protein kinase II beta ( PKAII beta ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( RII beta ) of the enzyme is tightly bound by A Kinase Anchor Proteins ( AKAPs ) .'
p11029
(lp11030
I10
aI11
a(lp11031
I24
aI25
atp11032
a(I1
S'The prototypic neuronal anchor protein AKAP75 has a COOH - terminal 22 - residue RII beta binding ( tethering ) site .'
p11033
(lp11034
I5
a(lp11035
I14
aI15
atp11036
a(I1
S'Mutagenesis , recombinant protein expression , and physicochemical characterization were used to investigate the structural basis for the homodimerization and AKAP75 binding activities of RII beta .'
p11037
(lp11038
I20
a(lp11039
I24
aI25
atp11040
a(I-1
S'Substitution of Ala for Leu13 or Phe36 generates monomeric RII beta subunits that cannot bind AKAP75 .'
p11041
(lp11042
I9
aI10
a(lp11043
I15
atp11044
a(I-1
S'The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild - type RII beta dimers .'
p11045
(lp11046
I10
aI11
a(lp11047
I21
aI22
atp11048
a(I-1
S'The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild - type RII beta dimers .'
p11049
(lp11050
I10
aI11
a(lp11051
I33
aI34
atp11052
a(I-1
S'The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild - type RII beta dimers .'
p11053
(lp11054
I21
aI22
a(lp11055
I33
aI34
atp11056
a(I1
S'Evidently , large hydrophobic side chains of Leu13 and Phe36 play pivotal roles in stabilizing RII beta - RII beta interactions .'
p11057
(lp11058
I15
aI16
a(lp11059
I18
aI19
atp11060
a(I-1
S'A secondary consequence of destabilizing RII beta dimers is the loss of intracellular targeting / anchoring capacity because monomers fail to bind AKAP75 .'
p11061
(lp11062
I5
aI6
a(lp11063
I22
atp11064
a(I1
S'Other NH2 - terminal residues directly modulate the affinity of RII beta dimers for the AKAP75 tethering site .'
p11065
(lp11066
I10
aI11
a(lp11067
I15
atp11068
a(I1
S'Replacement of Val20 - Leu21 with Ala - Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4 % as avidly as wild - type RII beta .'
p11069
(lp11070
I12
aI13
a(lp11071
I17
atp11072
a(I-1
S'Replacement of Val20 - Leu21 with Ala - Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4 % as avidly as wild - type RII beta .'
p11073
(lp11074
I12
aI13
a(lp11075
I27
aI28
atp11076
a(I-1
S'Replacement of Val20 - Leu21 with Ala - Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4 % as avidly as wild - type RII beta .'
p11077
(lp11078
I17
a(lp11079
I27
aI28
atp11080
a(I1
S'Human spleen tyrosine kinase p72Syk associates with the Src - family kinase p53 / 56Lyn and a 120 - kDa phosphoprotein .'
p11081
(lp11082
I4
a(lp11083
I12
atp11084
a(I1
S'Human spleen tyrosine kinase p72Syk associates with the Src - family kinase p53 / 56Lyn and a 120 - kDa phosphoprotein .'
p11085
(lp11086
I4
a(lp11087
I14
atp11088
a(I1
S'Human spleen tyrosine kinase p72Syk associates with the Src - family kinase p53 / 56Lyn and a 120 - kDa phosphoprotein .'
p11089
(lp11090
I4
a(lp11091
I17
aI18
aI19
aI20
atp11092
a(I-1
S'Human spleen tyrosine kinase p72Syk associates with the Src - family kinase p53 / 56Lyn and a 120 - kDa phosphoprotein .'
p11093
(lp11094
I12
a(lp11095
I14
atp11096
a(I-1
S'Human spleen tyrosine kinase p72Syk associates with the Src - family kinase p53 / 56Lyn and a 120 - kDa phosphoprotein .'
p11097
(lp11098
I12
a(lp11099
I17
aI18
aI19
aI20
atp11100
a(I-1
S'Human spleen tyrosine kinase p72Syk associates with the Src - family kinase p53 / 56Lyn and a 120 - kDa phosphoprotein .'
p11101
(lp11102
I14
a(lp11103
I17
aI18
aI19
aI20
atp11104
a(I-1
S'The 72 - kDa spleen tyrosine kinase ( Syk ) and Src - family kinase p53 / 56Lyn ( Lyn ) contribute to signaling via the B - cell antigen receptor complex .'
p11105
(lp11106
I8
a(lp11107
I15
atp11108
a(I-1
S'The 72 - kDa spleen tyrosine kinase ( Syk ) and Src - family kinase p53 / 56Lyn ( Lyn ) contribute to signaling via the B - cell antigen receptor complex .'
p11109
(lp11110
I8
a(lp11111
I17
atp11112
a(I-1
S'The 72 - kDa spleen tyrosine kinase ( Syk ) and Src - family kinase p53 / 56Lyn ( Lyn ) contribute to signaling via the B - cell antigen receptor complex .'
p11113
(lp11114
I8
a(lp11115
I19
atp11116
a(I-1
S'The 72 - kDa spleen tyrosine kinase ( Syk ) and Src - family kinase p53 / 56Lyn ( Lyn ) contribute to signaling via the B - cell antigen receptor complex .'
p11117
(lp11118
I15
a(lp11119
I17
atp11120
a(I-1
S'The 72 - kDa spleen tyrosine kinase ( Syk ) and Src - family kinase p53 / 56Lyn ( Lyn ) contribute to signaling via the B - cell antigen receptor complex .'
p11121
(lp11122
I15
a(lp11123
I19
atp11124
a(I-1
S'The 72 - kDa spleen tyrosine kinase ( Syk ) and Src - family kinase p53 / 56Lyn ( Lyn ) contribute to signaling via the B - cell antigen receptor complex .'
p11125
(lp11126
I17
a(lp11127
I19
atp11128
a(I1
S'Here we show that Syk and Lyn from human B lymphocytes can interact directly .'
p11129
(lp11130
I4
a(lp11131
I6
atp11132
a(I1
S'Syk and Lyn coimmunoprecipitated from mature and activated B - cell lines , and gel - purified Syk and Lyn reassociated in vitro , demonstrating their direct interaction .'
p11133
(lp11134
I0
a(lp11135
I2
atp11136
a(I-1
S'Syk and Lyn coimmunoprecipitated from mature and activated B - cell lines , and gel - purified Syk and Lyn reassociated in vitro , demonstrating their direct interaction .'
p11137
(lp11138
I0
a(lp11139
I17
atp11140
a(I-1
S'Syk and Lyn coimmunoprecipitated from mature and activated B - cell lines , and gel - purified Syk and Lyn reassociated in vitro , demonstrating their direct interaction .'
p11141
(lp11142
I0
a(lp11143
I19
atp11144
a(I-1
S'Syk and Lyn coimmunoprecipitated from mature and activated B - cell lines , and gel - purified Syk and Lyn reassociated in vitro , demonstrating their direct interaction .'
p11145
(lp11146
I2
a(lp11147
I17
atp11148
a(I-1
S'Syk and Lyn coimmunoprecipitated from mature and activated B - cell lines , and gel - purified Syk and Lyn reassociated in vitro , demonstrating their direct interaction .'
p11149
(lp11150
I2
a(lp11151
I19
atp11152
a(I1
S'Syk and Lyn coimmunoprecipitated from mature and activated B - cell lines , and gel - purified Syk and Lyn reassociated in vitro , demonstrating their direct interaction .'
p11153
(lp11154
I17
a(lp11155
I19
atp11156
a(I1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11157
(lp11158
I1
a(lp11159
I3
atp11160
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11161
(lp11162
I1
a(lp11163
I18
atp11164
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11165
(lp11166
I1
a(lp11167
I20
atp11168
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11169
(lp11170
I1
a(lp11171
I34
atp11172
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11173
(lp11174
I1
a(lp11175
I46
atp11176
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11177
(lp11178
I3
a(lp11179
I18
atp11180
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11181
(lp11182
I3
a(lp11183
I20
atp11184
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11185
(lp11186
I3
a(lp11187
I34
atp11188
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11189
(lp11190
I3
a(lp11191
I46
atp11192
a(I1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11193
(lp11194
I18
a(lp11195
I20
atp11196
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11197
(lp11198
I18
a(lp11199
I34
atp11200
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11201
(lp11202
I18
a(lp11203
I46
atp11204
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11205
(lp11206
I20
a(lp11207
I34
atp11208
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11209
(lp11210
I20
a(lp11211
I46
atp11212
a(I-1
S'This Syk - Lyn interaction may be dependent on the stage of B - cell differentiation , since Syk - Lyn associations were not detected in pre - B and myeloma cell lines and Syk from an immature B - cell line did not reassociate with Lyn in vitro .'
p11213
(lp11214
I34
a(lp11215
I46
atp11216
a(I-1
S'Crosslinking of cell surface IgM led to rapid activation of both tyrosine and serine / threonine protein kinase activities that resulted in phosphorylation in vitro of proteins coprecipitating with Syk - - in particular , a serine / threonine phosphorylated protein 120 kDa in size ( pp120 ) .'
p11217
(lp11218
I29
a(lp11219
I46
atp11220
a(I-1
S'Several phosphoproteins , including one of 72 kDa and one of 120 kDa , coprecipitated with phospholipase C - gamma 1 ( PLC gamma 1 ) .'
p11221
(lp11222
I16
aI17
aI18
aI19
aI20
a(lp11223
I22
aI23
aI24
atp11224
a(I1
S'Sequential immunoprecipitation identified the 72 - kDa protein associated with PLC gamma 1 as Syk .'
p11225
(lp11226
I10
aI11
aI12
a(lp11227
I14
atp11228
a(I-1
S'The 120 - kDa serine / threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk - associated pp120 by several criteria .'
p11229
(lp11230
I12
aI13
aI14
a(lp11231
I17
atp11232
a(I-1
S'The 120 - kDa serine / threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk - associated pp120 by several criteria .'
p11233
(lp11234
I12
aI13
aI14
a(lp11235
I20
atp11236
a(I1
S'The 120 - kDa serine / threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk - associated pp120 by several criteria .'
p11237
(lp11238
I17
a(lp11239
I20
atp11240
a(I1
S'Thus , pp120 may serve as a link between Syk and PLC gamma 1 , coupling the B - cell antigen receptor to the phosphatidylinositol pathway .'
p11241
(lp11242
I2
a(lp11243
I9
atp11244
a(I1
S'Thus , pp120 may serve as a link between Syk and PLC gamma 1 , coupling the B - cell antigen receptor to the phosphatidylinositol pathway .'
p11245
(lp11246
I2
a(lp11247
I11
aI12
aI13
atp11248
a(I1
S'Thus , pp120 may serve as a link between Syk and PLC gamma 1 , coupling the B - cell antigen receptor to the phosphatidylinositol pathway .'
p11249
(lp11250
I9
a(lp11251
I11
aI12
aI13
atp11252
a(I1
S'Cloning and functional analysis of BAG - 1 : a novel Bcl - 2 - binding protein with anti - cell death activity .'
p11253
(lp11254
I5
aI6
aI7
a(lp11255
I11
aI12
aI13
atp11256
a(I-1
S'Cloning and functional analysis of BAG - 1 : a novel Bcl - 2 - binding protein with anti - cell death activity .'
p11257
(lp11258
I5
aI6
aI7
a(lp11259
I11
aI12
aI13
aI14
aI15
aI16
atp11260
a(I-1
S'Cloning and functional analysis of BAG - 1 : a novel Bcl - 2 - binding protein with anti - cell death activity .'
p11261
(lp11262
I11
aI12
aI13
a(lp11263
I11
aI12
aI13
aI14
aI15
aI16
atp11264
a(I-1
S'Using a protein interaction cloning technique , we identified cDNAs that encode a novel Bcl - 2 - binding protein , termed BAG - 1 .'
p11265
(lp11266
I14
aI15
aI16
a(lp11267
I14
aI15
aI16
aI17
aI18
aI19
atp11268
a(I1
S'Using a protein interaction cloning technique , we identified cDNAs that encode a novel Bcl - 2 - binding protein , termed BAG - 1 .'
p11269
(lp11270
I14
aI15
aI16
a(lp11271
I22
aI23
aI24
atp11272
a(I-1
S'Using a protein interaction cloning technique , we identified cDNAs that encode a novel Bcl - 2 - binding protein , termed BAG - 1 .'
p11273
(lp11274
I14
aI15
aI16
aI17
aI18
aI19
a(lp11275
I22
aI23
aI24
atp11276
a(I-1
S'The BAG - 1 protein shares no significant homology with Bcl - 2 or other Bcl - 2 family proteins , which can form homo - and heterodimers .'
p11277
(lp11278
I1
aI2
aI3
a(lp11279
I10
aI11
aI12
atp11280
a(I-1
S'The BAG - 1 protein shares no significant homology with Bcl - 2 or other Bcl - 2 family proteins , which can form homo - and heterodimers .'
p11281
(lp11282
I1
aI2
aI3
a(lp11283
I15
aI16
aI17
atp11284
a(I-1
S'The BAG - 1 protein shares no significant homology with Bcl - 2 or other Bcl - 2 family proteins , which can form homo - and heterodimers .'
p11285
(lp11286
I10
aI11
aI12
a(lp11287
I15
aI16
aI17
atp11288
a(I-1
S'In gene transfer experiments using a human lymphoid cell line , Jurkat , coexpression of BAG - 1 and Bcl - 2 provided markedly increased protection from cell death induced by several stimuli , including staurosporine , anti - Fas antibody , and cytolytic T cells , relative to cells that contained gene transfer - mediated elevations in either BAG - 1 or Bcl - 2 protein alone .'
p11289
(lp11290
I15
aI16
aI17
a(lp11291
I19
aI20
aI21
atp11292
a(I-1
S'In gene transfer experiments using a human lymphoid cell line , Jurkat , coexpression of BAG - 1 and Bcl - 2 provided markedly increased protection from cell death induced by several stimuli , including staurosporine , anti - Fas antibody , and cytolytic T cells , relative to cells that contained gene transfer - mediated elevations in either BAG - 1 or Bcl - 2 protein alone .'
p11293
(lp11294
I15
aI16
aI17
a(lp11295
I59
aI60
aI61
atp11296
a(I-1
S'In gene transfer experiments using a human lymphoid cell line , Jurkat , coexpression of BAG - 1 and Bcl - 2 provided markedly increased protection from cell death induced by several stimuli , including staurosporine , anti - Fas antibody , and cytolytic T cells , relative to cells that contained gene transfer - mediated elevations in either BAG - 1 or Bcl - 2 protein alone .'
p11297
(lp11298
I15
aI16
aI17
a(lp11299
I63
aI64
aI65
atp11300
a(I-1
S'In gene transfer experiments using a human lymphoid cell line , Jurkat , coexpression of BAG - 1 and Bcl - 2 provided markedly increased protection from cell death induced by several stimuli , including staurosporine , anti - Fas antibody , and cytolytic T cells , relative to cells that contained gene transfer - mediated elevations in either BAG - 1 or Bcl - 2 protein alone .'
p11301
(lp11302
I19
aI20
aI21
a(lp11303
I59
aI60
aI61
atp11304
a(I-1
S'In gene transfer experiments using a human lymphoid cell line , Jurkat , coexpression of BAG - 1 and Bcl - 2 provided markedly increased protection from cell death induced by several stimuli , including staurosporine , anti - Fas antibody , and cytolytic T cells , relative to cells that contained gene transfer - mediated elevations in either BAG - 1 or Bcl - 2 protein alone .'
p11305
(lp11306
I19
aI20
aI21
a(lp11307
I63
aI64
aI65
atp11308
a(I-1
S'In gene transfer experiments using a human lymphoid cell line , Jurkat , coexpression of BAG - 1 and Bcl - 2 provided markedly increased protection from cell death induced by several stimuli , including staurosporine , anti - Fas antibody , and cytolytic T cells , relative to cells that contained gene transfer - mediated elevations in either BAG - 1 or Bcl - 2 protein alone .'
p11309
(lp11310
I59
aI60
aI61
a(lp11311
I63
aI64
aI65
atp11312
a(I-1
S'The findings indicate that bag - 1 represents a new type of anti - cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl - 2 - independent pathways may instead reflect a need for the combination of Bcl - 2 and BAG - 1 .'
p11313
(lp11314
I28
aI29
aI30
a(lp11315
I43
aI44
aI45
atp11316
a(I-1
S'The findings indicate that bag - 1 represents a new type of anti - cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl - 2 - independent pathways may instead reflect a need for the combination of Bcl - 2 and BAG - 1 .'
p11317
(lp11318
I28
aI29
aI30
a(lp11319
I47
aI48
aI49
atp11320
a(I-1
S'The findings indicate that bag - 1 represents a new type of anti - cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl - 2 - independent pathways may instead reflect a need for the combination of Bcl - 2 and BAG - 1 .'
p11321
(lp11322
I43
aI44
aI45
a(lp11323
I47
aI48
aI49
atp11324
a(I-1
S'Syntrophin binds to an alternatively spliced exon of dystrophin .'
p11325
(lp11326
I0
a(lp11327
I8
atp11328
a(I-1
S'We expressed the cDNA of human beta 1 - syntrophin and the COOH terminus of human dystrophin in reticulocyte lysates using an in vitro transcription / translation system .'
p11329
(lp11330
I6
aI7
aI8
aI9
a(lp11331
I16
atp11332
a(I1
S'We demonstrate that the 53 amino acids encoded on exon 74 of dystrophin , an alternatively spliced exon , are necessary and sufficient for interaction with translated beta 1 - syntrophin in our assay .'
p11333
(lp11334
I12
a(lp11335
I27
aI28
aI29
aI30
atp11336
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11337
(lp11338
I7
a(lp11339
I11
atp11340
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11341
(lp11342
I7
a(lp11343
I11
aI12
aI13
atp11344
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11345
(lp11346
I7
a(lp11347
I15
atp11348
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11349
(lp11350
I7
a(lp11351
I17
atp11352
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11353
(lp11354
I7
a(lp11355
I21
aI22
aI23
atp11356
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11357
(lp11358
I7
a(lp11359
I33
aI34
aI35
aI36
atp11360
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11361
(lp11362
I11
a(lp11363
I11
aI12
aI13
atp11364
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11365
(lp11366
I11
a(lp11367
I15
atp11368
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11369
(lp11370
I11
a(lp11371
I17
atp11372
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11373
(lp11374
I11
a(lp11375
I21
aI22
aI23
atp11376
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11377
(lp11378
I11
a(lp11379
I33
aI34
aI35
aI36
atp11380
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11381
(lp11382
I11
aI12
aI13
a(lp11383
I15
atp11384
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11385
(lp11386
I11
aI12
aI13
a(lp11387
I17
atp11388
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11389
(lp11390
I11
aI12
aI13
a(lp11391
I21
aI22
aI23
atp11392
a(I1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11393
(lp11394
I11
aI12
aI13
a(lp11395
I33
aI34
aI35
aI36
atp11396
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11397
(lp11398
I15
a(lp11399
I17
atp11400
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11401
(lp11402
I15
a(lp11403
I21
aI22
aI23
atp11404
a(I1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11405
(lp11406
I15
a(lp11407
I33
aI34
aI35
aI36
atp11408
a(I-1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11409
(lp11410
I17
a(lp11411
I21
aI22
aI23
atp11412
a(I1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11413
(lp11414
I17
a(lp11415
I33
aI34
aI35
aI36
atp11416
a(I1
S'In this recombinant expression system , the dystrophin relatives , human dystrophin related protein ( DRP or utrophin ) and the 87K postsynaptic protein from Torpedo electric organ , also bind to translated beta 1 - syntrophin .'
p11417
(lp11418
I21
aI22
aI23
a(lp11419
I33
aI34
aI35
aI36
atp11420
a(I1
S'We have found a COOH - terminal 37 - kD fragment of beta 1 - syntrophin sufficient to interact with translated dystrophin and its homologues , suggesting that the dystrophin binding site on beta 1 - syntrophin occurs on a region that is conserved among the three syntrophin homologues .'
p11421
(lp11422
I12
aI13
aI14
aI15
a(lp11423
I21
atp11424
a(I-1
S'We have found a COOH - terminal 37 - kD fragment of beta 1 - syntrophin sufficient to interact with translated dystrophin and its homologues , suggesting that the dystrophin binding site on beta 1 - syntrophin occurs on a region that is conserved among the three syntrophin homologues .'
p11425
(lp11426
I12
aI13
aI14
aI15
a(lp11427
I29
atp11428
a(I-1
S'We have found a COOH - terminal 37 - kD fragment of beta 1 - syntrophin sufficient to interact with translated dystrophin and its homologues , suggesting that the dystrophin binding site on beta 1 - syntrophin occurs on a region that is conserved among the three syntrophin homologues .'
p11429
(lp11430
I12
aI13
aI14
aI15
a(lp11431
I33
aI34
aI35
aI36
atp11432
a(I-1
S'We have found a COOH - terminal 37 - kD fragment of beta 1 - syntrophin sufficient to interact with translated dystrophin and its homologues , suggesting that the dystrophin binding site on beta 1 - syntrophin occurs on a region that is conserved among the three syntrophin homologues .'
p11433
(lp11434
I21
a(lp11435
I29
atp11436
a(I-1
S'We have found a COOH - terminal 37 - kD fragment of beta 1 - syntrophin sufficient to interact with translated dystrophin and its homologues , suggesting that the dystrophin binding site on beta 1 - syntrophin occurs on a region that is conserved among the three syntrophin homologues .'
p11437
(lp11438
I21
a(lp11439
I33
aI34
aI35
aI36
atp11440
a(I1
S'We have found a COOH - terminal 37 - kD fragment of beta 1 - syntrophin sufficient to interact with translated dystrophin and its homologues , suggesting that the dystrophin binding site on beta 1 - syntrophin occurs on a region that is conserved among the three syntrophin homologues .'
p11441
(lp11442
I29
a(lp11443
I33
aI34
aI35
aI36
atp11444
a(I-1
S'Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor .'
p11445
(lp11446
I2
a(lp11447
I5
atp11448
a(I1
S'Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor .'
p11449
(lp11450
I2
a(lp11451
I12
aI13
aI14
atp11452
a(I-1
S'Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor .'
p11453
(lp11454
I5
a(lp11455
I12
aI13
aI14
atp11456
a(I-1
S'A few general transcription factors , in particular TFIID and TFIIB , have been found to bind transcriptional activators .'
p11457
(lp11458
I8
a(lp11459
I10
atp11460
a(I-1
S'Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator , namely serum response factor ( SRF ) , which binds to the c - fos promoter .'
p11461
(lp11462
I8
a(lp11463
I19
aI20
aI21
atp11464
a(I-1
S'Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator , namely serum response factor ( SRF ) , which binds to the c - fos promoter .'
p11465
(lp11466
I8
a(lp11467
I23
atp11468
a(I-1
S'Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator , namely serum response factor ( SRF ) , which binds to the c - fos promoter .'
p11469
(lp11470
I8
a(lp11471
I30
aI31
aI32
atp11472
a(I-1
S'Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator , namely serum response factor ( SRF ) , which binds to the c - fos promoter .'
p11473
(lp11474
I19
aI20
aI21
a(lp11475
I23
atp11476
a(I-1
S'Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator , namely serum response factor ( SRF ) , which binds to the c - fos promoter .'
p11477
(lp11478
I19
aI20
aI21
a(lp11479
I30
aI31
aI32
atp11480
a(I-1
S'Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator , namely serum response factor ( SRF ) , which binds to the c - fos promoter .'
p11481
(lp11482
I23
a(lp11483
I30
aI31
aI32
atp11484
a(I1
S"Using a yeast interaction assay , we find that SRF binds the RAP74 subunit of TFIIF and that SRF ' s transcriptional activation domain is the region involved in this binding ."
p11485
(lp11486
I9
a(lp11487
I12
atp11488
a(I-1
S"Using a yeast interaction assay , we find that SRF binds the RAP74 subunit of TFIIF and that SRF ' s transcriptional activation domain is the region involved in this binding ."
p11489
(lp11490
I9
a(lp11491
I15
atp11492
a(I-1
S"Using a yeast interaction assay , we find that SRF binds the RAP74 subunit of TFIIF and that SRF ' s transcriptional activation domain is the region involved in this binding ."
p11493
(lp11494
I9
a(lp11495
I18
atp11496
a(I-1
S"Using a yeast interaction assay , we find that SRF binds the RAP74 subunit of TFIIF and that SRF ' s transcriptional activation domain is the region involved in this binding ."
p11497
(lp11498
I12
a(lp11499
I15
atp11500
a(I-1
S"Using a yeast interaction assay , we find that SRF binds the RAP74 subunit of TFIIF and that SRF ' s transcriptional activation domain is the region involved in this binding ."
p11501
(lp11502
I12
a(lp11503
I18
atp11504
a(I-1
S"Using a yeast interaction assay , we find that SRF binds the RAP74 subunit of TFIIF and that SRF ' s transcriptional activation domain is the region involved in this binding ."
p11505
(lp11506
I15
a(lp11507
I18
atp11508
a(I-1
S"Further , RAP74 ' s central charged cluster domain is required for binding to SRF ' s activation domain ."
p11509
(lp11510
I2
a(lp11511
I14
atp11512
a(I-1
S"Deletion of this domain impairs RAP74 ' s ability to support SRF - activated transcription in vitro but has little effect on the protein ' s basal transcription activity or its ability to support SP1 - activated transcription ."
p11513
(lp11514
I5
a(lp11515
I11
atp11516
a(I-1
S"Deletion of this domain impairs RAP74 ' s ability to support SRF - activated transcription in vitro but has little effect on the protein ' s basal transcription activity or its ability to support SP1 - activated transcription ."
p11517
(lp11518
I5
a(lp11519
I34
atp11520
a(I-1
S"Deletion of this domain impairs RAP74 ' s ability to support SRF - activated transcription in vitro but has little effect on the protein ' s basal transcription activity or its ability to support SP1 - activated transcription ."
p11521
(lp11522
I11
a(lp11523
I34
atp11524
a(I1
S'The correlation of SRF - RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF - activated transcription .'
p11525
(lp11526
I3
a(lp11527
I5
atp11528
a(I-1
S'The correlation of SRF - RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF - activated transcription .'
p11529
(lp11530
I3
a(lp11531
I12
atp11532
a(I-1
S'The correlation of SRF - RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF - activated transcription .'
p11533
(lp11534
I3
a(lp11535
I18
atp11536
a(I-1
S'The correlation of SRF - RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF - activated transcription .'
p11537
(lp11538
I5
a(lp11539
I12
atp11540
a(I-1
S'The correlation of SRF - RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF - activated transcription .'
p11541
(lp11542
I5
a(lp11543
I18
atp11544
a(I1
S'The correlation of SRF - RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF - activated transcription .'
p11545
(lp11546
I12
a(lp11547
I18
atp11548
a(I1
S'Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product .'
p11549
(lp11550
I7
a(lp11551
I10
atp11552
a(I-1
S'The protein encoded by the retinoblastoma susceptibility gene ( Rb ) functions as a tumour suppressor and negative growth regulator .'
p11553
(lp11554
I5
aI6
aI7
a(lp11555
I9
atp11556
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11557
(lp11558
I12
a(lp11559
I34
atp11560
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11561
(lp11562
I12
a(lp11563
I56
atp11564
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11565
(lp11566
I12
a(lp11567
I63
atp11568
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11569
(lp11570
I12
a(lp11571
I75
atp11572
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11573
(lp11574
I12
a(lp11575
I77
aI78
aI79
atp11576
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11577
(lp11578
I34
a(lp11579
I56
atp11580
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11581
(lp11582
I34
a(lp11583
I63
atp11584
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11585
(lp11586
I34
a(lp11587
I75
atp11588
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11589
(lp11590
I34
a(lp11591
I77
aI78
aI79
atp11592
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11593
(lp11594
I56
a(lp11595
I63
atp11596
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11597
(lp11598
I56
a(lp11599
I75
atp11600
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11601
(lp11602
I56
a(lp11603
I77
aI78
aI79
atp11604
a(I1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11605
(lp11606
I63
a(lp11607
I75
atp11608
a(I1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11609
(lp11610
I63
a(lp11611
I77
aI78
aI79
atp11612
a(I-1
S'Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .'
p11613
(lp11614
I75
a(lp11615
I77
aI78
aI79
atp11616
a(I1
S'This last observation was confirmed by affinity chromatography and immunoprecipitation , which demonstrated an interaction between Rb and UBF .'
p11617
(lp11618
I16
a(lp11619
I18
atp11620
a(I-1
S'These results indicate that there is an additional mechanism by which Rb suppresses cell growth , namely that Rb directly represses transcription of the rRNA genes .'
p11621
(lp11622
I11
a(lp11623
I18
atp11624
a(I-1
S'The beta : beta activin homodimer and alpha : beta inhibin heterodimer are mutual antagonists which share a common beta subunit .'
p11625
(lp11626
I3
aI4
a(lp11627
I9
aI10
atp11628
a(I-1
S'Activin type I receptors , SKR1 and SKR2 , were first cloned from well differentiated human hepatoma cells ( HepG2 ) .'
p11629
(lp11630
I5
a(lp11631
I7
atp11632
a(I1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11633
(lp11634
I6
aI7
a(lp11635
I11
aI12
aI13
aI14
aI15
atp11636
a(I1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11637
(lp11638
I6
aI7
a(lp11639
I17
atp11640
a(I-1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11641
(lp11642
I6
aI7
a(lp11643
I29
atp11644
a(I-1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11645
(lp11646
I6
aI7
a(lp11647
I32
atp11648
a(I-1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11649
(lp11650
I11
aI12
aI13
aI14
aI15
a(lp11651
I17
atp11652
a(I-1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11653
(lp11654
I11
aI12
aI13
aI14
aI15
a(lp11655
I29
atp11656
a(I-1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11657
(lp11658
I11
aI12
aI13
aI14
aI15
a(lp11659
I32
atp11660
a(I-1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11661
(lp11662
I17
a(lp11663
I29
atp11664
a(I-1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11665
(lp11666
I17
a(lp11667
I32
atp11668
a(I-1
S'Here we show that beta : beta activin binds to the activin type II receptor kinase ( ActRII ) which induces activin binding to the type I receptor kinase SKR2 to form ActRII . beta : beta .'
p11669
(lp11670
I29
a(lp11671
I32
atp11672
a(I-1
S'SKR2 complexes in which an activin beta chain occupies each receptor subunit .'
p11673
(lp11674
I0
a(lp11675
I5
aI6
atp11676
a(I1
S'Inhibin also binds to ActRII through its beta subunit , competes with the binding of activin to ActRII , but fails to form the ActRII .'
p11677
(lp11678
I0
a(lp11679
I4
atp11680
a(I-1
S'Inhibin also binds to ActRII through its beta subunit , competes with the binding of activin to ActRII , but fails to form the ActRII .'
p11681
(lp11682
I0
a(lp11683
I17
atp11684
a(I-1
S'Inhibin also binds to ActRII through its beta subunit , competes with the binding of activin to ActRII , but fails to form the ActRII .'
p11685
(lp11686
I0
a(lp11687
I24
atp11688
a(I-1
S'Inhibin also binds to ActRII through its beta subunit , competes with the binding of activin to ActRII , but fails to form the ActRII .'
p11689
(lp11690
I4
a(lp11691
I17
atp11692
a(I-1
S'Inhibin also binds to ActRII through its beta subunit , competes with the binding of activin to ActRII , but fails to form the ActRII .'
p11693
(lp11694
I4
a(lp11695
I24
atp11696
a(I-1
S'Inhibin also binds to ActRII through its beta subunit , competes with the binding of activin to ActRII , but fails to form the ActRII .'
p11697
(lp11698
I17
a(lp11699
I24
atp11700
a(I1
S'The p21 inhibitor of cyclin - dependent kinases controls DNA replication by interaction with PCNA .'
p11701
(lp11702
I1
a(lp11703
I14
atp11704
a(I-1
S'The p53 tumour - suppressor protein controls the expression of a gene encoding the p21 cyclin - dependent protein kinase ( CDK ) regulator .'
p11705
(lp11706
I1
a(lp11707
I14
atp11708
a(I-1
S'Levels of p21 protein are increased in senescent cells and p21 overexpression blocks the growth of tumour cells .'
p11709
(lp11710
I2
a(lp11711
I10
atp11712
a(I1
S'In normal human cells , but not in many tumour cells , p21 exists in a quaternary complex with a cyclin , a CDK , and the proliferating - cell nuclear antigen ( PCNA ) .'
p11713
(lp11714
I12
a(lp11715
I27
aI28
aI29
aI30
aI31
atp11716
a(I1
S'In normal human cells , but not in many tumour cells , p21 exists in a quaternary complex with a cyclin , a CDK , and the proliferating - cell nuclear antigen ( PCNA ) .'
p11717
(lp11718
I12
a(lp11719
I33
atp11720
a(I-1
S'In normal human cells , but not in many tumour cells , p21 exists in a quaternary complex with a cyclin , a CDK , and the proliferating - cell nuclear antigen ( PCNA ) .'
p11721
(lp11722
I27
aI28
aI29
aI30
aI31
a(lp11723
I33
atp11724
a(I-1
S'p21 controls CDK activity , thereby affecting cell - cycle control , whereas PCNA functions in both DNA replication and repair .'
p11725
(lp11726
I0
a(lp11727
I13
atp11728
a(I1
S'Here we use simian virus 40 DNA replication in vitro to show than p21 directly inhibits PCNA - dependent DNA replication in the absence of a cyclin / CDK .'
p11729
(lp11730
I13
a(lp11731
I16
atp11732
a(I1
S'Furthermore , p21 blocks the ability of PCNA to activate DNA polymerase delta , the principal replicative DNA polymerase .'
p11733
(lp11734
I2
a(lp11735
I7
atp11736
a(I-1
S'Furthermore , p21 blocks the ability of PCNA to activate DNA polymerase delta , the principal replicative DNA polymerase .'
p11737
(lp11738
I2
a(lp11739
I10
aI11
aI12
atp11740
a(I1
S'Furthermore , p21 blocks the ability of PCNA to activate DNA polymerase delta , the principal replicative DNA polymerase .'
p11741
(lp11742
I7
a(lp11743
I10
aI11
aI12
atp11744
a(I1
S'This regulation results from a direct interaction between p21 and PCNA .'
p11745
(lp11746
I8
a(lp11747
I10
atp11748
a(I-1
S'Thus , during p53 - mediated suppression of cell proliferation , p21 and PCNA may be important for coordinating cell - cycle progression , DNA replication and repair of damaged DNA .'
p11749
(lp11750
I3
a(lp11751
I11
atp11752
a(I-1
S'Thus , during p53 - mediated suppression of cell proliferation , p21 and PCNA may be important for coordinating cell - cycle progression , DNA replication and repair of damaged DNA .'
p11753
(lp11754
I3
a(lp11755
I13
atp11756
a(I-1
S'Thus , during p53 - mediated suppression of cell proliferation , p21 and PCNA may be important for coordinating cell - cycle progression , DNA replication and repair of damaged DNA .'
p11757
(lp11758
I11
a(lp11759
I13
atp11760
a(I1
S'Nuclear protein CBP is a coactivator for the transcription factor CREB .'
p11761
(lp11762
I2
a(lp11763
I10
atp11764
a(I1
S'CREB is activated through phosphorylation by protein kinase A ( PKA ) , but precisely how phosphorylation stimulates CREB function is unknown .'
p11765
(lp11766
I0
a(lp11767
I6
aI7
aI8
atp11768
a(I1
S'CREB is activated through phosphorylation by protein kinase A ( PKA ) , but precisely how phosphorylation stimulates CREB function is unknown .'
p11769
(lp11770
I0
a(lp11771
I10
atp11772
a(I-1
S'CREB is activated through phosphorylation by protein kinase A ( PKA ) , but precisely how phosphorylation stimulates CREB function is unknown .'
p11773
(lp11774
I0
a(lp11775
I18
atp11776
a(I-1
S'CREB is activated through phosphorylation by protein kinase A ( PKA ) , but precisely how phosphorylation stimulates CREB function is unknown .'
p11777
(lp11778
I6
aI7
aI8
a(lp11779
I10
atp11780
a(I-1
S'CREB is activated through phosphorylation by protein kinase A ( PKA ) , but precisely how phosphorylation stimulates CREB function is unknown .'
p11781
(lp11782
I6
aI7
aI8
a(lp11783
I18
atp11784
a(I-1
S'CREB is activated through phosphorylation by protein kinase A ( PKA ) , but precisely how phosphorylation stimulates CREB function is unknown .'
p11785
(lp11786
I10
a(lp11787
I18
atp11788
a(I-1
S'We have previously identified a nuclear protein of M ( r ) 265K , CBP , that binds specifically to the PKA - phosphorylated form of CREB .'
p11789
(lp11790
I14
a(lp11791
I21
atp11792
a(I1
S'We have previously identified a nuclear protein of M ( r ) 265K , CBP , that binds specifically to the PKA - phosphorylated form of CREB .'
p11793
(lp11794
I14
a(lp11795
I26
atp11796
a(I1
S'We have previously identified a nuclear protein of M ( r ) 265K , CBP , that binds specifically to the PKA - phosphorylated form of CREB .'
p11797
(lp11798
I21
a(lp11799
I26
atp11800
a(I1
S'We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB : CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus .'
p11801
(lp11802
I14
a(lp11803
I16
atp11804
a(I-1
S'We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB : CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus .'
p11805
(lp11806
I14
a(lp11807
I22
atp11808
a(I-1
S'We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB : CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus .'
p11809
(lp11810
I16
a(lp11811
I22
atp11812
a(I-1
S'The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA - 1 ( ref . 8 ) .'
p11813
(lp11814
I4
a(lp11815
I11
atp11816
a(I1
S'The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA - 1 ( ref . 8 ) .'
p11817
(lp11818
I4
a(lp11819
I22
aI23
aI24
atp11820
a(I-1
S'The activation domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA - 1 ( ref . 8 ) .'
p11821
(lp11822
I11
a(lp11823
I22
aI23
aI24
atp11824
a(I1
S'Consistent with its role as a coactivator , CBP augments the activity of phosphorylated CREB to activate transcription of cAMP - responsive genes .'
p11825
(lp11826
I8
a(lp11827
I14
atp11828
a(I1
S'Specific binding of the transglutaminase , platelet factor XIII , to HSP27 .'
p11829
(lp11830
I6
aI7
aI8
a(lp11831
I11
atp11832
a(I-1
S'However , the function of HSP27 and the identity of proteins that interact with HSP27 remain unknown .'
p11833
(lp11834
I5
a(lp11835
I14
atp11836
a(I-1
S'To identify specific HSP27 - protein interactions , a recombinant fusion protein affinity reagent was constructed and used to identify proteins associating with HSP27 from human platelet lysates and erythroleukemia cells .'
p11837
(lp11838
I3
a(lp11839
I23
atp11840
a(I1
S'Immunoblotting studies were used to confirm the binding of FXIII from fresh platelet lysates to the HSP27 fusion protein .'
p11841
(lp11842
I9
a(lp11843
I16
atp11844
a(I1
S'FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass - activated platelets .'
p11845
(lp11846
I0
a(lp11847
I7
atp11848
a(I-1
S'FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass - activated platelets .'
p11849
(lp11850
I0
a(lp11851
I15
atp11852
a(I-1
S'FXIII also was shown to coprecipitate with HSP27 in immunoprecipitation studies and to colocalize with HSP27 in immunofluorescence studies of intact glass - activated platelets .'
p11853
(lp11854
I7
a(lp11855
I15
atp11856
a(I1
S'The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and / or enzymatic regulation of platelet FXIII .'
p11857
(lp11858
I8
a(lp11859
I10
atp11860
a(I-1
S'The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and / or enzymatic regulation of platelet FXIII .'
p11861
(lp11862
I8
a(lp11863
I14
atp11864
a(I-1
S'The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and / or enzymatic regulation of platelet FXIII .'
p11865
(lp11866
I8
a(lp11867
I28
atp11868
a(I-1
S'The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and / or enzymatic regulation of platelet FXIII .'
p11869
(lp11870
I10
a(lp11871
I14
atp11872
a(I-1
S'The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and / or enzymatic regulation of platelet FXIII .'
p11873
(lp11874
I10
a(lp11875
I28
atp11876
a(I1
S'The data thus demonstrate specific binding of platelet FXIII to HSP27 and suggest that HSP27 may participate in the cellular localization and / or enzymatic regulation of platelet FXIII .'
p11877
(lp11878
I14
a(lp11879
I28
atp11880
a(I1
S'Several hydrophobic amino acids in the p53 amino - terminal domain are required for transcriptional activation , binding to mdm - 2 and the adenovirus 5 E1B 55 - kD protein .'
p11881
(lp11882
I6
a(lp11883
I19
aI20
aI21
atp11884
a(I-1
S'Several hydrophobic amino acids in the p53 amino - terminal domain are required for transcriptional activation , binding to mdm - 2 and the adenovirus 5 E1B 55 - kD protein .'
p11885
(lp11886
I6
a(lp11887
I26
atp11888
a(I1
S'Several hydrophobic amino acids in the p53 amino - terminal domain are required for transcriptional activation , binding to mdm - 2 and the adenovirus 5 E1B 55 - kD protein .'
p11889
(lp11890
I6
a(lp11891
I25
aI26
atp11892
a(I-1
S'Several hydrophobic amino acids in the p53 amino - terminal domain are required for transcriptional activation , binding to mdm - 2 and the adenovirus 5 E1B 55 - kD protein .'
p11893
(lp11894
I19
aI20
aI21
a(lp11895
I26
atp11896
a(I-1
S'Several hydrophobic amino acids in the p53 amino - terminal domain are required for transcriptional activation , binding to mdm - 2 and the adenovirus 5 E1B 55 - kD protein .'
p11897
(lp11898
I19
aI20
aI21
a(lp11899
I25
aI26
atp11900
a(I-1
S'Several hydrophobic amino acids in the p53 amino - terminal domain are required for transcriptional activation , binding to mdm - 2 and the adenovirus 5 E1B 55 - kD protein .'
p11901
(lp11902
I26
a(lp11903
I25
aI26
atp11904
a(I1
S'The acidic amino terminus of the p53 protein has been shown to contain this trans - activation activity as well as the domains for mdm - 2 and adenovirus 5 E1B 55 - kD protein binding .'
p11905
(lp11906
I6
a(lp11907
I24
aI25
aI26
atp11908
a(I-1
S'The acidic amino terminus of the p53 protein has been shown to contain this trans - activation activity as well as the domains for mdm - 2 and adenovirus 5 E1B 55 - kD protein binding .'
p11909
(lp11910
I6
a(lp11911
I30
atp11912
a(I1
S'The acidic amino terminus of the p53 protein has been shown to contain this trans - activation activity as well as the domains for mdm - 2 and adenovirus 5 E1B 55 - kD protein binding .'
p11913
(lp11914
I6
a(lp11915
I29
aI30
atp11916
a(I-1
S'The acidic amino terminus of the p53 protein has been shown to contain this trans - activation activity as well as the domains for mdm - 2 and adenovirus 5 E1B 55 - kD protein binding .'
p11917
(lp11918
I24
aI25
aI26
a(lp11919
I30
atp11920
a(I-1
S'The acidic amino terminus of the p53 protein has been shown to contain this trans - activation activity as well as the domains for mdm - 2 and adenovirus 5 E1B 55 - kD protein binding .'
p11921
(lp11922
I24
aI25
aI26
a(lp11923
I29
aI30
atp11924
a(I-1
S'The acidic amino terminus of the p53 protein has been shown to contain this trans - activation activity as well as the domains for mdm - 2 and adenovirus 5 E1B 55 - kD protein binding .'
p11925
(lp11926
I30
a(lp11927
I29
aI30
atp11928
a(I1
S'Rather , the hydrophobic amino acid residues Leu - 22 and Trp - 23 of human p53 are both required for trans - activation activity , binding to the adenovirus E1B 55 - kD protein and the human mdm - 2 - p53 protein in vitro .'
p11929
(lp11930
I16
a(lp11931
I30
atp11932
a(I-1
S'Rather , the hydrophobic amino acid residues Leu - 22 and Trp - 23 of human p53 are both required for trans - activation activity , binding to the adenovirus E1B 55 - kD protein and the human mdm - 2 - p53 protein in vitro .'
p11933
(lp11934
I16
a(lp11935
I38
aI39
aI40
atp11936
a(I-1
S'Rather , the hydrophobic amino acid residues Leu - 22 and Trp - 23 of human p53 are both required for trans - activation activity , binding to the adenovirus E1B 55 - kD protein and the human mdm - 2 - p53 protein in vitro .'
p11937
(lp11938
I16
a(lp11939
I42
atp11940
a(I-1
S'Rather , the hydrophobic amino acid residues Leu - 22 and Trp - 23 of human p53 are both required for trans - activation activity , binding to the adenovirus E1B 55 - kD protein and the human mdm - 2 - p53 protein in vitro .'
p11941
(lp11942
I30
a(lp11943
I38
aI39
aI40
atp11944
a(I-1
S'Rather , the hydrophobic amino acid residues Leu - 22 and Trp - 23 of human p53 are both required for trans - activation activity , binding to the adenovirus E1B 55 - kD protein and the human mdm - 2 - p53 protein in vitro .'
p11945
(lp11946
I30
a(lp11947
I42
atp11948
a(I1
S'Rather , the hydrophobic amino acid residues Leu - 22 and Trp - 23 of human p53 are both required for trans - activation activity , binding to the adenovirus E1B 55 - kD protein and the human mdm - 2 - p53 protein in vitro .'
p11949
(lp11950
I38
aI39
aI40
a(lp11951
I42
atp11952
a(I1
S'In addition , hydrophobic residues Leu - 14 and Phe - 19 are crucial for the interactions between p53 and human mdm - 2 ( hdm - 2 ) .'
p11953
(lp11954
I18
a(lp11955
I21
aI22
aI23
atp11956
a(I1
S'In addition , hydrophobic residues Leu - 14 and Phe - 19 are crucial for the interactions between p53 and human mdm - 2 ( hdm - 2 ) .'
p11957
(lp11958
I18
a(lp11959
I25
aI26
aI27
atp11960
a(I-1
S'In addition , hydrophobic residues Leu - 14 and Phe - 19 are crucial for the interactions between p53 and human mdm - 2 ( hdm - 2 ) .'
p11961
(lp11962
I21
aI22
aI23
a(lp11963
I25
aI26
aI27
atp11964
a(I-1
S'These mutations have no impact on the ability of the p53 protein to bind to a p53 - specific DNA element .'
p11965
(lp11966
I10
a(lp11967
I16
atp11968
a(I-1
S'These very same hydrophobic residues contact the hdm - 2 and Ad5 E1B 55 - kD oncogene products .'
p11969
(lp11970
I7
aI8
aI9
a(lp11971
I12
atp11972
a(I1
S'In previous studies ( Scott , J . D . , Stofko , R . E . , McDonald , J . R . , Comer , J . D . , Vitalis , E . A . , and Mangili J . ( 1990 ) J . Biol . Chem . 265 , 21561 - 21566 ) we have shown that dimerization of RII alpha was required for interaction with the cytoskeletal component microtubule - associated protein 2 .'
p11973
(lp11974
I64
aI65
a(lp11975
I74
aI75
aI76
aI77
aI78
atp11976
a(I1
S'Measurement of RII alpha I3A , I5A interaction with the human thyroid AKAP , Ht 31 , by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6 - fold .'
p11977
(lp11978
I2
aI3
a(lp11979
I11
aI12
atp11980
a(I1
S'Measurement of RII alpha I3A , I5A interaction with the human thyroid AKAP , Ht 31 , by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6 - fold .'
p11981
(lp11982
I2
aI3
a(lp11983
I14
aI15
atp11984
a(I-1
S'Measurement of RII alpha I3A , I5A interaction with the human thyroid AKAP , Ht 31 , by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6 - fold .'
p11985
(lp11986
I11
aI12
a(lp11987
I14
aI15
atp11988
a(I1
S'Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two - hybrid system .'
p11989
(lp11990
I5
aI6
aI7
aI8
a(lp11991
I11
aI12
atp11992
a(I-1
S'Insulin receptor substrate 1 ( IRS - 1 ) is a major substrate of the insulin receptor and has been implicated in insulin signaling .'
p11993
(lp11994
I0
aI1
aI2
aI3
a(lp11995
I5
aI6
aI7
atp11996
a(I1
S'Insulin receptor substrate 1 ( IRS - 1 ) is a major substrate of the insulin receptor and has been implicated in insulin signaling .'
p11997
(lp11998
I0
aI1
aI2
aI3
a(lp11999
I15
aI16
atp12000
a(I-1
S'Insulin receptor substrate 1 ( IRS - 1 ) is a major substrate of the insulin receptor and has been implicated in insulin signaling .'
p12001
(lp12002
I0
aI1
aI2
aI3
a(lp12003
I22
atp12004
a(I1
S'Insulin receptor substrate 1 ( IRS - 1 ) is a major substrate of the insulin receptor and has been implicated in insulin signaling .'
p12005
(lp12006
I5
aI6
aI7
a(lp12007
I15
aI16
atp12008
a(I-1
S'Insulin receptor substrate 1 ( IRS - 1 ) is a major substrate of the insulin receptor and has been implicated in insulin signaling .'
p12009
(lp12010
I5
aI6
aI7
a(lp12011
I22
atp12012
a(I-1
S'Insulin receptor substrate 1 ( IRS - 1 ) is a major substrate of the insulin receptor and has been implicated in insulin signaling .'
p12013
(lp12014
I15
aI16
a(lp12015
I22
atp12016
a(I-1
S'Although IRS - 1 is thought to interact with the insulin receptor , the nature of the interaction has not been defined .'
p12017
(lp12018
I1
aI2
aI3
a(lp12019
I10
atp12020
a(I1
S'Although IRS - 1 is thought to interact with the insulin receptor , the nature of the interaction has not been defined .'
p12021
(lp12022
I1
aI2
aI3
a(lp12023
I10
aI11
atp12024
a(I-1
S'Although IRS - 1 is thought to interact with the insulin receptor , the nature of the interaction has not been defined .'
p12025
(lp12026
I10
a(lp12027
I10
aI11
atp12028
a(I-1
S'In this study , we used the two - hybrid assay of protein - protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS - 1 and the insulin receptor .'
p12029
(lp12030
I27
aI28
aI29
a(lp12031
I32
atp12032
a(I1
S'In this study , we used the two - hybrid assay of protein - protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS - 1 and the insulin receptor .'
p12033
(lp12034
I27
aI28
aI29
a(lp12035
I32
aI33
atp12036
a(I-1
S'In this study , we used the two - hybrid assay of protein - protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS - 1 and the insulin receptor .'
p12037
(lp12038
I32
a(lp12039
I32
aI33
atp12040
a(I1
S'We demonstrate that IRS - 1 forms a specific complex with the cytoplasmic domain of the insulin receptor when both are expressed as hybrid proteins in yeast cells .'
p12041
(lp12042
I3
aI4
aI5
a(lp12043
I16
aI17
atp12044
a(I-1
S'Lastly , in agreement with our findings for yeast cells , we show that the insulin receptor is unable to phosphorylate an IRS - 1 protein containing a deletion of amino acids 45 to 516 when expressed in COS cells .'
p12045
(lp12046
I15
aI16
a(lp12047
I22
aI23
aI24
atp12048
a(I1
S'The protein Raf - 1 , a key mediator of mitogenesis and differentiation , associates with p21ras ( refs 1 - 3 ) .'
p12049
(lp12050
I2
aI3
aI4
a(lp12051
I16
atp12052
a(I-1
S'These proteins , 14 - 3 - 3 zeta ( PLA2 ) and 14 - 3 - 3 beta ( HS1 ) , are members of the 14 - 3 - 3 family of proteins .'
p12053
(lp12054
I3
aI4
aI5
aI6
aI7
aI8
a(lp12055
I10
atp12056
a(I-1
S'These proteins , 14 - 3 - 3 zeta ( PLA2 ) and 14 - 3 - 3 beta ( HS1 ) , are members of the 14 - 3 - 3 family of proteins .'
p12057
(lp12058
I3
aI4
aI5
aI6
aI7
aI8
a(lp12059
I13
aI14
aI15
aI16
aI17
aI18
atp12060
a(I-1
S'These proteins , 14 - 3 - 3 zeta ( PLA2 ) and 14 - 3 - 3 beta ( HS1 ) , are members of the 14 - 3 - 3 family of proteins .'
p12061
(lp12062
I3
aI4
aI5
aI6
aI7
aI8
a(lp12063
I20
atp12064
a(I-1
S'These proteins , 14 - 3 - 3 zeta ( PLA2 ) and 14 - 3 - 3 beta ( HS1 ) , are members of the 14 - 3 - 3 family of proteins .'
p12065
(lp12066
I10
a(lp12067
I13
aI14
aI15
aI16
aI17
aI18
atp12068
a(I-1
S'These proteins , 14 - 3 - 3 zeta ( PLA2 ) and 14 - 3 - 3 beta ( HS1 ) , are members of the 14 - 3 - 3 family of proteins .'
p12069
(lp12070
I10
a(lp12071
I20
atp12072
a(I-1
S'These proteins , 14 - 3 - 3 zeta ( PLA2 ) and 14 - 3 - 3 beta ( HS1 ) , are members of the 14 - 3 - 3 family of proteins .'
p12073
(lp12074
I13
aI14
aI15
aI16
aI17
aI18
a(lp12075
I20
atp12076
a(I-1
S'Expression of 14 - 3 - 3 proteins in Xenopus oocytes enhanced Raf - 1 activity and promoted Raf - 1 - dependent oocyte maturation .'
p12077
(lp12078
I12
aI13
aI14
a(lp12079
I18
aI19
aI20
atp12080
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12081
(lp12082
I3
aI4
aI5
a(lp12083
I14
aI15
aI16
atp12084
a(I1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12085
(lp12086
I3
aI4
aI5
a(lp12087
I20
aI21
aI22
aI23
aI24
atp12088
a(I1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12089
(lp12090
I3
aI4
aI5
a(lp12091
I26
aI27
aI28
aI29
aI30
atp12092
a(I1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12093
(lp12094
I3
aI4
aI5
a(lp12095
I32
aI33
aI34
atp12096
a(I1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12097
(lp12098
I3
aI4
aI5
a(lp12099
I37
atp12100
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12101
(lp12102
I14
aI15
aI16
a(lp12103
I20
aI21
aI22
aI23
aI24
atp12104
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12105
(lp12106
I14
aI15
aI16
a(lp12107
I26
aI27
aI28
aI29
aI30
atp12108
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12109
(lp12110
I14
aI15
aI16
a(lp12111
I32
aI33
aI34
atp12112
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12113
(lp12114
I14
aI15
aI16
a(lp12115
I37
atp12116
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12117
(lp12118
I20
aI21
aI22
aI23
aI24
a(lp12119
I26
aI27
aI28
aI29
aI30
atp12120
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12121
(lp12122
I20
aI21
aI22
aI23
aI24
a(lp12123
I32
aI33
aI34
atp12124
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12125
(lp12126
I20
aI21
aI22
aI23
aI24
a(lp12127
I37
atp12128
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12129
(lp12130
I26
aI27
aI28
aI29
aI30
a(lp12131
I32
aI33
aI34
atp12132
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12133
(lp12134
I26
aI27
aI28
aI29
aI30
a(lp12135
I37
atp12136
a(I-1
S'Interactions of the Bcl - 2 protein with itself and other members of the Bcl - 2 family , including Bcl - X - L , Bcl - X - S , Mcl - 1 , and Bax , were explored with a yeast two - hybrid system .'
p12137
(lp12138
I32
aI33
aI34
a(lp12139
I37
atp12140
a(I1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12141
(lp12142
I0
aI1
aI2
a(lp12143
I6
aI7
aI8
aI9
aI10
atp12144
a(I1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12145
(lp12146
I0
aI1
aI2
a(lp12147
I12
aI13
aI14
atp12148
a(I1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12149
(lp12150
I0
aI1
aI2
a(lp12151
I20
atp12152
a(I1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12153
(lp12154
I0
aI1
aI2
a(lp12155
I22
aI23
aI24
aI25
aI26
atp12156
a(I-1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12157
(lp12158
I6
aI7
aI8
aI9
aI10
a(lp12159
I12
aI13
aI14
atp12160
a(I-1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12161
(lp12162
I6
aI7
aI8
aI9
aI10
a(lp12163
I20
atp12164
a(I-1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12165
(lp12166
I6
aI7
aI8
aI9
aI10
a(lp12167
I22
aI23
aI24
aI25
aI26
atp12168
a(I-1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12169
(lp12170
I12
aI13
aI14
a(lp12171
I20
atp12172
a(I-1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12173
(lp12174
I12
aI13
aI14
a(lp12175
I22
aI23
aI24
aI25
aI26
atp12176
a(I-1
S'Bcl - 2 also interacted with Bcl - X - L and Mcl - 1 and with the dominant inhibitors Bax and Bcl - X - S .'
p12177
(lp12178
I20
a(lp12179
I22
aI23
aI24
aI25
aI26
atp12180
a(I-1
S'Bcl - X - L displayed the same pattern of combinatorial interactions with Bcl - 2 family proteins as Bcl - 2 .'
p12181
(lp12182
I0
aI1
aI2
aI3
aI4
a(lp12183
I13
aI14
aI15
atp12184
a(I-1
S'Bcl - X - L displayed the same pattern of combinatorial interactions with Bcl - 2 family proteins as Bcl - 2 .'
p12185
(lp12186
I0
aI1
aI2
aI3
aI4
a(lp12187
I19
aI20
aI21
atp12188
a(I-1
S'Bcl - X - L displayed the same pattern of combinatorial interactions with Bcl - 2 family proteins as Bcl - 2 .'
p12189
(lp12190
I13
aI14
aI15
a(lp12191
I19
aI20
aI21
atp12192
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12193
(lp12194
I5
aI6
aI7
a(lp12195
I10
aI11
aI12
atp12196
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12197
(lp12198
I5
aI6
aI7
a(lp12199
I22
aI23
aI24
atp12200
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12201
(lp12202
I5
aI6
aI7
a(lp12203
I32
aI33
aI34
atp12204
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12205
(lp12206
I5
aI6
aI7
a(lp12207
I49
aI50
aI51
atp12208
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12209
(lp12210
I5
aI6
aI7
a(lp12211
I66
aI67
aI68
atp12212
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12213
(lp12214
I10
aI11
aI12
a(lp12215
I22
aI23
aI24
atp12216
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12217
(lp12218
I10
aI11
aI12
a(lp12219
I32
aI33
aI34
atp12220
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12221
(lp12222
I10
aI11
aI12
a(lp12223
I49
aI50
aI51
atp12224
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12225
(lp12226
I10
aI11
aI12
a(lp12227
I66
aI67
aI68
atp12228
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12229
(lp12230
I22
aI23
aI24
a(lp12231
I32
aI33
aI34
atp12232
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12233
(lp12234
I22
aI23
aI24
a(lp12235
I49
aI50
aI51
atp12236
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12237
(lp12238
I22
aI23
aI24
a(lp12239
I66
aI67
aI68
atp12240
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12241
(lp12242
I32
aI33
aI34
a(lp12243
I49
aI50
aI51
atp12244
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12245
(lp12246
I32
aI33
aI34
a(lp12247
I66
aI67
aI68
atp12248
a(I-1
S'Use of deletion mutants of Bcl - 2 suggested that Bcl - 2 homodimerization involves interactions between two distinct regions within the Bcl - 2 protein , since a LexA protein containing Bcl - 2 amino acids 83 - 218 mediated functional interactions with a B42 fusion protein containing Bcl - 2 amino acids 1 - 81 but did not complement a B42 fusion protein containing Bcl - 2 amino acids 83 - 218 .'
p12249
(lp12250
I49
aI50
aI51
a(lp12251
I66
aI67
aI68
atp12252
a(I-1
S'In contrast to LexA / Bcl - 2 fusion proteins , expression of a LexA / Bax protein was lethal to yeast .'
p12253
(lp12254
I5
aI6
aI7
a(lp12255
I16
atp12256
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12257
(lp12258
I10
aI11
aI12
a(lp12259
I14
aI15
aI16
aI17
aI18
atp12260
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12261
(lp12262
I10
aI11
aI12
a(lp12263
I21
aI22
aI23
atp12264
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12265
(lp12266
I10
aI11
aI12
a(lp12267
I28
aI29
aI30
aI31
aI32
atp12268
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12269
(lp12270
I10
aI11
aI12
a(lp12271
I39
aI40
aI41
atp12272
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12273
(lp12274
I14
aI15
aI16
aI17
aI18
a(lp12275
I21
aI22
aI23
atp12276
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12277
(lp12278
I14
aI15
aI16
aI17
aI18
a(lp12279
I28
aI29
aI30
aI31
aI32
atp12280
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12281
(lp12282
I14
aI15
aI16
aI17
aI18
a(lp12283
I39
aI40
aI41
atp12284
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12285
(lp12286
I21
aI22
aI23
a(lp12287
I28
aI29
aI30
aI31
aI32
atp12288
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12289
(lp12290
I21
aI22
aI23
a(lp12291
I39
aI40
aI41
atp12292
a(I-1
S'This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl - 2 , Bcl - X - L , or Mcl - 1 but not those containing Bcl - X - S ( an alternatively spliced form of Bcl - X that lacks a well - conserved 63 - amino acid region ) .'
p12293
(lp12294
I28
aI29
aI30
aI31
aI32
a(lp12295
I39
aI40
aI41
atp12296
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12297
(lp12298
I6
a(lp12299
I8
aI9
aI10
aI11
aI12
atp12300
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12301
(lp12302
I6
a(lp12303
I15
aI16
aI17
atp12304
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12305
(lp12306
I6
a(lp12307
I25
aI26
aI27
atp12308
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12309
(lp12310
I6
a(lp12311
I29
atp12312
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12313
(lp12314
I6
a(lp12315
I37
aI38
aI39
atp12316
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12317
(lp12318
I6
a(lp12319
I41
aI42
aI43
atp12320
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12321
(lp12322
I8
aI9
aI10
aI11
aI12
a(lp12323
I15
aI16
aI17
atp12324
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12325
(lp12326
I8
aI9
aI10
aI11
aI12
a(lp12327
I25
aI26
aI27
atp12328
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12329
(lp12330
I8
aI9
aI10
aI11
aI12
a(lp12331
I29
atp12332
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12333
(lp12334
I8
aI9
aI10
aI11
aI12
a(lp12335
I37
aI38
aI39
atp12336
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12337
(lp12338
I8
aI9
aI10
aI11
aI12
a(lp12339
I41
aI42
aI43
atp12340
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12341
(lp12342
I15
aI16
aI17
a(lp12343
I25
aI26
aI27
atp12344
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12345
(lp12346
I15
aI16
aI17
a(lp12347
I29
atp12348
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12349
(lp12350
I15
aI16
aI17
a(lp12351
I37
aI38
aI39
atp12352
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12353
(lp12354
I15
aI16
aI17
a(lp12355
I41
aI42
aI43
atp12356
a(I1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12357
(lp12358
I25
aI26
aI27
a(lp12359
I29
atp12360
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12361
(lp12362
I25
aI26
aI27
a(lp12363
I37
aI38
aI39
atp12364
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12365
(lp12366
I25
aI26
aI27
a(lp12367
I41
aI42
aI43
atp12368
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12369
(lp12370
I29
a(lp12371
I37
aI38
aI39
atp12372
a(I-1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12373
(lp12374
I29
a(lp12375
I41
aI42
aI43
atp12376
a(I1
S'The findings suggest a model whereby Bax and Bcl - X - S differentially regulate Bcl - 2 function , and indicate that requirements for Bcl - 2 / Bax heterodimerization may be different from those for Bcl - 2 / Bcl - 2 homodimerization .'
p12377
(lp12378
I37
aI38
aI39
a(lp12379
I41
aI42
aI43
atp12380
a(I-1
S'The rates of commitment to renaturation of rhodanese and glutamine synthetase in the presence of the groE chaperonins .'
p12381
(lp12382
I7
a(lp12383
I9
aI10
atp12384
a(I-1
S'Using immunoprecipitation techniques , we have determined the rates at which rhodanese and glutamine synthetase ( GS ) are released from groEL in a form committed to refold to active enzyme .'
p12385
(lp12386
I11
a(lp12387
I13
aI14
atp12388
a(I-1
S'Using immunoprecipitation techniques , we have determined the rates at which rhodanese and glutamine synthetase ( GS ) are released from groEL in a form committed to refold to active enzyme .'
p12389
(lp12390
I11
a(lp12391
I16
atp12392
a(I1
S'Using immunoprecipitation techniques , we have determined the rates at which rhodanese and glutamine synthetase ( GS ) are released from groEL in a form committed to refold to active enzyme .'
p12393
(lp12394
I11
a(lp12395
I21
atp12396
a(I-1
S'Using immunoprecipitation techniques , we have determined the rates at which rhodanese and glutamine synthetase ( GS ) are released from groEL in a form committed to refold to active enzyme .'
p12397
(lp12398
I13
aI14
a(lp12399
I16
atp12400
a(I1
S'Using immunoprecipitation techniques , we have determined the rates at which rhodanese and glutamine synthetase ( GS ) are released from groEL in a form committed to refold to active enzyme .'
p12401
(lp12402
I13
aI14
a(lp12403
I21
atp12404
a(I1
S'Using immunoprecipitation techniques , we have determined the rates at which rhodanese and glutamine synthetase ( GS ) are released from groEL in a form committed to refold to active enzyme .'
p12405
(lp12406
I16
a(lp12407
I21
atp12408
a(I-1
S'Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable " folding arrested " complexes with groEL .'
p12409
(lp12410
I0
a(lp12411
I2
aI3
atp12412
a(I1
S'Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable " folding arrested " complexes with groEL .'
p12413
(lp12414
I0
a(lp12415
I28
atp12416
a(I1
S'Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable " folding arrested " complexes with groEL .'
p12417
(lp12418
I2
aI3
a(lp12419
I28
atp12420
a(I-1
S'At 25 degrees C , the rate profiles indicate the release and commitment to folding of GS to its native state occurs far earlier ( t1 / 2 < 1 min ) than for rhodanese ( t1 / 2 = 5 min ) .'
p12421
(lp12422
I16
a(lp12423
I34
atp12424
a(I-1
S'In contrast , the renaturation rate for rhodanese with the groE chaperonins mirrored the committed renaturation rates following groEL depletion .'
p12425
(lp12426
I7
a(lp12427
I18
atp12428
a(I1
S'This suggests that rhodanese must interact with groEL throughout most of its folding reaction before it acquires a folding competent ( groE independent ) state .'
p12429
(lp12430
I3
a(lp12431
I7
atp12432
a(I-1
S'If current models of chaperonin mechanism are correct , rhodanese undergoes more rebinding and release cycles than does GS .'
p12433
(lp12434
I9
a(lp12435
I18
atp12436
a(I1
S'Interaction of IL - 2R beta and gamma c chains with Jak1 and Jak3 : implications for XSCID and XCID .'
p12437
(lp12438
I2
aI3
aI4
aI5
a(lp12439
I11
atp12440
a(I1
S'Interaction of IL - 2R beta and gamma c chains with Jak1 and Jak3 : implications for XSCID and XCID .'
p12441
(lp12442
I2
aI3
aI4
aI5
a(lp12443
I13
atp12444
a(I-1
S'Interaction of IL - 2R beta and gamma c chains with Jak1 and Jak3 : implications for XSCID and XCID .'
p12445
(lp12446
I11
a(lp12447
I13
atp12448
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12449
(lp12450
I0
aI1
aI2
a(lp12451
I4
aI5
aI6
atp12452
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12453
(lp12454
I0
aI1
aI2
a(lp12455
I14
aI15
aI16
atp12456
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12457
(lp12458
I0
aI1
aI2
a(lp12459
I14
aI15
aI16
aI17
aI18
atp12460
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12461
(lp12462
I0
aI1
aI2
a(lp12463
I21
aI22
aI23
aI24
atp12464
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12465
(lp12466
I4
aI5
aI6
a(lp12467
I14
aI15
aI16
atp12468
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12469
(lp12470
I4
aI5
aI6
a(lp12471
I14
aI15
aI16
aI17
aI18
atp12472
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12473
(lp12474
I4
aI5
aI6
a(lp12475
I21
aI22
aI23
aI24
atp12476
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12477
(lp12478
I14
aI15
aI16
a(lp12479
I14
aI15
aI16
aI17
aI18
atp12480
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12481
(lp12482
I14
aI15
aI16
a(lp12483
I21
aI22
aI23
aI24
atp12484
a(I-1
S'Interleukin - 2 ( IL - 2 ) signaling requires the dimerization of the IL - 2 receptor beta . ( IL - 2R beta ) and common gamma ( gamma c ) chains .'
p12485
(lp12486
I14
aI15
aI16
aI17
aI18
a(lp12487
I21
aI22
aI23
aI24
atp12488
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12489
(lp12490
I0
aI1
aI2
a(lp12491
I4
aI5
aI6
atp12492
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12493
(lp12494
I0
aI1
aI2
a(lp12495
I8
aI9
aI10
atp12496
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12497
(lp12498
I0
aI1
aI2
a(lp12499
I23
aI24
aI25
atp12500
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12501
(lp12502
I0
aI1
aI2
a(lp12503
I49
atp12504
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12505
(lp12506
I0
aI1
aI2
a(lp12507
I51
atp12508
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12509
(lp12510
I4
aI5
aI6
a(lp12511
I8
aI9
aI10
atp12512
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12513
(lp12514
I4
aI5
aI6
a(lp12515
I23
aI24
aI25
atp12516
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12517
(lp12518
I4
aI5
aI6
a(lp12519
I49
atp12520
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12521
(lp12522
I4
aI5
aI6
a(lp12523
I51
atp12524
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12525
(lp12526
I8
aI9
aI10
a(lp12527
I23
aI24
aI25
atp12528
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12529
(lp12530
I8
aI9
aI10
a(lp12531
I49
atp12532
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12533
(lp12534
I8
aI9
aI10
a(lp12535
I51
atp12536
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12537
(lp12538
I23
aI24
aI25
a(lp12539
I49
atp12540
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12541
(lp12542
I23
aI24
aI25
a(lp12543
I51
atp12544
a(I-1
S'IL - 2 , IL - 4 , IL - 7 ( whose receptors are known to contain gamma c ) , and IL - 9 ( whose receptor is shown here to contain gamma c ) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3 .'
p12545
(lp12546
I49
a(lp12547
I51
atp12548
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12549
(lp12550
I0
a(lp12551
I2
atp12552
a(I1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12553
(lp12554
I0
a(lp12555
I5
aI6
aI7
aI8
atp12556
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12557
(lp12558
I0
a(lp12559
I15
aI16
aI17
atp12560
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12561
(lp12562
I0
a(lp12563
I19
atp12564
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12565
(lp12566
I0
a(lp12567
I21
aI22
aI23
aI24
atp12568
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12569
(lp12570
I0
a(lp12571
I27
atp12572
a(I1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12573
(lp12574
I2
a(lp12575
I5
aI6
aI7
aI8
atp12576
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12577
(lp12578
I2
a(lp12579
I15
aI16
aI17
atp12580
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12581
(lp12582
I2
a(lp12583
I19
atp12584
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12585
(lp12586
I2
a(lp12587
I21
aI22
aI23
aI24
atp12588
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12589
(lp12590
I2
a(lp12591
I27
atp12592
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12593
(lp12594
I5
aI6
aI7
aI8
a(lp12595
I15
aI16
aI17
atp12596
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12597
(lp12598
I5
aI6
aI7
aI8
a(lp12599
I19
atp12600
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12601
(lp12602
I5
aI6
aI7
aI8
a(lp12603
I21
aI22
aI23
aI24
atp12604
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12605
(lp12606
I5
aI6
aI7
aI8
a(lp12607
I27
atp12608
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12609
(lp12610
I15
aI16
aI17
a(lp12611
I19
atp12612
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12613
(lp12614
I15
aI16
aI17
a(lp12615
I21
aI22
aI23
aI24
atp12616
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12617
(lp12618
I15
aI16
aI17
a(lp12619
I27
atp12620
a(I1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12621
(lp12622
I19
a(lp12623
I21
aI22
aI23
aI24
atp12624
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12625
(lp12626
I19
a(lp12627
I27
atp12628
a(I-1
S'Jak1 and Jak3 associated with IL - 2R beta and gamma c , respectively ; IL - 2 induced Jak3 - IL - 2R beta and increased Jak3 - gamma c associations .'
p12629
(lp12630
I21
aI22
aI23
aI24
a(lp12631
I27
atp12632
a(I-1
S'Thus , gamma c mutations in at least some XSCID and XCID patients prevent normal Jak3 activation , suggesting that mutations of Jak3 may result in an XSCID - like phenotype .'
p12633
(lp12634
I15
a(lp12635
I22
atp12636
a(I-1
S'The X - ray structure of a growth hormone - prolactin receptor complex .'
p12637
(lp12638
I7
aI8
a(lp12639
I10
atp12640
a(I-1
S'The human pituitary hormones , growth hormone ( hGH ) and prolactin ( hPRL ) , regulate a large variety of physiological processes , among which are growth and differentiation of muscle , bone and cartilage cells , and lactation .'
p12641
(lp12642
I5
aI6
a(lp12643
I8
atp12644
a(I-1
S'The human pituitary hormones , growth hormone ( hGH ) and prolactin ( hPRL ) , regulate a large variety of physiological processes , among which are growth and differentiation of muscle , bone and cartilage cells , and lactation .'
p12645
(lp12646
I5
aI6
a(lp12647
I11
atp12648
a(I-1
S'The human pituitary hormones , growth hormone ( hGH ) and prolactin ( hPRL ) , regulate a large variety of physiological processes , among which are growth and differentiation of muscle , bone and cartilage cells , and lactation .'
p12649
(lp12650
I5
aI6
a(lp12651
I13
atp12652
a(I-1
S'The human pituitary hormones , growth hormone ( hGH ) and prolactin ( hPRL ) , regulate a large variety of physiological processes , among which are growth and differentiation of muscle , bone and cartilage cells , and lactation .'
p12653
(lp12654
I8
a(lp12655
I11
atp12656
a(I-1
S'The human pituitary hormones , growth hormone ( hGH ) and prolactin ( hPRL ) , regulate a large variety of physiological processes , among which are growth and differentiation of muscle , bone and cartilage cells , and lactation .'
p12657
(lp12658
I8
a(lp12659
I13
atp12660
a(I-1
S'The human pituitary hormones , growth hormone ( hGH ) and prolactin ( hPRL ) , regulate a large variety of physiological processes , among which are growth and differentiation of muscle , bone and cartilage cells , and lactation .'
p12661
(lp12662
I11
a(lp12663
I13
atp12664
a(I-1
S'The hGH and hPRL receptors ( hGHR and hPRLR , respectively ) are single - pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily .'
p12665
(lp12666
I1
a(lp12667
I3
atp12668
a(I1
S'The hGH and hPRL receptors ( hGHR and hPRLR , respectively ) are single - pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily .'
p12669
(lp12670
I1
a(lp12671
I6
atp12672
a(I-1
S'The hGH and hPRL receptors ( hGHR and hPRLR , respectively ) are single - pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily .'
p12673
(lp12674
I1
a(lp12675
I8
atp12676
a(I-1
S'The hGH and hPRL receptors ( hGHR and hPRLR , respectively ) are single - pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily .'
p12677
(lp12678
I3
a(lp12679
I6
atp12680
a(I1
S'The hGH and hPRL receptors ( hGHR and hPRLR , respectively ) are single - pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily .'
p12681
(lp12682
I3
a(lp12683
I8
atp12684
a(I-1
S'The hGH and hPRL receptors ( hGHR and hPRLR , respectively ) are single - pass transmembrane receptors from class 1 of the haematopoietic receptor superfamily .'
p12685
(lp12686
I6
a(lp12687
I8
atp12688
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12689
(lp12690
I4
a(lp12691
I42
atp12692
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12693
(lp12694
I4
a(lp12695
I48
atp12696
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12697
(lp12698
I4
a(lp12699
I52
atp12700
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12701
(lp12702
I4
a(lp12703
I57
atp12704
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12705
(lp12706
I4
a(lp12707
I59
atp12708
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12709
(lp12710
I4
a(lp12711
I73
atp12712
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12713
(lp12714
I42
a(lp12715
I48
atp12716
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12717
(lp12718
I42
a(lp12719
I52
atp12720
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12721
(lp12722
I42
a(lp12723
I57
atp12724
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12725
(lp12726
I42
a(lp12727
I59
atp12728
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12729
(lp12730
I42
a(lp12731
I73
atp12732
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12733
(lp12734
I48
a(lp12735
I52
atp12736
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12737
(lp12738
I48
a(lp12739
I57
atp12740
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12741
(lp12742
I48
a(lp12743
I59
atp12744
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12745
(lp12746
I48
a(lp12747
I73
atp12748
a(I1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12749
(lp12750
I52
a(lp12751
I57
atp12752
a(I1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12753
(lp12754
I52
a(lp12755
I59
atp12756
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12757
(lp12758
I52
a(lp12759
I73
atp12760
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12761
(lp12762
I57
a(lp12763
I59
atp12764
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12765
(lp12766
I57
a(lp12767
I73
atp12768
a(I-1
S'In the case of hGH , activation involves receptor homodimerization in a sequential process : the active ternary complex containing one ligand and two receptor molecules is formed by association of a receptor molecule to an intermediate 1 : 1 complex . hPRL does not bind to the hGH receptor , but hGH binds to both the hGHR and hPRLR , and mutagenesis studies have shown that the receptor - binding sites on hGH overlap .'
p12769
(lp12770
I59
a(lp12771
I73
atp12772
a(I1
S'We present here the crystal structure of the 1 : 1 complex of hGH bound to the extracellular domain of the hPRLR .'
p12773
(lp12774
I13
a(lp12775
I21
atp12776
a(I1
S'Comparisons with the hGH - hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces .'
p12777
(lp12778
I3
a(lp12779
I5
atp12780
a(I-1
S'Comparisons with the hGH - hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces .'
p12781
(lp12782
I3
a(lp12783
I9
atp12784
a(I-1
S'Comparisons with the hGH - hGHR complex reveal how hGH can bind to the two distinctly different receptor binding surfaces .'
p12785
(lp12786
I5
a(lp12787
I9
atp12788
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12789
(lp12790
I11
a(lp12791
I13
atp12792
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12793
(lp12794
I11
a(lp12795
I20
atp12796
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12797
(lp12798
I11
a(lp12799
I22
atp12800
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12801
(lp12802
I11
a(lp12803
I25
atp12804
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12805
(lp12806
I13
a(lp12807
I20
atp12808
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12809
(lp12810
I13
a(lp12811
I22
atp12812
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12813
(lp12814
I13
a(lp12815
I25
atp12816
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12817
(lp12818
I20
a(lp12819
I22
atp12820
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12821
(lp12822
I20
a(lp12823
I25
atp12824
a(I-1
S'Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90 , hsp70 , and three additional proteins , p54 , p50 , and p23 .'
p12825
(lp12826
I22
a(lp12827
I25
atp12828
a(I-1
S'p23 is also present in immunoaffinity - purified hsp90 complexes along with hsp70 and another protein , p60 .'
p12829
(lp12830
I0
a(lp12831
I8
atp12832
a(I-1
S'p23 is also present in immunoaffinity - purified hsp90 complexes along with hsp70 and another protein , p60 .'
p12833
(lp12834
I0
a(lp12835
I12
atp12836
a(I-1
S'p23 is also present in immunoaffinity - purified hsp90 complexes along with hsp70 and another protein , p60 .'
p12837
(lp12838
I0
a(lp12839
I17
atp12840
a(I-1
S'p23 is also present in immunoaffinity - purified hsp90 complexes along with hsp70 and another protein , p60 .'
p12841
(lp12842
I8
a(lp12843
I12
atp12844
a(I-1
S'p23 is also present in immunoaffinity - purified hsp90 complexes along with hsp70 and another protein , p60 .'
p12845
(lp12846
I8
a(lp12847
I17
atp12848
a(I-1
S'p23 is also present in immunoaffinity - purified hsp90 complexes along with hsp70 and another protein , p60 .'
p12849
(lp12850
I12
a(lp12851
I17
atp12852
a(I-1
S'Antibodies to p23 detect similar levels of p23 in all tissues tested and cross - react with a protein of the same size in mice , rabbits , guinea pigs , humans , and Saccharomyces cerevisiae , indicating that p23 is a conserved protein of broad tissue distribution .'
p12853
(lp12854
I2
a(lp12855
I7
atp12856
a(I-1
S'Antibodies to p23 detect similar levels of p23 in all tissues tested and cross - react with a protein of the same size in mice , rabbits , guinea pigs , humans , and Saccharomyces cerevisiae , indicating that p23 is a conserved protein of broad tissue distribution .'
p12857
(lp12858
I2
a(lp12859
I39
atp12860
a(I-1
S'Antibodies to p23 detect similar levels of p23 in all tissues tested and cross - react with a protein of the same size in mice , rabbits , guinea pigs , humans , and Saccharomyces cerevisiae , indicating that p23 is a conserved protein of broad tissue distribution .'
p12861
(lp12862
I7
a(lp12863
I39
atp12864
a(I-1
S'Bacterially overexpressed human p23 was used to raise several monoclonal antibodies to p23 .'
p12865
(lp12866
I3
a(lp12867
I12
atp12868
a(I1
S'These antibodies specifically immunoprecipitate p23 in complex with hsp90 in all tissues tested and can be used to immunoaffinity isolate progesterone receptor complexes from chicken oviduct cytosol .'
p12869
(lp12870
I4
a(lp12871
I8
atp12872
a(I-1
S'Cloning of the complete coding region for human protein phosphatase inhibitor 2 using the two hybrid system and expression of inhibitor 2 in E . coli .'
p12873
(lp12874
I8
aI9
aI10
aI11
a(lp12875
I20
aI21
atp12876
a(I-1
S'Expression cloning and characterization of a human IL - 10 receptor .'
p12877
(lp12878
I7
aI8
aI9
a(lp12879
I7
aI8
aI9
aI10
atp12880
a(I-1
S'cDNA clones encoding a human IL - 10R ( hIL - 10R ) from a Burkitt lymphoma cell line , BJAB , express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL - 10 specifically .'
p12881
(lp12882
I5
aI6
aI7
a(lp12883
I9
aI10
aI11
atp12884
a(I1
S'cDNA clones encoding a human IL - 10R ( hIL - 10R ) from a Burkitt lymphoma cell line , BJAB , express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL - 10 specifically .'
p12885
(lp12886
I5
aI6
aI7
a(lp12887
I34
aI35
aI36
atp12888
a(I1
S'cDNA clones encoding a human IL - 10R ( hIL - 10R ) from a Burkitt lymphoma cell line , BJAB , express a 90 to 110 kDa polypeptide in COS7 cells that binds hIL - 10 specifically .'
p12889
(lp12890
I9
aI10
aI11
a(lp12891
I34
aI35
aI36
atp12892
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12893
(lp12894
I6
aI7
aI8
a(lp12895
I19
aI20
aI21
atp12896
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12897
(lp12898
I6
aI7
aI8
a(lp12899
I23
aI24
aI25
atp12900
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12901
(lp12902
I6
aI7
aI8
a(lp12903
I28
aI29
aI30
atp12904
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12905
(lp12906
I6
aI7
aI8
a(lp12907
I34
aI35
aI36
atp12908
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12909
(lp12910
I6
aI7
aI8
a(lp12911
I51
aI52
aI53
atp12912
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12913
(lp12914
I6
aI7
aI8
a(lp12915
I73
aI74
aI75
atp12916
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12917
(lp12918
I19
aI20
aI21
a(lp12919
I23
aI24
aI25
atp12920
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12921
(lp12922
I19
aI20
aI21
a(lp12923
I28
aI29
aI30
atp12924
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12925
(lp12926
I19
aI20
aI21
a(lp12927
I34
aI35
aI36
atp12928
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12929
(lp12930
I19
aI20
aI21
a(lp12931
I51
aI52
aI53
atp12932
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12933
(lp12934
I19
aI20
aI21
a(lp12935
I73
aI74
aI75
atp12936
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12937
(lp12938
I23
aI24
aI25
a(lp12939
I28
aI29
aI30
atp12940
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12941
(lp12942
I23
aI24
aI25
a(lp12943
I34
aI35
aI36
atp12944
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12945
(lp12946
I23
aI24
aI25
a(lp12947
I51
aI52
aI53
atp12948
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12949
(lp12950
I23
aI24
aI25
a(lp12951
I73
aI74
aI75
atp12952
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12953
(lp12954
I28
aI29
aI30
a(lp12955
I34
aI35
aI36
atp12956
a(I1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12957
(lp12958
I28
aI29
aI30
a(lp12959
I51
aI52
aI53
atp12960
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12961
(lp12962
I28
aI29
aI30
a(lp12963
I73
aI74
aI75
atp12964
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12965
(lp12966
I34
aI35
aI36
a(lp12967
I51
aI52
aI53
atp12968
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12969
(lp12970
I34
aI35
aI36
a(lp12971
I73
aI74
aI75
atp12972
a(I-1
S'The predicted amino acid sequence of hIL - 10R is 60 % identical and 73 % similar to mouse IL - 10R ( mIL - 10R ) . rIL - 10R expressed in an IL - 3 - dependent mouse pro - B cell line ( Ba / F3 ) binds hIL - 10 with high affinity ( 200 to 250 pM ) , and the transfected cells exhibit a proliferative response to hIL - 10 .'
p12973
(lp12974
I51
aI52
aI53
a(lp12975
I73
aI74
aI75
atp12976
a(I-1
S'Mouse IL - 10 does not bind to hIL - 10R , and hIL - 10R - expressing Ba / F3 cells do not respond to the mouse cytokine , observations consistent with the known species specificity of IL - 10 .'
p12977
(lp12978
I1
aI2
aI3
a(lp12979
I8
aI9
aI10
atp12980
a(I-1
S'Mouse IL - 10 does not bind to hIL - 10R , and hIL - 10R - expressing Ba / F3 cells do not respond to the mouse cytokine , observations consistent with the known species specificity of IL - 10 .'
p12981
(lp12982
I1
aI2
aI3
a(lp12983
I13
aI14
aI15
atp12984
a(I-1
S'Mouse IL - 10 does not bind to hIL - 10R , and hIL - 10R - expressing Ba / F3 cells do not respond to the mouse cytokine , observations consistent with the known species specificity of IL - 10 .'
p12985
(lp12986
I1
aI2
aI3
a(lp12987
I38
aI39
aI40
atp12988
a(I-1
S'Mouse IL - 10 does not bind to hIL - 10R , and hIL - 10R - expressing Ba / F3 cells do not respond to the mouse cytokine , observations consistent with the known species specificity of IL - 10 .'
p12989
(lp12990
I8
aI9
aI10
a(lp12991
I13
aI14
aI15
atp12992
a(I-1
S'Mouse IL - 10 does not bind to hIL - 10R , and hIL - 10R - expressing Ba / F3 cells do not respond to the mouse cytokine , observations consistent with the known species specificity of IL - 10 .'
p12993
(lp12994
I8
aI9
aI10
a(lp12995
I38
aI39
aI40
atp12996
a(I-1
S'Mouse IL - 10 does not bind to hIL - 10R , and hIL - 10R - expressing Ba / F3 cells do not respond to the mouse cytokine , observations consistent with the known species specificity of IL - 10 .'
p12997
(lp12998
I13
aI14
aI15
a(lp12999
I38
aI39
aI40
atp13000
a(I-1
S'In a number of human T cell clones , expression of hIL - 10R mRNA is down - regulated after activation of the cells with anti - CD3 Ab and phorbol ester .'
p13001
(lp13002
I11
aI12
aI13
a(lp13003
I27
atp13004
a(I-1
S'Like mIL - 10R , hIL - 10R is structurally related to IFNR .'
p13005
(lp13006
I1
aI2
aI3
a(lp13007
I5
aI6
aI7
atp13008
a(I-1
S'Like mIL - 10R , hIL - 10R is structurally related to IFNR .'
p13009
(lp13010
I1
aI2
aI3
a(lp13011
I12
atp13012
a(I-1
S'Like mIL - 10R , hIL - 10R is structurally related to IFNR .'
p13013
(lp13014
I5
aI6
aI7
a(lp13015
I12
atp13016
a(I-1
S'Because IL - 10 inhibits macrophage activation by IFN - gamma , this relationship suggests possible shared receptor or signal transduction pathway components .'
p13017
(lp13018
I1
aI2
aI3
a(lp13019
I8
aI9
aI10
atp13020
a(I-1
S'Functional participation of the IL - 2 receptor gamma chain in IL - 7 receptor complexes .'
p13021
(lp13022
I4
aI5
aI6
a(lp13023
I4
aI5
aI6
aI7
aI8
atp13024
a(I-1
S'Functional participation of the IL - 2 receptor gamma chain in IL - 7 receptor complexes .'
p13025
(lp13026
I4
aI5
aI6
a(lp13027
I11
aI12
aI13
atp13028
a(I-1
S'Functional participation of the IL - 2 receptor gamma chain in IL - 7 receptor complexes .'
p13029
(lp13030
I4
aI5
aI6
a(lp13031
I11
aI12
aI13
aI14
atp13032
a(I-1
S'Functional participation of the IL - 2 receptor gamma chain in IL - 7 receptor complexes .'
p13033
(lp13034
I4
aI5
aI6
aI7
aI8
a(lp13035
I11
aI12
aI13
atp13036
a(I-1
S'Functional participation of the IL - 2 receptor gamma chain in IL - 7 receptor complexes .'
p13037
(lp13038
I4
aI5
aI6
aI7
aI8
a(lp13039
I11
aI12
aI13
aI14
atp13040
a(I-1
S'Functional participation of the IL - 2 receptor gamma chain in IL - 7 receptor complexes .'
p13041
(lp13042
I11
aI12
aI13
a(lp13043
I11
aI12
aI13
aI14
atp13044
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13045
(lp13046
I5
aI6
aI7
a(lp13047
I9
aI10
aI11
atp13048
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13049
(lp13050
I5
aI6
aI7
a(lp13051
I5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
atp13052
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13053
(lp13054
I5
aI6
aI7
a(lp13055
I19
aI20
aI21
atp13056
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13057
(lp13058
I5
aI6
aI7
a(lp13059
I19
aI20
aI21
aI22
atp13060
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13061
(lp13062
I9
aI10
aI11
a(lp13063
I5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
atp13064
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13065
(lp13066
I9
aI10
aI11
a(lp13067
I19
aI20
aI21
atp13068
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13069
(lp13070
I9
aI10
aI11
a(lp13071
I19
aI20
aI21
aI22
atp13072
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13073
(lp13074
I5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp13075
I19
aI20
aI21
atp13076
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13077
(lp13078
I5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp13079
I19
aI20
aI21
aI22
atp13080
a(I-1
S'The gamma chain of the interleukin - 2 ( IL - 2 ) receptor is shared with the functional IL - 4 receptor and is causatively related to X - linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .'
p13081
(lp13082
I19
aI20
aI21
a(lp13083
I19
aI20
aI21
aI22
atp13084
a(I-1
S'Studies with monoclonal antibodies specific for the IL - 2 receptor gamma chain showed that the gamma chain participates in the functional high - affinity receptor complexes for IL - 7 that are involved in the differentiation of T and B cells .'
p13085
(lp13086
I7
aI8
aI9
a(lp13087
I28
aI29
aI30
atp13088
a(I-1
S'JNK1 : a protein kinase stimulated by UV light and Ha - Ras that binds and phosphorylates the c - Jun activation domain .'
p13089
(lp13090
I0
a(lp13091
I10
aI11
aI12
atp13092
a(I1
S'JNK1 : a protein kinase stimulated by UV light and Ha - Ras that binds and phosphorylates the c - Jun activation domain .'
p13093
(lp13094
I0
a(lp13095
I18
aI19
aI20
atp13096
a(I-1
S'JNK1 : a protein kinase stimulated by UV light and Ha - Ras that binds and phosphorylates the c - Jun activation domain .'
p13097
(lp13098
I10
aI11
aI12
a(lp13099
I18
aI19
aI20
atp13100
a(I-1
S'The ultraviolet ( UV ) response of mammalian cells is characterized by a rapid and selective increase in gene expression mediated by AP - 1 and NF - kappa B .'
p13101
(lp13102
I22
aI23
aI24
a(lp13103
I26
aI27
aI28
aI29
atp13104
a(I-1
S'The effect on AP - 1 transcriptional activity results , in part , from enhanced phosphorylation of the c - Jun NH2 - terminal activation domain .'
p13105
(lp13106
I3
aI4
aI5
a(lp13107
I18
aI19
aI20
atp13108
a(I-1
S'Here , we describe the molecular cloning and characterization of JNK1 , a distant relative of the MAP kinase group that is activated by dual phosphorylation at Thr and Tyr during the UV response .'
p13109
(lp13110
I10
a(lp13111
I17
aI18
atp13112
a(I1
S'Significantly , Ha - Ras partially activates JNK1 and potentiates the activation caused by UV .'
p13113
(lp13114
I2
aI3
aI4
a(lp13115
I7
atp13116
a(I1
S'JNK1 binds to the c - Jun transactivation domain and phosphorylates it on Ser - 63 and Ser - 73 .'
p13117
(lp13118
I0
a(lp13119
I4
aI5
aI6
atp13120
a(I-1
S'B61 is a ligand for the ECK receptor protein - tyrosine kinase .'
p13121
(lp13122
I0
a(lp13123
I6
atp13124
a(I1
S'B61 is a ligand for the ECK receptor protein - tyrosine kinase .'
p13125
(lp13126
I0
a(lp13127
I6
aI7
aI8
aI9
aI10
aI11
atp13128
a(I-1
S'B61 is a ligand for the ECK receptor protein - tyrosine kinase .'
p13129
(lp13130
I6
a(lp13131
I6
aI7
aI8
aI9
aI10
aI11
atp13132
a(I-1
S'A protein ligand for the ECK receptor protein - tyrosine kinase has been isolated by using the extracellular domain ( ECK - X ) of the receptor as an affinity reagent .'
p13133
(lp13134
I5
a(lp13135
I5
aI6
aI7
aI8
aI9
aI10
atp13136
a(I-1
S'A protein ligand for the ECK receptor protein - tyrosine kinase has been isolated by using the extracellular domain ( ECK - X ) of the receptor as an affinity reagent .'
p13137
(lp13138
I5
a(lp13139
I20
atp13140
a(I-1
S'A protein ligand for the ECK receptor protein - tyrosine kinase has been isolated by using the extracellular domain ( ECK - X ) of the receptor as an affinity reagent .'
p13141
(lp13142
I5
aI6
aI7
aI8
aI9
aI10
a(lp13143
I20
atp13144
a(I-1
S'Subsequently , supernatants from selected cell lines were fractionated directly by receptor affinity chromatography , resulting in the single - step purification of B61 , a protein previously identified as the product of an early response gene induced by tumour necrosis factor - alpha .'
p13145
(lp13146
I23
a(lp13147
I39
aI40
aI41
aI42
aI43
atp13148
a(I1
S'We report here that recombinant B61 induces autophosphorylation of ECK in intact cells , consistent with B61 being an authentic ligand for ECK .'
p13149
(lp13150
I5
a(lp13151
I9
atp13152
a(I-1
S'We report here that recombinant B61 induces autophosphorylation of ECK in intact cells , consistent with B61 being an authentic ligand for ECK .'
p13153
(lp13154
I5
a(lp13155
I16
atp13156
a(I-1
S'We report here that recombinant B61 induces autophosphorylation of ECK in intact cells , consistent with B61 being an authentic ligand for ECK .'
p13157
(lp13158
I5
a(lp13159
I22
atp13160
a(I-1
S'We report here that recombinant B61 induces autophosphorylation of ECK in intact cells , consistent with B61 being an authentic ligand for ECK .'
p13161
(lp13162
I9
a(lp13163
I16
atp13164
a(I-1
S'We report here that recombinant B61 induces autophosphorylation of ECK in intact cells , consistent with B61 being an authentic ligand for ECK .'
p13165
(lp13166
I9
a(lp13167
I22
atp13168
a(I1
S'We report here that recombinant B61 induces autophosphorylation of ECK in intact cells , consistent with B61 being an authentic ligand for ECK .'
p13169
(lp13170
I16
a(lp13171
I22
atp13172
a(I-1
S'ECK is a member of a large orphan receptor protein - tyrosine kinase family headed by EPH , and we suggest that ligands for other members of this family will be related to B61 , and can be isolated in the same way .'
p13173
(lp13174
I0
a(lp13175
I33
atp13176
a(I-1
S'Tumor necrosis factor ( TNF ) and lymphotoxin - alpha ( LT - alpha ) are members of a family of secreted and cell surface cytokines that participate in the regulation of immune and inflammatory responses .'
p13177
(lp13178
I7
aI8
aI9
a(lp13179
I11
aI12
aI13
atp13180
a(I1
S'The cell surface form of LT - alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin - beta ( LT - beta ) , a type II transmembrane protein that is another member of the TNF ligand family .'
p13181
(lp13182
I5
aI6
aI7
a(lp13183
I17
aI18
aI19
atp13184
a(I1
S'The cell surface form of LT - alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin - beta ( LT - beta ) , a type II transmembrane protein that is another member of the TNF ligand family .'
p13185
(lp13186
I5
aI6
aI7
a(lp13187
I21
aI22
aI23
atp13188
a(I-1
S'The cell surface form of LT - alpha is assembled during biosynthesis as a heteromeric complex with lymphotoxin - beta ( LT - beta ) , a type II transmembrane protein that is another member of the TNF ligand family .'
p13189
(lp13190
I17
aI18
aI19
a(lp13191
I21
aI22
aI23
atp13192
a(I-1
S'Secreted LT - alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons ; however , these receptors do not recognize the major cell surface LT - alpha - LT - beta complex .'
p13193
(lp13194
I1
aI2
aI3
a(lp13195
I30
aI31
aI32
atp13196
a(I-1
S'Secreted LT - alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons ; however , these receptors do not recognize the major cell surface LT - alpha - LT - beta complex .'
p13197
(lp13198
I1
aI2
aI3
a(lp13199
I34
aI35
aI36
atp13200
a(I1
S'Secreted LT - alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons ; however , these receptors do not recognize the major cell surface LT - alpha - LT - beta complex .'
p13201
(lp13202
I30
aI31
aI32
a(lp13203
I34
aI35
aI36
atp13204
a(I-1
S'A receptor specific for human LT - beta was identified , which suggests that cell surface LT may have functions that are distinct from those of secreted LT - alpha .'
p13205
(lp13206
I5
aI6
aI7
a(lp13207
I27
aI28
aI29
atp13208
a(I-1
S'The cytokine , designated interleukin - 15 ( IL - 15 ) , is produced by a wide variety of cells and tissues and shares many biological properties with IL - 2 .'
p13209
(lp13210
I4
aI5
aI6
a(lp13211
I8
aI9
aI10
atp13212
a(I-1
S'The cytokine , designated interleukin - 15 ( IL - 15 ) , is produced by a wide variety of cells and tissues and shares many biological properties with IL - 2 .'
p13213
(lp13214
I4
aI5
aI6
a(lp13215
I29
aI30
aI31
atp13216
a(I-1
S'The cytokine , designated interleukin - 15 ( IL - 15 ) , is produced by a wide variety of cells and tissues and shares many biological properties with IL - 2 .'
p13217
(lp13218
I8
aI9
aI10
a(lp13219
I29
aI30
aI31
atp13220
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13221
(lp13222
I8
aI9
aI10
a(lp13223
I17
aI18
aI19
atp13224
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13225
(lp13226
I8
aI9
aI10
a(lp13227
I22
aI23
aI24
atp13228
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13229
(lp13230
I8
aI9
aI10
a(lp13231
I29
aI30
aI31
atp13232
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13233
(lp13234
I8
aI9
aI10
a(lp13235
I35
aI36
aI37
atp13236
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13237
(lp13238
I8
aI9
aI10
a(lp13239
I42
aI43
aI44
atp13240
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13241
(lp13242
I8
aI9
aI10
a(lp13243
I42
aI43
aI44
aI45
atp13244
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13245
(lp13246
I17
aI18
aI19
a(lp13247
I22
aI23
aI24
atp13248
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13249
(lp13250
I17
aI18
aI19
a(lp13251
I29
aI30
aI31
atp13252
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13253
(lp13254
I17
aI18
aI19
a(lp13255
I35
aI36
aI37
atp13256
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13257
(lp13258
I17
aI18
aI19
a(lp13259
I42
aI43
aI44
atp13260
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13261
(lp13262
I17
aI18
aI19
a(lp13263
I42
aI43
aI44
aI45
atp13264
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13265
(lp13266
I22
aI23
aI24
a(lp13267
I29
aI30
aI31
atp13268
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13269
(lp13270
I22
aI23
aI24
a(lp13271
I35
aI36
aI37
atp13272
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13273
(lp13274
I22
aI23
aI24
a(lp13275
I42
aI43
aI44
atp13276
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13277
(lp13278
I22
aI23
aI24
a(lp13279
I42
aI43
aI44
aI45
atp13280
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13281
(lp13282
I29
aI30
aI31
a(lp13283
I35
aI36
aI37
atp13284
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13285
(lp13286
I29
aI30
aI31
a(lp13287
I42
aI43
aI44
atp13288
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13289
(lp13290
I29
aI30
aI31
a(lp13291
I42
aI43
aI44
aI45
atp13292
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13293
(lp13294
I35
aI36
aI37
a(lp13295
I42
aI43
aI44
atp13296
a(I1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13297
(lp13298
I35
aI36
aI37
a(lp13299
I42
aI43
aI44
aI45
atp13300
a(I-1
S'Monoclonal antibodies to the beta chain of the IL - 2 receptor inhibited the biological activity of IL - 15 , and IL - 15 competed for binding with IL - 2 , indicating that IL - 15 uses components of the IL - 2 receptor .'
p13301
(lp13302
I42
aI43
aI44
a(lp13303
I42
aI43
aI44
aI45
atp13304
a(I-1
S'The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP .'
p13305
(lp13306
I5
a(lp13307
I7
atp13308
a(I1
S'The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP .'
p13309
(lp13310
I5
a(lp13311
I14
atp13312
a(I1
S'The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP .'
p13313
(lp13314
I7
a(lp13315
I14
atp13316
a(I-1
S'We had previously shown that the ubiquitous Oct1 and the lymphoid - specific Oct2 transcription factors stimulate transcription at the level of stable preinitiation complex formation .'
p13317
(lp13318
I7
a(lp13319
I13
atp13320
a(I-1
S'We have therefore investigated whether the octamer binding proteins might physically interact with TBP , the TATA box binding protein component of the TFIID factor .'
p13321
(lp13322
I13
a(lp13323
I16
aI17
aI18
aI19
atp13324
a(I-1
S'We have therefore investigated whether the octamer binding proteins might physically interact with TBP , the TATA box binding protein component of the TFIID factor .'
p13325
(lp13326
I13
a(lp13327
I23
atp13328
a(I-1
S'We have therefore investigated whether the octamer binding proteins might physically interact with TBP , the TATA box binding protein component of the TFIID factor .'
p13329
(lp13330
I16
aI17
aI18
aI19
a(lp13331
I23
atp13332
a(I1
S'By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2 .'
p13333
(lp13334
I9
a(lp13335
I13
atp13336
a(I1
S'By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2 .'
p13337
(lp13338
I9
a(lp13339
I15
atp13340
a(I-1
S'By using several different experimental systems we show that TBP efficiently associates with Oct1 and Oct2 .'
p13341
(lp13342
I13
a(lp13343
I15
atp13344
a(I1
S'We show that the POU homeodomain of Oct2 and the evolutionarily conserved C - terminal core domain of TBP are both required and sufficient for the interaction .'
p13345
(lp13346
I7
a(lp13347
I18
atp13348
a(I-1
S'The Oct1 POU domain , which is highly homologous to the Oct2 POU domain , likewise mediates interaction with TBP .'
p13349
(lp13350
I1
a(lp13351
I11
atp13352
a(I1
S'The Oct1 POU domain , which is highly homologous to the Oct2 POU domain , likewise mediates interaction with TBP .'
p13353
(lp13354
I1
a(lp13355
I19
atp13356
a(I-1
S'The Oct1 POU domain , which is highly homologous to the Oct2 POU domain , likewise mediates interaction with TBP .'
p13357
(lp13358
I11
a(lp13359
I19
atp13360
a(I1
S'The interaction can also be observed in vivo , as TBP can be co - precipitated with Oct2 from co - transfected Cos1 cells and TBP co - immunoprecipitates with the endogenous Oct1 from HeLa cells .'
p13361
(lp13362
I10
a(lp13363
I17
atp13364
a(I-1
S'The interaction can also be observed in vivo , as TBP can be co - precipitated with Oct2 from co - transfected Cos1 cells and TBP co - immunoprecipitates with the endogenous Oct1 from HeLa cells .'
p13365
(lp13366
I10
a(lp13367
I25
atp13368
a(I-1
S'The interaction can also be observed in vivo , as TBP can be co - precipitated with Oct2 from co - transfected Cos1 cells and TBP co - immunoprecipitates with the endogenous Oct1 from HeLa cells .'
p13369
(lp13370
I10
a(lp13371
I32
atp13372
a(I-1
S'The interaction can also be observed in vivo , as TBP can be co - precipitated with Oct2 from co - transfected Cos1 cells and TBP co - immunoprecipitates with the endogenous Oct1 from HeLa cells .'
p13373
(lp13374
I17
a(lp13375
I25
atp13376
a(I-1
S'The interaction can also be observed in vivo , as TBP can be co - precipitated with Oct2 from co - transfected Cos1 cells and TBP co - immunoprecipitates with the endogenous Oct1 from HeLa cells .'
p13377
(lp13378
I17
a(lp13379
I32
atp13380
a(I1
S'The interaction can also be observed in vivo , as TBP can be co - precipitated with Oct2 from co - transfected Cos1 cells and TBP co - immunoprecipitates with the endogenous Oct1 from HeLa cells .'
p13381
(lp13382
I25
a(lp13383
I32
atp13384
a(I-1
S'Co - transfection of human TBP and Oct2 expression vectors into B cells resulted in a synergistic activation of an octamer motif containing promoter .'
p13385
(lp13386
I5
a(lp13387
I7
atp13388
a(I1
S'Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60 - kD subunit to yeast PRP9 .'
p13389
(lp13390
I5
a(lp13391
I7
aI8
atp13392
a(I-1
S'Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60 - kD subunit to yeast PRP9 .'
p13393
(lp13394
I5
a(lp13395
I19
atp13396
a(I-1
S'Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60 - kD subunit to yeast PRP9 .'
p13397
(lp13398
I7
aI8
a(lp13399
I19
atp13400
a(I-1
S'In the assembly of a prespliceosome , U2 small nuclear ribonucleoprotein ( snRNP ) functions in pre - messenger RNA ( mRNA ) splicing together with splicing factors ( SFs ) 3a , SF3b , and several other proteins .'
p13401
(lp13402
I7
aI8
aI9
aI10
a(lp13403
I33
atp13404
a(I-1
S'Here it is shown that the SF3a subunits correspond to three of the 17S U2 snRNP - specific polypeptides .'
p13405
(lp13406
I6
a(lp13407
I14
aI15
atp13408
a(I1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13409
(lp13410
I0
a(lp13411
I3
aI4
atp13412
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13413
(lp13414
I0
a(lp13415
I9
atp13416
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13417
(lp13418
I0
a(lp13419
I17
aI18
atp13420
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13421
(lp13422
I0
a(lp13423
I25
atp13424
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13425
(lp13426
I0
a(lp13427
I27
atp13428
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13429
(lp13430
I0
a(lp13431
I32
aI33
atp13432
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13433
(lp13434
I3
aI4
a(lp13435
I9
atp13436
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13437
(lp13438
I3
aI4
a(lp13439
I17
aI18
atp13440
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13441
(lp13442
I3
aI4
a(lp13443
I25
atp13444
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13445
(lp13446
I3
aI4
a(lp13447
I27
atp13448
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13449
(lp13450
I3
aI4
a(lp13451
I32
aI33
atp13452
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13453
(lp13454
I9
a(lp13455
I17
aI18
atp13456
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13457
(lp13458
I9
a(lp13459
I25
atp13460
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13461
(lp13462
I9
a(lp13463
I27
atp13464
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13465
(lp13466
I9
a(lp13467
I32
aI33
atp13468
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13469
(lp13470
I17
aI18
a(lp13471
I25
atp13472
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13473
(lp13474
I17
aI18
a(lp13475
I27
atp13476
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13477
(lp13478
I17
aI18
a(lp13479
I32
aI33
atp13480
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13481
(lp13482
I25
a(lp13483
I27
atp13484
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13485
(lp13486
I25
a(lp13487
I32
aI33
atp13488
a(I-1
S'SF3a interacts with U2 snRNP in the presence of SF3b to generate a structure similar to 17S U2 snRNP , which suggests a function for SF3a and SF3b in the incorporation of U2 snRNP into the spliceosome .'
p13489
(lp13490
I27
a(lp13491
I32
aI33
atp13492
a(I-1
S'Furthermore , the 60 - kilodalton subunit of SF3a is related to the yeast splicing protein PRP9 .'
p13493
(lp13494
I8
a(lp13495
I16
atp13496
a(I-1
S'Spectrin cagliari . an Ala - - > Gly substitution in helix 1 of beta spectrin repeat 17 that severely disrupts the structure and self - association of the erythrocyte spectrin heterodimer .'
p13497
(lp13498
I0
aI1
a(lp13499
I14
aI15
atp13500
a(I1
S'The self - association site appears to be formed by interactions between helices 1 and 2 of beta spectrin repeat 17 of one dimer with helix 3 of alpha spectrin repeat 1 of the other dimer to form two combined alpha - beta triple - helical segments .'
p13501
(lp13502
I17
aI18
a(lp13503
I28
aI29
atp13504
a(I-1
S'Following linkage studies which were most consistent with a beta spectrin gene mutation , a nucleotide change was identified in codon 2018 , resulting in an Ala - - > Gly substitution in the first helical domain of beta spectrin repeat 17 .'
p13505
(lp13506
I9
aI10
a(lp13507
I38
aI39
atp13508
a(I1
S'Cdi1 , a human G1 and S phase protein phosphatase that associates with Cdk2 .'
p13509
(lp13510
I0
a(lp13511
I13
atp13512
a(I-1
S'We used the interaction trap , a yeast genetic selection for interacting proteins , to isolate human cyclin - dependent kinase interactor 1 ( Cdi1 ) .'
p13513
(lp13514
I17
aI18
aI19
aI20
aI21
aI22
a(lp13515
I24
atp13516
a(I1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13517
(lp13518
I3
a(lp13519
I13
atp13520
a(I1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13521
(lp13522
I3
a(lp13523
I15
atp13524
a(I1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13525
(lp13526
I3
a(lp13527
I18
atp13528
a(I-1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13529
(lp13530
I3
a(lp13531
I23
atp13532
a(I-1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13533
(lp13534
I13
a(lp13535
I15
atp13536
a(I-1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13537
(lp13538
I13
a(lp13539
I18
atp13540
a(I-1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13541
(lp13542
I13
a(lp13543
I23
atp13544
a(I-1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13545
(lp13546
I15
a(lp13547
I18
atp13548
a(I-1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13549
(lp13550
I15
a(lp13551
I23
atp13552
a(I-1
S'In yeast , Cdi1 interacts with cyclin - dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with Cdk4 .'
p13553
(lp13554
I18
a(lp13555
I23
atp13556
a(I1
S'In HeLa cells , Cdi1 is expressed at the G1 to S transition , and the protein forms stable complexes with Cdk2 .'
p13557
(lp13558
I4
a(lp13559
I21
atp13560
a(I-1
S'Overexpression of wild - type Cdi1 delays progression through the cell cycle in yeast and HeLa cells ; delay is dependent on Cdi1 phosphatase activity .'
p13561
(lp13562
I5
a(lp13563
I22
atp13564
a(I-1
S'The p21 Cdk - interacting protein Cip1 is a potent inhibitor of G1 cyclin - dependent kinases .'
p13565
(lp13566
I1
a(lp13567
I6
atp13568
a(I-1
S'The cyclin - dependent kinase Cdk2 associates with cyclins A , D , and E and has been implicated in the control of the G1 to S phase transition in mammals .'
p13569
(lp13570
I5
a(lp13571
I8
aI9
atp13572
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13573
(lp13574
I0
a(lp13575
I11
aI12
atp13576
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13577
(lp13578
I0
a(lp13579
I14
aI15
atp13580
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13581
(lp13582
I0
a(lp13583
I17
aI18
atp13584
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13585
(lp13586
I0
a(lp13587
I21
atp13588
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13589
(lp13590
I11
aI12
a(lp13591
I14
aI15
atp13592
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13593
(lp13594
I11
aI12
a(lp13595
I17
aI18
atp13596
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13597
(lp13598
I11
aI12
a(lp13599
I21
atp13600
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13601
(lp13602
I14
aI15
a(lp13603
I17
aI18
atp13604
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13605
(lp13606
I14
aI15
a(lp13607
I21
atp13608
a(I-1
S'CIP1 encodes a novel 21 kd protein that is found in cyclin A , cyclin D1 , cyclin E , and Cdk2 immunoprecipitates .'
p13609
(lp13610
I17
aI18
a(lp13611
I21
atp13612
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13613
(lp13614
I0
a(lp13615
I17
atp13616
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13617
(lp13618
I0
a(lp13619
I19
aI20
atp13620
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13621
(lp13622
I0
a(lp13623
I22
atp13624
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13625
(lp13626
I0
a(lp13627
I24
aI25
atp13628
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13629
(lp13630
I0
a(lp13631
I27
atp13632
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13633
(lp13634
I0
a(lp13635
I29
aI30
atp13636
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13637
(lp13638
I0
a(lp13639
I32
atp13640
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13641
(lp13642
I0
a(lp13643
I35
aI36
atp13644
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13645
(lp13646
I0
a(lp13647
I38
atp13648
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13649
(lp13650
I17
a(lp13651
I19
aI20
atp13652
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13653
(lp13654
I17
a(lp13655
I22
atp13656
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13657
(lp13658
I17
a(lp13659
I24
aI25
atp13660
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13661
(lp13662
I17
a(lp13663
I27
atp13664
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13665
(lp13666
I17
a(lp13667
I29
aI30
atp13668
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13669
(lp13670
I17
a(lp13671
I32
atp13672
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13673
(lp13674
I17
a(lp13675
I35
aI36
atp13676
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13677
(lp13678
I17
a(lp13679
I38
atp13680
a(I1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13681
(lp13682
I19
aI20
a(lp13683
I22
atp13684
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13685
(lp13686
I19
aI20
a(lp13687
I24
aI25
atp13688
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13689
(lp13690
I19
aI20
a(lp13691
I27
atp13692
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13693
(lp13694
I19
aI20
a(lp13695
I29
aI30
atp13696
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13697
(lp13698
I19
aI20
a(lp13699
I32
atp13700
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13701
(lp13702
I19
aI20
a(lp13703
I35
aI36
atp13704
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13705
(lp13706
I19
aI20
a(lp13707
I38
atp13708
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13709
(lp13710
I22
a(lp13711
I24
aI25
atp13712
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13713
(lp13714
I22
a(lp13715
I27
atp13716
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13717
(lp13718
I22
a(lp13719
I29
aI30
atp13720
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13721
(lp13722
I22
a(lp13723
I32
atp13724
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13725
(lp13726
I22
a(lp13727
I35
aI36
atp13728
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13729
(lp13730
I22
a(lp13731
I38
atp13732
a(I1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13733
(lp13734
I24
aI25
a(lp13735
I27
atp13736
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13737
(lp13738
I24
aI25
a(lp13739
I29
aI30
atp13740
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13741
(lp13742
I24
aI25
a(lp13743
I32
atp13744
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13745
(lp13746
I24
aI25
a(lp13747
I35
aI36
atp13748
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13749
(lp13750
I24
aI25
a(lp13751
I38
atp13752
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13753
(lp13754
I27
a(lp13755
I29
aI30
atp13756
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13757
(lp13758
I27
a(lp13759
I32
atp13760
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13761
(lp13762
I27
a(lp13763
I35
aI36
atp13764
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13765
(lp13766
I27
a(lp13767
I38
atp13768
a(I1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13769
(lp13770
I29
aI30
a(lp13771
I32
atp13772
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13773
(lp13774
I29
aI30
a(lp13775
I35
aI36
atp13776
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13777
(lp13778
I29
aI30
a(lp13779
I38
atp13780
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13781
(lp13782
I32
a(lp13783
I35
aI36
atp13784
a(I-1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13785
(lp13786
I32
a(lp13787
I38
atp13788
a(I1
S'p21CIP1 is a potent , tight - binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A - Cdk2 , cyclin E - Cdk2 , cyclin D1 - Cdk4 , and cyclin D2 - Cdk4 complexes .'
p13789
(lp13790
I35
aI36
a(lp13791
I38
atp13792
a(I-1
S'Cotransfection experiments indicate that CIP1 and SV40 T antigen function in a mutually antagonistic manner to control cell cycle progression .'
p13793
(lp13794
I4
a(lp13795
I6
aI7
aI8
atp13796
a(I1
S'Evidence for physical interaction between the zinc - finger transcription factors YY1 and Sp1 .'
p13797
(lp13798
I11
a(lp13799
I13
atp13800
a(I-1
S'The recently cloned YY1 is such an Inr - binding protein .'
p13801
(lp13802
I3
a(lp13803
I7
aI8
aI9
aI10
atp13804
a(I-1
S'The ability of YY1 to initiate transcription is augmented by the presence of a TATA motif or binding sites for transcription factor Sp1 .'
p13805
(lp13806
I3
a(lp13807
I22
atp13808
a(I-1
S'To study the mechanism underlying the apparent functional cooperation between YY1 and Sp1 , we explored the possibility of protein - protein interactions between these two transcription factors .'
p13809
(lp13810
I10
a(lp13811
I12
atp13812
a(I1
S'We found that YY1 and Sp1 can form a physical complex .'
p13813
(lp13814
I3
a(lp13815
I5
atp13816
a(I1
S'In addition , we identified domains within YY1 and Sp1 that mediate their interactions with each other .'
p13817
(lp13818
I7
a(lp13819
I9
atp13820
a(I1
S'The physical interaction between YY1 and Sp1 may thus form the basis for the functional interplay observed previously .'
p13821
(lp13822
I4
a(lp13823
I6
atp13824
a(I-1
S'Involvement of IL - 6 signal transducer gp130 in IL - 11 - mediated signal transduction .'
p13825
(lp13826
I2
aI3
aI4
a(lp13827
I7
atp13828
a(I-1
S'Involvement of IL - 6 signal transducer gp130 in IL - 11 - mediated signal transduction .'
p13829
(lp13830
I2
aI3
aI4
a(lp13831
I9
aI10
aI11
atp13832
a(I-1
S'Involvement of IL - 6 signal transducer gp130 in IL - 11 - mediated signal transduction .'
p13833
(lp13834
I7
a(lp13835
I9
aI10
aI11
atp13836
a(I-1
S'IL - 11 is a novel cytokine with a variety of biofunctions which overlap with those of IL - 6 .'
p13837
(lp13838
I0
aI1
aI2
a(lp13839
I17
aI18
aI19
atp13840
a(I-1
S'We have previously identified IL - 11 specific binding protein which is distinct from that of IL - 6 in a number of cell lines .'
p13841
(lp13842
I4
aI5
aI6
a(lp13843
I16
aI17
aI18
atp13844
a(I-1
S'The similarities in biofunctions and differences in ligand binding proteins between IL - 11 and IL - 6 prompted us to investigate whether IL - 11 shares common signal transduction mechanisms with IL - 6 .'
p13845
(lp13846
I11
aI12
aI13
a(lp13847
I15
aI16
aI17
atp13848
a(I-1
S'The similarities in biofunctions and differences in ligand binding proteins between IL - 11 and IL - 6 prompted us to investigate whether IL - 11 shares common signal transduction mechanisms with IL - 6 .'
p13849
(lp13850
I11
aI12
aI13
a(lp13851
I23
aI24
aI25
atp13852
a(I-1
S'The similarities in biofunctions and differences in ligand binding proteins between IL - 11 and IL - 6 prompted us to investigate whether IL - 11 shares common signal transduction mechanisms with IL - 6 .'
p13853
(lp13854
I11
aI12
aI13
a(lp13855
I32
aI33
aI34
atp13856
a(I-1
S'The similarities in biofunctions and differences in ligand binding proteins between IL - 11 and IL - 6 prompted us to investigate whether IL - 11 shares common signal transduction mechanisms with IL - 6 .'
p13857
(lp13858
I15
aI16
aI17
a(lp13859
I23
aI24
aI25
atp13860
a(I-1
S'The similarities in biofunctions and differences in ligand binding proteins between IL - 11 and IL - 6 prompted us to investigate whether IL - 11 shares common signal transduction mechanisms with IL - 6 .'
p13861
(lp13862
I15
aI16
aI17
a(lp13863
I32
aI33
aI34
atp13864
a(I-1
S'The similarities in biofunctions and differences in ligand binding proteins between IL - 11 and IL - 6 prompted us to investigate whether IL - 11 shares common signal transduction mechanisms with IL - 6 .'
p13865
(lp13866
I23
aI24
aI25
a(lp13867
I32
aI33
aI34
atp13868
a(I-1
S'We have examined early signals triggered by IL - 11 or IL - 6 in a multifactor - dependent human erythroleukemic cell line , TF - 1 .'
p13869
(lp13870
I7
aI8
aI9
a(lp13871
I11
aI12
aI13
atp13872
a(I-1
S'The results showed that IL - 11 and IL - 6 can both stimulate cell proliferation , induce similar pattern of protein tyrosine phosphorylation , and activate the same proto - oncogene ( junB ) expression in TF - 1 cells .'
p13873
(lp13874
I4
aI5
aI6
a(lp13875
I8
aI9
aI10
atp13876
a(I1
S'The results showed that IL - 11 and IL - 6 can both stimulate cell proliferation , induce similar pattern of protein tyrosine phosphorylation , and activate the same proto - oncogene ( junB ) expression in TF - 1 cells .'
p13877
(lp13878
I4
aI5
aI6
a(lp13879
I33
atp13880
a(I1
S'The results showed that IL - 11 and IL - 6 can both stimulate cell proliferation , induce similar pattern of protein tyrosine phosphorylation , and activate the same proto - oncogene ( junB ) expression in TF - 1 cells .'
p13881
(lp13882
I8
aI9
aI10
a(lp13883
I33
atp13884
a(I-1
S'These findings imply that IL - 11 and IL - 6 share similar early signaling events with the possibility of using the same signal transducer , gp130 .'
p13885
(lp13886
I4
aI5
aI6
a(lp13887
I8
aI9
aI10
atp13888
a(I-1
S'These findings imply that IL - 11 and IL - 6 share similar early signaling events with the possibility of using the same signal transducer , gp130 .'
p13889
(lp13890
I4
aI5
aI6
a(lp13891
I26
atp13892
a(I-1
S'These findings imply that IL - 11 and IL - 6 share similar early signaling events with the possibility of using the same signal transducer , gp130 .'
p13893
(lp13894
I8
aI9
aI10
a(lp13895
I26
atp13896
a(I-1
S'We next tested whether IL - 11 induced signaling can be inhibited by anti - gp130 antibodies which blocked IL - 6 - mediated functions .'
p13897
(lp13898
I4
aI5
aI6
a(lp13899
I15
atp13900
a(I-1
S'We next tested whether IL - 11 induced signaling can be inhibited by anti - gp130 antibodies which blocked IL - 6 - mediated functions .'
p13901
(lp13902
I4
aI5
aI6
a(lp13903
I19
aI20
aI21
atp13904
a(I-1
S'We next tested whether IL - 11 induced signaling can be inhibited by anti - gp130 antibodies which blocked IL - 6 - mediated functions .'
p13905
(lp13906
I15
a(lp13907
I19
aI20
aI21
atp13908
a(I-1
S'It was observed that anti - gp130 antibodies abolished cell proliferation , protein tyrosine phosphorylation , and junB gene expression elicited by IL - 11 or IL - 6 in TF - 1 cells .'
p13909
(lp13910
I6
a(lp13911
I17
atp13912
a(I-1
S'It was observed that anti - gp130 antibodies abolished cell proliferation , protein tyrosine phosphorylation , and junB gene expression elicited by IL - 11 or IL - 6 in TF - 1 cells .'
p13913
(lp13914
I6
a(lp13915
I22
aI23
aI24
atp13916
a(I-1
S'It was observed that anti - gp130 antibodies abolished cell proliferation , protein tyrosine phosphorylation , and junB gene expression elicited by IL - 11 or IL - 6 in TF - 1 cells .'
p13917
(lp13918
I6
a(lp13919
I26
aI27
aI28
atp13920
a(I-1
S'It was observed that anti - gp130 antibodies abolished cell proliferation , protein tyrosine phosphorylation , and junB gene expression elicited by IL - 11 or IL - 6 in TF - 1 cells .'
p13921
(lp13922
I17
a(lp13923
I22
aI23
aI24
atp13924
a(I-1
S'It was observed that anti - gp130 antibodies abolished cell proliferation , protein tyrosine phosphorylation , and junB gene expression elicited by IL - 11 or IL - 6 in TF - 1 cells .'
p13925
(lp13926
I17
a(lp13927
I26
aI27
aI28
atp13928
a(I-1
S'It was observed that anti - gp130 antibodies abolished cell proliferation , protein tyrosine phosphorylation , and junB gene expression elicited by IL - 11 or IL - 6 in TF - 1 cells .'
p13929
(lp13930
I22
aI23
aI24
a(lp13931
I26
aI27
aI28
atp13932
a(I-1
S'Finally , anti - IL - 6R antibody inhibited the ability of IL - 6 , but not IL - 11 , to transduce early signals in TF - 1 cells .'
p13933
(lp13934
I4
aI5
aI6
a(lp13935
I12
aI13
aI14
atp13936
a(I-1
S'Finally , anti - IL - 6R antibody inhibited the ability of IL - 6 , but not IL - 11 , to transduce early signals in TF - 1 cells .'
p13937
(lp13938
I4
aI5
aI6
a(lp13939
I18
aI19
aI20
atp13940
a(I-1
S'Finally , anti - IL - 6R antibody inhibited the ability of IL - 6 , but not IL - 11 , to transduce early signals in TF - 1 cells .'
p13941
(lp13942
I12
aI13
aI14
a(lp13943
I18
aI19
aI20
atp13944
a(I-1
S'These results demonstrate that IL - 11 and IL - 6 utilize different ligand binding proteins , but share common signal transducer , gp130 , in TF - 1 cells .'
p13945
(lp13946
I4
aI5
aI6
a(lp13947
I8
aI9
aI10
atp13948
a(I-1
S'These results demonstrate that IL - 11 and IL - 6 utilize different ligand binding proteins , but share common signal transducer , gp130 , in TF - 1 cells .'
p13949
(lp13950
I4
aI5
aI6
a(lp13951
I23
atp13952
a(I-1
S'These results demonstrate that IL - 11 and IL - 6 utilize different ligand binding proteins , but share common signal transducer , gp130 , in TF - 1 cells .'
p13953
(lp13954
I8
aI9
aI10
a(lp13955
I23
atp13956
a(I1
S'The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit .'
p13957
(lp13958
I1
aI2
a(lp13959
I6
aI7
aI8
aI9
atp13960
a(I-1
S'The retinoblastoma protein ( p110RB ) interacts with many cellular proteins in complexes potentially important for its growth - suppressing function .'
p13961
(lp13962
I1
aI2
a(lp13963
I4
atp13964
a(I-1
S'One clone encodes a novel type 1 protein phosphatase catalytic subunit ( PP - 1 alpha 2 ) , which differs from the originally defined PP - 1 alpha by an amino - terminal 11 - amino - acid insert .'
p13965
(lp13966
I5
aI6
aI7
aI8
a(lp13967
I12
aI13
aI14
aI15
aI16
atp13968
a(I-1
S'One clone encodes a novel type 1 protein phosphatase catalytic subunit ( PP - 1 alpha 2 ) , which differs from the originally defined PP - 1 alpha by an amino - terminal 11 - amino - acid insert .'
p13969
(lp13970
I5
aI6
aI7
aI8
a(lp13971
I25
aI26
aI27
aI28
atp13972
a(I-1
S'One clone encodes a novel type 1 protein phosphatase catalytic subunit ( PP - 1 alpha 2 ) , which differs from the originally defined PP - 1 alpha by an amino - terminal 11 - amino - acid insert .'
p13973
(lp13974
I12
aI13
aI14
aI15
aI16
a(lp13975
I25
aI26
aI27
aI28
atp13976
a(I1
S'In vitro - binding assays demonstrated that PP - 1 alpha isoforms preferentially bind the hypophosphorylated form of p110RB .'
p13977
(lp13978
I7
aI8
aI9
aI10
a(lp13979
I18
atp13980
a(I1
S'Moreover , similar p110RB sequences are required for binding PP - 1 alpha 2 and SV40 large T antigen .'
p13981
(lp13982
I3
a(lp13983
I9
aI10
aI11
aI12
aI13
atp13984
a(I1
S'Moreover , similar p110RB sequences are required for binding PP - 1 alpha 2 and SV40 large T antigen .'
p13985
(lp13986
I3
a(lp13987
I15
aI16
aI17
aI18
atp13988
a(I-1
S'Moreover , similar p110RB sequences are required for binding PP - 1 alpha 2 and SV40 large T antigen .'
p13989
(lp13990
I9
aI10
aI11
aI12
aI13
a(lp13991
I15
aI16
aI17
aI18
atp13992
a(I-1
S'The novel fold of the TNF receptor structure is likely to be representative of the nerve growth factor ( NGF ) / TNF receptor family as a whole .'
p13993
(lp13994
I15
aI16
aI17
a(lp13995
I19
atp13996
a(I-1
S'Characterization of a novel high affinity human IL - 7 receptor . Expression on T cells and association with IL - 7 driven proliferation .'
p13997
(lp13998
I7
aI8
aI9
a(lp13999
I7
aI8
aI9
aI10
atp14000
a(I-1
S'Characterization of a novel high affinity human IL - 7 receptor . Expression on T cells and association with IL - 7 driven proliferation .'
p14001
(lp14002
I7
aI8
aI9
a(lp14003
I19
aI20
aI21
atp14004
a(I-1
S'Characterization of a novel high affinity human IL - 7 receptor . Expression on T cells and association with IL - 7 driven proliferation .'
p14005
(lp14006
I7
aI8
aI9
aI10
a(lp14007
I19
aI20
aI21
atp14008
a(I-1
S'We have previously demonstrated such changes by affinity cross - linking studies , and have shown that unstimulated human T cells express a single IL - 7R of 90 kDa , whereas activated T cells express an additional 76 - kDa IL - 7 binding protein .'
p14009
(lp14010
I24
aI25
aI26
a(lp14011
I41
aI42
aI43
atp14012
a(I-1
S'In this study the origin and function of the p90 and p76 molecules have been investigated .'
p14013
(lp14014
I9
a(lp14015
I11
atp14016
a(I-1
S'To determine the role of each of these receptors in IL - 7 driven proliferation , IL - 7R expression and proliferative capacity were monitored during mitogenic stimulation .'
p14017
(lp14018
I10
aI11
aI12
a(lp14019
I16
aI17
aI18
atp14020
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14021
(lp14022
I11
aI12
aI13
a(lp14023
I19
atp14024
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14025
(lp14026
I11
aI12
aI13
a(lp14027
I20
aI21
aI22
atp14028
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14029
(lp14030
I11
aI12
aI13
a(lp14031
I30
atp14032
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14033
(lp14034
I11
aI12
aI13
a(lp14035
I31
aI32
aI33
atp14036
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14037
(lp14038
I19
a(lp14039
I20
aI21
aI22
atp14040
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14041
(lp14042
I19
a(lp14043
I30
atp14044
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14045
(lp14046
I19
a(lp14047
I31
aI32
aI33
atp14048
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14049
(lp14050
I20
aI21
aI22
a(lp14051
I30
atp14052
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14053
(lp14054
I20
aI21
aI22
a(lp14055
I31
aI32
aI33
atp14056
a(I-1
S'These analyses showed that the ability of PBMC to proliferate to IL - 7 correlated with expression of the p76 IL - 7R , and not with expression of the p90 IL - 7R .'
p14057
(lp14058
I30
a(lp14059
I31
aI32
aI33
atp14060
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14061
(lp14062
I0
aI1
aI2
a(lp14063
I11
aI12
aI13
atp14064
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14065
(lp14066
I0
aI1
aI2
a(lp14067
I25
atp14068
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14069
(lp14070
I0
aI1
aI2
a(lp14071
I26
aI27
aI28
atp14072
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14073
(lp14074
I0
aI1
aI2
a(lp14075
I31
atp14076
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14077
(lp14078
I0
aI1
aI2
a(lp14079
I32
aI33
aI34
atp14080
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14081
(lp14082
I0
aI1
aI2
a(lp14083
I36
aI37
aI38
atp14084
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14085
(lp14086
I11
aI12
aI13
a(lp14087
I25
atp14088
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14089
(lp14090
I11
aI12
aI13
a(lp14091
I26
aI27
aI28
atp14092
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14093
(lp14094
I11
aI12
aI13
a(lp14095
I31
atp14096
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14097
(lp14098
I11
aI12
aI13
a(lp14099
I32
aI33
aI34
atp14100
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14101
(lp14102
I11
aI12
aI13
a(lp14103
I36
aI37
aI38
atp14104
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14105
(lp14106
I25
a(lp14107
I26
aI27
aI28
atp14108
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14109
(lp14110
I25
a(lp14111
I31
atp14112
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14113
(lp14114
I25
a(lp14115
I32
aI33
aI34
atp14116
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14117
(lp14118
I25
a(lp14119
I36
aI37
aI38
atp14120
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14121
(lp14122
I26
aI27
aI28
a(lp14123
I31
atp14124
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14125
(lp14126
I26
aI27
aI28
a(lp14127
I32
aI33
aI34
atp14128
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14129
(lp14130
I26
aI27
aI28
a(lp14131
I36
aI37
aI38
atp14132
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14133
(lp14134
I31
a(lp14135
I32
aI33
aI34
atp14136
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14137
(lp14138
I31
a(lp14139
I36
aI37
aI38
atp14140
a(I-1
S'IL - 7 - driven proliferation is mediated via high affinity IL - 7R , and accordingly , Scatchard analysis revealed that , like the p90 IL - 7R , the p76 IL - 7R bound IL - 7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .'
p14141
(lp14142
I32
aI33
aI34
a(lp14143
I36
aI37
aI38
atp14144
a(I-1
S'Deglycosylation studies showed that the p90 and p76 IL - 7R are not simply differently glycosylated isoforms of a single receptor .'
p14145
(lp14146
I5
a(lp14147
I7
atp14148
a(I-1
S'Deglycosylation studies showed that the p90 and p76 IL - 7R are not simply differently glycosylated isoforms of a single receptor .'
p14149
(lp14150
I5
a(lp14151
I8
aI9
aI10
atp14152
a(I-1
S'Deglycosylation studies showed that the p90 and p76 IL - 7R are not simply differently glycosylated isoforms of a single receptor .'
p14153
(lp14154
I7
a(lp14155
I8
aI9
aI10
atp14156
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14157
(lp14158
I8
aI9
aI10
a(lp14159
I22
atp14160
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14161
(lp14162
I8
aI9
aI10
a(lp14163
I23
aI24
aI25
atp14164
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14165
(lp14166
I8
aI9
aI10
a(lp14167
I36
atp14168
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14169
(lp14170
I8
aI9
aI10
a(lp14171
I37
aI38
aI39
atp14172
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14173
(lp14174
I22
a(lp14175
I23
aI24
aI25
atp14176
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14177
(lp14178
I22
a(lp14179
I36
atp14180
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14181
(lp14182
I22
a(lp14183
I37
aI38
aI39
atp14184
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14185
(lp14186
I23
aI24
aI25
a(lp14187
I36
atp14188
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14189
(lp14190
I23
aI24
aI25
a(lp14191
I37
aI38
aI39
atp14192
a(I-1
S'In agreement , mAb to the previously cloned IL - 7R were found to stain unstimulated T cells that express only the p90 IL - 7R but not T - cell clones that express predominantly the p76 IL - 7R .'
p14193
(lp14194
I36
a(lp14195
I37
aI38
aI39
atp14196
a(I-1
S'These antibodies also immunoprecipitated the cloned IL - 7R as a 90 - kDa species from both 125 - I - surface - labeled resting and activated T cells , but were unable to precipitate the 76 - kDa IL - 7R .'
p14197
(lp14198
I6
aI7
aI8
a(lp14199
I39
aI40
aI41
atp14200
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14201
(lp14202
I6
a(lp14203
I21
aI22
aI23
atp14204
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14205
(lp14206
I6
a(lp14207
I31
atp14208
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14209
(lp14210
I6
a(lp14211
I32
aI33
aI34
atp14212
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14213
(lp14214
I6
a(lp14215
I44
aI45
aI46
atp14216
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14217
(lp14218
I21
aI22
aI23
a(lp14219
I31
atp14220
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14221
(lp14222
I21
aI22
aI23
a(lp14223
I32
aI33
aI34
atp14224
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14225
(lp14226
I21
aI22
aI23
a(lp14227
I44
aI45
aI46
atp14228
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14229
(lp14230
I31
a(lp14231
I32
aI33
aI34
atp14232
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14233
(lp14234
I31
a(lp14235
I44
aI45
aI46
atp14236
a(I-1
S'In addition , PCR analysis of p76 - expressing cells could not detect splicing of the extracellular domain of the cloned IL - 7R , thereby excluding the possibility that the p76 IL - 7R is a previously undescribed splice variant of the cloned IL - 7R .'
p14237
(lp14238
I32
aI33
aI34
a(lp14239
I44
aI45
aI46
atp14240
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14241
(lp14242
I5
a(lp14243
I6
aI7
aI8
atp14244
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14245
(lp14246
I5
a(lp14247
I18
aI19
aI20
atp14248
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14249
(lp14250
I5
a(lp14251
I26
atp14252
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14253
(lp14254
I5
a(lp14255
I28
atp14256
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14257
(lp14258
I5
a(lp14259
I29
aI30
aI31
atp14260
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14261
(lp14262
I6
aI7
aI8
a(lp14263
I18
aI19
aI20
atp14264
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14265
(lp14266
I6
aI7
aI8
a(lp14267
I26
atp14268
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14269
(lp14270
I6
aI7
aI8
a(lp14271
I28
atp14272
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14273
(lp14274
I6
aI7
aI8
a(lp14275
I29
aI30
aI31
atp14276
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14277
(lp14278
I18
aI19
aI20
a(lp14279
I26
atp14280
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14281
(lp14282
I18
aI19
aI20
a(lp14283
I28
atp14284
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14285
(lp14286
I18
aI19
aI20
a(lp14287
I29
aI30
aI31
atp14288
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14289
(lp14290
I26
a(lp14291
I28
atp14292
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14293
(lp14294
I26
a(lp14295
I29
aI30
aI31
atp14296
a(I-1
S'These data demonstrate that the p90 IL - 7R is the T - cell homologue of the cloned IL - 7R , and imply that the p90 and p76 IL - 7R have different extracellular domains .'
p14297
(lp14298
I28
a(lp14299
I29
aI30
aI31
atp14300
a(I-1
S'Taken together these data suggest that the 76 - kDa receptor is a novel high affinity IL - 7R that may be necessary for IL - 7 driven proliferation in human T cells .'
p14301
(lp14302
I16
aI17
aI18
a(lp14303
I24
aI25
aI26
atp14304
a(I1
S'Characterization of the retinoblastoma binding proteins RBP1 and RBP2 .'
p14305
(lp14306
I3
a(lp14307
I6
atp14308
a(I1
S'Characterization of the retinoblastoma binding proteins RBP1 and RBP2 .'
p14309
(lp14310
I3
a(lp14311
I8
atp14312
a(I-1
S'Characterization of the retinoblastoma binding proteins RBP1 and RBP2 .'
p14313
(lp14314
I6
a(lp14315
I8
atp14316
a(I-1
S'The retinoblastoma gene product , pRB , regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins .'
p14317
(lp14318
I1
a(lp14319
I5
atp14320
a(I-1
S'We have now isolated cDNA clones that contain the full - length coding sequence of two other proteins , RBP1 and RBP2 , cloned originally by their interaction with pRB .'
p14321
(lp14322
I19
a(lp14323
I21
atp14324
a(I1
S'We have now isolated cDNA clones that contain the full - length coding sequence of two other proteins , RBP1 and RBP2 , cloned originally by their interaction with pRB .'
p14325
(lp14326
I19
a(lp14327
I29
atp14328
a(I1
S'We have now isolated cDNA clones that contain the full - length coding sequence of two other proteins , RBP1 and RBP2 , cloned originally by their interaction with pRB .'
p14329
(lp14330
I21
a(lp14331
I29
atp14332
a(I-1
S'The products of the RBP1 and RBP2 genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .'
p14333
(lp14334
I4
a(lp14335
I6
atp14336
a(I-1
S'The products of the RBP1 and RBP2 genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .'
p14337
(lp14338
I4
a(lp14339
I17
atp14340
a(I-1
S'The products of the RBP1 and RBP2 genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .'
p14341
(lp14342
I4
a(lp14343
I22
atp14344
a(I-1
S'The products of the RBP1 and RBP2 genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .'
p14345
(lp14346
I6
a(lp14347
I17
atp14348
a(I-1
S'The products of the RBP1 and RBP2 genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .'
p14349
(lp14350
I6
a(lp14351
I22
atp14352
a(I-1
S'The products of the RBP1 and RBP2 genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .'
p14353
(lp14354
I17
a(lp14355
I22
atp14356
a(I1
S'In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein .'
p14357
(lp14358
I10
a(lp14359
I12
atp14360
a(I-1
S'In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein .'
p14361
(lp14362
I10
a(lp14363
I25
atp14364
a(I-1
S'In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein .'
p14365
(lp14366
I12
a(lp14367
I25
atp14368
a(I-1
S'Two potentially oncogenic cyclins , cyclin A and cyclin D1 , share common properties of subunit configuration , tyrosine phosphorylation and physical association with the Rb protein'
p14369
(lp14370
I5
aI6
a(lp14371
I8
aI9
atp14372
a(I1
S'Two potentially oncogenic cyclins , cyclin A and cyclin D1 , share common properties of subunit configuration , tyrosine phosphorylation and physical association with the Rb protein'
p14373
(lp14374
I5
aI6
a(lp14375
I25
atp14376
a(I1
S'Two potentially oncogenic cyclins , cyclin A and cyclin D1 , share common properties of subunit configuration , tyrosine phosphorylation and physical association with the Rb protein'
p14377
(lp14378
I8
aI9
a(lp14379
I25
atp14380
a(I-1
S". Originally identified as a ' mitotic cyclin ' , cyclin A exhibits properties of growth factor sensitivity , susceptibility to viral subversion and association with a tumor - suppressor protein , properties which are indicative of an S - phase - promoting factor ( SPF ) as well as a candidate proto - oncogene ."
p14381
(lp14382
I10
aI11
a(lp14383
I38
aI39
aI40
aI41
aI42
aI43
atp14384
a(I-1
S". Originally identified as a ' mitotic cyclin ' , cyclin A exhibits properties of growth factor sensitivity , susceptibility to viral subversion and association with a tumor - suppressor protein , properties which are indicative of an S - phase - promoting factor ( SPF ) as well as a candidate proto - oncogene ."
p14385
(lp14386
I10
aI11
a(lp14387
I45
atp14388
a(I-1
S". Originally identified as a ' mitotic cyclin ' , cyclin A exhibits properties of growth factor sensitivity , susceptibility to viral subversion and association with a tumor - suppressor protein , properties which are indicative of an S - phase - promoting factor ( SPF ) as well as a candidate proto - oncogene ."
p14389
(lp14390
I38
aI39
aI40
aI41
aI42
aI43
a(lp14391
I45
atp14392
a(I-1
S'Other recent studies have identified human cyclin D1 ( PRAD1 ) as a putative G1 cyclin and candidate proto - oncogene .'
p14393
(lp14394
I6
aI7
a(lp14395
I9
atp14396
a(I-1
S'Moreover , cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and , like cyclin A , was readily phosphorylated by pp60c - src in vitro .'
p14397
(lp14398
I2
aI3
a(lp14399
I17
aI18
atp14400
a(I1
S'Moreover , cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and , like cyclin A , was readily phosphorylated by pp60c - src in vitro .'
p14401
(lp14402
I2
aI3
a(lp14403
I24
aI25
aI26
atp14404
a(I1
S'Moreover , cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and , like cyclin A , was readily phosphorylated by pp60c - src in vitro .'
p14405
(lp14406
I17
aI18
a(lp14407
I24
aI25
aI26
atp14408
a(I1
S'In synchronized human osteosarcoma cells , cyclin D1 is induced in early G1 and becomes associated with p9Ckshs1 , a Cdk - binding subunit .'
p14409
(lp14410
I6
aI7
a(lp14411
I17
atp14412
a(I1
S"Immunoprecipitation experiments with human osteosarcoma cells and Ewing ' s sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2 , and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity ."
p14413
(lp14414
I14
aI15
a(lp14415
I20
atp14416
a(I1
S"Immunoprecipitation experiments with human osteosarcoma cells and Ewing ' s sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2 , and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity ."
p14417
(lp14418
I14
aI15
a(lp14419
I22
atp14420
a(I-1
S"Immunoprecipitation experiments with human osteosarcoma cells and Ewing ' s sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2 , and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity ."
p14421
(lp14422
I14
aI15
a(lp14423
I26
aI27
atp14424
a(I-1
S"Immunoprecipitation experiments with human osteosarcoma cells and Ewing ' s sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2 , and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity ."
p14425
(lp14426
I20
a(lp14427
I22
atp14428
a(I-1
S"Immunoprecipitation experiments with human osteosarcoma cells and Ewing ' s sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2 , and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity ."
p14429
(lp14430
I20
a(lp14431
I26
aI27
atp14432
a(I-1
S"Immunoprecipitation experiments with human osteosarcoma cells and Ewing ' s sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2 , and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity ."
p14433
(lp14434
I22
a(lp14435
I26
aI27
atp14436
a(I1
S'The SH2 / SH3 domain - containing protein GRB2 interacts with tyrosine - phosphorylated IRS1 and Shc : implications for insulin control of ras signalling .'
p14437
(lp14438
I8
a(lp14439
I14
atp14440
a(I1
S'The SH2 / SH3 domain - containing protein GRB2 interacts with tyrosine - phosphorylated IRS1 and Shc : implications for insulin control of ras signalling .'
p14441
(lp14442
I8
a(lp14443
I16
atp14444
a(I-1
S'The SH2 / SH3 domain - containing protein GRB2 interacts with tyrosine - phosphorylated IRS1 and Shc : implications for insulin control of ras signalling .'
p14445
(lp14446
I8
a(lp14447
I23
atp14448
a(I-1
S'The SH2 / SH3 domain - containing protein GRB2 interacts with tyrosine - phosphorylated IRS1 and Shc : implications for insulin control of ras signalling .'
p14449
(lp14450
I14
a(lp14451
I16
atp14452
a(I-1
S'The SH2 / SH3 domain - containing protein GRB2 interacts with tyrosine - phosphorylated IRS1 and Shc : implications for insulin control of ras signalling .'
p14453
(lp14454
I14
a(lp14455
I23
atp14456
a(I-1
S'The SH2 / SH3 domain - containing protein GRB2 interacts with tyrosine - phosphorylated IRS1 and Shc : implications for insulin control of ras signalling .'
p14457
(lp14458
I16
a(lp14459
I23
atp14460
a(I-1
S'GRB2 , a small protein comprising one SH2 domain and two SH3 domains , represents the human homologue of the Caenorhabditis elegans protein , sem - 5 .'
p14461
(lp14462
I0
a(lp14463
I24
aI25
aI26
atp14464
a(I-1
S'Both GRB2 and sem - 5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases .'
p14465
(lp14466
I1
a(lp14467
I3
aI4
aI5
atp14468
a(I-1
S'Both GRB2 and sem - 5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases .'
p14469
(lp14470
I1
a(lp14471
I16
atp14472
a(I-1
S'Both GRB2 and sem - 5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases .'
p14473
(lp14474
I3
aI4
aI5
a(lp14475
I16
atp14476
a(I-1
S'In this report we show that in response to insulin , GRB2 forms a stable complex with two tyrosine - phosphorylated proteins .'
p14477
(lp14478
I9
a(lp14479
I11
atp14480
a(I-1
S'One protein is the major insulin receptor substrate IRS - 1 and the second is the SH2 domain - containing oncogenic protein , Shc .'
p14481
(lp14482
I8
aI9
aI10
a(lp14483
I23
atp14484
a(I-1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14485
(lp14486
I3
a(lp14487
I13
aI14
atp14488
a(I-1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14489
(lp14490
I3
a(lp14491
I26
atp14492
a(I-1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14493
(lp14494
I3
a(lp14495
I31
aI32
aI33
atp14496
a(I-1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14497
(lp14498
I3
a(lp14499
I35
atp14500
a(I-1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14501
(lp14502
I13
aI14
a(lp14503
I26
atp14504
a(I-1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14505
(lp14506
I13
aI14
a(lp14507
I31
aI32
aI33
atp14508
a(I-1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14509
(lp14510
I13
aI14
a(lp14511
I35
atp14512
a(I1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14513
(lp14514
I26
a(lp14515
I31
aI32
aI33
atp14516
a(I1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14517
(lp14518
I26
a(lp14519
I35
atp14520
a(I-1
S'The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS - 1 and Shc .'
p14521
(lp14522
I31
aI32
aI33
a(lp14523
I35
atp14524
a(I1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14525
(lp14526
I1
a(lp14527
I4
aI5
aI6
atp14528
a(I1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14529
(lp14530
I1
a(lp14531
I8
atp14532
a(I-1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14533
(lp14534
I1
a(lp14535
I17
atp14536
a(I-1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14537
(lp14538
I1
a(lp14539
I22
atp14540
a(I-1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14541
(lp14542
I4
aI5
aI6
a(lp14543
I8
atp14544
a(I-1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14545
(lp14546
I4
aI5
aI6
a(lp14547
I17
atp14548
a(I-1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14549
(lp14550
I4
aI5
aI6
a(lp14551
I22
atp14552
a(I-1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14553
(lp14554
I8
a(lp14555
I17
atp14556
a(I-1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14557
(lp14558
I8
a(lp14559
I22
atp14560
a(I-1
S'Although GRB2 associates with IRS - 1 and Shc , it is not tyrosine - phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .'
p14561
(lp14562
I17
a(lp14563
I22
atp14564
a(I-1
S'Furthermore , we have identified a short sequence motif ( YV / IN ) present in IRS - 1 , EGFR and Shc , which specifically binds the SH2 domain of GRB2 with high affinity .'
p14565
(lp14566
I16
aI17
aI18
a(lp14567
I20
atp14568
a(I-1
S'Furthermore , we have identified a short sequence motif ( YV / IN ) present in IRS - 1 , EGFR and Shc , which specifically binds the SH2 domain of GRB2 with high affinity .'
p14569
(lp14570
I16
aI17
aI18
a(lp14571
I22
atp14572
a(I1
S'Furthermore , we have identified a short sequence motif ( YV / IN ) present in IRS - 1 , EGFR and Shc , which specifically binds the SH2 domain of GRB2 with high affinity .'
p14573
(lp14574
I16
aI17
aI18
a(lp14575
I31
atp14576
a(I-1
S'Furthermore , we have identified a short sequence motif ( YV / IN ) present in IRS - 1 , EGFR and Shc , which specifically binds the SH2 domain of GRB2 with high affinity .'
p14577
(lp14578
I20
a(lp14579
I22
atp14580
a(I1
S'Furthermore , we have identified a short sequence motif ( YV / IN ) present in IRS - 1 , EGFR and Shc , which specifically binds the SH2 domain of GRB2 with high affinity .'
p14581
(lp14582
I20
a(lp14583
I31
atp14584
a(I1
S'Furthermore , we have identified a short sequence motif ( YV / IN ) present in IRS - 1 , EGFR and Shc , which specifically binds the SH2 domain of GRB2 with high affinity .'
p14585
(lp14586
I22
a(lp14587
I31
atp14588
a(I-1
S'Interestingly , both GRB2 and phosphatidylinositol - 3 ( PI - 3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS - 1 molecule , suggesting a mechanism whereby IRS - 1 could provide the core for a large signalling complex .'
p14589
(lp14590
I3
a(lp14591
I5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
atp14592
a(I1
S'Interestingly , both GRB2 and phosphatidylinositol - 3 ( PI - 3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS - 1 molecule , suggesting a mechanism whereby IRS - 1 could provide the core for a large signalling complex .'
p14593
(lp14594
I3
a(lp14595
I24
aI25
aI26
atp14596
a(I-1
S'Interestingly , both GRB2 and phosphatidylinositol - 3 ( PI - 3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS - 1 molecule , suggesting a mechanism whereby IRS - 1 could provide the core for a large signalling complex .'
p14597
(lp14598
I3
a(lp14599
I33
aI34
aI35
atp14600
a(I1
S'Interestingly , both GRB2 and phosphatidylinositol - 3 ( PI - 3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS - 1 molecule , suggesting a mechanism whereby IRS - 1 could provide the core for a large signalling complex .'
p14601
(lp14602
I5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp14603
I24
aI25
aI26
atp14604
a(I-1
S'Interestingly , both GRB2 and phosphatidylinositol - 3 ( PI - 3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS - 1 molecule , suggesting a mechanism whereby IRS - 1 could provide the core for a large signalling complex .'
p14605
(lp14606
I5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
aI13
a(lp14607
I33
aI34
aI35
atp14608
a(I-1
S'Interestingly , both GRB2 and phosphatidylinositol - 3 ( PI - 3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS - 1 molecule , suggesting a mechanism whereby IRS - 1 could provide the core for a large signalling complex .'
p14609
(lp14610
I24
aI25
aI26
a(lp14611
I33
aI34
aI35
atp14612
a(I1
S'We propose a model whereby insulin stimulation leads to formation of multiple protein - - protein interactions between GRB2 and the two targets IRS - 1 and Shc .'
p14613
(lp14614
I18
a(lp14615
I23
aI24
aI25
atp14616
a(I1
S'We propose a model whereby insulin stimulation leads to formation of multiple protein - - protein interactions between GRB2 and the two targets IRS - 1 and Shc .'
p14617
(lp14618
I18
a(lp14619
I27
atp14620
a(I-1
S'We propose a model whereby insulin stimulation leads to formation of multiple protein - - protein interactions between GRB2 and the two targets IRS - 1 and Shc .'
p14621
(lp14622
I23
aI24
aI25
a(lp14623
I27
atp14624
a(I-1
S'Regulation of the Ets - related transcription factor Elf - 1 by binding to the retinoblastoma protein .'
p14625
(lp14626
I3
a(lp14627
I8
aI9
aI10
atp14628
a(I-1
S'Regulation of the Ets - related transcription factor Elf - 1 by binding to the retinoblastoma protein .'
p14629
(lp14630
I3
a(lp14631
I15
atp14632
a(I1
S'Regulation of the Ets - related transcription factor Elf - 1 by binding to the retinoblastoma protein .'
p14633
(lp14634
I8
aI9
aI10
a(lp14635
I15
atp14636
a(I-1
S'The retinoblastoma gene product ( Rb ) is a nuclear phosphoprotein that regulates cell cycle progression .'
p14637
(lp14638
I1
a(lp14639
I5
atp14640
a(I-1
S'Elf - 1 is a lymphoid - specific Ets transcription factor that regulates inducible gene expression during T cell activation .'
p14641
(lp14642
I0
aI1
aI2
a(lp14643
I8
atp14644
a(I-1
S'In this report , it is demonstrated that Elf - 1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo .'
p14645
(lp14646
I8
aI9
aI10
a(lp14647
I21
atp14648
a(I1
S'In this report , it is demonstrated that Elf - 1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo .'
p14649
(lp14650
I8
aI9
aI10
a(lp14651
I35
atp14652
a(I-1
S'In this report , it is demonstrated that Elf - 1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo .'
p14653
(lp14654
I21
a(lp14655
I35
atp14656
a(I-1
S'Elf - 1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma .'
p14657
(lp14658
I0
aI1
aI2
a(lp14659
I10
atp14660
a(I-1
S'Elf - 1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma .'
p14661
(lp14662
I0
aI1
aI2
a(lp14663
I16
atp14664
a(I-1
S'Elf - 1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma .'
p14665
(lp14666
I10
a(lp14667
I16
atp14668
a(I1
S'Co - immunoprecipitation experiments demonstrated an association between Elf - 1 and Rb in resting normal human T cells .'
p14669
(lp14670
I8
aI9
aI10
a(lp14671
I12
atp14672
a(I-1
S'After T cell activation , the phosphorylation of Rb results in the release of Elf - 1 , which is correlated temporally with the activation of Elf - 1 - mediated transcription .'
p14673
(lp14674
I8
a(lp14675
I14
aI15
aI16
atp14676
a(I-1
S'After T cell activation , the phosphorylation of Rb results in the release of Elf - 1 , which is correlated temporally with the activation of Elf - 1 - mediated transcription .'
p14677
(lp14678
I8
a(lp14679
I26
aI27
aI28
atp14680
a(I-1
S'After T cell activation , the phosphorylation of Rb results in the release of Elf - 1 , which is correlated temporally with the activation of Elf - 1 - mediated transcription .'
p14681
(lp14682
I14
aI15
aI16
a(lp14683
I26
aI27
aI28
atp14684
a(I-1
S'Overexpression of a phosphorylation - defective form of Rb inhibited Elf - 1 - dependent transcription during T cell activation .'
p14685
(lp14686
I8
a(lp14687
I10
aI11
aI12
atp14688
a(I-1
S'These results demonstrate that Rb interacts specifically with a lineage - restricted Ets transcription factor .'
p14689
(lp14690
I4
a(lp14691
I12
atp14692
a(I-1
S'The proximal sequence element ( PSE ) - binding transcription factor ( PTF ) specifically recognizes the PSEs of both RNA polymerase II - and RNA polymerase III - transcribed small nuclear RNA ( snRNA ) genes .'
p14693
(lp14694
I1
aI2
aI3
aI4
aI5
aI6
aI7
aI8
aI9
aI10
a(lp14695
I12
atp14696
a(I-1
S'We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha , - beta , - gamma , and - delta .'
p14697
(lp14698
I5
a(lp14699
I19
atp14700
a(I-1
S'We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha , - beta , - gamma , and - delta .'
p14701
(lp14702
I5
a(lp14703
I19
aI20
atp14704
a(I-1
S'We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated PTF alpha , - beta , - gamma , and - delta .'
p14705
(lp14706
I19
a(lp14707
I19
aI20
atp14708
a(I-1
S'We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta , as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts .'
p14709
(lp14710
I10
a(lp14711
I13
atp14712
a(I-1
S'We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta , as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts .'
p14713
(lp14714
I10
a(lp14715
I28
atp14716
a(I-1
S'We now report the isolation and expression of cDNAs encoding PTF gamma and PTF delta , as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts .'
p14717
(lp14718
I13
a(lp14719
I28
atp14720
a(I-1
S'Immunoprecipitation studies confirm that the four PTF subunits originally found to copurify during conventional chromatography indeed form a tightly associated complex ; they further show that the PTF so defined , including the gamma and delta subunits specifically , is essential for transcription of both class II and class III snRNA genes .'
p14721
(lp14722
I6
a(lp14723
I27
atp14724
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14725
(lp14726
I10
aI11
aI12
aI13
a(lp14727
I15
atp14728
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14729
(lp14730
I10
aI11
aI12
aI13
a(lp14731
I18
atp14732
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14733
(lp14734
I10
aI11
aI12
aI13
a(lp14735
I27
atp14736
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14737
(lp14738
I10
aI11
aI12
aI13
a(lp14739
I32
atp14740
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14741
(lp14742
I10
aI11
aI12
aI13
a(lp14743
I38
atp14744
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14745
(lp14746
I10
aI11
aI12
aI13
a(lp14747
I43
atp14748
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14749
(lp14750
I10
aI11
aI12
aI13
a(lp14751
I50
atp14752
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14753
(lp14754
I15
a(lp14755
I18
atp14756
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14757
(lp14758
I15
a(lp14759
I27
atp14760
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14761
(lp14762
I15
a(lp14763
I32
atp14764
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14765
(lp14766
I15
a(lp14767
I38
atp14768
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14769
(lp14770
I15
a(lp14771
I43
atp14772
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14773
(lp14774
I15
a(lp14775
I50
atp14776
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14777
(lp14778
I18
a(lp14779
I27
atp14780
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14781
(lp14782
I18
a(lp14783
I32
atp14784
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14785
(lp14786
I18
a(lp14787
I38
atp14788
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14789
(lp14790
I18
a(lp14791
I43
atp14792
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14793
(lp14794
I18
a(lp14795
I50
atp14796
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14797
(lp14798
I27
a(lp14799
I32
atp14800
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14801
(lp14802
I27
a(lp14803
I38
atp14804
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14805
(lp14806
I27
a(lp14807
I43
atp14808
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14809
(lp14810
I27
a(lp14811
I50
atp14812
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14813
(lp14814
I32
a(lp14815
I38
atp14816
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14817
(lp14818
I32
a(lp14819
I43
atp14820
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14821
(lp14822
I32
a(lp14823
I50
atp14824
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14825
(lp14826
I38
a(lp14827
I43
atp14828
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14829
(lp14830
I38
a(lp14831
I50
atp14832
a(I-1
S'Immunoprecipitation assays also show a weak substoichiometric association of the TATA - binding protein ( TBP ) with PTF , consistent with the previous report of a PTF - related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .'
p14833
(lp14834
I43
a(lp14835
I50
atp14836
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14837
(lp14838
I15
a(lp14839
I18
atp14840
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14841
(lp14842
I15
a(lp14843
I21
atp14844
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14845
(lp14846
I15
a(lp14847
I30
atp14848
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14849
(lp14850
I15
a(lp14851
I32
atp14852
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14853
(lp14854
I15
a(lp14855
I36
atp14856
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14857
(lp14858
I15
a(lp14859
I38
atp14860
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14861
(lp14862
I15
a(lp14863
I52
atp14864
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14865
(lp14866
I15
a(lp14867
I57
atp14868
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14869
(lp14870
I18
a(lp14871
I21
atp14872
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14873
(lp14874
I18
a(lp14875
I30
atp14876
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14877
(lp14878
I18
a(lp14879
I32
atp14880
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14881
(lp14882
I18
a(lp14883
I36
atp14884
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14885
(lp14886
I18
a(lp14887
I38
atp14888
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14889
(lp14890
I18
a(lp14891
I52
atp14892
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14893
(lp14894
I18
a(lp14895
I57
atp14896
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14897
(lp14898
I21
a(lp14899
I30
atp14900
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14901
(lp14902
I21
a(lp14903
I32
atp14904
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14905
(lp14906
I21
a(lp14907
I36
atp14908
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14909
(lp14910
I21
a(lp14911
I38
atp14912
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14913
(lp14914
I21
a(lp14915
I52
atp14916
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14917
(lp14918
I21
a(lp14919
I57
atp14920
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14921
(lp14922
I30
a(lp14923
I32
atp14924
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14925
(lp14926
I30
a(lp14927
I36
atp14928
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14929
(lp14930
I30
a(lp14931
I38
atp14932
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14933
(lp14934
I30
a(lp14935
I52
atp14936
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14937
(lp14938
I30
a(lp14939
I57
atp14940
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14941
(lp14942
I32
a(lp14943
I36
atp14944
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14945
(lp14946
I32
a(lp14947
I38
atp14948
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14949
(lp14950
I32
a(lp14951
I52
atp14952
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14953
(lp14954
I32
a(lp14955
I57
atp14956
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14957
(lp14958
I36
a(lp14959
I38
atp14960
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14961
(lp14962
I36
a(lp14963
I52
atp14964
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14965
(lp14966
I36
a(lp14967
I57
atp14968
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14969
(lp14970
I38
a(lp14971
I52
atp14972
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14973
(lp14974
I38
a(lp14975
I57
atp14976
a(I-1
S'Glutathione S - transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP - TBP - associated factor complex or with possible functional interactions between PSE - bound PTF and TATA - bound TBP during promoter activation .'
p14977
(lp14978
I52
a(lp14979
I57
atp14980
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p14981
(lp14982
I10
a(lp14983
I12
atp14984
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p14985
(lp14986
I10
a(lp14987
I26
atp14988
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p14989
(lp14990
I10
a(lp14991
I30
atp14992
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p14993
(lp14994
I10
a(lp14995
I32
atp14996
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p14997
(lp14998
I10
a(lp14999
I44
atp15000
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15001
(lp15002
I12
a(lp15003
I26
atp15004
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15005
(lp15006
I12
a(lp15007
I30
atp15008
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15009
(lp15010
I12
a(lp15011
I32
atp15012
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15013
(lp15014
I12
a(lp15015
I44
atp15016
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15017
(lp15018
I26
a(lp15019
I30
atp15020
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15021
(lp15022
I26
a(lp15023
I32
atp15024
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15025
(lp15026
I26
a(lp15027
I44
atp15028
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15029
(lp15030
I30
a(lp15031
I32
atp15032
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15033
(lp15034
I30
a(lp15035
I44
atp15036
a(I-1
S'In addition , we show that in extracts depleted of TBP and TBP - associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA - encoding genes .'
p15037
(lp15038
I32
a(lp15039
I44
atp15040
a(I1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15041
(lp15042
I0
a(lp15043
I2
atp15044
a(I-1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15045
(lp15046
I0
a(lp15047
I4
atp15048
a(I-1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15049
(lp15050
I0
a(lp15051
I6
atp15052
a(I-1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15053
(lp15054
I0
a(lp15055
I11
aI12
aI13
atp15056
a(I-1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15057
(lp15058
I2
a(lp15059
I4
atp15060
a(I-1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15061
(lp15062
I2
a(lp15063
I6
atp15064
a(I-1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15065
(lp15066
I2
a(lp15067
I11
aI12
aI13
atp15068
a(I1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15069
(lp15070
I4
a(lp15071
I6
atp15072
a(I-1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15073
(lp15074
I4
a(lp15075
I11
aI12
aI13
atp15076
a(I-1
S'TRADD - TRAF2 and TRADD - FADD interactions define two distinct TNF receptor 1 signal transduction pathways .'
p15077
(lp15078
I6
a(lp15079
I11
aI12
aI13
atp15080
a(I-1
S'Tumor necrosis factor ( TNF ) can induce apoptosis and activate NF - kappa B through signaling cascades emanating from TNF receptor 1 ( TNFR1 ) .'
p15081
(lp15082
I11
aI12
aI13
aI14
a(lp15083
I20
aI21
aI22
atp15084
a(I-1
S'Tumor necrosis factor ( TNF ) can induce apoptosis and activate NF - kappa B through signaling cascades emanating from TNF receptor 1 ( TNFR1 ) .'
p15085
(lp15086
I11
aI12
aI13
aI14
a(lp15087
I24
atp15088
a(I-1
S'Tumor necrosis factor ( TNF ) can induce apoptosis and activate NF - kappa B through signaling cascades emanating from TNF receptor 1 ( TNFR1 ) .'
p15089
(lp15090
I20
aI21
aI22
a(lp15091
I24
atp15092
a(I-1
S'TRADD is a TNFR1 - associated signal transducer that is involved in activating both pathways .'
p15093
(lp15094
I0
a(lp15095
I3
atp15096
a(I1
S'Here we show that TRADD directly interacts with TRAF2 and FADD , signal transducers that activate NF - kappa B and induce apoptosis , respectively .'
p15097
(lp15098
I4
a(lp15099
I8
atp15100
a(I1
S'Here we show that TRADD directly interacts with TRAF2 and FADD , signal transducers that activate NF - kappa B and induce apoptosis , respectively .'
p15101
(lp15102
I4
a(lp15103
I10
atp15104
a(I-1
S'Here we show that TRADD directly interacts with TRAF2 and FADD , signal transducers that activate NF - kappa B and induce apoptosis , respectively .'
p15105
(lp15106
I4
a(lp15107
I16
aI17
aI18
aI19
atp15108
a(I-1
S'Here we show that TRADD directly interacts with TRAF2 and FADD , signal transducers that activate NF - kappa B and induce apoptosis , respectively .'
p15109
(lp15110
I8
a(lp15111
I10
atp15112
a(I1
S'Here we show that TRADD directly interacts with TRAF2 and FADD , signal transducers that activate NF - kappa B and induce apoptosis , respectively .'
p15113
(lp15114
I8
a(lp15115
I16
aI17
aI18
aI19
atp15116
a(I1
S'Here we show that TRADD directly interacts with TRAF2 and FADD , signal transducers that activate NF - kappa B and induce apoptosis , respectively .'
p15117
(lp15118
I10
a(lp15119
I16
aI17
aI18
aI19
atp15120
a(I-1
S'A TRAF2 mutant lacking its N - terminal RING finger domain is a dominant - negative inhibitor of TNF - mediated NF - kappa B activation , but does not affect TNF - induced apoptosis .'
p15121
(lp15122
I1
a(lp15123
I21
aI22
aI23
aI24
atp15124
a(I-1
S'Conversely , a FADD mutant lacking its N - terminal 79 amino acids is a dominant - negative inhibitor of TNF - induced apoptosis , but does not inhibit NF - kappa B activation .'
p15125
(lp15126
I3
a(lp15127
I29
aI30
aI31
aI32
atp15128
a(I-1
S'Thus , these two TNFR1 - TRADD signaling cascades appear to bifurcate at TRADD .'
p15129
(lp15130
I4
a(lp15131
I6
atp15132
a(I-1
S'Thus , these two TNFR1 - TRADD signaling cascades appear to bifurcate at TRADD .'
p15133
(lp15134
I4
a(lp15135
I13
atp15136
a(I-1
S'Thus , these two TNFR1 - TRADD signaling cascades appear to bifurcate at TRADD .'
p15137
(lp15138
I6
a(lp15139
I13
atp15140
a(I1
S'Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response .'
p15141
(lp15142
I2
aI3
a(lp15143
I7
atp15144
a(I-1
S'CD26 , a T cell activation Ag , also known as dipeptidyl peptidase IV , is directly associated with adenosine deaminase ( ADA ) on the surface of T cells and T cell lines .'
p15145
(lp15146
I0
a(lp15147
I11
aI12
aI13
atp15148
a(I1
S'CD26 , a T cell activation Ag , also known as dipeptidyl peptidase IV , is directly associated with adenosine deaminase ( ADA ) on the surface of T cells and T cell lines .'
p15149
(lp15150
I0
a(lp15151
I19
aI20
atp15152
a(I1
S'CD26 , a T cell activation Ag , also known as dipeptidyl peptidase IV , is directly associated with adenosine deaminase ( ADA ) on the surface of T cells and T cell lines .'
p15153
(lp15154
I0
a(lp15155
I22
atp15156
a(I1
S'CD26 , a T cell activation Ag , also known as dipeptidyl peptidase IV , is directly associated with adenosine deaminase ( ADA ) on the surface of T cells and T cell lines .'
p15157
(lp15158
I11
aI12
aI13
a(lp15159
I19
aI20
atp15160
a(I1
S'CD26 , a T cell activation Ag , also known as dipeptidyl peptidase IV , is directly associated with adenosine deaminase ( ADA ) on the surface of T cells and T cell lines .'
p15161
(lp15162
I11
aI12
aI13
a(lp15163
I22
atp15164
a(I-1
S'CD26 , a T cell activation Ag , also known as dipeptidyl peptidase IV , is directly associated with adenosine deaminase ( ADA ) on the surface of T cells and T cell lines .'
p15165
(lp15166
I19
aI20
a(lp15167
I22
atp15168
a(I1
S'In the present study , we examined both the binding of ADA and CD26 and the functional consequences of this interaction .'
p15169
(lp15170
I11
a(lp15171
I13
atp15172
a(I1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15173
(lp15174
I3
a(lp15175
I7
atp15176
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15177
(lp15178
I3
a(lp15179
I14
atp15180
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15181
(lp15182
I3
a(lp15183
I16
aI17
aI18
atp15184
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15185
(lp15186
I3
a(lp15187
I27
aI28
aI29
atp15188
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15189
(lp15190
I3
a(lp15191
I31
atp15192
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15193
(lp15194
I7
a(lp15195
I14
atp15196
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15197
(lp15198
I7
a(lp15199
I16
aI17
aI18
atp15200
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15201
(lp15202
I7
a(lp15203
I27
aI28
aI29
atp15204
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15205
(lp15206
I7
a(lp15207
I31
atp15208
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15209
(lp15210
I14
a(lp15211
I16
aI17
aI18
atp15212
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15213
(lp15214
I14
a(lp15215
I27
aI28
aI29
atp15216
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15217
(lp15218
I14
a(lp15219
I31
atp15220
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15221
(lp15222
I16
aI17
aI18
a(lp15223
I27
aI28
aI29
atp15224
a(I-1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15225
(lp15226
I16
aI17
aI18
a(lp15227
I31
atp15228
a(I1
S'We found that ADA was associated with CD26 on T cell lines lacking either ADA or dipeptidyl peptidase IV enzymatic activity , indicating that the association between dipeptidyl peptidase IV and ADA did not require enzymatic activity .'
p15229
(lp15230
I27
aI28
aI29
a(lp15231
I31
atp15232
a(I-1
S'Moreover , using immunoelectron microscopy , we demonstrated that CD26 and ADA co - localized on the cell surface , but not inside cells , suggesting that CD26 did not transport ADA to the surface .'
p15233
(lp15234
I9
a(lp15235
I11
atp15236
a(I-1
S'Moreover , using immunoelectron microscopy , we demonstrated that CD26 and ADA co - localized on the cell surface , but not inside cells , suggesting that CD26 did not transport ADA to the surface .'
p15237
(lp15238
I9
a(lp15239
I27
atp15240
a(I-1
S'Moreover , using immunoelectron microscopy , we demonstrated that CD26 and ADA co - localized on the cell surface , but not inside cells , suggesting that CD26 did not transport ADA to the surface .'
p15241
(lp15242
I9
a(lp15243
I31
atp15244
a(I-1
S'Moreover , using immunoelectron microscopy , we demonstrated that CD26 and ADA co - localized on the cell surface , but not inside cells , suggesting that CD26 did not transport ADA to the surface .'
p15245
(lp15246
I11
a(lp15247
I27
atp15248
a(I-1
S'Moreover , using immunoelectron microscopy , we demonstrated that CD26 and ADA co - localized on the cell surface , but not inside cells , suggesting that CD26 did not transport ADA to the surface .'
p15249
(lp15250
I11
a(lp15251
I31
atp15252
a(I-1
S'Moreover , using immunoelectron microscopy , we demonstrated that CD26 and ADA co - localized on the cell surface , but not inside cells , suggesting that CD26 did not transport ADA to the surface .'
p15253
(lp15254
I27
a(lp15255
I31
atp15256
a(I-1
S'In keeping with this observation , we showed that human CD26 - transfected murine pre - B cell lines lacking human ADA acquired ADA from an extracellular source .'
p15257
(lp15258
I10
a(lp15259
I21
atp15260
a(I-1
S'In keeping with this observation , we showed that human CD26 - transfected murine pre - B cell lines lacking human ADA acquired ADA from an extracellular source .'
p15261
(lp15262
I10
a(lp15263
I23
atp15264
a(I-1
S'In keeping with this observation , we showed that human CD26 - transfected murine pre - B cell lines lacking human ADA acquired ADA from an extracellular source .'
p15265
(lp15266
I21
a(lp15267
I23
atp15268
a(I-1
S'More importantly , adenosine in the absence of cell surface ADA inhibited T cell proliferation and IL - 2 production induced by various stimuli .'
p15269
(lp15270
I10
a(lp15271
I16
aI17
aI18
atp15272
a(I-1
S'On the other hand , cells expressing ADA and CD26 on the surface were much more resistant to the inhibitory effect of adenosine .'
p15273
(lp15274
I7
a(lp15275
I9
atp15276
a(I-1
S'These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26 , and this complex is capable of reducing the local concentration of adenosine .'
p15277
(lp15278
I4
a(lp15279
I19
atp15280
a(I-1
S'These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26 , and this complex is capable of reducing the local concentration of adenosine .'
p15281
(lp15282
I4
a(lp15283
I24
atp15284
a(I1
S'These data suggest that ADA on the cell surface is involved in an important immunoregulatory mechanism by which released ADA binds to cell surface CD26 , and this complex is capable of reducing the local concentration of adenosine .'
p15285
(lp15286
I19
a(lp15287
I24
atp15288
a(I-1
S'We have cloned and characterized human acidic ( alpha 1 - ) syntrophin and a second isoform of human basic ( beta 2 - ) syntrophin .'
p15289
(lp15290
I6
aI7
aI8
aI9
aI10
aI11
aI12
a(lp15291
I19
aI20
aI21
aI22
aI23
aI24
aI25
atp15292
a(I-1
S'The deduced amino acid sequences of human alpha 1 - and beta 2 - syntrophin are nearly identical to their homologues in mouse , suggesting a strong functional conservation among the individual isoforms , Much like beta 1 - syntrophin , human beta 2 - syntrophin has multiple transcript classes and is expressed widely , although in a distinct pattern of relative abundance .'
p15293
(lp15294
I11
aI12
aI13
aI14
a(lp15295
I36
aI37
aI38
aI39
atp15296
a(I-1
S'The deduced amino acid sequences of human alpha 1 - and beta 2 - syntrophin are nearly identical to their homologues in mouse , suggesting a strong functional conservation among the individual isoforms , Much like beta 1 - syntrophin , human beta 2 - syntrophin has multiple transcript classes and is expressed widely , although in a distinct pattern of relative abundance .'
p15297
(lp15298
I11
aI12
aI13
aI14
a(lp15299
I42
aI43
aI44
aI45
atp15300
a(I-1
S'The deduced amino acid sequences of human alpha 1 - and beta 2 - syntrophin are nearly identical to their homologues in mouse , suggesting a strong functional conservation among the individual isoforms , Much like beta 1 - syntrophin , human beta 2 - syntrophin has multiple transcript classes and is expressed widely , although in a distinct pattern of relative abundance .'
p15301
(lp15302
I36
aI37
aI38
aI39
a(lp15303
I42
aI43
aI44
aI45
atp15304
a(I-1
S'Somatic cell hybrids and fluorescent in situ hybridization were both used to determine their chromosomal locations : beta 2 - syntrophin to chromosome 16q22 - 23 and alpha 1 - syntrophin to chromosome 20q11 . 2 .'
p15305
(lp15306
I17
aI18
aI19
aI20
a(lp15307
I27
aI28
aI29
aI30
atp15308
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15309
(lp15310
I17
aI18
aI19
aI20
a(lp15311
I27
aI28
aI29
aI30
atp15312
a(I1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15313
(lp15314
I17
aI18
aI19
aI20
a(lp15315
I41
atp15316
a(I1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15317
(lp15318
I17
aI18
aI19
aI20
a(lp15319
I43
atp15320
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15321
(lp15322
I17
aI18
aI19
aI20
a(lp15323
I45
atp15324
a(I1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15325
(lp15326
I17
aI18
aI19
aI20
a(lp15327
I45
aI46
aI47
atp15328
a(I1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15329
(lp15330
I17
aI18
aI19
aI20
a(lp15331
I51
aI52
aI53
atp15332
a(I1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15333
(lp15334
I27
aI28
aI29
aI30
a(lp15335
I41
atp15336
a(I1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15337
(lp15338
I27
aI28
aI29
aI30
a(lp15339
I43
atp15340
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15341
(lp15342
I27
aI28
aI29
aI30
a(lp15343
I45
atp15344
a(I1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15345
(lp15346
I27
aI28
aI29
aI30
a(lp15347
I45
aI46
aI47
atp15348
a(I1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15349
(lp15350
I27
aI28
aI29
aI30
a(lp15351
I51
aI52
aI53
atp15352
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15353
(lp15354
I41
a(lp15355
I43
atp15356
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15357
(lp15358
I41
a(lp15359
I45
atp15360
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15361
(lp15362
I41
a(lp15363
I45
aI46
aI47
atp15364
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15365
(lp15366
I41
a(lp15367
I51
aI52
aI53
atp15368
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15369
(lp15370
I43
a(lp15371
I45
atp15372
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15373
(lp15374
I43
a(lp15375
I45
aI46
aI47
atp15376
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15377
(lp15378
I43
a(lp15379
I51
aI52
aI53
atp15380
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15381
(lp15382
I45
a(lp15383
I45
aI46
aI47
atp15384
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15385
(lp15386
I45
a(lp15387
I51
aI52
aI53
atp15388
a(I-1
S'Finally , we used in vitro translated proteins in an immunoprecipitation assay to show that , like beta 1 - syntrophin , both beta 2 - and alpha 1 - syntrophin interact with peptides encoding the syntrophin - binding region of dystrophin , utrophin / dystrophin related protein , and the Torpedo 87K protein .'
p15389
(lp15390
I45
aI46
aI47
a(lp15391
I51
aI52
aI53
atp15392
a(I-1
S'The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding , commits promoters within chromatin to transcription , and mediates the action of transcriptional activators , a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID - promoter complexes .'
p15393
(lp15394
I4
a(lp15395
I37
atp15396
a(I-1
S'The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding , commits promoters within chromatin to transcription , and mediates the action of transcriptional activators , a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID - promoter complexes .'
p15397
(lp15398
I4
a(lp15399
I43
atp15400
a(I-1
S'The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding , commits promoters within chromatin to transcription , and mediates the action of transcriptional activators , a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID - promoter complexes .'
p15401
(lp15402
I37
a(lp15403
I43
atp15404
a(I-1
S'Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit ( TBP ) , TBP - associated factors ( TAFs ) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation .'
p15405
(lp15406
I5
a(lp15407
I11
aI12
aI13
atp15408
a(I-1
S'Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit ( TBP ) , TBP - associated factors ( TAFs ) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation .'
p15409
(lp15410
I5
a(lp15411
I15
atp15412
a(I-1
S'Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit ( TBP ) , TBP - associated factors ( TAFs ) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation .'
p15413
(lp15414
I11
aI12
aI13
a(lp15415
I15
atp15416
a(I-1
S'Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80 , hTAF31 and hTAF20 / 15 .'
p15417
(lp15418
I15
a(lp15419
I17
atp15420
a(I-1
S'Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80 , hTAF31 and hTAF20 / 15 .'
p15421
(lp15422
I15
a(lp15423
I19
atp15424
a(I-1
S'Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80 , hTAF31 and hTAF20 / 15 .'
p15425
(lp15426
I15
a(lp15427
I21
aI22
aI23
atp15428
a(I-1
S'Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80 , hTAF31 and hTAF20 / 15 .'
p15429
(lp15430
I17
a(lp15431
I19
atp15432
a(I-1
S'Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80 , hTAF31 and hTAF20 / 15 .'
p15433
(lp15434
I17
a(lp15435
I21
aI22
aI23
atp15436
a(I-1
S'Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80 , hTAF31 and hTAF20 / 15 .'
p15437
(lp15438
I19
a(lp15439
I21
aI22
aI23
atp15440
a(I-1
S'Together with analyses of native TFIID complexes and accompanying crystallographic studies , the results suggest that there is a histone octamer - like TAF complex within TFIID .'
p15441
(lp15442
I5
a(lp15443
I26
atp15444
a(I1
S'IRAK : a kinase associated with the interleukin - 1 receptor .'
p15445
(lp15446
I0
a(lp15447
I7
aI8
aI9
aI10
atp15448
a(I-1
S'The pleiotropic biological activities of interleukin - 1 ( IL - 1 ) are mediated by its type I receptor ( IL - 1RI ) .'
p15449
(lp15450
I5
aI6
aI7
a(lp15451
I9
aI10
aI11
atp15452
a(I1
S'The pleiotropic biological activities of interleukin - 1 ( IL - 1 ) are mediated by its type I receptor ( IL - 1RI ) .'
p15453
(lp15454
I5
aI6
aI7
a(lp15455
I21
aI22
aI23
atp15456
a(I1
S'The pleiotropic biological activities of interleukin - 1 ( IL - 1 ) are mediated by its type I receptor ( IL - 1RI ) .'
p15457
(lp15458
I9
aI10
aI11
a(lp15459
I21
aI22
aI23
atp15460
a(I-1
S'When the ligand binds , IL - 1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B ( NF - kappa B ) .'
p15461
(lp15462
I5
aI6
aI7
a(lp15463
I21
aI22
aI23
aI24
atp15464
a(I-1
S'When the ligand binds , IL - 1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B ( NF - kappa B ) .'
p15465
(lp15466
I5
aI6
aI7
a(lp15467
I26
aI27
aI28
aI29
atp15468
a(I-1
S'When the ligand binds , IL - 1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B ( NF - kappa B ) .'
p15469
(lp15470
I21
aI22
aI23
aI24
a(lp15471
I26
aI27
aI28
aI29
atp15472
a(I-1
S'A protein kinase designated IRAK ( IL - 1 receptor - associated kinase ) was purified , and its complementary DNA was molecularly cloned .'
p15473
(lp15474
I4
a(lp15475
I6
aI7
aI8
atp15476
a(I-1
S'A protein kinase designated IRAK ( IL - 1 receptor - associated kinase ) was purified , and its complementary DNA was molecularly cloned .'
p15477
(lp15478
I4
a(lp15479
I6
aI7
aI8
aI9
aI10
aI11
aI12
atp15480
a(I-1
S'A protein kinase designated IRAK ( IL - 1 receptor - associated kinase ) was purified , and its complementary DNA was molecularly cloned .'
p15481
(lp15482
I6
aI7
aI8
a(lp15483
I6
aI7
aI8
aI9
aI10
aI11
aI12
atp15484
a(I-1
S'When human embryonic kidney cells ( cell line 293 ) over - expressing IL - 1RI or HeLa cells were exposed to IL - 1 , IRAK rapidly associated with the IL - 1RI complex and was phosphorylated .'
p15485
(lp15486
I13
aI14
aI15
a(lp15487
I22
aI23
aI24
atp15488
a(I-1
S'When human embryonic kidney cells ( cell line 293 ) over - expressing IL - 1RI or HeLa cells were exposed to IL - 1 , IRAK rapidly associated with the IL - 1RI complex and was phosphorylated .'
p15489
(lp15490
I13
aI14
aI15
a(lp15491
I26
atp15492
a(I-1
S'When human embryonic kidney cells ( cell line 293 ) over - expressing IL - 1RI or HeLa cells were exposed to IL - 1 , IRAK rapidly associated with the IL - 1RI complex and was phosphorylated .'
p15493
(lp15494
I13
aI14
aI15
a(lp15495
I31
aI32
aI33
atp15496
a(I-1
S'When human embryonic kidney cells ( cell line 293 ) over - expressing IL - 1RI or HeLa cells were exposed to IL - 1 , IRAK rapidly associated with the IL - 1RI complex and was phosphorylated .'
p15497
(lp15498
I22
aI23
aI24
a(lp15499
I26
atp15500
a(I-1
S'When human embryonic kidney cells ( cell line 293 ) over - expressing IL - 1RI or HeLa cells were exposed to IL - 1 , IRAK rapidly associated with the IL - 1RI complex and was phosphorylated .'
p15501
(lp15502
I22
aI23
aI24
a(lp15503
I31
aI32
aI33
atp15504
a(I1
S'When human embryonic kidney cells ( cell line 293 ) over - expressing IL - 1RI or HeLa cells were exposed to IL - 1 , IRAK rapidly associated with the IL - 1RI complex and was phosphorylated .'
p15505
(lp15506
I26
a(lp15507
I31
aI32
aI33
atp15508
a(I-1
S'The primary amino acid sequence of IRAK shares similarity with that of pelle , a protein kinase that is essential for the activation of a NF - kappa B homolog in Drosophila .'
p15509
(lp15510
I6
a(lp15511
I25
aI26
aI27
aI28
atp15512
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15513
(lp15514
I20
a(lp15515
I23
aI24
atp15516
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15517
(lp15518
I20
a(lp15519
I26
atp15520
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15521
(lp15522
I20
a(lp15523
I28
atp15524
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15525
(lp15526
I20
a(lp15527
I35
aI36
aI37
aI38
atp15528
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15529
(lp15530
I20
a(lp15531
I40
atp15532
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15533
(lp15534
I23
aI24
a(lp15535
I26
atp15536
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15537
(lp15538
I23
aI24
a(lp15539
I28
atp15540
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15541
(lp15542
I23
aI24
a(lp15543
I35
aI36
aI37
aI38
atp15544
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15545
(lp15546
I23
aI24
a(lp15547
I40
atp15548
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15549
(lp15550
I26
a(lp15551
I28
atp15552
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15553
(lp15554
I26
a(lp15555
I35
aI36
aI37
aI38
atp15556
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15557
(lp15558
I26
a(lp15559
I40
atp15560
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15561
(lp15562
I28
a(lp15563
I35
aI36
aI37
aI38
atp15564
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15565
(lp15566
I28
a(lp15567
I40
atp15568
a(I-1
S"Similarly , in mammalian cells the cyclic adenosine 3 ' , 5 ' - monophosphate - dependent protein kinase ( PKA ) and phosphatase 2B [ calcineurin ( CaN ) ] are complexed by an A kinase anchoring protein , AKAP79 ."
p15569
(lp15570
I35
aI36
aI37
aI38
a(lp15571
I40
atp15572
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15573
(lp15574
I11
aI12
aI13
a(lp15575
I15
atp15576
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15577
(lp15578
I11
aI12
aI13
a(lp15579
I19
atp15580
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15581
(lp15582
I11
aI12
aI13
a(lp15583
I28
atp15584
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15585
(lp15586
I11
aI12
aI13
a(lp15587
I30
atp15588
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15589
(lp15590
I15
a(lp15591
I19
atp15592
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15593
(lp15594
I15
a(lp15595
I28
atp15596
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15597
(lp15598
I15
a(lp15599
I30
atp15600
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15601
(lp15602
I19
a(lp15603
I28
atp15604
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15605
(lp15606
I19
a(lp15607
I30
atp15608
a(I-1
S'Deletion analysis and binding studies demonstrate that a third enzyme , protein kinase C ( PKC ) , binds AKAP79 at a site distinct from those bound by PKA or CaN .'
p15609
(lp15610
I28
a(lp15611
I30
atp15612
a(I-1
S'The subcellular distributions of PKC and AKAP79 were similar in neurons .'
p15613
(lp15614
I4
a(lp15615
I6
atp15616
a(I-1
S'TNF - dependent recruitment of the protein kinase RIP to the TNF receptor - 1 signaling complex .'
p15617
(lp15618
I8
a(lp15619
I11
aI12
aI13
aI14
atp15620
a(I-1
S'The death domain of tumor necrosis factor ( TNF ) receptor - 1 ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and NF - kappa B activation through its interaction with the death domain protein TRADD .'
p15621
(lp15622
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
a(lp15623
I14
atp15624
a(I-1
S'The death domain of tumor necrosis factor ( TNF ) receptor - 1 ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and NF - kappa B activation through its interaction with the death domain protein TRADD .'
p15625
(lp15626
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
a(lp15627
I24
aI25
aI26
aI27
atp15628
a(I1
S'The death domain of tumor necrosis factor ( TNF ) receptor - 1 ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and NF - kappa B activation through its interaction with the death domain protein TRADD .'
p15629
(lp15630
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
a(lp15631
I37
atp15632
a(I-1
S'The death domain of tumor necrosis factor ( TNF ) receptor - 1 ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and NF - kappa B activation through its interaction with the death domain protein TRADD .'
p15633
(lp15634
I14
a(lp15635
I24
aI25
aI26
aI27
atp15636
a(I1
S'The death domain of tumor necrosis factor ( TNF ) receptor - 1 ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and NF - kappa B activation through its interaction with the death domain protein TRADD .'
p15637
(lp15638
I14
a(lp15639
I37
atp15640
a(I-1
S'The death domain of tumor necrosis factor ( TNF ) receptor - 1 ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and NF - kappa B activation through its interaction with the death domain protein TRADD .'
p15641
(lp15642
I24
aI25
aI26
aI27
a(lp15643
I37
atp15644
a(I1
S'Here , we show that TRADD interacts strongly with RIP , another death domain protein that was shown previously to associate with Fas antigen .'
p15645
(lp15646
I5
a(lp15647
I9
atp15648
a(I-1
S'Here , we show that TRADD interacts strongly with RIP , another death domain protein that was shown previously to associate with Fas antigen .'
p15649
(lp15650
I5
a(lp15651
I22
atp15652
a(I1
S'Here , we show that TRADD interacts strongly with RIP , another death domain protein that was shown previously to associate with Fas antigen .'
p15653
(lp15654
I9
a(lp15655
I22
atp15656
a(I-1
S'We also show that RIP is a serine - threonine kinase that is recruited by TRADD to TNFR1 in a TNF - dependent process .'
p15657
(lp15658
I4
a(lp15659
I15
atp15660
a(I-1
S'We also show that RIP is a serine - threonine kinase that is recruited by TRADD to TNFR1 in a TNF - dependent process .'
p15661
(lp15662
I4
a(lp15663
I17
atp15664
a(I-1
S'We also show that RIP is a serine - threonine kinase that is recruited by TRADD to TNFR1 in a TNF - dependent process .'
p15665
(lp15666
I15
a(lp15667
I17
atp15668
a(I-1
S'Overexpression of the intact RIP protein induces both NF - kappa B activation and apoptosis .'
p15669
(lp15670
I4
a(lp15671
I8
aI9
aI10
aI11
atp15672
a(I-1
S'However , expression of the death domain of RIP Induces apoptosis , but potently inhibits NF - kappa B activation by TNF .'
p15673
(lp15674
I8
a(lp15675
I15
aI16
aI17
aI18
atp15676
a(I-1
S'These results suggest that distinct domains of RIP participate in the TNF signaling cascades leading to apoptosis and NF - kappa B activation .'
p15677
(lp15678
I7
a(lp15679
I18
aI19
aI20
aI21
atp15680
a(I1
S'The carboxy - terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin , a cytoplasmic component of the dystrophin - glycoprotein complex , by in vitro biochemical studies such as overlay assay or immunoprecipitation .'
p15681
(lp15682
I6
a(lp15683
I15
aI16
atp15684
a(I-1
S'The carboxy - terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin , a cytoplasmic component of the dystrophin - glycoprotein complex , by in vitro biochemical studies such as overlay assay or immunoprecipitation .'
p15685
(lp15686
I6
a(lp15687
I23
atp15688
a(I-1
S'The carboxy - terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin , a cytoplasmic component of the dystrophin - glycoprotein complex , by in vitro biochemical studies such as overlay assay or immunoprecipitation .'
p15689
(lp15690
I15
aI16
a(lp15691
I23
atp15692
a(I-1
S'Identification of vascular endothelial growth factor determinants for binding KDR and FLT - 1 receptors . Generation of receptor - selective VEGF variants by site - directed mutagenesis .'
p15693
(lp15694
I9
a(lp15695
I11
aI12
aI13
atp15696
a(I-1
S'Identification of vascular endothelial growth factor determinants for binding KDR and FLT - 1 receptors . Generation of receptor - selective VEGF variants by site - directed mutagenesis .'
p15697
(lp15698
I9
a(lp15699
I21
atp15700
a(I-1
S'Identification of vascular endothelial growth factor determinants for binding KDR and FLT - 1 receptors . Generation of receptor - selective VEGF variants by site - directed mutagenesis .'
p15701
(lp15702
I11
aI12
aI13
a(lp15703
I21
atp15704
a(I-1
S'Vascular endothelial growth factor ( VEGF ) expression in various cell types is induced by hypoxia and other stimuli .'
p15705
(lp15706
I0
aI1
aI2
aI3
a(lp15707
I5
atp15708
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15709
(lp15710
I0
a(lp15711
I20
aI21
aI22
aI23
aI24
aI25
atp15712
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15713
(lp15714
I0
a(lp15715
I27
atp15716
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15717
(lp15718
I0
a(lp15719
I30
aI31
aI32
aI33
atp15720
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15721
(lp15722
I0
a(lp15723
I35
aI36
aI37
atp15724
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15725
(lp15726
I0
a(lp15727
I40
aI41
aI42
atp15728
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15729
(lp15730
I20
aI21
aI22
aI23
aI24
aI25
a(lp15731
I27
atp15732
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15733
(lp15734
I20
aI21
aI22
aI23
aI24
aI25
a(lp15735
I30
aI31
aI32
aI33
atp15736
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15737
(lp15738
I20
aI21
aI22
aI23
aI24
aI25
a(lp15739
I35
aI36
aI37
atp15740
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15741
(lp15742
I20
aI21
aI22
aI23
aI24
aI25
a(lp15743
I40
aI41
aI42
atp15744
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15745
(lp15746
I27
a(lp15747
I30
aI31
aI32
aI33
atp15748
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15749
(lp15750
I27
a(lp15751
I35
aI36
aI37
atp15752
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15753
(lp15754
I27
a(lp15755
I40
aI41
aI42
atp15756
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15757
(lp15758
I30
aI31
aI32
aI33
a(lp15759
I35
aI36
aI37
atp15760
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15761
(lp15762
I30
aI31
aI32
aI33
a(lp15763
I40
aI41
aI42
atp15764
a(I-1
S'VEGF mediates endothelial cell proliferation , angiogenesis , vascular growth , and vascular permeability via the endothelial cell receptors , kinase insert domain - containing receptor ( KDR ) / fetal liver kinase 1 ( Flk - 1 ) and FLT - 1 .'
p15765
(lp15766
I35
aI36
aI37
a(lp15767
I40
aI41
aI42
atp15768
a(I-1
S'Alanine - scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR / Flk - 1 .'
p15769
(lp15770
I13
a(lp15771
I18
atp15772
a(I-1
S'Alanine - scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR / Flk - 1 .'
p15773
(lp15774
I13
a(lp15775
I20
aI21
aI22
atp15776
a(I-1
S'Alanine - scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR / Flk - 1 .'
p15777
(lp15778
I18
a(lp15779
I20
aI21
aI22
atp15780
a(I-1
S'Arg82 , Lys84 and His86 , located in a hairpin loop , were found to be critical for binding KDR / Flk - 1 , while negatively charged residues , Asp63 , Glu64 , and Glu67 , were associated with FLT - 1 binding .'
p15781
(lp15782
I19
a(lp15783
I21
aI22
aI23
atp15784
a(I-1
S'Arg82 , Lys84 and His86 , located in a hairpin loop , were found to be critical for binding KDR / Flk - 1 , while negatively charged residues , Asp63 , Glu64 , and Glu67 , were associated with FLT - 1 binding .'
p15785
(lp15786
I19
a(lp15787
I40
aI41
aI42
atp15788
a(I-1
S'Arg82 , Lys84 and His86 , located in a hairpin loop , were found to be critical for binding KDR / Flk - 1 , while negatively charged residues , Asp63 , Glu64 , and Glu67 , were associated with FLT - 1 binding .'
p15789
(lp15790
I21
aI22
aI23
a(lp15791
I40
aI41
aI42
atp15792
a(I-1
S'A VEGF model based on PDGFb indicated these positively and negatively charged regions are distal in the monomer but are spatially close in the dimer .'
p15793
(lp15794
I1
a(lp15795
I5
atp15796
a(I-1
S'Mutations within the KDR site had minimal effect on FLT - 1 binding , and mutants deficient in FLT - 1 binding did not affect KDR binding .'
p15797
(lp15798
I3
a(lp15799
I9
aI10
aI11
atp15800
a(I-1
S'Mutations within the KDR site had minimal effect on FLT - 1 binding , and mutants deficient in FLT - 1 binding did not affect KDR binding .'
p15801
(lp15802
I3
a(lp15803
I18
aI19
aI20
atp15804
a(I-1
S'Mutations within the KDR site had minimal effect on FLT - 1 binding , and mutants deficient in FLT - 1 binding did not affect KDR binding .'
p15805
(lp15806
I3
a(lp15807
I25
atp15808
a(I-1
S'Mutations within the KDR site had minimal effect on FLT - 1 binding , and mutants deficient in FLT - 1 binding did not affect KDR binding .'
p15809
(lp15810
I9
aI10
aI11
a(lp15811
I18
aI19
aI20
atp15812
a(I-1
S'Mutations within the KDR site had minimal effect on FLT - 1 binding , and mutants deficient in FLT - 1 binding did not affect KDR binding .'
p15813
(lp15814
I9
aI10
aI11
a(lp15815
I25
atp15816
a(I-1
S'Mutations within the KDR site had minimal effect on FLT - 1 binding , and mutants deficient in FLT - 1 binding did not affect KDR binding .'
p15817
(lp15818
I18
aI19
aI20
a(lp15819
I25
atp15820
a(I-1
S'Endothelial cell mitogenesis was abolished in mutants lacking KDR affinity ; however , FLT - 1 deficient mutants induced normal proliferation .'
p15821
(lp15822
I8
a(lp15823
I13
aI14
aI15
atp15824
a(I-1
S'Furthermore , this mutational analysis implicates KDR , but not FLT - 1 , in VEGF induction of endothelial cell proliferation .'
p15825
(lp15826
I6
a(lp15827
I10
aI11
aI12
atp15828
a(I-1
S'Furthermore , this mutational analysis implicates KDR , but not FLT - 1 , in VEGF induction of endothelial cell proliferation .'
p15829
(lp15830
I6
a(lp15831
I15
atp15832
a(I-1
S'Furthermore , this mutational analysis implicates KDR , but not FLT - 1 , in VEGF induction of endothelial cell proliferation .'
p15833
(lp15834
I10
aI11
aI12
a(lp15835
I15
atp15836
a(I1
S'Use of the two hybrid system to detect the association of the protein - tyrosine - phosphatase , SHPTP2 , with another SH2 - containing protein , Grb7 .'
p15837
(lp15838
I18
a(lp15839
I27
atp15840
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15841
(lp15842
I0
a(lp15843
I4
aI5
aI6
aI7
aI8
atp15844
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15845
(lp15846
I0
a(lp15847
I10
atp15848
a(I1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15849
(lp15850
I0
a(lp15851
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
atp15852
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15853
(lp15854
I0
a(lp15855
I20
atp15856
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15857
(lp15858
I0
a(lp15859
I28
atp15860
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15861
(lp15862
I4
aI5
aI6
aI7
aI8
a(lp15863
I10
atp15864
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15865
(lp15866
I4
aI5
aI6
aI7
aI8
a(lp15867
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
atp15868
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15869
(lp15870
I4
aI5
aI6
aI7
aI8
a(lp15871
I20
atp15872
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15873
(lp15874
I4
aI5
aI6
aI7
aI8
a(lp15875
I28
atp15876
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15877
(lp15878
I10
a(lp15879
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
atp15880
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15881
(lp15882
I10
a(lp15883
I20
atp15884
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15885
(lp15886
I10
a(lp15887
I28
atp15888
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15889
(lp15890
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
a(lp15891
I20
atp15892
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15893
(lp15894
I4
aI5
aI6
aI7
aI8
aI9
aI10
aI11
aI12
a(lp15895
I28
atp15896
a(I-1
S'SHPTP2 associates with the platelet - derived growth factor ( PDGF ) receptor after ligand stimulation , and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2 .'
p15897
(lp15898
I20
a(lp15899
I28
atp15900
a(I-1
S'Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells , we have found that SHPTP2 interacts with another signaling protein , Grb7 .'
p15901
(lp15902
I1
a(lp15903
I20
atp15904
a(I-1
S'Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells , we have found that SHPTP2 interacts with another signaling protein , Grb7 .'
p15905
(lp15906
I1
a(lp15907
I27
atp15908
a(I1
S'Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells , we have found that SHPTP2 interacts with another signaling protein , Grb7 .'
p15909
(lp15910
I20
a(lp15911
I27
atp15912
a(I-1
S'We have localized the region of interaction to tyrosine 580 in the carboxyl end of SHPTP2 and to the SH2 domain in the carboxy - terminus of Grb7 .'
p15913
(lp15914
I15
a(lp15915
I27
atp15916
a(I1
S'We demonstrate that Grb7 binds to SHPTP2 in vitro under conditions where the latter is tyrosine - phosphorylated .'
p15917
(lp15918
I3
a(lp15919
I6
atp15920
a(I-1
S'We found that the human TR subtype beta 1 ( h - TR beta 1 ) physically interacted with p53 via its DNA binding domain .'
p15921
(lp15922
I5
aI6
aI7
aI8
a(lp15923
I10
aI11
aI12
aI13
aI14
atp15924
a(I1
S'We found that the human TR subtype beta 1 ( h - TR beta 1 ) physically interacted with p53 via its DNA binding domain .'
p15925
(lp15926
I5
aI6
aI7
aI8
a(lp15927
I19
atp15928
a(I1
S'We found that the human TR subtype beta 1 ( h - TR beta 1 ) physically interacted with p53 via its DNA binding domain .'
p15929
(lp15930
I10
aI11
aI12
aI13
aI14
a(lp15931
I19
atp15932
a(I1
S'As a result of this physical interaction , binding of h - TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration - dependent manner .'
p15933
(lp15934
I10
aI11
aI12
aI13
aI14
a(lp15935
I29
aI30
aI31
atp15936
a(I-1
S'As a result of this physical interaction , binding of h - TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration - dependent manner .'
p15937
(lp15938
I10
aI11
aI12
aI13
aI14
a(lp15939
I35
atp15940
a(I-1
S'As a result of this physical interaction , binding of h - TR beta 1 to its hormone response elements either as homodimer or as a heterodimer with the retinoic X receptor was inhibited by p53 in a concentration - dependent manner .'
p15941
(lp15942
I29
aI30
aI31
a(lp15943
I35
atp15944
a(I1
S'In transfected cells , wild - type p53 repressed the hormone - dependent transcriptional activation of h - TR beta 1 .'
p15945
(lp15946
I7
a(lp15947
I16
aI17
aI18
aI19
aI20
atp15948
a(I-1
S'In contrast , mutant p53 either had no effect or activated the transcriptional activity of h - TR beta 1 depending on the type of hormone response elements .'
p15949
(lp15950
I4
a(lp15951
I15
aI16
aI17
aI18
aI19
atp15952
a(I-1
S'Enhanced degradation of EGF receptors by a sorting nexin , SNX1 .'
p15953
(lp15954
I3
a(lp15955
I8
atp15956
a(I-1
S'Enhanced degradation of EGF receptors by a sorting nexin , SNX1 .'
p15957
(lp15958
I3
a(lp15959
I10
atp15960
a(I-1
S'Enhanced degradation of EGF receptors by a sorting nexin , SNX1 .'
p15961
(lp15962
I8
a(lp15963
I10
atp15964
a(I-1
S'A protein , sorting nexin - 1 ( SNX1 ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( EGFR ) containing the lysosomal targeting code .'
p15965
(lp15966
I3
aI4
aI5
aI6
a(lp15967
I8
atp15968
a(I1
S'A protein , sorting nexin - 1 ( SNX1 ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( EGFR ) containing the lysosomal targeting code .'
p15969
(lp15970
I3
aI4
aI5
aI6
a(lp15971
I25
aI26
aI27
aI28
atp15972
a(I1
S'A protein , sorting nexin - 1 ( SNX1 ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( EGFR ) containing the lysosomal targeting code .'
p15973
(lp15974
I3
aI4
aI5
aI6
a(lp15975
I30
atp15976
a(I1
S'A protein , sorting nexin - 1 ( SNX1 ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( EGFR ) containing the lysosomal targeting code .'
p15977
(lp15978
I8
a(lp15979
I25
aI26
aI27
aI28
atp15980
a(I1
S'A protein , sorting nexin - 1 ( SNX1 ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( EGFR ) containing the lysosomal targeting code .'
p15981
(lp15982
I8
a(lp15983
I30
atp15984
a(I-1
S'A protein , sorting nexin - 1 ( SNX1 ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( EGFR ) containing the lysosomal targeting code .'
p15985
(lp15986
I25
aI26
aI27
aI28
a(lp15987
I30
atp15988
a(I-1
S'SNX1 contains a region of homology to a yeast vacuolar sorting protein , and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand - induced degradation .'
p15989
(lp15990
I0
a(lp15991
I16
atp15992
a(I-1
S'SNX1 contains a region of homology to a yeast vacuolar sorting protein , and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand - induced degradation .'
p15993
(lp15994
I0
a(lp15995
I21
atp15996
a(I-1
S'SNX1 contains a region of homology to a yeast vacuolar sorting protein , and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand - induced degradation .'
p15997
(lp15998
I16
a(lp15999
I21
atp16000
a(I-1
S'Thus , SNX1 is likely to play a role in sorting EGFR to lysosomes .'
p16001
(lp16002
I2
a(lp16003
I11
atp16004
a(I1
S'The splicing factor U2AF ( U2 snRNP auxiliary factor ) is a heterodimer with subunits of 65 and 35 kD ( U2AF65 and U2AF35 ) .'
p16005
(lp16006
I21
a(lp16007
I23
atp16008
a(I-1
S"U2AF65 binds specifically to 3 ' splice sites , but previous studies failed to demonstrate a function for U2AF35 ."
p16009
(lp16010
I0
a(lp16011
I18
atp16012
a(I-1
S'Nuclear extracts deficient in U2AF35 were inactive ; however , both constitutive and enhancer - dependent splicing could be restored by the addition of purified recombinant U2AF35 .'
p16013
(lp16014
I4
a(lp16015
I26
atp16016
a(I-1
S'In vitro protein - RNA interaction studies with pre - mRNAs containing either a constitutive or regulated splicing enhancer revealed that U2AF35 directly mediates interactions between U2AF65 and proteins bound to the enhancers .'
p16017
(lp16018
I21
a(lp16019
I26
atp16020
a(I-1
S'Thus , U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron .'
p16021
(lp16022
I2
a(lp16023
I8
atp16024
a(I-1
S'Thus , U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron .'
p16025
(lp16026
I2
a(lp16027
I15
atp16028
a(I-1
S'Thus , U2AF35 functions as a bridge between U2AF65 and the enhancer complex to recruit U2AF65 to the adjacent intron .'
p16029
(lp16030
I8
a(lp16031
I15
atp16032
a(I-1
S'Interactions involving the human RNA polymerase II transcription / nucleotide excision repair complex TFIIH , the nucleotide excision repair protein XPG , and Cockayne syndrome group B ( CSB ) protein .'
p16033
(lp16034
I13
a(lp16035
I20
atp16036
a(I-1
S'Interactions involving the human RNA polymerase II transcription / nucleotide excision repair complex TFIIH , the nucleotide excision repair protein XPG , and Cockayne syndrome group B ( CSB ) protein .'
p16037
(lp16038
I13
a(lp16039
I28
atp16040
a(I-1
S'Interactions involving the human RNA polymerase II transcription / nucleotide excision repair complex TFIIH , the nucleotide excision repair protein XPG , and Cockayne syndrome group B ( CSB ) protein .'
p16041
(lp16042
I13
a(lp16043
I23
aI24
aI25
aI26
aI27
aI28
aI29
aI30
atp16044
a(I1
S'Interactions involving the human RNA polymerase II transcription / nucleotide excision repair complex TFIIH , the nucleotide excision repair protein XPG , and Cockayne syndrome group B ( CSB ) protein .'
p16045
(lp16046
I20
a(lp16047
I28
atp16048
a(I-1
S'Interactions involving the human RNA polymerase II transcription / nucleotide excision repair complex TFIIH , the nucleotide excision repair protein XPG , and Cockayne syndrome group B ( CSB ) protein .'
p16049
(lp16050
I20
a(lp16051
I23
aI24
aI25
aI26
aI27
aI28
aI29
aI30
atp16052
a(I-1
S'Interactions involving the human RNA polymerase II transcription / nucleotide excision repair complex TFIIH , the nucleotide excision repair protein XPG , and Cockayne syndrome group B ( CSB ) protein .'
p16053
(lp16054
I28
a(lp16055
I23
aI24
aI25
aI26
aI27
aI28
aI29
aI30
atp16056
a(I-1
S'At least two of the subunits of TFIIH ( XPB and XPD proteins ) are implicated in the disease xeroderma pigmentosum ( XP ) .'
p16057
(lp16058
I7
a(lp16059
I9
atp16060
a(I-1
S'At least two of the subunits of TFIIH ( XPB and XPD proteins ) are implicated in the disease xeroderma pigmentosum ( XP ) .'
p16061
(lp16062
I7
a(lp16063
I11
atp16064
a(I-1
S'At least two of the subunits of TFIIH ( XPB and XPD proteins ) are implicated in the disease xeroderma pigmentosum ( XP ) .'
p16065
(lp16066
I9
a(lp16067
I11
atp16068
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16069
(lp16070
I8
a(lp16071
I10
atp16072
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16073
(lp16074
I8
a(lp16075
I12
atp16076
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16077
(lp16078
I8
a(lp16079
I14
atp16080
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16081
(lp16082
I8
a(lp16083
I17
atp16084
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16085
(lp16086
I8
a(lp16087
I27
atp16088
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16089
(lp16090
I10
a(lp16091
I12
atp16092
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16093
(lp16094
I10
a(lp16095
I14
atp16096
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16097
(lp16098
I10
a(lp16099
I17
atp16100
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16101
(lp16102
I10
a(lp16103
I27
atp16104
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16105
(lp16106
I12
a(lp16107
I14
atp16108
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16109
(lp16110
I12
a(lp16111
I17
atp16112
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16113
(lp16114
I12
a(lp16115
I27
atp16116
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16117
(lp16118
I14
a(lp16119
I17
atp16120
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16121
(lp16122
I14
a(lp16123
I27
atp16124
a(I-1
S'We have exploited the availability of the cloned XPB , XPD , p62 , p44 , and p34 genes ( all of which encode polypeptide subunits of TFIIH ) to examine interactions between in vitro - translated polypeptides by co - immunoprecipitation .'
p16125
(lp16126
I17
a(lp16127
I27
atp16128
a(I-1
S'Additionally we have examined interactions between TFIIH components , the human NER protein XPG , and the CSB protein which is implicated in Cockayne syndrome ( CS ) .'
p16129
(lp16130
I6
a(lp16131
I13
atp16132
a(I-1
S'Additionally we have examined interactions between TFIIH components , the human NER protein XPG , and the CSB protein which is implicated in Cockayne syndrome ( CS ) .'
p16133
(lp16134
I6
a(lp16135
I17
atp16136
a(I-1
S'Additionally we have examined interactions between TFIIH components , the human NER protein XPG , and the CSB protein which is implicated in Cockayne syndrome ( CS ) .'
p16137
(lp16138
I13
a(lp16139
I17
atp16140
a(I1
S'Our analyses demonstrate that the XPB , XPD , p44 , and p62 proteins interact with each other .'
p16141
(lp16142
I5
a(lp16143
I7
atp16144
a(I-1
S'Our analyses demonstrate that the XPB , XPD , p44 , and p62 proteins interact with each other .'
p16145
(lp16146
I5
a(lp16147
I9
atp16148
a(I-1
S'Our analyses demonstrate that the XPB , XPD , p44 , and p62 proteins interact with each other .'
p16149
(lp16150
I5
a(lp16151
I12
atp16152
a(I-1
S'Our analyses demonstrate that the XPB , XPD , p44 , and p62 proteins interact with each other .'
p16153
(lp16154
I7
a(lp16155
I9
atp16156
a(I-1
S'Our analyses demonstrate that the XPB , XPD , p44 , and p62 proteins interact with each other .'
p16157
(lp16158
I7
a(lp16159
I12
atp16160
a(I-1
S'Our analyses demonstrate that the XPB , XPD , p44 , and p62 proteins interact with each other .'
p16161
(lp16162
I9
a(lp16163
I12
atp16164
a(I-1
S'XPG protein interacts with multiple subunits of TFIIH and with CSB protein .'
p16165
(lp16166
I0
a(lp16167
I7
atp16168
a(I1
S'XPG protein interacts with multiple subunits of TFIIH and with CSB protein .'
p16169
(lp16170
I0
a(lp16171
I10
atp16172
a(I-1
S'XPG protein interacts with multiple subunits of TFIIH and with CSB protein .'
p16173
(lp16174
I7
a(lp16175
I10
atp16176
a(I-1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16177
(lp16178
I3
aI4
aI5
a(lp16179
I7
atp16180
a(I1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16181
(lp16182
I3
aI4
aI5
a(lp16183
I16
aI17
atp16184
a(I1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16185
(lp16186
I3
aI4
aI5
a(lp16187
I22
atp16188
a(I-1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16189
(lp16190
I3
aI4
aI5
a(lp16191
I32
atp16192
a(I1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16193
(lp16194
I7
a(lp16195
I16
aI17
atp16196
a(I1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16197
(lp16198
I7
a(lp16199
I22
atp16200
a(I-1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16201
(lp16202
I7
a(lp16203
I32
atp16204
a(I-1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16205
(lp16206
I16
aI17
a(lp16207
I22
atp16208
a(I-1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16209
(lp16210
I16
aI17
a(lp16211
I32
atp16212
a(I-1
S'Residues in human leukemia inhibitory factor ( hLIF ) crucial for binding to both the human LIF receptor ( R ) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity .'
p16213
(lp16214
I22
a(lp16215
I32
atp16216
a(I1
S'The region of hLIF most important for binding to the hLIF - R is composed of residues from the amino terminus of the D - helix , carboxyl terminus of the B - helix , and C - D loop .'
p16217
(lp16218
I3
a(lp16219
I10
aI11
aI12
atp16220
a(I1
S'The two residues of hLIF that contribute the majority of free energy for hLIF - R binding , Phe - 156 and Lys - 159 are surrounded by other residues which have only a moderate impact .'
p16221
(lp16222
I4
a(lp16223
I13
aI14
aI15
atp16224
a(I1
S'A second region of hLIF that includes residues from the carboxyl terminus of the D - helix and A - B loop also had a weak influence on hLIF - R binding .'
p16225
(lp16226
I4
a(lp16227
I28
aI29
aI30
atp16228
a(I1
S'Residues in hLIF from both the A - and C - helices are involved in binding the gp130 co - receptor .'
p16229
(lp16230
I2
a(lp16231
I17
atp16232
a(I1
S'Abolition of the gp130 binding site in hLIF created antagonists of LIF action .'
p16233
(lp16234
I3
a(lp16235
I7
atp16236
a(I-1
S'Abolition of the gp130 binding site in hLIF created antagonists of LIF action .'
p16237
(lp16238
I3
a(lp16239
I11
atp16240
a(I-1
S'Abolition of the gp130 binding site in hLIF created antagonists of LIF action .'
p16241
(lp16242
I7
a(lp16243
I11
atp16244
a(I1
S'The glut 1 glucose transporter interacts with calnexin and calreticulin .'
p16245
(lp16246
I1
aI2
a(lp16247
I7
atp16248
a(I1
S'The glut 1 glucose transporter interacts with calnexin and calreticulin .'
p16249
(lp16250
I1
aI2
a(lp16251
I9
atp16252
a(I-1
S'The glut 1 glucose transporter interacts with calnexin and calreticulin .'
p16253
(lp16254
I7
a(lp16255
I9
atp16256
a(I-1
S'A truncated version of the integral membrane glycoprotein Glut 1 ( GT155 ) was synthesized in a rabbit reticulocyte translation system in the presence of canine pancreatic microsomes .'
p16257
(lp16258
I8
aI9
a(lp16259
I11
atp16260
a(I1
S'Following immunoprecipitation with an anticalnexin antiserum , a cross - linker - independent association was observed between GT155 and calnexin .'
p16261
(lp16262
I17
a(lp16263
I19
atp16264
a(I1
S'In addition , the anti - calnexin antiserum immunoprecipitated a UV - dependent cross - linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP - 60 ( calnexin - associated protein of 60 kDa ) .'
p16265
(lp16266
I19
a(lp16267
I28
aI29
aI30
atp16268
a(I1
S'In addition , the anti - calnexin antiserum immunoprecipitated a UV - dependent cross - linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP - 60 ( calnexin - associated protein of 60 kDa ) .'
p16269
(lp16270
I19
a(lp16271
I32
aI33
aI34
aI35
atp16272
a(I-1
S'In addition , the anti - calnexin antiserum immunoprecipitated a UV - dependent cross - linking product consisting of GT155 and a protein of approximately 60 kDa designated CAP - 60 ( calnexin - associated protein of 60 kDa ) .'
p16273
(lp16274
I28
aI29
aI30
a(lp16275
I32
aI33
aI34
aI35
atp16276
a(I1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16277
(lp16278
I2
a(lp16279
I4
atp16280
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16281
(lp16282
I2
a(lp16283
I7
atp16284
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16285
(lp16286
I2
a(lp16287
I9
aI10
aI11
atp16288
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16289
(lp16290
I2
a(lp16291
I25
atp16292
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16293
(lp16294
I2
a(lp16295
I31
atp16296
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16297
(lp16298
I4
a(lp16299
I7
atp16300
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16301
(lp16302
I4
a(lp16303
I9
aI10
aI11
atp16304
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16305
(lp16306
I4
a(lp16307
I25
atp16308
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16309
(lp16310
I4
a(lp16311
I31
atp16312
a(I1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16313
(lp16314
I7
a(lp16315
I9
aI10
aI11
atp16316
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16317
(lp16318
I7
a(lp16319
I25
atp16320
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16321
(lp16322
I7
a(lp16323
I31
atp16324
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16325
(lp16326
I9
aI10
aI11
a(lp16327
I25
atp16328
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16329
(lp16330
I9
aI10
aI11
a(lp16331
I31
atp16332
a(I-1
S'Both the GT155 - calnexin and the GT155 - CAP - 60 interactions were dependent on the presence of a correctly modified oligosaccharide group on GT155 , a characteristic of many calnexin interactions .'
p16333
(lp16334
I25
a(lp16335
I31
atp16336
a(I-1
S'A GT155 mutant that was not glycosylated ( AGGT155 ) did not associate with calnexin or CAP - 60 .'
p16337
(lp16338
I1
a(lp16339
I14
atp16340
a(I-1
S'A GT155 mutant that was not glycosylated ( AGGT155 ) did not associate with calnexin or CAP - 60 .'
p16341
(lp16342
I1
a(lp16343
I16
aI17
aI18
atp16344
a(I-1
S'A GT155 mutant that was not glycosylated ( AGGT155 ) did not associate with calnexin or CAP - 60 .'
p16345
(lp16346
I14
a(lp16347
I16
aI17
aI18
atp16348
a(I-1
S'Calreticulin , the soluble homologue of calnexin , was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group .'
p16349
(lp16350
I0
a(lp16351
I6
atp16352
a(I1
S'Calreticulin , the soluble homologue of calnexin , was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group .'
p16353
(lp16354
I0
a(lp16355
I14
atp16356
a(I-1
S'Calreticulin , the soluble homologue of calnexin , was also shown to interact with GT155 only when the protein bore a correctly modified oligosaccharide group .'
p16357
(lp16358
I6
a(lp16359
I14
atp16360
a(I-1
S'Thus , our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation - dependent manner .'
p16361
(lp16362
I7
a(lp16363
I9
atp16364
a(I1
S'Thus , our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation - dependent manner .'
p16365
(lp16366
I7
a(lp16367
I12
aI13
atp16368
a(I1
S'Thus , our data show that both calnexin and calreticulin interact with Glut 1 in a glycosylation - dependent manner .'
p16369
(lp16370
I9
a(lp16371
I12
aI13
atp16372
a(I-1
S'Identification of a critical ligand binding determinant of the human erythropoietin receptor . Evidence for common ligand binding motifs in the cytokine receptor family .'
p16373
(lp16374
I10
a(lp16375
I10
aI11
atp16376
a(I-1
S'The erythropoietin receptor ( EPOR ) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains .'
p16377
(lp16378
I1
a(lp16379
I1
aI2
atp16380
a(I1
S'The erythropoietin receptor ( EPOR ) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains .'
p16381
(lp16382
I1
a(lp16383
I4
atp16384
a(I-1
S'The erythropoietin receptor ( EPOR ) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains .'
p16385
(lp16386
I1
aI2
a(lp16387
I4
atp16388
a(I1
S'We have used site - specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin ( EPO ) binding .'
p16389
(lp16390
I13
a(lp16391
I22
atp16392
a(I1
S'We have used site - specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin ( EPO ) binding .'
p16393
(lp16394
I13
a(lp16395
I24
atp16396
a(I-1
S'We have used site - specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin ( EPO ) binding .'
p16397
(lp16398
I22
a(lp16399
I24
atp16400
a(I1
S'Mutant proteins were expressed in bacteria as soluble EPO binding proteins ( EBP ) and characterized for EPO binding activity in a number of different assays .'
p16401
(lp16402
I8
a(lp16403
I12
atp16404
a(I-1
S'Mutant proteins were expressed in bacteria as soluble EPO binding proteins ( EBP ) and characterized for EPO binding activity in a number of different assays .'
p16405
(lp16406
I8
a(lp16407
I17
atp16408
a(I-1
S'Mutant proteins were expressed in bacteria as soluble EPO binding proteins ( EBP ) and characterized for EPO binding activity in a number of different assays .'
p16409
(lp16410
I12
a(lp16411
I17
atp16412
a(I1
S'Substitution of phenylalanine at position 93 ( Phe93 ) with alanine ( F93A mutation ) resulted in a drastic reduction in EPO binding in the EBP .'
p16413
(lp16414
I21
a(lp16415
I25
atp16416
a(I1
S'Furthermore , the F93A mutation in full - length EPOR expressed in COS cells abolished detectable EPO binding .'
p16417
(lp16418
I9
a(lp16419
I16
atp16420
a(I1
S'These data indicate that Phe93 is a critical EPO binding determinant of the EPOR .'
p16421
(lp16422
I8
a(lp16423
I13
atp16424
a(I-1
S'Cloning and characterization of a specific interleukin ( IL ) - 13 binding protein structurally related to the IL - 5 receptor alpha chain .'
p16425
(lp16426
I6
aI7
aI8
aI9
aI10
aI11
a(lp16427
I18
aI19
aI20
atp16428
a(I-1
S'Cloning and characterization of a specific interleukin ( IL ) - 13 binding protein structurally related to the IL - 5 receptor alpha chain .'
p16429
(lp16430
I6
aI7
aI8
aI9
aI10
aI11
a(lp16431
I18
aI19
aI20
aI21
atp16432
a(I-1
S'Cloning and characterization of a specific interleukin ( IL ) - 13 binding protein structurally related to the IL - 5 receptor alpha chain .'
p16433
(lp16434
I18
aI19
aI20
a(lp16435
I18
aI19
aI20
aI21
atp16436
a(I-1
S'Interleukin - 13 ( IL - 13 ) is a cytokine secreted by activated T lymphocytes that shares many , but not all , biological activities with IL - 4 .'
p16437
(lp16438
I0
aI1
aI2
a(lp16439
I4
aI5
aI6
atp16440
a(I-1
S'Interleukin - 13 ( IL - 13 ) is a cytokine secreted by activated T lymphocytes that shares many , but not all , biological activities with IL - 4 .'
p16441
(lp16442
I0
aI1
aI2
a(lp16443
I27
aI28
aI29
atp16444
a(I-1
S'Interleukin - 13 ( IL - 13 ) is a cytokine secreted by activated T lymphocytes that shares many , but not all , biological activities with IL - 4 .'
p16445
(lp16446
I4
aI5
aI6
a(lp16447
I27
aI28
aI29
atp16448
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16449
(lp16450
I9
aI10
aI11
a(lp16451
I21
aI22
aI23
atp16452
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16453
(lp16454
I9
aI10
aI11
a(lp16455
I34
aI35
aI36
atp16456
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16457
(lp16458
I9
aI10
aI11
a(lp16459
I34
aI35
aI36
aI37
atp16460
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16461
(lp16462
I9
aI10
aI11
a(lp16463
I45
aI46
aI47
atp16464
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16465
(lp16466
I21
aI22
aI23
a(lp16467
I34
aI35
aI36
atp16468
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16469
(lp16470
I21
aI22
aI23
a(lp16471
I34
aI35
aI36
aI37
atp16472
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16473
(lp16474
I21
aI22
aI23
a(lp16475
I45
aI46
aI47
atp16476
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16477
(lp16478
I34
aI35
aI36
a(lp16479
I34
aI35
aI36
aI37
atp16480
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16481
(lp16482
I34
aI35
aI36
a(lp16483
I45
aI46
aI47
atp16484
a(I-1
S'Two proteins have been described as constituents of the IL - 4 receptor , a approximately 140 - kDa glycoprotein ( IL - 4R ) and the gamma chain ( gammac ) of the IL - 2 receptor , but neither of these proteins binds IL - 13 .'
p16485
(lp16486
I34
aI35
aI36
aI37
a(lp16487
I45
aI46
aI47
atp16488
a(I1
S'We have cloned a cDNA encoding an IL - 13 binding protein ( IL - 13R ) from the Caki - 1 human renal carcinoma cell line .'
p16489
(lp16490
I7
aI8
aI9
a(lp16491
I13
aI14
aI15
atp16492
a(I-1
S'The IL - 13R shows homology with the IL - 5 receptor , and to a lesser extent , with the prolactin receptor .'
p16493
(lp16494
I1
aI2
aI3
a(lp16495
I8
aI9
aI10
atp16496
a(I1
S'COS - 7 cells transfected with the IL - 13R cDNA bind IL - 13 with high affinity but do not bind IL - 4 .'
p16497
(lp16498
I7
aI8
aI9
a(lp16499
I12
aI13
aI14
atp16500
a(I-1
S'COS - 7 cells transfected with the IL - 13R cDNA bind IL - 13 with high affinity but do not bind IL - 4 .'
p16501
(lp16502
I7
aI8
aI9
a(lp16503
I22
aI23
aI24
atp16504
a(I-1
S'COS - 7 cells transfected with the IL - 13R cDNA bind IL - 13 with high affinity but do not bind IL - 4 .'
p16505
(lp16506
I12
aI13
aI14
a(lp16507
I22
aI23
aI24
atp16508
a(I-1
S'COS - 7 cells co - transfected with the cloned IL - 13R cDNA and IL - 4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL - 4 and IL - 13 .'
p16509
(lp16510
I10
aI11
aI12
a(lp16511
I15
aI16
aI17
atp16512
a(I-1
S'COS - 7 cells co - transfected with the cloned IL - 13R cDNA and IL - 4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL - 4 and IL - 13 .'
p16513
(lp16514
I10
aI11
aI12
a(lp16515
I32
aI33
aI34
atp16516
a(I-1
S'COS - 7 cells co - transfected with the cloned IL - 13R cDNA and IL - 4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL - 4 and IL - 13 .'
p16517
(lp16518
I10
aI11
aI12
a(lp16519
I36
aI37
aI38
atp16520
a(I-1
S'COS - 7 cells co - transfected with the cloned IL - 13R cDNA and IL - 4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL - 4 and IL - 13 .'
p16521
(lp16522
I15
aI16
aI17
a(lp16523
I32
aI33
aI34
atp16524
a(I-1
S'COS - 7 cells co - transfected with the cloned IL - 13R cDNA and IL - 4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL - 4 and IL - 13 .'
p16525
(lp16526
I15
aI16
aI17
a(lp16527
I36
aI37
aI38
atp16528
a(I-1
S'COS - 7 cells co - transfected with the cloned IL - 13R cDNA and IL - 4R cDNA resulted in the reconstitution of a small number of receptors that recognized both IL - 4 and IL - 13 .'
p16529
(lp16530
I32
aI33
aI34
a(lp16531
I36
aI37
aI38
atp16532
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16533
(lp16534
I2
aI3
a(lp16535
I9
aI10
atp16536
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16537
(lp16538
I2
aI3
a(lp16539
I15
aI16
aI17
atp16540
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16541
(lp16542
I2
aI3
a(lp16543
I19
aI20
aI21
atp16544
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16545
(lp16546
I2
aI3
a(lp16547
I28
aI29
aI30
atp16548
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16549
(lp16550
I2
aI3
a(lp16551
I32
aI33
aI34
atp16552
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16553
(lp16554
I2
aI3
a(lp16555
I37
atp16556
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16557
(lp16558
I2
aI3
a(lp16559
I46
aI47
atp16560
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16561
(lp16562
I9
aI10
a(lp16563
I15
aI16
aI17
atp16564
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16565
(lp16566
I9
aI10
a(lp16567
I19
aI20
aI21
atp16568
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16569
(lp16570
I9
aI10
a(lp16571
I28
aI29
aI30
atp16572
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16573
(lp16574
I9
aI10
a(lp16575
I32
aI33
aI34
atp16576
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16577
(lp16578
I9
aI10
a(lp16579
I37
atp16580
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16581
(lp16582
I9
aI10
a(lp16583
I46
aI47
atp16584
a(I1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16585
(lp16586
I15
aI16
aI17
a(lp16587
I19
aI20
aI21
atp16588
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16589
(lp16590
I15
aI16
aI17
a(lp16591
I28
aI29
aI30
atp16592
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16593
(lp16594
I15
aI16
aI17
a(lp16595
I32
aI33
aI34
atp16596
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16597
(lp16598
I15
aI16
aI17
a(lp16599
I37
atp16600
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16601
(lp16602
I15
aI16
aI17
a(lp16603
I46
aI47
atp16604
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16605
(lp16606
I19
aI20
aI21
a(lp16607
I28
aI29
aI30
atp16608
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16609
(lp16610
I19
aI20
aI21
a(lp16611
I32
aI33
aI34
atp16612
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16613
(lp16614
I19
aI20
aI21
a(lp16615
I37
atp16616
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16617
(lp16618
I19
aI20
aI21
a(lp16619
I46
aI47
atp16620
a(I1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16621
(lp16622
I28
aI29
aI30
a(lp16623
I32
aI33
aI34
atp16624
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16625
(lp16626
I28
aI29
aI30
a(lp16627
I37
atp16628
a(I1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16629
(lp16630
I28
aI29
aI30
a(lp16631
I46
aI47
atp16632
a(I-1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16633
(lp16634
I32
aI33
aI34
a(lp16635
I37
atp16636
a(I1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16637
(lp16638
I32
aI33
aI34
a(lp16639
I46
aI47
atp16640
a(I1
S'The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 ( comprised of subunits p22 - phox and gp91 - phox ) and three cytosol proteins ( p47 - phox , p67 - phox , and p21rac ) that translocate to membrane and bind to cytochrome b558 .'
p16641
(lp16642
I37
a(lp16643
I46
aI47
atp16644
a(I-1
S'This is the first report to demonstrate that two of cytosolic components of cytochrome b558 , p47 - phox binding to p67 - phox each other .'
p16645
(lp16646
I13
aI14
a(lp16647
I16
aI17
aI18
atp16648
a(I-1
S'This is the first report to demonstrate that two of cytosolic components of cytochrome b558 , p47 - phox binding to p67 - phox each other .'
p16649
(lp16650
I13
aI14
a(lp16651
I21
aI22
aI23
atp16652
a(I1
S'This is the first report to demonstrate that two of cytosolic components of cytochrome b558 , p47 - phox binding to p67 - phox each other .'
p16653
(lp16654
I16
aI17
aI18
a(lp16655
I21
aI22
aI23
atp16656
a(I1
S'Crystal structure of the p27Kip1 cyclin - dependent - kinase inhibitor bound to the cyclin A - Cdk2 complex .'
p16657
(lp16658
I4
a(lp16659
I14
aI15
atp16660
a(I1
S'Crystal structure of the p27Kip1 cyclin - dependent - kinase inhibitor bound to the cyclin A - Cdk2 complex .'
p16661
(lp16662
I4
a(lp16663
I17
atp16664
a(I1
S'Crystal structure of the p27Kip1 cyclin - dependent - kinase inhibitor bound to the cyclin A - Cdk2 complex .'
p16665
(lp16666
I14
aI15
a(lp16667
I17
atp16668
a(I1
S'The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A - cyclin - dependent kinase 2 ( Cdk2 ) complex has been determined at 2 . 3 angstrom .'
p16669
(lp16670
I6
aI7
a(lp16671
I14
aI15
atp16672
a(I-1
S'The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A - cyclin - dependent kinase 2 ( Cdk2 ) complex has been determined at 2 . 3 angstrom .'
p16673
(lp16674
I6
aI7
a(lp16675
I17
aI18
aI19
aI20
aI21
atp16676
a(I1
S'The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A - cyclin - dependent kinase 2 ( Cdk2 ) complex has been determined at 2 . 3 angstrom .'
p16677
(lp16678
I6
aI7
a(lp16679
I23
atp16680
a(I-1
S'The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A - cyclin - dependent kinase 2 ( Cdk2 ) complex has been determined at 2 . 3 angstrom .'
p16681
(lp16682
I14
aI15
a(lp16683
I17
aI18
aI19
aI20
aI21
atp16684
a(I1
S'The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A - cyclin - dependent kinase 2 ( Cdk2 ) complex has been determined at 2 . 3 angstrom .'
p16685
(lp16686
I14
aI15
a(lp16687
I23
atp16688
a(I-1
S'The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A - cyclin - dependent kinase 2 ( Cdk2 ) complex has been determined at 2 . 3 angstrom .'
p16689
(lp16690
I17
aI18
aI19
aI20
aI21
a(lp16691
I23
atp16692
a(I1
S'p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2 .'
p16693
(lp16694
I0
a(lp16695
I11
aI12
atp16696
a(I1
S'p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2 .'
p16697
(lp16698
I0
a(lp16699
I14
atp16700
a(I-1
S'p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2 .'
p16701
(lp16702
I11
aI12
a(lp16703
I14
atp16704
a(I-1
S'Vascular endothelial growth factor - related protein : a ligand and specific activator of the tyrosine kinase receptor Flt4 .'
p16705
(lp16706
I0
aI1
aI2
aI3
a(lp16707
I0
aI1
aI2
aI3
aI4
aI5
aI6
atp16708
a(I-1
S'Vascular endothelial growth factor - related protein : a ligand and specific activator of the tyrosine kinase receptor Flt4 .'
p16709
(lp16710
I0
aI1
aI2
aI3
a(lp16711
I18
atp16712
a(I1
S'Vascular endothelial growth factor - related protein : a ligand and specific activator of the tyrosine kinase receptor Flt4 .'
p16713
(lp16714
I0
aI1
aI2
aI3
aI4
aI5
aI6
a(lp16715
I18
atp16716
a(I-1
S'The tyrosine kinases Flt4 , Flt1 , and Flk1 ( or KDR ) constitute a family of endothelial cell - specific receptors with seven immunoglobulin - like domains and a split kinase domain .'
p16717
(lp16718
I3
a(lp16719
I5
atp16720
a(I-1
S'The tyrosine kinases Flt4 , Flt1 , and Flk1 ( or KDR ) constitute a family of endothelial cell - specific receptors with seven immunoglobulin - like domains and a split kinase domain .'
p16721
(lp16722
I3
a(lp16723
I8
atp16724
a(I-1
S'The tyrosine kinases Flt4 , Flt1 , and Flk1 ( or KDR ) constitute a family of endothelial cell - specific receptors with seven immunoglobulin - like domains and a split kinase domain .'
p16725
(lp16726
I3
a(lp16727
I11
atp16728
a(I-1
S'The tyrosine kinases Flt4 , Flt1 , and Flk1 ( or KDR ) constitute a family of endothelial cell - specific receptors with seven immunoglobulin - like domains and a split kinase domain .'
p16729
(lp16730
I5
a(lp16731
I8
atp16732
a(I-1
S'The tyrosine kinases Flt4 , Flt1 , and Flk1 ( or KDR ) constitute a family of endothelial cell - specific receptors with seven immunoglobulin - like domains and a split kinase domain .'
p16733
(lp16734
I5
a(lp16735
I11
atp16736
a(I-1
S'The tyrosine kinases Flt4 , Flt1 , and Flk1 ( or KDR ) constitute a family of endothelial cell - specific receptors with seven immunoglobulin - like domains and a split kinase domain .'
p16737
(lp16738
I8
a(lp16739
I11
atp16740
a(I-1
S'Flt1 and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( VEGF ) .'
p16741
(lp16742
I0
a(lp16743
I2
atp16744
a(I1
S'Flt1 and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( VEGF ) .'
p16745
(lp16746
I0
a(lp16747
I22
aI23
aI24
aI25
atp16748
a(I1
S'Flt1 and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( VEGF ) .'
p16749
(lp16750
I0
a(lp16751
I27
atp16752
a(I1
S'Flt1 and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( VEGF ) .'
p16753
(lp16754
I2
a(lp16755
I22
aI23
aI24
aI25
atp16756
a(I1
S'Flt1 and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( VEGF ) .'
p16757
(lp16758
I2
a(lp16759
I27
atp16760
a(I-1
S'Flt1 and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( VEGF ) .'
p16761
(lp16762
I22
aI23
aI24
aI25
a(lp16763
I27
atp16764
a(I-1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16765
(lp16766
I4
a(lp16767
I4
aI5
aI6
aI7
atp16768
a(I-1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16769
(lp16770
I4
a(lp16771
I9
atp16772
a(I-1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16773
(lp16774
I4
a(lp16775
I19
atp16776
a(I-1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16777
(lp16778
I4
a(lp16779
I26
atp16780
a(I-1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16781
(lp16782
I4
aI5
aI6
aI7
a(lp16783
I9
atp16784
a(I1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16785
(lp16786
I4
aI5
aI6
aI7
a(lp16787
I19
atp16788
a(I-1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16789
(lp16790
I4
aI5
aI6
aI7
a(lp16791
I26
atp16792
a(I1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16793
(lp16794
I9
a(lp16795
I19
atp16796
a(I-1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16797
(lp16798
I9
a(lp16799
I26
atp16800
a(I-1
S'This protein , designated VEGF - related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .'
p16801
(lp16802
I19
a(lp16803
I26
atp16804
a(I-1
S'VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1 .'
p16805
(lp16806
I0
a(lp16807
I10
atp16808
a(I-1
S'VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1 .'
p16809
(lp16810
I0
a(lp16811
I12
atp16812
a(I-1
S'VRP fails to bind appreciably to the extracellular domain of Flt1 or Flk1 .'
p16813
(lp16814
I10
a(lp16815
I12
atp16816
a(I-1
S'The kinetics of amyloid fibril formation by beta - amyloid peptide ( Abeta ) are typical of a nucleation - dependent polymerization mechanism .'
p16817
(lp16818
I7
aI8
aI9
aI10
a(lp16819
I12
atp16820
a(I-1
S'Fusion proteins were created by linking the Abeta fragment to a LexA DNA - binding domain ( bait ) and also to a B42 transactivation domain ( prey ) .'
p16821
(lp16822
I7
a(lp16823
I11
atp16824
a(I-1
S'Fusion proteins were created by linking the Abeta fragment to a LexA DNA - binding domain ( bait ) and also to a B42 transactivation domain ( prey ) .'
p16825
(lp16826
I7
a(lp16827
I23
atp16828
a(I-1
S'Fusion proteins were created by linking the Abeta fragment to a LexA DNA - binding domain ( bait ) and also to a B42 transactivation domain ( prey ) .'
p16829
(lp16830
I11
a(lp16831
I23
atp16832
a(I-1
S'Protein - protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ ( beta - galactosidase ) and LEU2 ( leucine utilization ) genes under the control of LexA - dependent operators .'
p16833
(lp16834
I16
a(lp16835
I18
aI19
aI20
atp16836
a(I-1
S'Protein - protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ ( beta - galactosidase ) and LEU2 ( leucine utilization ) genes under the control of LexA - dependent operators .'
p16837
(lp16838
I16
a(lp16839
I23
atp16840
a(I-1
S'Protein - protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ ( beta - galactosidase ) and LEU2 ( leucine utilization ) genes under the control of LexA - dependent operators .'
p16841
(lp16842
I16
a(lp16843
I25
aI26
atp16844
a(I-1
S'Protein - protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ ( beta - galactosidase ) and LEU2 ( leucine utilization ) genes under the control of LexA - dependent operators .'
p16845
(lp16846
I18
aI19
aI20
a(lp16847
I23
atp16848
a(I-1
S'Protein - protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ ( beta - galactosidase ) and LEU2 ( leucine utilization ) genes under the control of LexA - dependent operators .'
p16849
(lp16850
I18
aI19
aI20
a(lp16851
I25
aI26
atp16852
a(I-1
S'Protein - protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ ( beta - galactosidase ) and LEU2 ( leucine utilization ) genes under the control of LexA - dependent operators .'
p16853
(lp16854
I23
a(lp16855
I25
aI26
atp16856
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16857
(lp16858
I0
a(lp16859
I7
atp16860
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16861
(lp16862
I0
a(lp16863
I9
atp16864
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16865
(lp16866
I0
a(lp16867
I11
atp16868
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16869
(lp16870
I0
a(lp16871
I18
atp16872
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16873
(lp16874
I0
a(lp16875
I22
atp16876
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16877
(lp16878
I0
a(lp16879
I28
atp16880
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16881
(lp16882
I0
a(lp16883
I30
atp16884
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16885
(lp16886
I7
a(lp16887
I9
atp16888
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16889
(lp16890
I7
a(lp16891
I11
atp16892
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16893
(lp16894
I7
a(lp16895
I18
atp16896
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16897
(lp16898
I7
a(lp16899
I22
atp16900
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16901
(lp16902
I7
a(lp16903
I28
atp16904
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16905
(lp16906
I7
a(lp16907
I30
atp16908
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16909
(lp16910
I9
a(lp16911
I11
atp16912
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16913
(lp16914
I9
a(lp16915
I18
atp16916
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16917
(lp16918
I9
a(lp16919
I22
atp16920
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16921
(lp16922
I9
a(lp16923
I28
atp16924
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16925
(lp16926
I9
a(lp16927
I30
atp16928
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16929
(lp16930
I11
a(lp16931
I18
atp16932
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16933
(lp16934
I11
a(lp16935
I22
atp16936
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16937
(lp16938
I11
a(lp16939
I28
atp16940
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16941
(lp16942
I11
a(lp16943
I30
atp16944
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16945
(lp16946
I18
a(lp16947
I22
atp16948
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16949
(lp16950
I18
a(lp16951
I28
atp16952
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16953
(lp16954
I18
a(lp16955
I30
atp16956
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16957
(lp16958
I22
a(lp16959
I28
atp16960
a(I-1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16961
(lp16962
I22
a(lp16963
I30
atp16964
a(I1
S'LexA protein fused to the Drosophila protein bicoid ( LexA - bicoid ) failed to interact with the B42 fragment fused to Abeta , indicating that the observed Abeta - Abeta interaction was specific .'
p16965
(lp16966
I28
a(lp16967
I30
atp16968
a(I-1
S'Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA - Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe - Phe at residues 19 and 20 replaced by Thr - Thr ( AbetaTT ) , a finding that is consistent with in vitro observations made by others .'
p16969
(lp16970
I16
a(lp16971
I18
atp16972
a(I-1
S'Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA - Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe - Phe at residues 19 and 20 replaced by Thr - Thr ( AbetaTT ) , a finding that is consistent with in vitro observations made by others .'
p16973
(lp16974
I16
a(lp16975
I22
atp16976
a(I-1
S'Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA - Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe - Phe at residues 19 and 20 replaced by Thr - Thr ( AbetaTT ) , a finding that is consistent with in vitro observations made by others .'
p16977
(lp16978
I16
a(lp16979
I29
atp16980
a(I-1
S'Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA - Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe - Phe at residues 19 and 20 replaced by Thr - Thr ( AbetaTT ) , a finding that is consistent with in vitro observations made by others .'
p16981
(lp16982
I18
a(lp16983
I22
atp16984
a(I-1
S'Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA - Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe - Phe at residues 19 and 20 replaced by Thr - Thr ( AbetaTT ) , a finding that is consistent with in vitro observations made by others .'
p16985
(lp16986
I18
a(lp16987
I29
atp16988
a(I-1
S'Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA - Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe - Phe at residues 19 and 20 replaced by Thr - Thr ( AbetaTT ) , a finding that is consistent with in vitro observations made by others .'
p16989
(lp16990
I22
a(lp16991
I29
atp16992
a(I-1
S'Influence of interleukin - 6 ( IL - 6 ) dimerization on formation of the high affinity hexameric IL - 6 . receptor complex .'
p16993
(lp16994
I2
aI3
aI4
a(lp16995
I6
aI7
aI8
atp16996
a(I-1
S'Influence of interleukin - 6 ( IL - 6 ) dimerization on formation of the high affinity hexameric IL - 6 . receptor complex .'
p16997
(lp16998
I2
aI3
aI4
a(lp16999
I18
aI19
aI20
atp17000
a(I-1
S'Influence of interleukin - 6 ( IL - 6 ) dimerization on formation of the high affinity hexameric IL - 6 . receptor complex .'
p17001
(lp17002
I2
aI3
aI4
a(lp17003
I18
aI19
aI20
aI21
aI22
atp17004
a(I-1
S'Influence of interleukin - 6 ( IL - 6 ) dimerization on formation of the high affinity hexameric IL - 6 . receptor complex .'
p17005
(lp17006
I6
aI7
aI8
a(lp17007
I18
aI19
aI20
atp17008
a(I-1
S'Influence of interleukin - 6 ( IL - 6 ) dimerization on formation of the high affinity hexameric IL - 6 . receptor complex .'
p17009
(lp17010
I6
aI7
aI8
a(lp17011
I18
aI19
aI20
aI21
aI22
atp17012
a(I-1
S'Influence of interleukin - 6 ( IL - 6 ) dimerization on formation of the high affinity hexameric IL - 6 . receptor complex .'
p17013
(lp17014
I18
aI19
aI20
a(lp17015
I18
aI19
aI20
aI21
aI22
atp17016
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17017
(lp17018
I3
aI4
aI5
a(lp17019
I7
aI8
aI9
atp17020
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17021
(lp17022
I3
aI4
aI5
a(lp17023
I15
aI16
aI17
atp17024
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17025
(lp17026
I3
aI4
aI5
a(lp17027
I31
aI32
aI33
atp17028
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17029
(lp17030
I3
aI4
aI5
a(lp17031
I31
aI32
aI33
aI34
atp17032
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17033
(lp17034
I3
aI4
aI5
a(lp17035
I43
atp17036
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17037
(lp17038
I7
aI8
aI9
a(lp17039
I15
aI16
aI17
atp17040
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17041
(lp17042
I7
aI8
aI9
a(lp17043
I31
aI32
aI33
atp17044
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17045
(lp17046
I7
aI8
aI9
a(lp17047
I31
aI32
aI33
aI34
atp17048
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17049
(lp17050
I7
aI8
aI9
a(lp17051
I43
atp17052
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17053
(lp17054
I15
aI16
aI17
a(lp17055
I31
aI32
aI33
atp17056
a(I1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17057
(lp17058
I15
aI16
aI17
a(lp17059
I31
aI32
aI33
aI34
atp17060
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17061
(lp17062
I15
aI16
aI17
a(lp17063
I43
atp17064
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17065
(lp17066
I31
aI32
aI33
a(lp17067
I31
aI32
aI33
aI34
atp17068
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17069
(lp17070
I31
aI32
aI33
a(lp17071
I43
atp17072
a(I-1
S'The high affinity interleukin - 6 ( IL - 6 ) signaling complex consists of IL - 6 and two membrane - associated receptor components : a low affinity but specific IL - 6 receptor and the affinity converter / signal transducing protein gp130 .'
p17073
(lp17074
I31
aI32
aI33
aI34
a(lp17075
I43
atp17076
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17077
(lp17078
I2
aI3
aI4
a(lp17079
I9
aI10
aI11
atp17080
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17081
(lp17082
I2
aI3
aI4
a(lp17083
I20
aI21
aI22
atp17084
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17085
(lp17086
I2
aI3
aI4
a(lp17087
I34
aI35
aI36
atp17088
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17089
(lp17090
I2
aI3
aI4
a(lp17091
I34
aI35
aI36
aI37
atp17092
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17093
(lp17094
I2
aI3
aI4
a(lp17095
I39
aI40
aI41
atp17096
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17097
(lp17098
I2
aI3
aI4
a(lp17099
I44
atp17100
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17101
(lp17102
I2
aI3
aI4
a(lp17103
I55
aI56
aI57
atp17104
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17105
(lp17106
I9
aI10
aI11
a(lp17107
I20
aI21
aI22
atp17108
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17109
(lp17110
I9
aI10
aI11
a(lp17111
I34
aI35
aI36
atp17112
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17113
(lp17114
I9
aI10
aI11
a(lp17115
I34
aI35
aI36
aI37
atp17116
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17117
(lp17118
I9
aI10
aI11
a(lp17119
I39
aI40
aI41
atp17120
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17121
(lp17122
I9
aI10
aI11
a(lp17123
I44
atp17124
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17125
(lp17126
I9
aI10
aI11
a(lp17127
I55
aI56
aI57
atp17128
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17129
(lp17130
I20
aI21
aI22
a(lp17131
I34
aI35
aI36
atp17132
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17133
(lp17134
I20
aI21
aI22
a(lp17135
I34
aI35
aI36
aI37
atp17136
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17137
(lp17138
I20
aI21
aI22
a(lp17139
I39
aI40
aI41
atp17140
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17141
(lp17142
I20
aI21
aI22
a(lp17143
I44
atp17144
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17145
(lp17146
I20
aI21
aI22
a(lp17147
I55
aI56
aI57
atp17148
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17149
(lp17150
I34
aI35
aI36
a(lp17151
I34
aI35
aI36
aI37
atp17152
a(I1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17153
(lp17154
I34
aI35
aI36
a(lp17155
I39
aI40
aI41
atp17156
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17157
(lp17158
I34
aI35
aI36
a(lp17159
I44
atp17160
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17161
(lp17162
I34
aI35
aI36
a(lp17163
I55
aI56
aI57
atp17164
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17165
(lp17166
I34
aI35
aI36
aI37
a(lp17167
I39
aI40
aI41
atp17168
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17169
(lp17170
I34
aI35
aI36
aI37
a(lp17171
I44
atp17172
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17173
(lp17174
I34
aI35
aI36
aI37
a(lp17175
I55
aI56
aI57
atp17176
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17177
(lp17178
I39
aI40
aI41
a(lp17179
I44
atp17180
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17181
(lp17182
I39
aI40
aI41
a(lp17183
I55
aI56
aI57
atp17184
a(I-1
S'Monomeric ( IL - 6M ) and dimeric ( IL - 6D ) forms of Escherichia coli - derived human IL - 6 and the extracellular ( " soluble " ) portions of the IL - 6 receptor ( sIL - 6R ) and gp130 have been purified in order to investigate the effect of IL - 6 dimerization on binding to the receptor complex .'
p17185
(lp17186
I44
a(lp17187
I55
aI56
aI57
atp17188
a(I1
S'Although IL - 6D has a higher binding affinity for immobilized sIL - 6R , as determined by biosensor analysis employing surface plasmon resonance detection , IL - 6M is more potent than IL - 6D in a STAT3 phosphorylation assay .'
p17189
(lp17190
I1
aI2
aI3
a(lp17191
I11
aI12
aI13
atp17192
a(I-1
S'Although IL - 6D has a higher binding affinity for immobilized sIL - 6R , as determined by biosensor analysis employing surface plasmon resonance detection , IL - 6M is more potent than IL - 6D in a STAT3 phosphorylation assay .'
p17193
(lp17194
I1
aI2
aI3
a(lp17195
I26
aI27
aI28
atp17196
a(I-1
S'Although IL - 6D has a higher binding affinity for immobilized sIL - 6R , as determined by biosensor analysis employing surface plasmon resonance detection , IL - 6M is more potent than IL - 6D in a STAT3 phosphorylation assay .'
p17197
(lp17198
I1
aI2
aI3
a(lp17199
I33
aI34
aI35
atp17200
a(I-1
S'Although IL - 6D has a higher binding affinity for immobilized sIL - 6R , as determined by biosensor analysis employing surface plasmon resonance detection , IL - 6M is more potent than IL - 6D in a STAT3 phosphorylation assay .'
p17201
(lp17202
I11
aI12
aI13
a(lp17203
I26
aI27
aI28
atp17204
a(I-1
S'Although IL - 6D has a higher binding affinity for immobilized sIL - 6R , as determined by biosensor analysis employing surface plasmon resonance detection , IL - 6M is more potent than IL - 6D in a STAT3 phosphorylation assay .'
p17205
(lp17206
I11
aI12
aI13
a(lp17207
I33
aI34
aI35
atp17208
a(I-1
S'Although IL - 6D has a higher binding affinity for immobilized sIL - 6R , as determined by biosensor analysis employing surface plasmon resonance detection , IL - 6M is more potent than IL - 6D in a STAT3 phosphorylation assay .'
p17209
(lp17210
I26
aI27
aI28
a(lp17211
I33
aI34
aI35
atp17212
a(I1
S'The increased binding affinity of IL - 6D appears to be due to its ability to cross - link two sIL - 6R molecules on the biosensor surface .'
p17213
(lp17214
I5
aI6
aI7
a(lp17215
I20
aI21
aI22
atp17216
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17217
(lp17218
I3
aI4
aI5
a(lp17219
I16
aI17
aI18
atp17220
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17221
(lp17222
I3
aI4
aI5
a(lp17223
I26
aI27
aI28
atp17224
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17225
(lp17226
I3
aI4
aI5
a(lp17227
I30
aI31
aI32
atp17228
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17229
(lp17230
I3
aI4
aI5
a(lp17231
I43
atp17232
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17233
(lp17234
I16
aI17
aI18
a(lp17235
I26
aI27
aI28
atp17236
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17237
(lp17238
I16
aI17
aI18
a(lp17239
I30
aI31
aI32
atp17240
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17241
(lp17242
I16
aI17
aI18
a(lp17243
I43
atp17244
a(I1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17245
(lp17246
I26
aI27
aI28
a(lp17247
I30
aI31
aI32
atp17248
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17249
(lp17250
I26
aI27
aI28
a(lp17251
I43
atp17252
a(I-1
S'Studies of the IL - 6 ternary complex formation demonstrated that the reduced biological potency of IL - 6D resulted from a decreased ability of the IL - 6D ( sIL - 6R ) 2 complex to couple with the soluble portion of gp130 .'
p17253
(lp17254
I30
aI31
aI32
a(lp17255
I43
atp17256
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17257
(lp17258
I4
aI5
aI6
a(lp17259
I11
aI12
aI13
atp17260
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17261
(lp17262
I4
aI5
aI6
a(lp17263
I26
aI27
aI28
atp17264
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17265
(lp17266
I4
aI5
aI6
a(lp17267
I29
aI30
aI31
atp17268
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17269
(lp17270
I4
aI5
aI6
a(lp17271
I32
atp17272
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17273
(lp17274
I11
aI12
aI13
a(lp17275
I26
aI27
aI28
atp17276
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17277
(lp17278
I11
aI12
aI13
a(lp17279
I29
aI30
aI31
atp17280
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17281
(lp17282
I11
aI12
aI13
a(lp17283
I32
atp17284
a(I1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17285
(lp17286
I26
aI27
aI28
a(lp17287
I29
aI30
aI31
atp17288
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17289
(lp17290
I26
aI27
aI28
a(lp17291
I32
atp17292
a(I-1
S'These data imply that IL - 6 - induced dimerization of sIL - 6R is not the driving force in promoting formation of the hexameric ( IL - 6 IL - 6R gp130 ) 2 complex .'
p17293
(lp17294
I29
aI30
aI31
a(lp17295
I32
atp17296
a(I1
S'A model is presented whereby the trimeric complex of IL - 6R , gp130 , and IL - 6M forms before the functional hexamer .'
p17297
(lp17298
I9
aI10
aI11
a(lp17299
I13
atp17300
a(I-1
S'A model is presented whereby the trimeric complex of IL - 6R , gp130 , and IL - 6M forms before the functional hexamer .'
p17301
(lp17302
I9
aI10
aI11
a(lp17303
I16
aI17
aI18
atp17304
a(I-1
S'A model is presented whereby the trimeric complex of IL - 6R , gp130 , and IL - 6M forms before the functional hexamer .'
p17305
(lp17306
I13
a(lp17307
I16
aI17
aI18
atp17308
a(I-1
S'Due to its increased affinity for the IL - 6R but its decreased ability to couple with gp130 , we suggest that a stable IL - 6 dimer may be an efficient IL - 6 antagonist .'
p17309
(lp17310
I7
aI8
aI9
a(lp17311
I17
atp17312
a(I1
S'Due to its increased affinity for the IL - 6R but its decreased ability to couple with gp130 , we suggest that a stable IL - 6 dimer may be an efficient IL - 6 antagonist .'
p17313
(lp17314
I7
aI8
aI9
a(lp17315
I24
aI25
aI26
atp17316
a(I-1
S'Due to its increased affinity for the IL - 6R but its decreased ability to couple with gp130 , we suggest that a stable IL - 6 dimer may be an efficient IL - 6 antagonist .'
p17317
(lp17318
I7
aI8
aI9
a(lp17319
I32
aI33
aI34
atp17320
a(I1
S'Due to its increased affinity for the IL - 6R but its decreased ability to couple with gp130 , we suggest that a stable IL - 6 dimer may be an efficient IL - 6 antagonist .'
p17321
(lp17322
I17
a(lp17323
I24
aI25
aI26
atp17324
a(I-1
S'Due to its increased affinity for the IL - 6R but its decreased ability to couple with gp130 , we suggest that a stable IL - 6 dimer may be an efficient IL - 6 antagonist .'
p17325
(lp17326
I17
a(lp17327
I32
aI33
aI34
atp17328
a(I-1
S'Due to its increased affinity for the IL - 6R but its decreased ability to couple with gp130 , we suggest that a stable IL - 6 dimer may be an efficient IL - 6 antagonist .'
p17329
(lp17330
I24
aI25
aI26
a(lp17331
I32
aI33
aI34
atp17332
a(I1
S'Physical interaction of mammalian CDC37 with CDK4'
p17333
(lp17334
I4
a(lp17335
I6
atp17336
a(I-1
S'. CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins .'
p17337
(lp17338
I0
aI1
a(lp17339
I22
atp17340
a(I-1
S'CDK4 is a cyclin D - dependent kinase that controls progression through G1 of the mammalian cell cycle .'
p17341
(lp17342
I0
a(lp17343
I3
aI4
aI5
aI6
aI7
atp17344
a(I1
S'We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44 - kDa protein that we identify as mammalian CDC37 .'
p17345
(lp17346
I7
a(lp17347
I12
atp17348
a(I1
S'We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44 - kDa protein that we identify as mammalian CDC37 .'
p17349
(lp17350
I7
a(lp17351
I24
atp17352
a(I-1
S'We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44 - kDa protein that we identify as mammalian CDC37 .'
p17353
(lp17354
I12
a(lp17355
I24
atp17356
a(I1
S'A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4 .'
p17357
(lp17358
I4
a(lp17359
I6
atp17360
a(I-1
S'A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4 .'
p17361
(lp17362
I4
a(lp17363
I9
atp17364
a(I-1
S'A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4 .'
p17365
(lp17366
I4
a(lp17367
I21
atp17368
a(I-1
S'A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4 .'
p17369
(lp17370
I6
a(lp17371
I9
atp17372
a(I-1
S'A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4 .'
p17373
(lp17374
I6
a(lp17375
I21
atp17376
a(I1
S'A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4 .'
p17377
(lp17378
I9
a(lp17379
I21
atp17380
a(I1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17381
(lp17382
I2
a(lp17383
I5
atp17384
a(I1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17385
(lp17386
I2
a(lp17387
I7
atp17388
a(I-1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17389
(lp17390
I2
a(lp17391
I18
atp17392
a(I-1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17393
(lp17394
I2
a(lp17395
I20
atp17396
a(I-1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17397
(lp17398
I5
a(lp17399
I7
atp17400
a(I-1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17401
(lp17402
I5
a(lp17403
I18
atp17404
a(I-1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17405
(lp17406
I5
a(lp17407
I20
atp17408
a(I-1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17409
(lp17410
I7
a(lp17411
I18
atp17412
a(I-1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17413
(lp17414
I7
a(lp17415
I20
atp17416
a(I-1
S'Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .'
p17417
(lp17418
I18
a(lp17419
I20
atp17420
a(I-1
S'Interactions of p60 , a mediator of progesterone receptor assembly , with heat shock proteins hsp90 and hsp70 .'
p17421
(lp17422
I2
a(lp17423
I7
aI8
atp17424
a(I1
S'Interactions of p60 , a mediator of progesterone receptor assembly , with heat shock proteins hsp90 and hsp70 .'
p17425
(lp17426
I2
a(lp17427
I15
atp17428
a(I1
S'Interactions of p60 , a mediator of progesterone receptor assembly , with heat shock proteins hsp90 and hsp70 .'
p17429
(lp17430
I2
a(lp17431
I17
atp17432
a(I-1
S'Interactions of p60 , a mediator of progesterone receptor assembly , with heat shock proteins hsp90 and hsp70 .'
p17433
(lp17434
I7
aI8
a(lp17435
I15
atp17436
a(I-1
S'Interactions of p60 , a mediator of progesterone receptor assembly , with heat shock proteins hsp90 and hsp70 .'
p17437
(lp17438
I7
aI8
a(lp17439
I17
atp17440
a(I-1
S'Interactions of p60 , a mediator of progesterone receptor assembly , with heat shock proteins hsp90 and hsp70 .'
p17441
(lp17442
I15
a(lp17443
I17
atp17444
a(I-1
S'Previous studies on the assembly of progesterone receptor ( PR ) complexes in vitro have suggested that PR assembly is a dynamic , ordered process involving at least eight nonreceptor proteins .'
p17445
(lp17446
I6
aI7
a(lp17447
I9
atp17448
a(I-1
S'Previous studies on the assembly of progesterone receptor ( PR ) complexes in vitro have suggested that PR assembly is a dynamic , ordered process involving at least eight nonreceptor proteins .'
p17449
(lp17450
I6
aI7
a(lp17451
I17
atp17452
a(I-1
S'Previous studies on the assembly of progesterone receptor ( PR ) complexes in vitro have suggested that PR assembly is a dynamic , ordered process involving at least eight nonreceptor proteins .'
p17453
(lp17454
I9
a(lp17455
I17
atp17456
a(I-1
S'One of these proteins , p60 , appears transiently during assembly and is not a component of functionally mature PR complexes .'
p17457
(lp17458
I5
a(lp17459
I19
atp17460
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17461
(lp17462
I12
a(lp17463
I24
atp17464
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17465
(lp17466
I12
a(lp17467
I27
aI28
aI29
aI30
atp17468
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17469
(lp17470
I12
a(lp17471
I32
atp17472
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17473
(lp17474
I12
a(lp17475
I35
atp17476
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17477
(lp17478
I12
a(lp17479
I49
atp17480
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17481
(lp17482
I12
a(lp17483
I52
atp17484
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17485
(lp17486
I12
a(lp17487
I54
atp17488
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17489
(lp17490
I12
a(lp17491
I56
atp17492
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17493
(lp17494
I24
a(lp17495
I27
aI28
aI29
aI30
atp17496
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17497
(lp17498
I24
a(lp17499
I32
atp17500
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17501
(lp17502
I24
a(lp17503
I35
atp17504
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17505
(lp17506
I24
a(lp17507
I49
atp17508
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17509
(lp17510
I24
a(lp17511
I52
atp17512
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17513
(lp17514
I24
a(lp17515
I54
atp17516
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17517
(lp17518
I24
a(lp17519
I56
atp17520
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17521
(lp17522
I27
aI28
aI29
aI30
a(lp17523
I32
atp17524
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17525
(lp17526
I27
aI28
aI29
aI30
a(lp17527
I35
atp17528
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17529
(lp17530
I27
aI28
aI29
aI30
a(lp17531
I49
atp17532
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17533
(lp17534
I27
aI28
aI29
aI30
a(lp17535
I52
atp17536
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17537
(lp17538
I27
aI28
aI29
aI30
a(lp17539
I54
atp17540
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17541
(lp17542
I27
aI28
aI29
aI30
a(lp17543
I56
atp17544
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17545
(lp17546
I32
a(lp17547
I35
atp17548
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17549
(lp17550
I32
a(lp17551
I49
atp17552
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17553
(lp17554
I32
a(lp17555
I52
atp17556
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17557
(lp17558
I32
a(lp17559
I54
atp17560
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17561
(lp17562
I32
a(lp17563
I56
atp17564
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17565
(lp17566
I35
a(lp17567
I49
atp17568
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17569
(lp17570
I35
a(lp17571
I52
atp17572
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17573
(lp17574
I35
a(lp17575
I54
atp17576
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17577
(lp17578
I35
a(lp17579
I56
atp17580
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17581
(lp17582
I49
a(lp17583
I52
atp17584
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17585
(lp17586
I49
a(lp17587
I54
atp17588
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17589
(lp17590
I49
a(lp17591
I56
atp17592
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17593
(lp17594
I52
a(lp17595
I54
atp17596
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17597
(lp17598
I52
a(lp17599
I56
atp17600
a(I-1
S'In the present study we observe that a monoclonal antibody specific for p60 can , on the one hand , inhibit formation of mature PR complexes containing heat shock protein 90 ( hsp90 ) , p23 , and immunophilins and , on the other , enhance recovery of early PR complexes containing hsp70 and Hip ( p48 ) .'
p17601
(lp17602
I54
a(lp17603
I56
atp17604
a(I-1
S'This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60 .'
p17605
(lp17606
I7
a(lp17607
I14
atp17608
a(I-1
S'This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60 .'
p17609
(lp17610
I7
a(lp17611
I21
atp17612
a(I-1
S'This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60 .'
p17613
(lp17614
I7
a(lp17615
I24
atp17616
a(I-1
S'This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60 .'
p17617
(lp17618
I14
a(lp17619
I21
atp17620
a(I-1
S'This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60 .'
p17621
(lp17622
I14
a(lp17623
I24
atp17624
a(I-1
S'This observation supports a model in which p60 functions at an intermediate stage of PR assembly to facilitate formation of subsequent PR complexes lacking p60 .'
p17625
(lp17626
I21
a(lp17627
I24
atp17628
a(I1
S'Since p60 is typically found in a complex with hsp90 and hsp70 , we have further characterized its interactions with these proteins .'
p17629
(lp17630
I1
a(lp17631
I9
atp17632
a(I1
S'Since p60 is typically found in a complex with hsp90 and hsp70 , we have further characterized its interactions with these proteins .'
p17633
(lp17634
I1
a(lp17635
I11
atp17636
a(I-1
S'Since p60 is typically found in a complex with hsp90 and hsp70 , we have further characterized its interactions with these proteins .'
p17637
(lp17638
I9
a(lp17639
I11
atp17640
a(I1
S'P60 can bind either hsp70 or hsp90 independently and in an ATP - independent manner .'
p17641
(lp17642
I0
a(lp17643
I4
atp17644
a(I1
S'P60 can bind either hsp70 or hsp90 independently and in an ATP - independent manner .'
p17645
(lp17646
I0
a(lp17647
I6
atp17648
a(I-1
S'P60 can bind either hsp70 or hsp90 independently and in an ATP - independent manner .'
p17649
(lp17650
I4
a(lp17651
I6
atp17652
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17653
(lp17654
I1
a(lp17655
I3
atp17656
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17657
(lp17658
I1
a(lp17659
I15
atp17660
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17661
(lp17662
I1
a(lp17663
I23
atp17664
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17665
(lp17666
I1
a(lp17667
I25
atp17668
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17669
(lp17670
I1
a(lp17671
I27
atp17672
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17673
(lp17674
I3
a(lp17675
I15
atp17676
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17677
(lp17678
I3
a(lp17679
I23
atp17680
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17681
(lp17682
I3
a(lp17683
I25
atp17684
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17685
(lp17686
I3
a(lp17687
I27
atp17688
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17689
(lp17690
I15
a(lp17691
I23
atp17692
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17693
(lp17694
I15
a(lp17695
I25
atp17696
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17697
(lp17698
I15
a(lp17699
I27
atp17700
a(I1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17701
(lp17702
I23
a(lp17703
I25
atp17704
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17705
(lp17706
I23
a(lp17707
I27
atp17708
a(I-1
S'Since hsp90 and hsp70 do not readily associate on their own , it appears that p60 is the central organizing component of an hsp90 - p60 - hsp70 complex .'
p17709
(lp17710
I25
a(lp17711
I27
atp17712
a(I1
S'Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding , and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70 .'
p17713
(lp17714
I3
a(lp17715
I12
atp17716
a(I1
S'Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding , and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70 .'
p17717
(lp17718
I3
a(lp17719
I27
atp17720
a(I1
S'Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding , and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70 .'
p17721
(lp17722
I3
a(lp17723
I29
atp17724
a(I-1
S'Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding , and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70 .'
p17725
(lp17726
I12
a(lp17727
I27
atp17728
a(I-1
S'Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding , and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70 .'
p17729
(lp17730
I12
a(lp17731
I29
atp17732
a(I-1
S'Mutational analysis of p60 indicates that the N terminus is required for hsp70 binding , and a central region containing tetratricopeptide repeat motifs is necessary for binding hsp90 and hsp70 .'
p17733
(lp17734
I27
a(lp17735
I29
atp17736
a(I1
S'The hsp90 - p60 - hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90 - binding drug geldanamycin .'
p17737
(lp17738
I1
a(lp17739
I3
atp17740
a(I-1
S'The hsp90 - p60 - hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90 - binding drug geldanamycin .'
p17741
(lp17742
I1
a(lp17743
I5
atp17744
a(I-1
S'The hsp90 - p60 - hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90 - binding drug geldanamycin .'
p17745
(lp17746
I1
a(lp17747
I20
atp17748
a(I-1
S'The hsp90 - p60 - hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90 - binding drug geldanamycin .'
p17749
(lp17750
I3
a(lp17751
I5
atp17752
a(I-1
S'The hsp90 - p60 - hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90 - binding drug geldanamycin .'
p17753
(lp17754
I3
a(lp17755
I20
atp17756
a(I-1
S'The hsp90 - p60 - hsp70 multichaperone complex is highly dynamic and does not appear to be affected by the hsp90 - binding drug geldanamycin .'
p17757
(lp17758
I5
a(lp17759
I20
atp17760
a(I1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17761
(lp17762
I3
a(lp17763
I5
atp17764
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17765
(lp17766
I3
a(lp17767
I8
atp17768
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17769
(lp17770
I3
a(lp17771
I21
atp17772
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17773
(lp17774
I3
a(lp17775
I24
atp17776
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17777
(lp17778
I3
a(lp17779
I29
atp17780
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17781
(lp17782
I5
a(lp17783
I8
atp17784
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17785
(lp17786
I5
a(lp17787
I21
atp17788
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17789
(lp17790
I5
a(lp17791
I24
atp17792
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17793
(lp17794
I5
a(lp17795
I29
atp17796
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17797
(lp17798
I8
a(lp17799
I21
atp17800
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17801
(lp17802
I8
a(lp17803
I24
atp17804
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17805
(lp17806
I8
a(lp17807
I29
atp17808
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17809
(lp17810
I21
a(lp17811
I24
atp17812
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17813
(lp17814
I21
a(lp17815
I29
atp17816
a(I-1
S'The interactions of hsp70 and hsp90 in intermediate PR complexes are shown to be distinct from their separate interactions in early PR complexes ( hsp70 ) or in mature PR complexes ( hsp90 ) .'
p17817
(lp17818
I24
a(lp17819
I29
atp17820
a(I-1
S'From these results , it appears that p60 is a key mediator in the chaperoned assembly and functional maturation of PR complexes .'
p17821
(lp17822
I7
a(lp17823
I20
atp17824
a(I1
S'We have selected such mutations in the transcription factor E2F1 that affect its ability to heterodimerize with DP1 .'
p17825
(lp17826
I9
a(lp17827
I17
atp17828
a(I1
S'In vitro and in nonproliferating cells , p27 associates with and inhibits cyclin / cycin - dependent kinase ( CDK ) holoenzymes containing either CDK4 , CDK6 , or CDK2 .'
p17829
(lp17830
I7
a(lp17831
I24
atp17832
a(I1
S'In vitro and in nonproliferating cells , p27 associates with and inhibits cyclin / cycin - dependent kinase ( CDK ) holoenzymes containing either CDK4 , CDK6 , or CDK2 .'
p17833
(lp17834
I7
a(lp17835
I26
atp17836
a(I1
S'In vitro and in nonproliferating cells , p27 associates with and inhibits cyclin / cycin - dependent kinase ( CDK ) holoenzymes containing either CDK4 , CDK6 , or CDK2 .'
p17837
(lp17838
I7
a(lp17839
I29
atp17840
a(I-1
S'In vitro and in nonproliferating cells , p27 associates with and inhibits cyclin / cycin - dependent kinase ( CDK ) holoenzymes containing either CDK4 , CDK6 , or CDK2 .'
p17841
(lp17842
I24
a(lp17843
I26
atp17844
a(I-1
S'In vitro and in nonproliferating cells , p27 associates with and inhibits cyclin / cycin - dependent kinase ( CDK ) holoenzymes containing either CDK4 , CDK6 , or CDK2 .'
p17845
(lp17846
I24
a(lp17847
I29
atp17848
a(I-1
S'In vitro and in nonproliferating cells , p27 associates with and inhibits cyclin / cycin - dependent kinase ( CDK ) holoenzymes containing either CDK4 , CDK6 , or CDK2 .'
p17849
(lp17850
I26
a(lp17851
I29
atp17852
a(I-1
S'Although many different types of proliferating cells contain p27 protein , neither the interactions of p27 with cyclin / CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored .'
p17853
(lp17854
I8
a(lp17855
I15
atp17856
a(I1
S'In addition , p27 associates with three different CDKs : CDK2 , CDK4 , and CDK6 .'
p17857
(lp17858
I3
a(lp17859
I10
atp17860
a(I1
S'In addition , p27 associates with three different CDKs : CDK2 , CDK4 , and CDK6 .'
p17861
(lp17862
I3
a(lp17863
I12
atp17864
a(I1
S'In addition , p27 associates with three different CDKs : CDK2 , CDK4 , and CDK6 .'
p17865
(lp17866
I3
a(lp17867
I15
atp17868
a(I-1
S'In addition , p27 associates with three different CDKs : CDK2 , CDK4 , and CDK6 .'
p17869
(lp17870
I10
a(lp17871
I12
atp17872
a(I-1
S'In addition , p27 associates with three different CDKs : CDK2 , CDK4 , and CDK6 .'
p17873
(lp17874
I10
a(lp17875
I15
atp17876
a(I-1
S'In addition , p27 associates with three different CDKs : CDK2 , CDK4 , and CDK6 .'
p17877
(lp17878
I12
a(lp17879
I15
atp17880
a(I-1
S'Furthermore , the amount of p27 is significantly lower than the amount of cyclin D3 in these cells .'
p17881
(lp17882
I5
a(lp17883
I13
aI14
atp17884
a(I-1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17885
(lp17886
I3
a(lp17887
I5
atp17888
a(I1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17889
(lp17890
I3
a(lp17891
I8
atp17892
a(I-1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17893
(lp17894
I3
a(lp17895
I26
atp17896
a(I-1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17897
(lp17898
I3
a(lp17899
I29
atp17900
a(I1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17901
(lp17902
I5
a(lp17903
I8
atp17904
a(I-1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17905
(lp17906
I5
a(lp17907
I26
atp17908
a(I-1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17909
(lp17910
I5
a(lp17911
I29
atp17912
a(I-1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17913
(lp17914
I8
a(lp17915
I26
atp17916
a(I-1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17917
(lp17918
I8
a(lp17919
I29
atp17920
a(I1
S'The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle - dependent fashion ; in contrast , the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid - G1 phase , reaching a steady - state level in late G1 - phase cells .'
p17921
(lp17922
I26
a(lp17923
I29
atp17924
a(I-1
S'The substrate specificity , the expression pattern of this kinase , and the ability to deplete 50 % of this kinase activity with a CDK6 - specific antibody suggest that the CDK6 protein mediates , in part , the p27 - associated Rb - kinase activity .'
p17925
(lp17926
I24
a(lp17927
I31
atp17928
a(I-1
S'The substrate specificity , the expression pattern of this kinase , and the ability to deplete 50 % of this kinase activity with a CDK6 - specific antibody suggest that the CDK6 protein mediates , in part , the p27 - associated Rb - kinase activity .'
p17929
(lp17930
I24
a(lp17931
I39
atp17932
a(I-1
S'The substrate specificity , the expression pattern of this kinase , and the ability to deplete 50 % of this kinase activity with a CDK6 - specific antibody suggest that the CDK6 protein mediates , in part , the p27 - associated Rb - kinase activity .'
p17933
(lp17934
I24
a(lp17935
I42
atp17936
a(I-1
S'The substrate specificity , the expression pattern of this kinase , and the ability to deplete 50 % of this kinase activity with a CDK6 - specific antibody suggest that the CDK6 protein mediates , in part , the p27 - associated Rb - kinase activity .'
p17937
(lp17938
I31
a(lp17939
I39
atp17940
a(I-1
S'The substrate specificity , the expression pattern of this kinase , and the ability to deplete 50 % of this kinase activity with a CDK6 - specific antibody suggest that the CDK6 protein mediates , in part , the p27 - associated Rb - kinase activity .'
p17941
(lp17942
I31
a(lp17943
I42
atp17944
a(I-1
S'The substrate specificity , the expression pattern of this kinase , and the ability to deplete 50 % of this kinase activity with a CDK6 - specific antibody suggest that the CDK6 protein mediates , in part , the p27 - associated Rb - kinase activity .'
p17945
(lp17946
I39
a(lp17947
I42
atp17948
a(I1
S'In contrast , p27 complexes containing CDK2 are incapable of phosphorylating histone H1 .'
p17949
(lp17950
I3
a(lp17951
I6
atp17952
a(I-1
S'In contrast , p27 complexes containing CDK2 are incapable of phosphorylating histone H1 .'
p17953
(lp17954
I3
a(lp17955
I11
aI12
atp17956
a(I-1
S'In contrast , p27 complexes containing CDK2 are incapable of phosphorylating histone H1 .'
p17957
(lp17958
I6
a(lp17959
I11
aI12
atp17960
a(I-1
S'These data are consistent with a model wherein cyclin D / CDK complexes sequester the CDK2 - dependent kinase inhibitory activity of p27 .'
p17961
(lp17962
I8
aI9
a(lp17963
I15
atp17964
a(I-1
S'These data are consistent with a model wherein cyclin D / CDK complexes sequester the CDK2 - dependent kinase inhibitory activity of p27 .'
p17965
(lp17966
I8
aI9
a(lp17967
I22
atp17968
a(I-1
S'These data are consistent with a model wherein cyclin D / CDK complexes sequester the CDK2 - dependent kinase inhibitory activity of p27 .'
p17969
(lp17970
I15
a(lp17971
I22
atp17972
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p17973
(lp17974
I0
a(lp17975
I5
atp17976
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p17977
(lp17978
I0
a(lp17979
I5
aI6
atp17980
a(I1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p17981
(lp17982
I0
a(lp17983
I5
aI6
aI7
aI8
atp17984
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p17985
(lp17986
I0
a(lp17987
I13
atp17988
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p17989
(lp17990
I0
a(lp17991
I16
aI17
aI18
aI19
atp17992
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p17993
(lp17994
I5
a(lp17995
I5
aI6
atp17996
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p17997
(lp17998
I5
a(lp17999
I5
aI6
aI7
aI8
atp18000
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p18001
(lp18002
I5
a(lp18003
I13
atp18004
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p18005
(lp18006
I5
a(lp18007
I16
aI17
aI18
aI19
atp18008
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p18009
(lp18010
I5
aI6
a(lp18011
I5
aI6
aI7
aI8
atp18012
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p18013
(lp18014
I5
aI6
a(lp18015
I13
atp18016
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p18017
(lp18018
I5
aI6
a(lp18019
I16
aI17
aI18
aI19
atp18020
a(I1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p18021
(lp18022
I5
aI6
aI7
aI8
a(lp18023
I13
atp18024
a(I1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p18025
(lp18026
I5
aI6
aI7
aI8
a(lp18027
I16
aI17
aI18
aI19
atp18028
a(I-1
S'Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3 - kinase .'
p18029
(lp18030
I13
a(lp18031
I16
aI17
aI18
aI19
atp18032
a(I-1
S'The growth - promoting effects of gastrin on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the gastrin / CCKB receptor , which belongs to the family of G protein - coupled receptors .'
p18033
(lp18034
I6
a(lp18035
I21
atp18036
a(I-1
S'The growth - promoting effects of gastrin on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the gastrin / CCKB receptor , which belongs to the family of G protein - coupled receptors .'
p18037
(lp18038
I6
a(lp18039
I23
aI24
atp18040
a(I-1
S'The growth - promoting effects of gastrin on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the gastrin / CCKB receptor , which belongs to the family of G protein - coupled receptors .'
p18041
(lp18042
I21
a(lp18043
I23
aI24
atp18044
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18045
(lp18046
I8
a(lp18047
I13
atp18048
a(I1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18049
(lp18050
I8
a(lp18051
I13
aI14
aI15
aI16
atp18052
a(I1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18053
(lp18054
I8
a(lp18055
I18
aI19
aI20
atp18056
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18057
(lp18058
I8
a(lp18059
I29
atp18060
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18061
(lp18062
I8
a(lp18063
I29
aI30
atp18064
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18065
(lp18066
I13
a(lp18067
I13
aI14
aI15
aI16
atp18068
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18069
(lp18070
I13
a(lp18071
I18
aI19
aI20
atp18072
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18073
(lp18074
I13
a(lp18075
I29
atp18076
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18077
(lp18078
I13
a(lp18079
I29
aI30
atp18080
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18081
(lp18082
I13
aI14
aI15
aI16
a(lp18083
I18
aI19
aI20
atp18084
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18085
(lp18086
I13
aI14
aI15
aI16
a(lp18087
I29
atp18088
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18089
(lp18090
I13
aI14
aI15
aI16
a(lp18091
I29
aI30
atp18092
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18093
(lp18094
I18
aI19
aI20
a(lp18095
I29
atp18096
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18097
(lp18098
I18
aI19
aI20
a(lp18099
I29
aI30
atp18100
a(I-1
S'In the present study , we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 ( IRS - 1 ) , the major cytoplasmic substrate of the insulin receptor .'
p18101
(lp18102
I29
a(lp18103
I29
aI30
atp18104
a(I1
S'The gastrin - induced phosphorylation of IRS - 1 was rapid and transient , occurring within 30 s of treatment and diminishing thereafter .'
p18105
(lp18106
I1
a(lp18107
I6
aI7
aI8
atp18108
a(I-1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18109
(lp18110
I1
a(lp18111
I15
aI16
aI17
atp18112
a(I-1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18113
(lp18114
I1
a(lp18115
I20
atp18116
a(I-1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18117
(lp18118
I1
a(lp18119
I24
aI25
aI26
aI27
atp18120
a(I-1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18121
(lp18122
I1
a(lp18123
I29
aI30
aI31
aI32
atp18124
a(I-1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18125
(lp18126
I15
aI16
aI17
a(lp18127
I20
atp18128
a(I1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18129
(lp18130
I15
aI16
aI17
a(lp18131
I24
aI25
aI26
aI27
atp18132
a(I1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18133
(lp18134
I15
aI16
aI17
a(lp18135
I29
aI30
aI31
aI32
atp18136
a(I-1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18137
(lp18138
I20
a(lp18139
I24
aI25
aI26
aI27
atp18140
a(I-1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18141
(lp18142
I20
a(lp18143
I29
aI30
aI31
aI32
atp18144
a(I-1
S'Following gastrin stimulation , we observed a time - and dose - dependent association of IRS - 1 with the p85 regulatory subunit of phosphatidylinositol 3 - kinase ( PI 3 - kinase ) .'
p18145
(lp18146
I24
aI25
aI26
aI27
a(lp18147
I29
aI30
aI31
aI32
atp18148
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18149
(lp18150
I5
aI6
aI7
aI8
a(lp18151
I14
aI15
aI16
atp18152
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18153
(lp18154
I5
aI6
aI7
aI8
a(lp18155
I19
atp18156
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18157
(lp18158
I5
aI6
aI7
aI8
a(lp18159
I29
aI30
aI31
atp18160
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18161
(lp18162
I5
aI6
aI7
aI8
a(lp18163
I40
atp18164
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18165
(lp18166
I5
aI6
aI7
aI8
a(lp18167
I48
atp18168
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18169
(lp18170
I5
aI6
aI7
aI8
a(lp18171
I51
aI52
aI53
aI54
atp18172
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18173
(lp18174
I14
aI15
aI16
a(lp18175
I19
atp18176
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18177
(lp18178
I14
aI15
aI16
a(lp18179
I29
aI30
aI31
atp18180
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18181
(lp18182
I14
aI15
aI16
a(lp18183
I40
atp18184
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18185
(lp18186
I14
aI15
aI16
a(lp18187
I48
atp18188
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18189
(lp18190
I14
aI15
aI16
a(lp18191
I51
aI52
aI53
aI54
atp18192
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18193
(lp18194
I19
a(lp18195
I29
aI30
aI31
atp18196
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18197
(lp18198
I19
a(lp18199
I40
atp18200
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18201
(lp18202
I19
a(lp18203
I48
atp18204
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18205
(lp18206
I19
a(lp18207
I51
aI52
aI53
aI54
atp18208
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18209
(lp18210
I29
aI30
aI31
a(lp18211
I40
atp18212
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18213
(lp18214
I29
aI30
aI31
a(lp18215
I48
atp18216
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18217
(lp18218
I29
aI30
aI31
a(lp18219
I51
aI52
aI53
aI54
atp18220
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18221
(lp18222
I40
a(lp18223
I48
atp18224
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18225
(lp18226
I40
a(lp18227
I51
aI52
aI53
aI54
atp18228
a(I-1
S'In addition , activation of PI 3 - kinase was detected in anti - IRS - 1 immunoprecipitates from gastrin - treated cells , suggesting that tyrosine phosphorylation of IRS - 1 , which leads to the rapid recruitment of p85 , might be one mechanism used by gastrin to activate PI 3 - kinase .'
p18229
(lp18230
I48
a(lp18231
I51
aI52
aI53
aI54
atp18232
a(I1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18233
(lp18234
I8
a(lp18235
I14
atp18236
a(I1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18237
(lp18238
I8
a(lp18239
I16
atp18240
a(I-1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18241
(lp18242
I8
a(lp18243
I25
aI26
aI27
aI28
aI29
atp18244
a(I-1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18245
(lp18246
I8
a(lp18247
I32
atp18248
a(I1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18249
(lp18250
I14
a(lp18251
I16
atp18252
a(I-1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18253
(lp18254
I14
a(lp18255
I25
aI26
aI27
aI28
aI29
atp18256
a(I-1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18257
(lp18258
I14
a(lp18259
I32
atp18260
a(I-1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18261
(lp18262
I16
a(lp18263
I25
aI26
aI27
aI28
aI29
atp18264
a(I-1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18265
(lp18266
I16
a(lp18267
I32
atp18268
a(I-1
S'We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2 - Sos complex may contribute to the activation of the mitogen - activated protein kinase pathway by gastrin .'
p18269
(lp18270
I25
aI26
aI27
aI28
aI29
a(lp18271
I32
atp18272
a(I1
S'We report here that Grb2 also interacts with tyrosine - phosphorylated IRS - 1 in response to gastrin .'
p18273
(lp18274
I4
a(lp18275
I11
aI12
aI13
atp18276
a(I-1
S'We report here that Grb2 also interacts with tyrosine - phosphorylated IRS - 1 in response to gastrin .'
p18277
(lp18278
I4
a(lp18279
I17
atp18280
a(I-1
S'We report here that Grb2 also interacts with tyrosine - phosphorylated IRS - 1 in response to gastrin .'
p18281
(lp18282
I11
aI12
aI13
a(lp18283
I17
atp18284
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18285
(lp18286
I7
aI8
aI9
a(lp18287
I32
atp18288
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18289
(lp18290
I7
aI8
aI9
a(lp18291
I34
atp18292
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18293
(lp18294
I7
aI8
aI9
a(lp18295
I34
aI35
aI36
aI37
aI38
aI39
atp18296
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18297
(lp18298
I7
aI8
aI9
a(lp18299
I42
atp18300
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18301
(lp18302
I7
aI8
aI9
a(lp18303
I42
aI43
atp18304
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18305
(lp18306
I32
a(lp18307
I34
atp18308
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18309
(lp18310
I32
a(lp18311
I34
aI35
aI36
aI37
aI38
aI39
atp18312
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18313
(lp18314
I32
a(lp18315
I42
atp18316
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18317
(lp18318
I32
a(lp18319
I42
aI43
atp18320
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18321
(lp18322
I34
a(lp18323
I34
aI35
aI36
aI37
aI38
aI39
atp18324
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18325
(lp18326
I34
a(lp18327
I42
atp18328
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18329
(lp18330
I34
a(lp18331
I42
aI43
atp18332
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18333
(lp18334
I34
aI35
aI36
aI37
aI38
aI39
a(lp18335
I42
atp18336
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18337
(lp18338
I34
aI35
aI36
aI37
aI38
aI39
a(lp18339
I42
aI43
atp18340
a(I-1
S'Taken together , our results suggest that IRS - 1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families , such as the gastrin / CCKB G protein - coupled receptor and the insulin receptor .'
p18341
(lp18342
I42
a(lp18343
I42
aI43
atp18344
a(I-1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18345
(lp18346
I0
aI1
aI2
a(lp18347
I4
atp18348
a(I-1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18349
(lp18350
I0
aI1
aI2
a(lp18351
I6
aI7
aI8
atp18352
a(I-1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18353
(lp18354
I0
aI1
aI2
a(lp18355
I10
atp18356
a(I1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18357
(lp18358
I0
aI1
aI2
a(lp18359
I14
aI15
aI16
atp18360
a(I1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18361
(lp18362
I0
aI1
aI2
a(lp18363
I18
atp18364
a(I-1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18365
(lp18366
I4
a(lp18367
I6
aI7
aI8
atp18368
a(I-1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18369
(lp18370
I4
a(lp18371
I10
atp18372
a(I1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18373
(lp18374
I4
a(lp18375
I14
aI15
aI16
atp18376
a(I1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18377
(lp18378
I4
a(lp18379
I18
atp18380
a(I-1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18381
(lp18382
I6
aI7
aI8
a(lp18383
I10
atp18384
a(I1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18385
(lp18386
I6
aI7
aI8
a(lp18387
I14
aI15
aI16
atp18388
a(I1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18389
(lp18390
I6
aI7
aI8
a(lp18391
I18
atp18392
a(I1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18393
(lp18394
I10
a(lp18395
I14
aI15
aI16
atp18396
a(I1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18397
(lp18398
I10
a(lp18399
I18
atp18400
a(I-1
S'GAP - 43 ( neuromodulin , B - 50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .'
p18401
(lp18402
I14
aI15
aI16
a(lp18403
I18
atp18404
a(I-1
S'In the yeast - based cloning system , the only strong interaction that was detected between GAP - 43 and the calcium effector protein , calmodulin ( CaM ) .'
p18405
(lp18406
I16
aI17
aI18
a(lp18407
I21
aI22
aI23
atp18408
a(I1
S'In the yeast - based cloning system , the only strong interaction that was detected between GAP - 43 and the calcium effector protein , calmodulin ( CaM ) .'
p18409
(lp18410
I16
aI17
aI18
a(lp18411
I25
atp18412
a(I1
S'In the yeast - based cloning system , the only strong interaction that was detected between GAP - 43 and the calcium effector protein , calmodulin ( CaM ) .'
p18413
(lp18414
I16
aI17
aI18
a(lp18415
I27
atp18416
a(I-1
S'In the yeast - based cloning system , the only strong interaction that was detected between GAP - 43 and the calcium effector protein , calmodulin ( CaM ) .'
p18417
(lp18418
I21
aI22
aI23
a(lp18419
I25
atp18420
a(I-1
S'In the yeast - based cloning system , the only strong interaction that was detected between GAP - 43 and the calcium effector protein , calmodulin ( CaM ) .'
p18421
(lp18422
I21
aI22
aI23
a(lp18423
I27
atp18424
a(I-1
S'In the yeast - based cloning system , the only strong interaction that was detected between GAP - 43 and the calcium effector protein , calmodulin ( CaM ) .'
p18425
(lp18426
I25
a(lp18427
I27
atp18428
a(I1
S'PKC phosphorylates GAP - 43 on serine 41 .'
p18429
(lp18430
I0
a(lp18431
I2
aI3
aI4
atp18432
a(I1
S"Surprisingly , the N - terminal third of GAP - 43 alone bound CaM more strongly than did intact GAP - 43 , suggesting that the protein ' s C - terminus may play a role in modulating the interaction with CaM ."
p18433
(lp18434
I8
aI9
aI10
a(lp18435
I13
atp18436
a(I-1
S"Surprisingly , the N - terminal third of GAP - 43 alone bound CaM more strongly than did intact GAP - 43 , suggesting that the protein ' s C - terminus may play a role in modulating the interaction with CaM ."
p18437
(lp18438
I8
aI9
aI10
a(lp18439
I19
aI20
aI21
atp18440
a(I-1
S"Surprisingly , the N - terminal third of GAP - 43 alone bound CaM more strongly than did intact GAP - 43 , suggesting that the protein ' s C - terminus may play a role in modulating the interaction with CaM ."
p18441
(lp18442
I8
aI9
aI10
a(lp18443
I41
atp18444
a(I1
S"Surprisingly , the N - terminal third of GAP - 43 alone bound CaM more strongly than did intact GAP - 43 , suggesting that the protein ' s C - terminus may play a role in modulating the interaction with CaM ."
p18445
(lp18446
I13
a(lp18447
I19
aI20
aI21
atp18448
a(I-1
S"Surprisingly , the N - terminal third of GAP - 43 alone bound CaM more strongly than did intact GAP - 43 , suggesting that the protein ' s C - terminus may play a role in modulating the interaction with CaM ."
p18449
(lp18450
I13
a(lp18451
I41
atp18452
a(I-1
S"Surprisingly , the N - terminal third of GAP - 43 alone bound CaM more strongly than did intact GAP - 43 , suggesting that the protein ' s C - terminus may play a role in modulating the interaction with CaM ."
p18453
(lp18454
I19
aI20
aI21
a(lp18455
I41
atp18456
a(I1
S'These results , along with other recent findings , suggest a novel role for the interaction between GAP - 43 and CaM .'
p18457
(lp18458
I17
aI18
aI19
a(lp18459
I21
atp18460
a(I1
S'Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2 .'
p18461
(lp18462
I3
a(lp18463
I14
atp18464
a(I1
S'The core domain contains the sequence - specific DNA binding activity and the in vitro 53BP2 protein binding activity of p53 .'
p18465
(lp18466
I15
a(lp18467
I20
atp18468
a(I1
S'The crystal structure of the p53 core domain bound to the 53BP2 protein , which contains an SH3 ( Src homology 3 ) domain and four ankyrin repeats , revealed that ( i ) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3 - polyproline peptide complexes , and ( ii ) an ankyrin repeat , which forms an L - shaped structure consisting of a beta hairpin and two alpha helices , binds the L2 loop of p53 .'
p18469
(lp18470
I5
a(lp18471
I11
atp18472
a(I-1
S'The crystal structure of the p53 core domain bound to the 53BP2 protein , which contains an SH3 ( Src homology 3 ) domain and four ankyrin repeats , revealed that ( i ) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3 - polyproline peptide complexes , and ( ii ) an ankyrin repeat , which forms an L - shaped structure consisting of a beta hairpin and two alpha helices , binds the L2 loop of p53 .'
p18473
(lp18474
I5
a(lp18475
I42
atp18476
a(I-1
S'The crystal structure of the p53 core domain bound to the 53BP2 protein , which contains an SH3 ( Src homology 3 ) domain and four ankyrin repeats , revealed that ( i ) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3 - polyproline peptide complexes , and ( ii ) an ankyrin repeat , which forms an L - shaped structure consisting of a beta hairpin and two alpha helices , binds the L2 loop of p53 .'
p18477
(lp18478
I5
a(lp18479
I88
atp18480
a(I-1
S'The crystal structure of the p53 core domain bound to the 53BP2 protein , which contains an SH3 ( Src homology 3 ) domain and four ankyrin repeats , revealed that ( i ) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3 - polyproline peptide complexes , and ( ii ) an ankyrin repeat , which forms an L - shaped structure consisting of a beta hairpin and two alpha helices , binds the L2 loop of p53 .'
p18481
(lp18482
I11
a(lp18483
I42
atp18484
a(I-1
S'The crystal structure of the p53 core domain bound to the 53BP2 protein , which contains an SH3 ( Src homology 3 ) domain and four ankyrin repeats , revealed that ( i ) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3 - polyproline peptide complexes , and ( ii ) an ankyrin repeat , which forms an L - shaped structure consisting of a beta hairpin and two alpha helices , binds the L2 loop of p53 .'
p18485
(lp18486
I11
a(lp18487
I88
atp18488
a(I-1
S'The crystal structure of the p53 core domain bound to the 53BP2 protein , which contains an SH3 ( Src homology 3 ) domain and four ankyrin repeats , revealed that ( i ) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3 - polyproline peptide complexes , and ( ii ) an ankyrin repeat , which forms an L - shaped structure consisting of a beta hairpin and two alpha helices , binds the L2 loop of p53 .'
p18489
(lp18490
I42
a(lp18491
I88
atp18492
a(I1
S'The structure of the complex shows that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding .'
p18493
(lp18494
I8
a(lp18495
I13
atp18496
a(I1
S'The six most frequently observed p53 mutations disrupt 53BP2 binding in vitro .'
p18497
(lp18498
I5
a(lp18499
I8
atp18500
a(I1
S'The structure provides evidence that the 53BP2 - p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression .'
p18501
(lp18502
I6
a(lp18503
I8
atp18504
a(I-1
S'The structure provides evidence that the 53BP2 - p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression .'
p18505
(lp18506
I6
a(lp18507
I21
atp18508
a(I-1
S'The structure provides evidence that the 53BP2 - p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression .'
p18509
(lp18510
I8
a(lp18511
I21
atp18512
a(I1
S'Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain .'
p18513
(lp18514
I3
a(lp18515
I8
atp18516
a(I1
S'The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription .'
p18517
(lp18518
I1
a(lp18519
I9
atp18520
a(I1
S'The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription .'
p18521
(lp18522
I1
a(lp18523
I21
atp18524
a(I-1
S'The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription .'
p18525
(lp18526
I9
a(lp18527
I21
atp18528
a(I-1
S'In certain cancers , MDM2 amplification is a common event and contributes to the inactivation of p53 .'
p18529
(lp18530
I4
a(lp18531
I16
atp18532
a(I1
S'The crystal structure of the 109 - residue amino - terminal domain of MDM2 bound to a 15 - residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix .'
p18533
(lp18534
I13
a(lp18535
I24
atp18536
a(I-1
S'The crystal structure of the 109 - residue amino - terminal domain of MDM2 bound to a 15 - residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix .'
p18537
(lp18538
I13
a(lp18539
I27
atp18540
a(I-1
S'The crystal structure of the 109 - residue amino - terminal domain of MDM2 bound to a 15 - residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix .'
p18541
(lp18542
I13
a(lp18543
I36
atp18544
a(I-1
S'The crystal structure of the 109 - residue amino - terminal domain of MDM2 bound to a 15 - residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix .'
p18545
(lp18546
I24
a(lp18547
I27
atp18548
a(I-1
S'The crystal structure of the 109 - residue amino - terminal domain of MDM2 bound to a 15 - residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix .'
p18549
(lp18550
I24
a(lp18551
I36
atp18552
a(I1
S'The crystal structure of the 109 - residue amino - terminal domain of MDM2 bound to a 15 - residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix .'
p18553
(lp18554
I27
a(lp18555
I36
atp18556
a(I-1
S'The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and , in particular , on a triad of p53 amino acids - Phe19 , Trp23 , and Leu26 - which insert deep into the MDM2 cleft .'
p18557
(lp18558
I9
a(lp18559
I17
atp18560
a(I-1
S'The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and , in particular , on a triad of p53 amino acids - Phe19 , Trp23 , and Leu26 - which insert deep into the MDM2 cleft .'
p18561
(lp18562
I9
a(lp18563
I29
atp18564
a(I-1
S'The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and , in particular , on a triad of p53 amino acids - Phe19 , Trp23 , and Leu26 - which insert deep into the MDM2 cleft .'
p18565
(lp18566
I9
a(lp18567
I45
atp18568
a(I-1
S'The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and , in particular , on a triad of p53 amino acids - Phe19 , Trp23 , and Leu26 - which insert deep into the MDM2 cleft .'
p18569
(lp18570
I17
a(lp18571
I29
atp18572
a(I-1
S'The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and , in particular , on a triad of p53 amino acids - Phe19 , Trp23 , and Leu26 - which insert deep into the MDM2 cleft .'
p18573
(lp18574
I17
a(lp18575
I45
atp18576
a(I1
S'The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and , in particular , on a triad of p53 amino acids - Phe19 , Trp23 , and Leu26 - which insert deep into the MDM2 cleft .'
p18577
(lp18578
I29
a(lp18579
I45
atp18580
a(I-1
S'These same p53 residues are also involved in transactivation , supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain .'
p18581
(lp18582
I2
a(lp18583
I14
atp18584
a(I-1
S'These same p53 residues are also involved in transactivation , supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain .'
p18585
(lp18586
I2
a(lp18587
I16
atp18588
a(I1
S'These same p53 residues are also involved in transactivation , supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain .'
p18589
(lp18590
I14
a(lp18591
I16
atp18592
a(I1
S'The cytokine - activated tyrosine kinase JAK2 activates Raf - 1 in a p21ras - dependent manner .'
p18593
(lp18594
I6
a(lp18595
I8
aI9
aI10
atp18596
a(I-1
S'The cytokine - activated tyrosine kinase JAK2 activates Raf - 1 in a p21ras - dependent manner .'
p18597
(lp18598
I6
a(lp18599
I13
atp18600
a(I-1
S'The cytokine - activated tyrosine kinase JAK2 activates Raf - 1 in a p21ras - dependent manner .'
p18601
(lp18602
I8
aI9
aI10
a(lp18603
I13
atp18604
a(I1
S'JAK2 , a member of the Janus kinase superfamily was found to interact functionally with Raf - 1 , a central component of the ras / mitogen - activated protein kinase signal transduction pathway .'
p18605
(lp18606
I0
a(lp18607
I15
aI16
aI17
atp18608
a(I-1
S'JAK2 , a member of the Janus kinase superfamily was found to interact functionally with Raf - 1 , a central component of the ras / mitogen - activated protein kinase signal transduction pathway .'
p18609
(lp18610
I0
a(lp18611
I24
atp18612
a(I-1
S'JAK2 , a member of the Janus kinase superfamily was found to interact functionally with Raf - 1 , a central component of the ras / mitogen - activated protein kinase signal transduction pathway .'
p18613
(lp18614
I0
a(lp18615
I26
aI27
aI28
aI29
aI30
atp18616
a(I-1
S'JAK2 , a member of the Janus kinase superfamily was found to interact functionally with Raf - 1 , a central component of the ras / mitogen - activated protein kinase signal transduction pathway .'
p18617
(lp18618
I15
aI16
aI17
a(lp18619
I24
atp18620
a(I-1
S'JAK2 , a member of the Janus kinase superfamily was found to interact functionally with Raf - 1 , a central component of the ras / mitogen - activated protein kinase signal transduction pathway .'
p18621
(lp18622
I15
aI16
aI17
a(lp18623
I26
aI27
aI28
aI29
aI30
atp18624
a(I-1
S'JAK2 , a member of the Janus kinase superfamily was found to interact functionally with Raf - 1 , a central component of the ras / mitogen - activated protein kinase signal transduction pathway .'
p18625
(lp18626
I24
a(lp18627
I26
aI27
aI28
aI29
aI30
atp18628
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18629
(lp18630
I0
aI1
aI2
a(lp18631
I12
atp18632
a(I1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18633
(lp18634
I0
aI1
aI2
a(lp18635
I12
aI13
atp18636
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18637
(lp18638
I0
aI1
aI2
a(lp18639
I19
aI20
aI21
atp18640
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18641
(lp18642
I0
aI1
aI2
a(lp18643
I19
aI20
aI21
aI22
atp18644
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18645
(lp18646
I0
aI1
aI2
a(lp18647
I25
aI26
aI27
atp18648
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18649
(lp18650
I12
a(lp18651
I12
aI13
atp18652
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18653
(lp18654
I12
a(lp18655
I19
aI20
aI21
atp18656
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18657
(lp18658
I12
a(lp18659
I19
aI20
aI21
aI22
atp18660
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18661
(lp18662
I12
a(lp18663
I25
aI26
aI27
atp18664
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18665
(lp18666
I12
aI13
a(lp18667
I19
aI20
aI21
atp18668
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18669
(lp18670
I12
aI13
a(lp18671
I19
aI20
aI21
aI22
atp18672
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18673
(lp18674
I12
aI13
a(lp18675
I25
aI26
aI27
atp18676
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18677
(lp18678
I19
aI20
aI21
a(lp18679
I19
aI20
aI21
aI22
atp18680
a(I-1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18681
(lp18682
I19
aI20
aI21
a(lp18683
I25
aI26
aI27
atp18684
a(I1
S'Interferon - gamma and several other cytokines that are known to activate JAK2 kinase were also found to stimulate Raf - 1 kinase activity toward MEK - 1 in mammalian cells .'
p18685
(lp18686
I19
aI20
aI21
aI22
a(lp18687
I25
aI26
aI27
atp18688
a(I1
S'In the baculovirus coexpression system , Raf - 1 was activated by JAK2 in the presence of p21ras .'
p18689
(lp18690
I6
aI7
aI8
a(lp18691
I12
atp18692
a(I-1
S'In the baculovirus coexpression system , Raf - 1 was activated by JAK2 in the presence of p21ras .'
p18693
(lp18694
I6
aI7
aI8
a(lp18695
I17
atp18696
a(I-1
S'In the baculovirus coexpression system , Raf - 1 was activated by JAK2 in the presence of p21ras .'
p18697
(lp18698
I12
a(lp18699
I17
atp18700
a(I1
S'Under these conditions , a ternary complex of p21ras , JAK2 , and Raf - 1 was observed .'
p18701
(lp18702
I8
a(lp18703
I10
atp18704
a(I-1
S'Under these conditions , a ternary complex of p21ras , JAK2 , and Raf - 1 was observed .'
p18705
(lp18706
I8
a(lp18707
I13
aI14
aI15
atp18708
a(I-1
S'Under these conditions , a ternary complex of p21ras , JAK2 , and Raf - 1 was observed .'
p18709
(lp18710
I10
a(lp18711
I13
aI14
aI15
atp18712
a(I-1
S'In contrast , in the absence of p21ras , coexpression of JAK2 and Raf - 1 resulted in an overall decrease in the Raf - 1 kinase activity .'
p18713
(lp18714
I7
a(lp18715
I11
atp18716
a(I-1
S'In contrast , in the absence of p21ras , coexpression of JAK2 and Raf - 1 resulted in an overall decrease in the Raf - 1 kinase activity .'
p18717
(lp18718
I7
a(lp18719
I13
aI14
aI15
atp18720
a(I-1
S'In contrast , in the absence of p21ras , coexpression of JAK2 and Raf - 1 resulted in an overall decrease in the Raf - 1 kinase activity .'
p18721
(lp18722
I7
a(lp18723
I23
aI24
aI25
atp18724
a(I-1
S'In contrast , in the absence of p21ras , coexpression of JAK2 and Raf - 1 resulted in an overall decrease in the Raf - 1 kinase activity .'
p18725
(lp18726
I11
a(lp18727
I13
aI14
aI15
atp18728
a(I-1
S'In contrast , in the absence of p21ras , coexpression of JAK2 and Raf - 1 resulted in an overall decrease in the Raf - 1 kinase activity .'
p18729
(lp18730
I11
a(lp18731
I23
aI24
aI25
atp18732
a(I-1
S'In contrast , in the absence of p21ras , coexpression of JAK2 and Raf - 1 resulted in an overall decrease in the Raf - 1 kinase activity .'
p18733
(lp18734
I13
aI14
aI15
a(lp18735
I23
aI24
aI25
atp18736
a(I1
S'In addition , JAK2 phosphorylated Raf - 1 at sites different from those phosphorylated by pp60v - src .'
p18737
(lp18738
I3
a(lp18739
I5
aI6
aI7
atp18740
a(I-1
S'In addition , JAK2 phosphorylated Raf - 1 at sites different from those phosphorylated by pp60v - src .'
p18741
(lp18742
I3
a(lp18743
I15
aI16
aI17
atp18744
a(I1
S'In addition , JAK2 phosphorylated Raf - 1 at sites different from those phosphorylated by pp60v - src .'
p18745
(lp18746
I5
aI6
aI7
a(lp18747
I15
aI16
aI17
atp18748
a(I1
S'In mammalian cells treated with either erythropoietin or interferon - gamma , a small fraction of Raf - 1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation .'
p18749
(lp18750
I16
aI17
aI18
a(lp18751
I21
atp18752
a(I-1
S'In mammalian cells treated with either erythropoietin or interferon - gamma , a small fraction of Raf - 1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation .'
p18753
(lp18754
I16
aI17
aI18
a(lp18755
I28
atp18756
a(I-1
S'In mammalian cells treated with either erythropoietin or interferon - gamma , a small fraction of Raf - 1 coimmunoprecipitated with JAK2 in lysates of cells in which JAK2 was activated as judged by its state of tyrosine phosphorylation .'
p18757
(lp18758
I21
a(lp18759
I28
atp18760
a(I1
S'Taken together , these data suggest that JAK2 and p21ras cooperate to activate Raf - 1 .'
p18761
(lp18762
I7
a(lp18763
I9
atp18764
a(I-1
S'Taken together , these data suggest that JAK2 and p21ras cooperate to activate Raf - 1 .'
p18765
(lp18766
I7
a(lp18767
I13
aI14
aI15
atp18768
a(I-1
S'Taken together , these data suggest that JAK2 and p21ras cooperate to activate Raf - 1 .'
p18769
(lp18770
I9
a(lp18771
I13
aI14
aI15
atp18772
a(I1
S'CD4 - induced interaction of primary HIV - 1 gp120 glycoproteins with the chemokine receptor CCR - 5 .'
p18773
(lp18774
I0
a(lp18775
I9
atp18776
a(I-1
S'CD4 - induced interaction of primary HIV - 1 gp120 glycoproteins with the chemokine receptor CCR - 5 .'
p18777
(lp18778
I0
a(lp18779
I15
aI16
aI17
atp18780
a(I-1
S'CD4 - induced interaction of primary HIV - 1 gp120 glycoproteins with the chemokine receptor CCR - 5 .'
p18781
(lp18782
I9
a(lp18783
I15
aI16
aI17
atp18784
a(I-1
S'For efficient entry into target cells , primary macrophage - tropic and laboratory - adapted human immunodeficiency viruses type 1 ( HIV - 1 ) require particular chemokine receptors , CCR - 5 and CXCR - 4 , respectively , as well as the primary receptor CD4 ( refs 1 - 6 ) .'
p18785
(lp18786
I30
aI31
aI32
a(lp18787
I34
aI35
aI36
atp18788
a(I-1
S'For efficient entry into target cells , primary macrophage - tropic and laboratory - adapted human immunodeficiency viruses type 1 ( HIV - 1 ) require particular chemokine receptors , CCR - 5 and CXCR - 4 , respectively , as well as the primary receptor CD4 ( refs 1 - 6 ) .'
p18789
(lp18790
I30
aI31
aI32
a(lp18791
I46
atp18792
a(I-1
S'For efficient entry into target cells , primary macrophage - tropic and laboratory - adapted human immunodeficiency viruses type 1 ( HIV - 1 ) require particular chemokine receptors , CCR - 5 and CXCR - 4 , respectively , as well as the primary receptor CD4 ( refs 1 - 6 ) .'
p18793
(lp18794
I34
aI35
aI36
a(lp18795
I46
atp18796
a(I1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18797
(lp18798
I7
a(lp18799
I24
atp18800
a(I1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18801
(lp18802
I7
a(lp18803
I28
aI29
aI30
atp18804
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18805
(lp18806
I7
a(lp18807
I38
aI39
aI40
atp18808
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18809
(lp18810
I7
a(lp18811
I43
aI44
aI45
aI46
aI47
aI48
aI49
aI50
atp18812
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18813
(lp18814
I7
a(lp18815
I52
aI53
aI54
atp18816
a(I1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18817
(lp18818
I24
a(lp18819
I28
aI29
aI30
atp18820
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18821
(lp18822
I24
a(lp18823
I38
aI39
aI40
atp18824
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18825
(lp18826
I24
a(lp18827
I43
aI44
aI45
aI46
aI47
aI48
aI49
aI50
atp18828
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18829
(lp18830
I24
a(lp18831
I52
aI53
aI54
atp18832
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18833
(lp18834
I28
aI29
aI30
a(lp18835
I38
aI39
aI40
atp18836
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18837
(lp18838
I28
aI29
aI30
a(lp18839
I43
aI44
aI45
aI46
aI47
aI48
aI49
aI50
atp18840
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18841
(lp18842
I28
aI29
aI30
a(lp18843
I52
aI53
aI54
atp18844
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18845
(lp18846
I38
aI39
aI40
a(lp18847
I43
aI44
aI45
aI46
aI47
aI48
aI49
aI50
atp18848
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18849
(lp18850
I38
aI39
aI40
a(lp18851
I52
aI53
aI54
atp18852
a(I-1
S'Here we show that a complex of gp120 , the exterior envelope glycoprotein , of macrophage - tropic primary HIV - 1 and soluble CD4 interacts specifically with CCR - 5 and inhibits the binding of the natural CCR - 5 ligands , macrophage inflammatory protein ( MIP ) - 1alpha and MIP - 1beta ( refs 7 , 8 ) .'
p18853
(lp18854
I43
aI44
aI45
aI46
aI47
aI48
aI49
aI50
a(lp18855
I52
aI53
aI54
atp18856
a(I1
S'The apparent affinity of the interaction between gp120 and CCR - 5 was dramatically lower in the absence of soluble CD4 .'
p18857
(lp18858
I7
a(lp18859
I9
aI10
aI11
atp18860
a(I-1
S'The apparent affinity of the interaction between gp120 and CCR - 5 was dramatically lower in the absence of soluble CD4 .'
p18861
(lp18862
I7
a(lp18863
I20
atp18864
a(I-1
S'The apparent affinity of the interaction between gp120 and CCR - 5 was dramatically lower in the absence of soluble CD4 .'
p18865
(lp18866
I9
aI10
aI11
a(lp18867
I20
atp18868
a(I-1
S'Additionally , in the absence of gp120 , an interaction between a two - domain CD4 fragment and CCR - 5 was observed .'
p18869
(lp18870
I6
a(lp18871
I15
atp18872
a(I-1
S'Additionally , in the absence of gp120 , an interaction between a two - domain CD4 fragment and CCR - 5 was observed .'
p18873
(lp18874
I6
a(lp18875
I18
aI19
aI20
atp18876
a(I1
S'Additionally , in the absence of gp120 , an interaction between a two - domain CD4 fragment and CCR - 5 was observed .'
p18877
(lp18878
I15
a(lp18879
I18
aI19
aI20
atp18880
a(I1
S'A gp120 fragment retaining the CD4 - binding site and overlapping epitopes was able to interact with CCR - 5 only if the V3 loop , which can specify HIV - 1 tropism and chemokine receptor choice , was also present on the molecule .'
p18881
(lp18882
I1
a(lp18883
I5
atp18884
a(I1
S'A gp120 fragment retaining the CD4 - binding site and overlapping epitopes was able to interact with CCR - 5 only if the V3 loop , which can specify HIV - 1 tropism and chemokine receptor choice , was also present on the molecule .'
p18885
(lp18886
I1
a(lp18887
I17
aI18
aI19
atp18888
a(I-1
S'A gp120 fragment retaining the CD4 - binding site and overlapping epitopes was able to interact with CCR - 5 only if the V3 loop , which can specify HIV - 1 tropism and chemokine receptor choice , was also present on the molecule .'
p18889
(lp18890
I5
a(lp18891
I17
aI18
aI19
atp18892
a(I-1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18893
(lp18894
I5
a(lp18895
I12
atp18896
a(I-1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18897
(lp18898
I5
a(lp18899
I17
atp18900
a(I-1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18901
(lp18902
I5
a(lp18903
I19
atp18904
a(I-1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18905
(lp18906
I5
a(lp18907
I22
aI23
aI24
atp18908
a(I-1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18909
(lp18910
I12
a(lp18911
I17
atp18912
a(I-1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18913
(lp18914
I12
a(lp18915
I19
atp18916
a(I-1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18917
(lp18918
I12
a(lp18919
I22
aI23
aI24
atp18920
a(I1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18921
(lp18922
I17
a(lp18923
I19
atp18924
a(I1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18925
(lp18926
I17
a(lp18927
I22
aI23
aI24
atp18928
a(I1
S'Neutralizing antibodies directed against either CD4 - induced or V3 epitopes on gp120 blocked the interaction of gp12O - CD4 complexes with CCR - 5 .'
p18929
(lp18930
I19
a(lp18931
I22
aI23
aI24
atp18932
a(I-1
S'These results suggest that HIV - 1 attachment to CD4 creates a high - affinity binding site for CCR - 5 , leading to membrane fusion and virus entry .'
p18933
(lp18934
I9
a(lp18935
I18
aI19
aI20
atp18936
a(I-1
S'Stat3 recruitment by two distinct ligand - induced , tyrosine - phosphorylated docking sites in the interleukin - 10 receptor intracellular domain .'
p18937
(lp18938
I0
a(lp18939
I16
aI17
aI18
atp18940
a(I1
S'Stat3 recruitment by two distinct ligand - induced , tyrosine - phosphorylated docking sites in the interleukin - 10 receptor intracellular domain .'
p18941
(lp18942
I0
a(lp18943
I16
aI17
aI18
aI19
atp18944
a(I-1
S'Stat3 recruitment by two distinct ligand - induced , tyrosine - phosphorylated docking sites in the interleukin - 10 receptor intracellular domain .'
p18945
(lp18946
I16
aI17
aI18
a(lp18947
I16
aI17
aI18
aI19
atp18948
a(I-1
S'To define the mechanism underlying signal transducer and activator of transcription ( STAT ) protein recruitment to the interleukin 10 ( IL - 10 ) receptor , the STAT proteins activated by IL - 10 in different cell populations were first defined using electrophoretic mobility shift assays .'
p18949
(lp18950
I18
aI19
a(lp18951
I21
aI22
aI23
atp18952
a(I-1
S'To define the mechanism underlying signal transducer and activator of transcription ( STAT ) protein recruitment to the interleukin 10 ( IL - 10 ) receptor , the STAT proteins activated by IL - 10 in different cell populations were first defined using electrophoretic mobility shift assays .'
p18953
(lp18954
I18
aI19
a(lp18955
I18
aI19
aI20
aI21
aI22
aI23
aI24
aI25
atp18956
a(I-1
S'To define the mechanism underlying signal transducer and activator of transcription ( STAT ) protein recruitment to the interleukin 10 ( IL - 10 ) receptor , the STAT proteins activated by IL - 10 in different cell populations were first defined using electrophoretic mobility shift assays .'
p18957
(lp18958
I18
aI19
a(lp18959
I32
aI33
aI34
atp18960
a(I-1
S'To define the mechanism underlying signal transducer and activator of transcription ( STAT ) protein recruitment to the interleukin 10 ( IL - 10 ) receptor , the STAT proteins activated by IL - 10 in different cell populations were first defined using electrophoretic mobility shift assays .'
p18961
(lp18962
I21
aI22
aI23
a(lp18963
I18
aI19
aI20
aI21
aI22
aI23
aI24
aI25
atp18964
a(I-1
S'To define the mechanism underlying signal transducer and activator of transcription ( STAT ) protein recruitment to the interleukin 10 ( IL - 10 ) receptor , the STAT proteins activated by IL - 10 in different cell populations were first defined using electrophoretic mobility shift assays .'
p18965
(lp18966
I21
aI22
aI23
a(lp18967
I32
aI33
aI34
atp18968
a(I-1
S'To define the mechanism underlying signal transducer and activator of transcription ( STAT ) protein recruitment to the interleukin 10 ( IL - 10 ) receptor , the STAT proteins activated by IL - 10 in different cell populations were first defined using electrophoretic mobility shift assays .'
p18969
(lp18970
I18
aI19
aI20
aI21
aI22
aI23
aI24
aI25
a(lp18971
I32
aI33
aI34
atp18972
a(I1
S'In all cells tested , IL - 10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors .'
p18973
(lp18974
I5
aI6
aI7
a(lp18975
I9
atp18976
a(I1
S'In all cells tested , IL - 10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors .'
p18977
(lp18978
I5
aI6
aI7
a(lp18979
I11
atp18980
a(I-1
S'In all cells tested , IL - 10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors .'
p18981
(lp18982
I9
a(lp18983
I11
atp18984
a(I1
S'IL - 10 also activated Stat5 in Ba / F3 cells that stably expressed the murine IL - 10 receptor .'
p18985
(lp18986
I0
aI1
aI2
a(lp18987
I5
atp18988
a(I-1
S'IL - 10 also activated Stat5 in Ba / F3 cells that stably expressed the murine IL - 10 receptor .'
p18989
(lp18990
I0
aI1
aI2
a(lp18991
I16
aI17
aI18
atp18992
a(I-1
S'IL - 10 also activated Stat5 in Ba / F3 cells that stably expressed the murine IL - 10 receptor .'
p18993
(lp18994
I0
aI1
aI2
a(lp18995
I16
aI17
aI18
aI19
atp18996
a(I-1
S'IL - 10 also activated Stat5 in Ba / F3 cells that stably expressed the murine IL - 10 receptor .'
p18997
(lp18998
I5
a(lp18999
I16
aI17
aI18
atp19000
a(I-1
S'IL - 10 also activated Stat5 in Ba / F3 cells that stably expressed the murine IL - 10 receptor .'
p19001
(lp19002
I5
a(lp19003
I16
aI17
aI18
aI19
atp19004
a(I-1
S'IL - 10 also activated Stat5 in Ba / F3 cells that stably expressed the murine IL - 10 receptor .'
p19005
(lp19006
I16
aI17
aI18
a(lp19007
I16
aI17
aI18
aI19
atp19008
a(I-1
S'Using a structure - function mutagenesis approach , two tyrosine residues ( Tyr427 and Tyr477 ) in the intracellular domain of the murine IL - 10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5 .'
p19009
(lp19010
I23
aI24
aI25
a(lp19011
I23
aI24
aI25
aI26
atp19012
a(I-1
S'Using a structure - function mutagenesis approach , two tyrosine residues ( Tyr427 and Tyr477 ) in the intracellular domain of the murine IL - 10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5 .'
p19013
(lp19014
I23
aI24
aI25
a(lp19015
I40
atp19016
a(I-1
S'Using a structure - function mutagenesis approach , two tyrosine residues ( Tyr427 and Tyr477 ) in the intracellular domain of the murine IL - 10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5 .'
p19017
(lp19018
I23
aI24
aI25
a(lp19019
I44
atp19020
a(I1
S'Using a structure - function mutagenesis approach , two tyrosine residues ( Tyr427 and Tyr477 ) in the intracellular domain of the murine IL - 10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5 .'
p19021
(lp19022
I23
aI24
aI25
aI26
a(lp19023
I40
atp19024
a(I-1
S'Using a structure - function mutagenesis approach , two tyrosine residues ( Tyr427 and Tyr477 ) in the intracellular domain of the murine IL - 10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5 .'
p19025
(lp19026
I23
aI24
aI25
aI26
a(lp19027
I44
atp19028
a(I-1
S'Using a structure - function mutagenesis approach , two tyrosine residues ( Tyr427 and Tyr477 ) in the intracellular domain of the murine IL - 10 receptor were found to be redundantly required for receptor function and for activation of Stat3 but not for Stat1 or Stat5 .'
p19029
(lp19030
I40
a(lp19031
I44
atp19032
a(I-1
S'Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL - 10 - induced Stat3 phosphorylation in a cell - free system .'
p19033
(lp19034
I15
a(lp19035
I18
atp19036
a(I-1
S'Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL - 10 - induced Stat3 phosphorylation in a cell - free system .'
p19037
(lp19038
I15
a(lp19039
I21
aI22
aI23
atp19040
a(I-1
S'Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL - 10 - induced Stat3 phosphorylation in a cell - free system .'
p19041
(lp19042
I15
a(lp19043
I26
atp19044
a(I-1
S'Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL - 10 - induced Stat3 phosphorylation in a cell - free system .'
p19045
(lp19046
I18
a(lp19047
I21
aI22
aI23
atp19048
a(I-1
S'Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL - 10 - induced Stat3 phosphorylation in a cell - free system .'
p19049
(lp19050
I18
a(lp19051
I26
atp19052
a(I-1
S'Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL - 10 - induced Stat3 phosphorylation in a cell - free system .'
p19053
(lp19054
I21
aI22
aI23
a(lp19055
I26
atp19056
a(I-1
S'In contrast , tyrosine - phosphorylated peptides containing Tyr374 or Tyr396 did not interact with Stat3 or block Stat3 activation .'
p19057
(lp19058
I15
a(lp19059
I18
atp19060
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19061
(lp19062
I4
a(lp19063
I7
atp19064
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19065
(lp19066
I4
a(lp19067
I9
atp19068
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19069
(lp19070
I4
a(lp19071
I18
aI19
aI20
atp19072
a(I1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19073
(lp19074
I4
a(lp19075
I18
aI19
aI20
aI21
atp19076
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19077
(lp19078
I7
a(lp19079
I9
atp19080
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19081
(lp19082
I7
a(lp19083
I18
aI19
aI20
atp19084
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19085
(lp19086
I7
a(lp19087
I18
aI19
aI20
aI21
atp19088
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19089
(lp19090
I9
a(lp19091
I18
aI19
aI20
atp19092
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19093
(lp19094
I9
a(lp19095
I18
aI19
aI20
aI21
atp19096
a(I-1
S'These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand - activated IL - 10 receptor by binding to specific but redundant receptor intracellular domain sequences containing phosphotyrosine .'
p19097
(lp19098
I18
aI19
aI20
a(lp19099
I18
aI19
aI20
aI21
atp19100
a(I-1
S'cDNA cloning and characterization of the human interleukin 13 receptor alpha chain .'
p19101
(lp19102
I7
aI8
a(lp19103
I7
aI8
aI9
atp19104
a(I-1
S'cDNA cloning and characterization of the human interleukin 13 receptor alpha chain .'
p19105
(lp19106
I7
aI8
a(lp19107
I7
aI8
aI9
aI10
aI11
atp19108
a(I-1
S'cDNA cloning and characterization of the human interleukin 13 receptor alpha chain .'
p19109
(lp19110
I7
aI8
aI9
a(lp19111
I7
aI8
aI9
aI10
aI11
atp19112
a(I-1
S'We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain ( IL - 13Ralpha ) .'
p19113
(lp19114
I8
aI9
a(lp19115
I8
aI9
aI10
atp19116
a(I-1
S'We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain ( IL - 13Ralpha ) .'
p19117
(lp19118
I8
aI9
a(lp19119
I8
aI9
aI10
aI11
aI12
atp19120
a(I-1
S'We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain ( IL - 13Ralpha ) .'
p19121
(lp19122
I8
aI9
a(lp19123
I14
aI15
aI16
atp19124
a(I-1
S'We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain ( IL - 13Ralpha ) .'
p19125
(lp19126
I8
aI9
aI10
a(lp19127
I8
aI9
aI10
aI11
aI12
atp19128
a(I-1
S'We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain ( IL - 13Ralpha ) .'
p19129
(lp19130
I8
aI9
aI10
a(lp19131
I14
aI15
aI16
atp19132
a(I-1
S'We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain ( IL - 13Ralpha ) .'
p19133
(lp19134
I8
aI9
aI10
aI11
aI12
a(lp19135
I14
aI15
aI16
atp19136
a(I1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19137
(lp19138
I2
aI3
aI4
a(lp19139
I14
aI15
aI16
atp19140
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19141
(lp19142
I2
aI3
aI4
a(lp19143
I24
aI25
aI26
atp19144
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19145
(lp19146
I2
aI3
aI4
a(lp19147
I28
aI29
aI30
atp19148
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19149
(lp19150
I2
aI3
aI4
a(lp19151
I54
aI55
aI56
atp19152
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19153
(lp19154
I2
aI3
aI4
a(lp19155
I54
aI55
aI56
aI57
atp19156
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19157
(lp19158
I14
aI15
aI16
a(lp19159
I24
aI25
aI26
atp19160
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19161
(lp19162
I14
aI15
aI16
a(lp19163
I28
aI29
aI30
atp19164
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19165
(lp19166
I14
aI15
aI16
a(lp19167
I54
aI55
aI56
atp19168
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19169
(lp19170
I14
aI15
aI16
a(lp19171
I54
aI55
aI56
aI57
atp19172
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19173
(lp19174
I24
aI25
aI26
a(lp19175
I28
aI29
aI30
atp19176
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19177
(lp19178
I24
aI25
aI26
a(lp19179
I54
aI55
aI56
atp19180
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19181
(lp19182
I24
aI25
aI26
a(lp19183
I54
aI55
aI56
aI57
atp19184
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19185
(lp19186
I28
aI29
aI30
a(lp19187
I54
aI55
aI56
atp19188
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19189
(lp19190
I28
aI29
aI30
a(lp19191
I54
aI55
aI56
aI57
atp19192
a(I-1
S'Only weak IL - 13 binding activity was found in cells transfected with only IL - 13Ralpha ; however , the combination of both IL - 13Ralpha and IL - 4Ralpha resulted in substantial binding activity , with a Kd of approximately 400 pM , indicating that both chains are essential components of the IL - 13 receptor .'
p19193
(lp19194
I54
aI55
aI56
a(lp19195
I54
aI55
aI56
aI57
atp19196
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19197
(lp19198
I1
aI2
aI3
a(lp19199
I13
aI14
aI15
aI16
atp19200
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19201
(lp19202
I1
aI2
aI3
a(lp19203
I18
atp19204
a(I1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19205
(lp19206
I1
aI2
aI3
a(lp19207
I21
aI22
aI23
atp19208
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19209
(lp19210
I1
aI2
aI3
a(lp19211
I33
atp19212
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19213
(lp19214
I1
aI2
aI3
a(lp19215
I37
aI38
aI39
atp19216
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19217
(lp19218
I13
aI14
aI15
aI16
a(lp19219
I18
atp19220
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19221
(lp19222
I13
aI14
aI15
aI16
a(lp19223
I21
aI22
aI23
atp19224
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19225
(lp19226
I13
aI14
aI15
aI16
a(lp19227
I33
atp19228
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19229
(lp19230
I13
aI14
aI15
aI16
a(lp19231
I37
aI38
aI39
atp19232
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19233
(lp19234
I18
a(lp19235
I21
aI22
aI23
atp19236
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19237
(lp19238
I18
a(lp19239
I33
atp19240
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19241
(lp19242
I18
a(lp19243
I37
aI38
aI39
atp19244
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19245
(lp19246
I21
aI22
aI23
a(lp19247
I33
atp19248
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19249
(lp19250
I21
aI22
aI23
a(lp19251
I37
aI38
aI39
atp19252
a(I-1
S'Whereas IL - 13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ( gammac ) for IL - 4 signaling , it could not replace the function of gammac in allowing enhanced IL - 2 binding activity .'
p19253
(lp19254
I33
a(lp19255
I37
aI38
aI39
atp19256
a(I-1
S'Nevertheless , the overall size and length of the cytoplasmic domain of IL - 13Ralpha and gammac are similar , and like gammac , IL - 13Ralpha is located on chromosome X .'
p19257
(lp19258
I12
aI13
aI14
a(lp19259
I16
atp19260
a(I-1
S'Nevertheless , the overall size and length of the cytoplasmic domain of IL - 13Ralpha and gammac are similar , and like gammac , IL - 13Ralpha is located on chromosome X .'
p19261
(lp19262
I12
aI13
aI14
a(lp19263
I22
atp19264
a(I-1
S'Nevertheless , the overall size and length of the cytoplasmic domain of IL - 13Ralpha and gammac are similar , and like gammac , IL - 13Ralpha is located on chromosome X .'
p19265
(lp19266
I12
aI13
aI14
a(lp19267
I24
aI25
aI26
atp19268
a(I-1
S'Nevertheless , the overall size and length of the cytoplasmic domain of IL - 13Ralpha and gammac are similar , and like gammac , IL - 13Ralpha is located on chromosome X .'
p19269
(lp19270
I16
a(lp19271
I22
atp19272
a(I-1
S'Nevertheless , the overall size and length of the cytoplasmic domain of IL - 13Ralpha and gammac are similar , and like gammac , IL - 13Ralpha is located on chromosome X .'
p19273
(lp19274
I16
a(lp19275
I24
aI25
aI26
atp19276
a(I-1
S'Nevertheless , the overall size and length of the cytoplasmic domain of IL - 13Ralpha and gammac are similar , and like gammac , IL - 13Ralpha is located on chromosome X .'
p19277
(lp19278
I22
a(lp19279
I24
aI25
aI26
atp19280
a(I1
S'Interaction of transthyretin with amyloid beta - protein : binding and inhibition of amyloid formation .'
p19281
(lp19282
I2
a(lp19283
I4
aI5
aI6
aI7
atp19284
a(I-1
S"Aggregated amyloid beta - protein ( A beta ) is a key component of the amyloid depositions found in the brains of patients with Alzheimer ' s disease ."
p19285
(lp19286
I1
aI2
aI3
aI4
a(lp19287
I6
aI7
atp19288
a(I-1
S'The analysis of complexes of A beta with CSF proteins in a KBr gradient revealed an association of A beta only with free proteins and not with lipoprotein particles .'
p19289
(lp19290
I5
aI6
a(lp19291
I18
aI19
atp19292
a(I-1
S'Transthyretin ( TTR ) , a second major CSF protein , formed SDS - stable complexes with A beta and significantly decreased the rate of A beta fibril formation .'
p19293
(lp19294
I0
a(lp19295
I2
atp19296
a(I1
S'Transthyretin ( TTR ) , a second major CSF protein , formed SDS - stable complexes with A beta and significantly decreased the rate of A beta fibril formation .'
p19297
(lp19298
I0
a(lp19299
I17
aI18
atp19300
a(I-1
S'Transthyretin ( TTR ) , a second major CSF protein , formed SDS - stable complexes with A beta and significantly decreased the rate of A beta fibril formation .'
p19301
(lp19302
I0
a(lp19303
I25
aI26
atp19304
a(I1
S'Transthyretin ( TTR ) , a second major CSF protein , formed SDS - stable complexes with A beta and significantly decreased the rate of A beta fibril formation .'
p19305
(lp19306
I2
a(lp19307
I17
aI18
atp19308
a(I-1
S'Transthyretin ( TTR ) , a second major CSF protein , formed SDS - stable complexes with A beta and significantly decreased the rate of A beta fibril formation .'
p19309
(lp19310
I2
a(lp19311
I25
aI26
atp19312
a(I-1
S'Transthyretin ( TTR ) , a second major CSF protein , formed SDS - stable complexes with A beta and significantly decreased the rate of A beta fibril formation .'
p19313
(lp19314
I17
aI18
a(lp19315
I25
aI26
atp19316
a(I-1
S'In physiological buffers and CSF , TTR exclusively decreased the level of A beta pentamers .'
p19317
(lp19318
I6
a(lp19319
I12
aI13
atp19320
a(I1
S'Endogenous TTR - A beta complexes were detected in human CSF by immunoprecipitation .'
p19321
(lp19322
I1
a(lp19323
I3
aI4
atp19324
a(I1
S'Using site - directed mutagenesis and computer - assisted modelling , we identified amino acid residues on the surface of the TTR monomer that interact with A beta .'
p19325
(lp19326
I21
a(lp19327
I26
aI27
atp19328
a(I-1
S'We propose that A beta binding proteins play a key role in the modulation of A beta aggregation and normally prevent amyloid formation in biological fluids and in the brain .'
p19329
(lp19330
I3
aI4
a(lp19331
I15
aI16
atp19332
a(I-1
S'SREBP transcriptional activity is mediated through an interaction with the CREB - binding protein .'
p19333
(lp19334
I10
a(lp19335
I10
aI11
aI12
aI13
atp19336
a(I-1
S'In an unbiased search for potential coactivators of SREBP , we isolated a protein of 265 kD from HeLa cells that directly bound SREBP - 1 and SREBP - 2 .'
p19337
(lp19338
I23
aI24
aI25
a(lp19339
I27
aI28
aI29
atp19340
a(I-1
S'Peptide sequencing and Western blot analysis established that the 265 - kD protein was CBP ( CREB - binding protein ) , a recently identified transcriptional coactivator .'
p19341
(lp19342
I14
a(lp19343
I16
aI17
aI18
aI19
atp19344
a(I-1
S'The putative activation domain of SREBP was shown to bind specifically to amino - terminal domains of recombinant CBP and p300 ( a CBP - related protein ) .'
p19345
(lp19346
I18
a(lp19347
I20
atp19348
a(I-1
S'The putative activation domain of SREBP was shown to bind specifically to amino - terminal domains of recombinant CBP and p300 ( a CBP - related protein ) .'
p19349
(lp19350
I18
a(lp19351
I23
atp19352
a(I-1
S'The putative activation domain of SREBP was shown to bind specifically to amino - terminal domains of recombinant CBP and p300 ( a CBP - related protein ) .'
p19353
(lp19354
I20
a(lp19355
I23
atp19356
a(I1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19357
(lp19358
I2
a(lp19359
I4
atp19360
a(I1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19361
(lp19362
I2
a(lp19363
I6
atp19364
a(I1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19365
(lp19366
I2
a(lp19367
I8
atp19368
a(I1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19369
(lp19370
I2
a(lp19371
I11
atp19372
a(I-1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19373
(lp19374
I4
a(lp19375
I6
atp19376
a(I-1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19377
(lp19378
I4
a(lp19379
I8
atp19380
a(I-1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19381
(lp19382
I4
a(lp19383
I11
atp19384
a(I-1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19385
(lp19386
I6
a(lp19387
I8
atp19388
a(I-1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19389
(lp19390
I6
a(lp19391
I11
atp19392
a(I-1
S'Associations of UBE2I with RAD52 , UBL1 , p53 , and RAD51 proteins in a yeast two - hybrid system .'
p19393
(lp19394
I8
a(lp19395
I11
atp19396
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19397
(lp19398
I3
a(lp19399
I26
atp19400
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19401
(lp19402
I3
a(lp19403
I29
atp19404
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19405
(lp19406
I3
a(lp19407
I34
atp19408
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19409
(lp19410
I3
a(lp19411
I36
atp19412
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19413
(lp19414
I3
a(lp19415
I38
atp19416
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19417
(lp19418
I3
a(lp19419
I46
atp19420
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19421
(lp19422
I26
a(lp19423
I29
atp19424
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19425
(lp19426
I26
a(lp19427
I34
atp19428
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19429
(lp19430
I26
a(lp19431
I36
atp19432
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19433
(lp19434
I26
a(lp19435
I38
atp19436
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19437
(lp19438
I26
a(lp19439
I46
atp19440
a(I1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19441
(lp19442
I29
a(lp19443
I34
atp19444
a(I1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19445
(lp19446
I29
a(lp19447
I36
atp19448
a(I1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19449
(lp19450
I29
a(lp19451
I38
atp19452
a(I1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19453
(lp19454
I29
a(lp19455
I46
atp19456
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19457
(lp19458
I34
a(lp19459
I36
atp19460
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19461
(lp19462
I34
a(lp19463
I38
atp19464
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19465
(lp19466
I34
a(lp19467
I46
atp19468
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19469
(lp19470
I36
a(lp19471
I38
atp19472
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19473
(lp19474
I36
a(lp19475
I46
atp19476
a(I-1
S'Using the human RAD52 protein as the " bait " in a yeast two - hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin - like protein UBL1 .'
p19477
(lp19478
I38
a(lp19479
I46
atp19480
a(I-1
S'These interactions are UBE2I - specific , since another DNA repair - related ubiquitin - conjugating enzyme , RAD6 ( UBC2 ) , does not interact with these proteins .'
p19481
(lp19482
I3
a(lp19483
I18
atp19484
a(I-1
S'These interactions are UBE2I - specific , since another DNA repair - related ubiquitin - conjugating enzyme , RAD6 ( UBC2 ) , does not interact with these proteins .'
p19485
(lp19486
I3
a(lp19487
I20
atp19488
a(I-1
S'These interactions are UBE2I - specific , since another DNA repair - related ubiquitin - conjugating enzyme , RAD6 ( UBC2 ) , does not interact with these proteins .'
p19489
(lp19490
I18
a(lp19491
I20
atp19492
a(I1
S"The interaction of UBE2I with RAD52 is mediated by RAD52 ' s self - association region ."
p19493
(lp19494
I3
a(lp19495
I5
atp19496
a(I-1
S"The interaction of UBE2I with RAD52 is mediated by RAD52 ' s self - association region ."
p19497
(lp19498
I3
a(lp19499
I9
atp19500
a(I-1
S"The interaction of UBE2I with RAD52 is mediated by RAD52 ' s self - association region ."
p19501
(lp19502
I5
a(lp19503
I9
atp19504
a(I-1
S'These results suggest that the RAD52 - dependent processes , cell cycle control , p53 - mediated pathway ( s ) , and ubiquitination interact through human UBE2I .'
p19505
(lp19506
I5
a(lp19507
I14
atp19508
a(I-1
S'These results suggest that the RAD52 - dependent processes , cell cycle control , p53 - mediated pathway ( s ) , and ubiquitination interact through human UBE2I .'
p19509
(lp19510
I5
a(lp19511
I27
atp19512
a(I-1
S'These results suggest that the RAD52 - dependent processes , cell cycle control , p53 - mediated pathway ( s ) , and ubiquitination interact through human UBE2I .'
p19513
(lp19514
I14
a(lp19515
I27
atp19516
a(I1
S'Discrete protein interactions with the Grb2 / c - Cbl complex in SCF - and TPO - mediated myeloid cell proliferation .'
p19517
(lp19518
I5
a(lp19519
I7
aI8
aI9
atp19520
a(I-1
S'Discrete protein interactions with the Grb2 / c - Cbl complex in SCF - and TPO - mediated myeloid cell proliferation .'
p19521
(lp19522
I5
a(lp19523
I12
atp19524
a(I-1
S'Discrete protein interactions with the Grb2 / c - Cbl complex in SCF - and TPO - mediated myeloid cell proliferation .'
p19525
(lp19526
I5
a(lp19527
I15
atp19528
a(I-1
S'Discrete protein interactions with the Grb2 / c - Cbl complex in SCF - and TPO - mediated myeloid cell proliferation .'
p19529
(lp19530
I7
aI8
aI9
a(lp19531
I12
atp19532
a(I-1
S'Discrete protein interactions with the Grb2 / c - Cbl complex in SCF - and TPO - mediated myeloid cell proliferation .'
p19533
(lp19534
I7
aI8
aI9
a(lp19535
I15
atp19536
a(I-1
S'Discrete protein interactions with the Grb2 / c - Cbl complex in SCF - and TPO - mediated myeloid cell proliferation .'
p19537
(lp19538
I12
a(lp19539
I15
atp19540
a(I-1
S'Hemopoietic cell proliferation is mediated by non - tyrosine and tyrosine kinases that signal via uncommon and common sets of downstream effector molecules including the Grb2 / c - Cbl .'
p19541
(lp19542
I25
a(lp19543
I27
aI28
aI29
atp19544
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19545
(lp19546
I9
aI10
aI11
a(lp19547
I17
atp19548
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19549
(lp19550
I9
aI10
aI11
a(lp19551
I19
aI20
aI21
atp19552
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19553
(lp19554
I9
aI10
aI11
a(lp19555
I33
aI34
aI35
atp19556
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19557
(lp19558
I9
aI10
aI11
a(lp19559
I41
aI42
aI43
atp19560
a(I1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19561
(lp19562
I17
a(lp19563
I19
aI20
aI21
atp19564
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19565
(lp19566
I17
a(lp19567
I33
aI34
aI35
atp19568
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19569
(lp19570
I17
a(lp19571
I41
aI42
aI43
atp19572
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19573
(lp19574
I19
aI20
aI21
a(lp19575
I33
aI34
aI35
atp19576
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19577
(lp19578
I19
aI20
aI21
a(lp19579
I41
aI42
aI43
atp19580
a(I-1
S'In the present study we evaluated tyrosine phosphorylation of c - Cbl and the interaction of the Grb2 / c - Cbl complex with signaling proteins upon activation of non - tyrosine ( c - Mpl ) and tyrosine kinase ( c - Kit ) receptors leading to myeloid cell proliferation .'
p19581
(lp19582
I33
aI34
aI35
a(lp19583
I41
aI42
aI43
atp19584
a(I-1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19585
(lp19586
I16
aI17
aI18
a(lp19587
I20
aI21
aI22
atp19588
a(I-1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19589
(lp19590
I16
aI17
aI18
a(lp19591
I27
atp19592
a(I-1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19593
(lp19594
I16
aI17
aI18
a(lp19595
I29
atp19596
a(I-1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19597
(lp19598
I16
aI17
aI18
a(lp19599
I32
aI33
aI34
atp19600
a(I-1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19601
(lp19602
I20
aI21
aI22
a(lp19603
I27
atp19604
a(I-1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19605
(lp19606
I20
aI21
aI22
a(lp19607
I29
atp19608
a(I-1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19609
(lp19610
I20
aI21
aI22
a(lp19611
I32
aI33
aI34
atp19612
a(I-1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19613
(lp19614
I27
a(lp19615
I29
atp19616
a(I1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19617
(lp19618
I27
a(lp19619
I32
aI33
aI34
atp19620
a(I1
S'By using the growth factor dependent M - 07e cell line , we found that both c - Mpl and c - Kit ligands , namely : SCF and TPO , induce c - Cbl tyrosine phosphorylation .'
p19621
(lp19622
I29
a(lp19623
I32
aI33
aI34
atp19624
a(I1
S'In these cells the adaptor protein Grb2 constitutively binds a substantial fraction of c - Cbl through the N - terminal SH3 domain .'
p19625
(lp19626
I6
a(lp19627
I13
aI14
aI15
atp19628
a(I1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19629
(lp19630
I7
a(lp19631
I9
aI10
aI11
atp19632
a(I-1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19633
(lp19634
I7
a(lp19635
I17
atp19636
a(I-1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19637
(lp19638
I7
a(lp19639
I23
atp19640
a(I-1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19641
(lp19642
I7
a(lp19643
I26
aI27
aI28
atp19644
a(I-1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19645
(lp19646
I9
aI10
aI11
a(lp19647
I17
atp19648
a(I-1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19649
(lp19650
I9
aI10
aI11
a(lp19651
I23
atp19652
a(I-1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19653
(lp19654
I9
aI10
aI11
a(lp19655
I26
aI27
aI28
atp19656
a(I-1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19657
(lp19658
I17
a(lp19659
I23
atp19660
a(I1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19661
(lp19662
I17
a(lp19663
I26
aI27
aI28
atp19664
a(I1
S'In vitro experiments showed that the stable Grb2 / c - Cbl complex interacts , through the Grb2 SH2 domain , with the SCF - activated c - Kit .'
p19665
(lp19666
I23
a(lp19667
I26
aI27
aI28
atp19668
a(I-1
S'By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2 .'
p19669
(lp19670
I4
a(lp19671
I11
atp19672
a(I-1
S'By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2 .'
p19673
(lp19674
I4
a(lp19675
I14
atp19676
a(I1
S'By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2 .'
p19677
(lp19678
I11
a(lp19679
I14
atp19680
a(I-1
S'In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c - Kit with c - Cbl .'
p19681
(lp19682
I10
a(lp19683
I15
aI16
aI17
atp19684
a(I-1
S'In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c - Kit with c - Cbl .'
p19685
(lp19686
I10
a(lp19687
I19
aI20
aI21
atp19688
a(I1
S'In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c - Kit with c - Cbl .'
p19689
(lp19690
I15
aI16
aI17
a(lp19691
I19
aI20
aI21
atp19692
a(I-1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19693
(lp19694
I6
a(lp19695
I10
atp19696
a(I-1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19697
(lp19698
I6
a(lp19699
I12
aI13
aI14
atp19700
a(I-1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19701
(lp19702
I6
a(lp19703
I17
atp19704
a(I-1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19705
(lp19706
I6
a(lp19707
I21
atp19708
a(I1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19709
(lp19710
I10
a(lp19711
I12
aI13
aI14
atp19712
a(I-1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19713
(lp19714
I10
a(lp19715
I17
atp19716
a(I-1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19717
(lp19718
I10
a(lp19719
I21
atp19720
a(I-1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19721
(lp19722
I12
aI13
aI14
a(lp19723
I17
atp19724
a(I-1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19725
(lp19726
I12
aI13
aI14
a(lp19727
I21
atp19728
a(I1
S'Moreover we found that , upon SCF stimulation , the Grb2 / c - Cbl complex recruits Shc , probably via Grb2 .'
p19729
(lp19730
I17
a(lp19731
I21
atp19732
a(I1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19733
(lp19734
I3
a(lp19735
I7
atp19736
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19737
(lp19738
I3
a(lp19739
I15
aI16
aI17
atp19740
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19741
(lp19742
I3
a(lp19743
I21
atp19744
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19745
(lp19746
I3
a(lp19747
I23
atp19748
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19749
(lp19750
I3
a(lp19751
I25
atp19752
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19753
(lp19754
I3
a(lp19755
I27
aI28
aI29
atp19756
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19757
(lp19758
I7
a(lp19759
I15
aI16
aI17
atp19760
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19761
(lp19762
I7
a(lp19763
I21
atp19764
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19765
(lp19766
I7
a(lp19767
I23
atp19768
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19769
(lp19770
I7
a(lp19771
I25
atp19772
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19773
(lp19774
I7
a(lp19775
I27
aI28
aI29
atp19776
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19777
(lp19778
I15
aI16
aI17
a(lp19779
I21
atp19780
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19781
(lp19782
I15
aI16
aI17
a(lp19783
I23
atp19784
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19785
(lp19786
I15
aI16
aI17
a(lp19787
I25
atp19788
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19789
(lp19790
I15
aI16
aI17
a(lp19791
I27
aI28
aI29
atp19792
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19793
(lp19794
I21
a(lp19795
I23
atp19796
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19797
(lp19798
I21
a(lp19799
I25
atp19800
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19801
(lp19802
I21
a(lp19803
I27
aI28
aI29
atp19804
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19805
(lp19806
I23
a(lp19807
I25
atp19808
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19809
(lp19810
I23
a(lp19811
I27
aI28
aI29
atp19812
a(I-1
S'By contrast the Ras exchanger factor ( Sos1 ) was not detected in anti - c - Cbl immunoprecipitates suggesting that Grb2 / Sos1 and Grb2 / c - Cbl are present in different complexes .'
p19813
(lp19814
I25
a(lp19815
I27
aI28
aI29
atp19816
a(I-1
S'Taken together our results demonstrate that c - Cbl plays an important role in coupling both tyrosine and non - tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2 / c - Cbl complex when non - tyrosine or tyrosine kinase receptors are activated .'
p19817
(lp19818
I6
aI7
aI8
a(lp19819
I34
atp19820
a(I-1
S'Taken together our results demonstrate that c - Cbl plays an important role in coupling both tyrosine and non - tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2 / c - Cbl complex when non - tyrosine or tyrosine kinase receptors are activated .'
p19821
(lp19822
I6
aI7
aI8
a(lp19823
I36
aI37
aI38
atp19824
a(I1
S'Taken together our results demonstrate that c - Cbl plays an important role in coupling both tyrosine and non - tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2 / c - Cbl complex when non - tyrosine or tyrosine kinase receptors are activated .'
p19825
(lp19826
I34
a(lp19827
I36
aI37
aI38
atp19828
a(I-1
S'We now find that HIV - 1 begins reverse transcription much more efficiently in DCs than T cells , even though T cells have higher levels of CD4 and gp120 binding .'
p19829
(lp19830
I27
a(lp19831
I29
atp19832
a(I1
S'RANTES interacts with CCR5 and SDF - 1 with CXCR4 receptors .'
p19833
(lp19834
I0
a(lp19835
I3
atp19836
a(I-1
S'RANTES interacts with CCR5 and SDF - 1 with CXCR4 receptors .'
p19837
(lp19838
I0
a(lp19839
I5
aI6
aI7
atp19840
a(I-1
S'RANTES interacts with CCR5 and SDF - 1 with CXCR4 receptors .'
p19841
(lp19842
I0
a(lp19843
I9
atp19844
a(I-1
S'RANTES interacts with CCR5 and SDF - 1 with CXCR4 receptors .'
p19845
(lp19846
I3
a(lp19847
I5
aI6
aI7
atp19848
a(I-1
S'RANTES interacts with CCR5 and SDF - 1 with CXCR4 receptors .'
p19849
(lp19850
I3
a(lp19851
I9
atp19852
a(I1
S'RANTES interacts with CCR5 and SDF - 1 with CXCR4 receptors .'
p19853
(lp19854
I5
aI6
aI7
a(lp19855
I9
atp19856
a(I-1
S'DCs express more CCR5 and CXCR4 mRNA than T cells .'
p19857
(lp19858
I3
a(lp19859
I5
atp19860
a(I-1
S'Activation of interferon - gamma inducing factor mediated by interleukin - 1beta converting enzyme .'
p19861
(lp19862
I2
aI3
aI4
a(lp19863
I2
aI3
aI4
aI5
aI6
atp19864
a(I-1
S'Activation of interferon - gamma inducing factor mediated by interleukin - 1beta converting enzyme .'
p19865
(lp19866
I2
aI3
aI4
a(lp19867
I9
aI10
aI11
atp19868
a(I-1
S'Activation of interferon - gamma inducing factor mediated by interleukin - 1beta converting enzyme .'
p19869
(lp19870
I2
aI3
aI4
a(lp19871
I9
aI10
aI11
aI12
aI13
atp19872
a(I-1
S'Activation of interferon - gamma inducing factor mediated by interleukin - 1beta converting enzyme .'
p19873
(lp19874
I2
aI3
aI4
aI5
aI6
a(lp19875
I9
aI10
aI11
atp19876
a(I1
S'Activation of interferon - gamma inducing factor mediated by interleukin - 1beta converting enzyme .'
p19877
(lp19878
I2
aI3
aI4
aI5
aI6
a(lp19879
I9
aI10
aI11
aI12
aI13
atp19880
a(I-1
S'Activation of interferon - gamma inducing factor mediated by interleukin - 1beta converting enzyme .'
p19881
(lp19882
I9
aI10
aI11
a(lp19883
I9
aI10
aI11
aI12
aI13
atp19884
a(I-1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19885
(lp19886
I1
aI2
aI3
a(lp19887
I5
aI6
aI7
atp19888
a(I-1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19889
(lp19890
I1
aI2
aI3
a(lp19891
I1
aI2
aI3
aI4
aI5
aI6
aI7
aI8
aI9
aI10
atp19892
a(I1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19893
(lp19894
I1
aI2
aI3
a(lp19895
I12
atp19896
a(I-1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19897
(lp19898
I1
aI2
aI3
a(lp19899
I17
aI18
aI19
atp19900
a(I-1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19901
(lp19902
I5
aI6
aI7
a(lp19903
I1
aI2
aI3
aI4
aI5
aI6
aI7
aI8
aI9
aI10
atp19904
a(I1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19905
(lp19906
I5
aI6
aI7
a(lp19907
I12
atp19908
a(I-1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19909
(lp19910
I5
aI6
aI7
a(lp19911
I17
aI18
aI19
atp19912
a(I-1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19913
(lp19914
I1
aI2
aI3
aI4
aI5
aI6
aI7
aI8
aI9
aI10
a(lp19915
I12
atp19916
a(I-1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19917
(lp19918
I1
aI2
aI3
aI4
aI5
aI6
aI7
aI8
aI9
aI10
a(lp19919
I17
aI18
aI19
atp19920
a(I-1
S'The interleukin - 1beta ( IL - 1beta ) converting enzyme ( ICE ) processes the inactive IL - 1beta precursor to the proinflammatory cytokine .'
p19921
(lp19922
I12
a(lp19923
I17
aI18
aI19
atp19924
a(I-1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19925
(lp19926
I0
a(lp19927
I9
aI10
aI11
atp19928
a(I1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19929
(lp19930
I0
a(lp19931
I9
aI10
aI11
aI12
aI13
atp19932
a(I1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19933
(lp19934
I0
a(lp19935
I15
atp19936
a(I1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19937
(lp19938
I0
a(lp19939
I28
atp19940
a(I-1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19941
(lp19942
I9
aI10
aI11
a(lp19943
I9
aI10
aI11
aI12
aI13
atp19944
a(I-1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19945
(lp19946
I9
aI10
aI11
a(lp19947
I15
atp19948
a(I-1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19949
(lp19950
I9
aI10
aI11
a(lp19951
I28
atp19952
a(I-1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19953
(lp19954
I9
aI10
aI11
aI12
aI13
a(lp19955
I15
atp19956
a(I-1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19957
(lp19958
I9
aI10
aI11
aI12
aI13
a(lp19959
I28
atp19960
a(I-1
S'ICE was also shown to cleave the precursor of interferon - gamma inducing factor ( IGIF ) at the authentic processing site with high efficiency , thereby activating IGIF and facilitating its export .'
p19961
(lp19962
I15
a(lp19963
I28
atp19964
a(I-1
S'Lipopolysaccharide - activated ICE - deficient ( ICE - / - ) Kupffer cells synthesized the IGIF precursor but failed to process it into the active form .'
p19965
(lp19966
I3
a(lp19967
I16
atp19968
a(I-1
S'Interferon - gamma and IGIF were diminished in the sera of ICE - / - mice exposed to Propionibacterium acnes and lipopolysaccharide .'
p19969
(lp19970
I0
aI1
aI2
a(lp19971
I4
atp19972
a(I-1
S'Interferon - gamma and IGIF were diminished in the sera of ICE - / - mice exposed to Propionibacterium acnes and lipopolysaccharide .'
p19973
(lp19974
I0
aI1
aI2
a(lp19975
I11
atp19976
a(I-1
S'Interferon - gamma and IGIF were diminished in the sera of ICE - / - mice exposed to Propionibacterium acnes and lipopolysaccharide .'
p19977
(lp19978
I4
a(lp19979
I11
atp19980
a(I1
S'Physical and functional interactions between the transcriptional inhibitors Id3 and ITF - 2b . Evidence toward a novel mechanism regulating muscle - specific gene expression .'
p19981
(lp19982
I8
a(lp19983
I10
aI11
aI12
atp19984
a(I-1
S'We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF - 2 transcription factor , ITF - 2b , that interacts with the transcriptional inhibitor Id3 / HLH462 .'
p19985
(lp19986
I14
aI15
aI16
a(lp19987
I20
aI21
aI22
atp19988
a(I-1
S'We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF - 2 transcription factor , ITF - 2b , that interacts with the transcriptional inhibitor Id3 / HLH462 .'
p19989
(lp19990
I14
aI15
aI16
a(lp19991
I30
atp19992
a(I-1
S'We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF - 2 transcription factor , ITF - 2b , that interacts with the transcriptional inhibitor Id3 / HLH462 .'
p19993
(lp19994
I14
aI15
aI16
a(lp19995
I32
atp19996
a(I1
S'We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF - 2 transcription factor , ITF - 2b , that interacts with the transcriptional inhibitor Id3 / HLH462 .'
p19997
(lp19998
I20
aI21
aI22
a(lp19999
I30
atp20000
a(I1
S'We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF - 2 transcription factor , ITF - 2b , that interacts with the transcriptional inhibitor Id3 / HLH462 .'
p20001
(lp20002
I20
aI21
aI22
a(lp20003
I32
atp20004
a(I-1
S'We have used an interaction cloning strategy to identify an inhibitory isoform of the ITF - 2 transcription factor , ITF - 2b , that interacts with the transcriptional inhibitor Id3 / HLH462 .'
p20005
(lp20006
I30
a(lp20007
I32
atp20008
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20009
(lp20010
I6
a(lp20011
I8
atp20012
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20013
(lp20014
I6
a(lp20015
I10
aI11
aI12
atp20016
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20017
(lp20018
I6
a(lp20019
I22
aI23
atp20020
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20021
(lp20022
I6
a(lp20023
I30
atp20024
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20025
(lp20026
I8
a(lp20027
I10
aI11
aI12
atp20028
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20029
(lp20030
I8
a(lp20031
I22
aI23
atp20032
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20033
(lp20034
I8
a(lp20035
I30
atp20036
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20037
(lp20038
I10
aI11
aI12
a(lp20039
I22
aI23
atp20040
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20041
(lp20042
I10
aI11
aI12
a(lp20043
I30
atp20044
a(I-1
S'As expected , overexpression of either Id3 / HLH462 or ITF - 2b effectively inhibited the activation of the muscle - specific creatine kinase promoter by the myogenic transcription factor MyoD .'
p20045
(lp20046
I22
aI23
a(lp20047
I30
atp20048
a(I-1
S'Moreover , while ITF - 2b inhibited the creatine kinase promoter , it acted as a weak transactivator on an artificial promoter consisting of three tandem copies of the consensus myogenic factor DNA binding site .'
p20049
(lp20050
I3
aI4
aI5
a(lp20051
I8
aI9
atp20052
a(I1
S'Further investigation indicated that the ITF - 2b / MyoD heterodimer bound to its specific DNA binding site in vitro , and the DNA binding was effectively blocked by Id3 / HLH462 .'
p20053
(lp20054
I5
aI6
aI7
a(lp20055
I9
atp20056
a(I-1
S'Further investigation indicated that the ITF - 2b / MyoD heterodimer bound to its specific DNA binding site in vitro , and the DNA binding was effectively blocked by Id3 / HLH462 .'
p20057
(lp20058
I5
aI6
aI7
a(lp20059
I29
atp20060
a(I-1
S'Further investigation indicated that the ITF - 2b / MyoD heterodimer bound to its specific DNA binding site in vitro , and the DNA binding was effectively blocked by Id3 / HLH462 .'
p20061
(lp20062
I5
aI6
aI7
a(lp20063
I31
atp20064
a(I-1
S'Further investigation indicated that the ITF - 2b / MyoD heterodimer bound to its specific DNA binding site in vitro , and the DNA binding was effectively blocked by Id3 / HLH462 .'
p20065
(lp20066
I9
a(lp20067
I29
atp20068
a(I-1
S'Further investigation indicated that the ITF - 2b / MyoD heterodimer bound to its specific DNA binding site in vitro , and the DNA binding was effectively blocked by Id3 / HLH462 .'
p20069
(lp20070
I9
a(lp20071
I31
atp20072
a(I-1
S'Further investigation indicated that the ITF - 2b / MyoD heterodimer bound to its specific DNA binding site in vitro , and the DNA binding was effectively blocked by Id3 / HLH462 .'
p20073
(lp20074
I29
a(lp20075
I31
atp20076
a(I-1
S'Additional analysis revealed the presence of transcripts for both the activating ( ITF - 2a ) and inhibitory ( ITF - 2b ) isoforms in differentiating C2C12 cultures , suggesting that both isoforms might participate in regulating the differentiation process .'
p20077
(lp20078
I12
aI13
aI14
a(lp20079
I19
aI20
aI21
atp20080
a(I-1
S'Competitive binding of alpha - actinin and calmodulin to the NMDA receptor .'
p20081
(lp20082
I3
aI4
aI5
a(lp20083
I7
atp20084
a(I1
S'Competitive binding of alpha - actinin and calmodulin to the NMDA receptor .'
p20085
(lp20086
I3
aI4
aI5
a(lp20087
I10
aI11
atp20088
a(I1
S'Competitive binding of alpha - actinin and calmodulin to the NMDA receptor .'
p20089
(lp20090
I7
a(lp20091
I10
aI11
atp20092
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20093
(lp20094
I22
a(lp20095
I37
aI38
aI39
aI40
aI41
atp20096
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20097
(lp20098
I22
a(lp20099
I49
atp20100
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20101
(lp20102
I22
a(lp20103
I52
atp20104
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20105
(lp20106
I22
a(lp20107
I82
aI83
aI84
atp20108
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20109
(lp20110
I22
a(lp20111
I86
aI87
aI88
aI89
aI90
atp20112
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20113
(lp20114
I22
a(lp20115
I103
atp20116
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20117
(lp20118
I22
a(lp20119
I105
atp20120
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20121
(lp20122
I22
a(lp20123
I109
aI110
atp20124
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20125
(lp20126
I22
a(lp20127
I120
aI121
aI122
atp20128
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20129
(lp20130
I37
aI38
aI39
aI40
aI41
a(lp20131
I49
atp20132
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20133
(lp20134
I37
aI38
aI39
aI40
aI41
a(lp20135
I52
atp20136
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20137
(lp20138
I37
aI38
aI39
aI40
aI41
a(lp20139
I82
aI83
aI84
atp20140
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20141
(lp20142
I37
aI38
aI39
aI40
aI41
a(lp20143
I86
aI87
aI88
aI89
aI90
atp20144
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20145
(lp20146
I37
aI38
aI39
aI40
aI41
a(lp20147
I103
atp20148
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20149
(lp20150
I37
aI38
aI39
aI40
aI41
a(lp20151
I105
atp20152
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20153
(lp20154
I37
aI38
aI39
aI40
aI41
a(lp20155
I109
aI110
atp20156
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20157
(lp20158
I37
aI38
aI39
aI40
aI41
a(lp20159
I120
aI121
aI122
atp20160
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20161
(lp20162
I49
a(lp20163
I52
atp20164
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20165
(lp20166
I49
a(lp20167
I82
aI83
aI84
atp20168
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20169
(lp20170
I49
a(lp20171
I86
aI87
aI88
aI89
aI90
atp20172
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20173
(lp20174
I49
a(lp20175
I103
atp20176
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20177
(lp20178
I49
a(lp20179
I105
atp20180
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20181
(lp20182
I49
a(lp20183
I109
aI110
atp20184
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20185
(lp20186
I49
a(lp20187
I120
aI121
aI122
atp20188
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20189
(lp20190
I52
a(lp20191
I82
aI83
aI84
atp20192
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20193
(lp20194
I52
a(lp20195
I86
aI87
aI88
aI89
aI90
atp20196
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20197
(lp20198
I52
a(lp20199
I103
atp20200
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20201
(lp20202
I52
a(lp20203
I105
atp20204
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20205
(lp20206
I52
a(lp20207
I109
aI110
atp20208
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20209
(lp20210
I52
a(lp20211
I120
aI121
aI122
atp20212
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20213
(lp20214
I82
aI83
aI84
a(lp20215
I86
aI87
aI88
aI89
aI90
atp20216
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20217
(lp20218
I82
aI83
aI84
a(lp20219
I103
atp20220
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20221
(lp20222
I82
aI83
aI84
a(lp20223
I105
atp20224
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20225
(lp20226
I82
aI83
aI84
a(lp20227
I109
aI110
atp20228
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20229
(lp20230
I82
aI83
aI84
a(lp20231
I120
aI121
aI122
atp20232
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20233
(lp20234
I86
aI87
aI88
aI89
aI90
a(lp20235
I103
atp20236
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20237
(lp20238
I86
aI87
aI88
aI89
aI90
a(lp20239
I105
atp20240
a(I1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20241
(lp20242
I86
aI87
aI88
aI89
aI90
a(lp20243
I109
aI110
atp20244
a(I1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20245
(lp20246
I86
aI87
aI88
aI89
aI90
a(lp20247
I120
aI121
aI122
atp20248
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20249
(lp20250
I103
a(lp20251
I105
atp20252
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20253
(lp20254
I103
a(lp20255
I109
aI110
atp20256
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20257
(lp20258
I103
a(lp20259
I120
aI121
aI122
atp20260
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20261
(lp20262
I105
a(lp20263
I109
aI110
atp20264
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20265
(lp20266
I105
a(lp20267
I120
aI121
aI122
atp20268
a(I-1
S'The activity of NMDA ( N - methyl - D - aspartate ) receptors is mechanosensitive and dependent on the integrity of actin , suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton . alpha - Actinin - 2 , a member of the spectrin / dystrophin family of actin - binding proteins , is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor - clustering molecule PSD - 95 . alpha - Actinin - 2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor , and can be immunoprecipitated with NMDA receptors and PSD - 95 from rat brain .'
p20269
(lp20270
I109
aI110
a(lp20271
I120
aI121
aI122
atp20272
a(I-1
S'Intriguingly , NR1 - alpha - actinin binding is directly antagonized by Ca2 + / calmodulin .'
p20273
(lp20274
I2
a(lp20275
I4
aI5
aI6
atp20276
a(I-1
S'Intriguingly , NR1 - alpha - actinin binding is directly antagonized by Ca2 + / calmodulin .'
p20277
(lp20278
I2
a(lp20279
I15
atp20280
a(I-1
S'Intriguingly , NR1 - alpha - actinin binding is directly antagonized by Ca2 + / calmodulin .'
p20281
(lp20282
I4
aI5
aI6
a(lp20283
I15
atp20284
a(I1
S'HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2 / M cell - cycle checkpoint .'
p20285
(lp20286
I0
a(lp20287
I5
atp20288
a(I1
S'HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2 / M cell - cycle checkpoint .'
p20289
(lp20290
I0
a(lp20291
I7
atp20292
a(I-1
S'HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2 / M cell - cycle checkpoint .'
p20293
(lp20294
I5
a(lp20295
I7
atp20296
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20297
(lp20298
I5
a(lp20299
I9
aI10
aI11
aI12
aI13
atp20300
a(I1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20301
(lp20302
I5
a(lp20303
I9
aI10
aI11
aI12
aI13
aI14
aI15
atp20304
a(I1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20305
(lp20306
I5
a(lp20307
I17
atp20308
a(I1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20309
(lp20310
I5
a(lp20311
I23
aI24
aI25
atp20312
a(I1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20313
(lp20314
I5
a(lp20315
I27
atp20316
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20317
(lp20318
I9
aI10
aI11
aI12
aI13
a(lp20319
I9
aI10
aI11
aI12
aI13
aI14
aI15
atp20320
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20321
(lp20322
I9
aI10
aI11
aI12
aI13
a(lp20323
I17
atp20324
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20325
(lp20326
I9
aI10
aI11
aI12
aI13
a(lp20327
I23
aI24
aI25
atp20328
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20329
(lp20330
I9
aI10
aI11
aI12
aI13
a(lp20331
I27
atp20332
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20333
(lp20334
I9
aI10
aI11
aI12
aI13
aI14
aI15
a(lp20335
I17
atp20336
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20337
(lp20338
I9
aI10
aI11
aI12
aI13
aI14
aI15
a(lp20339
I23
aI24
aI25
atp20340
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20341
(lp20342
I9
aI10
aI11
aI12
aI13
aI14
aI15
a(lp20343
I27
atp20344
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20345
(lp20346
I17
a(lp20347
I23
aI24
aI25
atp20348
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20349
(lp20350
I17
a(lp20351
I27
atp20352
a(I-1
S'We observed that the protein HOX11 interacted with protein serine - threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .'
p20353
(lp20354
I23
aI24
aI25
a(lp20355
I27
atp20356
a(I1
S'Thus HOX11 is a cellular oncogene that targets PP2A and PP1 , both of which are targets for oncogenic viruses and chemical tumour promoters .'
p20357
(lp20358
I1
a(lp20359
I8
atp20360
a(I1
S'Thus HOX11 is a cellular oncogene that targets PP2A and PP1 , both of which are targets for oncogenic viruses and chemical tumour promoters .'
p20361
(lp20362
I1
a(lp20363
I10
atp20364
a(I-1
S'Thus HOX11 is a cellular oncogene that targets PP2A and PP1 , both of which are targets for oncogenic viruses and chemical tumour promoters .'
p20365
(lp20366
I8
a(lp20367
I10
atp20368
a(I-1
S'Analysis of the human interleukin - 6 / human interleukin - 6 receptor binding interface at the amino acid level : proposed mechanism of interaction .'
p20369
(lp20370
I4
aI5
aI6
a(lp20371
I9
aI10
aI11
atp20372
a(I1
S'Analysis of the human interleukin - 6 / human interleukin - 6 receptor binding interface at the amino acid level : proposed mechanism of interaction .'
p20373
(lp20374
I4
aI5
aI6
a(lp20375
I9
aI10
aI11
aI12
atp20376
a(I-1
S'Analysis of the human interleukin - 6 / human interleukin - 6 receptor binding interface at the amino acid level : proposed mechanism of interaction .'
p20377
(lp20378
I9
aI10
aI11
a(lp20379
I9
aI10
aI11
aI12
atp20380
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20381
(lp20382
I3
aI4
aI5
a(lp20383
I7
aI8
aI9
atp20384
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20385
(lp20386
I3
aI4
aI5
a(lp20387
I12
aI13
aI14
atp20388
a(I1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20389
(lp20390
I3
aI4
aI5
a(lp20391
I12
aI13
aI14
aI15
atp20392
a(I1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20393
(lp20394
I3
aI4
aI5
a(lp20395
I17
aI18
aI19
atp20396
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20397
(lp20398
I3
aI4
aI5
a(lp20399
I30
aI31
aI32
atp20400
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20401
(lp20402
I7
aI8
aI9
a(lp20403
I12
aI13
aI14
atp20404
a(I1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20405
(lp20406
I7
aI8
aI9
a(lp20407
I12
aI13
aI14
aI15
atp20408
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20409
(lp20410
I7
aI8
aI9
a(lp20411
I17
aI18
aI19
atp20412
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20413
(lp20414
I7
aI8
aI9
a(lp20415
I30
aI31
aI32
atp20416
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20417
(lp20418
I12
aI13
aI14
a(lp20419
I12
aI13
aI14
aI15
atp20420
a(I1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20421
(lp20422
I12
aI13
aI14
a(lp20423
I17
aI18
aI19
atp20424
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20425
(lp20426
I12
aI13
aI14
a(lp20427
I30
aI31
aI32
atp20428
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20429
(lp20430
I12
aI13
aI14
aI15
a(lp20431
I17
aI18
aI19
atp20432
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20433
(lp20434
I12
aI13
aI14
aI15
a(lp20435
I30
aI31
aI32
atp20436
a(I-1
S'The interaction between interleukin - 6 ( IL - 6 ) and IL - 6 receptor ( IL - 6R ) is the initial and most specific step in the IL - 6 signaling pathway .'
p20437
(lp20438
I17
aI18
aI19
a(lp20439
I30
aI31
aI32
atp20440
a(I-1
S'We studied the human IL - 6 ( hIL - 6 ) / hIL - 6R binding interface by a combination of molecular modelling and site - directed mutagenesis .'
p20441
(lp20442
I4
aI5
aI6
a(lp20443
I8
aI9
aI10
atp20444
a(I1
S'We studied the human IL - 6 ( hIL - 6 ) / hIL - 6R binding interface by a combination of molecular modelling and site - directed mutagenesis .'
p20445
(lp20446
I4
aI5
aI6
a(lp20447
I13
aI14
aI15
atp20448
a(I1
S'We studied the human IL - 6 ( hIL - 6 ) / hIL - 6R binding interface by a combination of molecular modelling and site - directed mutagenesis .'
p20449
(lp20450
I8
aI9
aI10
a(lp20451
I13
aI14
aI15
atp20452
a(I1
S'Following this hypothesis , we altered in hIL - 6 and hIL - 6R residues predicted to reside in the contact region and to interact with each other .'
p20453
(lp20454
I7
aI8
aI9
a(lp20455
I11
aI12
aI13
atp20456
a(I1
S'We studied the capacity of these mutants to form an IL - 6 / IL - 6R complex and their ability to transduce the signal .'
p20457
(lp20458
I10
aI11
aI12
a(lp20459
I14
aI15
aI16
atp20460
a(I-1
S'Mutagenesis studies of the human erythropoietin receptor . Establishment of structure - function relationships .'
p20461
(lp20462
I5
a(lp20463
I5
aI6
atp20464
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20465
(lp20466
I3
a(lp20467
I3
aI4
atp20468
a(I1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20469
(lp20470
I3
a(lp20471
I6
atp20472
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20473
(lp20474
I3
a(lp20475
I20
atp20476
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20477
(lp20478
I3
a(lp20479
I22
atp20480
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20481
(lp20482
I3
aI4
a(lp20483
I6
atp20484
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20485
(lp20486
I3
aI4
a(lp20487
I20
atp20488
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20489
(lp20490
I3
aI4
a(lp20491
I22
atp20492
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20493
(lp20494
I6
a(lp20495
I20
atp20496
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20497
(lp20498
I6
a(lp20499
I22
atp20500
a(I-1
S'Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .'
p20501
(lp20502
I20
a(lp20503
I22
atp20504
a(I-1
S'We employed both random and site - specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as EPO binding protein , EBP ) of the EPOR .'
p20505
(lp20506
I25
a(lp20507
I25
aI26
aI27
atp20508
a(I1
S'We employed both random and site - specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as EPO binding protein , EBP ) of the EPOR .'
p20509
(lp20510
I25
a(lp20511
I29
atp20512
a(I-1
S'We employed both random and site - specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as EPO binding protein , EBP ) of the EPOR .'
p20513
(lp20514
I25
a(lp20515
I33
atp20516
a(I-1
S'We employed both random and site - specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as EPO binding protein , EBP ) of the EPOR .'
p20517
(lp20518
I25
aI26
aI27
a(lp20519
I29
atp20520
a(I-1
S'We employed both random and site - specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as EPO binding protein , EBP ) of the EPOR .'
p20521
(lp20522
I25
aI26
aI27
a(lp20523
I33
atp20524
a(I-1
S'We employed both random and site - specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as EPO binding protein , EBP ) of the EPOR .'
p20525
(lp20526
I29
a(lp20527
I33
atp20528
a(I-1
S'Site - specific mutants were expressed in Escherichia coli as soluble EBP and analyzed for EPO binding in several different assay formats .'
p20529
(lp20530
I11
a(lp20531
I15
atp20532
a(I-1
S'In addition , selected mutant proteins were expressed as full - length EPOR on the surface of COS cells and analyzed for 125I - EPO binding in receptor binding assays .'
p20533
(lp20534
I12
a(lp20535
I24
atp20536
a(I-1
S'Using these methods , we have identified residues that appear to be involved in EPO binding as well as other residues , most of which are conserved in receptors of the cytokine receptor family , that appear to be necessary for the proper folding and / or stability of the EPOR .'
p20537
(lp20538
I14
a(lp20539
I50
atp20540
a(I-1
S'Stimulation of fibroblast growth factor receptor 3 ( FGFR3 ) results in a variety of functional effects , including regulation of epithelial cell growth and differentiation .'
p20541
(lp20542
I2
aI3
aI4
aI5
aI6
a(lp20543
I8
atp20544
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20545
(lp20546
I9
a(lp20547
I30
atp20548
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20549
(lp20550
I9
a(lp20551
I30
aI31
atp20552
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20553
(lp20554
I9
a(lp20555
I33
atp20556
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20557
(lp20558
I9
a(lp20559
I33
aI34
atp20560
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20561
(lp20562
I9
a(lp20563
I46
atp20564
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20565
(lp20566
I30
a(lp20567
I30
aI31
atp20568
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20569
(lp20570
I30
a(lp20571
I33
atp20572
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20573
(lp20574
I30
a(lp20575
I33
aI34
atp20576
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20577
(lp20578
I30
a(lp20579
I46
atp20580
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20581
(lp20582
I30
aI31
a(lp20583
I33
atp20584
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20585
(lp20586
I30
aI31
a(lp20587
I33
aI34
atp20588
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20589
(lp20590
I30
aI31
a(lp20591
I46
atp20592
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20593
(lp20594
I33
a(lp20595
I33
aI34
atp20596
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20597
(lp20598
I33
a(lp20599
I46
atp20600
a(I-1
S'In order to characterize the signaling pathway through which FGFR3 regulates cell growth , L6 cells lacking any endogenous FGFR were stably transfected with the two different human isoforms , FGFR3 IIIb and FGFR3 IIIc , that result from alternative splicing of exon III of the FGFR3 gene encoding the ligand binding domain .'
p20601
(lp20602
I33
aI34
a(lp20603
I46
atp20604
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20605
(lp20606
I2
a(lp20607
I2
aI3
atp20608
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20609
(lp20610
I2
a(lp20611
I20
aI21
aI22
atp20612
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20613
(lp20614
I2
a(lp20615
I35
atp20616
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20617
(lp20618
I2
a(lp20619
I35
aI36
atp20620
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20621
(lp20622
I2
a(lp20623
I43
aI44
aI45
atp20624
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20625
(lp20626
I2
aI3
a(lp20627
I20
aI21
aI22
atp20628
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20629
(lp20630
I2
aI3
a(lp20631
I35
atp20632
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20633
(lp20634
I2
aI3
a(lp20635
I35
aI36
atp20636
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20637
(lp20638
I2
aI3
a(lp20639
I43
aI44
aI45
atp20640
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20641
(lp20642
I20
aI21
aI22
a(lp20643
I35
atp20644
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20645
(lp20646
I20
aI21
aI22
a(lp20647
I35
aI36
atp20648
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20649
(lp20650
I20
aI21
aI22
a(lp20651
I43
aI44
aI45
atp20652
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20653
(lp20654
I35
a(lp20655
I35
aI36
atp20656
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20657
(lp20658
I35
a(lp20659
I43
aI44
aI45
atp20660
a(I-1
S'Expression of FGFR3 IIIc in stably transfected L6 cells conferred growth responses to several members of the FGF family including FGF - 1 , - 2 , - 4 , and - 6 , while FGFR3 IIIb - expressing cells responded only to FGF - 1 .'
p20661
(lp20662
I35
aI36
a(lp20663
I43
aI44
aI45
atp20664
a(I-1
S'Activation of FGFR3 upon ligand binding resulted in activation of mitogen - activated protein kinase pathway .'
p20665
(lp20666
I2
a(lp20667
I10
aI11
aI12
aI13
aI14
atp20668
a(I-1
S'FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras .'
p20669
(lp20670
I0
a(lp20671
I8
atp20672
a(I-1
S'FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras .'
p20673
(lp20674
I0
a(lp20675
I12
atp20676
a(I-1
S'FGFR3 utilizes two different pools of adapter protein GRB2 to link to Ras .'
p20677
(lp20678
I8
a(lp20679
I12
atp20680
a(I1
S'Activated FGFR3 predominantly interacts with GRB2 .'
p20681
(lp20682
I1
a(lp20683
I5
atp20684
a(I-1
S'Sos in complex with a previously identified 90 - kDa protein and designated protein 80K - H .'
p20685
(lp20686
I0
a(lp20687
I14
aI15
aI16
atp20688
a(I-1
S'Tyrosine phophorylation of the 66 - kDa protein was dependent on ligand activation of FGFR3 , suggesting that the 66 - kDa protein may play an important role in FGFR3 - specific signaling .'
p20689
(lp20690
I14
a(lp20691
I29
atp20692
a(I-1
S'In addition to this unique pathway , FGFR3 also links to GRB2 .'
p20693
(lp20694
I7
a(lp20695
I11
atp20696
a(I-1
S'Sos complex via the adapter protein Shc .'
p20697
(lp20698
I0
a(lp20699
I6
atp20700
a(I-1
S'Furthermore , activated FGFR3 was not able to induce dissociation of GRB2 .'
p20701
(lp20702
I3
a(lp20703
I11
atp20704
a(I-1
S'Sos complex following Sos phosphorylation .'
p20705
(lp20706
I0
a(lp20707
I3
atp20708
a(I-1
S'In summary , FGFR3 signaling pathway utilizes two GRB2 - containing complexes ; Shc .'
p20709
(lp20710
I3
a(lp20711
I8
atp20712
a(I-1
S'In summary , FGFR3 signaling pathway utilizes two GRB2 - containing complexes ; Shc .'
p20713
(lp20714
I3
a(lp20715
I13
atp20716
a(I-1
S'In summary , FGFR3 signaling pathway utilizes two GRB2 - containing complexes ; Shc .'
p20717
(lp20718
I8
a(lp20719
I13
atp20720
a(I-1
S'Sos and 80K - H . pp66 .'
p20721
(lp20722
I0
a(lp20723
I2
aI3
aI4
atp20724
a(I-1
S'Sos and 80K - H . pp66 .'
p20725
(lp20726
I0
a(lp20727
I6
atp20728
a(I1
S'Sos and 80K - H . pp66 .'
p20729
(lp20730
I2
aI3
aI4
a(lp20731
I6
atp20732
a(I-1
S'Sos ; these two complexes may alternatively link FGFG3 to mitogen - activated protein kinase .'
p20733
(lp20734
I0
a(lp20735
I8
atp20736
a(I-1
S'Sos ; these two complexes may alternatively link FGFG3 to mitogen - activated protein kinase .'
p20737
(lp20738
I0
a(lp20739
I10
aI11
aI12
aI13
aI14
atp20740
a(I-1
S'Sos ; these two complexes may alternatively link FGFG3 to mitogen - activated protein kinase .'
p20741
(lp20742
I8
a(lp20743
I10
aI11
aI12
aI13
aI14
atp20744
a(I-1
S'Finally , activated FGFR3 was also found to result in phosphorylation of phospholipase C - gamma but reduced phosphorylation of c - Src .'
p20745
(lp20746
I3
a(lp20747
I12
aI13
aI14
aI15
atp20748
a(I-1
S'Finally , activated FGFR3 was also found to result in phosphorylation of phospholipase C - gamma but reduced phosphorylation of c - Src .'
p20749
(lp20750
I3
a(lp20751
I20
aI21
aI22
atp20752
a(I-1
S'Finally , activated FGFR3 was also found to result in phosphorylation of phospholipase C - gamma but reduced phosphorylation of c - Src .'
p20753
(lp20754
I12
aI13
aI14
aI15
a(lp20755
I20
aI21
aI22
atp20756
a(I1
S'Using epitope - tagging , interaction of E47 basic - helix - loop - helix protein with the eip1 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells .'
p20757
(lp20758
I7
a(lp20759
I18
atp20760
a(I-1
S'Interactions with human PARP and mouse replication factor 1a were confirmed using glutathione transferase - tagged cDNAs .'
p20761
(lp20762
I3
a(lp20763
I6
aI7
aI8
atp20764
a(I1
S'A cDNA encoding part of the nucleolin protein sequence interacted with the E47 basic - helix - loop - helix only when fused to a beta - galactosidase tag .'
p20765
(lp20766
I6
a(lp20767
I12
atp20768
a(I-1
S'Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5 .'
p20769
(lp20770
I0
aI1
aI2
aI3
aI4
a(lp20771
I12
aI13
aI14
atp20772
a(I-1
S'Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5 .'
p20773
(lp20774
I0
aI1
aI2
aI3
aI4
a(lp20775
I17
aI18
aI19
aI20
aI21
atp20776
a(I-1
S'Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5 .'
p20777
(lp20778
I12
aI13
aI14
a(lp20779
I17
aI18
aI19
aI20
aI21
atp20780
a(I-1
S'Hepatitis B virus X protein ( HBx ) transactivates viral and cellular genes through a wide variety of cis - elements .'
p20781
(lp20782
I0
aI1
aI2
aI3
aI4
a(lp20783
I6
atp20784
a(I1
S'Our finding that HBx directly interacts with RNA polymerase II subunit 5 ( RPB5 ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J . H . , Yi , M . , Lin , Y . , and Murakami , S . ( 1995 ) EMBO J . 14 , 142 - 150 ) .'
p20785
(lp20786
I3
a(lp20787
I7
aI8
aI9
aI10
aI11
atp20788
a(I1
S'Our finding that HBx directly interacts with RNA polymerase II subunit 5 ( RPB5 ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J . H . , Yi , M . , Lin , Y . , and Murakami , S . ( 1995 ) EMBO J . 14 , 142 - 150 ) .'
p20789
(lp20790
I3
a(lp20791
I13
atp20792
a(I-1
S'Our finding that HBx directly interacts with RNA polymerase II subunit 5 ( RPB5 ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J . H . , Yi , M . , Lin , Y . , and Murakami , S . ( 1995 ) EMBO J . 14 , 142 - 150 ) .'
p20793
(lp20794
I3
a(lp20795
I25
atp20796
a(I-1
S'Our finding that HBx directly interacts with RNA polymerase II subunit 5 ( RPB5 ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J . H . , Yi , M . , Lin , Y . , and Murakami , S . ( 1995 ) EMBO J . 14 , 142 - 150 ) .'
p20797
(lp20798
I7
aI8
aI9
aI10
aI11
a(lp20799
I13
atp20800
a(I-1
S'Our finding that HBx directly interacts with RNA polymerase II subunit 5 ( RPB5 ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J . H . , Yi , M . , Lin , Y . , and Murakami , S . ( 1995 ) EMBO J . 14 , 142 - 150 ) .'
p20801
(lp20802
I7
aI8
aI9
aI10
aI11
a(lp20803
I25
atp20804
a(I-1
S'Our finding that HBx directly interacts with RNA polymerase II subunit 5 ( RPB5 ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J . H . , Yi , M . , Lin , Y . , and Murakami , S . ( 1995 ) EMBO J . 14 , 142 - 150 ) .'
p20805
(lp20806
I13
a(lp20807
I25
atp20808
a(I-1
S'In this context , we examined the possibility that HBx and RPB5 interact with other general transcription factors .'
p20809
(lp20810
I9
a(lp20811
I11
atp20812
a(I-1
S'HBx and RPB5 specifically bound to transcription factor IIB ( TFIIB ) in vitro , both of which were detected by either far - Western blotting or the glutathione S - transferase - resin pull - down assay .'
p20813
(lp20814
I0
a(lp20815
I2
atp20816
a(I-1
S'HBx and RPB5 specifically bound to transcription factor IIB ( TFIIB ) in vitro , both of which were detected by either far - Western blotting or the glutathione S - transferase - resin pull - down assay .'
p20817
(lp20818
I0
a(lp20819
I6
aI7
aI8
atp20820
a(I-1
S'HBx and RPB5 specifically bound to transcription factor IIB ( TFIIB ) in vitro , both of which were detected by either far - Western blotting or the glutathione S - transferase - resin pull - down assay .'
p20821
(lp20822
I0
a(lp20823
I10
atp20824
a(I-1
S'HBx and RPB5 specifically bound to transcription factor IIB ( TFIIB ) in vitro , both of which were detected by either far - Western blotting or the glutathione S - transferase - resin pull - down assay .'
p20825
(lp20826
I2
a(lp20827
I6
aI7
aI8
atp20828
a(I-1
S'HBx and RPB5 specifically bound to transcription factor IIB ( TFIIB ) in vitro , both of which were detected by either far - Western blotting or the glutathione S - transferase - resin pull - down assay .'
p20829
(lp20830
I2
a(lp20831
I10
atp20832
a(I-1
S'HBx and RPB5 specifically bound to transcription factor IIB ( TFIIB ) in vitro , both of which were detected by either far - Western blotting or the glutathione S - transferase - resin pull - down assay .'
p20833
(lp20834
I6
aI7
aI8
a(lp20835
I10
atp20836
a(I1
S'Delineation of the binding regions of these three proteins revealed that HBx , RPB5 , and TFIIB each has two binding regions for the other two proteins .'
p20837
(lp20838
I11
a(lp20839
I13
atp20840
a(I-1
S'Delineation of the binding regions of these three proteins revealed that HBx , RPB5 , and TFIIB each has two binding regions for the other two proteins .'
p20841
(lp20842
I11
a(lp20843
I16
atp20844
a(I-1
S'Delineation of the binding regions of these three proteins revealed that HBx , RPB5 , and TFIIB each has two binding regions for the other two proteins .'
p20845
(lp20846
I13
a(lp20847
I16
atp20848
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20849
(lp20850
I1
a(lp20851
I18
atp20852
a(I1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20853
(lp20854
I1
a(lp20855
I20
atp20856
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20857
(lp20858
I1
a(lp20859
I29
atp20860
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20861
(lp20862
I1
a(lp20863
I36
atp20864
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20865
(lp20866
I1
a(lp20867
I38
atp20868
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20869
(lp20870
I18
a(lp20871
I20
atp20872
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20873
(lp20874
I18
a(lp20875
I29
atp20876
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20877
(lp20878
I18
a(lp20879
I36
atp20880
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20881
(lp20882
I18
a(lp20883
I38
atp20884
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20885
(lp20886
I20
a(lp20887
I29
atp20888
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20889
(lp20890
I20
a(lp20891
I36
atp20892
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20893
(lp20894
I20
a(lp20895
I38
atp20896
a(I1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20897
(lp20898
I29
a(lp20899
I36
atp20900
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20901
(lp20902
I29
a(lp20903
I38
atp20904
a(I-1
S'Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .'
p20905
(lp20906
I36
a(lp20907
I38
atp20908
a(I-1
S'These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB .'
p20909
(lp20910
I4
a(lp20911
I22
atp20912
a(I-1
S'These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB .'
p20913
(lp20914
I4
a(lp20915
I26
atp20916
a(I-1
S'These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB .'
p20917
(lp20918
I4
a(lp20919
I28
atp20920
a(I-1
S'These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB .'
p20921
(lp20922
I22
a(lp20923
I26
atp20924
a(I-1
S'These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB .'
p20925
(lp20926
I22
a(lp20927
I28
atp20928
a(I-1
S'These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB .'
p20929
(lp20930
I26
a(lp20931
I28
atp20932
a(I-1
S'Crystal structure of the type - I interleukin - 1 receptor complexed with interleukin - 1beta .'
p20933
(lp20934
I7
aI8
aI9
a(lp20935
I4
aI5
aI6
aI7
aI8
aI9
aI10
atp20936
a(I-1
S'Crystal structure of the type - I interleukin - 1 receptor complexed with interleukin - 1beta .'
p20937
(lp20938
I7
aI8
aI9
a(lp20939
I13
aI14
aI15
atp20940
a(I1
S'Crystal structure of the type - I interleukin - 1 receptor complexed with interleukin - 1beta .'
p20941
(lp20942
I4
aI5
aI6
aI7
aI8
aI9
aI10
a(lp20943
I13
aI14
aI15
atp20944
a(I-1
S'Interleukin - 1 ( IL - 1 ) is an important mediator of inflammatory disease .'
p20945
(lp20946
I0
aI1
aI2
a(lp20947
I4
aI5
aI6
atp20948
a(I-1
S'The IL - 1 family currently consists of two agonists , IL - 1alpha and IL - 1beta , and one antagonist , IL - 1ra .'
p20949
(lp20950
I1
aI2
aI3
a(lp20951
I11
aI12
aI13
atp20952
a(I-1
S'The IL - 1 family currently consists of two agonists , IL - 1alpha and IL - 1beta , and one antagonist , IL - 1ra .'
p20953
(lp20954
I1
aI2
aI3
a(lp20955
I15
aI16
aI17
atp20956
a(I-1
S'The IL - 1 family currently consists of two agonists , IL - 1alpha and IL - 1beta , and one antagonist , IL - 1ra .'
p20957
(lp20958
I1
aI2
aI3
a(lp20959
I23
aI24
aI25
atp20960
a(I-1
S'The IL - 1 family currently consists of two agonists , IL - 1alpha and IL - 1beta , and one antagonist , IL - 1ra .'
p20961
(lp20962
I11
aI12
aI13
a(lp20963
I15
aI16
aI17
atp20964
a(I-1
S'The IL - 1 family currently consists of two agonists , IL - 1alpha and IL - 1beta , and one antagonist , IL - 1ra .'
p20965
(lp20966
I11
aI12
aI13
a(lp20967
I23
aI24
aI25
atp20968
a(I-1
S'The IL - 1 family currently consists of two agonists , IL - 1alpha and IL - 1beta , and one antagonist , IL - 1ra .'
p20969
(lp20970
I15
aI16
aI17
a(lp20971
I23
aI24
aI25
atp20972
a(I-1
S'Each of these molecules binds to the type I IL - 1 receptor ( IL1R ) .'
p20973
(lp20974
I9
aI10
aI11
a(lp20975
I7
aI8
aI9
aI10
aI11
aI12
atp20976
a(I-1
S'Each of these molecules binds to the type I IL - 1 receptor ( IL1R ) .'
p20977
(lp20978
I9
aI10
aI11
a(lp20979
I14
atp20980
a(I-1
S'Each of these molecules binds to the type I IL - 1 receptor ( IL1R ) .'
p20981
(lp20982
I7
aI8
aI9
aI10
aI11
aI12
a(lp20983
I14
atp20984
a(I-1
S'The binding of IL - 1alpha or IL - 1beta to IL1R is an early step in IL - 1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs .'
p20985
(lp20986
I3
aI4
aI5
a(lp20987
I7
aI8
aI9
atp20988
a(I1
S'The binding of IL - 1alpha or IL - 1beta to IL1R is an early step in IL - 1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs .'
p20989
(lp20990
I3
aI4
aI5
a(lp20991
I11
atp20992
a(I-1
S'The binding of IL - 1alpha or IL - 1beta to IL1R is an early step in IL - 1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs .'
p20993
(lp20994
I3
aI4
aI5
a(lp20995
I17
aI18
aI19
atp20996
a(I1
S'The binding of IL - 1alpha or IL - 1beta to IL1R is an early step in IL - 1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs .'
p20997
(lp20998
I7
aI8
aI9
a(lp20999
I11
atp21000
a(I-1
S'The binding of IL - 1alpha or IL - 1beta to IL1R is an early step in IL - 1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs .'
p21001
(lp21002
I7
aI8
aI9
a(lp21003
I17
aI18
aI19
atp21004
a(I-1
S'The binding of IL - 1alpha or IL - 1beta to IL1R is an early step in IL - 1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs .'
p21005
(lp21006
I11
a(lp21007
I17
aI18
aI19
atp21008
a(I1
S'Here we report the three - dimensional structure of IL - 1beta bound to the extracellular domain of IL1R ( s - IL1R ) at 2 . 5 A resolution .'
p21009
(lp21010
I9
aI10
aI11
a(lp21011
I18
atp21012
a(I1
S'Here we report the three - dimensional structure of IL - 1beta bound to the extracellular domain of IL1R ( s - IL1R ) at 2 . 5 A resolution .'
p21013
(lp21014
I9
aI10
aI11
a(lp21015
I20
aI21
aI22
atp21016
a(I-1
S'Here we report the three - dimensional structure of IL - 1beta bound to the extracellular domain of IL1R ( s - IL1R ) at 2 . 5 A resolution .'
p21017
(lp21018
I18
a(lp21019
I20
aI21
aI22
atp21020
a(I1
S'IL - 1beta binds to s - IL1R with a 1 : 1 stoichiometry .'
p21021
(lp21022
I0
aI1
aI2
a(lp21023
I5
aI6
aI7
atp21024
a(I1
S'The crystal structure shows that s - IL1R consists of three immunoglobulin - like domains which wrap around IL - 1beta in a manner distinct from the structures of previously described cytokine - receptor complexes .'
p21025
(lp21026
I5
aI6
aI7
a(lp21027
I18
aI19
aI20
atp21028
a(I-1
S'A new cytokine - receptor binding mode revealed by the crystal structure of the IL - 1 receptor with an antagonist .'
p21029
(lp21030
I14
aI15
aI16
a(lp21031
I14
aI15
aI16
aI17
atp21032
a(I-1
S'Inflammation , regardless of whether it is provoked by infection or by tissue damage , starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin - 1 ( IL - 1 ) and tumour necrosis factor - alpha ( ref . 1 ) .'
p21033
(lp21034
I32
aI33
aI34
a(lp21035
I36
aI37
aI38
atp21036
a(I-1
S'Inflammation , regardless of whether it is provoked by infection or by tissue damage , starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin - 1 ( IL - 1 ) and tumour necrosis factor - alpha ( ref . 1 ) .'
p21037
(lp21038
I32
aI33
aI34
a(lp21039
I41
aI42
aI43
aI44
aI45
atp21040
a(I-1
S'Inflammation , regardless of whether it is provoked by infection or by tissue damage , starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin - 1 ( IL - 1 ) and tumour necrosis factor - alpha ( ref . 1 ) .'
p21041
(lp21042
I36
aI37
aI38
a(lp21043
I41
aI42
aI43
aI44
aI45
atp21044
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21045
(lp21046
I6
aI7
aI8
a(lp21047
I6
aI7
aI8
aI9
atp21048
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21049
(lp21050
I6
aI7
aI8
a(lp21051
I11
atp21052
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21053
(lp21054
I6
aI7
aI8
a(lp21055
I17
aI18
aI19
atp21056
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21057
(lp21058
I6
aI7
aI8
a(lp21059
I21
aI22
aI23
atp21060
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21061
(lp21062
I6
aI7
aI8
a(lp21063
I26
aI27
aI28
atp21064
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21065
(lp21066
I6
aI7
aI8
a(lp21067
I26
aI27
aI28
aI29
aI30
atp21068
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21069
(lp21070
I6
aI7
aI8
a(lp21071
I26
aI27
aI28
aI29
aI30
aI31
atp21072
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21073
(lp21074
I6
aI7
aI8
a(lp21075
I32
atp21076
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21077
(lp21078
I6
aI7
aI8
aI9
a(lp21079
I11
atp21080
a(I1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21081
(lp21082
I6
aI7
aI8
aI9
a(lp21083
I17
aI18
aI19
atp21084
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21085
(lp21086
I6
aI7
aI8
aI9
a(lp21087
I21
aI22
aI23
atp21088
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21089
(lp21090
I6
aI7
aI8
aI9
a(lp21091
I26
aI27
aI28
atp21092
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21093
(lp21094
I6
aI7
aI8
aI9
a(lp21095
I26
aI27
aI28
aI29
aI30
atp21096
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21097
(lp21098
I6
aI7
aI8
aI9
a(lp21099
I26
aI27
aI28
aI29
aI30
aI31
atp21100
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21101
(lp21102
I6
aI7
aI8
aI9
a(lp21103
I32
atp21104
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21105
(lp21106
I11
a(lp21107
I17
aI18
aI19
atp21108
a(I1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21109
(lp21110
I11
a(lp21111
I21
aI22
aI23
atp21112
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21113
(lp21114
I11
a(lp21115
I26
aI27
aI28
atp21116
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21117
(lp21118
I11
a(lp21119
I26
aI27
aI28
aI29
aI30
atp21120
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21121
(lp21122
I11
a(lp21123
I26
aI27
aI28
aI29
aI30
aI31
atp21124
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21125
(lp21126
I11
a(lp21127
I32
atp21128
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21129
(lp21130
I17
aI18
aI19
a(lp21131
I21
aI22
aI23
atp21132
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21133
(lp21134
I17
aI18
aI19
a(lp21135
I26
aI27
aI28
atp21136
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21137
(lp21138
I17
aI18
aI19
a(lp21139
I26
aI27
aI28
aI29
aI30
atp21140
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21141
(lp21142
I17
aI18
aI19
a(lp21143
I26
aI27
aI28
aI29
aI30
aI31
atp21144
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21145
(lp21146
I17
aI18
aI19
a(lp21147
I32
atp21148
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21149
(lp21150
I21
aI22
aI23
a(lp21151
I26
aI27
aI28
atp21152
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21153
(lp21154
I21
aI22
aI23
a(lp21155
I26
aI27
aI28
aI29
aI30
atp21156
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21157
(lp21158
I21
aI22
aI23
a(lp21159
I26
aI27
aI28
aI29
aI30
aI31
atp21160
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21161
(lp21162
I21
aI22
aI23
a(lp21163
I32
atp21164
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21165
(lp21166
I26
aI27
aI28
a(lp21167
I26
aI27
aI28
aI29
aI30
atp21168
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21169
(lp21170
I26
aI27
aI28
a(lp21171
I26
aI27
aI28
aI29
aI30
aI31
atp21172
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21173
(lp21174
I26
aI27
aI28
a(lp21175
I32
atp21176
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21177
(lp21178
I26
aI27
aI28
aI29
aI30
a(lp21179
I26
aI27
aI28
aI29
aI30
aI31
atp21180
a(I1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21181
(lp21182
I26
aI27
aI28
aI29
aI30
a(lp21183
I32
atp21184
a(I-1
S'Three naturally occurring ligands for the IL - 1 receptor ( IL1R ) exist : the agonists IL - 1alpha and IL - 1beta and the IL - 1 - receptor antagonist IL1RA ( ref . 2 ) .'
p21185
(lp21186
I26
aI27
aI28
aI29
aI30
aI31
a(lp21187
I32
atp21188
a(I-1
S'Here we describe the crystal structure at 2 . 7 A resolution of the soluble extracellular part of type - I IL1R complexed with IL1RA .'
p21189
(lp21190
I21
a(lp21191
I18
aI19
aI20
aI21
atp21192
a(I-1
S'Here we describe the crystal structure at 2 . 7 A resolution of the soluble extracellular part of type - I IL1R complexed with IL1RA .'
p21193
(lp21194
I21
a(lp21195
I24
atp21196
a(I1
S'Here we describe the crystal structure at 2 . 7 A resolution of the soluble extracellular part of type - I IL1R complexed with IL1RA .'
p21197
(lp21198
I18
aI19
aI20
aI21
a(lp21199
I24
atp21200
a(I-1
S"A region that is important for biological function in IL - 1beta , the ' receptor trigger site ' is not in direct contact with the receptor in the IL1RA complex ."
p21201
(lp21202
I9
aI10
aI11
a(lp21203
I29
atp21204
a(I-1
S'The catalytic domain of activated collagenase I ( MMP - 1 ) is absolutely required for interaction with its specific inhibitor , tissue inhibitor of metalloproteinases - 1 ( TIMP - 1 ) .'
p21205
(lp21206
I5
aI6
a(lp21207
I8
aI9
aI10
atp21208
a(I-1
S'The catalytic domain of activated collagenase I ( MMP - 1 ) is absolutely required for interaction with its specific inhibitor , tissue inhibitor of metalloproteinases - 1 ( TIMP - 1 ) .'
p21209
(lp21210
I5
aI6
a(lp21211
I22
aI23
aI24
aI25
aI26
aI27
atp21212
a(I-1
S'The catalytic domain of activated collagenase I ( MMP - 1 ) is absolutely required for interaction with its specific inhibitor , tissue inhibitor of metalloproteinases - 1 ( TIMP - 1 ) .'
p21213
(lp21214
I5
aI6
a(lp21215
I29
aI30
aI31
atp21216
a(I1
S'The catalytic domain of activated collagenase I ( MMP - 1 ) is absolutely required for interaction with its specific inhibitor , tissue inhibitor of metalloproteinases - 1 ( TIMP - 1 ) .'
p21217
(lp21218
I8
aI9
aI10
a(lp21219
I22
aI23
aI24
aI25
aI26
aI27
atp21220
a(I1
S'The catalytic domain of activated collagenase I ( MMP - 1 ) is absolutely required for interaction with its specific inhibitor , tissue inhibitor of metalloproteinases - 1 ( TIMP - 1 ) .'
p21221
(lp21222
I8
aI9
aI10
a(lp21223
I29
aI30
aI31
atp21224
a(I-1
S'The catalytic domain of activated collagenase I ( MMP - 1 ) is absolutely required for interaction with its specific inhibitor , tissue inhibitor of metalloproteinases - 1 ( TIMP - 1 ) .'
p21225
(lp21226
I22
aI23
aI24
aI25
aI26
aI27
a(lp21227
I29
aI30
aI31
atp21228
a(I-1
S'Here , we describe the production of recombinant human tissue inhibitor of metalloproteinases - 1 ( rTIMP - 1 ) and wild - type and mutant human collagenase type I ( rMMP - 1 ) proteins in SF9 cells by the baculovirus expression system .'
p21229
(lp21230
I7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
a(lp21231
I16
aI17
aI18
atp21232
a(I-1
S'Here , we describe the production of recombinant human tissue inhibitor of metalloproteinases - 1 ( rTIMP - 1 ) and wild - type and mutant human collagenase type I ( rMMP - 1 ) proteins in SF9 cells by the baculovirus expression system .'
p21233
(lp21234
I7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
a(lp21235
I27
aI28
aI29
atp21236
a(I-1
S'Here , we describe the production of recombinant human tissue inhibitor of metalloproteinases - 1 ( rTIMP - 1 ) and wild - type and mutant human collagenase type I ( rMMP - 1 ) proteins in SF9 cells by the baculovirus expression system .'
p21237
(lp21238
I7
aI8
aI9
aI10
aI11
aI12
aI13
aI14
a(lp21239
I31
aI32
aI33
atp21240
a(I-1
S'Here , we describe the production of recombinant human tissue inhibitor of metalloproteinases - 1 ( rTIMP - 1 ) and wild - type and mutant human collagenase type I ( rMMP - 1 ) proteins in SF9 cells by the baculovirus expression system .'
p21241
(lp21242
I16
aI17
aI18
a(lp21243
I27
aI28
aI29
atp21244
a(I-1
S'Here , we describe the production of recombinant human tissue inhibitor of metalloproteinases - 1 ( rTIMP - 1 ) and wild - type and mutant human collagenase type I ( rMMP - 1 ) proteins in SF9 cells by the baculovirus expression system .'
p21245
(lp21246
I16
aI17
aI18
a(lp21247
I31
aI32
aI33
atp21248
a(I-1
S'Here , we describe the production of recombinant human tissue inhibitor of metalloproteinases - 1 ( rTIMP - 1 ) and wild - type and mutant human collagenase type I ( rMMP - 1 ) proteins in SF9 cells by the baculovirus expression system .'
p21249
(lp21250
I27
aI28
aI29
a(lp21251
I31
aI32
aI33
atp21252
a(I-1
S'Wild - type MMP - 1 , as well as the MMP - 1 mutant lacking the C - terminal hemopexin - like domain [ des - ( 248 - 450 ) - MMP - 1 ] , exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4 - aminophenylmercuric acetate .'
p21253
(lp21254
I3
aI4
aI5
a(lp21255
I11
aI12
aI13
atp21256
a(I-1
S'Wild - type MMP - 1 , as well as the MMP - 1 mutant lacking the C - terminal hemopexin - like domain [ des - ( 248 - 450 ) - MMP - 1 ] , exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4 - aminophenylmercuric acetate .'
p21257
(lp21258
I3
aI4
aI5
a(lp21259
I33
aI34
aI35
atp21260
a(I-1
S'Wild - type MMP - 1 , as well as the MMP - 1 mutant lacking the C - terminal hemopexin - like domain [ des - ( 248 - 450 ) - MMP - 1 ] , exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4 - aminophenylmercuric acetate .'
p21261
(lp21262
I3
aI4
aI5
a(lp21263
I49
atp21264
a(I-1
S'Wild - type MMP - 1 , as well as the MMP - 1 mutant lacking the C - terminal hemopexin - like domain [ des - ( 248 - 450 ) - MMP - 1 ] , exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4 - aminophenylmercuric acetate .'
p21265
(lp21266
I11
aI12
aI13
a(lp21267
I33
aI34
aI35
atp21268
a(I-1
S'Wild - type MMP - 1 , as well as the MMP - 1 mutant lacking the C - terminal hemopexin - like domain [ des - ( 248 - 450 ) - MMP - 1 ] , exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4 - aminophenylmercuric acetate .'
p21269
(lp21270
I11
aI12
aI13
a(lp21271
I49
atp21272
a(I-1
S'Wild - type MMP - 1 , as well as the MMP - 1 mutant lacking the C - terminal hemopexin - like domain [ des - ( 248 - 450 ) - MMP - 1 ] , exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4 - aminophenylmercuric acetate .'
p21273
(lp21274
I33
aI34
aI35
a(lp21275
I49
atp21276
a(I-1
S'Deletion of the complete active - site [ des - ( 161 - 228 ) - MMP - 1 ] within the catalytic domain , or mutation of a single His residue of the Zn2 + binding domain ( His199 ) , generates stable forms of MMP - 1 proteins which are unable to digest collagen type I or beta - casein .'
p21277
(lp21278
I16
aI17
aI18
a(lp21279
I46
aI47
aI48
atp21280
a(I-1
S'Deletion of the complete active - site [ des - ( 161 - 228 ) - MMP - 1 ] within the catalytic domain , or mutation of a single His residue of the Zn2 + binding domain ( His199 ) , generates stable forms of MMP - 1 proteins which are unable to digest collagen type I or beta - casein .'
p21281
(lp21282
I16
aI17
aI18
a(lp21283
I55
aI56
aI57
atp21284
a(I-1
S'Deletion of the complete active - site [ des - ( 161 - 228 ) - MMP - 1 ] within the catalytic domain , or mutation of a single His residue of the Zn2 + binding domain ( His199 ) , generates stable forms of MMP - 1 proteins which are unable to digest collagen type I or beta - casein .'
p21285
(lp21286
I16
aI17
aI18
a(lp21287
I59
aI60
aI61
atp21288
a(I-1
S'Deletion of the complete active - site [ des - ( 161 - 228 ) - MMP - 1 ] within the catalytic domain , or mutation of a single His residue of the Zn2 + binding domain ( His199 ) , generates stable forms of MMP - 1 proteins which are unable to digest collagen type I or beta - casein .'
p21289
(lp21290
I46
aI47
aI48
a(lp21291
I55
aI56
aI57
atp21292
a(I-1
S'Deletion of the complete active - site [ des - ( 161 - 228 ) - MMP - 1 ] within the catalytic domain , or mutation of a single His residue of the Zn2 + binding domain ( His199 ) , generates stable forms of MMP - 1 proteins which are unable to digest collagen type I or beta - casein .'
p21293
(lp21294
I46
aI47
aI48
a(lp21295
I59
aI60
aI61
atp21296
a(I-1
S'Deletion of the complete active - site [ des - ( 161 - 228 ) - MMP - 1 ] within the catalytic domain , or mutation of a single His residue of the Zn2 + binding domain ( His199 ) , generates stable forms of MMP - 1 proteins which are unable to digest collagen type I or beta - casein .'
p21297
(lp21298
I55
aI56
aI57
a(lp21299
I59
aI60
aI61
atp21300
a(I-1
S'In addition to co - immunoprecipitation analysis , we have established a rapid and sensitive ELISA assay using immobilized rTIMP to determine the structural requirements of MMP - 1 to form complexes with its inhibitor .'
p21301
(lp21302
I19
a(lp21303
I26
aI27
aI28
atp21304
a(I1
S'Only the activated and not the latent forms of wild - type and C - terminal mutant des - ( 248 - 450 ) - MMP - 1 proteins are able to form complexes with TIMP .'
p21305
(lp21306
I25
aI26
aI27
a(lp21307
I35
atp21308
a(I-1
S'Neither mutation of His199 , nor deletion mutants des - ( 161 - 228 ) - MMP - 1 and des - ( 161 - 228 / 248 - 450 ) - MMP - 1 , interact with TIMP .'
p21309
(lp21310
I16
aI17
aI18
a(lp21311
I32
aI33
aI34
atp21312
a(I-1
S'Neither mutation of His199 , nor deletion mutants des - ( 161 - 228 ) - MMP - 1 and des - ( 161 - 228 / 248 - 450 ) - MMP - 1 , interact with TIMP .'
p21313
(lp21314
I16
aI17
aI18
a(lp21315
I38
atp21316
a(I-1
S'Neither mutation of His199 , nor deletion mutants des - ( 161 - 228 ) - MMP - 1 and des - ( 161 - 228 / 248 - 450 ) - MMP - 1 , interact with TIMP .'
p21317
(lp21318
I32
aI33
aI34
a(lp21319
I38
atp21320
a(I-1
S'This demonstrates that the C - terminal hemopexin domain of MMP - 1 , in contrast to the corresponding regions of gelatinase A and gelatinase B , does not interact with TIMP - 1 .'
p21321
(lp21322
I10
aI11
aI12
a(lp21323
I21
aI22
atp21324
a(I-1
S'This demonstrates that the C - terminal hemopexin domain of MMP - 1 , in contrast to the corresponding regions of gelatinase A and gelatinase B , does not interact with TIMP - 1 .'
p21325
(lp21326
I10
aI11
aI12
a(lp21327
I24
aI25
atp21328
a(I-1
S'This demonstrates that the C - terminal hemopexin domain of MMP - 1 , in contrast to the corresponding regions of gelatinase A and gelatinase B , does not interact with TIMP - 1 .'
p21329
(lp21330
I10
aI11
aI12
a(lp21331
I31
aI32
aI33
atp21332
a(I-1
S'This demonstrates that the C - terminal hemopexin domain of MMP - 1 , in contrast to the corresponding regions of gelatinase A and gelatinase B , does not interact with TIMP - 1 .'
p21333
(lp21334
I21
aI22
a(lp21335
I24
aI25
atp21336
a(I1
S'This demonstrates that the C - terminal hemopexin domain of MMP - 1 , in contrast to the corresponding regions of gelatinase A and gelatinase B , does not interact with TIMP - 1 .'
p21337
(lp21338
I21
aI22
a(lp21339
I31
aI32
aI33
atp21340
a(I1
S'This demonstrates that the C - terminal hemopexin domain of MMP - 1 , in contrast to the corresponding regions of gelatinase A and gelatinase B , does not interact with TIMP - 1 .'
p21341
(lp21342
I24
aI25
a(lp21343
I31
aI32
aI33
atp21344
a(I1
S'In summary , we have shown that the integrity of the catalytic domain of MMP - 1 and its ability to bind Zn2 + is absolutely required for complex formation with TIMP - 1 , which further underlines the importance of this region for proper regulation of enzymatic activity of MMP - 1 .'
p21345
(lp21346
I14
aI15
aI16
a(lp21347
I31
aI32
aI33
atp21348
a(I-1
S'In summary , we have shown that the integrity of the catalytic domain of MMP - 1 and its ability to bind Zn2 + is absolutely required for complex formation with TIMP - 1 , which further underlines the importance of this region for proper regulation of enzymatic activity of MMP - 1 .'
p21349
(lp21350
I14
aI15
aI16
a(lp21351
I50
aI51
aI52
atp21352
a(I-1
S'In summary , we have shown that the integrity of the catalytic domain of MMP - 1 and its ability to bind Zn2 + is absolutely required for complex formation with TIMP - 1 , which further underlines the importance of this region for proper regulation of enzymatic activity of MMP - 1 .'
p21353
(lp21354
I31
aI32
aI33
a(lp21355
I50
aI51
aI52
atp21356
a(I-1
S'Thymocyte activation induces the association of phosphatidylinositol 3 - kinase and pp120 with CD5 .'
p21357
(lp21358
I6
aI7
aI8
aI9
a(lp21359
I11
atp21360
a(I1
S'Thymocyte activation induces the association of phosphatidylinositol 3 - kinase and pp120 with CD5 .'
p21361
(lp21362
I6
aI7
aI8
aI9
a(lp21363
I13
atp21364
a(I1
S'Thymocyte activation induces the association of phosphatidylinositol 3 - kinase and pp120 with CD5 .'
p21365
(lp21366
I11
a(lp21367
I13
atp21368
a(I-1
S'Antibody - mediated cross - linking studies or studies on CD5 knockout mice implicate CD5 as a co - stimulatory or negative regulatory molecule .'
p21369
(lp21370
I10
a(lp21371
I14
atp21372
a(I-1
S'Y429 and Y441 occur in an imperfect immunoreceptor tyrosine - based activation motif ( ITAM ) - like sequence .'
p21373
(lp21374
I7
aI8
aI9
aI10
aI11
aI12
a(lp21375
I14
atp21376
a(I1
S'We investigated whether phosphatidylinositol ( PI ) 3 - kinase , which binds to tyrosine - phosphorylated ITAM , interacts with CD5 following T cell activation .'
p21377
(lp21378
I3
aI4
aI5
aI6
aI7
aI8
aI9
a(lp21379
I17
atp21380
a(I-1
S'We investigated whether phosphatidylinositol ( PI ) 3 - kinase , which binds to tyrosine - phosphorylated ITAM , interacts with CD5 following T cell activation .'
p21381
(lp21382
I3
aI4
aI5
aI6
aI7
aI8
aI9
a(lp21383
I21
atp21384
a(I-1
S'We investigated whether phosphatidylinositol ( PI ) 3 - kinase , which binds to tyrosine - phosphorylated ITAM , interacts with CD5 following T cell activation .'
p21385
(lp21386
I17
a(lp21387
I21
atp21388
a(I-1
S'PI 3 - kinase activity and the regulatory p85 subunit of PI 3 - kinase associated with CD5 in pervanadate - stimulated , but not in unstimulated thymocytes .'
p21389
(lp21390
I0
aI1
aI2
aI3
a(lp21391
I8
atp21392
a(I-1
S'PI 3 - kinase activity and the regulatory p85 subunit of PI 3 - kinase associated with CD5 in pervanadate - stimulated , but not in unstimulated thymocytes .'
p21393
(lp21394
I0
aI1
aI2
aI3
a(lp21395
I11
aI12
aI13
aI14
atp21396
a(I-1
S'PI 3 - kinase activity and the regulatory p85 subunit of PI 3 - kinase associated with CD5 in pervanadate - stimulated , but not in unstimulated thymocytes .'
p21397
(lp21398
I0
aI1
aI2
aI3
a(lp21399
I17
atp21400
a(I-1
S'PI 3 - kinase activity and the regulatory p85 subunit of PI 3 - kinase associated with CD5 in pervanadate - stimulated , but not in unstimulated thymocytes .'
p21401
(lp21402
I8
a(lp21403
I11
aI12
aI13
aI14
atp21404
a(I-1
S'PI 3 - kinase activity and the regulatory p85 subunit of PI 3 - kinase associated with CD5 in pervanadate - stimulated , but not in unstimulated thymocytes .'
p21405
(lp21406
I8
a(lp21407
I17
atp21408
a(I1
S'PI 3 - kinase activity and the regulatory p85 subunit of PI 3 - kinase associated with CD5 in pervanadate - stimulated , but not in unstimulated thymocytes .'
p21409
(lp21410
I11
aI12
aI13
aI14
a(lp21411
I17
atp21412
a(I-1
S'Cellular p85 as well as the recombinant Src homology 2 ( SH2 ) domains of p85 bound a tyrosine - phosphorylated peptide encompassing Y463 with approximately threefold greater affinity than a doubly tyrosine - phosphorylated Y429 - Y441 peptide .'
p21413
(lp21414
I1
a(lp21415
I15
atp21416
a(I-1
S'A 120 - kDa phosphoprotein ( pp120 ) associated with CD5 and specifically with the Y429 - Y441 phosphopeptide in stimulated thymocytes .'
p21417
(lp21418
I1
aI2
aI3
aI4
a(lp21419
I6
atp21420
a(I1
S'A 120 - kDa phosphoprotein ( pp120 ) associated with CD5 and specifically with the Y429 - Y441 phosphopeptide in stimulated thymocytes .'
p21421
(lp21422
I1
aI2
aI3
aI4
a(lp21423
I10
atp21424
a(I1
S'A 120 - kDa phosphoprotein ( pp120 ) associated with CD5 and specifically with the Y429 - Y441 phosphopeptide in stimulated thymocytes .'
p21425
(lp21426
I6
a(lp21427
I10
atp21428
a(I-1
S'We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3 - kinase and pp120 to CD5 .'
p21429
(lp21430
I12
aI13
aI14
aI15
a(lp21431
I17
atp21432
a(I1
S'We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3 - kinase and pp120 to CD5 .'
p21433
(lp21434
I12
aI13
aI14
aI15
a(lp21435
I19
atp21436
a(I1
S'We conclude that stimulation of thymocytes with pervanadate induces the recruitment of PI 3 - kinase and pp120 to CD5 .'
p21437
(lp21438
I17
a(lp21439
I19
atp21440
a(I-1
S'As CD9 forms complexes with beta 1 integrins and the integrins are known to regulate keratinocyte behaviour , we investigated CD9 expression and function in human epidermal keratinocytes .'
p21441
(lp21442
I1
a(lp21443
I20
atp21444
a(I-1
S'There was extensive co - localisation of CD9 and beta 1 integrins on microvilli and at cell - cell borders of basal keratinocytes ; however , in contrast to the integrins , CD9 was not found in focal adhesions .'
p21445
(lp21446
I7
a(lp21447
I32
atp21448
a(I-1
S'CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan , but not of cadherins .'
p21449
(lp21450
I0
a(lp21451
I13
atp21452
a(I-1
S'CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan , but not of cadherins .'
p21453
(lp21454
I0
a(lp21455
I15
atp21456
a(I-1
S'CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and syndecan , but not of cadherins .'
p21457
(lp21458
I13
a(lp21459
I15
atp21460
a(I-1
S'CD9 was associated with alpha 3 beta 1 but not alpha 5 beta 1 ; small amounts of CD9 also co - immunoprecipitated with antibodies to alpha 2 beta 1 and alpha 6 beta 4 .'
p21461
(lp21462
I0
a(lp21463
I18
atp21464
a(I-1
S'Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1 , type IV collagen and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .'
p21465
(lp21466
I2
a(lp21467
I13
aI14
atp21468
a(I-1
S'Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1 , type IV collagen and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .'
p21469
(lp21470
I2
a(lp21471
I16
aI17
aI18
atp21472
a(I-1
S'Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1 , type IV collagen and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .'
p21473
(lp21474
I2
a(lp21475
I20
atp21476
a(I-1
S'Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1 , type IV collagen and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .'
p21477
(lp21478
I13
aI14
a(lp21479
I16
aI17
aI18
atp21480
a(I-1
S'Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1 , type IV collagen and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .'
p21481
(lp21482
I13
aI14
a(lp21483
I20
atp21484
a(I-1
S'Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1 , type IV collagen and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .'
p21485
(lp21486
I16
aI17
aI18
a(lp21487
I20
atp21488
a(I-1
S'Like antibodies to the beta 1 integrin subunit , anti - CD9 inhibited suspension - induced terminal differentiation .'
p21489
(lp21490
I4
aI5
aI6
a(lp21491
I11
atp21492
a(I-1
S'MyoD prevents cyclinA / cdk2 containing E2F complexes formation in terminally differentiated myocytes .'
p21493
(lp21494
I0
a(lp21495
I2
atp21496
a(I-1
S'MyoD prevents cyclinA / cdk2 containing E2F complexes formation in terminally differentiated myocytes .'
p21497
(lp21498
I0
a(lp21499
I4
atp21500
a(I-1
S'MyoD prevents cyclinA / cdk2 containing E2F complexes formation in terminally differentiated myocytes .'
p21501
(lp21502
I0
a(lp21503
I6
atp21504
a(I1
S'MyoD prevents cyclinA / cdk2 containing E2F complexes formation in terminally differentiated myocytes .'
p21505
(lp21506
I2
a(lp21507
I4
atp21508
a(I-1
S'MyoD prevents cyclinA / cdk2 containing E2F complexes formation in terminally differentiated myocytes .'
p21509
(lp21510
I2
a(lp21511
I6
atp21512
a(I-1
S'MyoD prevents cyclinA / cdk2 containing E2F complexes formation in terminally differentiated myocytes .'
p21513
(lp21514
I4
a(lp21515
I6
atp21516
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21517
(lp21518
I12
aI13
aI14
aI15
aI16
aI17
aI18
a(lp21519
I20
atp21520
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21521
(lp21522
I12
aI13
aI14
aI15
aI16
aI17
aI18
a(lp21523
I23
atp21524
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21525
(lp21526
I12
aI13
aI14
aI15
aI16
aI17
aI18
a(lp21527
I28
atp21528
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21529
(lp21530
I12
aI13
aI14
aI15
aI16
aI17
aI18
a(lp21531
I30
atp21532
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21533
(lp21534
I12
aI13
aI14
aI15
aI16
aI17
aI18
a(lp21535
I32
atp21536
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21537
(lp21538
I12
aI13
aI14
aI15
aI16
aI17
aI18
a(lp21539
I34
atp21540
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21541
(lp21542
I20
a(lp21543
I23
atp21544
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21545
(lp21546
I20
a(lp21547
I28
atp21548
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21549
(lp21550
I20
a(lp21551
I30
atp21552
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21553
(lp21554
I20
a(lp21555
I32
atp21556
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21557
(lp21558
I20
a(lp21559
I34
atp21560
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21561
(lp21562
I23
a(lp21563
I28
atp21564
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21565
(lp21566
I23
a(lp21567
I30
atp21568
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21569
(lp21570
I23
a(lp21571
I32
atp21572
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21573
(lp21574
I23
a(lp21575
I34
atp21576
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21577
(lp21578
I28
a(lp21579
I30
atp21580
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21581
(lp21582
I28
a(lp21583
I32
atp21584
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21585
(lp21586
I28
a(lp21587
I34
atp21588
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21589
(lp21590
I30
a(lp21591
I32
atp21592
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21593
(lp21594
I30
a(lp21595
I34
atp21596
a(I-1
S'Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix - loop - helix ( bHLH ) protein MyoD and the pocket proteins pRb , p107 and pRb2 / p130 .'
p21597
(lp21598
I32
a(lp21599
I34
atp21600
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21601
(lp21602
I1
a(lp21603
I5
atp21604
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21605
(lp21606
I1
a(lp21607
I7
atp21608
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21609
(lp21610
I1
a(lp21611
I9
atp21612
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21613
(lp21614
I1
a(lp21615
I11
atp21616
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21617
(lp21618
I1
a(lp21619
I26
atp21620
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21621
(lp21622
I1
a(lp21623
I28
atp21624
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21625
(lp21626
I1
a(lp21627
I30
atp21628
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21629
(lp21630
I1
a(lp21631
I36
atp21632
a(I1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21633
(lp21634
I5
a(lp21635
I7
atp21636
a(I1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21637
(lp21638
I5
a(lp21639
I9
atp21640
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21641
(lp21642
I5
a(lp21643
I11
atp21644
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21645
(lp21646
I5
a(lp21647
I26
atp21648
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21649
(lp21650
I5
a(lp21651
I28
atp21652
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21653
(lp21654
I5
a(lp21655
I30
atp21656
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21657
(lp21658
I5
a(lp21659
I36
atp21660
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21661
(lp21662
I7
a(lp21663
I9
atp21664
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21665
(lp21666
I7
a(lp21667
I11
atp21668
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21669
(lp21670
I7
a(lp21671
I26
atp21672
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21673
(lp21674
I7
a(lp21675
I28
atp21676
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21677
(lp21678
I7
a(lp21679
I30
atp21680
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21681
(lp21682
I7
a(lp21683
I36
atp21684
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21685
(lp21686
I9
a(lp21687
I11
atp21688
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21689
(lp21690
I9
a(lp21691
I26
atp21692
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21693
(lp21694
I9
a(lp21695
I28
atp21696
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21697
(lp21698
I9
a(lp21699
I30
atp21700
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21701
(lp21702
I9
a(lp21703
I36
atp21704
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21705
(lp21706
I11
a(lp21707
I26
atp21708
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21709
(lp21710
I11
a(lp21711
I28
atp21712
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21713
(lp21714
I11
a(lp21715
I30
atp21716
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21717
(lp21718
I11
a(lp21719
I36
atp21720
a(I1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21721
(lp21722
I26
a(lp21723
I28
atp21724
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21725
(lp21726
I26
a(lp21727
I30
atp21728
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21729
(lp21730
I26
a(lp21731
I36
atp21732
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21733
(lp21734
I28
a(lp21735
I30
atp21736
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21737
(lp21738
I28
a(lp21739
I36
atp21740
a(I-1
S'An E2F complex containing mainly E2F4 and pRb2 / p130 ( E2F - G0 / G1 complex ) appears when DNA synthesis arrests , replacing the cyclinA / cdk2 containing E2F complex of proliferating myoblasts ( E2F - G1 / S complex ) .'
p21741
(lp21742
I30
a(lp21743
I36
atp21744
a(I-1
S'In differentiating C2C12 cells , E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced .'
p21745
(lp21746
I5
a(lp21747
I18
atp21748
a(I-1
S'In differentiating C2C12 cells , E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced .'
p21749
(lp21750
I5
a(lp21751
I26
atp21752
a(I-1
S'In differentiating C2C12 cells , E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced .'
p21753
(lp21754
I5
a(lp21755
I29
atp21756
a(I-1
S'In differentiating C2C12 cells , E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced .'
p21757
(lp21758
I18
a(lp21759
I26
atp21760
a(I-1
S'In differentiating C2C12 cells , E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced .'
p21761
(lp21762
I18
a(lp21763
I29
atp21764
a(I-1
S'In differentiating C2C12 cells , E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced .'
p21765
(lp21766
I26
a(lp21767
I29
atp21768
a(I1
S'Thus , during myogenic differentiation , formation of E2F4 and pRb2 / p130 containing complexes is an early event , but not enough on its own to prevent the reactivation of DNA synthesis .'
p21769
(lp21770
I8
a(lp21771
I10
atp21772
a(I1
S'Thus , during myogenic differentiation , formation of E2F4 and pRb2 / p130 containing complexes is an early event , but not enough on its own to prevent the reactivation of DNA synthesis .'
p21773
(lp21774
I8
a(lp21775
I12
atp21776
a(I-1
S'Thus , during myogenic differentiation , formation of E2F4 and pRb2 / p130 containing complexes is an early event , but not enough on its own to prevent the reactivation of DNA synthesis .'
p21777
(lp21778
I10
a(lp21779
I12
atp21780
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21781
(lp21782
I11
aI12
a(lp21783
I14
atp21784
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21785
(lp21786
I11
aI12
a(lp21787
I16
atp21788
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21789
(lp21790
I11
aI12
a(lp21791
I18
atp21792
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21793
(lp21794
I11
aI12
a(lp21795
I27
atp21796
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21797
(lp21798
I11
aI12
a(lp21799
I33
atp21800
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21801
(lp21802
I11
aI12
a(lp21803
I35
atp21804
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21805
(lp21806
I11
aI12
a(lp21807
I38
atp21808
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21809
(lp21810
I11
aI12
a(lp21811
I50
atp21812
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21813
(lp21814
I14
a(lp21815
I16
atp21816
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21817
(lp21818
I14
a(lp21819
I18
atp21820
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21821
(lp21822
I14
a(lp21823
I27
atp21824
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21825
(lp21826
I14
a(lp21827
I33
atp21828
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21829
(lp21830
I14
a(lp21831
I35
atp21832
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21833
(lp21834
I14
a(lp21835
I38
atp21836
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21837
(lp21838
I14
a(lp21839
I50
atp21840
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21841
(lp21842
I16
a(lp21843
I18
atp21844
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21845
(lp21846
I16
a(lp21847
I27
atp21848
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21849
(lp21850
I16
a(lp21851
I33
atp21852
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21853
(lp21854
I16
a(lp21855
I35
atp21856
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21857
(lp21858
I16
a(lp21859
I38
atp21860
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21861
(lp21862
I16
a(lp21863
I50
atp21864
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21865
(lp21866
I18
a(lp21867
I27
atp21868
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21869
(lp21870
I18
a(lp21871
I33
atp21872
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21873
(lp21874
I18
a(lp21875
I35
atp21876
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21877
(lp21878
I18
a(lp21879
I38
atp21880
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21881
(lp21882
I18
a(lp21883
I50
atp21884
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21885
(lp21886
I27
a(lp21887
I33
atp21888
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21889
(lp21890
I27
a(lp21891
I35
atp21892
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21893
(lp21894
I27
a(lp21895
I38
atp21896
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21897
(lp21898
I27
a(lp21899
I50
atp21900
a(I1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21901
(lp21902
I33
a(lp21903
I35
atp21904
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21905
(lp21906
I33
a(lp21907
I38
atp21908
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21909
(lp21910
I33
a(lp21911
I50
atp21912
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21913
(lp21914
I35
a(lp21915
I38
atp21916
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21917
(lp21918
I35
a(lp21919
I50
atp21920
a(I-1
S'Using a subclone of C3H10T1 / 2 mouse fibroblasts stably expressing Estrogen Receptor - MyoD ( ER - MyoD ) chimerae , we found that estrogen directed MyoD activation prevents the reassociation of cyclinA / cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re - enter the cell cycle .'
p21921
(lp21922
I38
a(lp21923
I50
atp21924
a(I-1
S'Our data indicate that , in differentiating myocytes , one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation - associated cdks - containing E2F complexes formation .'
p21925
(lp21926
I13
a(lp21927
I20
atp21928
a(I-1
S'Our data indicate that , in differentiating myocytes , one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation - associated cdks - containing E2F complexes formation .'
p21929
(lp21930
I13
a(lp21931
I32
atp21932
a(I-1
S'Our data indicate that , in differentiating myocytes , one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation - associated cdks - containing E2F complexes formation .'
p21933
(lp21934
I20
a(lp21935
I32
atp21936
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21937
(lp21938
I30
a(lp21939
I32
atp21940
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21941
(lp21942
I30
a(lp21943
I34
atp21944
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21945
(lp21946
I30
a(lp21947
I36
atp21948
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21949
(lp21950
I30
a(lp21951
I38
atp21952
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21953
(lp21954
I30
a(lp21955
I40
atp21956
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21957
(lp21958
I30
a(lp21959
I50
atp21960
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21961
(lp21962
I30
a(lp21963
I52
atp21964
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21965
(lp21966
I32
a(lp21967
I34
atp21968
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21969
(lp21970
I32
a(lp21971
I36
atp21972
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21973
(lp21974
I32
a(lp21975
I38
atp21976
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21977
(lp21978
I32
a(lp21979
I40
atp21980
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21981
(lp21982
I32
a(lp21983
I50
atp21984
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21985
(lp21986
I32
a(lp21987
I52
atp21988
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21989
(lp21990
I34
a(lp21991
I36
atp21992
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21993
(lp21994
I34
a(lp21995
I38
atp21996
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p21997
(lp21998
I34
a(lp21999
I40
atp22000
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22001
(lp22002
I34
a(lp22003
I50
atp22004
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22005
(lp22006
I34
a(lp22007
I52
atp22008
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22009
(lp22010
I36
a(lp22011
I38
atp22012
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22013
(lp22014
I36
a(lp22015
I40
atp22016
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22017
(lp22018
I36
a(lp22019
I50
atp22020
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22021
(lp22022
I36
a(lp22023
I52
atp22024
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22025
(lp22026
I38
a(lp22027
I40
atp22028
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22029
(lp22030
I38
a(lp22031
I50
atp22032
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22033
(lp22034
I38
a(lp22035
I52
atp22036
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22037
(lp22038
I40
a(lp22039
I50
atp22040
a(I1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22041
(lp22042
I40
a(lp22043
I52
atp22044
a(I-1
S'The cloning of members of these gene families and the identification of the protein - interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD / MORT , RIP , FLICE / MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .'
p22045
(lp22046
I50
a(lp22047
I52
atp22048
a(I1
S'Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl - terminal domain .'
p22049
(lp22050
I1
a(lp22051
I7
atp22052
a(I-1
S'Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl - terminal domain .'
p22053
(lp22054
I1
a(lp22055
I7
aI8
aI9
atp22056
a(I-1
S'Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl - terminal domain .'
p22057
(lp22058
I7
a(lp22059
I7
aI8
aI9
atp22060
a(I1
S'We now show that full - length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding .'
p22061
(lp22062
I7
a(lp22063
I11
atp22064
a(I-1
S'We now show that full - length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding .'
p22065
(lp22066
I7
a(lp22067
I26
atp22068
a(I-1
S'We now show that full - length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding .'
p22069
(lp22070
I11
a(lp22071
I26
atp22072
a(I1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22073
(lp22074
I0
a(lp22075
I9
atp22076
a(I-1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22077
(lp22078
I0
a(lp22079
I13
atp22080
a(I-1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22081
(lp22082
I0
a(lp22083
I33
atp22084
a(I-1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22085
(lp22086
I0
a(lp22087
I37
atp22088
a(I-1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22089
(lp22090
I9
a(lp22091
I13
atp22092
a(I-1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22093
(lp22094
I9
a(lp22095
I33
atp22096
a(I-1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22097
(lp22098
I9
a(lp22099
I37
atp22100
a(I-1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22101
(lp22102
I13
a(lp22103
I33
atp22104
a(I-1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22105
(lp22106
I13
a(lp22107
I37
atp22108
a(I1
S'RIN1 interacts with the " effector domain " of RAS and employs some RAS determinants that are common to , and others that are distinct from , those required for the binding of RAF1 , a known RAS effector .'
p22109
(lp22110
I33
a(lp22111
I37
atp22112
a(I1
S'The same domain of RIN1 that binds RAS also interacts with 14 - 3 - 3 proteins , extending the similarity between RIN1 and other RAS effectors .'
p22113
(lp22114
I4
a(lp22115
I7
atp22116
a(I-1
S'The same domain of RIN1 that binds RAS also interacts with 14 - 3 - 3 proteins , extending the similarity between RIN1 and other RAS effectors .'
p22117
(lp22118
I4
a(lp22119
I22
atp22120
a(I-1
S'The same domain of RIN1 that binds RAS also interacts with 14 - 3 - 3 proteins , extending the similarity between RIN1 and other RAS effectors .'
p22121
(lp22122
I4
a(lp22123
I25
atp22124
a(I-1
S'The same domain of RIN1 that binds RAS also interacts with 14 - 3 - 3 proteins , extending the similarity between RIN1 and other RAS effectors .'
p22125
(lp22126
I7
a(lp22127
I22
atp22128
a(I-1
S'The same domain of RIN1 that binds RAS also interacts with 14 - 3 - 3 proteins , extending the similarity between RIN1 and other RAS effectors .'
p22129
(lp22130
I7
a(lp22131
I25
atp22132
a(I-1
S'The same domain of RIN1 that binds RAS also interacts with 14 - 3 - 3 proteins , extending the similarity between RIN1 and other RAS effectors .'
p22133
(lp22134
I22
a(lp22135
I25
atp22136
a(I1
S'When expressed in mammalian cells , the RAS binding domain of RIN1 can act as a dominant negative signal transduction blocker .'
p22137
(lp22138
I7
a(lp22139
I11
atp22140
a(I1
S'This RIN1 sequence shows preferential binding to the ABL - SH3 domain in vitro .'
p22141
(lp22142
I1
a(lp22143
I8
aI9
aI10
atp22144
a(I1
S'Moreover , the amino - terminal domain of RIN1 directly associates with , and is tyrosine phosphorylated by , c - ABL .'
p22145
(lp22146
I8
a(lp22147
I19
aI20
aI21
atp22148
a(I1
S'Cross - family interaction between the bHLHZip USF and bZip Fra1 proteins results in down - regulation of AP1 activity .'
p22149
(lp22150
I7
a(lp22151
I10
atp22152
a(I-1
S'Cross - family interaction between the bHLHZip USF and bZip Fra1 proteins results in down - regulation of AP1 activity .'
p22153
(lp22154
I7
a(lp22155
I18
atp22156
a(I-1
S'Cross - family interaction between the bHLHZip USF and bZip Fra1 proteins results in down - regulation of AP1 activity .'
p22157
(lp22158
I10
a(lp22159
I18
atp22160
a(I-1
S'To further examine the function of the bHLHZip protein , USF , we screened for cellular proteins which could directly interact with USF using the yeast two - hybrid system .'
p22161
(lp22162
I10
a(lp22163
I22
atp22164
a(I1
S'A bZip protein , Fra1 , was found to efficiently interact with USF .'
p22165
(lp22166
I4
a(lp22167
I12
atp22168
a(I1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22169
(lp22170
I0
a(lp22171
I4
atp22172
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22173
(lp22174
I0
a(lp22175
I14
aI15
aI16
atp22176
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22177
(lp22178
I0
a(lp22179
I18
atp22180
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22181
(lp22182
I0
a(lp22183
I20
atp22184
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22185
(lp22186
I0
a(lp22187
I24
aI25
aI26
atp22188
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22189
(lp22190
I4
a(lp22191
I14
aI15
aI16
atp22192
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22193
(lp22194
I4
a(lp22195
I18
atp22196
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22197
(lp22198
I4
a(lp22199
I20
atp22200
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22201
(lp22202
I4
a(lp22203
I24
aI25
aI26
atp22204
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22205
(lp22206
I14
aI15
aI16
a(lp22207
I18
atp22208
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22209
(lp22210
I14
aI15
aI16
a(lp22211
I20
atp22212
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22213
(lp22214
I14
aI15
aI16
a(lp22215
I24
aI25
aI26
atp22216
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22217
(lp22218
I18
a(lp22219
I20
atp22220
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22221
(lp22222
I18
a(lp22223
I24
aI25
aI26
atp22224
a(I-1
S'USF specifically interacts with Fra1 but not with other closely related family members , c - Fos , Fra2 , FosB , or with c - Jun .'
p22225
(lp22226
I20
a(lp22227
I24
aI25
aI26
atp22228
a(I1
S'Both the bHLHZip and the N - terminal regions of Fra1 are required for efficient interaction with USF .'
p22229
(lp22230
I10
a(lp22231
I17
atp22232
a(I1
S'In vivo association between USF and Fra1 has been demonstrated by co - immunoprecipitation .'
p22233
(lp22234
I4
a(lp22235
I6
atp22236
a(I-1
S'Expression of exogenous USF led to a decrease in AP1 - dependent transcription in F9 cells .'
p22237
(lp22238
I3
a(lp22239
I9
atp22240
a(I-1
S'Co - expression of exogenous Fra1 restored the AP1 activity in a dose - dependent manner .'
p22241
(lp22242
I5
a(lp22243
I8
atp22244
a(I1
S'These data show that USF and Fra1 physically and functionally interact demonstrating that cross - talk occurs between factors of distantly related transcription families .'
p22245
(lp22246
I4
a(lp22247
I6
atp22248
a(I-1
S'Through their interaction with the ErbB family of receptors ( ErbB2 , ErbB3 and ErbB4 ) , neuregulins help to regulate cell growth and differentiation in many tissues .'
p22249
(lp22250
I10
a(lp22251
I12
atp22252
a(I-1
S'Through their interaction with the ErbB family of receptors ( ErbB2 , ErbB3 and ErbB4 ) , neuregulins help to regulate cell growth and differentiation in many tissues .'
p22253
(lp22254
I10
a(lp22255
I14
atp22256
a(I-1
S'Through their interaction with the ErbB family of receptors ( ErbB2 , ErbB3 and ErbB4 ) , neuregulins help to regulate cell growth and differentiation in many tissues .'
p22257
(lp22258
I12
a(lp22259
I14
atp22260
a(I-1
S'The encoded product of the neuregulin - 2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor ( EGF ) - like domain gives rise to two isoforms ( alpha and beta ) .'
p22261
(lp22262
I5
aI6
aI7
a(lp22263
I25
aI26
aI27
atp22264
a(I-1
S'The encoded product of the neuregulin - 2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor ( EGF ) - like domain gives rise to two isoforms ( alpha and beta ) .'
p22265
(lp22266
I5
aI6
aI7
a(lp22267
I29
atp22268
a(I-1
S'The encoded product of the neuregulin - 2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor ( EGF ) - like domain gives rise to two isoforms ( alpha and beta ) .'
p22269
(lp22270
I25
aI26
aI27
a(lp22271
I29
atp22272
a(I1
S'Recombinant neuregulin - 2beta induces the tyrosine - phosphorylation of ErbB2 , ErbB3 and ErbB4 in cell lines expressing all of these ErbB - family receptors .'
p22273
(lp22274
I1
aI2
aI3
a(lp22275
I10
atp22276
a(I1
S'Recombinant neuregulin - 2beta induces the tyrosine - phosphorylation of ErbB2 , ErbB3 and ErbB4 in cell lines expressing all of these ErbB - family receptors .'
p22277
(lp22278
I1
aI2
aI3
a(lp22279
I12
atp22280
a(I1
S'Recombinant neuregulin - 2beta induces the tyrosine - phosphorylation of ErbB2 , ErbB3 and ErbB4 in cell lines expressing all of these ErbB - family receptors .'
p22281
(lp22282
I1
aI2
aI3
a(lp22283
I14
atp22284
a(I-1
S'Recombinant neuregulin - 2beta induces the tyrosine - phosphorylation of ErbB2 , ErbB3 and ErbB4 in cell lines expressing all of these ErbB - family receptors .'
p22285
(lp22286
I10
a(lp22287
I12
atp22288
a(I-1
S'Recombinant neuregulin - 2beta induces the tyrosine - phosphorylation of ErbB2 , ErbB3 and ErbB4 in cell lines expressing all of these ErbB - family receptors .'
p22289
(lp22290
I10
a(lp22291
I14
atp22292
a(I-1
S'Recombinant neuregulin - 2beta induces the tyrosine - phosphorylation of ErbB2 , ErbB3 and ErbB4 in cell lines expressing all of these ErbB - family receptors .'
p22293
(lp22294
I12
a(lp22295
I14
atp22296
a(I1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22297
(lp22298
I11
aI12
aI13
a(lp22299
I18
atp22300
a(I1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22301
(lp22302
I11
aI12
aI13
a(lp22303
I22
atp22304
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22305
(lp22306
I11
aI12
aI13
a(lp22307
I28
aI29
aI30
atp22308
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22309
(lp22310
I11
aI12
aI13
a(lp22311
I34
atp22312
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22313
(lp22314
I11
aI12
aI13
a(lp22315
I38
atp22316
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22317
(lp22318
I18
a(lp22319
I22
atp22320
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22321
(lp22322
I18
a(lp22323
I28
aI29
aI30
atp22324
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22325
(lp22326
I18
a(lp22327
I34
atp22328
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22329
(lp22330
I18
a(lp22331
I38
atp22332
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22333
(lp22334
I22
a(lp22335
I28
aI29
aI30
atp22336
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22337
(lp22338
I22
a(lp22339
I34
atp22340
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22341
(lp22342
I22
a(lp22343
I38
atp22344
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22345
(lp22346
I28
aI29
aI30
a(lp22347
I34
atp22348
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22349
(lp22350
I28
aI29
aI30
a(lp22351
I38
atp22352
a(I-1
S'However , in cell lines with defined combinations of ErbBs , neuregulin - 2beta only activates those with ErbB3 and / or ErbB4 , suggesting that signalling by neuregulin - 2 is mediated by ErbB3 and / or ErbB4 receptors .'
p22353
(lp22354
I34
a(lp22355
I38
atp22356
a(I1
S'Interaction between ATM protein and c - Abl in response to DNA damage .'
p22357
(lp22358
I2
a(lp22359
I5
aI6
aI7
atp22360
a(I-1
S"The gene mutated in the autosomal recessive disorder ataxia telangiectasia ( AT ) , designated ATM ( for ' AT mutated ' ) , is a member of a family of phosphatidylinositol - 3 - kinase - like enzymes that are involved in cell - cycle control , meiotic recombination , telomere length monitoring and DNA - damage response ."
p22361
(lp22362
I15
a(lp22363
I19
aI20
atp22364
a(I-1
S'Because cells lacking the protein tyrosine kinase c - Abl are also defective in radiation - induced G1 arrest , we investigated the possibility that ATM might interact with c - Abl in response to radiation damage .'
p22365
(lp22366
I7
aI8
aI9
a(lp22367
I25
atp22368
a(I-1
S'Because cells lacking the protein tyrosine kinase c - Abl are also defective in radiation - induced G1 arrest , we investigated the possibility that ATM might interact with c - Abl in response to radiation damage .'
p22369
(lp22370
I7
aI8
aI9
a(lp22371
I29
aI30
aI31
atp22372
a(I1
S'Because cells lacking the protein tyrosine kinase c - Abl are also defective in radiation - induced G1 arrest , we investigated the possibility that ATM might interact with c - Abl in response to radiation damage .'
p22373
(lp22374
I25
a(lp22375
I29
aI30
aI31
atp22376
a(I1
S'Here we show that ATM binds c - Abl constitutively in control cells but not in AT cells .'
p22377
(lp22378
I4
a(lp22379
I6
aI7
aI8
atp22380
a(I1
S'Our results demonstrate that the SH3 domain of c - Abl interacts with a DPAPNPPHFP motif ( residues 1 , 373 - 1 , 382 ) of ATM .'
p22381
(lp22382
I8
aI9
aI10
a(lp22383
I27
atp22384
a(I1
S'These findings indicate that ATM is involved in the activation of c - Abl by DNA damage and this interaction may in part mediate radiation - induced G1 arrest .'
p22385
(lp22386
I4
a(lp22387
I11
aI12
aI13
atp22388
a(I-1
S'In addition , previous work indicated that p300 and CBP might be involved in YY1 - mediated repression .'
p22389
(lp22390
I7
a(lp22391
I9
atp22392
a(I-1
S'In addition , previous work indicated that p300 and CBP might be involved in YY1 - mediated repression .'
p22393
(lp22394
I7
a(lp22395
I14
atp22396
a(I-1
S'In addition , previous work indicated that p300 and CBP might be involved in YY1 - mediated repression .'
p22397
(lp22398
I9
a(lp22399
I14
atp22400
a(I1
S'We show that the physical interaction between YY1 and p300 , a coactivator for CREB , is not sufficient for repression of CREB - mediated transcription .'
p22401
(lp22402
I7
a(lp22403
I9
atp22404
a(I-1
S'We show that the physical interaction between YY1 and p300 , a coactivator for CREB , is not sufficient for repression of CREB - mediated transcription .'
p22405
(lp22406
I7
a(lp22407
I14
atp22408
a(I-1
S'We show that the physical interaction between YY1 and p300 , a coactivator for CREB , is not sufficient for repression of CREB - mediated transcription .'
p22409
(lp22410
I7
a(lp22411
I22
atp22412
a(I1
S'We show that the physical interaction between YY1 and p300 , a coactivator for CREB , is not sufficient for repression of CREB - mediated transcription .'
p22413
(lp22414
I9
a(lp22415
I14
atp22416
a(I-1
S'We show that the physical interaction between YY1 and p300 , a coactivator for CREB , is not sufficient for repression of CREB - mediated transcription .'
p22417
(lp22418
I9
a(lp22419
I22
atp22420
a(I-1
S'We show that the physical interaction between YY1 and p300 , a coactivator for CREB , is not sufficient for repression of CREB - mediated transcription .'
p22421
(lp22422
I14
a(lp22423
I22
atp22424
a(I-1
S'Repression of CTF - 1 - directed transcription may be accomplished through direct physical interaction between YY1 and this activator .'
p22425
(lp22426
I2
aI3
aI4
a(lp22427
I16
atp22428
a(I-1
S'In contrast , physical interaction is not necessary for YY1 to repress Sp1 - and CREB - mediated transcription .'
p22429
(lp22430
I9
a(lp22431
I12
atp22432
a(I-1
S'In contrast , physical interaction is not necessary for YY1 to repress Sp1 - and CREB - mediated transcription .'
p22433
(lp22434
I9
a(lp22435
I15
atp22436
a(I-1
S'In contrast , physical interaction is not necessary for YY1 to repress Sp1 - and CREB - mediated transcription .'
p22437
(lp22438
I12
a(lp22439
I15
atp22440
a(I1
S'Proto - oncoprotein Vav interacts with c - Cbl in activated thymocytes and peripheral T cells .'
p22441
(lp22442
I3
a(lp22443
I6
aI7
aI8
atp22444
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22445
(lp22446
I3
aI4
aI5
a(lp22447
I14
atp22448
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22449
(lp22450
I3
aI4
aI5
a(lp22451
I18
atp22452
a(I1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22453
(lp22454
I3
aI4
aI5
a(lp22455
I34
atp22456
a(I1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22457
(lp22458
I3
aI4
aI5
a(lp22459
I36
atp22460
a(I1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22461
(lp22462
I3
aI4
aI5
a(lp22463
I39
aI40
aI41
atp22464
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22465
(lp22466
I14
a(lp22467
I18
atp22468
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22469
(lp22470
I14
a(lp22471
I34
atp22472
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22473
(lp22474
I14
a(lp22475
I36
atp22476
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22477
(lp22478
I14
a(lp22479
I39
aI40
aI41
atp22480
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22481
(lp22482
I18
a(lp22483
I34
atp22484
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22485
(lp22486
I18
a(lp22487
I36
atp22488
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22489
(lp22490
I18
a(lp22491
I39
aI40
aI41
atp22492
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22493
(lp22494
I34
a(lp22495
I36
atp22496
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22497
(lp22498
I34
a(lp22499
I39
aI40
aI41
atp22500
a(I-1
S'The molecular adapter c - Cbl is rapidly tyrosine phosphorylated following stimulation through the TCR and associates with Src homology domain - 2 ( SH2 ) / SH3 domain - containing adapters such as Grb2 , Crk , and Crk - L , which interact with guanine nucleotide exchange factors specific for the Ras family .'
p22501
(lp22502
I36
a(lp22503
I39
aI40
aI41
atp22504
a(I-1
S'This suggests that c - Cbl may link TCR activation to molecules that regulate GTP binding proteins .'
p22505
(lp22506
I3
aI4
aI5
a(lp22507
I8
atp22508
a(I-1
S'The SH2 / SH3 - containing protein Vav also contains a guanine nucleotide exchange factor domain , and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR .'
p22509
(lp22510
I7
a(lp22511
I18
atp22512
a(I-1
S'The SH2 / SH3 - containing protein Vav also contains a guanine nucleotide exchange factor domain , and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR .'
p22513
(lp22514
I7
a(lp22515
I36
atp22516
a(I-1
S'The SH2 / SH3 - containing protein Vav also contains a guanine nucleotide exchange factor domain , and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR .'
p22517
(lp22518
I18
a(lp22519
I36
atp22520
a(I1
S'Here we show that Vav and c - Cbl form inducible molecular complexes in TCR - activated murine thymocytes and peripheral T cells as well as pervanadate - treated T cells .'
p22521
(lp22522
I4
a(lp22523
I6
aI7
aI8
atp22524
a(I-1
S'Here we show that Vav and c - Cbl form inducible molecular complexes in TCR - activated murine thymocytes and peripheral T cells as well as pervanadate - treated T cells .'
p22525
(lp22526
I4
a(lp22527
I14
atp22528
a(I-1
S'Here we show that Vav and c - Cbl form inducible molecular complexes in TCR - activated murine thymocytes and peripheral T cells as well as pervanadate - treated T cells .'
p22529
(lp22530
I6
aI7
aI8
a(lp22531
I14
atp22532
a(I1
S'Vav / c - Cbl interactions are also detectable in freshly isolated T cells from gene - targeted mice that lack the T cell - specific inhibitory receptor CTLA - 4 , in which c - Cbl is hyperphosphorylated on tyrosine residues .'
p22533
(lp22534
I0
a(lp22535
I2
aI3
aI4
atp22536
a(I-1
S'Vav / c - Cbl interactions are also detectable in freshly isolated T cells from gene - targeted mice that lack the T cell - specific inhibitory receptor CTLA - 4 , in which c - Cbl is hyperphosphorylated on tyrosine residues .'
p22537
(lp22538
I0
a(lp22539
I28
aI29
aI30
atp22540
a(I-1
S'Vav / c - Cbl interactions are also detectable in freshly isolated T cells from gene - targeted mice that lack the T cell - specific inhibitory receptor CTLA - 4 , in which c - Cbl is hyperphosphorylated on tyrosine residues .'
p22541
(lp22542
I0
a(lp22543
I34
aI35
aI36
atp22544
a(I-1
S'Vav / c - Cbl interactions are also detectable in freshly isolated T cells from gene - targeted mice that lack the T cell - specific inhibitory receptor CTLA - 4 , in which c - Cbl is hyperphosphorylated on tyrosine residues .'
p22545
(lp22546
I2
aI3
aI4
a(lp22547
I28
aI29
aI30
atp22548
a(I-1
S'Vav / c - Cbl interactions are also detectable in freshly isolated T cells from gene - targeted mice that lack the T cell - specific inhibitory receptor CTLA - 4 , in which c - Cbl is hyperphosphorylated on tyrosine residues .'
p22549
(lp22550
I2
aI3
aI4
a(lp22551
I34
aI35
aI36
atp22552
a(I-1
S'Vav / c - Cbl interactions are also detectable in freshly isolated T cells from gene - targeted mice that lack the T cell - specific inhibitory receptor CTLA - 4 , in which c - Cbl is hyperphosphorylated on tyrosine residues .'
p22553
(lp22554
I28
aI29
aI30
a(lp22555
I34
aI35
aI36
atp22556
a(I1
S'The interaction between Vav and c - Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c - Cbl .'
p22557
(lp22558
I3
a(lp22559
I5
aI6
aI7
atp22560
a(I-1
S'The interaction between Vav and c - Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c - Cbl .'
p22561
(lp22562
I3
a(lp22563
I16
atp22564
a(I-1
S'The interaction between Vav and c - Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c - Cbl .'
p22565
(lp22566
I3
a(lp22567
I24
aI25
aI26
atp22568
a(I-1
S'The interaction between Vav and c - Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c - Cbl .'
p22569
(lp22570
I5
aI6
aI7
a(lp22571
I16
atp22572
a(I-1
S'The interaction between Vav and c - Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c - Cbl .'
p22573
(lp22574
I5
aI6
aI7
a(lp22575
I24
aI25
aI26
atp22576
a(I-1
S'The interaction between Vav and c - Cbl is directly mediated via the SH2 domain of Vav and is dependent on tyrosine phosphorylation of c - Cbl .'
p22577
(lp22578
I16
a(lp22579
I24
aI25
aI26
atp22580
a(I1
S'In addition , we show that the conserved motif Y699 MTP present in c - Cbl is the binding site for the Vav SH2 domain in vitro .'
p22581
(lp22582
I13
aI14
aI15
a(lp22583
I22
atp22584
a(I-1
S'These data imply that c - Cbl is a molecular adapter that regulates the function of Vav in thymocytes and peripheral T cells .'
p22585
(lp22586
I4
aI5
aI6
a(lp22587
I16
atp22588
a(I1
S'Induction of cell migration by matrix metalloprotease - 2 cleavage of laminin - 5 .'
p22589
(lp22590
I5
aI6
aI7
aI8
a(lp22591
I11
aI12
aI13
atp22592
a(I-1
S'Specific cleavage of laminin - 5 ( Ln - 5 ) by matrix metalloprotease - 2 ( MMP2 ) was shown to induce migration of breast epithelial cells .'
p22593
(lp22594
I3
aI4
aI5
a(lp22595
I7
aI8
aI9
atp22596
a(I1
S'Specific cleavage of laminin - 5 ( Ln - 5 ) by matrix metalloprotease - 2 ( MMP2 ) was shown to induce migration of breast epithelial cells .'
p22597
(lp22598
I3
aI4
aI5
a(lp22599
I12
aI13
aI14
aI15
atp22600
a(I1
S'Specific cleavage of laminin - 5 ( Ln - 5 ) by matrix metalloprotease - 2 ( MMP2 ) was shown to induce migration of breast epithelial cells .'
p22601
(lp22602
I3
aI4
aI5
a(lp22603
I17
atp22604
a(I1
S'Specific cleavage of laminin - 5 ( Ln - 5 ) by matrix metalloprotease - 2 ( MMP2 ) was shown to induce migration of breast epithelial cells .'
p22605
(lp22606
I7
aI8
aI9
a(lp22607
I12
aI13
aI14
aI15
atp22608
a(I1
S'Specific cleavage of laminin - 5 ( Ln - 5 ) by matrix metalloprotease - 2 ( MMP2 ) was shown to induce migration of breast epithelial cells .'
p22609
(lp22610
I7
aI8
aI9
a(lp22611
I17
atp22612
a(I-1
S'Specific cleavage of laminin - 5 ( Ln - 5 ) by matrix metalloprotease - 2 ( MMP2 ) was shown to induce migration of breast epithelial cells .'
p22613
(lp22614
I12
aI13
aI14
aI15
a(lp22615
I17
atp22616
a(I1
S'MMP2 cleaved the Ln - 5 gamma2 subunit at residue 587 , exposing a putative cryptic promigratory site on Ln - 5 that triggers cell motility .'
p22617
(lp22618
I0
a(lp22619
I3
aI4
aI5
atp22620
a(I-1
S'MMP2 cleaved the Ln - 5 gamma2 subunit at residue 587 , exposing a putative cryptic promigratory site on Ln - 5 that triggers cell motility .'
p22621
(lp22622
I0
a(lp22623
I3
aI4
aI5
aI6
atp22624
a(I-1
S'MMP2 cleaved the Ln - 5 gamma2 subunit at residue 587 , exposing a putative cryptic promigratory site on Ln - 5 that triggers cell motility .'
p22625
(lp22626
I0
a(lp22627
I19
aI20
aI21
atp22628
a(I-1
S'MMP2 cleaved the Ln - 5 gamma2 subunit at residue 587 , exposing a putative cryptic promigratory site on Ln - 5 that triggers cell motility .'
p22629
(lp22630
I3
aI4
aI5
a(lp22631
I3
aI4
aI5
aI6
atp22632
a(I-1
S'MMP2 cleaved the Ln - 5 gamma2 subunit at residue 587 , exposing a putative cryptic promigratory site on Ln - 5 that triggers cell motility .'
p22633
(lp22634
I3
aI4
aI5
a(lp22635
I19
aI20
aI21
atp22636
a(I-1
S'MMP2 cleaved the Ln - 5 gamma2 subunit at residue 587 , exposing a putative cryptic promigratory site on Ln - 5 that triggers cell motility .'
p22637
(lp22638
I3
aI4
aI5
aI6
a(lp22639
I19
aI20
aI21
atp22640
a(I1
S'Cleavage of Ln - 5 by MMP2 and the resulting activation of the Ln - 5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling .'
p22641
(lp22642
I2
aI3
aI4
a(lp22643
I6
atp22644
a(I-1
S'Cleavage of Ln - 5 by MMP2 and the resulting activation of the Ln - 5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling .'
p22645
(lp22646
I2
aI3
aI4
a(lp22647
I13
aI14
aI15
atp22648
a(I-1
S'Cleavage of Ln - 5 by MMP2 and the resulting activation of the Ln - 5 cryptic site may provide new targets for modulation of tumor cell invasion and tissue remodeling .'
p22649
(lp22650
I6
a(lp22651
I13
aI14
aI15
atp22652
a(I1
S'The Ras - RasGAP complex : structural basis for GTPase activation and its loss in oncogenic Ras mutants .'
p22653
(lp22654
I1
a(lp22655
I3
atp22656
a(I-1
S'The Ras - RasGAP complex : structural basis for GTPase activation and its loss in oncogenic Ras mutants .'
p22657
(lp22658
I1
a(lp22659
I16
atp22660
a(I-1
S'The Ras - RasGAP complex : structural basis for GTPase activation and its loss in oncogenic Ras mutants .'
p22661
(lp22662
I3
a(lp22663
I16
atp22664
a(I-1
S'The three - dimensional structure of the complex between human H - Ras bound to guanosine diphosphate and the guanosine triphosphatase ( GTPase ) - activating domain of the human GTPase - activating protein p120GAP ( GAP - 334 ) in the presence of aluminum fluoride was solved at a resolution of 2 . 5 angstroms .'
p22665
(lp22666
I10
aI11
aI12
a(lp22667
I30
aI31
aI32
aI33
atp22668
a(I1
S'The three - dimensional structure of the complex between human H - Ras bound to guanosine diphosphate and the guanosine triphosphatase ( GTPase ) - activating domain of the human GTPase - activating protein p120GAP ( GAP - 334 ) in the presence of aluminum fluoride was solved at a resolution of 2 . 5 angstroms .'
p22669
(lp22670
I10
aI11
aI12
a(lp22671
I34
atp22672
a(I1
S'The three - dimensional structure of the complex between human H - Ras bound to guanosine diphosphate and the guanosine triphosphatase ( GTPase ) - activating domain of the human GTPase - activating protein p120GAP ( GAP - 334 ) in the presence of aluminum fluoride was solved at a resolution of 2 . 5 angstroms .'
p22673
(lp22674
I10
aI11
aI12
a(lp22675
I36
aI37
aI38
atp22676
a(I-1
S'The three - dimensional structure of the complex between human H - Ras bound to guanosine diphosphate and the guanosine triphosphatase ( GTPase ) - activating domain of the human GTPase - activating protein p120GAP ( GAP - 334 ) in the presence of aluminum fluoride was solved at a resolution of 2 . 5 angstroms .'
p22677
(lp22678
I30
aI31
aI32
aI33
a(lp22679
I34
atp22680
a(I-1
S'The three - dimensional structure of the complex between human H - Ras bound to guanosine diphosphate and the guanosine triphosphatase ( GTPase ) - activating domain of the human GTPase - activating protein p120GAP ( GAP - 334 ) in the presence of aluminum fluoride was solved at a resolution of 2 . 5 angstroms .'
p22681
(lp22682
I30
aI31
aI32
aI33
a(lp22683
I36
aI37
aI38
atp22684
a(I-1
S'The three - dimensional structure of the complex between human H - Ras bound to guanosine diphosphate and the guanosine triphosphatase ( GTPase ) - activating domain of the human GTPase - activating protein p120GAP ( GAP - 334 ) in the presence of aluminum fluoride was solved at a resolution of 2 . 5 angstroms .'
p22685
(lp22686
I34
a(lp22687
I36
aI37
aI38
atp22688
a(I-1
S'An arginine side chain ( arginine - 789 ) of GAP - 334 is supplied into the active site of Ras to neutralize developing charges in the transition state .'
p22689
(lp22690
I10
aI11
aI12
a(lp22691
I20
atp22692
a(I1
S'The switch II region of Ras is stabilized by GAP - 334 , thus allowing glutamine - 61 of Ras , mutation of which activates the oncogenic potential , to participate in catalysis .'
p22693
(lp22694
I5
a(lp22695
I9
aI10
aI11
atp22696
a(I-1
S'The switch II region of Ras is stabilized by GAP - 334 , thus allowing glutamine - 61 of Ras , mutation of which activates the oncogenic potential , to participate in catalysis .'
p22697
(lp22698
I5
a(lp22699
I19
atp22700
a(I-1
S'The switch II region of Ras is stabilized by GAP - 334 , thus allowing glutamine - 61 of Ras , mutation of which activates the oncogenic potential , to participate in catalysis .'
p22701
(lp22702
I9
aI10
aI11
a(lp22703
I19
atp22704
a(I-1
S'Glycine - 12 in the transition state mimic is within van der Waals distance of both arginine - 789 of GAP - 334 and glutamine - 61 of Ras , and even its mutation to alanine would disturb the arrangements of residues in the transition state .'
p22705
(lp22706
I20
aI21
aI22
a(lp22707
I28
atp22708
a(I-1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22709
(lp22710
I2
a(lp22711
I4
aI5
aI6
atp22712
a(I-1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22713
(lp22714
I2
a(lp22715
I8
atp22716
a(I-1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22717
(lp22718
I2
a(lp22719
I11
atp22720
a(I1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22721
(lp22722
I2
a(lp22723
I11
aI12
atp22724
a(I-1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22725
(lp22726
I4
aI5
aI6
a(lp22727
I8
atp22728
a(I-1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22729
(lp22730
I4
aI5
aI6
a(lp22731
I11
atp22732
a(I1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22733
(lp22734
I4
aI5
aI6
a(lp22735
I11
aI12
atp22736
a(I-1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22737
(lp22738
I8
a(lp22739
I11
atp22740
a(I1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22741
(lp22742
I8
a(lp22743
I11
aI12
atp22744
a(I-1
S'Characterization of Fas ( Apo - 1 , CD95 ) - Fas ligand interaction .'
p22745
(lp22746
I11
a(lp22747
I11
aI12
atp22748
a(I-1
S'The death - inducing receptor Fas is activated when cross - linked by the type II membrane protein Fas ligand ( FasL ) .'
p22749
(lp22750
I5
a(lp22751
I18
atp22752
a(I1
S'The death - inducing receptor Fas is activated when cross - linked by the type II membrane protein Fas ligand ( FasL ) .'
p22753
(lp22754
I5
a(lp22755
I18
aI19
atp22756
a(I1
S'The death - inducing receptor Fas is activated when cross - linked by the type II membrane protein Fas ligand ( FasL ) .'
p22757
(lp22758
I5
a(lp22759
I21
atp22760
a(I-1
S'The death - inducing receptor Fas is activated when cross - linked by the type II membrane protein Fas ligand ( FasL ) .'
p22761
(lp22762
I18
a(lp22763
I18
aI19
atp22764
a(I1
S'The death - inducing receptor Fas is activated when cross - linked by the type II membrane protein Fas ligand ( FasL ) .'
p22765
(lp22766
I18
a(lp22767
I21
atp22768
a(I-1
S'The death - inducing receptor Fas is activated when cross - linked by the type II membrane protein Fas ligand ( FasL ) .'
p22769
(lp22770
I18
aI19
a(lp22771
I21
atp22772
a(I-1
S'When human soluble FasL ( sFasL , containing the extracellular portion ) was expressed in human embryo kidney 293 cells , the three N - linked glycans of each FasL monomer were found to be essential for efficient secretion .'
p22773
(lp22774
I3
a(lp22775
I29
atp22776
a(I1
S'Based on the structure of the closely related lymphotoxin alpha - tumor necrosis factor receptor I complex , a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge - based protein modeling methods .'
p22777
(lp22778
I8
aI9
a(lp22779
I11
aI12
aI13
aI14
aI15
atp22780
a(I-1
S'Based on the structure of the closely related lymphotoxin alpha - tumor necrosis factor receptor I complex , a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge - based protein modeling methods .'
p22781
(lp22782
I8
aI9
a(lp22783
I23
atp22784
a(I-1
S'Based on the structure of the closely related lymphotoxin alpha - tumor necrosis factor receptor I complex , a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge - based protein modeling methods .'
p22785
(lp22786
I8
aI9
a(lp22787
I28
atp22788
a(I-1
S'Based on the structure of the closely related lymphotoxin alpha - tumor necrosis factor receptor I complex , a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge - based protein modeling methods .'
p22789
(lp22790
I11
aI12
aI13
aI14
aI15
a(lp22791
I23
atp22792
a(I-1
S'Based on the structure of the closely related lymphotoxin alpha - tumor necrosis factor receptor I complex , a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge - based protein modeling methods .'
p22793
(lp22794
I11
aI12
aI13
aI14
aI15
a(lp22795
I28
atp22796
a(I1
S'Based on the structure of the closely related lymphotoxin alpha - tumor necrosis factor receptor I complex , a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge - based protein modeling methods .'
p22797
(lp22798
I23
a(lp22799
I28
atp22800
a(I-1
S'Mutants P206R , P206D , and P206F displayed reduced cytotoxicity toward Fas - positive cells with a concomitant decrease in the binding affinity for the recombinant Fas - immunoglobulin Fc fusion proteins .'
p22801
(lp22802
I11
a(lp22803
I26
atp22804
a(I1
S'Although the cytotoxic activity of mutant Y218D was unaltered , mutant Y218R was inactive , correlating with the prediction that Tyr - 218 of FasL interacts with a cluster of three basic amino acid side chains of Fas .'
p22805
(lp22806
I24
a(lp22807
I37
atp22808
a(I-1
S'Thrombopoietin ( TPO ) is a hematopoietin important for megakaryocyte proliferation and production of blood platelets .'
p22809
(lp22810
I0
a(lp22811
I2
atp22812
a(I1
S'We sought to characterize how TPO binds and activates its receptor , myeloproliferative leukemia virus receptor .'
p22813
(lp22814
I5
a(lp22815
I12
aI13
aI14
aI15
atp22816
a(I-1
S'The erythropoietin - like domain of TPO ( TPO1 - 153 ) has been fused to the gIII coat protein of M13 bacteriophage .'
p22817
(lp22818
I1
a(lp22819
I6
atp22820
a(I-1
S'The erythropoietin - like domain of TPO ( TPO1 - 153 ) has been fused to the gIII coat protein of M13 bacteriophage .'
p22821
(lp22822
I1
a(lp22823
I17
atp22824
a(I-1
S'The erythropoietin - like domain of TPO ( TPO1 - 153 ) has been fused to the gIII coat protein of M13 bacteriophage .'
p22825
(lp22826
I6
a(lp22827
I17
atp22828
a(I-1
S'Phage enzyme - linked immunosorbent assay was used to determine affinities for binding to both the TPO receptor and five anti - TPO1 - 153 monoclonal antibodies .'
p22829
(lp22830
I16
a(lp22831
I22
atp22832
a(I-1
S'In contrast , the other three monoclonal antibodies , which were effective at blocking TPO activity but did not block initial binding of TPO to its receptor , had epitopes predominantly on helix or 3 .'
p22833
(lp22834
I14
a(lp22835
I23
atp22836
a(I-1
S'These results suggest that TPO has two distinct receptor - binding sites that function to dimerize TPO receptors in a sequential fashion .'
p22837
(lp22838
I4
a(lp22839
I16
atp22840
a(I1
S'14 - 3 - 3 zeta negatively regulates raf - 1 activity by interactions with the Raf - 1 cysteine - rich domain .'
p22841
(lp22842
I0
aI1
aI2
aI3
aI4
aI5
a(lp22843
I8
aI9
aI10
atp22844
a(I1
S'14 - 3 - 3 zeta negatively regulates raf - 1 activity by interactions with the Raf - 1 cysteine - rich domain .'
p22845
(lp22846
I0
aI1
aI2
aI3
aI4
aI5
a(lp22847
I16
aI17
aI18
atp22848
a(I-1
S'14 - 3 - 3 zeta negatively regulates raf - 1 activity by interactions with the Raf - 1 cysteine - rich domain .'
p22849
(lp22850
I8
aI9
aI10
a(lp22851
I16
aI17
aI18
atp22852
a(I-1
S'Although Raf - 1 is a critical effector of Ras signaling and transformation , the mechanism by which Ras promotes Raf - 1 activation is complex and remains poorly understood .'
p22853
(lp22854
I1
aI2
aI3
a(lp22855
I9
atp22856
a(I-1
S'Although Raf - 1 is a critical effector of Ras signaling and transformation , the mechanism by which Ras promotes Raf - 1 activation is complex and remains poorly understood .'
p22857
(lp22858
I1
aI2
aI3
a(lp22859
I18
atp22860
a(I-1
S'Although Raf - 1 is a critical effector of Ras signaling and transformation , the mechanism by which Ras promotes Raf - 1 activation is complex and remains poorly understood .'
p22861
(lp22862
I1
aI2
aI3
a(lp22863
I20
aI21
aI22
atp22864
a(I-1
S'Although Raf - 1 is a critical effector of Ras signaling and transformation , the mechanism by which Ras promotes Raf - 1 activation is complex and remains poorly understood .'
p22865
(lp22866
I9
a(lp22867
I18
atp22868
a(I-1
S'Although Raf - 1 is a critical effector of Ras signaling and transformation , the mechanism by which Ras promotes Raf - 1 activation is complex and remains poorly understood .'
p22869
(lp22870
I9
a(lp22871
I20
aI21
aI22
atp22872
a(I-1
S'Although Raf - 1 is a critical effector of Ras signaling and transformation , the mechanism by which Ras promotes Raf - 1 activation is complex and remains poorly understood .'
p22873
(lp22874
I18
a(lp22875
I20
aI21
aI22
atp22876
a(I-1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22877
(lp22878
I4
a(lp22879
I8
aI9
aI10
atp22880
a(I1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22881
(lp22882
I4
a(lp22883
I8
aI9
aI10
aI11
aI12
aI13
aI14
atp22884
a(I1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22885
(lp22886
I4
a(lp22887
I16
aI17
aI18
atp22888
a(I-1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22889
(lp22890
I4
a(lp22891
I29
aI30
aI31
atp22892
a(I-1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22893
(lp22894
I8
aI9
aI10
a(lp22895
I8
aI9
aI10
aI11
aI12
aI13
aI14
atp22896
a(I-1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22897
(lp22898
I8
aI9
aI10
a(lp22899
I16
aI17
aI18
atp22900
a(I-1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22901
(lp22902
I8
aI9
aI10
a(lp22903
I29
aI30
aI31
atp22904
a(I-1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22905
(lp22906
I8
aI9
aI10
aI11
aI12
aI13
aI14
a(lp22907
I16
aI17
aI18
atp22908
a(I-1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22909
(lp22910
I8
aI9
aI10
aI11
aI12
aI13
aI14
a(lp22911
I29
aI30
aI31
atp22912
a(I-1
S'We recently reported that Ras interaction with the Raf - 1 cysteine - rich domain ( Raf - CRD , residues 139 - 184 ) may be required for Raf - 1 activation .'
p22913
(lp22914
I16
aI17
aI18
a(lp22915
I29
aI30
aI31
atp22916
a(I-1
S'The Raf - CRD is located in the NH2 - terminal negative regulatory domain of Raf - 1 and is highly homologous to cysteine - rich domains found in protein kinase C family members .'
p22917
(lp22918
I1
aI2
aI3
a(lp22919
I15
aI16
aI17
atp22920
a(I-1
S'Recent studies indicate that the structural integrity of the Raf - CRD is also critical for Raf - 1 interaction with 14 - 3 - 3 proteins .'
p22921
(lp22922
I9
aI10
aI11
a(lp22923
I16
aI17
aI18
atp22924
a(I-1
S'However , whether 14 - 3 - 3 proteins interact directly with the Raf - CRD and how this interaction may mediate Raf - 1 function has not been determined .'
p22925
(lp22926
I13
aI14
aI15
a(lp22927
I22
aI23
aI24
atp22928
a(I1
S'In the present study , we demonstrate that 14 - 3 - 3 zeta binds directly to the isolated Raf - CRD .'
p22929
(lp22930
I8
aI9
aI10
aI11
aI12
aI13
a(lp22931
I19
aI20
aI21
atp22932
a(I1
S'Moreover , mutation of Raf - 1 residues 143 - 145 impairs binding of 14 - 3 - 3 , but not Ras , to the Raf - CRD .'
p22933
(lp22934
I4
aI5
aI6
a(lp22935
I22
atp22936
a(I1
S'Moreover , mutation of Raf - 1 residues 143 - 145 impairs binding of 14 - 3 - 3 , but not Ras , to the Raf - CRD .'
p22937
(lp22938
I4
aI5
aI6
a(lp22939
I26
aI27
aI28
atp22940
a(I-1
S'Moreover , mutation of Raf - 1 residues 143 - 145 impairs binding of 14 - 3 - 3 , but not Ras , to the Raf - CRD .'
p22941
(lp22942
I22
a(lp22943
I26
aI27
aI28
atp22944
a(I-1
S'Thus , 14 - 3 - 3 interaction with the Raf - CRD may serve in negative regulation of Raf - 1 function by facilitating dissociation of 14 - 3 - 3 from the NH2 terminus of Raf - 1 to promote subsequent events necessary for full activation of Raf - 1 .'
p22945
(lp22946
I10
aI11
aI12
a(lp22947
I19
aI20
aI21
atp22948
a(I-1
S'Thus , 14 - 3 - 3 interaction with the Raf - CRD may serve in negative regulation of Raf - 1 function by facilitating dissociation of 14 - 3 - 3 from the NH2 terminus of Raf - 1 to promote subsequent events necessary for full activation of Raf - 1 .'
p22949
(lp22950
I10
aI11
aI12
a(lp22951
I37
aI38
aI39
atp22952
a(I-1
S'Thus , 14 - 3 - 3 interaction with the Raf - CRD may serve in negative regulation of Raf - 1 function by facilitating dissociation of 14 - 3 - 3 from the NH2 terminus of Raf - 1 to promote subsequent events necessary for full activation of Raf - 1 .'
p22953
(lp22954
I10
aI11
aI12
a(lp22955
I49
aI50
aI51
atp22956
a(I-1
S'Thus , 14 - 3 - 3 interaction with the Raf - CRD may serve in negative regulation of Raf - 1 function by facilitating dissociation of 14 - 3 - 3 from the NH2 terminus of Raf - 1 to promote subsequent events necessary for full activation of Raf - 1 .'
p22957
(lp22958
I19
aI20
aI21
a(lp22959
I37
aI38
aI39
atp22960
a(I-1
S'Thus , 14 - 3 - 3 interaction with the Raf - CRD may serve in negative regulation of Raf - 1 function by facilitating dissociation of 14 - 3 - 3 from the NH2 terminus of Raf - 1 to promote subsequent events necessary for full activation of Raf - 1 .'
p22961
(lp22962
I19
aI20
aI21
a(lp22963
I49
aI50
aI51
atp22964
a(I-1
S'Thus , 14 - 3 - 3 interaction with the Raf - CRD may serve in negative regulation of Raf - 1 function by facilitating dissociation of 14 - 3 - 3 from the NH2 terminus of Raf - 1 to promote subsequent events necessary for full activation of Raf - 1 .'
p22965
(lp22966
I37
aI38
aI39
a(lp22967
I49
aI50
aI51
atp22968
a(I-1
S'Interactions between brain - derived neurotrophic factor and the TRKB receptor . Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross - linking .'
p22969
(lp22970
I2
aI3
aI4
aI5
aI6
a(lp22971
I9
atp22972
a(I1
S'Interactions between brain - derived neurotrophic factor and the TRKB receptor . Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross - linking .'
p22973
(lp22974
I2
aI3
aI4
aI5
aI6
a(lp22975
I9
aI10
atp22976
a(I-1
S'Interactions between brain - derived neurotrophic factor and the TRKB receptor . Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross - linking .'
p22977
(lp22978
I2
aI3
aI4
aI5
aI6
a(lp22979
I20
atp22980
a(I-1
S'Interactions between brain - derived neurotrophic factor and the TRKB receptor . Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross - linking .'
p22981
(lp22982
I9
a(lp22983
I9
aI10
atp22984
a(I-1
S'Interactions between brain - derived neurotrophic factor and the TRKB receptor . Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross - linking .'
p22985
(lp22986
I9
a(lp22987
I20
atp22988
a(I-1
S'Interactions between brain - derived neurotrophic factor and the TRKB receptor . Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross - linking .'
p22989
(lp22990
I9
aI10
a(lp22991
I20
atp22992
a(I-1
S'The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein , possessing binding ability for brain - derived neurotrophic factor ( BDNF ) .'
p22993
(lp22994
I7
a(lp22995
I6
aI7
aI8
atp22996
a(I-1
S'The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein , possessing binding ability for brain - derived neurotrophic factor ( BDNF ) .'
p22997
(lp22998
I7
a(lp22999
I25
aI26
aI27
aI28
aI29
atp23000
a(I-1
S'The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein , possessing binding ability for brain - derived neurotrophic factor ( BDNF ) .'
p23001
(lp23002
I7
a(lp23003
I31
atp23004
a(I1
S'The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein , possessing binding ability for brain - derived neurotrophic factor ( BDNF ) .'
p23005
(lp23006
I6
aI7
aI8
a(lp23007
I25
aI26
aI27
aI28
aI29
atp23008
a(I1
S'The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein , possessing binding ability for brain - derived neurotrophic factor ( BDNF ) .'
p23009
(lp23010
I6
aI7
aI8
a(lp23011
I31
atp23012
a(I-1
S'The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein , possessing binding ability for brain - derived neurotrophic factor ( BDNF ) .'
p23013
(lp23014
I25
aI26
aI27
aI28
aI29
a(lp23015
I31
atp23016
a(I-1
S'Two distinct ligand binding domains of TRKB were isolated from proteolytic digests of the receptor by affinity separation on immobilized BDNF .'
p23017
(lp23018
I6
a(lp23019
I20
atp23020
a(I-1
S'These results , obtained from a variety of experimental techniques , highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF .'
p23021
(lp23022
I24
a(lp23023
I24
aI25
atp23024
a(I-1
S'These results , obtained from a variety of experimental techniques , highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF .'
p23025
(lp23026
I24
a(lp23027
I28
atp23028
a(I1
S'These results , obtained from a variety of experimental techniques , highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF .'
p23029
(lp23030
I24
aI25
a(lp23031
I28
atp23032
a(I-1
S'A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak - Stat pathway and induce an antiviral state .'
p23033
(lp23034
I8
aI9
a(lp23035
I8
aI9
aI10
atp23036
a(I-1
S'A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak - Stat pathway and induce an antiviral state .'
p23037
(lp23038
I8
aI9
a(lp23039
I17
atp23040
a(I-1
S'A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak - Stat pathway and induce an antiviral state .'
p23041
(lp23042
I8
aI9
a(lp23043
I24
atp23044
a(I1
S'A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak - Stat pathway and induce an antiviral state .'
p23045
(lp23046
I8
aI9
aI10
a(lp23047
I17
atp23048
a(I-1
S'A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak - Stat pathway and induce an antiviral state .'
p23049
(lp23050
I8
aI9
aI10
a(lp23051
I24
atp23052
a(I-1
S'A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak - Stat pathway and induce an antiviral state .'
p23053
(lp23054
I17
a(lp23055
I24
atp23056
a(I-1
S'Coexpression of the alpha and betaL subunits of the human interferon alpha ( IFNalpha ) receptor is required for the induction of an antiviral state by human IFNalpha .'
p23057
(lp23058
I10
aI11
a(lp23059
I13
atp23060
a(I-1
S'Coexpression of the alpha and betaL subunits of the human interferon alpha ( IFNalpha ) receptor is required for the induction of an antiviral state by human IFNalpha .'
p23061
(lp23062
I10
aI11
a(lp23063
I10
aI11
aI12
aI13
aI14
aI15
atp23064
a(I-1
S'Coexpression of the alpha and betaL subunits of the human interferon alpha ( IFNalpha ) receptor is required for the induction of an antiviral state by human IFNalpha .'
p23065
(lp23066
I10
aI11
a(lp23067
I27
atp23068
a(I-1
S'Coexpression of the alpha and betaL subunits of the human interferon alpha ( IFNalpha ) receptor is required for the induction of an antiviral state by human IFNalpha .'
p23069
(lp23070
I13
a(lp23071
I10
aI11
aI12
aI13
aI14
aI15
atp23072
a(I-1
S'Coexpression of the alpha and betaL subunits of the human interferon alpha ( IFNalpha ) receptor is required for the induction of an antiviral state by human IFNalpha .'
p23073
(lp23074
I13
a(lp23075
I27
atp23076
a(I-1
S'Coexpression of the alpha and betaL subunits of the human interferon alpha ( IFNalpha ) receptor is required for the induction of an antiviral state by human IFNalpha .'
p23077
(lp23078
I10
aI11
aI12
aI13
aI14
aI15
a(lp23079
I27
atp23080
a(I-1
S'Our results demonstrated that the first 82 amino acids ( AAs ) ( AAs 265 - 346 ) of the cytoplasmic domain of the betaL chain are sufficient to activate the Jak - Stat pathway and trigger an antiviral state after IFNalpha2 binding to the receptor .'
p23081
(lp23082
I31
a(lp23083
I41
atp23084
a(I-1
S'This region of the betaL chain , required for Jak1 binding and activation , contains the Box 1 motif that is important for the interaction of some cytokine receptors with Jak kinases .'
p23085
(lp23086
I9
a(lp23087
I30
atp23088
a(I1
S'The protein product of c - cbl proto - oncogene is known to interact with several proteins , including Grb2 , Crk and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .'
p23089
(lp23090
I4
aI5
aI6
a(lp23091
I19
atp23092
a(I1
S'The protein product of c - cbl proto - oncogene is known to interact with several proteins , including Grb2 , Crk and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .'
p23093
(lp23094
I4
aI5
aI6
a(lp23095
I21
atp23096
a(I1
S'The protein product of c - cbl proto - oncogene is known to interact with several proteins , including Grb2 , Crk and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .'
p23097
(lp23098
I4
aI5
aI6
a(lp23099
I23
aI24
atp23100
a(I-1
S'The protein product of c - cbl proto - oncogene is known to interact with several proteins , including Grb2 , Crk and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .'
p23101
(lp23102
I19
a(lp23103
I21
atp23104
a(I-1
S'The protein product of c - cbl proto - oncogene is known to interact with several proteins , including Grb2 , Crk and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .'
p23105
(lp23106
I19
a(lp23107
I23
aI24
atp23108
a(I-1
S'The protein product of c - cbl proto - oncogene is known to interact with several proteins , including Grb2 , Crk and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .'
p23109
(lp23110
I21
a(lp23111
I23
aI24
atp23112
a(I-1
S'The precise function of c - Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c - Cbl is a negative regulator of the epidermal growth factor receptor .'
p23113
(lp23114
I4
aI5
aI6
a(lp23115
I23
aI24
aI25
atp23116
a(I-1
S'The precise function of c - Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c - Cbl is a negative regulator of the epidermal growth factor receptor .'
p23117
(lp23118
I4
aI5
aI6
a(lp23119
I32
aI33
aI34
atp23120
a(I-1
S'The precise function of c - Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c - Cbl is a negative regulator of the epidermal growth factor receptor .'
p23121
(lp23122
I4
aI5
aI6
a(lp23123
I32
aI33
aI34
aI35
atp23124
a(I-1
S'The precise function of c - Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c - Cbl is a negative regulator of the epidermal growth factor receptor .'
p23125
(lp23126
I23
aI24
aI25
a(lp23127
I32
aI33
aI34
atp23128
a(I1
S'The precise function of c - Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c - Cbl is a negative regulator of the epidermal growth factor receptor .'
p23129
(lp23130
I23
aI24
aI25
a(lp23131
I32
aI33
aI34
aI35
atp23132
a(I-1
S'The precise function of c - Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c - Cbl is a negative regulator of the epidermal growth factor receptor .'
p23133
(lp23134
I32
aI33
aI34
a(lp23135
I32
aI33
aI34
aI35
atp23136
a(I1
S'The screen identified interactions involving c - Cbl and two 14 - 3 - 3 isoforms , cytokeratin 18 , human unconventional myosin IC , and a recently identified SH3 domain containing protein , SH3 P17 .'
p23137
(lp23138
I5
aI6
aI7
a(lp23139
I17
aI18
atp23140
a(I1
S'The screen identified interactions involving c - Cbl and two 14 - 3 - 3 isoforms , cytokeratin 18 , human unconventional myosin IC , and a recently identified SH3 domain containing protein , SH3 P17 .'
p23141
(lp23142
I5
aI6
aI7
a(lp23143
I34
aI35
atp23144
a(I-1
S'The screen identified interactions involving c - Cbl and two 14 - 3 - 3 isoforms , cytokeratin 18 , human unconventional myosin IC , and a recently identified SH3 domain containing protein , SH3 P17 .'
p23145
(lp23146
I17
aI18
a(lp23147
I34
aI35
atp23148
a(I1
S'Interaction between cell cycle regulator , E2F - 1 , and NF - kappaB mediates repression of HIV - 1 gene transcription .'
p23149
(lp23150
I6
aI7
aI8
a(lp23151
I11
aI12
aI13
atp23152
a(I-1
S'The NF - kappaB / Rel family of transcription factors is one of the main targets of cytokines and other agents that induce HIV - 1 gene expression .'
p23153
(lp23154
I1
aI2
aI3
a(lp23155
I5
atp23156
a(I1
S'Some of these extracellular stimuli arrest cells in the G1 phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein Rb and its partner E2F - 1 .'
p23157
(lp23158
I25
a(lp23159
I29
aI30
aI31
atp23160
a(I-1
S'Here , we demonstrate that E2F - 1 may regulate the activity of the HIV - 1 long terminal repeat through its ability to bind sequences in the NF - kappaB enhancer region and to interact with the NF - kappaB subunit , p50 .'
p23161
(lp23162
I5
aI6
aI7
a(lp23163
I28
aI29
aI30
atp23164
a(I1
S'Here , we demonstrate that E2F - 1 may regulate the activity of the HIV - 1 long terminal repeat through its ability to bind sequences in the NF - kappaB enhancer region and to interact with the NF - kappaB subunit , p50 .'
p23165
(lp23166
I5
aI6
aI7
a(lp23167
I38
aI39
aI40
atp23168
a(I1
S'Here , we demonstrate that E2F - 1 may regulate the activity of the HIV - 1 long terminal repeat through its ability to bind sequences in the NF - kappaB enhancer region and to interact with the NF - kappaB subunit , p50 .'
p23169
(lp23170
I5
aI6
aI7
a(lp23171
I43
atp23172
a(I-1
S'Here , we demonstrate that E2F - 1 may regulate the activity of the HIV - 1 long terminal repeat through its ability to bind sequences in the NF - kappaB enhancer region and to interact with the NF - kappaB subunit , p50 .'
p23173
(lp23174
I28
aI29
aI30
a(lp23175
I38
aI39
aI40
atp23176
a(I-1
S'Here , we demonstrate that E2F - 1 may regulate the activity of the HIV - 1 long terminal repeat through its ability to bind sequences in the NF - kappaB enhancer region and to interact with the NF - kappaB subunit , p50 .'
p23177
(lp23178
I28
aI29
aI30
a(lp23179
I43
atp23180
a(I-1
S'Here , we demonstrate that E2F - 1 may regulate the activity of the HIV - 1 long terminal repeat through its ability to bind sequences in the NF - kappaB enhancer region and to interact with the NF - kappaB subunit , p50 .'
p23181
(lp23182
I38
aI39
aI40
a(lp23183
I43
atp23184
a(I-1
S'Gel retardation and methylation interference assays show that E2F - 1 is able to bind specifically to a site embedded within the two NF - kappaB elements .'
p23185
(lp23186
I8
aI9
aI10
a(lp23187
I23
aI24
aI25
atp23188
a(I-1
S'Gel retardation / immunoblot analysis using purified E2F - 1 and p50 homodimers reveals the presence of complexes containing both proteins .'
p23189
(lp23190
I7
aI8
aI9
a(lp23191
I11
atp23192
a(I1
S'Affinity chromatography and co - immunoprecipitation assays provide evidence for direct interaction of E2F - 1 and p50 in the absence of their DNA target sequences .'
p23193
(lp23194
I13
aI14
aI15
a(lp23195
I17
atp23196
a(I-1
S'In vitro transcription assay demonstrates that E2F - 1 represses NF - kappaB mediated transcription in a cell - free system .'
p23197
(lp23198
I6
aI7
aI8
a(lp23199
I10
aI11
aI12
atp23200
a(I-1
S'Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF - kappaB binding sites in E2F - 1 mediated repression of HIV - 1 promoter , in vivo .'
p23201
(lp23202
I14
a(lp23203
I16
aI17
aI18
atp23204
a(I-1
S'Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF - kappaB binding sites in E2F - 1 mediated repression of HIV - 1 promoter , in vivo .'
p23205
(lp23206
I14
a(lp23207
I22
aI23
aI24
atp23208
a(I-1
S'Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF - kappaB binding sites in E2F - 1 mediated repression of HIV - 1 promoter , in vivo .'
p23209
(lp23210
I16
aI17
aI18
a(lp23211
I22
aI23
aI24
atp23212
a(I1
S'The results of this study suggest that NF - kappaB activity may be regulated by its interaction with the cell cycle regulatory protein , E2F - 1 .'
p23213
(lp23214
I7
aI8
aI9
a(lp23215
I24
aI25
aI26
atp23216
a(I-1
S'TAP - and tapasin - dependent HLA - E surface expression correlates with the binding of an MHC class I leader peptide .'
p23217
(lp23218
I0
a(lp23219
I3
atp23220
a(I-1
S'TAP - and tapasin - dependent HLA - E surface expression correlates with the binding of an MHC class I leader peptide .'
p23221
(lp23222
I0
a(lp23223
I6
aI7
aI8
atp23224
a(I-1
S'TAP - and tapasin - dependent HLA - E surface expression correlates with the binding of an MHC class I leader peptide .'
p23225
(lp23226
I3
a(lp23227
I6
aI7
aI8
atp23228
a(I-1
S'We demonstrate that HLA - E surface expression is correlated with the presence of MHC class I molecules which provide suitable leader sequence peptides capable of binding to HLA - E .'
p23229
(lp23230
I3
aI4
aI5
a(lp23231
I28
aI29
aI30
atp23232
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23233
(lp23234
I6
aI7
aI8
a(lp23235
I17
aI18
aI19
atp23236
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23237
(lp23238
I6
aI7
aI8
a(lp23239
I23
aI24
aI25
aI26
aI27
atp23240
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23241
(lp23242
I6
aI7
aI8
a(lp23243
I29
atp23244
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23245
(lp23246
I6
aI7
aI8
a(lp23247
I32
atp23248
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23249
(lp23250
I6
aI7
aI8
a(lp23251
I36
aI37
aI38
atp23252
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23253
(lp23254
I6
aI7
aI8
a(lp23255
I41
atp23256
a(I1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23257
(lp23258
I17
aI18
aI19
a(lp23259
I23
aI24
aI25
aI26
aI27
atp23260
a(I1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23261
(lp23262
I17
aI18
aI19
a(lp23263
I29
atp23264
a(I1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23265
(lp23266
I17
aI18
aI19
a(lp23267
I32
atp23268
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23269
(lp23270
I17
aI18
aI19
a(lp23271
I36
aI37
aI38
atp23272
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23273
(lp23274
I17
aI18
aI19
a(lp23275
I41
atp23276
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23277
(lp23278
I23
aI24
aI25
aI26
aI27
a(lp23279
I29
atp23280
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23281
(lp23282
I23
aI24
aI25
aI26
aI27
a(lp23283
I32
atp23284
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23285
(lp23286
I23
aI24
aI25
aI26
aI27
a(lp23287
I36
aI37
aI38
atp23288
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23289
(lp23290
I23
aI24
aI25
aI26
aI27
a(lp23291
I41
atp23292
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23293
(lp23294
I29
a(lp23295
I32
atp23296
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23297
(lp23298
I29
a(lp23299
I36
aI37
aI38
atp23300
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23301
(lp23302
I29
a(lp23303
I41
atp23304
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23305
(lp23306
I32
a(lp23307
I36
aI37
aI38
atp23308
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23309
(lp23310
I32
a(lp23311
I41
atp23312
a(I-1
S'Further studies on the interaction of HLA - E with molecules in the endoplasmic reticulum revealed that HLA - E associates with the transporter associated with antigen processing ( TAP ) and calreticulin , and that HLA - E expression is TAP - dependent and tapasin - dependent .'
p23313
(lp23314
I36
aI37
aI38
a(lp23315
I41
atp23316
a(I1
S'In addition , HLA - E dissociates from TAP upon binding of MHC class I leader sequence peptides .'
p23317
(lp23318
I3
aI4
aI5
a(lp23319
I8
atp23320
a(I-1
S'The correlation between HLA - E and MHC class I surface expression might be relevant to the function of HLA - E .'
p23321
(lp23322
I3
aI4
aI5
a(lp23323
I19
aI20
aI21
atp23324
a(I-1
S'Our results also show that , although these HLA - E binding peptides are derived from signal sequences , they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA - E molecules .'
p23325
(lp23326
I8
aI9
aI10
a(lp23327
I32
atp23328
a(I-1
S'Our results also show that , although these HLA - E binding peptides are derived from signal sequences , they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA - E molecules .'
p23329
(lp23330
I8
aI9
aI10
a(lp23331
I37
aI38
aI39
atp23332
a(I-1
S'Our results also show that , although these HLA - E binding peptides are derived from signal sequences , they may be released back into the cytosol and subsequently translocated by the TAP complex and loaded onto HLA - E molecules .'
p23333
(lp23334
I32
a(lp23335
I37
aI38
aI39
atp23336
a.